



# Effective Health Care Program

---

Comparative Effectiveness Review  
Number 54

## **Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report**



Agency for Healthcare Research and Quality  
Advancing Excellence in Health Care • [www.ahrq.gov](http://www.ahrq.gov)

# *Comparative Effectiveness Review*

---

Number 54

## **Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report**

**Prepared for:**

Agency for Healthcare Research and Quality  
U.S. Department of Health and Human Services  
540 Gaither Road  
Rockville, MD 20850  
www.ahrq.gov

**Contract No. HHSA-290-2007-10056-I**

**Prepared by:**

RTI International–University of North Carolina Evidence-based Practice Center  
Research Triangle Park, NC

**Investigators:**

Katrina E. Donahue, M.D., M.P.H.  
Dan Jonas, M.D., M.P.H.  
Richard A. Hansen, Ph.D.  
Robert Roubey, M.D.  
Beth Jonas, M.D., M.P.H.  
Linda J. Lux, M.P.A.  
Gerald Gartlehner, M.D., M.P.H.  
Elizabeth Harden, M.P.H.  
Andrea Yuen, B.S.  
Patricia Thieda, M.A.  
Laura C. Morgan, M.A.  
Karen Crotty, Ph.D.  
Megan Van Noord, M.S.L.S.

**Errata: Tables 2, 3, and 4 have been corrected**

**AHRQ Publication No. 12-EHC024-EF  
Updated June 2012**

This report is based on research conducted by the RTI International–University of North Carolina (RTI–UNC) Evidence-based Practice Center under contract to the Agency for Healthcare Research and Quality (AHRQ), Rockville, MD (Contract No. HHS-290-2007-10056-I). The findings and conclusions in this document are those of the authors, who are responsible for its content, and do not necessarily represent the views of AHRQ. No statement in this report should be construed as an official position of AHRQ or of the U.S. Department of Health and Human Services.

The information in this report is intended to help healthcare decisionmakers—patients and clinicians, health system leaders, and policymakers, among others—make well-informed decisions and thereby improve the quality of health care services. This report is not intended to be a substitute for the application of clinical judgment. Anyone who makes decisions concerning the provision of clinical care should consider this report in the same way as any medical reference and in conjunction with all other pertinent information, i.e., in the context of available resources and circumstances presented by individual patients.

This report may be used, in whole or in part, as the basis for the development of clinical practice guidelines and other quality enhancement tools, or as a basis for reimbursement and coverage policies. AHRQ or U.S. Department of Health and Human Services endorsement of such derivative products may not be stated or implied.

This document is in the public domain and may be used and reprinted without permission except those copyrighted materials noted for which further reproduction is prohibited without the specific permission of copyright holders.

Persons using assistive technology may not be able to fully access information in this report. For assistance contact [EffectiveHealthCare@ahrq.hhs.gov](mailto:EffectiveHealthCare@ahrq.hhs.gov).

None of the investigators has any affiliations or financial involvement that conflicts with the material presented in this report.
--

**Suggested Citation:** Donahue KE, Jonas DE, Hansen RA, Roubey R, Jonas B, Lux LJ, Gartlehner G, Harden E, Yuen A, Thieda P, Morgan LC, Crotty K, Van Noord M. Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report. Comparative Effectiveness Review No. 54. (Prepared by RTI-UNC Evidence-based Practice Center under Contract No. 290-02-0016-I.) Rockville, MD: Agency for Healthcare Research and Quality; April 2012. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).

## Preface

The Agency for Healthcare Research and Quality (AHRQ) conducts the Effective Health Care Program as part of its mission to organize knowledge and make it available to inform decisions about health care. As part of the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, Congress directed AHRQ to conduct and support research on the comparative outcomes, clinical effectiveness, and appropriateness of pharmaceuticals, devices, and health care services to meet the needs of Medicare, Medicaid, and the Children's Health Insurance Program (CHIP).

AHRQ has an established network of Evidence-based Practice Centers (EPCs) that produce Evidence Reports/Technology Assessments to assist public- and private-sector organizations in their efforts to improve the quality of health care. The EPCs now lend their expertise to the Effective Health Care Program by conducting comparative effectiveness reviews (CERs) of medications, devices, and other relevant interventions, including strategies for how these items and services can best be organized, managed, and delivered.

Systematic reviews are the building blocks underlying evidence-based practice; they focus attention on the strength and limits of evidence from research studies about the effectiveness and safety of a clinical intervention. In the context of developing recommendations for practice, systematic reviews are useful because they define the strengths and limits of the evidence, clarifying whether assertions about the value of the intervention are based on strong evidence from clinical studies. For more information about systematic reviews, see <http://www.effectivehealthcare.ahrq.gov/reference/purpose.cfm>

AHRQ expects that CERs will be helpful to health plans, providers, purchasers, government programs, and the health care system as a whole. In addition, AHRQ is committed to presenting information in different formats so that consumers who make decisions about their own and their family's health can benefit from the evidence.

Transparency and stakeholder input from are essential to the Effective Health Care Program. Please visit the Web site ([www.effectivehealthcare.ahrq.gov](http://www.effectivehealthcare.ahrq.gov)) to see draft research questions and reports or to join an email list to learn about new program products and opportunities for input. Comparative Effectiveness Reviews will be updated regularly.

We welcome comments on this CER. They may be sent by mail to the Task Order Officer named below at: Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, MD 20850, or by email to [epc@ahrq.hhs.gov](mailto:epc@ahrq.hhs.gov).

Carolyn M. Clancy, M.D.  
Director  
Agency for Healthcare Research and Quality

Stephanie Chang, M.D., M.P.H.  
Director, EPC Program  
Agency for Healthcare Research and Quality

Jean Slutsky, P.A., M.S.P.H.  
Director, Centre for Outcomes and Evidence  
Agency for Healthcare Research and Quality

Carmen Kelly, Pharm.D., R.Ph.  
EPC Program Task Order Officer  
Agency for Healthcare Research and Quality

## Acknowledgments

We acknowledge Stephanie Chang, M.D., M.P.H. Director of the AHRQ Evidence-based Practice Center (EPC) Program and Carmen Kelly, Pharm.D., the AHRQ Task Order Officer for this project.

We extend our appreciation to our Technical Expert Panel: Teresa J. Brady, Ph.D., our Patient Representative; Dr. Jeffrey Curtis, M.D., M.P.H., Assistant Professor, Clinical Immunology and Rheumatology, University of Alabama at Birmingham; Marion McDonagh, Pharm.D., Assistant Professor, Informatics and Clinical Epidemiology and Project Director for DERP reports, Oregon Health & Science University; and Christopher T. Ritchlin, M.D., M.P.H., Rheumatologist, University of Rochester, our psoriatic arthritis clinical expert. All provided thoughtful advice and input during our research process.

The investigators deeply appreciate the considerable support, commitment, and contributions of the EPC team staff at RTI International and the University of North Carolina at Chapel Hill. We express our gratitude to research analysts: Tammeka Swinson Evans, B.A., Stacey Lloyd, M.P.H., and Loraine Monroe, our EPC publications specialist.

## Technical Expert Panel

Teresa J. Brady, Ph.D.  
Patient Representative

Jeffrey R. Curtis, M.D., M.P.H.  
Assistant Professor  
Division of Clinical Immunology and  
Rheumatology  
Associate Director  
Center for Education and Research on  
Therapeutics of MSK Disorders  
University of Alabama at Birmingham  
Birmingham, AL

Marion McDonagh, Pharm.D.  
Assistant Professor  
Informatics and Clinical Epidemiology  
Oregon Health & Science University  
Portland, OR

Christopher T. Ritchlin, M.D., M.P.H.  
Internal Medicine, Rheumatology  
School of Medicine and Dentistry  
University of Rochester  
Rochester, NY

## Peer Reviewers

Marion McDonagh, Pharm.D.  
Assistant Professor  
Informatics and Clinical Epidemiology  
Oregon Health & Science University  
Portland OR

Christopher T. Ritchlin, M.D., M.P.H.  
Internal Medicine, Rheumatology  
School of Medicine and Dentistry  
University of Rochester  
Rochester, NY

# Drug Therapy for Psoriatic Arthritis in Adults: Update of a 2007 Report

## Structured Abstract

**Objectives.** To compare the benefits and harms of corticosteroids and oral and biologic disease-modifying antirheumatic drugs (DMARDs) for adults with psoriatic arthritis (PsA).

**Data Sources.** English language articles from 1980 to February 2011 identified through PubMed, Embase, Cochrane Library and International Pharmaceutical Abstracts; unpublished literature including dossiers from pharmaceutical companies.

**Methods.** Two people independently selected relevant head-to-head trials of any sample size, observational studies with at least 100 participants, and relevant good- or fair-quality meta-analyses that compared benefits or harms of 14 drug therapies. Observational studies were included only for harms. For biologic DMARDs, placebo-controlled, double-blind randomized controlled trials (RCTs) also were included. We required trials and observational studies to be at least 12 weeks in duration. Literature was synthesized qualitatively within and between the two main drug classes (oral and biologic DMARDs).

**Results.** No head-to-head controlled trials meeting inclusion criteria existed for any drugs in this review for treating patients with PsA. The available evidence was limited to two head-to-head cohort studies and placebo-controlled trials. For oral DMARDs, including sulfasalazine and methotrexate, the sparse data available involved placebo comparisons. For biologic DMARDs, evidence supported the efficacy of adalimumab, etanercept, golimumab, and infliximab for the treatment of PsA when compared with placebo. Qualitatively, these biologic DMARDs appeared to achieve similar improvements in disease activity, functional capacity, and health-related quality of life (American College of Rheumatology 20 percent improvement from baseline to endpoint, Health Assessment Questionnaire, and Short Form 36 Physical Component scores) in these trials. No difference in treatment response was found between the combination of an anti-tumor necrosis factor (TNF) (adalimumab, etanercept, or infliximab) with methotrexate compared with anti-TNF only. Evidence was insufficient to draw conclusions about the comparative harms for oral DMARDs. Among biologics, low evidence indicated that etanercept had a lower rate of withdrawals due to adverse events compared with infliximab. Compared with placebo, adalimumab and etanercept had more injection site reactions and adalimumab had few events of aggravated psoriasis. No comparative evidence was identified for subgroups.

**Conclusions.** Overall, the data are quite limited and the evidence is insufficient to draw firm conclusions on comparative efficacy, effectiveness, and harms of either oral or biologic DMARDs for PsA. This report's findings did not reveal any differences with current standard of care. Head-to-head (RCTs) are needed to establish the comparative efficacy and safety of different treatments with and without corticosteroids, oral DMARDs, and biologic DMARDs, to determine the best therapy to prevent or minimize debilitating joint damage and optimize quality of life for people with PsA.

# Contents

<b>Executive Summary</b> .....	ES-1
<b>Introduction</b> .....	1
Background .....	1
Causes and Diagnosis .....	1
Treatment of Psoriatic Arthritis .....	2
Treatment Strategies .....	6
Scope and Key Questions .....	6
<b>Methods</b> .....	8
Topic Development .....	8
Literature Search .....	8
Study Selection .....	9
Data Extraction .....	11
Quality Assessment .....	11
Applicability Assessment .....	12
Grading Strength of Evidence .....	12
Data Synthesis .....	13
Peer Review .....	13
<b>Results</b> .....	14
KQ 1: Reductions in Disease Activity, Limitations of Disease Progression, and Maintenance of Remission .....	16
Overview .....	16
Psoriatic Arthritis: Detailed Analysis .....	18
KQ 2: Functional Capacity and Quality of Life .....	24
Overview .....	24
Detailed Analysis .....	25
KQ 3: Harms, Tolerability, Adverse Effects, or Adherence .....	30
Overview .....	30
Psoriatic Arthritis: Detailed Analysis .....	31
<b>Discussion</b> .....	35
Key Findings .....	37
Future Research .....	39
<b>References</b> .....	40

## Tables

Table A. Summary of Findings .....	ES-4
Table B. Comparison of Effect Sizes From Placebo-Controlled Trials for ACR 20, HAQ, and SF-36 PCS by Drug .....	ES-6
Table 1. CASPAR Criteria for the Diagnosis of Psoriatic Arthritis .....	2
Table 2. Pharmaceutical Treatments for Psoriatic Arthritis: Corticosteroids .....	4
Table 3. Pharmaceutical Treatments for Psoriatic Arthritis: Oral DMARDs .....	5
Table 4. Pharmaceutical Treatments for Psoriatic Arthritis: Biologic DMARDs .....	5
Table 5. Outcome Measures and Study Eligibility Criteria .....	10
Table 6. Strength of Evidence Grades and Their Definitions .....	13

Table 7. Number of Trials or Studies by Drug Comparison and Study Design for Psoriatic Arthritis .....	15
Table 8. Disease Activity, Radiographic Progression, Functional Capacity, and Quality-of-Life Measures.....	15
Table 9. Disease Activity of Oral DMARD Versus Placebo.....	19
Table 10. Disease Activity of Biologic DMARD + Oral DMARD Versus Biologic DMARD....	20
Table 11. Disease Activity of Biologic DMARD + Oral DMARD Versus Sulfasalazine .....	20
Table 12. Disease Activity in Biologic DMARD Versus Placebo .....	21
Table 13. Oral DMARD Versus Placebo Studies: Functional Capacity and Health-Related Quality of Life Outcomes: Leflunomide Versus Placebo.....	26
Table 14. Biologic DMARD Versus Placebo Studies: Functional Capacity and Health-Related Quality-of-Life Outcomes.....	26
Table 15. Studies Assessing Adverse Events, Discontinuation Rates, and Adherence in Psoriatic Arthritis.....	31
Table 16. Summary of Findings.....	35
Table 17. Comparison of Effect Sizes From Placebo-Controlled Trials for ACR 20, HAQ, and SF-36 PCS by Drug.....	38

## Figures

Figure A. Figure A. Analytic framework for treatment for psoriatic arthritis.....	ES-2
Figure 1. Disposition of Articles (PRISMA figure).....	14

## Appendixes

Appendix A. Search Strings	
Appendix B. Review and Abstraction Forms	
Appendix C. Articles by Database Searched	
Appendix D. Excluded Studies	
Appendix E. Evidence Tables	
Appendix F. Criteria for Assessing the Quality of Individual Studies	
Appendix G. Clinical and Self-Reported Scales and Instruments Commonly Used in Studies of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis	
Appendix H. Characteristics of Studies With Poor Internal Validity	
Appendix I. Strength of Evidence Tables	



# Executive Summary

## Background

Psoriatic arthritis (PsA) is among the most disabling forms of arthritis, even though it affects fewer people than other types of arthritis. PsA has a highly variable presentation, which generally involves pain and inflammation in joints and progressive joint involvement and damage. The condition is associated with the skin disease psoriasis, but not all people with psoriasis will develop PsA. Additionally, PsA may predate the development of skin disease, leading to some diagnostic uncertainty. Among people with psoriasis, the prevalence of arthritis varies from 6 percent to 42 percent. In the general population, the prevalence of PsA is estimated to be 0.3 percent to 1 percent. Based on estimates from the 2000 U.S. Census, 520,000 people ages 18 or older in the United States have PsA.

Treatment of patients with PsA aims to control pain and inflammation and, ultimately, to slow the progression of joint destruction and disability. Available therapies for PsA include corticosteroids, oral disease-modifying antirheumatic drugs or DMARDs (hydroxychloroquine, leflunomide, methotrexate [MTX], and sulfasalazine), and biologic DMARDs. Five biologics (adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab) are also classified as antitumor necrosis factor (anti-TNF) drugs. The U.S. Food and Drug Administration (FDA) has approved adalimumab, etanercept, golimumab, and infliximab for use in patients with PsA. This report also reviews evidence for abatacept, anakinra, certolizumab, rituximab, and tocilizumab, which are approved for rheumatoid arthritis (RA).

Historically, few trials have been conducted with patients having PsA, with only minimal research before biologic agents were introduced; management options tended to be adapted from RA trial evidence. Similar to RA trials, many questions remain about the risks of these agents across a spectrum of adverse events from relatively minor side effects such as injection-site reactions to severe and possibly life-threatening problems such as severe infections or infusion reactions.

Experts have not arrived at a consensus about the comparative effectiveness of corticosteroids, oral DMARDs, and biologic DMARDs for treating PsA. More importantly, it is unclear how the effectiveness and safety of different types of combination therapy compare. In addition, there is debate about how early in the disease process combination therapy should be initiated and whether patients will respond to a biologic agent if they have previously failed a different biologic agent. Finally, very little is known about the benefits or risks of these drugs in different patient subgroups, including ethnic minorities, the elderly, pregnant women, and patients with other comorbidities.

## Objectives

This report summarizes the evidence on the comparative efficacy, effectiveness, and harms of corticosteroids, oral DMARDs, and biologic DMARDs in the treatment of patients with PsA. This report updates a previous version published in 2007. The Key Questions (KQs) are as follows:

**KQ 1:** For patients with PsA, do drug therapies differ in their ability to reduce disease activity, to slow or limit the progression of radiographic joint damage, or to maintain remission?

**KQ 2:** For patients with PsA, do drug therapies differ in their ability to improve patient-reported symptoms, functional capacity, or quality of life?


**KQ 3:** For patients with PsA, do drug therapies differ in harms, tolerability, patient adherence, or adverse effects?

**KQ 4:** What are the comparative benefits and harms of drug therapies for PsA in subgroups of patients based on stage of disease, prior therapy, demographics, concomitant therapies, or comorbidities?

## Analytic Framework

Figure A lays out the analytic framework that guided the research.

**Figure A. Analytic framework for treatment for psoriatic arthritis**



DMARDs = disease-modifying antirheumatic drugs; KQ = Key Question

## Methods

A Technical Expert Panel was employed for the finalization of the KQs and review of the planned analysis strategy. Our KQs and protocol were posted on the AHRQ Web site for public review and comment. Two reviewers performed an external peer review; one a leading expert in psoriatic arthritis and one a faculty member in clinical epidemiology and informatics as well the project director for the Oregon Health and Science University's Drug Effectiveness Review Project reports. The report was also posted for public review. We compiled all comments and addressed each one individually, revising the text as appropriate.

We searched MEDLINE<sup>®</sup>, Embase, the Cochrane Library, and the International Pharmaceutical Abstracts to identify relevant articles. We limited the electronic searches to "human" and "English language." For this update, the searches went up to January 2011. Hand searches were conducted on the Center for Drug Evaluation and Research (CDER) database of the FDA and unpublished literature, including dossiers from pharmaceutical companies.

Study eligibility (inclusion and exclusion) criteria were designed with respect to study design or duration, patient population, interventions, outcomes, and comparisons for each KQ. For efficacy and effectiveness, we focused on head-to-head trials and prospective cohort studies

comparing one drug with another. For biologic DMARDs, we also included placebo-controlled, double-blind RCTs. For harms and tolerability, as well as for efficacy and effectiveness in subgroups, we included head-to-head trials, high-quality systematic reviews, and observational studies. We included studies with sample sizes of at least 100 and duration of at least 3 months. We included only studies that used doses within the recommended dosing range or that used doses that could be considered equivalent to recommended doses.

Two individuals independently reviewed abstracts identified by searches. If both reviewers agreed that a study did not meet eligibility criteria, we excluded it. We obtained the full text of all remaining articles. Two individuals again independently reviewed the full text of all remaining articles to determine whether they should be included.

We designed and used a structured data abstraction form to ensure consistency of appraisal for each included study. Trained reviewers abstracted data from each study. A senior reviewer evaluated the completeness of each data abstraction.

We rated the quality of individual studies using the predefined criteria based on those developed by the U.S. Preventive Services Task Force (ratings: good, fair, poor)<sup>1</sup> and the National Health Service Centre for Reviews and Dissemination.<sup>2</sup> Two independent reviewers assigned quality ratings. They resolved any disagreements by discussion and consensus or by consulting with a third reviewer. We gave a good-quality rating to studies that met all criteria. We gave a poor-quality rating to studies that had a fatal flaw (defined as a methodological shortcoming that leads to a very high risk of bias) in one or more categories and excluded them from our analyses.

We synthesized the literature qualitatively. We graded the strength of evidence as high, moderate, low, or insufficient based on methods guidance for the EPC program.<sup>3,4</sup> We graded strength of evidence for the outcomes determined to be most important: measures of disease activity (e.g., ACR 20/50/70,<sup>a</sup> DAS), radiographic changes, functional capacity, quality of life, withdrawals due to adverse events, and specific adverse events if data were available (e.g., injection-site reactions, infections, malignancy).

## Results

We identified 3,868 citations from our searches. We included 24 published articles reporting on 16 studies: 0 head-to-head randomized controlled trials, 0 head-to-head nonrandomized controlled trials, 10 placebo-controlled trials, 3 meta-analyses or systematic reviews, and 3 observational studies. Our findings included studies rated good or fair for internal validity. Most studies were of fair quality.

Our major findings are presented in this section by type of drug comparison and important outcomes (both benefits and harms as described in KQ 1, KQ 2, and KQ 3) (Table A). No comparative evidence was identified for KQ 4.

---

<sup>a</sup>American College of Rheumatology measure of disease activity: response scores based on 20, 50, or 70 percent criteria for improvement

**Table A. Summary of findings**

Key Comparisons	Efficacy and Effectiveness Strength of Evidence Grade	Harms Strength of Evidence Grade
<b><i>Oral DMARDs</i></b>		
Leflunomide	<p>No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative efficacy of leflunomide and other treatments.</p> <p>INSUFFICIENT</p> <p>Compared with placebo in one study, leflunomide produced better improvement in health-related quality of life and statistically significant, but not clinically significant, improvement in disease activity and functional capacity.</p> <p>LOW</p>	<p>No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative harms of leflunomide and other treatments.</p> <p>INSUFFICIENT</p> <p>Current evidence was limited to placebo-controlled trials. Compared with placebo, leflunomide led to higher rates of withdrawals because of adverse events, diarrhea, and clinically significant increases in alanine aminotransferase.</p> <p>INSUFFICIENT</p>
Methotrexate	<p>No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative efficacy of MTX and other treatments.</p> <p>INSUFFICIENT</p> <p>Current evidence was limited to placebo-controlled trials. Compared with placebo in one fair study, MTX resulted in greater improvement in physician assessment of disease activity than placebo.</p> <p>LOW</p>	<p>No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative harms of MTX and other treatments.</p> <p>INSUFFICIENT</p>
Sulfasalazine	<p>No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative efficacy of sulfasalazine and other treatments.</p> <p>INSUFFICIENT</p> <p>Current evidence was limited to placebo-controlled trials. Compared with placebo in one good systematic review study, sulfasalazine reduced disease activity.</p> <p>MODERATE</p>	<p>No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative harms of sulfasalazine and other treatments.</p> <p>INSUFFICIENT</p>
<b><i>Biologic DMARDs</i></b>		
Biologic DMARD + Oral DMARD vs. Biologic DMARD or Oral DMARD	<p>The current evidence was limited to two cohort studies. Compared to anti-TNF monotherapy (adalimumab, etanercept, or infliximab), MTX plus anti-TNF produced similar disease activity response rates.</p> <p>LOW</p> <p>One systematic review of TNF inhibitors found that both TNF inhibitors and sulfasalazine are effective (similar withdrawals due to lack of efficacy); however, the data were insufficient to determine if the effect reached MCID.</p> <p>INSUFFICIENT</p>	<p>No head-to-head evidence met inclusion criteria; unable to draw conclusions on the comparative harms of biologic DMARD + oral DMARD and other treatments.</p> <p>INSUFFICIENT</p>

**Table A. Summary of findings (continued)**

Key Comparisons	Efficacy and Effectiveness Strength of Evidence Grade	Harms Strength of Evidence Grade
Biologic	<p>No head-to-head trials met inclusion criteria; unable to draw conclusions on the comparative efficacy of biologics and other treatments.</p> <p>INSUFFICIENT</p> <p>Compared with placebo, adalimumab, etanercept, golimumab, and infliximab led to greater improvement in disease activity, functional capacity<sup>a</sup> and health-related quality of life.<sup>b</sup></p> <p>LOW to MODERATE<sup>c</sup></p>	<p>Etanercept had a lower rate of withdrawals because of adverse events than infliximab in a prospective cohort study.</p> <p>LOW</p> <p>Additional evidence was limited to placebo-controlled trials, where adverse events were not the primary outcome. Overall adverse event profiles appeared to be similar for biologic DMARDs and placebo. However, compared with placebo, we noted the following: adalimumab and etanercept had more injection-site reactions and adalimumab had fewer events of aggravated psoriasis than placebo</p> <p>LOW</p> <p>Golimumab was associated with more malignancies than placebo in one RCT</p> <p>INSUFFICIENT</p>

ACR 20 = American College of Rheumatology 20 percent improvement from baseline to endpoint; ADA = adalimumab; DMARD =, disease-modifying antirheumatic drug; ETN = etanercept; INF = infliximab; LEF = leflunomide, MCID = minimal clinically important difference; MTX = methotrexate; PCS = physical component score; SF-36 = Medical Outcomes Study Short Form 36; SSZ = sulfasalazine; TNF = tumor necrosis factor

<sup>a</sup>Of seven studies reporting outcomes for the Health Assessment Questionnaire (HAQ), the magnitude of benefit in functional capacity compared with placebo reached the MCID (HAQ change of  $\geq 0.22$ ) for all but one study of adalimumab (which found a between-group difference of 0.2).<sup>7</sup> The magnitude of benefit for functional capacity (between-group difference for improvement in HAQ) ranged from 0.2 to 0.3 for adalimumab, 0.5 to 1.1 for etanercept, 0.34 to 0.4 for golimumab, and 0.4 to 0.6 for infliximab.

<sup>b</sup>The magnitude of benefit in quality of life reached the MCID for the SF-36 PCS for all five studies that reported the PCS and ranged from 2.9 to 7.9 for adalimumab, 8.6 for etanercept, 5.9 to 7.2 for golimumab, and 6.4 to 8 for infliximab.

<sup>c</sup>Low for golimumab and moderate for adalimumab, etanercept, and infliximab.

Overall, the data are quite limited and the evidence is insufficient to draw firm conclusions on comparative efficacy, effectiveness, and harms of either oral or biologic DMARDs in this condition. Table B gives a range for effect sizes for commonly reported measures, including the American College of Rheumatology 20 percent improvement from baseline to endpoint (ACR 20), the Health Assessment Questionnaire (HAQ), and Medical Outcomes Study Short Form 36 Physical Component Score (SF-36 PCS). For the oral DMARDs, including sulfasalazine and methotrexate, sparse data are available.

**Table B. Comparison of effect sizes\* from placebo-controlled trials for ACR 20, HAQ, and SF-36 PCS by drug**

Drug	Studies/Participants	ACR 20 (% of Subjects Achieving)	HAQ (Mean Improvement)	SF-36 PCS (Mean Improvement)
<b>Oral DMARDs</b>				
Leflunomide	1 RCT/ 190	36	0.14	NR
Methotrexate	1 RCT/ 37	NR	NR	NR
Sulfasalazine	1 SER/ 1,022	NR	NR	NR
<b>Biologic DMARDs</b>				
Adalimumab	2 RCTs/ 415	39 to 57	0.2 to 0.3	2.9 to 7.9
Etanercept	3 RCTs/ 633	59 to 65	0.5 to 1.1	8.6
Golimumab	1 RCT/ 405	45 to 51	0.34 to 0.4	5.9 to 7.2
Infliximab	2RCTs,1SER/ 673	58 to 62	0.4 to 0.6	6.4 to 8

ACR 20 = American College of Rheumatology 20 percent improvement from baseline to endpoint; HAQ = Health Assessment Questionnaire; PCS = physical component score; SF-36 = Medical Outcomes Study Short Form 36; RCT = Randomized controlled trial; SER = systematic evidence review

\*Effect sizes represent the range of point estimates from individual studies for the absolute difference between drug and placebo. Minimally Clinically Important Differences (MCIDs): ACR 20 is 20% minimal improvement; ACR 50/70 considered more clinically significant; HAQ  $\geq 0.22$  change, SF36 PCS  $\geq 2$  standard error of the mean (SEM).

## Discussion

No head-to-head controlled trials meeting inclusion criteria existed for any drugs in this review for treating patients with PsA. Two cohort studies with low strength of evidence indicated that the combination of an anti-tumor necrosis factor (TNF) (adalimumab, etanercept, or infliximab) with methotrexate (MTX) only was not different in treatment response<sup>5,6</sup> than treatment with anti-TNF only.

For the oral DMARDs, including sulfasalazine and methotrexate, the sparse data available involved placebo comparisons. For biologic DMARDs, evidence supported the efficacy of adalimumab, etanercept, golimumab, and infliximab for the treatment of PsA when compared to placebo.<sup>7-17</sup> Qualitatively, these biologic DMARDs appeared to achieve similar ACR 20, HAQ, and SF-36 PCS scores in these trials (Table B). However, findings should be interpreted cautiously given these were not head-to-head trials. Evidence was insufficient to draw firm conclusions about the comparative efficacy, effectiveness, functional status, health-related quality of life, or tolerability of abatacept, adalimumab, anakinra, certolizumab, golimumab, etanercept, infliximab, rituximab, and tocilizumab for treating PsA.

Information generally was insufficient for the comparative harms, tolerability, adverse events, and adherence for patients with PsA. The available studies included two relatively small prospective cohort studies and placebo-controlled studies; no head-to-head studies meeting inclusion criteria have been published.

In terms of applicability to populations, the studies were generally multicenter involving adults with diagnosed PsA. Prior medications tried before these studies were variable, but in general patients had failed a DMARD prior to starting any of the biologic agents. It is also important to note that the diagnostic criteria for PsA before the 2006 publication of the CLASSification of Psoriatic Arthritis (CASPAR) criteria were not validated, which could lead to enrollment of patients that were not explicitly defined.

This report's findings did not reveal any differences with current standard of care. However the current available evidence for PsA was limited. Several areas need further research to help clinicians and researchers arrive at stronger conclusions on the comparative efficacy, effectiveness, quality of life, and harms of medications for PsA. For this condition, the available evidence was limited to two head-to-head cohort studies and placebo-controlled trials. Head-to-head randomized controlled trials are needed to establish the comparative efficacy and safety of different treatments with and without corticosteroids, oral DMARDs, and biologic DMARDs to determine the best therapy to prevent or minimize debilitating joint damage and optimize quality of life for people with PsA. Furthermore, head-to-head RCTs are needed to determine the comparative effectiveness and safety of biologic DMARDs for treating PsA. More generally, the issues of effectiveness, subgroups, and use in ordinary clinical settings warrant attention for PsA.

## Abbreviations

ACR	American College of Rheumatology
AHRQ	Agency for Healthcare Research and Quality
CASPAR	CLASSification of Psoriatic Arthritis
DMARD	disease-modifying antirheumatic drug
FDA	U.S. Food and Drug administration
HAQ	Health Assessment Questionnaire
MTX	methotrexate
PsA	psoriatic arthritis
RCT	randomized controlled trial
SF-36 PCS	Short Form 36 Physical Functioning Scale

## References

1. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. *Am J Prev Med.* 2001 Apr;20(3 Suppl):21-35.
2. Anonymous. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report Number 4 (2nd edition). 2001.
3. Agency for Healthcare Research and Quality. Methods reference guide for effectiveness and comparative effectiveness reviews, version 1.0. [Draft posted Oct. 2007]. Rockville, MD. [http://effectivehealthcare.ahrq.gov/repFiles/2007\\_10DraftMethodsGuide.pdf](http://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdf).
4. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. *J Clin Epidemiol.* 2010 May;63(5):513-23.
5. Kristensen LE, Gulfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. *Ann Rheum Dis.* 2008;67(3):364-9.
6. Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford)* 2010;49:697-705.

7. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. *J Rheumatol.* 2007;34(5):1040-50.
8. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum.* 2005;52(10):3279-89.
9. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet.* 2000 Jul 29;356(9227):385-90.
10. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis Rheum.* 2004;50(7):2264-72.
11. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. *J Rheumatol.* 2006;33(4):712-21.
12. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. *Arthritis Rheum.* 2009;60(4):976-86.
13. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum.* 2005 Apr;52(4):1227-36.
14. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. *Ann Rheum Dis.* 2006 Aug;65(8):1038-43.
15. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. *Ann Rheum Dis.* 2005 Aug;64(8):1150-7.
16. Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. *Ann Rheum Dis.* 2006 Apr;65(4):471-7.
17. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. *Health Technol Assess.* 2006 Sep;10(31):1-258.



# Introduction

## Background

Arthritis and other rheumatic conditions constitute the leading cause of disability among United States (U.S.) adults,<sup>1</sup> with more than 46 million Americans reporting doctor-diagnosed arthritis.<sup>2</sup> Noninflammatory arthritic conditions (e.g., osteoarthritis) are most common, but inflammatory arthritides such as spondyloarthropathies (e.g., ankylosing spondylitis, psoriatic arthritis [PsA]), and reactive arthritis) and rheumatoid arthritis (RA) can be equally or more disabling.

Among patients with arthritis, the burden of disease is evidenced by decreased quality of life,<sup>3-6</sup> decreased employment rates,<sup>7,8</sup> and increased direct and indirect costs.<sup>9-12</sup> In 2003, arthritis and other rheumatic conditions cost the United States \$127.8 billion (\$80.8 billion in medical care expenditures and \$47.0 billion in lost earnings).<sup>13</sup>

Costs associated with PsA are not as well studied as costs associated with other arthritic conditions, although they are believed to be just slightly lower than those associated with RA.<sup>11</sup> Indirect costs are believed to increase over time because as the disease progresses so does the loss of function and inability to work. Based on 1997 estimates for psoriasis and PsA, annual direct costs are approximately \$650 million.<sup>14</sup> Of these costs, hospitalizations accounted for \$31 million, outpatient physician visits for \$87 million, photochemotherapy for \$27 million, dermatologic prescription drugs for \$148 million, and over-the-counter medications for \$357 million.<sup>14,15</sup> These estimates do not include indirect costs, and the specific direct costs of PsA are not known.

## Causes and Diagnosis

Psoriasis, a skin disease, affects 2.2 percent of U.S. adults; approximately 6 percent to 42 percent of patients with psoriasis develop PsA.<sup>16</sup> Approximately 520,000 adults in the United States have PsA.<sup>17</sup> PsA can develop at any age but most often appears between 30 and 50 years of age. Unlike RA, PsA appears to affect men slightly more often than women.

Clinically PsA is a multifaceted disease and may have skin presentations that help with its diagnosis. The presentation is highly variable. Patients with PsA can have moderate to severe involvement of skin and joints, and this combination can have profound effects on function and quality of life. In most cases, the psoriasis predates the onset of the PsA, although arthritis has been described as the initial manifestation of psoriatic disease. Common presentations include a symmetric small-joint polyarthritis (RA-like) and an axial arthritis with involvement of the sacroiliac joints, axial skeleton (spine), and large joints. In all cases, symptoms include pain and stiffness in the affected joint, enthesial areas (where tendons insert into bone) with joint line tenderness, swelling, and often loss of range of motion. Pitting of the fingernails often correlates with the extent and severity of the disease. Dactylitis—swelling of a whole digit—is a characteristic clinical finding, and inflammatory eye disease (iritis, uveitis) may occur. More than one-third of patients with PsA will develop dactylitis and enthesopathy (a disease process at the site where muscle tendons or ligaments insert into bones or joints).

The etiology and pathogenesis of psoriasis and PsA are not completely understood, but genetic, immunologic, and environmental factors are all likely to play a role.<sup>18</sup> Several

classification systems have been proposed for the diagnosis of PsA,<sup>19</sup> but which one best represents true PsA remains unclear.

Table 1 presents the CASPAR (CIASsification of Psoriatic ARthritis) as an example of one classification.<sup>20</sup>

**Table 1. CASPAR criteria for the diagnosis of psoriatic arthritis**

<b>Inflammatory articular disease (joint, spine, or enthesial areas) with <math>\geq 3</math> points from the following:</b>
1. Evidence of current psoriasis, a personal history of psoriasis, or a family history of psoriasis
2. Typical psoriatic nail dystrophy, including onycholysis, pitting, or hyperkeratosis
3. Negative test result for the presence of rheumatoid factor
4. Current dactylitis or history of dactylitis
5. Radiographic evidence of juxtaarticular new bone formation

Source: Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum.* 2006 Aug;54(8):2665-73.<sup>20</sup>

## Treatment of Psoriatic Arthritis

Treatment of patients with PsA is aimed primarily at controlling pain and inflammation and, ultimately, at slowing or arresting the progression of joint destruction. Historically, few trials have been conducted in patients with PsA, with only minimal research before biologic agents were introduced; management options tended to be adapted from RA trial evidence. Like in RA trials, many questions remain about the risks of these agents across a spectrum of adverse events from relatively minor side effects such as injection-site reactions to severe and possibly life-threatening problems such as severe infections or infusion reactions. Unlike RA, there is no diagnostic marker for PsA, which can lead to misdiagnosis. Additionally, studies performed before the CASPAR criteria were used included patients that are not explicitly defined.

### Corticosteroids

Corticosteroids—sometimes referred to as glucocorticoids or steroids—are used for many inflammatory and autoimmune conditions. As a class, corticosteroids have been used since the discovery of cortisone in the 1940s. Commonly used oral corticosteroids include methylprednisolone, prednisone, and prednisolone.

Corticosteroids are a synthetic form of cortisol, a hormone produced by the adrenal glands. They produce their anti-inflammatory and immunosuppressive response by interacting with steroid-specific receptors in the cytoplasm of cells, thereby inhibiting the movement of inflammatory cells into the site of inflammation, inhibiting neutrophil function, and inhibiting prostaglandin production. When used to treat PsA, corticosteroids are most often given as a joint injection rather than orally. Although they can be very effective in controlling joint inflammation, oral steroids are generally avoided in treating PsA, because a flare of skin disease has been described when steroids are tapered or withdrawn.

### Oral Disease-Modifying Antirheumatic Drugs (DMARDs)

Oral DMARDs such as methotrexate (MTX), sulfasalazine, hydroxychloroquine, and leflunomide modify the course of inflammatory conditions, presumably through their effects on the immune system. Most of the oral DMARDs have been used in clinical practice for more than 20 years. MTX was developed in the 1940s as a treatment for leukemia but was not approved for the treatment of arthritis until 1988. Sulfasalazine also has been available since the 1940s; it is a

combination salicylate (acetylsalicylic acid) and antibiotic (sulfapyridine) that originally was used to treat patients with inflammatory bowel disease. Hydroxychloroquine, approved in the 1950s for the treatment of malaria, is believed to work in treating arthritis by interfering with antigen presentation and the activation of immune response by increasing the pH within macrophage phagolysosomes. Additionally, hydroxychloroquine possibly inhibits toll-like receptors that mediate proinflammatory cytokine production. Only leflunomide, an isoxazole immunomodulatory agent, was specifically developed for treating inflammatory arthritis; the U.S. Food and Drug Administration (FDA) approved its use in 1998.

Oral DMARDs are not members of a single drug family. They are classified together, however, because they all are slow acting with the aim of improving symptoms, reducing or preventing joint damage, and preserving structure and function in patients with inflammatory disease. All the oral DMARDs covered in this review can be given orally, although MTX can also be injected (subcutaneous [SQ] or intramuscular [IM]).

## **Biologic DMARDs**

Biologic DMARDs—commonly referred to as biological response modifiers or simply biologics—are a relatively new category of DMARDs that differ from oral DMARDs in that they target specific components of the immune system. FDA approved the first of the biologics (infliximab) in 1998; this report covers eight additional agents approved since that time: etanercept (1998), anakinra (2001), adalimumab (2002), abatacept (2005), rituximab (2006), certolizumab pegol (2008), golimumab (2009), and tocilizumab (2010). Of the nine agents, all are currently FDA approved for treating RA, but only adalimumab, etanercept, golimumab, and infliximab are approved for treating PsA. Even though anakinra, abatacept, certolizumab pegol, rituximab, and tocilizumab are not FDA approved for PsA, this report reviews the evidence for all of these agents.

The biologic DMARDs work by selectively blocking mechanisms involved in the inflammatory and immune response. Adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab are known as tumor necrosis factor (TNF) inhibitors (i.e., drugs that block specific proinflammatory mediators known as cytokines). They produce their primary effect by blocking TNF from interacting with cell surface TNF receptors. Adalimumab, golimumab, and infliximab are monoclonal antibodies. Adalimumab is a fully human monoclonal antibody that binds specifically to TNF, blocking its interaction with both the p55 and p75 cell surface TNF receptor. Golimumab is also a human monoclonal antibody that binds to TNF alpha with high affinity. Infliximab is a chimeric (i.e., made from human and mouse proteins) monoclonal antibody that binds specifically to human TNF-alpha. Certolizumab pegol is a pegylated humanized antibody fragment of tumor necrosis factor monoclonal antibody. The drug binds to the TNF alpha-receptor and blocks TNF alpha activity. It only possesses the Fab fragment and lacks the Fc region. Hence, it does not induce antibody-dependant cell-mediated apoptosis or toxicity. Etanercept is not a monoclonal antibody, but rather a TNF-soluble receptor protein. More specifically, it is a soluble dimeric form of the p75 TNF receptor linked to the Fc portion of human immunoglobulin G1 (IgG1). Etanercept exerts its action by binding circulating TNF and preventing it from interacting with a cell surface receptor. It does not form neutralizing antibodies or mediate cell lysis in the presence or absence of complement.

Interleukin-1 (IL-1), another naturally occurring cytokine, has both immune and proinflammatory actions. Anakinra is a human recombinant protein that competitively blocks the IL-1 receptor, thus blocking various inflammatory and immunological responses.

The immunosuppressant agent abatacept produces its immune response by interfering with T lymphocyte activation. Abatacept is a soluble fusion protein that consists of the extracellular domain of human cytotoxic T lymphocyte-associated antigen (CTLA-4) and the modified Fc portion of IgG1.

Rituximab, a chimeric murine/human monoclonal antibody, works by binding to the CD20 antigen found on the surface of B lymphocytes. Thus, it in effect removes circulating B cells from the pre-B cell stage through the activated B cells. B cells are believed to play a role in autoimmune and inflammatory processes.

Interleukin-6 (IL-6) is a naturally occurring cytokine involved in regulating immune responses and inflammation. Tocilizumab is a monoclonal antibody that inhibits IL-6 receptors, blocking the action of IL-6 and leading to a reduction in cytokine and inflammatory response.

Tables 2 through 4 provide detailed information (names, manufacturers, and available dosage forms) on agents used in the treatment of RA that we have included in this review. Also presented are routes of administration, labeled uses, and usual (recommended) adult doses and frequency for PsA.

**Table 2. Pharmaceutical treatments for psoriatic arthritis: corticosteroids**

Generic Name	Manufacturer U.S. Trade Name(s) <sup>*</sup>	How Supplied	Usual Adult Dose
Methyl-prednisolone	Multiple Medrol <sup>®</sup> , Depo-Medrol <sup>®</sup> , Solu-Medrol <sup>®</sup>	Acetate - Injectable IM—20, 40, and 80 mg/ml  Sodium succinate - Injectable: IM—40, 125, and 500 mg, 1 and 2 g vials  Oral: Tabs—2, 4, 8, 16, and 32 mg	Acetate: IM—10 to 80 mg every 1 to 2 weeks Intra-articular, intralesional—4 to 80 mg every 1 to 5 weeks  Sodium succinate: IM—10 to 80 mg daily IV—10 to 40 mg every 4 to 6 hours; up to 30 mg/kg every 4 to 6 hours  Oral: 2 to 60 mg in 1 to 4 divided doses to start, followed by gradual reduction
Prednisone	Multiple Deltasone <sup>®</sup> , Sterapred <sup>®</sup> , LiquiPred <sup>®</sup>	Oral Solution—1 and 5 mg/ml Tabs—1, 2.5, 5, 10, 20, and 50 mg	Use lowest effective dose (5-60 mg/day)
Prednisolone	Multiple Orapred <sup>®</sup> , Pediapred <sup>®</sup> , Prelone <sup>®</sup> , Delta-Cortef <sup>®</sup> , Econopred <sup>®</sup>	Oral Solution/Syrup—5, 15, and 20 mg/5 ml Oral Tabs—5 and 15 mg	Use lowest effective dose (5 to 7.5 mg/day)

IM = intramuscular; IV = intravenous; kg = kilogram; mg = milligram; ml = milliliter

<sup>\*</sup>Listed trade names are limited to commonly prescribed U.S. products when multiple trade names are available.

**Table 3. Pharmaceutical treatments for psoriatic arthritis: oral DMARDs**

Generic Name	Manufacturer U.S. Trade Name(s) <sup>c</sup>	How Supplied	Usual Adult Dose
Hydroxy-chloroquine <sup>b</sup>	Multiple Plaquenil <sup>®</sup>	Oral Tabs—200 mg	200 to 400 <sup>a</sup> mg/day in 1 or 2 divided doses
Leflunomide <sup>b</sup>	Multiple Arava <sup>®</sup>	Oral Tabs—10 and 20 mg	10 to 20 mg/day in a single dose
Methotrexate <sup>b</sup>	Multiple Trexall <sup>®</sup> , Folex <sup>®</sup> , Rheumatrex <sup>®</sup>	Injectable—25 mg/ml, 20 mg and 1 g vials Oral Tabs—2.5, 5, 7.5, 10, and 15 mg	IM, SQ, oral—7.5 to 20 mg/week in a single dose
Sulfasalazine <sup>b</sup>	Multiple Azulfidine <sup>®</sup> , EN-tabs <sup>®</sup> , Sulfazine <sup>®</sup>	Oral Suspension—250 mg/5 ml Oral Tabs—500 mg	500 to 3,000 mg/day in 2 to 4 divided doses

g = gram; IM = intramuscular; mg = milligram; ml = milliliter

<sup>c</sup>Listed trade names are limited to commonly prescribed U.S. products when multiple trade names are available.

<sup>a</sup>Initial dose is 400 to 600 mg/day for 4 to 12 weeks.

<sup>b</sup>Dosed according to the RA dosing recommendations.

**Table 4. Pharmaceutical treatments for psoriatic arthritis: biologic DMARDs**

Generic Name	Manufacturer U.S. Trade Name(s)	Injectable Supply	Usual Adult Dose
<i>Biologic DMARDs</i>			
Abatacept <sup>a</sup>	Bristol Myers Squibb Orencia <sup>®</sup>	250 mg vial	IV—Dosed according to body weight (<60 kg=500 mg; 60-100 kg=750 mg; >100 kg=1,000 mg); dose repeated at 2 weeks and 4 weeks after initial dose, and every 4 weeks thereafter SQ—May give weight-based IV loading dose, then 125 mg SQ once weekly
Adalimumab	Abbott Humira <sup>®</sup>	40 mg/0.8 ml, 20 mg/0.4 ml prefilled syringe	SQ—40 mg every other week alone or in combination with other DMARDs
Anakinra <sup>a</sup>	Amgen Kineret <sup>®</sup>	100 mg/0.67 ml syringe	SQ—100 mg/day; dose should be decreased to 100 mg every other day in renal insufficiency
Certolizumab Pegol <sup>a</sup>	UCB Cimzia <sup>®</sup>	200 mg powder for reconstitution, 200 mg/ml solution	SQ—Initial dose of 400 mg (as 2 SQ injections of 200 mg), repeat dose 2 and 4 weeks after initial dose; maintenance dose is 200 mg every other week (may consider maintenance dose of 400 every 4 weeks)
Etanercept	Amgen Pfizer Immunex Enbrel <sup>®</sup>	50 mg/ml in 25 mg or 50 mg single use prefilled syringe	SQ—50 mg once weekly with or without MTX
Golimumab	Centocor Ortho Biotech Simponi <sup>®</sup>	50 mg/0.5 ml syringe	SQ—50 mg once per month, alone or in combination with MTX

**Table 4. Pharmaceutical treatments for psoriatic arthritis: biologic DMARDs (continued)**

Generic Name	Manufacturer U.S. Trade Name(s) <sup>†</sup>	Injectable Supply	Usual Adult Dose
Infliximab	Centocor Ortho Biotech  Remicade <sup>®</sup>	100 mg in a 20 ml vial	IV—5 mg/kg at 0, 2, and 6 weeks followed by maintenance every 8 weeks thereafter; may be given with or without MTX
Rituximab <sup>a</sup>	Biogen Idec / Genentech  Rituxan <sup>®</sup>	100 mg/10 ml and 500 mg/50 ml vial	IV—1,000 mg IV infusion separated by 2 weeks (one course) every 24 weeks or based on clinical evaluation, but not sooner than every 16 weeks
Tocilizumab <sup>a</sup>	Genentech / Roche  Actemra <sup>®</sup> , RoActemra <sup>®</sup>	80 mg/4 ml, 200 mg/10 ml, 400 mg/20 ml vial	IV—4 mg/kg every 4 weeks; increase to 8 mg/kg every 4 weeks based on clinical response

kg = kilogram; mg = milligram; ml = milliliter; MTX = methotrexate; IV = intravenous SQ = subcutaneously

<sup>†</sup>Listed trade names are limited to commonly prescribed U.S. products when multiple trade names are available.

<sup>a</sup>Dosed according to the RA dosing recommendations.

## Treatment Strategies

The first line of treatment of PsA is nonsteroidal anti-inflammatory drugs (NSAIDs), although in most cases DMARDs are necessary. MTX is particularly useful because it treats the psoriasis in addition to the arthropathy. Corticosteroids may be used to control inflammation, but they do not have much of a role in chronic disease management in psoriatic disease. The tapering or withdrawal of steroids in PsA has been associated with severe flares of skin disease. When chronic disease continues to be active despite the use of MTX, biologics are indicated. Biologics most often are given in combination with oral DMARDs (e.g., MTX).<sup>21</sup>

Historically, few PsA trials have been conducted, and management has been adapted from RA trial data. Since the introduction of biologic therapy, however, dedicated PsA trials have demonstrated efficacy in this distinct disease. Detailed and comparative examination of the efficacy, effectiveness, and harms of treatments for PsA is needed.

## Scope and Key Questions

The purpose of this review is to compare the efficacy, effectiveness, and harms of corticosteroids, oral DMARDs, and biologic DMARDs in the treatment of patients' PsA. We address the following four Key Questions (KQs):

- KQ 1: For patients with PsA, do drug therapies differ in their ability to reduce disease activity, to slow or limit progression of radiographic joint damage, or to maintain remission?
- KQ 2: For patients with PsA, do drug therapies differ in their ability to improve patient-reported symptoms, functional capacity, or quality of life?
- KQ 3: For patients with PsA, do drug therapies differ in harms, tolerability, adherence, or adverse effects?
- KQ 4: What are the comparative benefits and harms of drug therapies for PsA in subgroups of patients based on stage of disease, history of prior therapy, demographics, concomitant therapies, or comorbidities?

Appendix A presents our search strategy; Appendix B contains our review criteria and abstraction forms; Appendix C lists our full bibliography and the source retrieved from; Appendix D lists excluded studies; Appendix E presents evidence tables; Appendix F presents the criteria for assessing the quality of individual studies; Appendix G describes clinical assessment scales commonly used in arthritis trials; Appendix H presents the poor quality studies; and Appendix I contains our strength of evidence tables.

## Methods

In this chapter, we document the procedures that the RTI International–University of North Carolina Evidence-based Practice Center (RTI–UNC EPC) used to develop this comparative effectiveness review (CER) on pharmacologic treatments for psoriatic arthritis. We briefly describe the topic development process below. We then document our literature search and retrieval process and describe methods of abstracting relevant information from the eligible articles to generate evidence tables. We also document our criteria for rating the quality of individual studies and for grading the strength of the evidence as a whole.

### Topic Development

This report is an update of a CER completed in 2007.<sup>22</sup> The topic of the original report and the preliminary Key Questions (KQs) arose through a public process involving the public, the Scientific Resource Center (SRC, at [www.effectivehealthcare.ahrq.gov/aboutUs/index.cfm#RC](http://www.effectivehealthcare.ahrq.gov/aboutUs/index.cfm#RC)) for the Agency for Healthcare Research and Quality’s (AHRQ’s) Effective Health Care program ([www.effectivehealthcare.ahrq.gov](http://www.effectivehealthcare.ahrq.gov)), and various stakeholder groups ([www.effectivehealthcare.ahrq.gov/aboutUs/index.cfm#SG](http://www.effectivehealthcare.ahrq.gov/aboutUs/index.cfm#SG)). Investigators from the RTI–UNC EPC then refined the original questions, in consultation with AHRQ, the SRC, and the Technical Expert Panel (TEP) during multiple conference calls, into the KQs used for the original report. For this update, the KQs were again refined into the final set of KQs listed in the introduction. No substantive changes to the KQs were made for this update other than adding new medications that have been approved since the previous report. The protocol for the project was posted on the AHRQ Web site (<http://www.effectivehealthcare.ahrq.gov>). The original report included both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). When updating the material, the decision was made to divide the material into two separate reports, one for RA and one for PsA. This report includes only the information related to patients with PsA. This report is intended to replace the original report; it includes the information from the original report as well as the new information we identified.

### Literature Search

To identify articles relevant to each KQ, we searched MEDLINE<sup>®</sup>, Embase, the Cochrane Library, and the International Pharmaceutical Abstracts. The full search strategy is presented in Appendix A. We conducted this review at the same time as a review on RA; that is, we conducted the literature searches and review processes in parallel, shown in Appendix A. We used either Medical Subject Headings (MeSH or MH) as search terms when available or key words when appropriate. We combined terms for selected indications (PsA and RA), drug interactions, and adverse events with a list of included medications. We included the following medications: corticosteroids (methylprednisolone, prednisone, and prednisolone), four oral disease-modifying antirheumatic drugs (DMARDs) (methotrexate [MTX], leflunomide, sulfasalazine, and hydroxychloroquine), and nine biologic DMARDs (abatacept, adalimumab, anakinra, certolizumab pegol, etanercept, golimumab, infliximab, rituximab, and tocilizumab). We limited the electronic searches to “human” and “English language.” For the original report, sources were searched from 1980 to September 2006. For this update, sources were searched from June 2006 to January 2011. We overlapped the update search with the original search to account for delays in indexing. We used the National Library of Medicine (NLM) publication type tags to identify reviews, randomized controlled trials (RCTs), and meta-analyses. We



manually searched reference lists of pertinent review articles and letters to the editor to supplement searches for the original report. We used the Scopus abstract and citation database to supplement searches for this update. We imported all citations into an electronic database (EndNote X.0.2). Additionally, we hand-searched the Center for Drug Evaluation and Research (CDER) database to identify unpublished research submitted to the U.S. Food and Drug Administration (FDA). The SRC contacted pharmaceutical manufacturers and invited them to submit dossiers, including citations. We received dossiers from five pharmaceutical companies (Abbott, Amgen, Bristol-Myers Squibb, Centocor, and Genentech) for the original report. We received dossiers from three pharmaceutical companies (Abbott, Amgen, and Centocor) for this update. The SRC also searched the following for potentially relevant unpublished and ongoing literature: FDA Web site; Health Canada; Authorized Medicines for EU; ClinicalTrial.gov; Current Controlled Trials; Clinical Study Results; WHO Clinical Trials; Conference Papers Index; Scopus; NIH RePORTER; HSRPROJ; Hayes, Inc. Health Technology Assessment; and the New York Academy of Medicine's Grey Literature Index.

## **Study Selection**

We developed eligibility (inclusion and exclusion) criteria with respect to study design or duration, patient population, interventions, outcomes, and comparisons as described in Table 5 below. For efficacy and effectiveness, we focused on head-to-head trials and prospective observational studies comparing one drug with another. For biologic DMARDs, we also included placebo-controlled, double-blind RCTs. For safety and tolerability, as well as for efficacy and effectiveness in subgroups, we included head-to-head trials, high-quality systematic reviews, and prospective and retrospective observational studies.

For this review, results from well-conducted, valid head-to-head trials provide the strongest evidence to compare drugs with respect to efficacy, effectiveness, and harms. We defined head-to-head trials as those comparing one drug of interest with another. RCTs or prospective cohort studies of at least 3 months' duration and an adult study population were eligible for inclusion. For harms (i.e., evidence pertaining to tolerability, adverse effects, and adverse events), we examined data from both experimental and prospective and retrospective observational studies. We included RCTs (no sample size limit) and observational studies (with sample sizes  $\geq 100$  patients) that lasted at least 3 months and reported an outcome of interest.

Because equipotency among the reviewed drugs is not well established, we assumed that comparisons made within the recommended dosing ranges in the Introduction chapter are appropriate. Dose comparisons made outside the recommended daily dosing range are not in our report.

**Table 5. Outcome measures and study eligibility criteria**

Key Questions and Outcomes of Interest	Study Eligibility Criteria
<p><b>KQ 1 /KQ 2:<sup>a</sup></b>  <b>Efficacy/effectiveness</b></p> <p><b>KQ 1:</b>  Disease activity<sup>b</sup>  Radiographic joint damage  Remission</p> <p><b>KQ 2:</b>  Functional capacity  Quality of life  Patient-reported symptoms</p>	<p><b>Study Design</b></p> <ul style="list-style-type: none"> <li>• Head-to-head double-blind RCTs</li> <li>• High-quality systematic reviews</li> <li>• Prospective, controlled observational studies</li> </ul> <p><b>Minimum Study Duration</b></p> <ul style="list-style-type: none"> <li>• RCT—3 months</li> <li>• Observational—3 months</li> </ul> <p><b>Study Population</b></p> <ul style="list-style-type: none"> <li>• Ages 19 or older</li> <li>• Patients with PsA</li> </ul> <p><b>Sample Size</b></p> <ul style="list-style-type: none"> <li>• RCT no limit</li> <li>• Observational N ≥ 100</li> </ul>
<p><b>KQ 3:</b>  <b>Harms, tolerability, adherence, adverse effects</b></p>	<p><b>Study Design</b></p> <ul style="list-style-type: none"> <li>• Head-to-head double-blind RCTs</li> <li>• High-quality systematic reviews</li> <li>• Observational studies, prospective and retrospective</li> </ul> <p><b>Minimum Study Duration</b></p> <ul style="list-style-type: none"> <li>• RCT—3 months</li> <li>• Observational—3 months</li> </ul> <p><b>Study Population</b></p> <ul style="list-style-type: none"> <li>• Ages 19 or older</li> <li>• Patients with PsA</li> </ul> <p><b>Sample Size</b></p> <ul style="list-style-type: none"> <li>• RCT no limit</li> <li>• Observational N ≥ 100</li> </ul>
<p><b>KQ 4:</b>  <b>Benefits and harms in subgroups based on stage, history of prior therapy, demographics, concomitant therapies, comorbidities</b></p>	<p><b>Study Design</b></p> <ul style="list-style-type: none"> <li>• Head-to-head double-blind RCTs</li> <li>• High-quality systematic reviews</li> <li>• Observational studies</li> </ul> <p><b>Minimum Study Duration</b></p> <ul style="list-style-type: none"> <li>• RCT—3 months</li> <li>• Observational—3 months</li> </ul> <p><b>Study Population</b></p> <ul style="list-style-type: none"> <li>• Ages 19 or older</li> <li>• Patients with PsA</li> </ul> <p><b>Sample Size</b></p> <ul style="list-style-type: none"> <li>• RCT no limit</li> <li>• Observational N ≥ 100</li> </ul>

KQ = Key Question; PsA = psoriatic arthritis; RCT = randomized controlled trial

<sup>a</sup>We divided the assessment of efficacy/effectiveness into two KQs based on two groups of outcomes: those addressing disease activity, radiographic measures, and remission (KQ 1) and those addressing functional capacity, quality of life, and other patient-reported symptoms (KQ 2). We did this to group measures that are based on more objective measures under KQ 1 and those that are based more on subjective patient-reported outcomes under KQ 2.

<sup>b</sup>Disease activity reflects the overall PsA activity. Measures of disease activity, such as the Psoriasis Area and Severity Index (PASI), the Psoriatic Arthritis Response Criteria (PsARC), or the American College of Rheumatology 20 percent response (ACR 20), include assessment of some or all of the following: the number of swollen and tender joints, the patient’s global assessment of his/her disease activity, the physician’s global assessment of the patient’s disease activity, patient’s pain score, patient’s physical function score, acute phase reactants (C-reactive protein), scaling, erythema, induration, severity, and affected body surface area. Appendix G provides additional details about these measures.

Two individuals independently reviewed abstracts. If both reviewers agreed that a study did not meet eligibility criteria, we excluded it. We obtained the full text of all remaining articles and used the same eligibility criteria to determine which, if any, to exclude at this stage. We did not include studies that met eligibility criteria but were reported as an abstract only. Appendix C lists our full bibliography and their source database. Appendix D summarizes reasons for excluding studies that were reviewed as full-text articles but did not meet eligibility criteria.

We reviewed studies that reported health outcomes for efficacy or effectiveness. For example, these outcomes included clinical response to treatment, remission, functional capacity, and quality of life. In addition, we included radiographic outcomes as intermediate outcome measures. For harms, we looked for both total adverse events and specific adverse events ranging in severity (e.g., serious infections, malignancies, hepatotoxicity, hematological adverse events, infusion and injection reactions, nausea), withdrawals attributable to adverse events, and drug interactions. We included systematic reviews and meta-analyses in our evidence report if we found them to be relevant for a KQ and of good or fair methodological quality. We did not abstract individual studies if they had been used in a systematic review or meta-analysis of good quality. However, we reviewed them to determine whether any other outcomes of interest were reported.

## Data Extraction

We designed and used a structured data abstraction form to ensure consistency of appraisal for each study. Trained reviewers abstracted data from each study. A senior reviewer read each abstracted article and evaluated the completeness of the data abstraction.

We abstracted the following data from included articles: study design, eligibility criteria, intervention (drugs, dose, and duration), additional medications allowed, methods of outcome assessment, population characteristics (such as age, sex, race or ethnicity, or mean disease duration), sample size, loss to followup, withdrawals because of adverse events, results, and adverse events reported. We recorded intention-to-treat results if available. All data abstraction employed SRS 4.0, Mobius Analytics™. Evidence tables containing all abstracted data of included studies are presented in Appendix E.

## Quality Assessment

To assess the quality (internal validity) of trials, we used predefined criteria based on those developed by the U.S. Preventive Services Task Force (ratings: good, fair, poor)<sup>23</sup> and the National Health Service Centre for Reviews and Dissemination.<sup>24</sup> Elements of quality assessment included randomization and allocation concealment, similarity of compared groups at baseline, use of ITT analysis (i.e., all patients were analyzed as randomized), adequacy of blinding, and overall and differential loss to followup.

In general terms, a “good” study has a low risk of bias and results are considered to be valid. A “fair” study is susceptible to some risk of bias but probably not sufficient to invalidate its results. The fair-quality category is likely to be broad, so studies with this rating will vary in their strengths and weaknesses. A “poor” rating indicates significant risk of bias (stemming from, e.g., serious errors in design, analysis reporting a large amount of missing information, or discrepancies in reporting) that may invalidate the study’s results.

To assess the quality of observational studies, we used criteria outlined by Deeks et al.<sup>25</sup> Items assessed included selection of cases or cohorts and controls, adjustment for confounders, methods of outcomes assessment, length of followup, and statistical analysis. To assess the

quality of systematic reviews and meta-analyses, we assessed the following: whether the review was based on a clear question, clear reporting of inclusion criteria, methods used for identifying literature (the search strategy), whether two reviewers independently reviewed publications to determine eligibility, whether authors used a standard method of critical appraisal (or quality rating or validity assessment), assessment of heterogeneity, assessment of publication bias, and statistical analysis. Systematic reviews were categorized as good when all criteria were met.

Two independent reviewers assigned quality ratings. They resolved any disagreements by discussion and consensus or by consulting with a third reviewer. Appendix G details the predefined criteria used for evaluating the quality of all included studies. Studies that met all criteria were rated good quality. Studies that had a fatal flaw (defined as a methodological shortcoming that leads to a very high risk of bias) in one or more categories were rated poor quality and excluded from our analyses.

## **Applicability Assessment**

Using the parameters for evaluation in guidance provided by AHRQ's Methods Guide for Comparative Effectiveness Reviews,<sup>26</sup> we evaluated the applicability of the included studies. Applicability is similar to generalizability or external validity of the studies included in the evidence base. We evaluated applicability using a qualitative assessment of the population, intervention/treatment, comparator, outcomes measured, timing of followup, and setting. We specifically considered whether populations enrolled in these trials or studies differed from target populations as laid out in Chapter 1, whether studied interventions are comparable with those in routine use, whether comparators reflect best alternatives, whether measured outcomes reflect the most important clinical outcomes, whether followup was sufficient, and whether study settings were representative of most settings.

## **Grading Strength of Evidence**

We evaluated the strength of evidence based on methods guidance for the EPC program.<sup>26, 27</sup> For this report, we graded the strength of evidence for the outcomes determined to be most important: measures of disease activity (e.g., Psoriasis Area and Severity Index-PASI, Disease Activity Score-DAS, Psoriasis Arthritis Response Criteria-PsARC), radiographic changes, functional capacity, quality of life, withdrawals due to adverse events, and specific adverse events if data were available (e.g., injection-site reactions, infections, malignancy). Because no head-to-head trials were identified, we graded the strength of evidence for each of the included medications compared with placebo. The strength of evidence for each outcome or comparison that we graded incorporates scores on four domains: risk of bias, consistency, directness, and precision; it can also reflect ratings for other domains that can be factored in when relevant (e.g., dose-response relationships).

As described in Owens et al.,<sup>27</sup> the evaluation of risk of bias includes assessment of study design and aggregate quality of studies. We judged good quality studies to result in evidence with low risk of bias. We graded evidence as consistent when effect sizes across studies were in the same direction. When the evidence linked the interventions directly to health outcomes, we graded the evidence as being direct. We graded evidence as being precise when results had a low degree of uncertainty. A precise estimate is an estimate that would allow a clinically useful conclusion. An imprecise estimate is one for which the confidence interval is wide enough to include clinically distinct conclusions.<sup>27</sup>

We dually evaluated the overall strength of evidence for each major outcome based on a qualitative assessment of strength of evidence for each domain and reconciled all disagreements. The levels of strength of evidence are shown in Table 6.

**Table 6. Strength of evidence grades and their definitions**

Grade	Definition
High	High confidence that the evidence reflects the true effect. Further research is very unlikely to change our confidence in the estimate of effect.
Moderate	Moderate confidence that the evidence reflects the true effect. Further research may change our confidence in the estimate of effect and may change the estimate.
Low	Low confidence that the evidence reflects the true effect. Further research is likely to change our confidence in the estimate of effect and is likely to change the estimate.
Insufficient	Evidence either is unavailable or does not permit estimation of an effect.

Source: Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions—agency for healthcare research and quality and the effective health-care program. *J Clin Epidemiol.* 2010 May;63(5):513-23.<sup>27</sup>

## Data Synthesis

Throughout this CER we synthesized the literature qualitatively because there were too few studies for each of the comparisons of interest to justify combining them in quantitative analyses. We constructed tables showing the study characteristics, quality ratings, and main results for all included studies.


## Peer Review

This CER underwent external peer review from individuals who were experts in rheumatology and from various stakeholder and user communities (listed in the Front Matter). The SRC oversaw the peer-review process. Peer reviewers were charged with commenting on the content, structure, and format of the evidence report; providing additional relevant citations; and pointing out issues related to how we had conceptualized and defined the topic and KQs. Our peer reviewers, also Technical Expert Panel members, gave us permission to acknowledge their review of the draft. We compiled all comments and addressed each one individually, revising the text as appropriate. AHRQ and the SRC also requested review from its own staff.

# Results

Figure 1 documents the results of the literature search (Appendix A). We included 24 published articles reporting on 16 studies: 0 head-to-head randomized controlled trials (RCTs), 0 head-to-head nonrandomized controlled trials, 10 placebo-controlled trials, 3 meta-analyses or systematic reviews, and 3 observational studies. Our findings include studies rated good or fair for internal validity. Most studies were of fair quality; we designate in the text only those of good quality. Evidence tables for included studies can be found in Appendix E.

**Figure 1. Disposition of articles (PRISMA figure)\***



KQ = Key Question; n = number of studies; PRISMA = Preferred Reporting Items for Systematic Reviews and Meta-Analyses  
\*The first number listed includes all references identified in both the original and update reports. The number in parentheses indicates references identified in the update report only.

Note: Number of included articles differs from number of included studies because some studies have multiple publications.

We included articles based on eligibility criteria or methodological criteria (quality rating) as explained in the Methods chapter.

Of the 16 included studies, 8 (50 percent) were supported by pharmaceutical companies; 4 (25 percent) were funded by governmental or independent funds; 3 (19 percent) were supported by a combination of pharmaceutical and government funding; and 1 did not report the funding source (6 percent).

This chapter is organized by Key Question (KQ). When comparative evidence is available, we discuss it before presenting placebo controlled trials. Generally, the chapter is organized by oral DMARD comparisons followed by biologic DMARD comparisons.

Across all KQs, we have included head-to-head studies, observational studies, and systematic reviews. When comparative evidence is available, we discuss it before presenting placebo-controlled trials. Table 7 gives the numbers of trials or studies for drug class comparisons; when some groupings have important subcomparisons, we note these. We do not, however, offer an exhaustive list of all possible comparisons among corticosteroids, oral DMARDs, and biologic DMARDs simply because of the sheer number of potential combinations of drugs within classes and across classes, which cannot be clearly and concisely presented here.

**Table 7. Number of trials or studies by drug comparison and study design for psoriatic arthritis**

Drug Comparison	Number of Studies; Study Design
Oral DMARDs vs. placebo	1 SR, 2 RCTs
Biologic DMARDs vs. placebo	1 SR, 8 RCTs
Oral DMARDs vs. Oral DMARDs	0
Biologic DMARDs vs. biologic DMARDs	1 OS
Biologic DMARDs vs. oral DMARDs	0
Biologic DMARDs + oral DMARDs vs. biologic DMARDs	2 OS
Biologic DMARDs + oral DMARDs vs. oral DMARDs	1 SR

DMARD = disease modifying anti-rheumatic drug; vs. = versus; SR = systematic review; RCT = randomized controlled trial; OS = observational study

Table 8 lists abbreviations and full names of diagnostic scales and health status or quality-of-life instruments encountered in these studies, as well information about clinical significance when available. For further details about such instruments and scales, see Appendix G.

**Table 8. Disease activity, radiographic progression, functional capacity, and quality-of-life measures**

Abbreviated Name	Complete Name of Measure or Instrument	Range of Scores	Improvement Denoted by	Clinically Significant Improvement
ACR-N	American College of Rheumatology percent improvement from baseline to endpoint	0 to 100 percent	Increase	--
ACR 20/50/70*	American College of Rheumatology response scores based on 20, 50, or 70 percent criteria for improvement	0 to 100 percent	Increase	ACR 20 is 20% minimal improvement ;ACR 50/70 considered more clinically significant <sup>28</sup>
ASHI	Arthritis-Specific Health Index (Medical Outcomes Study Short Form SF-36 Arthritis-specific Health Index)	0 to 100	Increase	--

**Table 8. Disease activity, radiographic progression, functional capacity, and quality-of-life measures (continued)**

Abbreviated Name	Complete Name of Measure or Instrument	Range of Scores	Improvement Denoted by	Clinically Significant Improvement
DAS*	Disease Activity Score	0 to 10	Decrease	DAS <1.6 correlates with remission <sup>28, 29</sup>
DAS 28	Disease Activity Score Short Form	0 to 10	Decrease	DAS28 <2.6 correlates with remission <sup>28, 30</sup>
DLQI	Dermatology Life Quality Index	0 to 30	Decrease	--
EQ-5D*	EuroQol EQ-5D Quality of Life Questionnaire	0 to 1	Increase	--
EULAR response	European League Against Rheumatism response	N/A	N/A	--
HAQ* (D-HAQ)	Health Assessment Questionnaire (Dutch Version)	0 to 3	Decrease	HAQ $\geq$ 0.22 change <sup>31</sup>
HAQ-DI	Disability Index of the Health Assessment Questionnaire	0 to 3	Decrease	--
PASI*	Psoriasis Area and Severity Index	0 to 72	Decrease	Improvement needs to be at least 50% (used to be 75% but has since been lowered <sup>32</sup> )
PsARC*	Psoriatic Arthritis Response Criteria	0 to 100 percent	Increase	Has not been assessed to be clinically significant <sup>33</sup>
SF-36*	Medical Outcomes Study Short Form 36 Health Survey	0 to 100	Increase	SF36 physical or mental component two standard error of the mean (SEM) <sup>34-37</sup>
SHS*	Sharp/van der Heijde Method (SHS) for Scoring Radiographs (SHS is frequently modified by individual authors to meet study requirements and needs; there is no standard modified SHS)	Erosion: 0 to 160 for hands; 0 to 120 for feet Joint space narrowing: 0 to 168 Total: 0 to 448	Decrease	Changes in joint damage around the level of 5 units of the Sharp/van der Heijde method as minimal clinically important <sup>38</sup>

\* These key scales are defined in Appendix G.

-- Less commonly used measures for which there is sparse data regarding what constitutes a clinically significant improvement.

## KQ 1: Reductions in Disease Activity, Limitations of Disease Progression, and Maintenance of Remission

KQ 1 concerned three main topics. Specifically, “for patients with psoriatic arthritis, do drug therapies differ in their ability to reduce disease activity, to slow or limit progression of radiographic joint damage, or to maintain remission?” We use the term *disease activity* to refer to condition-specific measures such as the Psoriasis Area and Severity Index (PASI), the Psoriatic Arthritis Response Criteria (PsARC), or the American College of Rheumatology (ACR) response. Strength of evidence is presented, and additional tables provide selected study-specific information on outcomes, broken out by primary outcomes and radiologic outcomes. Evidence Tables in Appendix E document details about all these studies.



## Overview

A total of nine placebo-controlled randomized controlled trials (RCTs), two observational studies, and three systematic reviews or meta-analyses examined symptom response, radiographic joint damage, and remission. The main drug classes compared included oral disease-modifying antirheumatic drugs (DMARDs), biologic DMARDs (also referred to simply as biologics), and combined strategies. Overall strength of evidence is listed in Appendix I. When possible, we describe whether treatment effects reach minimal clinically important differences (MCIDs). In this section, achieving at least an ACR of 20 or above or a PASI of at least 50 percent improvement is considered minimally clinically important (Table 8).

### Oral DMARD Versus Oral DMARD

We did not find any studies meeting our criteria for inclusion.

### Oral DMARD Versus Placebo

Evidence from one 12-week study provides low strength of evidence that parenteral high-dose methotrexate (MTX) improves physician assessment of disease severity, compared with placebo (median change 1 vs. 0;  $P=0.001$ ).<sup>39</sup> The MCID cannot be determined from this comparison.

One systematic review found that, compared with placebo, sulfasalazine improved patient outcomes (pooled index of variables in the OMERACT: 0.38 units; 95% CI, 0.21 to 0.54).<sup>40</sup> The MCID cannot be determined from this comparison.

Evidence from one 24-week trial provides low strength of evidence that leflunomide patients experienced improved disease activity compared with those in the placebo arm (PsARC primary outcome 58.9 percent vs. 29.7 percent,  $P<0.0001$ ).<sup>41, 42</sup> The strength of evidence is low. Improvements in additional outcomes including ACR 20 did reach MCID, but the PASI did not.

### Biologic DMARD + Oral DMARD Versus Biologic DMARD

We did not find any head-to-head controlled trials for any of the included drugs, but two observational cohort studies provide some evidence. One cohort study compared the combination of an anti-tumor necrosis factor (TNF) (adalimumab, etanercept, or infliximab) with MTX versus anti-TNF only and found no difference in treatment response.<sup>43</sup> Another cohort study compared adalimumab, etanercept, and infliximab and found no differences in efficacy among the groups.<sup>44</sup> The strength of evidence is low.

### Biologic DMARD + Oral DMARD Versus Oral DMARD

A systematic review provided low strength of evidence of a comparison between TNF inhibitors (adalimumab, etanercept, and infliximab) compared with sulfasalazine and found that the TNF inhibitors were relatively effective and had the largest effect size (risk ratio: 0.25, 95% CI, 0.13 to 0.48), and sulfasalazine was moderately effective (risk ratio: 0.45, 95% CI, 0.23 to 0.89).<sup>45</sup> The MCID cannot be determined from this comparison.

### Biologic DMARD Versus Placebo

The use of four biologics—adalimumab, etanercept, golimumab, and infliximab—provided low to moderate evidence of improved disease activity compared with placebo.<sup>46-54</sup> The magnitude of benefit for ACR 20 ranged from 39 percent to 57 percent for adalimumab, 59

percent to 65 percent for etanercept, 45 percent to 51 percent for golimumab, and 58 percent to 62 percent for infliximab.

## **Psoriatic Arthritis: Detailed Analysis**

### **Oral DMARD Versus Oral DMARD**

We did not find any studies meeting our criteria for inclusion. We did not identify any studies meeting our inclusion/exclusion criteria that examined the use of corticosteroids in the treatment of psoriatic arthritis (PsA). Because of the paucity of head-to-head trials, we additionally reviewed placebo-controlled trials to summarize the general efficacy of oral and biologic DMARDs. Summarizing the general efficacy, however, does not provide evidence on the comparative efficacy and tolerability of treatments for PsA.

### **Oral DMARD Versus Placebo**

One systematic review examined the efficacy of oral DMARDs used in placebo-controlled trials.<sup>40</sup> The investigators used data from 13 RCTs that included 1,022 adults with PsA in a meta-analysis that focused on comparisons of sulfasalazine, auranofin, etretinate, fumaric acid, intramuscular injection of gold, azathioprine, efamol marine, and MTX with placebo (Table 9). Two drugs (MTX and sulfasalazine) are of interest for our report. The primary outcome measure included individual component variables validated by the Outcome Measures in Rheumatology Clinical Trials (OMERACT) to create a pooled index; components used include acute phase reactants, disability, pain, patient global assessment, physician global assessment, swollen joint count, tender joint count, and radiographic changes of joints in any trial of 1 year or longer. The primary outcome was change in a pooled disease index.

### **Methotrexate**

One multicenter 12-week RCT (N=37),<sup>39</sup> included in the systematic review described above, compared MTX (weekly dose of 7.5 mg to 15 mg) with placebo. The study reported some improvement in PsA as measured by change in grip strength, morning stiffness, and patient assessment in the drug treatment group, but statistically significant improvement compared with placebo occurred only in physician assessment of disease severity ( $P=0.001$ ); there were no differences between groups in joint swelling or pain/tenderness. Psoriatic skin lesions showed no significant changes in scaling, induration, or erythema from entry appearance, but surface area involvement improved significantly compared with placebo ( $P=0.039$ ) in 14 of the MTX patients assessed (Table 9). The systematic review used this single study comparing MTX with placebo to calculate an overall improvement in the OMERACT index of 0.65 units (95% CI, 0.00 to 1.30).<sup>40</sup> The MCID cannot be determined.

### **Sulfasalazine**

The investigators pooled six trials involving comparisons of sulfasalazine (average dose of 2 g/day to 3 g/day) with placebo (N=564). Sulfasalazine showed an improvement in the pooled index of 0.38 units (95% CI, 0.21 to 0.54).<sup>40</sup> The MCID cannot be determined.

**Table 9. Disease activity of oral DMARD versus placebo**

Study	Study Design N Duration	Study Population	Comparison (dose)	Results of Primary Outcome Measure	Quality Rating
Jones et al., 2000 <sup>40</sup>	Systematic review and meta-analysis 1,022	Active PsA, concomitant MTX NR	SSZ vs. placebo (6 RCTs)	Change in pooled index: SSZ 0.38 units (95% CI, 0.21 to 0.54)	Good
Willkens et al., 1984 <sup>39</sup>	RCT 37 12 weeks	Active PsA, MTX naive	MTX (7.5 mg-15 mg/week vs. placebo)	Median change in physician assessment of disease severity: MTX, 1 vs. placebo, 0 ( $P=0.001$ )	Fair
Kaltwasser et al., 2004 <sup>41, 42</sup>	RCT 190 24 weeks	Active PsA, failed at least one DMARD, concomitant MTX 0%	LEF (100 mg/day 3 days then 20 mg/day) vs. placebo	PsARC at week 24: LEF 58.9% vs. placebo 29.7% ( $P<0.0001$ )	Fair

CI = confidence interval; DMARD = disease-modifying antirheumatic drug; LEF = leflunomide; mg = milligram; MTX = methotrexate; NR = not reported; PsA = psoriatic arthritis; PsARC = Psoriatic Arthritis Response Scale; RCT = randomized controlled trial; SSZ = sulfasalazine; vs. = versus

## Leflunomide

One trial (two publications) evaluated the efficacy of leflunomide against placebo in 190 patients over 24 weeks;<sup>41, 42</sup> PsA was defined as having at least three swollen joints and three tender or painful joints and psoriasis over at least 3 percent of the body surface area. In this study, almost 50 percent of the patients were DMARD naive. Patients who were not DMARD naive were required to discontinue all oral DMARDs as well as biologic agents and investigational drugs 28 days before baseline.

The leflunomide group had significantly greater improvements in measures of disease activity than the placebo group. These improvements included response rates on a modified ACR 20 (36.3 percent vs. 20 percent;  $P=0.014$ ), the PsARC (achieved in 58.9 percent vs. 29.7 percent;  $P=0.0001$ ), and the PASI (17.4 percent vs. 7.8 percent reached threshold;  $P=0.048$ ). The ACR 20 did reach MCID, but the PASI did not.

## Biologic DMARD + Oral DMARD Versus Biologic DMARD

One retrospective cohort (N=261) of anti-TNF naive patients with active PsA in Sweden compared patients taking MTX concomitant with anti-TNF (adalimumab—40 mg every other week; etanercept—25 mg twice a week; or infliximab—3 mg/kg at 0, 2, and 6 weeks and then every 8 weeks) versus anti-TNF alone.<sup>43</sup> Eligible patients had active PsA with high disease activity and/or unacceptably high steroid use. Over 12 months, there were no significant differences in European League Against Rheumatism response (EULAR) good or EULAR overall between patients taking MTX with anti-TNF compared with anti-TNF only, see Table 10.

Also in Table 10 is the second cohort study, conducted in Great Britain, that found no significant differences in EULAR response rates at six ( $P=0.679$ ), 12 ( $P=0.904$ ), and 18 ( $P=0.583$ ) months between the three anti-TNF therapies of adalimumab, etanercept, and infliximab.<sup>44</sup> Furthermore, EULAR response rates for the whole anti-TNF cohort were similar in patients receiving anti-TNF agents in combination with MTX (78.1 percent at 6 months), another DMARD (73.3 percent), or anti-TNF monotherapy (79.5 percent).<sup>44</sup>

**Table 10. Disease activity of biologic DMARD + oral DMARD versus biologic DMARD**

Study	Study Design N Duration	Study Population	Comparison (Dose)	Results of Primary Outcome Measure	Quality Rating
Kristensen et al., 2008 <sup>43*</sup>	Cohort 261 12 months	Active PsA, anti-TNF naïve, concomitant MTX 62%	ADA (40 mg every other week) or ETN (25 mg twice a week) or INF (3 mg/kg at 0, 2, 6 weeks, then every 8th week) + MTX (median—15 mg/week) vs. monotherapy with ADA, ETN, or INF	No difference in anti-TNF + MTX vs. anti-TNF only (data NR)	Fair
Saad et al., 2010 <sup>44</sup>	Cohort 596 18 months	Patients with PsA, mean disease duration varied	ETN 25 mg twice weekly or 50 mg once weekly; ADA 40 mg every 2 weeks; INF 5 mg/kg administered at weeks 0, 2, 6, and 8 and then every 8 weeks	No difference in anti-TNF MTX vs. anti-TNF	Fair

ADA = adalimumab; DMARD = disease-modifying antirheumatic drug; ETN = etanercept; INF = infliximab; kg = kilogram; mg = milligram; MTX = methotrexate; NR = not reported; PsA = psoriatic arthritis; TNF = tumor necrosis factor; vs. = versus  
\*New study added since last review.

## Biologic DMARD + Oral DMARD Versus Oral DMARD

One systematic review, as seen in Table 11, included an analysis of TNF inhibitors and sulfasalazine for the treatment of PsA and examined efficacy as defined by the number of patients that withdrew because of lack of effect.<sup>45</sup> The TNF inhibitors analysis included five studies with 882 patients and found that the risk ratio for efficacy was 0.25 (95% CI, 0.13 to 0.48). The analysis of sulfasalazine found that the risk ratio for efficacy was 0.45 (95% CI, 0.23 to 0.89). The MCID cannot be determined from this comparison.

**Table 11. Disease activity of biologic DMARD + oral DMARD versus sulfasalazine**

Study	Study Design N Duration	Study Population	Comparison (Dose)	Results of Primary Outcome Measure	Quality Rating
Ravindran et al., 2008 <sup>45</sup>	Meta-analysis NR	Patients with PsA, mean disease duration varied	TNF inhibitors as a class vs. sulfasalazine	TNF inhibitors were relatively effective and sulfasalazine was moderately effective	Fair

DMARD = disease-modifying antirheumatic drug; NR = not reported; PsA = psoriatic arthritis; TNF = tumor necrosis factor; vs. = versus

## Biologic DMARD Versus Placebo

Seven RCTs (11 articles) and 1 systematic review examined the efficacy of biologics against placebo in treating patients with PsA (Table 12).<sup>46-56</sup> Two trials were of adalimumab, 2 of etanercept, 3 of infliximab, and 1 of golimumab. All trials allowed patients to continue an oral DMARD, usually MTX. The systematic review examined etanercept and infliximab versus placebo.<sup>55</sup> All showed that the use of biologics led to significantly better outcomes than placebo.

**Table 12. Disease activity in biologic DMARD versus placebo**

Study	Study Design N Duration	Study Population	Comparison (Dose)	Results of Primary Outcome Measure	Quality Rating
<b>Adalimumab vs. Placebo</b>					
Genovese et al., 2007 <sup>56*</sup>	RCT 102 12 weeks	Active PsA, failed at least one DMARD, concomitant MTX 46%	ADA (40 mg every other week) vs. placebo	ACR 20 at week 12: ADA 39% vs. placebo 16% ( $P=0.012$ )	Fair
Mease et al., 2005 ADEPT Trial <sup>46</sup>	RCT 313 24 weeks	Active PsA, failed at least one DMARD, concomitant MTX 51%	ADA (40 mg every other week) vs. placebo	ACR 20 at week 24: ADA 57% vs. placebo 15% ( $P<0.001$ ) Mean change in the modified total Sharp score at week 24: ADA -0.2 vs. placebo 1.0 ( $P<0.001$ ) Erosion scores (mean change): ADA 0.0 vs. placebo 0.6 Joint space narrowing scores (mean change): ADA -0.2 vs. placebo 0.4 ( $P<0.001$ for both)	Fair
<b>Etanercept vs. Placebo</b>					
Woolacott et al., 2006 <sup>55</sup>	Systematic review and meta-analysis 369	Adults with PsA, concomitant MTX 46% to 56%	ETN (25 mg twice a week) vs. placebo (two studies)	ACR 20 at week 12: ETN 65% vs. placebo NR (RR, 4.19 [95% CI, 2.74 to 6.42])	Good
Mease et al., 2000 <sup>47</sup>	RCT 60 12 weeks	Active PsA, failed at least one DMARD, concomitant MTX use 47%	ETN (25 mg twice a week) vs. placebo	PsARC at week 12: ETN 87% vs. placebo 23% ( $P<0.0001$ )	Fair
Mease et al., 2004 <sup>48</sup> Mease et al., 2004 <sup>49</sup>	RCT 205 24 weeks (with additional 48 weeks open label)	Active PsA, failed at least one DMARD, concomitant MTX 47%	ETN (25 mg twice a week) vs. placebo	ACR 20 at week 24: ETN 59% vs. placebo 15% ( $P<0.001$ ) Mean annualized rate of change over 1 year of treatment in modified Sharp score: ETN -0.03 unit vs. placebo 1.00 unit ( $P=0.0001$ )	Fair
<b>Golimumab vs. Placebo</b>					
Kavanaugh, 2009 <sup>54</sup> GO-REVEAL*	RCT 405 14 weeks <sup>a</sup>	Active PsA, failed at least one DMARD or NSAID, concomitant MTX 35%	GOL (50 mg every 4 weeks), GOL (100 mg every 4 weeks) vs. placebo	ACR 20 at week 14: GOL 50 mg 51%, GOL 100 mg 45%, placebo 9% ( $P<0.001$ )	Good
<b>Infliximab vs. Placebo</b>					
Woolacott et al., 2006 <sup>55</sup>	Systematic review and meta-analysis 369	Adults with PsA, concomitant MTX 46% to 56%	INF (5 mg/kg) vs. placebo (one study)	ACR 20 at weeks 14–16: INF 62% vs. placebo NR (RR, 5.75; 95% CI, 3.55 to 9.30)	Good

**Table 12. Disease activity in biologic DMARD versus placebo (continued)**

Study	Study Design N Duration	Study Population	Comparison (Dose)	Results of Primary Outcome Measure	Quality Rating
Antoni et al., 2005 IMPACT Study <sup>50, 51</sup>	RCT 104 50 weeks (16 blinded, 34 open-label)	Active PsA, failed at least one DMARD or NSAID, concomitant MTX 56%	INF (5 mg/kg at weeks 0, 2, 6, 14 then every 8 weeks) vs. placebo <sup>b</sup> 71% received a concomitant DMARD	ACR 20 at week 16: INF 65.4% vs. placebo 9.6% ( $P<0.001$ )	Fair
Antoni et al., 2005 IMPACT 2 Study <sup>52, 53</sup> Vander Heijde et al., 2007 <sup>57*</sup>	RCT 200 54 weeks (at week 16, patients could enter early escape and be reassigned from placebo to INF if not improving; all placebo subjects crossed over to INF at week 24)	Active PsA, failed at least one DMARD, concomitant MTX 46%	INF (5 mg/kg at weeks 0, 2, 6, 14, 22) vs. placebo <sup>c</sup> 46% received concomitant MTX	ACR 20 at week 14: INF 58% vs. placebo 11% ( $P<0.001$ ) Mean change in total Sharp/van der Heijde score at week 24: ADA -0.70 +/- 2.53 (SD) vs. placebo 0.82 +/- 2.62 ( $P<0.001$ )	Fair

ACR 20 = American College of Rheumatology 20 percent improvement from baseline to endpoint; ADA = adalimumab; ADEPT = Adalimumab Effectiveness in Psoriatic Arthritis Trial; DMARD = disease-modifying antirheumatic drug; ETN = , etanercept; GOL = golimumab; IMPACT = Infliximab Multinational Psoriatic Arthritis Controlled Trial; INF =, infliximab; kg = kilogram; mg = milligram; MTX = methotrexate; NR = not reported; PsA = psoriatic arthritis; PsARC = Psoriatic Arthritis Response Scale; RCT = randomized controlled trial; RR = relative risk

\*New studies since last review.

<sup>a</sup>GO-REVEAL is planned to continue through 5 years; results have been published through week 24.

<sup>b</sup>INF 5 mg/kg or placebo at weeks 0, 2, 6, and 14, followed by open-label treatment with INF 5 mg/kg every 8 weeks.

<sup>c</sup>Placebo-treated patients with <10% improvement could cross over to INF 5 mg/kg at week 16. All remaining placebo patients crossed over to receive INF at weeks 24, 26, 30, 38, and 46. INF patients with <20% improvement received INF 10 mg/kg at weeks 38 and 46.

## Adalimumab

Two RCTs examined the use of adalimumab (40 mg every other week) in patients suffering from moderate to severe PsA (defined as having at least three swollen joints and three tender or painful joints) who had an inadequate response or intolerance to nonsteroidal anti-inflammatory drug (NSAID) therapy<sup>46</sup> or previous oral DMARD therapy.<sup>56</sup> Patients were allowed to continue current MTX therapy as long as the dose had been stable for 4 weeks. In the first study,<sup>46</sup> the double-blind phase of the study lasted 24 weeks, but patients who failed to achieve at least a 20 percent decrease in both swollen and tender joint counts on two consecutive visits could receive rescue therapy with corticosteroids or oral DMARDs. A significantly higher percentage of the adalimumab group met ACR 20/50/70 response criteria than the placebo group (all  $P<0.001$ ). According to the PsARC, 60 percent of the adalimumab group and 23 percent of the placebo group responded ( $P=NR$ ). PASI 75 was achieved by 59 percent of the adalimumab group and 1 percent of the placebo group ( $P<0.001$ ). At 24 weeks, the changes in the modified Sharp score, erosion score, and joint space narrowing score were significantly less in adalimumab-treated than placebo-treated patients ( $P=0.001$ ). The second trial<sup>56</sup> randomized 102 patients for 12 weeks and

similarly found a higher percentage of patients meeting ACR 20 at week 12 compared with placebo (39 vs. 16 percent,  $P=0.012$ ).<sup>56</sup>

## **Etanercept**

Two RCTs examined the efficacy of etanercept (25 mg twice weekly by subcutaneous injections) in a total of 265 patients with active PsA who were not adequately responding to conventional DMARD therapies.<sup>47, 48</sup> In both studies, patients were allowed to continue MTX therapy as long as the dose had been stable for 4 weeks before entry into the study. One study lasted 12 weeks ( $N=60$ );<sup>47</sup> the other ( $N=205$ ) was double-blinded for 24 weeks.<sup>48</sup> In both studies, the proportions of patients on etanercept meeting ACR 20 response criteria were significantly higher than those for patients on placebo. In the 12-week study, 87 percent of patients on etanercept and 23 percent of those on placebo achieved a PsARC response ( $P<0.0001$ ).<sup>47</sup> The 24-week study had similar results at 12 weeks: 72 percent of patients on etanercept and 31 percent of those on placebo achieved a PsARC response ( $P=NR$ ).<sup>48</sup> PASI 75 criteria were met by a greater proportion of patients in the etanercept groups than in the placebo groups in both studies. In the 12-week study, 26 percent of patients on etanercept met PASI 75 criteria versus zero patients on placebo ( $P=0.015$ ); in the longer study, the figures were 23 percent on etanercept versus 3 percent on placebo ( $P<0.001$ ). The longer study assessed the radiographic progression of disease at 24 weeks in 205 patients; the mean annualized change in the modified Sharp score was significantly lower in etanercept-treated patients (decrease of  $-0.03$ ) than in placebo-treated patients (increase of  $1.0$ ;  $P=0.0001$ ).<sup>49</sup>

A systematic review pooled the 12-week data from these two studies; the ACR 20 threshold for improvement was achieved by 65 percent of the etanercept groups (placebo NR), with a pooled relative risk of 4.19 (95% CI, 2.74 to 6.42) compared with placebo.<sup>55</sup> The ACR 50 and ACR 70 criteria were achieved by 45 percent and 12 percent of those treated with etanercept, respectively. In addition, the PsARC was reached by almost 85 percent, with a pooled relative risk of 2.6 (95% CI, 1.96 to 3.45) compared with placebo (placebo NR).<sup>55</sup>

## **Golimumab**

One 14-week RCT of 405 patients with active PsA compared golimumab (50 mg every 4 weeks or 100 mg every 4 weeks) with placebo.<sup>54</sup> At 14 weeks, all patients on either golimumab dose achieved a higher ACR 20 when compared with placebo (48 percent vs. 9 percent,  $P<0.001$ ). Significantly greater improvements were also noted for those treated with golimumab for 75 percent improvement in the PASI (40 percent in the 50 mg group, 58 percent in the 100 mg group, and 3 percent in the placebo group;  $P<0.001$ ).

## **Infliximab**

Two RCTs (five articles) of infliximab compared with placebo included a total of 304 patients with active PsA who had not adequately responded to conventional DMARD therapies.<sup>50-53, 57</sup> In both studies, patients were allowed to continue MTX therapy as long as the dose had been stable for 4 weeks before study entry. One RCT ( $N=104$ ) was double-blinded for 16 weeks.<sup>50</sup> The other RCT was double-blinded for 24 weeks ( $N=200$  patients with cross-over allowed at week 16 for nonresponders); the primary outcomes were evaluated at 14 weeks and before any crossover.<sup>52</sup> Both studies had the same dosing regimen of 5 mg/kg of infliximab at weeks 0, 2, 6, and 14; the longer study had an additional infusion at week 22. In both studies, the percentages meeting ACR 20 response criteria were significantly greater for subjects treated with

infliximab than for those treated with placebo. In the shorter study, 75 percent of the patients on infliximab and 21 percent on placebo achieved a PsARC response ( $P<0.001$ ). The longer study had similar results in patients achieving a PsARC response at 14 weeks: 77 percent of the patients on infliximab and 27 percent on placebo ( $P<0.001$ ). PASI 75 was achieved by a greater proportion of patients in the infliximab groups than the placebo groups in both studies: for the 16-week study, 68 percent on infliximab versus zero on placebo ( $P<0.01$ ) and, for the later study, 50 percent on infliximab versus 1 percent on placebo ( $P<0.001$ ). Radiographic changes were also less at 24 weeks (Sharp/van der Heijde (-0.70+/-2.53 vs. 0.82+/-2.62,  $P<0.001$ ).<sup>57</sup>

A systematic review described above in the etanercept studies<sup>55</sup> pooled the 14- and 16-week data from these two infliximab studies;<sup>50, 52</sup> the ACR 20 threshold for improvement was achieved by 62 percent of the etanercept groups (placebo NR), with a pooled relative risk of 5.75 (95% CI, 3.55 to 9.30) compared with placebo.<sup>55</sup> In addition, the PsARC was reached by almost 76 percent, with a pooled relative risk of 3.05 (95% CI, 2.29 to 4.08) compared with placebo (placebo NR).<sup>55</sup>

## KQ 2: Functional Capacity and Quality of Life

KQ 2 specifically examined the issue of whether, for patients with psoriatic arthritis (PsA), drug therapies differed in their ability to improve patient-reported symptoms, functional capacity, or quality of life. Findings are organized as for KQ 1. Table 7 lists the abbreviated and full names of all instruments and scales referred to in this chapter. Functional capacity, functional status, and functional ability are three concepts often used interchangeably to refer to similar capabilities. Quality of life is a far broader construct comprising physical health; mental or emotional health; a variety of symptom states (e.g., pain, fatigue); and coping, spiritual, and other domains. For the purposes of this report, we divided outcomes into functional capacity and health-related quality of life. We use the terms *functional capacity*, *functional status*, or *functional ability* to refer to condition-specific measures, such as the Health Assessment Questionnaire (HAQ), developed to assess function in patients with PsA or other types of arthritis. We use *health-related quality of life* when referring to generic measures, such as the Medical Outcomes Study Short Form 36 Health Survey (SF-36), that have been developed to assess quality of life in both healthy people and those with different conditions; we also use health-related quality of life when referring to measures developed to assess quality of life for a specific condition or group of conditions, such as the Dermatology Life Quality Index (DLQI), a quality-of-life instrument for dermatologic diseases. We attempted to use terminology consistent with reporting from individual studies; if the authors used the term *functional ability* rather than *functional capacity*, we used the same term. Outcomes for functional capacity and health-related quality of life were often secondary outcomes in these studies; that is, studies were not all designed to detect a difference between groups for these types of outcomes.

## Overview

A total of eight RCTs examined functional capacity or quality of life in patients being treated for PsA. Details are found in the Evidence Tables in Appendix E. Tables 12 and 13 provide information on comparisons made, quality-of-life outcomes, and quality ratings. Conclusions are limited because we found no good or fair quality head-to-head studies. The available studies are all placebo-controlled studies evaluating the efficacy of one oral disease-modifying antirheumatic drug (DMARD) or one biologic DMARD. In total, we found one study (two



articles) comparing an oral DMARD with placebo<sup>41, 42</sup> and seven studies comparing a biologic DMARD with placebo. Overall results and strength of evidence are described in Appendix H.

Small differences in outcome measures may be statistically significant, yet clinically unimportant. Therefore, in the text below, we describe whether treatment effects reach minimal clinically important differences (MCIDs) for the HAQ and SF-36, the two most commonly reported outcome measures in KQ2. For the HAQ, we considered a change of  $\geq 0.22$  to be an MCID.<sup>31</sup> For the SF-36, some have suggested an improvement of 3 to 5 for the MCID.<sup>35, 58</sup> We found no published PsA ranges but found some developed using data from clinical trials of RA patients that suggest slightly lower values, with ranges of 2.6 to 4.4 for the physical component score (PCS) and 2.2 to 4.7 for the mental component score (MCS).<sup>34</sup> We used these lower ranges to take a conservative approach on what might be an MCID.

## Head-to-Head Evidence

We did not find any head-to-head studies meeting our inclusion/exclusion criteria.

### Oral DMARD Versus Placebo

Evidence from one 24-week study provides a low strength of evidence that patients treated with leflunomide had statistically significant greater improvement in functional capacity (mean change in HAQ: -0.19 vs. -0.05;  $P=0.027$ ) and quality-of-life outcomes (mean change in DLQI: -1.9 vs. -0.2;  $P=0.017$ ) than those treated with placebo.<sup>41, 42</sup> However, the improvement in functional capacity did not reach the MCID (change of  $\geq 0.22$ ).

### Biologic DMARD Versus Placebo

Evidence from seven studies comparing either adalimumab (two studies),<sup>46, 56, 59</sup> etanercept (two studies),<sup>47-49, 60</sup> golimumab (one study),<sup>54</sup> or infliximab (two studies)<sup>50-53, 61</sup> with placebo provides a low to moderate strength of evidence for the efficacy of each of these biologic DMARDs for improving functional capacity and quality of life. The magnitude of benefit in functional capacity reached the MCID (HAQ change of  $\geq 0.22$ ) for all but one study of adalimumab (which found a between-group difference of 0.2).<sup>56</sup> Overall, the magnitude of benefit for functional capacity (between-group difference for improvement in HAQ) ranged from 0.2 to 0.3 for adalimumab, 0.5 to 1.1 for etanercept, 0.34 to 0.4 for golimumab, and 0.4 to 0.6 for infliximab.

The magnitude of benefit in quality of life reached the MCID for the PCS for all five studies that reported the PCS and ranged from 2.9 to 7.9 for adalimumab, was 8.6 for etanercept, 5.9 to 7.2 for golimumab, and 6.4 to 8 for infliximab. The magnitude of benefit in quality of life reached the MCID for the MCS for two of the four studies that reported the MCS<sup>48, 49, 52, 53, 60, 61</sup> and ranged from 1.2 to 1.7 for adalimumab, was 2.8 for etanercept, and 3.5 to 5 for infliximab.

## Detailed Analysis

### Oral DMARD Versus Placebo

We did not identify any studies that examined the use of corticosteroids in the treatment of PsA or any head-to-head studies of oral DMARDs reporting outcomes relevant for this section. One study met inclusion criteria for this section. It compared leflunomide with placebo (Table 13).<sup>41, 42</sup>

**Table 13. Oral DMARD versus placebo studies: functional capacity and health-related quality of life outcomes: leflunomide vs. placebo**

Study	Study Design N Duration	Study Population	Comparison (Dose)	Results	Quality Rating
Kaltwasser et al., 2004 <sup>41, 42</sup>	RCT 190 24 weeks	Active PsA, failed at least 1 DMARD	LEF (100 mg/day, 3 days then 20 mg/day) vs. placebo	Mean change in HAQ: -0.19 vs. -0.05; $P=0.027$  Mean change in DLQI: -1.9 vs. -0.2; $P=0.017$	Fair

DLQI = Dermatology Life Quality Index; DMARD = disease-modifying antirheumatic drug; HAQ = Health Assessment Questionnaire; LEF = leflunomide; PsA = psoriatic arthritis; RCT = randomized controlled trials

## Leflunomide

One 24-week trial (two publications) evaluated the efficacy of leflunomide in PsA patients.<sup>41, 42</sup> The study randomized 190 subjects to leflunomide or placebo; PsA was defined as having at least three swollen joints and three tender or painful joints and psoriasis over at least 3 percent of the body surface area. Almost 50 percent of the patients were DMARD naïve. Those who were not DMARD naïve were required to discontinue all oral DMARDs, biologic DMARDs, and investigational drugs 28 days before baseline measures were done. At 24 weeks, subjects treated with leflunomide had greater improvement in functional capacity and quality of life than those treated with placebo.

## Biologic DMARD Versus Placebo

We did not identify any head-to-head studies of biologic DMARDs reporting outcomes relevant for this section. Seven studies (13 articles) compared one biologic DMARD with placebo (Table 14).<sup>46-54, 56, 59-61</sup>

**Table 14. Biologic DMARD versus placebo studies: functional capacity and health-related quality-of-life outcomes**

Study	Study Design N Duration	Study Population	Comparison (Dose)	Results	Quality Rating
<b>Adalimumab vs. Placebo</b>					
Genovese et al., 2007 <sup>56*</sup>	RCT 102 12 weeks	Active PsA, failed at least one DMARD	ADA (40 mg every other week) vs. placebo	Mean change in HAQ (12 weeks): ADA -0.3 vs. placebo -0.1; $P=0.010$ Mean change in SF-36 PCS (12 weeks): ADA 5.7 vs. placebo 2.8, $P=0.082$ Mean change in SF-36 MCS (12 weeks): ADA 1.1 vs. placebo -0.6, $P=0.242$ Mean change in DLQI (12 weeks): -3.4 vs. -1.7 ( $P=0.171$ )	Fair
Mease et al., 2005; <sup>46</sup> Gladman et al., 2007 <sup>59</sup> ADEPT	RCT 313 24 weeks	Active PsA, failed at least one DMARD	ADA (40 mg every other week) vs. placebo 51% received concomitant MTX	Mean change in HAQ-DI at 24 weeks: ADA -0.4 vs. placebo -0.1, $P<0.001$ Mean change in SF-36 PCS at 24 weeks: ADA 9.3 vs. placebo 1.4, $P<0.001$ Mean change in SF-36 MCS at 24 weeks: ADA 1.8 vs. 0.6, $P=0.288$ Mean change in DLQI at 24 weeks: -6.1 vs. -0.7 ( $P<0.001$ )	Fair

**Table 14. Biologic DMARD versus placebo studies: functional capacity and health-related quality-of-life outcomes (continued)**

Study	Study Design N Duration	Study Population	Comparison (Dose)	Results	Quality Rating
<b>Etanercept vs. Placebo</b>					
Mease et al., 2000 <sup>47</sup>	RCT 60 12 weeks	Active PsA, failed at least one DMARD	ETN (25 mg twice a week) vs. placebo 51% received concomitant MTX	Improvement in HAQ from baseline ETN 83% (change in median from 1.3 to 0.1) vs. placebo 3% (from 1.2 to 1.1) ( $P<0.0001$ )	Fair
Mease et al., 2004 <sup>48, 49, 60</sup>	RCT 205 96 weeks (24 double-blinded, 24 blinded maintenance, 48 open label) <sup>a</sup>	Active PsA, failed at least one DMARD	ETN (25 mg twice a week) vs. placebo 41% received concomitant MTX	Improvement in HAQ from baseline to 24 weeks: ETN 54% vs. placebo 6% ( $P<0.0001$ ); between-group difference in mean change in HAQ at week 24: 0.5 ( $P<0.0001$ ) Mean HAQ-DI scores at start and end of the open-label extension: ETN 0.4 vs. placebo 1.0 at start ETN 0.4 vs. placebo-ETN 0.6 at end Mean change in SF-36 PCS at 24 weeks: ETN 9.3 vs. placebo 0.7 ( $P<0.001$ ) Mean change in SF-36 MCS at 24 weeks: ETN 2.7 vs. -0.1 ( $P=0.062$ )	Fair
<b>Golimumab vs. Placebo</b>					
Kavanaugh et al., 2009 <sup>54</sup> GO-REVEAL*	RCT 405 24 weeks <sup>b</sup> (at week 16, patients could be reassigned from placebo to golimumab if not improving)	Treatment resistant active PsA despite therapy with DMARDs or NSAIDs, multinational	GOL (50 mg every 4 weeks) vs. GOL (100 mg every 4 weeks) vs. placebo At week 16, patients with <10% improvement from baseline in both SJC and TJC entered early escape= dose escalation from placebo to 50 mg GOL every 4 weeks or from 50 mg GOL to 100 mg GOL every 4 weeks	Mean change in HAQ at 14 weeks was not reported. Mean change at 24 weeks, including the early escape phase: GOL (50 mg) 0.33 vs. GOL (100 mg) 0.39 vs. -0.01 placebo, $P<0.001$ for either GOL group vs. placebo Mean change in SF-36 PCS at 14 weeks: GOL (50 mg) 6.53 vs. GOL (100 mg) 7.85 vs. 0.63 placebo, $P<0.001$ for either GOL group vs. placebo Mean change in SF-36 MCS: NR	Good
Antoni et al., 2005 <sup>50, 51</sup> IMPACT study	RCT 104 50 weeks (16 blinded, 34 open label)	Active PsA, failed at least one DMARD	INF (5 mg/kg at weeks 0, 2, 6, 14 and then every 8 weeks) vs. placebo <sup>c</sup>  All subjects received INF from week 16 to study completion 71% received a concomitant DMARD	Mean percentage improvement in HAQ at week 16: 49.8 vs. -1.6; $P<0.001$ ; between-group difference in mean change in HAQ at week 16: 0.6; $P<0.001$	Fair

**Table 14. Biologic DMARD versus placebo studies: functional capacity and health-related quality-of-life outcomes (continued)**

Study	Study Design N Duration	Study Population	Comparison (Dose)	Results	Quality Rating
<b><i>Infliximab vs. Placebo</i></b>					
Antoni et al., 2005 <sup>52, 53, 61</sup> IMPACT2 study	RCT 200 54 weeks (at week 16, patients could enter early escape and be reassigned from placebo to INF if not improving; all placebo subjects crossed over to INF at week 24)	Active PsA, failed at least one DMARD or NSAID	INF (5 mg/kg at weeks 0, 2, 6, 14, 22) vs. placebo <sup>d</sup>  All subjects received INF from week 24 to study completion 46% received concomitant MTX	Mean percentage improvement in HAQ, at week 14: 48.6% vs. -18.4%; $P<0.001$ ; between-group difference in mean change at weeks 14 and 24: 0.4 and 0.4, $P<0.001$  SF-36 PCS; change from baseline: to week 14: 9.1 vs. 1.1; $P<0.001$ to week 24: 7.7 vs. 1.3; $P<0.001$ SF36 MCS; change from baseline to week 14: 3.8 vs. -1.2; $P=0.001$ to week 24: 3.9 vs. 0.4; $P=0.047$ Improvement in employment status from unemployed at baseline to employed at week 14: 11.5% vs. 0%; $P=0.084$ From part-time to full-time employment: 30.0% vs. 10.0%; $P=0.582$ No significant difference in percentage of missed workdays in past 4 weeks at 14 weeks among patients who were employed full-time at baseline and week 14: 3.7% vs. 13%; $P=0.138$	Fair

ADA = adalimumab; DLQI = Dermatology Life Quality Index; DMARD = disease-modifying antirheumatic drug; ETN = etanercept; GO = golimumab; HAQ = Health Assessment Questionnaire; HAQ DI = Health Assessment Questionnaire Disability Index, INF = infliximab; LEF = leflunomide; MCS = mental component score; MTX = methotrexate; PCS = physical component score; PsA = psoriatic arthritis; SJC = Swollen Joint Count; TJC = Total Joint Count; vs. = versus

<sup>\*</sup>New study since last update.

<sup>a</sup>Additional outcomes for the EuroQol EQ-5D Quality of Life questionnaire, EQ-5D, and for the open-label extension are provided in the Evidence Tables in Appendix E.

<sup>b</sup>GO-REVEAL is planned to continue through 5 years; results have been published through week 24.

<sup>c</sup>INF 5 mg/kg or placebo at weeks 0, 2, 6, and 14, followed by open-label treatment with INF 5 mg/kg every 8 weeks.

<sup>d</sup>Placebo-treated patients with <10% improvement could cross over to INF 5 mg/kg at week 16. All remaining placebo patients crossed over to receive INF at weeks 24, 26, 30, 38, and 46. INF patients with <20% improvement received INF 10 mg/kg at weeks 38 and 46.

## Adalimumab

Two RCTs compared adalimumab (40 mg every other week) with placebo.<sup>46, 56, 59</sup> In both studies, patients were allowed to continue current MTX therapy as long as the dose had been stable. Both enrolled subjects who had an inadequate response or intolerance to previous treatments. Both studies found greater improvement in functional capacity for subjects treated with adalimumab than those treated with placebo. For health-related quality of life, several outcome measures were reported in both studies; results for each measure either statistically significantly favored adalimumab or were not statistically significantly different but point estimates favored adalimumab.

The Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT) included 313 patients suffering from moderate to severe PsA, which was defined as having at least three swollen joints

and three tender or painful joints, who had had an inadequate response or intolerance to NSAID therapy.<sup>46, 59</sup> The double-blind phase of the study was 24 weeks, but patients who failed to achieve at least a 20 percent decrease in both swollen and tender joint counts on two consecutive visits could receive rescue therapy with corticosteroids or DMARDs. Subjects treated with adalimumab had greater improvements in functional capacity and two quality-of-life measures (SF-36 PCS and DLQI) than those who received placebo.

The other RCTs enrolled 102 subjects with PsA and at least three swollen joints and three tender joints who were receiving concomitant DMARD therapy or had a history of DMARD therapy with an inadequate response.<sup>56</sup> Subjects treated with adalimumab had greater improvements in functional capacity than those who received placebo. Differences between groups for quality-of-life outcome measures were not statistically significantly different between groups, but there was a trend toward greater improvement in subjects treated with adalimumab.

### **Etanercept**

Two studies (three articles) that examined the efficacy of etanercept included a total of 265 patients with active PsA who were not adequately responding to conventional DMARD therapies.<sup>47-49</sup> In both studies, patients were allowed to continue MTX therapy as long as it had been stable for 4 weeks prior to enrollment. One of these trials lasted 12 weeks (N=60);<sup>47</sup> the other was double-blinded for 24 weeks (N=205).<sup>48</sup> Both studies had the same dosing regimen of 25 mg of etanercept twice weekly by subcutaneous injections. Functional capacity improved significantly more with etanercept than with placebo in both studies. The longer study also had an additional 24-week blinded maintenance phase and a 48-week open-label extension during which all subjects received etanercept.<sup>60</sup> Subjects originally assigned to etanercept maintained or improved their HAQ-DI scores, SF-36 physical component summary scores, and EQ-5D scores from the double-blind period through the end of the open-label extension period. Subjects originally assigned to placebo demonstrated improvement in their HAQ-DI scores, SF-36 physical component summary scores, and EQ-5D scores during the open-label extension while receiving etanercept.

### **Golimumab**

The “Golimumab-A Randomized Evaluation of Safety and Efficacy in Subjects with Psoriatic Arthritis Using a Human Anti-TNF Monoclonal Antibody” (GO-REVEAL) study randomized 405 subjects with active PsA to golimumab 50 mg every 4 weeks, golimumab 100 mg every 4 weeks, or placebo.<sup>54</sup> The subjects maintained the treatment to which they were randomized for the first 14 weeks; at week 16, subjects with less than 10 percent improvement from baseline in both swollen joint count and tender joint count entered early escape, with dose escalation from placebo to 50 mg golimumab (every 4 weeks) or from 50 mg to 100 mg golimumab (every 4 weeks). Subjects in both golimumab groups had greater improvements in functional capacity and in quality of life (measured by the SF-36 PCS) than those in the placebo group.

### **Infliximab**

Two studies, “Infliximab Multinational Psoriatic Arthritis Controlled Trial” (IMPACT) and IMPACT 2, randomized a total of 304 patients with active PsA who were not adequately responding to conventional DMARD therapies to infliximab or placebo.<sup>50, 52</sup> Both studies permitted patients to continue MTX therapy as long as it had been stable for 4 weeks before

enrollment. One trial was double-blinded for 16 weeks (N=104);<sup>50</sup> the other was double-blinded for 24 weeks (N=200), with crossover allowed at week 16 for nonresponders on the primary outcomes measured at the 14-week evaluation.<sup>52</sup> Both studies had the same dosing regimen of 5 mg/kg of infliximab at weeks 0, 2, 6, and 14; the longer study had an additional injection at week 22. Subjects treated with infliximab had significantly greater improvement in functional capacity than those treated with placebo in both studies. In IMPACT 2, subjects treated with infliximab had greater improvement in functional capacity and quality of life than those treated with placebo. Increases in the physical and mental component summary (PCS and MCS) scores and all eight scales of the SF-36 in the infliximab group were greater than those in the placebo group at week 14 ( $P \leq 0.001$ ). These benefits were sustained through week 24. Compared with the placebo group, higher proportions of patients in the infliximab group improved employment status from unemployed at baseline to employed at week 14 and from part-time to full-time employment.

### **KQ 3: Harms, Tolerability, Adverse Effects, or Adherence**

KQ 3 concerned the potential negative aspects of drug therapies for psoriatic arthritis (PsA) (i.e., harms, tolerability, and adverse effects), as well as patient adherence to treatments. Strength of evidence is presented and additional tables provide selected study-specific information on outcomes, broken out by overall tolerability, specific adverse events, and adherence. Evidence Tables in Appendix E document details about all of these studies.

### **Overview**

A total of one systematic review and meta-analysis, eight randomized controlled trials (RCTs), and two observational studies compared tolerability, harms, and adherence in patients with PsA. The drugs examined in RCTs and the systematic review of RCTs included two oral disease-modifying antirheumatic drugs (DMARDs) (leflunomide and sulfasalazine) and four biologic DMARDs (adalimumab, etanercept, golimumab, and infliximab), all in comparison with placebo. Both prospective cohort studies included patients on adalimumab, etanercept, and infliximab (with or without methotrexate [MTX]), and all of these groups were compared with each other. Overall strength of evidence is insufficient (Appendix H), except for the assessment of withdrawals due to adverse events for the comparison of adalimumab, etanercept, and infliximab, and placebo comparisons of adalimumab and etanercept, which has a low strength of evidence.

### **Oral DMARDs Versus Placebo**

The use of leflunomide versus placebo can increase the likelihood of diarrhea. It can also lead to clinically significant increases in alanine aminotransferase. The rates of adherence are similar for leflunomide and placebo. Withdrawals due to adverse events are higher with leflunomide than placebo based on a single study. Withdrawals due to adverse events with sulfasalazine are not statistically significantly greater than placebo based on a meta-analysis<sup>45</sup> of five trials. The strength of evidence is insufficient given the indirectness of the evidence.

### **Biologic DMARDs Versus Placebo**

Seven placebo-controlled studies of biologics, including two each on adalimumab, etanercept, and infliximab, and one on golimumab, provide indirect evidence on harms. When the individual drugs were compared with placebo, the authors reported few differences in the rate

of adverse events. Exceptions to this finding were increased rates of injection-site reactions with the use of adalimumab and etanercept and increased rates of infections and malignancies with golimumab. Adalimumab-treated patients had fewer reports of aggravated psoriasis compared with placebo-treated patients. Based on data from two prospective cohort studies, etanercept had a statistically significantly lower risk of discontinuation because of adverse events than infliximab. Infusion reactions with infliximab largely contributed to this difference in withdrawal rates. No evidence addressed adherence. The strength of evidence is low for adalimumab and etanercept and insufficient for golimumab and infliximab based on placebo-controlled data and low for the observational evidence addressing withdrawals due to adverse events.

## Psoriatic Arthritis: Detailed Analysis

One systematic review and meta-analysis, eight RCTs, and two observational studies compared tolerability, harms, and adherence in patients with PsA. Summary information on these studies is highlighted in Table 15, and full details are found in Evidence Tables in Appendix E.

**Table 15. Studies assessing adverse events, discontinuation rates, and adherence in psoriatic arthritis**

Study	Study Design Duration	Study Population	Drug	Results	Quality Rating
<i>Oral DMARDs</i>					
Kaltwasser et al., 2004 <sup>41</sup>	RCT 190 24 weeks	Patients with active PsA	LEF	Differences in rates of withdrawals because of adverse events, diarrhea, and clinically significant increases in ALT (for all, $P=NR$ ). Compliance of $\geq 80\%$ to $<110\%$ : LEF, 85%; placebo, 78%	Fair
Ravindran et al., 2008 <sup>45*</sup>	Meta-analysis SFZ: five studies LEF: one study	Placebo-controlled RCTs of oral or biological DMARDs for patients with PsA	LEF, SFZ	Withdrawals due to adverse events vs. placebo: LEF: RR 3.86 (1.2-12.39) SFZ: RR 1.76 (0.98-3.14)	Fair
<i>Biologic DMARDs</i>					
Antoni et al., 2005 <sup>50</sup> IMPACT study	RCT 104 16 weeks	Patients with active PsA despite background biologic or synthetic DMARD treatment	INF	No statistically significant differences in adverse events	Fair
Antoni et al., 2005 <sup>52</sup> IMPACT2 study	RCT 200 24 weeks	Patients with active PsA despite background biologic or synthetic DMARD treatment	INF	No statistically significant differences in adverse events	Fair
Genovese et al., 2007 <sup>56*</sup>	RCT 102 12 weeks	Patients with active PsA despite synthetic DMARD treatment	ADA	More adverse events for placebo (79.6%) than ADA (52.9%); $P \leq 0.01$ . Aggravation of psoriasis more common for placebo (16.3%) than ADA (3.9%); $P \leq 0.05$	Fair
Kavanaugh et al., 2009 <sup>54</sup> GO-REVEAL*	RCT 405 24 weeks	Patients with active PsA despite synthetic DMARD or NSAID treatment	GOL	Infections and malignancies more common with GOL than placebo (for all, $P=NR$ )	Fair

**Table 15. Studies assessing adverse events, discontinuation rates, and adherence in psoriatic arthritis (continued)**

Study	Study Design Duration	Study Population	Drug	Results	Quality Rating
Kristensen et al., 2008 <sup>43*</sup>	Prospective cohort 261 12 months	Patients with active PsA, biologic DMARD naïve	ADA, ETN, INF, MTX	Concomitant MTX associated with significantly fewer withdrawals due to adverse events HR, 0.25; 95% CI, 0.11 to 0.52; $P<0.01$ ). Compared with INF, ETN had lower risk of withdrawals due to adverse events (HR, 0.30; 95% CI, 0.11 to 0.80, $P=0.02$ )	Fair
Mease et al., 2000 <sup>47</sup>	RCT 60 12 weeks	Patients with active PsA despite background biologic or synthetic DMARD treatment	ETN	No statistically significant differences in adverse events except for ISRs. ETN 20% vs. placebo 3% ( $P=NS$ )	Fair
Mease et al., 2005 <sup>62</sup>	RCT 313 24 weeks	Patients with active PsA despite background biologic or synthetic DMARD treatment	ADA	No statistically significant differences in adverse events except for ISRs. ADA 6.6% vs. placebo 3.1% ( $P=NR$ )	Fair
Mease et al., 2006 <sup>49</sup>	RCT 205 72 weeks (24 blinded, 48 open label)	Patients with active PsA despite background biologic or synthetic DMARD treatment	ETN	No statistically significant differences in adverse events except for ISRs. ETN 20% vs. placebo 9% ( $P<0.001$ )	Fair
Ravindran et al., 2008 <sup>45*</sup>	Meta-analysis TNF-inhibitors: five studies	Placebo-controlled RCTs of oral or biological DMARDs for patients with PsA	ADA, ETN, INF	Withdrawals due to adverse events vs. placebo: TNF Inhibitors: RR 2.2 (0.82-5.91)	Fair
Saad et al., 2009 <sup>63*</sup>	Observational 566 3 years	Patients from the British Society for Rheumatology Biologics Register (BSRBR) with PsA	ADA, ETN, INF	Withdrawals due to adverse events: ADA 14.8%, ETN 12.3%, INF 23.5%. Hazard ratio for INF vs. ETN 3.1 (95% CI, 1.4 to 6.2)	Good

ADA = adalimumab; ALT = alanine aminotransferase; DMARD = disease-modifying antirheumatic drug; ETN = etanercept; GOL = golimumab; HR = hazard ratio, INF = infliximab; ISR = injection-site reaction; LEF = leflunomide; MTX = methotrexate; NR = not reported; NS = not significant; NSAID = nonsteroidal anti-inflammatory drugs; PsA = psoriatic arthritis; RCT = randomized controlled trial; RR = relative risk; SFZ = sulfasalazine; TNF = tumor necrosis factor  
\*New studies added since last review.

## Oral DMARDs

### Overall Tolerability

We did not identify any studies meeting our inclusion/exclusion criteria that examined the use of corticosteroids in the treatment of PsA. One 24-week trial with 190 patients examined adverse events in the treatment of PsA using leflunomide versus placebo.<sup>41</sup> The overall rates of adverse events were the same in each group: 85.4 percent of both trial arms experienced an adverse event. In meta-analyses of placebo-controlled trials, withdrawals due to adverse events were not statistically significantly more common for sulfasalazine than for placebo (five studies: RR, 1.76; 95% CI 0.98 to 3.14,  $P=0.06$ ) but were statistically significantly more common for leflunomide than placebo based on one contributing study (RR, 3.86; 95% CI 1.20 to 12.39,  $P=0.02$ ).<sup>45</sup>



## Specific Adverse Events

One trial showed some differences in specific adverse events for leflunomide, in particular diarrhea (leflunomide, 24%; placebo, 13%;  $P=NR$ ) and increases in alanine aminotransferase (leflunomide, 13%; placebo, 5%;  $P=NR$ ).<sup>41</sup>

## Adherence

This same trial also reported adherence in the treatment of PsA.<sup>41</sup> Over 24 weeks, treatment adherence of between 80 percent and 100 percent was reported by 85 percent of leflunomide patients and 78 percent of placebo patients ( $P=NR$ ). Additionally, one patient was withdrawn by the investigator from the placebo group because of poor adherence.

## Biologic DMARDs

### Overall Tolerability

Based on a Swedish prospective cohort study that included patients treated with adalimumab, etanercept, and infliximab, severe adverse events occurred in 5 to 6 percent of patients per year.<sup>43</sup> Two anaphylactic infusion reactions occurred, both with infliximab. Other adverse event rates were similar. Concomitant MTX was associated with significantly fewer withdrawals due to adverse events (HR, 0.25; 95% CI, 0.11 to 0.52;  $P<0.01$ ). Compared with infliximab, etanercept had a lower risk of withdrawal because of adverse events (HR, 0.30; 95% CI, 0.11 to 0.80;  $P=0.02$ ).<sup>43</sup> Based on 3 years of data from another observational study of patients from the British Society for Rheumatology Biologics Register (BSRBR), withdrawals due to adverse events were 14.8% for ADA, 12.3% for etanercept, and 23.5% for infliximab. Differences were statistically significant for infliximab compared with etanercept (HR, 3.1; 95% CI, 1.4 to 6.2). The most common reason for discontinuation with infliximab was infusion reactions ( $n=12$ ; 7.4%).<sup>63</sup> As a class for TNF inhibitors (including adalimumab, etanercept, and infliximab), withdrawals due to adverse events were not statistically significantly more common than with placebo (RR, 2.20; 95% CI, 0.82 to 5.91,  $P=0.12$ ) in a meta-analysis of five studies.<sup>45</sup> In efficacy trials for patients with PsA, overall tolerability profiles appeared to be similar for biologic DMARDs (adalimumab, etanercept, and infliximab) and placebo.<sup>41, 46, 47, 49, 50, 52, 54, 56</sup> Injection-site reactions, dizziness, headaches, and upper respiratory tract infections were the most commonly reported individual adverse events. Of these, injection-site reactions appeared to occur more often in the active group than in the control group.

### Specific Adverse Events

Adalimumab and etanercept used to treat PsA showed some differences in injection-site reactions. In a 24-week RCT examining adalimumab versus placebo, the adalimumab group experienced more injection-site reactions (6.6 percent) than the placebo group (3.1%;  $P=NR$ ).<sup>46</sup> Two other studies comparing etanercept to placebo also showed higher rates of injection-site reactions in the active arms.<sup>47, 49</sup> A 12-week RCT reported injection-site reaction rates of 20 percent in the etanercept group and 3 percent in the placebo group; these results were not significant, probably owing to the small sample size ( $N=60$ ).<sup>47</sup> In an RCT with 205 patients, however, the difference between these two groups was statistically different.<sup>49</sup> In the 24-week blinded portion of this study, injection-site reactions occurred in 36 percent of the etanercept patients and 9 percent of the placebo patients ( $P<0.001$ ). Infusion reactions with infliximab

(n=12; 7.4%) were more common than injection-site reactions with adalimumab (n=1; 1.1%) or etanercept (n=2; 0.6%) in a 3-year observational study.<sup>63</sup>

Most studies reported no statistically significant differences in adverse events between active treatment and placebo. In the only RCT of golimumab, more infections and malignancies were reported in golimumab-treated patients than placebo-treated patients ( $P=NR$ ).<sup>54</sup>

## **Adherence**

No study specifically addressed adherence with biologic DMARDs in the treatment of PsA.

# Discussion

This report provides a comprehensive review of the comparative efficacy, effectiveness, and harms of members of three main classes of drugs used to treat adult patients with psoriatic arthritis (PsA). These drugs include corticosteroids, oral disease-modifying antirheumatic drugs (DMARDs), and biologic DMARDs. The objective of this report is to evaluate the comparative efficacy, effectiveness, and harms of monotherapies, combination therapies, and different treatment strategies.

Table 16 summarizes our findings and the strength of evidence for the Key Questions (KQs) addressed by this report. In brief, the KQs addressed benefits of these drugs, alone or in combination, in terms of slowing or limiting the progression of radiographic joint damage and maintaining remission (KQ 1); reduction of patient-reported symptoms and improved functional capacity and quality of life (KQ 2); harms and risks of these drugs (KQ 3); and the benefits or harms in various patient subpopulations defined by sociodemographic characteristics or health states (KQ 4).

**Table 16. Summary of findings**

Key Comparisons	Efficacy and Effectiveness Strength of Evidence Grade	Harms Strength of Evidence Grade
<i>Oral DMARDs</i>		
Leflunomide	No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative efficacy of leflunomide and other treatments.  INSUFFICIENT  Compared with placebo in one study, leflunomide produced better improvement in health-related quality of life and statistically significant, but not clinically significant, improvement in disease activity and functional capacity.  LOW	No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative harms of leflunomide and other treatments.  INSUFFICIENT  Current evidence was limited to placebo-controlled trials. Compared with placebo, leflunomide led to higher rates of withdrawals because of adverse events, diarrhea, and clinically significant increases in alanine aminotransferase.  INSUFFICIENT
Methotrexate	No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative efficacy of MTX and other treatments.  INSUFFICIENT  Current evidence was limited to placebo-controlled trials. Compared with placebo in one fair study, MTX resulted in greater improvement in physician assessment of disease activity than placebo.  LOW	No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative harms of MTX and other treatments.  INSUFFICIENT

**Table 16. Summary of findings (continued)**

Key Comparisons	Efficacy and Effectiveness Strength of Evidence Grade	Harms Strength of Evidence Grade
Sulfasalazine	<p>No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative efficacy of sulfasalazine and other treatments.</p> <p>INSUFFICIENT</p> <p>Current evidence was limited to placebo-controlled trials. Compared with placebo in one good systematic review study, sulfasalazine reduced disease activity.</p> <p>MODERATE</p>	<p>No head-to-head studies met inclusion criteria; unable to draw conclusions on the comparative harms of sulfasalazine and other treatments.</p> <p>INSUFFICIENT</p>
<b><i>Biologic DMARDs</i></b>		
Biologic DMARD + Oral DMARD vs. Biologic DMARD or Oral DMARD	<p>The current evidence was limited to two cohort studies. Compared to anti-TNF monotherapy (adalimumab, etanercept, or infliximab), MTX plus anti-TNF produced similar disease activity response rates.</p> <p>LOW</p> <p>One systematic review of TNF inhibitors found that both TNF inhibitors and sulfasalazine are effective (similar withdrawals due to lack of efficacy); however, the data were insufficient to determine if the effect reached MCID.</p> <p>INSUFFICIENT</p>	<p>No head-to-head evidence met inclusion criteria; unable to draw conclusions on the comparative harms of biologic DMARD + oral DMARD and other treatments.</p> <p>INSUFFICIENT</p>

**Table 16. Summary of findings (continued)**

Key Comparisons	Efficacy and Effectiveness Strength of Evidence Grade	Harms Strength of Evidence Grade
Biologic	<p>No head-to-head trials met inclusion criteria; unable to draw conclusions on the comparative efficacy of biologics and other treatments.</p> <p>INSUFFICIENT</p> <p>Compared with placebo, adalimumab, etanercept, golimumab, and infliximab led to greater improvement in disease activity, functional capacity* and health-related quality of life.<sup>†</sup></p> <p>LOW to MODERATE<sup>‡</sup></p>	<p>Etanercept had a lower rate of withdrawals because of adverse events than infliximab in a prospective cohort study.</p> <p>LOW</p> <p>Additional evidence was limited to placebo-controlled trials, where adverse events were not the primary outcome. Overall adverse event profiles appeared to be similar for biologic DMARDs and placebo. However, compared with placebo, we noted the following: adalimumab and etanercept had more injection-site reactions and adalimumab had fewer events of aggravated psoriasis than placebo</p> <p>LOW</p> <p>Golimumab was associated with more malignancies than placebo in one RCT</p> <p>INSUFFICIENT</p>

ADA = adalimumab; DMARD = disease-modifying antirheumatic drug; ETN = etanercept; INF = infliximab; LEF = leflunomide; MCID = minimal clinically important difference; MTX = methotrexate; PCS = physical component score; SF-36 = Medical Outcomes Study Short Form 36; SSZ = sulfasalazine; TNF = tumor necrosis factor\*Of seven studies reporting outcomes for the Health Assessment Questionnaire (HAQ), the magnitude of benefit in functional capacity compared with placebo reached the MCID (HAQ change of  $\geq 0.22$ ) for all but one study of adalimumab (which found a between-group difference of 0.2).<sup>a</sup> The magnitude of benefit for functional capacity (between-group difference for improvement in HAQ) ranged from 0.2 to 0.3 for adalimumab, 0.5 to 1.1 for etanercept, 0.34 to 0.4 for golimumab, and 0.4 to 0.6 for infliximab.  
<sup>†</sup>The magnitude of benefit in quality of life reached the MCID for the SF-36 PCS for all five studies that reported the PCS and ranged from 2.9 to 7.9 for adalimumab, 8.6 for etanercept, 5.9 to 7.2 for golimumab, and 6.4 to 8 for infliximab.  
<sup>‡</sup>Low for golimumab and moderate for adalimumab, etanercept and infliximab.

Data are quite limited for PsA patients, and the evidence is insufficient to draw firm conclusions on comparative efficacy, effectiveness, and harms of either oral or biologic DMARDs in this condition.

## Key Findings

No head-to-head controlled trials meeting inclusion criteria exist for any drugs in this review for treating patients with PsA. Two cohort studies with low evidence indicated that the combination of an anti-tumor necrosis factor (TNF) (adalimumab, etanercept, or infliximab) with methotrexate (MTX) only was not different in treatment response<sup>43, 44</sup> than treatment with anti-TNF only.

Table 17 gives a range for effect sizes for commonly reported measures, including American College of Rheumatology 20 percent improvement from baseline to endpoint (ACR 20), Health

<sup>a</sup>Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. J Rheumatol 2007;34(5):1040-50.

Assessment Questionnaire (HAQ), and Short Form 36 Physical Component Score (SF-36 PCS). For the oral DMARDs, including sulfasalazine and methotrexate, sparse data are available. Parenteral high-dose MTX and sulfasalazine improved physician assessment of disease activity compared with placebo.<sup>40</sup> For both of these comparisons, minimally clinically important differences (MCIDs) cannot be determined. Additionally, patients taking leflunomide had higher response rates and better quality-of-life outcomes than those taking placebo, however these reached MCID by ACR 20, but not by the Psoriasis Area and Severity Index (PASI) or by the HAQ scales.<sup>41, 42</sup>

**Table 17. Comparison of effect sizes\* from placebo-controlled trials for ACR 20, HAQ, and SF-36 PCS by Drug**

Drug	Studies/ Participants	ACR 20 (% of Subjects Achieving)	HAQ (Mean Improvement)	SF-36 PCS (Mean Improvement)
<b>Oral DMARDs</b>				
Leflunomide	1 RCT/ 190	36	0.14	NR
Methotrexate	1 RCT/ 37	NR	NR	NR
Sulfasalazine	1 SER/ 1,022	NR	NR	NR
<b>Biologic DMARDs</b>				
Adalimumab	2 RCTs/ 415	39 to 57	0.2 to 0.3	2.9 to 7.9
Etanercept	3 RCTs/ 633	59 to 65	0.5 to 1.1	8.6
Golimumab	1 RCT/ 405	45 to 51	0.34 to 0.4	5.9 to 7.2
Infliximab	2RCTs, 1SER/ 673	58 to 62	0.4 to 0.6	6.4 to 8

ACR 20 = American College of Rheumatology 20 percent improvement from baseline to endpoint; HAQ = Health Assessment Questionnaire; PCS = physical component score; SF-36 = Medical Outcomes Study Short Form 36; RCT = Randomized controlled trial; SER = systematic evidence review

\*Effect sizes represent the range of point estimates from individual studies for the absolute difference between drug and placebo. Minimally Clinically Important Differences (MCIDs): ACR 20 is 20% minimal improvement; ACR 50/70 considered more clinically significant; HAQ  $\geq 0.22$  change, SF36 PCS  $\geq 2$  standard error of the mean (SEM).

Evidence supports the efficacy of adalimumab, etanercept, golimumab, and infliximab for the treatment of PsA.<sup>46-56</sup> However, evidence is insufficient to draw firm conclusions about the comparative efficacy, effectiveness, functional status, health-related quality of life, or tolerability of abatacept, adalimumab, anakinra, certolizumab, golimumab, etanercept, infliximab, rituximab, and tocilizumab for treating PsA.

As noted in Table 17, DMARDs, including adalimumab, etanercept, golimumab, and infliximab, appear to achieve similar ACR 20, HAQ, and SF-36 PCS scores when compared with placebo.

Information is generally insufficient to compare drugs for PsA with respect to harms, tolerability, adverse events, and adherence. The available studies include two relatively small prospective cohort studies and placebo-controlled studies; no head-to-head studies meeting inclusion criteria have been published.

In terms of applicability to patient subgroups, the studies are generally multicenter involving adults with diagnosed PsA. Prior medications tried before these studies were variable, but, in general, patients had failed a DMARD prior to starting any of the biologic agents. It is also important to note that the diagnostic criteria for PsA before the publication of the CASPAR criteria were not validated, which could lead to enrollment of patients that were not explicitly defined.

This report's findings did not reveal any differences with current standard of care. DMARDs are needed in most cases for PsA treatment. MTX is commonly used and useful treating psoriasis in addition to arthropathy. However, when chronic disease continues to be active despite use of

MTX, biologics are indicated and most often given in combination with oral DMARDs (e.g., MTX).<sup>21</sup> Comparative effectiveness remains lacking among and between oral and biologic DMARDs.

## **Future Research**

We have identified several areas needing further research to help clinicians and researchers arrive at stronger conclusions on the comparative efficacy, effectiveness, quality of life, and harms of medications for PsA. For this condition, the available evidence is limited to two head-to-head cohort studies and placebo-controlled trials. The quality of studies on oral DMARDs is sparse and fraught with methodological issues. Head-to-head RCTs are required to establish the comparative efficacy and safety of different treatment strategies to determine the best therapy to prevent or minimize debilitating joint damage. Specifically, we need better studies that include head-to-head comparisons particularly between oral DMARDs and biologics versus DMARDs and with combination therapies of different types. Furthermore, head-to-head RCTs have to determine the comparative effectiveness and safety of biologic DMARDs for the treatment of PsA. More generally, the issues of effectiveness, subgroups, and use in ordinary clinical settings highlighted for RA warrant attention for PsA as well. Future studies should also include outcome measures for axial disease, enthesitis, and dactylitis along with more traditional joint counts. An organized effort to identify diagnostic markers and surrogate endpoints for PsA is also a major unmet need and will help better define and treat this population.

## References

1. Bolen J, Helmick CG, Sacks JJ, et al. Prevalence of self-reported arthritis or chronic joint symptoms among adults--United States, 2001. *MMWR Morb Mortal Wkly Rep.* 2002 Oct 25;51(42):948-50. PMID: 12437034.
2. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis Rheum.* 2008 Jan;58(1):15-25. PMID: 18163481.
3. Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. *Curr Psychiatry Rep.* 2008 Jun;10(3):258-64. PMID: 18652795.
4. Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. *Arthritis Rheum.* 2001 Apr;45(2):151-8. PMID: 11324779.
5. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. *J Rheumatol.* 2001 Aug;28(8):1842-6. PMID: 11508587.
6. Borman P, Toy GG, Babaoğlu S, et al. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. *Clin Rheumatol.* 2006 Apr 19;26(3):330-4. PMID: 16622591.
7. Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. *Med Care.* 2006 Apr;44(4):304-10. PMID: 16565630.
8. Mau W, Listing J, Huscher D, et al. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. *J Rheumatol.* 2005 Apr;32(4):721-8. PMID: 15801031.
9. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. *Arthritis Rheum.* 2003 Oct;48(10):2750-62. PMID: 14558079.
10. Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). *Rheumatology (Oxford).* 2006 Mar;45(3):325-31. PMID: 16287927.
11. Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. *Ann Rheum Dis.* 2006 Sep;65(9):1175-83. PMID: 16540552.
12. Ozminkowski RJ, Burton WN, Goetzel RZ, et al. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. *J Occup Environ Med.* 2006 Feb;48(2):135-48. PMID: 16474262.
13. National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions--United States, 2003. *MMWR Morb Mortal Wkly Rep.* 2007 Jan 12;56(1):4-7. PMID: 17218935.
14. Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. *Pharmacoeconomics.* 2008;26(2):121-9. PMID: 18198932.
15. Olivieri I, Mantovani LG, D'Angelo S, et al. Psoriatic arthritis: pharmacoeconomic considerations. *Curr Rheumatol Rep.* 2009 Aug;11(4):263-9. PMID: 19691929.
16. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis.* 2005 Mar;64 Suppl 2:ii14-7. PMID: 15708927.
17. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. *J Am Acad Dermatol.* 2005 Oct;53(4):573. PMID: 16198775.
18. Anandarajah AP, Ritchlin CT. Pathogenesis of psoriatic arthritis. *Curr Opin Rheumatol.* 2004 Jul;16(4):338-43. PMID: 15201594.
19. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. *Ann Rheum Dis.* 2005 Mar;64 Suppl 2:ii3-8. PMID: 15708931.



20. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum.* 2006 Aug;54(8):2665-73. PMID: 16871531.
21. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. *Ann Rheum Dis.* 2009 Sep;68(9):1387-94. PMID: 18952643.
22. Donahue KE, Gartlehner G, Jonas DE, et al. Comparative effectiveness of drug therapy for rheumatoid arthritis and psoriatic arthritis in adults. Comparative Effectiveness Review No. 11. (Prepared by RTI-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016.) AHRQ Pub. No. 08-EHC004-1. Rockville, MD: Agency for Healthcare Research and Quality; November 2007. [www.effectivehealthcare.ahrq.gov/reports/final.cfm](http://www.effectivehealthcare.ahrq.gov/reports/final.cfm).
23. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. *Am J Prev Med.* 2001 Apr;20(3 Suppl):21-35. PMID: 11306229.
24. Anonymous. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report Number 4 (2nd edition). 2001.
25. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. *Health Technol Assess.* 2003;7(27):iii-x, 1-173. PMID: 14499048.
26. Agency for Healthcare Research and Quality. Methods reference guide for effectiveness and comparative effectiveness reviews, version 1.0. [Draft posted Oct. 2007]. Rockville, MD. Available at: [http://effectivehealthcare.ahrq.gov/repFiles/2007\\_10DraftMethodsGuide.pdf](http://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdf).
27. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. *J Clin Epidemiol.* 2010 May;63(5):513-23. PMID: 19595577.
28. van Tuyl LH, Vlad SC, Felson DT, et al. Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. *Arthritis Rheum.* 2009 May 15;61(5):704-10. PMID: 19405006.
29. Prevoo ML, van Gestel AM, van T. Hof MA, et al. Remission in a prospective study of patients with rheumatoid arthritis. American Rheumatism Association preliminary remission criteria in relation to the disease activity score. *Br J Rheumatol.* 1996 Nov;35(11):1101-5. PMID: 8948296.
30. Landewe R, van der Heijde D, van der Linden S, et al. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. *Ann Rheum Dis.* 2006 May;65(5):637-41. PMID: 16219709.
31. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. *J Rheumatol.* 1993 Mar;20(3):557-60. PMID: 8478873.
32. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. *J Am Acad Dermatol.* 2004 Jun;50(6):859-66. PMID: 15153885.
33. Reddy SM, Bingham Iii CO. Outcome measures in psoriatic arthritis clinical trials. *Curr Rheumatol Rep.* 2005 Aug;7(4):299-305. PMID: 16045833.
34. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. *Arthritis Rheum.* 2000 Jul;43(7):1478-87. PMID: 10902749.
35. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. *Health Qual Life Outcomes.* 2003;1:4. PMID: 12737635.
36. Ware JE, Snow KK, Kosinski M, et al. SF-36<sup>®</sup> Health Survey Manual and Interpretation Guide. Boston, MA: New England Medical Center, The Health Institute; 1993.

37. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. *Arthritis Rheum.* 2001 Aug;45(4):384-91. PMID: 11501727.
38. Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. *Arthritis Rheum.* 2002 Apr;46(4):913-20. PMID: 11953967.
39. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. *Arthritis Rheum.* 1984 Apr;27(4):376-81. PMID: 6712754.
40. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis. *Cochrane Database Syst Rev.* 2000(3):CD000212. PMID: 10908464.
41. Kaltwasser J, Nash P, Gladman D, et al. Efficacy and Safety of Leflunomide in the Treatment of Psoriatic Arthritis and Psoriasis: a Multinational, Double-Blind, Randomized, Placebo-Controlled Clinical Trial. *Arthritis and rheumatism.* 2004;50(6):1393-50.
42. Nash P, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. *Dermatology.* 2006;212(3):238-49. PMID: 16549920.
43. Kristensen LE, Gulfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. *Ann Rheum Dis.* 2008 Mar;67(3):364-9. PMID: 17644547.
44. Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford).* 2010;49(4):697-705. PMID: 20056769.
45. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. *Ann Rheum Dis.* 2008 Jun;67(6):855-9. PMID: 17827183.
46. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum.* 2005 Oct;52(10):3279-89. PMID: 16200601.
47. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet.* 2000 Jul 29;356(9227):385-90. PMID: 10972371.
48. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis Rheum.* 2004 Jul;50(7):2264-72. PMID: 15248226.
49. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. *J Rheumatol.* 2006 Apr;33(4):712-21. PMID: 16463435.
50. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum.* 2005 Apr;52(4):1227-36. PMID: 15818699.
51. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. *Ann Rheum Dis.* 2006 Aug;65(8):1038-43. PMID: 16439444.

52. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. *Ann Rheum Dis*. 2005 Aug;64(8):1150-7. PMID: 15677701.
53. Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. *Ann Rheum Dis*. 2006 Apr;65(4):471-7. PMID: 16096330.
54. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. *Arthritis Rheum*. 2009 Apr;60(4):976-86. PMID: 19333944.
55. Woolcott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. *Health Technol Assess*. 2006 Sep;10(31):1-258. PMID: 16948890.
56. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. *J Rheumatol*. 2007 May;34(5):1040-50. PMID: 17444593.
57. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: results from the induction and maintenance psoriatic arthritis clinical trial 2. *Arthritis Rheum*. 2007 Aug;56(8):2698-707. PMID: 17665424.
58. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. *Pharmacoeconomics*. 1999 Feb;15(2):141-55. PMID: 10351188.
59. Gladman DD, Mease PJ, Cifaldi MA, et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. *Ann Rheum Dis*. 2007 Feb;66(2):163-8. PMID: 17046964.
60. Mease PJ, Woolley JM, Singh A, et al. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. *J Rheumatol*. 2010 Jun;37(6):1221-7. PMID: 20395648.
61. Kavanaugh A, Antoni C, Mease P, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. *J Rheumatol*. 2006 Nov;33(11):2254-9. PMID: 16960923.
62. Mease PJ. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. *Expert Opin Biol Ther*. 2005 Nov;5(11):1491-504. PMID: 16255652.
63. Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. *Arthritis Res Ther*. 2009;11(2):R52. PMID: 19356232.

# Appendix A. Search Strings

## 2007 Search

Search	Most Recent Queries	Result
#2	Search ("Arthritis, Psoriatic"[MeSH] OR "Arthritis, Rheumatoid"[MeSH])	82356
#3	Search ("Arthritis, Psoriatic"[MeSH] OR "Arthritis, Rheumatoid"[MeSH]) Limits: All Adult: 19+ years, English, Publication Date from 1990, Humans	16462
#5	Search "Adrenal Cortex Hormones"[MeSH] OR corticosteroid*	190820
#6	Search #3 AND #5	686
#7	Search #3 AND #5 Limits: Editorial, Letter, Practice Guideline	18
#8	Search #6 NOT #7	668
#18	Search "Methotrexate"[MeSH] OR "leflunomide"[Substance Name] OR "Sulfasalazine"[MeSH] OR "Hydroxychloroquine"[MeSH]	28712
#28	Search "TNFR-Fc fusion protein"[Substance Name] OR etanercept OR "infliximab"[Substance Name] OR "adalimumab"[Substance Name] OR "cytotoxic T lymphocyte-associated antigen 4-immunoglobulin"[Substance Name] OR abatacept OR remicade OR enbrel OR humira OR "rituximab"[Substance Name] OR "interleukin 1 receptor antagonist protein"[Substance Name] OR anakinra	8701
#29	Search #3 AND #18	1365
#30	Search #3 AND #28	777
#31	Search #3 AND #18 Limits: Editorial, Letter, Practice Guideline	237
#32	Search #29 NOT #31	1128
#33	Search #3 AND #28 Limits: Editorial, Letter, Practice Guideline	178
#34	Search #30 NOT #33	599
#35	Search #8 OR #30 OR #34	1405

## July 2009 Search

Search	Most Recent Queries	Result
#1 Search	"Arthritis, Psoriatic"[MeSH] OR "Arthritis, Rheumatoid"[MeSH]	85528
#2 Search	"Adrenal Cortex Hormones"[MeSH] OR corticosteroid*	239378
#3 Search	"Methotrexate"[MeSH] OR "leflunomide"[Substance Name] OR "Sulfasalazine"[MeSH] OR "Hydroxychloroquine"[MeSH]	31900
#4 Search	"TNFR-Fc fusion protein"[Substance Name] OR etanercept OR "infliximab"[Substance Name] OR "adalimumab"[Substance Name] OR "cytotoxic T lymphocyte-associated antigen 4-immunoglobulin"[Substance Name] OR abatacept OR remicade OR enbrel OR humira OR "rituximab"[Substance Name] OR "interleukin 1 receptor antagonist protein"[Substance Name] OR anakinra	15567
#5 Search	((("CDP870 "[Substance Name] OR certolizumab OR cimzia) OR "efalizumab "[Substance Name] OR raptiva) OR "alefacept "[Substance Name] OR amevive) OR "natalizumab "[Substance Name] OR tysabri	1127
#6 Search	"golimumab "[Substance Name]	12
#7 Search	#2 OR #3 OR #4 OR #5 OR #6	283303
#8 Search	#7 AND #1	11283
#9 Search	#7 AND #1 Limits: <b>Editorial, Letter, Practice Guideline</b>	1368
#10 Search	#8 NOT #9	9915
#11 Search	#8 NOT #9 Limits: <b>Humans, English, All Adult: 19+ years</b>	4079
#12 Search	Limits: <b>Entrez Date from 2006/06/01, Humans, English, All Adult: 19+ years</b>	498212
#13 Search	#11 AND #12	1027

## August 2009 Search (for Tocilizumab)

Search	Most Recent Queries	Result
#1	Search "Arthritis, Psoriatic"[MeSH] OR "Arthritis, Rheumatoid"[MeSH]	85692
#2	Search actemra	4
#4	Search "tocilizumab "[Substance Name]	103
#5	Search #2 OR #4	104
#6	Search #5 AND #1	75
#7	Search #5 AND #1 Limits: <b>Editorial, Letter, Practice Guideline</b>	8
#8	Search #6 NOT #7	67
#9	Search #6 NOT #7 Limits: <b>Humans, English, All Adult: 19+ years</b>	14
#10	Search #9 Limits: <b>Entrez Date from 2006/06/01</b>	14

## March 2010 Search

Search	Most Recent Queries	Result
#1	Search "Arthritis, Psoriatic"[MeSH] OR "Arthritis, Rheumatoid"[MeSH]	87507
#2	Search "Adrenal Cortex Hormones"[MeSH] OR corticosteroid*	244454
#3	Search "Methotrexate"[MeSH] OR "leflunomide"[Substance Name] OR "Sulfasalazine"[MeSH] OR "Hydroxychloroquine"[MeSH]	32512
#12	Search "TNFR-Fc fusion protein"[Substance Name] OR etanercept OR "infliximab"[Substance Name] OR "adalimumab"[Substance Name] OR "cytotoxic T lymphocyte-associated antigen 4-immunoglobulin" OR abatacept OR remicade OR enbrel OR humira OR "rituximab"[Substance Name] OR "interleukin 1 receptor antagonist protein"[Substance Name] OR anakinra	16979
#13	Search (((("CDP870 "[Substance Name] OR certolizumab OR cimzia) OR "efalizumab "[Substance Name] OR raptiva) OR "alefacept "[Substance Name] OR amevive) OR "natalizumab "[Substance Name] OR tysabri	1309
#14	Search actemra OR "tocilizumab"[Substance Name]	134
#15	Search "golimumab "[Substance Name]	32
#16	Search #2 OR #3 OR #12 OR #13 OR #14 OR #15	290354
#17	Search #16 AND #1	11855
#18	Search #17 Limits: Editorial, Letter, Practice Guideline	1450
#19	Search #17 NOT #18	10405
#20	Search #19 Limits: Humans, English, All Adult: 19+ years	4358
#21	Search "2009/05/01"[Entrez Date] : "3000"[Entrez Date] Limits: Humans, English, All Adult: 19+ years	89610
#22	Search #20 AND #21 Limits: Humans, English, All Adult: 19+ years Sort by: PublicationDate	176

## August 2010 Search

Search	Most Recent Queries	Result
#1	Search "Arthritis, Psoriatic"[MeSH] OR "Arthritis, Rheumatoid"[MeSH]	89162
#2	Search "Adrenal Cortex Hormones"[MeSH] OR corticosteroid*	248455
#3	Search "Methotrexate"[MeSH] OR "leflunomide"[Substance Name] OR "Sulfasalazine"[MeSH] OR "Hydroxychloroquine"[MeSH]	33034
#4	Search "TNFR-Fc fusion protein"[Substance Name] OR etanercept OR "infliximab"[Substance Name] OR "adalimumab"[Substance Name] OR "cytotoxic T lymphocyte-associated antigen 4-immunoglobulin" OR abatacept OR remicade OR enbrel OR humira OR "rituximab"[Substance Name] OR "interleukin 1 receptor antagonist protein"[Substance Name] OR anakinra	18212
#5	Search (((("CDP870 "[Substance Name] OR certolizumab OR cimzia) OR "efalizumab "[Substance Name] OR raptiva) OR "alefacept "[Substance Name] OR amevive) OR "natalizumab "[Substance Name] OR tysabri	1468
#6	Search actemra OR "tocilizumab"[Substance Name]	250
#7	Search "golimumab "[Substance Name]	47
#8	Search #2 OR #3 OR #4 OR #5 OR #6 OR #7	296041
#9	Search #1 AND #8	12290
#10	Search #9 Limits: Editorial, Letter, Practice Guideline	1498
#11	Search #9 NOT #10	10792
#12	Search #11 Limits: Humans, English, All Adult: 19+ years	4578
#13	Search ((#12) AND "2010/01/01"[Entrez Date] : "3000"[Entrez Date]) AND "0"[Entrez Date] : "3000"[Entrez Date] Sort by: Author	125



## January 2011 Search

Search	Most Recent Queries	Result
#1	Search "Arthritis, Psoriatic"[MeSH] OR "Arthritis, Rheumatoid"[MeSH]	90392
#2	Search "Adrenal Cortex Hormones"[MeSH] OR corticosteroid*	251312
#3	Search "Methotrexate"[MeSH] OR "leflunomide"[Substance Name] OR "Sulfasalazine"[MeSH] OR "Hydroxychloroquine"[MeSH]	33430
#4	Search "TNFR-Fc fusion protein"[Substance Name] OR etanercept OR "infliximab"[Substance Name] OR "adalimumab"[Substance Name] OR "cytotoxic T lymphocyte-associated antigen 4-immunoglobulin" OR abatacept OR remicade OR enbrel OR humira OR "rituximab"[Substance Name] OR "interleukin 1 receptor antagonist protein"[Substance Name] OR anakinra	19150
#5	Search (("CDP870 "[Substance Name] OR certolizumab OR cimzia) OR "efalizumab "[Substance Name] OR raptiva) OR "alefacept "[Substance Name] OR amevive) OR "natalizumab "[Substance Name] OR tysabri	1583
#6	Search actemra OR "tocilizumab"[Substance Name]	305
#7	Search "golimumab "[Substance Name]	56
#8	Search #2 OR #3 OR #4 OR #5 OR #6 OR #7	300191
#9	Search #1 AND #8	12597
#10	Search #9 Limits: Editorial, Letter, Practice Guideline	1540
#11	Search #9 NOT #10	11057
#12	Search #11 Limits: Humans, English, All Adult: 19+ years	4714
#13	Search ((#12) AND "2010/05/01"[Entrez Date] : "3000"[Entrez Date]) AND "0"[Entrez Date] : "3000"[Entrez Date] Sort by: Author	116

# Appendix B. Review and Abstraction Forms

Previewing Only: You cannot submit data from this form



Previewing at Level 1

Reviewer Comments ( [Add a Comment](#) )

Refid: 2161, P. Efthimiou, A. Kontzias, C. M. Ward and N. S. Ogden, Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?, *Nat Clin Pract Rheumatol*, 3(6), 2007, p. 328-35  
State: Excluded, Level: 1

Keywords:

Adrenal Cortex Hormones/therapeutic use

Increase Font Size

Decrease Font Size

#### Abstract

Adult-onset Still's disease is a rare systemic inflammatory disease of unknown etiology, characterized by daily high spiking fevers, evanescent rash, and arthritis. There is no single diagnostic test for adult-onset Still's disease; rather, the diagnosis is based on clinical criteria and necessitates the exclusion of infections, neoplasia, and other 'autoimmune' diseases. Proinflammatory cytokines such as interleukin (IL)-1, IL-6, and IL-18, interleukin-gamma, tumor necrosis factor, and macrophage colony-stimulating factor are elevated in patients with adult-onset Still's disease and are thought to have a major role in the pathogenesis of the disease. Treatment consists of nonsteroidal anti-inflammatory drugs, corticosteroids, immunosuppressants (methotrexate, gold, azathioprine, leflunomide, cyclosporin, and cyclophosphamide), intravenous immunoglobulin, and cytokine (tumor necrosis factor, IL-1 and IL-6) inhibitors. Recent advances in basic immunology have enhanced our ability to understand the pathogenic mechanisms associated with adult-onset Still's disease and have led to a paradigm shift where targeted treatments have an increasingly important role.

Increase Font Size

Decrease Font Size

Save to finish later

Submit Data

1. Original research (no review articles, editorials, letters to the editor) published in English after 1990 in adult patients with rheumatoid or psoriatic arthritis AND is not a case report or case series?

- Yes
- No
- Cannot determine
- No, but article will be used for background

Clear Selection

2. Study includes one or more of the following pharmaceutical interventions (check all that apply):

- Corticosteroids
- Oral DMARDs including methotrexate, leflunomide, sulfasalazine, cyclosporine, hydroxychloroquine
- Biologic DMARDs including anakinra, etanercept, infliximab, adalimumab, abatacept, certolizumab, golimumab, tocilizumab, rituximab
- Cannot determine
- Comparison is not of interest

3. Study compares-

- Two of the included drugs
- Biologic DMARD (TIM) versus placebo
- One of the included drugs versus placebo but is of interest because of specific outcome such as adverse events
- Nothing of interest and article should not be included
- Cannot determine

Clear Selection

4. Addresses one or more of the following key questions (check all that apply):

- KQ1 For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in their ability to reduce patient-reported symptoms, to slow or limit progression of radiographic joint damage, or to maintain remission (reduce the likelihood of relapse)?
- KQ2- For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in their ability to improve functional capacity or quality of life?
- KQ3 For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in harms, tolerability, adherence, or adverse effects?
- KQ4 What are the comparative benefits and harms of drug therapies for rheumatoid arthritis and psoriatic arthritis in subgroups of patients based on stage of disease, history of prior therapy, demographics, concomitant therapies, or comorbidities?
- Cannot determine by the title or abstract
- None of the above

5. Study design is one of the following:

- RCT 3 months or longer

---

Form took 0.1367188 seconds to render  
Form Creation Date: Not available  
Form Last Modified: Aug 11 2009 11:02AM

Previewing Only: You cannot submit data from this form



Previewing at Level 2

Reviewer Comments ([Add a Comment](#))

Refid: 2161, P. Efthimiou, A. Koutzias, C. M. Ward and N. S. Ogden, Advancing et Stills disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy?, *Nat Clin Pract Rheumatol*, 3(5), 2007, p. 328-35  
State: Excluded, Level: 1

[Save to finish later](#)

[Submit Data](#)

1. Should the article be *excluded* for any of the following reasons?

- Study reported only in abstract
- Wrong outcome (i.e. pharmacologic or late mediate outcomes)
- Wrong drug (not one of the following: corticosteroids, methotrexate, leflunomide, sulfasalazine, cyclosporine, hydroxychloroquine, abatacept, etanercept, infliximab, adalimumab, abatacept, certolizumab, golimumab, tocilizumab, rituximab)
- Wrong population (For example pediatric studies)
- Wrong publication type (e.g. letter or editorial)
- Wrong design (i.e. non-systematic meta-analysis or non-comparative arm)
- RCT (n < 100)
- Other? (Please explain)
- Background article
- None of the above - should be included!

If the article has been excluded in the above question, the next two questions do not need to be answered.

2. Which of the following key questions are addressed by the article

- KQ1- For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in the ability to reduce patient-reported symptoms, to slow or limit progression of radiographic joint damage, or to maintain remission (reduce the incidence flares-ups)?
- KQ2- For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in the ability to improve functional capacity or quality of life?
- KQ3- For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in harms, tolerability, adherence, or adverse effects?
- KQ4- What are the comparative benefits and harms of drug therapies for rheumatoid arthritis and psoriatic arthritis in subgroups of patients based on stage of disease, history of prior therapy, demographics, concomitant therapies, or comorbidities?
- None of the above

3. What is the study design?

- RCT > or equal to 100
- Observational > or equal to 100
- Meta-analysis or systematic review (i.e. Cochrane Review)

- None of the above, but its worth being abstracted-please note why in the box!
- None of the above, so exclude.

Clear Selections

Save to finish later

Submit Data

Form took 0.1054688 seconds to render  
Form Creation Date: Not available  
Form Last Modified: Sep 11 2009 8:53AM

Previewing Only: You cannot submit data from this form

Previewing at Level 3

Reviewer Comments ([Add a Comment](#))

RefId:2161, P. Ehrlich, A. Kozlowski, C. M. Ward and N. S. Ogden, Adjuvant and Still's disease: can recent advances in osteoarthritis  
State: Excluded, Level: 1

[Save to finish later](#)

[Submit Data](#)

1. Author, Year, Study name if applicable (i.e. BeST):

Enlarge [Strik](#) 

2. Country and setting:

*If more than a couple of countries are included just call it multinational. Settings include primary care, hospitals, uni*

3. Source of funding

Pharmaceutical company or other commercial source - please list name.

Government or non-profit organization - please list name.

Not reported

4. Condition being treated:

Rheumatoid arthritis

Psoriatic arthritis

Other? Please explain

5. STUDY DESIGN

Controlled Trial

Observational

[Clear Selections](#)

6.

What is being compared?

1 0 [DMARD](#) us 1 0 [DMARD](#)

1 0 [DMARD](#) us 1 [BIOLOGIC](#)

1 0 [DMARD](#) us 1 [Corticosteroid](#)

1 [BIOLOGIC](#) us 1 [BIOLOGIC](#)

1 [BIOLOGIC](#) us 1 [Corticosteroid](#)

1 BIOLOGIC vs Placebo

Combination therapy vs Combination therapy

SINGLE DRUG vs Combination therapy

Strategy (Describe the strategy in detail for each arm in the 'Other' text box for numbers 8-12)

7. How many comparison arms does this study have?

2 ARMS

3 ARMS

4 ARMS

5 ARMS

[Clear Selection](#)

8. Check off the drug(s) studied for **ARM 1** and put dosage and frequency in the adjacent box

Methylprednisolone  

Prednisone  

Prednisolone  

Methotrexate  

Leflunomide  

Sulfasalazine  

Hydroxychlorquine  

Etanercept  

Infliximab  

Adalimumab  

Anakinra  

Abatacept  

Rituximab  

Certolizumab  

Golimumab  

Tocilizumab  

Placebo  

Other (describe)  

9. Check off the drug(s) studied for **ARM 2** and put dosage and frequency in the adjacent box

Methylprednisolone  

Prednisone  





Prednisolone  



- Methotrexate
- Leflunomide
- Sulfasalazine
- Hydroxychlorquine
- Etanercept
- Infliximab
- Adalimumab
- Anakinra
- Abatacept
- Rituximab
- Certolizumab
- Golimumab
- Tocilizumab
- Placebo
- Other (describe)

10. Check off the drug(s) studied for **ARM 3** and put dosage and frequency in the adjacent box







- Methylprednisolone
- Prednisone
- Prednisolone
- Methotrexate
- Leflunomide
- Sulfasalazine
- Hydroxychlorquine
- Etanercept
- Infliximab
- Adalimumab
- Anakinra
- Abatacept
- Rituximab
- Certolizumab



- Golimumab  
- Tocilizumab  
- Placebo  
- Other (describe)  

11. Check off the drug(s) studied for **ARM 4** and put dosage and frequency in the adjacent box

- Methylprednisolone  
- Prednisone  
- Prednisolone  
- Methotrexate  
- Leflunomide  
- Sulfasalazine  
- Hydroxychlorquine  
- Etanercept  
- Infliximab  
- Adalimumab  
- Anakinra  
- Abatacept  
- Rituximab  
- Certolizumab  
- Golimumab  
- Tocilizumab  
- Placebo  
- Other (describe)  

12. Check off the drug(s) studied for **ARM 5** and put dosage and frequency in the adjacent box

- Methylprednisolone  
- Prednisone  
- Prednisolone  
- Methotrexate  
- Leflunomide  
- Sulfasalazine  

- Hydroxychlorquine  
- Etanercept  
- Infliximab  
- Adalimumab  
- Anakinra  
- Abatacept  
- Rituximab  
- Certolizumab  
- Golimumab  
- Tocilizumab  
- Placebo  
- Other (describe)  

13. Research objective (*Please be brief and concise*):

Enlarge Shrink 

14. Overall study n =

Enlarge Shrink 


15. Duration of study:

Enlarge Shrink 

16. Inclusion criteria (check all that apply and list additional criteria in the text box)

- MTX Naive  
- Early RA  
- Treatment resistant  

Additional inclusion criteria

17.

Exclusion criteria


















Enlarge Shrink 

**POPULATION CHARACTERISTICS**








	ARM 1	ARM 2	
18. <b>Intervention/Treatment</b>	<input type="text"/>	<input type="text"/>	<input type="text"/>
19. # in group (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
20. Age (mean):	<input type="text"/>	<input type="text"/>	<input type="text"/>
21. Sex, female (%):	<input type="text"/>	<input type="text"/>	<input type="text"/>
22. Race, white (%):	<input type="text"/>	<input type="text"/>	<input type="text"/>
23. Race, black (%):	<input type="text"/>	<input type="text"/>	<input type="text"/>
24. Ethnicity, Latino (%):	<input type="text"/>	<input type="text"/>	<input type="text"/>
25. Disease duration (mean & SD):	<input type="text"/>	<input type="text"/>	<input type="text"/>
26. DMARD use (%):	<input type="text"/>	<input type="text"/>	<input type="text"/>
27. Corticosteroid use (%):	<input type="text"/>	<input type="text"/>	<input type="text"/>
28. MTX naive (%):	<input type="text"/>	<input type="text"/>	<input type="text"/>
29. Treatment resistant (%):	<input type="text"/>	<input type="text"/>	<input type="text"/>
30. Patients with early RA, three years or less, (%):	<input type="text"/>	<input type="text"/>	<input type="text"/>
31. Baseline DAS score:	<input type="text"/>	<input type="text"/>	<input type="text"/>
32. Tender joint count:	<input type="text"/>	<input type="text"/>	<input type="text"/>
33. Swollen joint count:	<input type="text"/>	<input type="text"/>	<input type="text"/>
34. Required treatment for latent TB:	<input type="text"/>	<input type="text"/>	<input type="text"/>
35. Other population characteristics?	<input type="text"/>	<input type="text"/>	<input type="text"/>

**RESULTS: Outcome Measures and Health Outcomes**  
*(Enter results for all time points and please specify units for all results)*

	ARM 1	ARM 2	
36. ACR 20, %, (CI/SD/P value):	<input type="text"/>	<input type="text"/>	<input type="text"/>
37. ACR 50, %, (CI/SD/P value):	<input type="text"/>	<input type="text"/>	<input type="text"/>
38. ACR 70, %, (CI/SD/P value):	<input type="text"/>	<input type="text"/>	<input type="text"/>
39. PASI 20, %, (CI/SD/P value):	<input type="text"/>	<input type="text"/>	<input type="text"/>

40. PASI 50, %, (CI/SD/P value):    
41. PASI 70, %, (CI/SD/P value):    
42. HAQ, mean difference/absolute difference (CI/SD/P Value):    
43. DAS, mean difference/absolute difference (CI/SD/P Value):    
44. SF-36, mean difference/absolute difference (CI/SD/P Value):    
45. PsARC, mean difference/absolute difference (CI/SD/P Value):    
46. Radiographic measures, mean difference/absolute difference (CI/SD/P Value):    
47. Quality of life scales (please name), mean difference/absolute difference (CI/SD/P Value):    
48. Others, (please name); mean difference/absolute difference (CI/SD/P Value):  

**ATTRITION AND ADHERENCE**

- |  | ARM 1  | ARM 2  |
|--|--|--|
| 49. Overall attrition/withdrawal (n):        | <input type="text"/>  | <input type="text"/>  |
| 50. Withdrawals due to adverse events (n):   | <input type="text"/>  | <input type="text"/>  |
| 51. Withdrawals due to lack of efficacy (n): | <input type="text"/>  | <input type="text"/>  |
| 52. Adherent/compliant (n):                  | <input type="text"/>  | <input type="text"/>  |

53. Other attrition related comments?

[Enlarge](#) [Shrink](#) 

**RESULTS: Adverse Events, n**

	ARM 1	ARM 2	
54. Overall adverse events reported (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
55. Death (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
56. Lymphoma or leukemia (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
57. Skin cancer (basal cell or squamous cell) (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
58. Other cancer (specify) (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
59. Cardiovascular events (specify) (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
60. Hepatotoxicity/elevated liver enzymes (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
61. Tuberculosis (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
62. Pneumonia (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
63. Upper respiratory infection (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
64. Urinary tract infection (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
65. Other infections (specify) (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
66. Fractures (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
67. Infusion/injection site reactions (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
68. Skin rash (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
69. Demyelination or multiple sclerosis (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
70. Progressive multifocal leukoencephalopathy (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
71. Headache (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
72. Dizziness (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
73. Nausea or vomiting (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
74. Abdominal pain (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
75. GI bleed or ulcer (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
76. Bowel obstruction (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
77. Other GI symptoms (specify) (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
78. Other AEs 1 (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
79. Other AEs 2 (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>
80. Other AEs 3 (n):	<input type="text"/>	<input type="text"/>	<input type="text"/>

81. Other AEs 4 (n):

82. Any other AEs:

[Enlarge](#) [Shrink](#) 

83. Which Key Question(s) does this study address (check all that apply)?

- KQ1- For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in their ability to reduce disease activity, to
- KQ2- For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in their ability to improve functional capac
- KQ3- For patients with rheumatoid arthritis or psoriatic arthritis, do drug therapies differ in harms, tolerability, adherence, or adver
- KQ4- What are the comparative benefits and harms of drug therapies for rheumatoid arthritis and psoriatic arthritis in subgroups c

## Quality Review for Controlled Trials

84. Randomization adequate?

- Yes
- No
- Not randomized
- Method not reported

[Clear Selection](#)

85. Allocation concealment adequate?

- Yes
- No
- Not randomized
- Method not reported

[Clear Selection](#)

86. Groups similar at baseline?

- Yes
- No (what are the differences)  
- Not reported
- Not applicable  

[Clear Selection](#)

87. Outcome assessors blinded?

- Yes
- No
- Yes, but method not described
- Not reported

[Clear Selection](#)

88. Care provider blinded?

- Yes
- No
- Yes, but method not described
- Not reported

[Clear Selection](#)

89. Patient blinded?

- Yes
- No
- Yes, but method not described
- Not reported

[Clear Selection](#)

90. Overall attrition high ( $\geq 20\%$ )?

- Yes (please state how high)
- No

[Clear Selection](#)

91. Differential attrition high ( $\geq 15\%$ )?

- Yes (please state difference)
- No

[Clear Selection](#)

92. Were the outcome measures valid and reliable?

- Yes
- No
- Not reported

[Clear Selection](#)

93. Were the outcome measures equally applied?

- Yes
- No
- Not reported

[Clear Selection](#)

94. Was the statistical analysis based on intention-to-treat (ITT)?

- Yes
- No
- Cannot tell
- Not applicable

[Clear Selection](#)

95. Were there any post-randomization exclusions?

- Yes (how many?)
- No
- Cannot tell

[Clear Selection](#)

96. Quality rating for efficacy/effectiveness

- Good
- Fair
- Poor

If poor, why?



## Quality Review for Observational Studies

97. Were both groups selected from the same source population?

- Yes
- No
- Yes, but method not described
- Not reported

[Clear Selection](#)

98. Did both groups have the same risk of having the outcome of interest at baseline?

- Yes
- No
- Not reported

[Clear Selection](#)

99. Were subjects in both groups recruited over the same time period?

- Yes
- No
- Yes, but method not described
- Not reported

[Clear Selection](#)

100. Were measurement methods adequate and equally applied to both groups?

- Yes
- No
- Not reported

[Clear Selection](#)

101. Was an attempt made to blind the outcome assessors?

- Yes
- No
- Yes, but method not described
- Not reported

[Clear Selection](#)

102. Was the time of follow-up equal in both groups?

- Yes
- No
- Not reported

[Clear Selection](#)

103. Overall attrition high ( $\geq 20\%$ )?

- Yes (please state how high)  
- No

[Clear Selection](#)

104. Differential attrition high ( $\geq 15\%$ )?

- Yes (please state difference)  
- No

[Clear Selection](#)

105. Was confounding accounted for either through study design or statistical analysis?

- Yes
- No
- Yes, but method not described
- Not reported

[Clear Selection](#)

106. Did the statistical analysis adjust for different lengths of follow-up?

- Yes
- No
- Yes, but method not described
- Not reported

[Clear Selection](#)

107. Was the length of follow-up adequate to assess the outcome of interest?

- Yes
- No
- Not reported

[Clear Selection](#)

108. Quality rating for observational studies

- Good
- Fair
- Poor

Why?

109. Any other quality related comments?

[Enlarge](#) [Shrink](#) 

## Quality Review for Adverse Events

110. Methods of adverse effects assessment

- Patient reported
- Physical exam at study visits
- Lab evaluations
- Standardized scale (e.g. WHO, UKU-SES)
- other (please specify)

111. Adverse events pre-specified and defined?

- Yes
- No

[Clear Selection](#)

112. Measurement techniques non-biased and adequately described?

- Yes
- No

[Clear Selection](#)

113. Quality rating adverse events assessment:

- Good
- Fair
- Poor

Clear Selections

114. First abstraction done by:

- Karen Crotty
- Katrina Douville
- Rick Haise
- Dan Jones
- Linda Lix
- Robert Roubey
- Rachael Scelimitas

Other (please write your name in the adjacent box):

Clear Selections

115. Second abstraction done by:

- Karen Crotty
- Katrina Douville
- Rick Haise
- Dan Jones
- Linda Lix
- Robert Roubey
- Rachael Scelimitas

Other (please write your name in the adjacent box):

Clear Selections

116. Study is already included in systematic review/meta-analysis and does not need to be put in an evidence table

- Yes
- No

Clear Selections

Save to finish later

Submit Data

Form took 1.550781 seconds to render  
Form Creation Date: Not available  
Form Last Modified: Nov 6 2009 2:28PM

## Appendix C. Articles by Database Searched

### Reference Source: PubMed

1. Juvenile and adult systemic-onset Still's disease. *Lancet*. 1990 Jul 14;336(8707):92.
2. Double blind controlled phase III multicenter clinical trial with interferon gamma in rheumatoid arthritis. German Lymphokine Study Group. *Rheumatol Int*. 1992;12(5):175-85.
3. A randomized trial of hydroxychloroquine in early rheumatoid arthritis: the HERA Study. *Am J Med*. 1995 Feb;98(2):156-68.
4. Treatment methods. Nonsurgical treatment methods for diseases in multiple joints (polyarthritis). *Scand J Rheumatol Suppl*. 1999;110:7-14.
5. Etanercept and infliximab for rheumatoid arthritis. *Drug Ther Bull*. 2001 Jul;39(7):49-52.
6. One million U.S. adults may suffer from psoriatic arthritis. *Dermatol Nurs*. 2002 Jun;14(3):207-8.
7. Anakinra (Kineret) for rheumatoid arthritis. *Med Lett Drugs Ther*. 2002 Feb 18;44(1124):18-9.
8. Summaries for patients. Tumor necrosis factor antagonists and heart failure. *Ann Intern Med*. 2003 May 20;138(10):I48.
9. Is it true that vaccines may not be safe for people with rheumatoid arthritis (which I have)? Does that mean I shouldn't get a flu shot? *Johns Hopkins Med Lett Health After 50*. 2004 Oct;17(8):8.
10. Summaries for patients. Abatacept for people with active rheumatoid arthritis. *Ann Intern Med*. 2006 Jun 20;144(12):I18.
11. Rituximab and abatacept for rheumatoid arthritis. *Drug Ther Bull*. 2008 Aug;46(8):57-61.
12. The Chinese herbal remedy *Tripterygium wilfordii* Hook F in the treatment of rheumatoid arthritis. *Ann Intern Med*. 2009 Aug 18;151(4):I-36.
13. New drug information: Simponi. *Jaapa*. 2009 Aug;22(8):13.
14. Abarca J, Malone DC, Armstrong EP, et al. Longitudinal analysis of the use of etanercept versus infliximab determined from medical chart audit. *J Manag Care Pharm*. 2004 Nov-Dec;10(6):538-42.
15. Abe K, Mitsuka T, Kanamori S, et al. Gynecomastia associated with low-dose methotrexate therapy for rheumatoid arthritis. *Mod Rheumatol*. 2007;17(6):511-3.
16. Abe T, Takeuchi T, Miyasaka N, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. *J Rheumatol*. 2006 Jan;33(1):37-44.
17. Abedin M, Scheurich D, Reimold SC, et al. Acute coronary syndrome after infliximab infusion. *Cardiol Rev*. 2006 Jan-Feb;14(1):50-2.
18. Ablin JN, Boguslavski V, Aloush V, et al. Effect of anti-TNFalpha treatment on circulating endothelial progenitor cells (EPCs) in rheumatoid arthritis. *Life Sci*. 2006 Nov 17;79(25):2364-9.
19. Aboulafia DM, Bundow D, Wilske K, et al. Etanercept for the treatment of human immunodeficiency virus-associated psoriatic arthritis. *Mayo Clin Proc*. 2000 Oct;75(10):1093-8.
20. Abramovits W, Arrazola P, Gupta AK. Enbrel (etanercept). *Skinmed*. 2004 Nov-Dec;3(6):333-5.
21. Acero J, Navarro-Cuellar C, Menarguez J, et al. Naso-maxillary non-Hodgkin lymphoma associated with methotrexate treatment in a patient with rheumatoid arthritis. *J Oral Maxillofac Surg*. 2006 Apr;64(4):708-11.

22. Adachi J, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. *J Rheumatol.* 1994 Oct;21(10):1922-6.
23. Adam DJ, Nawroz I, Petrie PW. Pyoderma gangrenosum severely affecting both hands. *J Hand Surg [Br].* 1996 Dec;21(6):792-4.
24. Adebayo D, Popat R, Thjodleifsson B, et al. Granulomatous ileitis in a patient with ankylosing spondylitis. *Nat Clin Pract Gastroenterol Hepatol.* 2007 Jun;4(6):347-51.
25. Adhikesavan LG, Newman ED, Diehl MP, et al. American College of Rheumatology quality indicators for rheumatoid arthritis: benchmarking, variability, and opportunities to improve quality of care using the electronic health record. *Arthritis Rheum.* 2008 Dec 15;59(12):1705-12.
26. Adisen E, Karaca F, Gurer MA. When there is no single best biological agent: psoriasis and psoriatic arthritis in the same patient responding to two different biological agents. *Clin Exp Dermatol.* 2008 Mar;33(2):164-6.
27. Adzic TN, Stojisic JM, Radosavljevic-Asic GD, et al. Multinodular pulmonary amyloidosis in primary Sjogren's syndrome. *Eur J Intern Med.* 2008 Dec;19(8):e97-8.
28. Aeberli D, Oertle S, Mauron H, et al. Inhibition of the TNF-pathway: use of infliximab and etanercept as remission-inducing agents in cases of therapy-resistant chronic inflammatory disorders. *Swiss Med Wkly.* 2002 Jul 27;132(29-30):414-22.
29. Aeberli D, Seitz M, Juni P, et al. Increase of peripheral CXCR3 positive T lymphocytes upon treatment of RA patients with TNF-alpha inhibitors. *Rheumatology (Oxford).* 2005 Feb;44(2):172-5.
30. Aerts NE, Ebo DG, Bridts CH, et al. Flow cytometric analysis of phospho-p38 mitogen-activated kinase (MAPK): p38 MAPK does not mediate the effect of adalimumab on peripheral T cell cytokine production in rheumatoid arthritis. *Cytokine.* 2009 Sep;47(3):178-84.
31. Agarwal PK, Gallagher M, Murphy E, et al. Endogenous endophthalmitis in a rheumatoid patient on tumor necrosis factor alpha blocker. *Indian J Ophthalmol.* 2007 May-Jun;55(3):230-2.
32. Agarwal S, Zaman T, Handa R. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. *Singapore Med J* 2009;50(7):686-92.
33. Agarwal SK, Maier AL, Chibnik LB, et al. Pattern of infliximab utilization in rheumatoid arthritis patients at an academic medical center. *Arthritis Rheum.* 2005 Dec 15;53(6):872-8.
34. Aggarwal A, Panda S, Misra R. Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study. *Ann Rheum Dis.* 2004 Jul;63(7):891-2.
35. Aggarwal P, Naik S, Mishra KP, et al. Correlation between methotrexate efficacy & toxicity with C677T polymorphism of the methylenetetrahydrofolate gene in rheumatoid arthritis patients on folate supplementation. *Indian J Med Res.* 2006 Nov;124(5):521-6.
36. Agirbasli M, Inanc N, Baykan OA, et al. The effects of TNF alpha inhibition on plasma fibrinolytic balance in patients with chronic inflammatory rheumatological disorders. *Clin Exp Rheumatol.* 2006 Sep-Oct;24(5):580-3.
37. Ahmadi-Simab K, Lamprecht P, Nolle B, et al. Successful treatment of refractory anterior scleritis in primary Sjogren's syndrome with rituximab. *Ann Rheum Dis.* 2005 Jul;64(7):1087-8.
38. Ahmed M, Luggen M, Herman JH, et al. Hypertrophic pachymeningitis in rheumatoid arthritis after adalimumab administration. *J Rheumatol.* 2006 Nov;33(11):2344-6.
39. Ahmed MM, Mubashir E, Wolf RE, et al. Impact of treatment with infliximab on anticyclic citrullinated peptide antibody and rheumatoid factor in patients with rheumatoid arthritis. *South Med J.* 2006 Nov;99(11):1209-15.

40. Aida S, Okawa-Takatsuji M, Aotsuka S, et al. Calcitonin inhibits production of immunoglobulins, rheumatoid factor and interleukin-1 by mononuclear cells from patients with rheumatoid arthritis. *Ann Rheum Dis.* 1994 Apr;53(4):247-9.
41. Akai M, Ohno T, Kamura S, et al. Epidural abscess following septic arthritis in a rheumatoid patient. A case report. *Spine.* 1990 Jun;15(6):603-5.
42. Akay OM, Korkmaz C, Gulbas Z. Development of acute inflammatory arthritis by granulocyte-macrophage colony-stimulating factor during autologous stem cell transplantation for cryoglobulinemia. *Rheumatol Int.* 2007 Oct;27(12):1167-9.
43. Akritidis N, Papadopoulos A, Pappas G. Long-term follow-up of patients with adult-onset Still's disease. *Scand J Rheumatol.* 2006 Sep-Oct;35(5):395-7.
44. Alarcon GS. Early rheumatoid arthritis: combination therapy of doxycycline plus methotrexate versus methotrexate monotherapy. *Nat Clin Pract Rheumatol.* 2006 Jun;2(6):296-7.
45. Al-Arfaj AS, Al-Saleh S. Adult-Onset Still's disease in Saudi Arabia. *Clin Rheumatol.* 2001;20(3):197-200.
46. Alegre-Sancho JJ, Juanola X, Narvaez FJ, et al. Septic arthritis due to *Prevotella bivia* in a patient with rheumatoid arthritis. *Joint Bone Spine.* 2000;67(3):228-9.
47. Alessandri C, Bombardieri M, Papa N, et al. Decrease of anti-cyclic citrullinated peptide antibodies and rheumatoid factor following anti-TNFalpha therapy (infliximab) in rheumatoid arthritis is associated with clinical improvement. *Ann Rheum Dis.* 2004 Oct;63(10):1218-21.
48. Aletaha D, Funovits J, Keystone EC, et al. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. *Arthritis Rheum.* 2007 Oct;56(10):3226-35.
49. Alex P, Szodoray P, Arthur E, et al. Influence of intraarticular corticosteroid administration on serum cytokines in rheumatoid arthritis. *Clin Rheumatol.* 2007 May;26(5):845-8.
50. Alex P, Szodoray P, Knowlton N, et al. Multiplex serum cytokine monitoring as a prognostic tool in rheumatoid arthritis. *Clin Exp Rheumatol.* 2007 Jul-Aug;25(4):584-92.
51. Alexander D, Friedrich B, Abruzzese T, et al. The active form of leflunomide, HMR1726, facilitates TNF-alpha and IL-17 induced MMP-1 and MMP-3 expression. *Cell Physiol Biochem.* 2006;17(1-2):69-78.
52. Ali AA, Moatter T, Baig JA, et al. Polymorphism of HLA-DR and HLA-DQ in rheumatoid arthritis patients and clinical response to methotrexate--a hospital-based study. *J Pak Med Assoc.* 2006 Oct;56(10):452-6.
53. Alivernini S, Mazzotta D, Zoli A, et al. Leflunomide treatment in elderly patients with rheumatoid or psoriatic arthritis: retrospective analysis of safety and adherence to treatment. *Drugs Aging.* 2009;26(5):395-402.
54. Alkassab F. Overlap of systemic sclerosis and rheumatoid arthritis. *J Rheumatol.* 2007 Jul;34(7):1593-4.
55. Allanore Y, Bremont C, Kahan A, et al. Transient hyperthyroidism in a patient with rheumatoid arthritis treated by etanercept. *Clin Exp Rheumatol.* 2001 May-Jun;19(3):356-7.
56. Allanore Y, Sellam J, Batteux F, et al. Induction of autoantibodies in refractory rheumatoid arthritis treated by infliximab. *Clin Exp Rheumatol.* 2004 Nov-Dec;22(6):756-8.
57. Allantaz F, Chaussabel D, Stichweh D, et al. Blood leukocyte microarrays to diagnose systemic onset juvenile idiopathic arthritis and follow the response to IL-1 blockade. *J Exp Med.* 2007 Sep 3;204(9):2131-44.
58. Almodovar R, Izquierdo M, Zarco P, et al. Pulmonary sarcoidosis in a patient with ankylosing spondylitis treated with infliximab. *Clin Exp Rheumatol.* 2007 Jan-Feb;25(1):99-101.
59. Almodovar R, Zarco P, Quiros FJ, et al. Infliximab treatment efficacy in lymphoedema associated with ankylosing spondylitis. *Rheumatology (Oxford).* 2004 Nov;43(11):1456.

60. al-Mughales J, Blyth TH, Hunter JA, et al. The chemoattractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. *Clin Exp Immunol*. 1996 Nov;106(2):230-6.
61. Alonso-Bartolome P, Martinez-Taboada VM, Blanco R, et al. Insufficiency fractures of the tibia and fibula. *Semin Arthritis Rheum*. 1999 Jun;28(6):413-20.
62. Alshekhlee A, Basiri K, Miles JD, et al. Chronic inflammatory demyelinating polyneuropathy associated with tumor necrosis factor-alpha antagonists. *Muscle Nerve*. 2010 May;41(5):723-7.
63. Alstergren P, Larsson PT, Kopp S. Successful treatment with multiple intra-articular injections of infliximab in a patient with psoriatic arthritis. *Scand J Rheumatol*. 2008 Mar-Apr;37(2):155-7.
64. Altintop L, Cakar B, Hokelek M, et al. *Strongyloides stercoralis* hyperinfection in a patient with rheumatoid arthritis and bronchial asthma: a case report. *Ann Clin Microbiol Antimicrob*. 2010;9:27.
65. Alvarez-Rodriguez L, Carrasco-Marin E, Lopez-Hoyos M, et al. Interleukin-1RN gene polymorphisms in elderly patients with rheumatic inflammatory chronic conditions: Association of IL-1RN\*2/2 genotype with polymyalgia rheumatica. *Hum Immunol*. 2009 Jan;70(1):49-54.
66. Aman S, Hakala M, Silvennoinen J, et al. Low incidence of osteoporosis in a two year follow-up of early community based patients with rheumatoid arthritis. *Scand J Rheumatol*. 1998;27(3):188-93.
67. Amenomori M, Migita K, Miyashita T, et al. Cytomegalovirus-associated hemophagocytic syndrome in a patient with adult onset Still's disease. *Clin Exp Rheumatol*. 2005 Jan-Feb;23(1):100-2.
68. Amichai B, Gat A, Grunwald MH. Cutaneous hyperpigmentation during therapy with hydroxychloroquine. *J Clin Rheumatol*. 2007 Apr;13(2):113.
69. Amital H, Aamar S, Rubinow A. Bilateral septic arthritis of the hip: does etanercept play a role? A case report. *J Bone Joint Surg Am*. 2003 Nov;85-A(11):2205-6.
70. Amital H, Arnson Y, Chodick G, et al. Hepatotoxicity rates do not differ in patients with rheumatoid arthritis and psoriasis treated with methotrexate. *Rheumatology (Oxford)*. 2009 Sep;48(9):1107-10.
71. Anandacoomarasamy A, Kannagara S, Barnsley L. Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis. *Intern Med J*. 2005 Oct;35(10):638-40.
72. Anandarajah AP, Schwarz EM, Totterman S, et al. The effect of etanercept on osteoclast precursor frequency and enhancing bone marrow oedema in patients with psoriatic arthritis. *Ann Rheum Dis*. 2008 Mar;67(3):296-301.
73. Ancuta C, Ancuta E, Miu S, et al. Adalimumab therapy in patients with active rheumatoid arthritis. *Rev Med Chir Soc Med Nat Iasi*. 2009 Jul-Sep;113(3):710-5.
74. Andonopoulos AP, Meimaris N, Daoussis D, et al. Intra-articular anti-tumor necrosis factor alpha antibody in recalcitrant arthritis of Behcet's disease. *Clin Exp Rheumatol*. 2003 Jul-Aug;21(4 Suppl 30):S57-8.
75. Andres E, Limbach FX, Goichot B, et al. Silent thyroiditis associated with etanercept in rheumatoid arthritis. *Ann Rheum Dis*. 2002 Jun;61(6):565.
76. Anelli MG, Torres DD, Manno C, et al. Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab. *Arthritis Rheum*. 2005 Aug;52(8):2519-20.
77. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? *J Rheumatol*. 2003 Nov;30(11):2315-8.
78. Anis A, Zhang W, Emery P, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. *Rheumatology (Oxford)* 2009;48(10):1283-9.

79. Anolik JH, Ravikumar R, Barnard J, et al. Cutting edge: anti-tumor necrosis factor therapy in rheumatoid arthritis inhibits memory B lymphocytes via effects on lymphoid germinal centers and follicular dendritic cell networks. *J Immunol.* 2008 Jan 15;180(2):688-92.
80. Antolin J, Azahara M, Hernandez C, et al. Tuberculous peritonitis after treatment with adalimumab. *Scand J Infect Dis.* 2008;40(8):677-8.
81. Antoni C, Dechant C, Hanns-Martin Lorenz PD, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. *Arthritis Rheum.* 2002 Oct 15;47(5):506-12.
82. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. *Ann Rheum Dis.* 2005 Aug;64(8):1150-7.
83. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum.* 2005 Apr;52(4):1227-36.
84. Antoni CE, Kavanaugh A, van der Heijde D, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). *J Rheumatol.* 2008 May;35(5):869-76.
85. Antoniou KM, Mamoulaki M, Malagari K, et al. Infliximab therapy in pulmonary fibrosis associated with collagen vascular disease. *Clin Exp Rheumatol.* 2007 Jan-Feb;25(1):23-8.
86. Antony T, Jose VM, Paul BJ, et al. Efficacy and safety of leflunomide alone and in combination with methotrexate in the treatment of refractory rheumatoid arthritis. *Indian J Med Sci.* 2006 Aug;60(8):318-26.
87. Aouba A, De Bandt M, Aslangul E, et al. Haemophagocytic syndrome in a rheumatoid arthritis patient treated with infliximab. *Rheumatology (Oxford).* 2003 Jun;42(6):800-2.
88. Aparicio AG, Munoz-Fernandez S, Bonilla G, et al. Report of an additional case of anti-tumor necrosis factor therapy and *Listeria monocytogenes* infection: comment on the letter by Gluck et al. *Arthritis Rheum.* 2003 Jun;48(6):1764-5; author reply 5-6.
89. Appel da Silva F, Appel da Silva MC, Romagna ES. Clinical images: Psoriatic arthritis mutilans. *Arthritis Rheum.* 2010 Jul;62(7):2159.
90. Appenzeller S, Castro GR, Costallat LT, et al. Adult-onset Still disease in southeast Brazil. *J Clin Rheumatol.* 2005 Apr;11(2):76-80.
91. Arabelovic S, Sam G, Dallal GE, et al. Preliminary evidence shows that folic acid fortification of the food supply is associated with higher methotrexate dosing in patients with rheumatoid arthritis. *J Am Coll Nutr.* 2007 Oct;26(5):453-5.
92. Aramaki T, Kawakami A, Iwamoto N, et al. Prediction of DAS28-CRP remission in patients with rheumatoid arthritis treated with tacrolimus at 6 months by baseline variables. *Mod Rheumatol.* 2009;19(6):652-6.
93. Ardalan MR, Shoja MM. Multiple myeloma presented as acute interstitial nephritis and rheumatoid arthritis-like polyarthritis. *Am J Hematol.* 2007 Apr;82(4):309-13.
94. Arend SM, Kuijper EJ, Allaart CF, et al. Cavitating pneumonia after treatment with infliximab and prednisone. *Eur J Clin Microbiol Infect Dis.* 2004 Aug;23(8):638-41.
95. Argyropoulou MI, Glatzouni A, Voulgari PV, et al. Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with infliximab. *Joint Bone Spine.* 2005 Dec;72(6):557-61.
96. Arif S, Cox P, Afzali B, et al. Anti-TNFalpha therapy--killing two birds with one stone? *Lancet* 2010;375(9733):2278.
97. Arkachaisri T, Lehman TJ. Use of biologics in the treatment of childhood rheumatic diseases. *Curr Rheumatol Rep.* 2000 Aug;2(4):330-6.



98. Arman A, Yilmaz B, Coker A, et al. Interleukin-1 receptor antagonist (IL-1RN) and interleukin-1B gene polymorphisms in Turkish patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2006 Nov-Dec;24(6):643-8.
99. Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. *J Rheumatol*. 2005 Apr;32(4):759; author reply -60.
100. Arnold EL, Khanna D, Paulus H, et al. Acute injection site reaction to intraarticular etanercept administration. *Arthritis Rheum*. 2003 Jul;48(7):2078-9.
101. Arvidson NG, Larsen A, Aaseth J, et al. Short-term effects of the TNFalpha antagonist infliximab on the acute phase reaction and activities of daily life in patients with rheumatoid arthritis. *Scand J Clin Lab Invest*. 2007;67(3):337-42.
102. Asanuma Y, Chung CP, Oeser A, et al. Serum osteoprotegerin is increased and independently associated with coronary-artery atherosclerosis in patients with rheumatoid arthritis. *Atherosclerosis*. 2007 Dec;195(2):e135-41.
103. Asherson RA, Pascoe L. Adult onset Still's disease: response to Enbrel. *Ann Rheum Dis*. 2002 Sep;61(9):859-60; author reply 60.
104. Ashok D, Ayliffe WH, Kiely PD. Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. *Rheumatology (Oxford)*. 2005 Jul;44(7):950-1.
105. Ashok D, Dubey S, Tomlinson I. C-ANCA positive systemic vasculitis in a patient with rheumatoid arthritis treated with infliximab. *Clin Rheumatol*. 2008 Feb;27(2):261-4.
106. Askling J, Fored CM, Brandt L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. *Arthritis Rheum*. 2005 Jul;52(7):1986-92.
107. Askling J, van Vollenhoven RF, Granath F, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? *Arthritis Rheum* 2009;60(11):3180-9.
108. Aslangul E, Perrot S, Durand E, et al. Successful etanercept treatment of constrictive pericarditis complicating rheumatoid arthritis. *Rheumatology (Oxford)*. 2005 Dec;44(12):1581-3.
109. Aslanidis S, Pырpasopoulou A, Douma S, et al. Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? *Arthritis Rheum*. 2008 Jan;58(1):327-8.
110. Aslanidis S, Vassiliadis T, Pырpasopoulou A, et al. Inhibition of TNFalpha does not induce viral reactivation in patients with chronic hepatitis C infection: two cases. *Clin Rheumatol*. 2007 Feb;26(2):261-4.
111. Asli B, Wechsler B, Lemaitre C. Inhibition of tumor necrosis factor alpha and ankylosing spondylitis. *N Engl J Med*. 2003 Jan 23;348(4):359-61; author reply -61.
112. Asplund MS, Hagberg H, Holmstrom M. Chemotherapy in severe nasal polyposis--a possible beneficial effect? A report of three cases. *Rhinology*. 2010 Sep;48(3):374-6.
113. Assimakopoulos SF, Michalopoulou S, Melachrinou M, et al. Primary Sjogren syndrome complicated by autoimmune hemolytic anemia and pure red cell aplasia. *Am J Med Sci*. 2007 Dec;334(6):493-6.
114. Assmann G, Pfreundschuh M, Voswinkel J. Rituximab in patients with rheumatoid arthritis and vasculitis-associated cutaneous ulcers. *Clin Exp Rheumatol*. 2010 Jan-Feb;28(1 Suppl 57):81-3.
115. Assous N, Gossec L, Dieude P, et al. Rituximab therapy in rheumatoid arthritis in daily practice. *J Rheumatol*. 2008 Jan;35(1):31-4.
116. Atchia, II, Kidd CE, Bell RW. Rheumatoid arthritis-associated necrotizing scleritis and peripheral ulcerative keratitis treated successfully with infliximab. *J Clin Rheumatol*. 2006 Dec;12(6):291-3.

117. Atteno M, Peluso R, Costa L, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. *Clin Rheumatol* 2010;29(4):399-403.
118. Atzeni F, Doria A, Ghirardello A, et al. Organ-specific autoantibodies in patients with rheumatoid arthritis treated with adalimumab: a prospective long-term follow-up. *Autoimmunity*. 2008 Feb;41(1):87-91.
119. Atzeni F, Sarzi-Puttini P, DePortu S, et al. In etanercept-treated psoriatic arthritis patients clinical improvement correlated with an increase of serum cortisol relative to other adrenal hormones. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1):103-8.
120. Augustsson J, Eksborg S, Ernestam S, et al. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2007 Nov;66(11):1462-6.
121. Augustsson J, Neovius M, Cullinane-Carli C, et al. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). *Ann Rheum Dis* 2010;69(1):126-31.
122. Avancini-Dobrovic V, Vrbancic TS, Kukuljan M, et al. Spontaneous serial fractures of metatarsal bones in female patient with rheumatoid arthritis on long-term steroid therapy. *Coll Antropol*. 2010 Sep;34(3):1123-6.
123. Avriel A, Zeller L, Flusser D, et al. Coexistence of psoriatic arthritis and systemic lupus erythematosus. *Isr Med Assoc J*. 2007 Jan;9(1):48-9.
124. Ayaz NA, Demirkaya E, Bilginer Y, et al. Preventing tuberculosis in children receiving anti-TNF treatment. *Clin Rheumatol*. 2010 Apr;29(4):389-92.
125. Aydin T, Karacan I, Demir SE, et al. Bone loss in males with ankylosing spondylitis: its relation to sex hormone levels. *Clin Endocrinol (Oxf)*. 2005 Oct;63(4):467-9.
126. Aydintug AO, D'Cruz D, Cervera R, et al. Low dose methotrexate treatment in adult Still's disease. *J Rheumatol*. 1992 Mar;19(3):431-5.
127. Aydog E, Yesilli O, Sever A, et al. Dermatitis herpetiformis and rheumatoid arthritis. *Saudi Med J*. 2006 Jun;27(6):881-4.
128. Azuma T, Ishimaru H, Hatta K, et al. Improved response to infliximab after leukocytapheresis in a patient with rheumatoid arthritis. *Mod Rheumatol*. 2007;17(3):253-5.
129. Babacan T, Onat AM, Pehlivan Y, et al. Successful treatment of refractory adult Still's disease and membranous glomerulonephritis with infliximab. *Clin Rheumatol*. 2010 Apr;29(4):423-6.
130. Bacquet-Deschryver H, Jouen F, Quillard M, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. *J Clin Immunol*. 2008 Sep;28(5):445-55.
131. Bae SC, Corzillius M, Kuntz KM, et al. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. *Rheumatology (Oxford)*. 2003 Jan;42(1):46-53.
132. Baer AN, Dessypris EN, Krantz SB. The pathogenesis of anemia in rheumatoid arthritis: a clinical and laboratory analysis. *Semin Arthritis Rheum*. 1990 Feb;19(4):209-23.
133. Baeten D, De Keyser F, Veys EM, et al. Tumour necrosis factor alpha independent disease mechanisms in rheumatoid arthritis: a histopathological study on the effect of infliximab on rheumatoid nodules. *Ann Rheum Dis*. 2004 May;63(5):489-93.
134. Baeten D, Van Damme N, Van den Bosch F, et al. Impaired Th1 cytokine production in spondyloarthropathy is restored by anti-TNFalpha. *Ann Rheum Dis*. 2001 Aug;60(8):750-5.

135. Bagalas V, Kioumis I, Argyropoulou P, et al. Visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with etanercept. *Clin Rheumatol*. 2007 Aug;26(8):1344-5.
136. Baghai M, Osmon DR, Wolk DM, et al. Fatal sepsis in a patient with rheumatoid arthritis treated with etanercept. *Mayo Clin Proc*. 2001 Jun;76(6):653-6.
137. Baig MA, Aksoy T, McClain D, et al. Calciphylaxis in a hemodialysis patient on corticosteroids and etanercept for psoriatic arthritis. *J Clin Rheumatol*. 2010 Mar;16(2):92-3.
138. Bakewell C, Dugowson C. Images in clinical medicine. Baker's cyst in a patient with rheumatoid arthritis. *N Engl J Med*. 2009 Sep 10;361(11):1098.
139. Bakland G, Nossent H. Acute myelogenous leukaemia following etanercept therapy. *Rheumatology (Oxford)*. 2003 Jul;42(7):900-1.
140. Balandraud N, Guis S, Baptiste Meynard J, et al. Long-term treatment with methotrexate or tumor necrosis factor alpha inhibitors does not increase epstein-barr virus load in patients with rheumatoid arthritis. *Arthritis Rheum*. 2007 Jun 15;57(5):762-7.
141. Balanescu A, Radu E, Nat R, et al. Early and late effect of infliximab on circulating dendritic cells phenotype in rheumatoid arthritis patients. *Int J Clin Pharmacol Res*. 2005;25(1):9-18.
142. Balbir-Gurman A, Guralnik L, Best LA, et al. Accelerated pulmonary nodulosis and sterile pleural effusion in a patient with psoriatic arthropathy during methotrexate therapy: a case report. *J Clin Rheumatol*. 2009 Feb;15(1):29-30.
143. Bambery P, Thomas RJ, Malhotra HS, et al. Adult onset Still's disease: clinical experience with 18 patients over 15 years in northern India. *Ann Rheum Dis*. 1992 Apr;51(4):529-32.
144. Bandelier C, Guerne PA, Genevay S, et al. Clinical experience with mycophenolate mofetil in systemic autoimmune conditions refractory to common immunosuppressive therapies. *Swiss Med Wkly*. 2009 Jan 24;139(3-4):41-6.
145. Bang LM, Keating GM. Adalimumab: a review of its use in rheumatoid arthritis. *BioDrugs*. 2004;18(2):121-39.
146. Bankhurst AD. Etanercept and methotrexate combination therapy. *Clin Exp Rheumatol*. 1999 Nov-Dec;17(6 Suppl 18):S69-72.
147. Baraliakos X, Brandt J, Listing J, et al. Outcome of patients with active ankylosing spondylitis after two years of therapy with etanercept: clinical and magnetic resonance imaging data. *Arthritis Rheum*. 2005 Dec 15;53(6):856-63.
148. Baraliakos X, Davis J, Tsuji W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. *Arthritis Rheum*. 2005 Apr;52(4):1216-23.
149. Baraliakos X, Listing J, Rudwaleit M, et al. Radiographic progression in patients with ankylosing spondylitis after 2 years of treatment with the tumour necrosis factor alpha antibody infliximab. *Ann Rheum Dis*. 2005 Oct;64(10):1462-6.
150. Barber J, Sheeran T, Mulherin D. Anti-tumour necrosis factor treatment in a patient with anorexia nervosa and juvenile idiopathic arthritis. *Ann Rheum Dis*. 2003 May;62(5):490-1.
151. Bargagli E, Galeazzi M, Rottoli P. Infliximab treatment in a patient with rheumatoid arthritis and pulmonary fibrosis. *Eur Respir J*. 2004 Oct;24(4):708.
152. Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. *J Rheumatol*. 2009 Jul;36(7):1421-8.
153. Barrera P, Oyen WJ, Boerman OC, et al. Scintigraphic detection of tumour necrosis factor in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2003 Sep;62(9):825-8.
154. Barrera P, van der Laken CJ, Boerman OC, et al. Radiolabelled interleukin-1 receptor antagonist for detection of synovitis in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2000 Aug;39(8):870-4.

155. Bartelds GM, Wijbrandts CA, Nurmohamed MT, et al. Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. *Ann Rheum Dis*. 2007 Jul;66(7):921-6.
156. Barthel HR. Rapid remission of treatment-resistant ankylosing spondylitis with etanercept--a drug for refractory ankylosing spondylitis? *Arthritis Rheum*. 2001 Aug;45(4):404.
157. Bartke U, Venten I, Kreuter A, et al. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. *Br J Dermatol*. 2004 Apr;150(4):784-6.
158. Bartolucci P, Ramanoelina J, Cohen P, et al. Efficacy of the anti-TNF-alpha antibody infliximab against refractory systemic vasculitides: an open pilot study on 10 patients. *Rheumatology (Oxford)*. 2002 Oct;41(10):1126-32.
159. Barton A, Myerscough A, John S, et al. A single nucleotide polymorphism in exon 1 of cytotoxic T-lymphocyte-associated-4 (CTLA-4) is not associated with rheumatoid arthritis. *Rheumatology (Oxford)*. 2000 Jan;39(1):63-6.
160. Barton P, Jobanputra P, Wilson J, et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. *Health Technol Assess*. 2004 Mar;8(11):iii, 1-91.
161. Bartram D, Sheeran T, Price T, et al. Anti-tumour necrosis factor therapy in the West Midlands. *Rheumatology (Oxford)*. 2004 Mar;43(3):400; author reply -1.
162. Bas S, Gauthier BR, Spenato U, et al. CD14 is an acute-phase protein. *J Immunol*. 2004 Apr 1;172(7):4470-9.
163. Baskan BM, Sivas F, Alemdaroglu E, et al. Association of bone mineral density and vertebral deformity in patients with rheumatoid arthritis. *Rheumatol Int*. 2007 Apr;27(6):579-84.
164. Bassetti S, Wasmer S, Hasler P, et al. Staphylococcus aureus in patients with rheumatoid arthritis under conventional and anti-tumor necrosis factor-alpha treatment. *J Rheumatol*. 2005 Nov;32(11):2125-9.
165. Bathon JM, Fleischmann RM, Van der Heijde D, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. *J Rheumatol*. 2006 Feb;33(2):234-43.
166. Bathon JM, Martin RW, Fleischmann RM, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *N Engl J Med*. 2000 Nov 30;343(22):1586-93.
167. Batsis JA, Phy MP. West Nile virus meningitis in a chronic immunosuppressed patient with rheumatoid arthritis. *Clin Rheumatol*. 2005 Sep;24(5):548-50.
168. Bauer AS, Blazar PE, Earp BE, et al. Mycobacterial hand infections occurring postoperatively in patients treated with tumor necrosis factor-alpha inhibitors for inflammatory arthritis: report of three cases. *J Hand Surg Am*. 2010 Jan;35(1):104-8.
169. Baumgartner SW, Fleischmann RM, Moreland LW, et al. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. *J Rheumatol*. 2004 Aug;31(8):1532-7.
170. Bayer M, Stepan J, Nemcova D, et al. Juvenile chronic arthritis--bone mineral density in relation to corticosteroid therapy. *Acta Univ Carol [Med] (Praha)*. 1994;40(1-4):33-5.
171. Bejarano V, Quinn M, Conaghan PG, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. *Arthritis Rheum* 2008;59(10):1467-74.
172. Bejot Y, Osseby GV, Ben Salem D, et al. Bilateral optic neuropathy revealing Sjogren's syndrome. *Rev Neurol (Paris)*. 2008 Dec;164(12):1044-7.
173. Belknap R, Reves R, Burman W. Immune reconstitution to Mycobacterium tuberculosis after discontinuing infliximab. *Int J Tuberc Lung Dis*. 2005 Sep;9(9):1057-8.

174. Bellisai F, Giannitti C, Donvito A, et al. Combination therapy with cyclosporine A and anti-TNF-alpha agents in the treatment of rheumatoid arthritis and concomitant hepatitis C virus infection. *Clin Rheumatol*. 2007 Jul;26(7):1127-9.
175. Belostocki K, Pricop L, Redecha PB, et al. Infliximab treatment shifts the balance between stimulatory and inhibitory Fcgamma receptor type II isoforms on neutrophils in patients with rheumatoid arthritis. *Arthritis Rheum*. 2008 Feb;58(2):384-8.
176. Bender NK, Heilig CE, Droll B, et al. Immunogenicity, efficacy and adverse events of adalimumab in RA patients. *Rheumatol Int*. 2007 Jan;27(3):269-74.
177. Ben-Horin S, Goldstein I, Koltakov A, et al. The effect of blockade of tumor necrosis factor alpha on VLA-1+ T-cells in rheumatoid arthritis patients. *J Clin Immunol*. 2007 Nov;27(6):580-8.
178. Benito-Garcia E, Heller JE, Chibnik LB, et al. Dietary caffeine intake does not affect methotrexate efficacy in patients with rheumatoid arthritis. *J Rheumatol*. 2006 Jul;33(7):1275-81.
179. Bennett AN, Peterson P, Zain A, et al. Adalimumab in clinical practice. Outcome in 70 rheumatoid arthritis patients, including comparison of patients with and without previous anti-TNF exposure. *Rheumatology (Oxford)*. 2005 Aug;44(8):1026-31.
180. Bennett AN, Wong M, Zain A, et al. Adalimumab-induced asthma. *Rheumatology (Oxford)*. 2005 Sep;44(9):1199-200.
181. Benucci M, Li GF, Del Rosso A, et al. Adalimumab (anti-TNF-alpha) therapy to improve the clinical course of adult-onset Still's disease: the first case report. *Clin Exp Rheumatol*. 2005 Sep-Oct;23(5):733.
182. Benucci M, Li Gobbi F, Fossi F, et al. Drug-induced lupus after treatment with infliximab in rheumatoid arthritis. *J Clin Rheumatol*. 2005 Feb;11(1):47-9.
183. Benucci M, Li Gobbi F, Saviola G, et al. Improved rheumatoid digital vasculitis in a patient treated with TNFalpha agent blocking (infliximab). *Rheumatol Int*. 2008 Oct;28(12):1253-5.
184. Benucci M, Manfredi M, Mecocci L. Effect of etanercept plus lamivudine in a patient with rheumatoid arthritis and viral hepatitis B. *J Clin Rheumatol*. 2008 Aug;14(4):245-6.
185. Benucci M, Saviola G, Baiardi P, et al. Antinucleosome antibodies as prediction factor of development of autoantibodies during therapy with three different TNFalpha blocking agents in rheumatoid arthritis. *Clin Rheumatol*. 2008 Jan;27(1):91-5.
186. Berard A, Solomon DH, Avorn J. Patterns of drug use in rheumatoid arthritis. *J Rheumatol*. 2000 Jul;27(7):1648-55.
187. Berg L, Lampa J, Rogberg S, et al. Increased peripheral T cell reactivity to microbial antigens and collagen type II in rheumatoid arthritis after treatment with soluble TNFalpha receptors. *Ann Rheum Dis*. 2001 Feb;60(2):133-9.
188. Berger A, Edelsberg J, Li TT, et al. Dose intensification with infliximab in patients with rheumatoid arthritis. *Ann Pharmacother*. 2005 Dec;39(12):2021-5.
189. Bergman J, Schjott J. Hepatitis caused by Lotus-f3? *Basic Clin Pharmacol Toxicol*. 2009 May;104(5):414-6.
190. Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. *Arthritis Rheum*. 2004 Jun;50(6):1959-66.
191. Berkun Y, Abou Atta I, Rubinow A, et al. 2756GG genotype of methionine synthase reductase gene is more prevalent in rheumatoid arthritis patients treated with methotrexate and is associated with methotrexate-induced nodulosis. *J Rheumatol*. 2007 Aug;34(8):1664-9.
192. Bernatsky S, Ehrmann Feldman D. Discontinuation of methotrexate therapy in older patients with newly diagnosed rheumatoid arthritis: analysis of administrative health databases in Quebec, Canada. *Drugs Aging*. 2008;25(10):879-84.
193. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. *Rheumatology (Oxford)* 2007;46(7):1157-60.

194. Berookhim B, Fischer HD, Weinberg JM. Treatment of recalcitrant pemphigus vulgaris with the tumor necrosis factor alpha antagonist etanercept. *Cutis*. 2004 Oct;74(4):245-7.
195. Berthelot C, Cather J, Jones D, et al. Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy. *Clin Lymphoma Myeloma*. 2006 Jan;6(4):329-32.
196. Berthelot JM, De Bandt M, Goupille P, et al. Exposition to anti-TNF drugs during pregnancy: outcome of 15 cases and review of the literature. *Joint Bone Spine*. 2009 Jan;76(1):28-34.
197. Berthelot JM, Glemarec J, Maugars Y, et al. Lethal medium-vessel panarteritis mimicking deep sepsis following etanercept and minocycline therapy in a patient with severe rheumatoid arthritis. *Rheumatology (Oxford)*. 2002 Jun;41(6):703-5.
198. Berthelot JM, Varin S, Cormier G, et al. 25 mg etanercept once weekly in rheumatoid arthritis and spondylarthropathy. *Joint Bone Spine*. 2007 Mar;74(2):144-7.
199. Bertoli AM, Strusberg I, Baravalle M, et al. Rate and causes of infliximab discontinuation in patients with rheumatoid arthritis in a private clinical practice. *J Clin Rheumatol*. 2008 Dec;14(6):313-7.
200. Beuthien W, Mellinshoff HU, von Kempis J. Skin reaction to adalimumab. *Arthritis Rheum*. 2004 May;50(5):1690-2.
201. Beyeler C, Frey BM, Bird HA. Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. *Br J Rheumatol*. 1997 Jan;36(1):54-8.
202. Bhagat S, Ostor AJ. Diagnosing joint pain in the older people. *Practitioner*. 2010 Jan;254(1725):17-21, 2.
203. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. *Foot Ankle Int*. 2004 May;25(5):331-5.
204. Bicer A, Tursen U, Cimen OB, et al. Prevalence of dermatophytosis in patients with rheumatoid arthritis. *Rheumatol Int*. 2003 Jan;23(1):37-40.
205. Biester S, Deuter C, Michels H, et al. Adalimumab in the therapy of uveitis in childhood. *Br J Ophthalmol*. 2007 Mar;91(3):319-24.
206. Bilsborough W, Keen H, Taylor A, et al. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with rheumatoid arthritis. *Rheumatol Int*. 2006 Oct;26(12):1125-31.
207. Biro T, Griger Z, Kiss E, et al. Abnormal cell-specific expressions of certain protein kinase C isoenzymes in peripheral mononuclear cells of patients with systemic lupus erythematosus: effect of corticosteroid application. *Scand J Immunol*. 2004 Oct;60(4):421-8.
208. Biyikoglu B, Buduneli N, Kardesler L, et al. Evaluation of t-PA, PAI-2, IL-1beta and PGE(2) in gingival crevicular fluid of rheumatoid arthritis patients with periodontal disease. *J Clin Periodontol*. 2006 Sep;33(9):605-11.
209. Biyikoglu B, Buduneli N, Kardesler L, et al. Gingival crevicular fluid MMP-8 and -13 and TIMP-1 levels in patients with rheumatoid arthritis and inflammatory periodontal disease. *J Periodontol*. 2009 Aug;80(8):1307-14.
210. Blackman MR, Muniyappa R, Wilson M, et al. Diurnal secretion of growth hormone, cortisol, and dehydroepiandrosterone in pre- and perimenopausal women with active rheumatoid arthritis: a pilot case-control study. *Arthritis Res Ther*. 2007;9(4):R73.
211. Blanco R, Martinez-Taboada VM, Rodriguez-Valverde V, et al. Successful therapy with danazol in refractory autoimmune thrombocytopenia associated with rheumatic diseases. *Br J Rheumatol*. 1997 Oct;36(10):1095-9.
212. Bleumink GS, ter Borg EJ, Ramselaar CG, et al. Etanercept-induced subacute cutaneous lupus erythematosus. *Rheumatology (Oxford)*. 2001 Nov;40(11):1317-9.
213. Blom M, Kievit W, Fransen J, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. *J Rheumatol*. 2009 Oct;36(10):2171-7.

214. Blom M, Kievit W, Kuper HH, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. *Arthritis Care Res (Hoboken)*. 2010 Sep;62(9):1335-41.
215. Blumberg SN, Fox DA. Rheumatoid arthritis: guidelines for emerging therapies. *Am J Manag Care*. 2001 Jun;7(6):617-26.
216. Blyth T, Hunter JA, Stirling A. Pain relief in the rheumatoid knee after steroid injection. A single-blind comparison of hydrocortisone succinate, and triamcinolone acetonide or hexacetonide. *Br J Rheumatol*. 1994 May;33(5):461-3.
217. Boatright MD, Wang BW. Clinical infection with *Strongyloides stercoralis* following etanercept use for rheumatoid arthritis. *Arthritis Rheum*. 2005 Apr;52(4):1336-7.
218. Bobbio-Pallavicini F, Alpini C, Caporali R, et al. Autoantibody profile in rheumatoid arthritis during long-term infliximab treatment. *Arthritis Res Ther*. 2004;6(3):R264-72.
219. Bobbio-Pallavicini F, Caporali R, Alpini C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. *Ann Rheum Dis*. 2007 Mar;66(3):302-7.
220. Bodur H, Ataman S, Akbulut L, et al. Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. *Clin Rheumatol*. 2008 Sep;27(9):1119-25.
221. Bodur H, Seckin U, Eser F, et al. Coexistence of familial Mediterranean fever and psoriasis in a patient with seronegative spondyloarthropathy. *Rheumatol Int*. 2008 Nov;29(1):107-10.
222. Boeger CA, Wittwer H, Schattenkirchner M, et al. Treatment of ankylosing spondylitis with infliximab. *Ann Rheum Dis*. 2001 Dec;60(12):1159-60.
223. Boers M, Verhoeven AC, Markusse HM, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet*. 1997 Aug 2;350(9074):309-18.
224. Boesen M, Boesen L, Jensen KE, et al. Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. *J Rheumatol*. 2008 Apr;35(4):584-91.
225. Boesen M, Jensen KE, Torp-Pedersen S, et al. Intra-articular distribution pattern after ultrasound-guided injections in wrist joints of patients with rheumatoid arthritis. *Eur J Radiol*. 2009 Feb;69(2):331-8.
226. Boey O, Van Hooland S, Woestenburg A, et al. Methotrexate should not be used for patients with end-stage kidney disease. *Acta Clin Belg*. 2006 Jul-Aug;61(4):166-9.
227. Bogoch E, Ouellette G, Hastings D. Failure of internal fixation of displaced femoral neck fractures in rheumatoid patients. *J Bone Joint Surg Br*. 1991 Jan;73(1):7-10.
228. Bogoch ER, Ouellette G, Hastings DE. Intertrochanteric fractures of the femur in rheumatoid arthritis patients. *Clin Orthop Relat Res*. 1993 Sep(294):181-6.
229. Bohanec Grabar P, Grabnar I, Rozman B, et al. Investigation of the influence of CYP1A2 and CYP2C19 genetic polymorphism on 2-Cyano-3-hydroxy-N-[4-(trifluoromethyl)phenyl]-2-butenamide (A77 1726) pharmacokinetics in leflunomide-treated patients with rheumatoid arthritis. *Drug Metab Dispos*. 2009 Oct;37(10):2061-8.
230. Bohanec Grabar P, Logar D, Lestan B, et al. Genetic determinants of methotrexate toxicity in rheumatoid arthritis patients: a study of polymorphisms affecting methotrexate transport and folate metabolism. *Eur J Clin Pharmacol*. 2008 Nov;64(11):1057-68.
231. Bohanec Grabar P, Rozman B, Tomsic M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. *Eur J Clin Pharmacol*. 2008 Sep;64(9):871-6.
232. Bolla G, Disdier P, Harle JR, et al. Concurrent acute megaloblastic anaemia and pneumonitis: a severe side-effect of low-dose methotrexate therapy during rheumatoid arthritis. *Clin Rheumatol*. 1993 Dec;12(4):535-7.

233. Bollow M, Braun J, Taupitz M, et al. CT-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with spondyloarthritis: indication and follow-up with contrast-enhanced MRI. *J Comput Assist Tomogr.* 1996 Jul-Aug;20(4):512-21.
234. Bologna C, Jorgensen C, Sany J. Association of methotrexate and corticosteroids in the treatment of patients with rheumatoid arthritis. *Clin Exp Rheumatol.* 1996 Jul-Aug;14(4):401-6.
235. Bolstad AI, Eiken HG, Rosenlund B, et al. Increased salivary gland tissue expression of Fas, Fas ligand, cytotoxic T lymphocyte-associated antigen 4, and programmed cell death 1 in primary Sjogren's syndrome. *Arthritis Rheum.* 2003 Jan;48(1):174-85.
236. Bombardieri S, Ruiz AA, Fardellone P, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. *Rheumatology (Oxford).* 2007 Jul;46(7):1191-9.
237. Bongartz T, Harle P, Friedrich S, et al. Successful treatment of psoriatic onychopachydermo periostitis (POPP) with adalimumab. *Arthritis Rheum.* 2005 Jan;52(1):280-2.
238. Bongiorno MR, Pistone G, Doukaki S, et al. Adalimumab for treatment of moderate to severe psoriasis and psoriatic arthritis. *Dermatol Ther.* 2008 Oct;21 Suppl 2:S15-20.
239. Book C, Karlsson M, Akesson K, et al. Disease activity and disability but probably not glucocorticoid treatment predicts loss in bone mineral density in women with early rheumatoid arthritis. *Scand J Rheumatol.* 2008 Jul-Aug;37(4):248-54.
240. Book C, Karlsson MK, Akesson K, et al. Early rheumatoid arthritis and body composition. *Rheumatology (Oxford).* 2009 Sep;48(9):1128-32.
241. Book C, Saxne T, Jacobsson LT. Prediction of mortality in rheumatoid arthritis based on disease activity markers. *J Rheumatol.* 2005 Mar;32(3):430-4.
242. Boonen A, van der Heijde D, Severens JL, et al. Markov model into the cost-utility over five years of etanercept and infliximab compared with usual care in patients with active ankylosing spondylitis. *Ann Rheum Dis.* 2006 Feb;65(2):201-8.
243. Borowski LC, Lopes RP, Gonzalez TP, et al. Is steroid resistance related to multidrug resistance-I (MDR-I) in rheumatoid arthritis? *Int Immunopharmacol.* 2007 Jun;7(6):836-44.
244. Borrás-Blasco J, Gracia-Perez A, Nunez-Cornejo C, et al. Exacerbation of psoriatic skin lesions in a patient with psoriatic arthritis receiving adalimumab. *J Clin Pharm Ther.* 2008 Jun;33(3):321-5.
245. Borrás-Blasco J, Gracia-Perez A, Rosique-Robles JD, et al. Urticaria due to etanercept in a patient with psoriatic arthritis. *South Med J.* 2009 Mar;102(3):304-5.
246. Borrás-Blasco J, Nunez-Cornejo C, Gracia-Perez A, et al. Parapharyngeal abscess in a patient receiving etanercept. *Ann Pharmacother.* 2007 Feb;41(2):341-4.
247. Bos WH, Bartelds GM, Vis M, et al. Preferential decrease in IgG4 anti-citrullinated protein antibodies during treatment with tumour necrosis factor blocking agents in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2009 Apr;68(4):558-63.
248. Bos WH, Bartelds GM, Wolbink GJ, et al. Differential response of the rheumatoid factor and anticitrullinated protein antibodies during adalimumab treatment in patients with rheumatoid arthritis. *J Rheumatol.* 2008 Oct;35(10):1972-7.
249. Boscarino JA. Posttraumatic stress disorder and physical illness: results from clinical and epidemiologic studies. *Ann N Y Acad Sci.* 2004 Dec;1032:141-53.
250. Bosello S, Santoliquido A, Zoli A, et al. TNF-alpha blockade induces a reversible but transient effect on endothelial dysfunction in patients with long-standing severe rheumatoid arthritis. *Clin Rheumatol.* 2008 Jul;27(7):833-9.



251. Boss B, Neeck G, Engelhardt B, et al. Influence of corticosteroids on neutrophils, lymphocytes, their subsets, and T-cell activity markers in patients with active rheumatoid arthritis, compared to healthy controls. *Ann N Y Acad Sci*. 1999 Jun 22;876:198-200.
252. Bostrom EA, d'Elia HF, Dahlgren U, et al. Salivary resistin reflects local inflammation in Sjogren's syndrome. *J Rheumatol*. 2008 Oct;35(10):2005-11.
253. Botez SA, Herrmann DN. Prolonged remission of a demyelinating neuropathy in a patient with lymphoma and Sjogren's syndrome after Rituximab therapy. *J Clin Neuromuscul Dis*. 2010 Mar;11(3):127-31.
254. Bourgeois E, Caulier MT, Rose C, et al. Role of splenectomy in the treatment of myelodysplastic syndromes with peripheral thrombocytopenia: a report on six cases. *Leukemia*. 2001 Jun;15(6):950-3.
255. Boveri E, Castagnola C, Castello A, et al. Aberrant phenotype of plasmacytoid monocytes in acute myeloid leukemia. *Am J Hematol*. 2008 May;83(5):428-9.
256. Bowie VL, Snella KA, Gopalachar AS, et al. Listeria meningitis associated with infliximab. *Ann Pharmacother*. 2004 Jan;38(1):58-61.
257. Bozkurt FY, Berker E, Akkus S, et al. Relationship between interleukin-6 levels in gingival crevicular fluid and periodontal status in patients with rheumatoid arthritis and adult periodontitis. *J Periodontol*. 2000 Nov;71(11):1756-60.
258. Bramlage CP, Kaps C, Ungethum U, et al. Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium. *Scand J Rheumatol*. 2008 Nov-Dec;37(6):401-9.
259. Brandt J, Haibel H, Cornely D, et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. *Arthritis Rheum*. 2000 Jun;43(6):1346-52.
260. Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. *Arthritis Rheum*. 2003 Jun;48(6):1667-75.
261. Brandt J, Listing J, Haibel H, et al. Long-term efficacy and safety of etanercept after readministration in patients with active ankylosing spondylitis. *Rheumatology (Oxford)*. 2005 Mar;44(3):342-8.
262. Brandt J, Listing J, Sieper J, et al. Development and preselection of criteria for short term improvement after anti-TNF alpha treatment in ankylosing spondylitis. *Ann Rheum Dis*. 2004 Nov;63(11):1438-44.
263. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. *Clin Infect Dis* 2006;43(6):717-22.
264. Brassard P, Lowe AM, Bernatsky S, et al. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. *Arthritis Rheum* 2009;61(3):300-4.
265. Braun J, Baraliakos X, Brandt J, et al. Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. *Rheumatology (Oxford)*. 2005 May;44(5):670-6.
266. Braun J, Baraliakos X, Golder W, et al. Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab: evaluation of a new scoring system. *Arthritis Rheum*. 2003 Apr;48(4):1126-36.
267. Braun J, Bollow M, Seyrekbasan F, et al. Computed tomography guided corticosteroid injection of the sacroiliac joint in patients with spondyloarthropathy with sacroiliitis: clinical outcome and followup by dynamic magnetic resonance imaging. *J Rheumatol*. 1996 Apr;23(4):659-64.
268. Braun J, Brandt J, Listing J, et al. Long-term efficacy and safety of infliximab in the treatment of ankylosing spondylitis: an open, observational, extension study of a three-month, randomized, placebo-controlled trial. *Arthritis Rheum*. 2003 Aug;48(8):2224-33.
269. Braun J, Brandt J, Listing J, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. *Ann Rheum Dis*. 2005 Feb;64(2):229-34.

270. Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. *Lancet*. 2002 Apr 6;359(9313):1187-93.
271. Braun J, Kastner P, Flaxenberg P, et al. Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. *Arthritis Rheum*. 2008 Jan;58(1):73-81.
272. Braun J, Landewe R, Hermann KG, et al. Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. *Arthritis Rheum*. 2006 May;54(5):1646-52.
273. Braun J, Sieper J, Breban M, et al. Anti-tumour necrosis factor alpha therapy for ankylosing spondylitis: international experience. *Ann Rheum Dis*. 2002 Dec;61 Suppl 3:iii51-60.
274. Braun J, van der Heijde D. Imaging and scoring in ankylosing spondylitis. *Best Pract Res Clin Rheumatol*. 2002 Sep;16(4):573-604.
275. Braun-Moscovici Y, Markovits D, Rozin A, et al. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. *Isr Med Assoc J*. 2008 Apr;10(4):277-81.
276. Bravo Vergel Y, Hawkins NS, Claxton K, et al. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis. *Rheumatology (Oxford)*. 2007 Nov;46(11):1729-35.
277. Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study. *Rheumatology (Oxford)*. 2002 Nov;41(11):1280-5.
278. Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. *J Clin Pharmacol*. 2007 Sep;47(9):1119-28.
279. Breedveld FC, Emery P, Keystone E, et al. Infliximab in active early rheumatoid arthritis. *Ann Rheum Dis* 2004;63(2):149-55.
280. Breedveld FC, Weisman MH, Kavanaugh AF, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum*. 2006 Jan;54(1):26-37.
281. Breglia MD, Carter JD. Atypical insufficiency fracture of the tibia associated with long-term bisphosphonate therapy. *J Clin Rheumatol*. 2010 Mar;16(2):76-8.
282. Bremner R, Simpson E, White CR, et al. Palisaded neutrophilic and granulomatous dermatitis: an unusual cutaneous manifestation of immune-mediated disorders. *Semin Arthritis Rheum*. 2004 Dec;34(3):610-6.
283. Brennan A, Bansback N, Nixon R, et al. Modelling the cost effectiveness of TNF-alpha antagonists in the management of rheumatoid arthritis: results from the British Society for Rheumatology Biologics Registry. *Rheumatology (Oxford)*. 2007 Aug;46(8):1345-54.
284. Brennan MT, Sankar V, Leakan RA, et al. Sex steroid hormones in primary Sjogren's syndrome. *J Rheumatol*. 2003 Jun;30(6):1267-71.
285. Bresnihan B. Treating early rheumatoid arthritis in the younger patient. *J Rheumatol Suppl*. 2001 Jun;62:4-9.
286. Bresnihan B, Alvaro-Gracia JM, Cobby M, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis Rheum* 1998;41(12):2196-204.
287. Bresnihan B, Newmark R, Robbins S, et al. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. *J Rheumatol*. 2004 Jun;31(6):1103-11.

288. Brocq O, Albert C, Roux C, et al. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients. *Joint Bone Spine*. 2004 Nov;71(6):601-3.
289. Brocq O, Roux CH, Albert C, et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. *Joint Bone Spine* 2007;74(2):148-54.
290. Brooks H, Taylor HG, Nichol FE. The three week sulphasalazine syndrome. *Clin Rheumatol*. 1992 Dec;11(4):566-8.
291. Brophy RH, MacKenzie CR, Gamradt SC, et al. The diagnosis and management of psoriatic arthritis in a professional football player presenting with a knee effusion: a case report. *Clin J Sport Med*. 2008 Jul;18(4):369-71.
292. Broussais F, Kawashima M, Marotte H, et al. Chronic myeloid leukaemia and tuberculosis in a patient with rheumatoid arthritis treated with infliximab. *Ann Rheum Dis*. 2005 Mar;64(3):509-10.
293. Broussard JS, Jr. Derangement, osteoarthritis, and rheumatoid arthritis of the temporomandibular joint: implications, diagnosis, and management. *Dent Clin North Am*. 2005 Apr;49(2):327-42.
294. Brown A, Grubbs P, Mongey AB. Infection of total hip prosthesis by *Mycobacterium tuberculosis* and *Mycobacterium chelonae* in a patient with rheumatoid arthritis. *Clin Rheumatol*. 2008 Apr;27(4):543-5.
295. Brown ES, Frol A, Bobadilla L, et al. Effect of lamotrigine on mood and cognition in patients receiving chronic exogenous corticosteroids. *Psychosomatics*. 2003 May-Jun;44(3):204-8.
296. Brown ES, Woolston DJ, Frol AB. Amygdala volume in patients receiving chronic corticosteroid therapy. *Biol Psychiatry*. 2008 Apr 1;63(7):705-9.
297. Brown GT, Wright FV, Lang BA, et al. Clinical responsiveness of self-report functional assessment measures for children with juvenile idiopathic arthritis undergoing intraarticular corticosteroid injections. *Arthritis Rheum*. 2005 Dec 15;53(6):897-904.
298. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. *Arthritis Rheum*. 2002 Dec;46(12):3151-8.
299. Bruckle W, Eisenhut C, Goebel FD. Cerebral involvement in adult onset Still's disease. *Clin Rheumatol*. 1992 Jun;11(2):276-9.
300. Brunasso AM, Massone C. Thrombocytopenia associated with the use of anti-tumor necrosis factor-alpha agents for psoriasis. *J Am Acad Dermatol*. 2009 May;60(5):781-5.
301. Bruns A, Nicaise-Roland P, Hayem G, et al. Prospective cohort study of effects of infliximab on rheumatoid factor, anti-cyclic citrullinated peptide antibodies and antinuclear antibodies in patients with long-standing rheumatoid arthritis. *Joint Bone Spine*. 2009 May;76(3):248-53.
302. Bruns H, Meinken C, Schauenberg P, et al. Anti-TNF immunotherapy reduces CD8+ T cell-mediated antimicrobial activity against *Mycobacterium tuberculosis* in humans. *J Clin Invest*. 2009 May;119(5):1167-77.
303. Bruyn GA, Tate G, Caeiro F, et al. Everolimus in patients with rheumatoid arthritis receiving concomitant methotrexate: a 3-month, double-blind, randomised, placebo-controlled, parallel-group, proof-of-concept study. *Ann Rheum Dis*. 2008 Aug;67(8):1090-5.
304. Bryl E, Vallejo AN, Matteson EL, et al. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. *Arthritis Rheum*. 2005 Oct;52(10):2996-3003.
305. Buccoliero G, Lonero G, Romanelli C, et al. Varicella zoster virus encephalitis during treatment with anti-tumor necrosis factor-alpha agent in a psoriatic arthritis patient. *New Microbiol*. 2010 Jul;33(3):271-4.
306. Buccoliero R, Gambelli S, Sicurelli F, et al. Leukoencephalopathy as a rare complication of hepatitis C infection. *Neurol Sci*. 2006 Nov;27(5):360-3.

307. Buch MH, Bingham SJ, Bryer D, et al. Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders. *Rheumatology (Oxford)*. 2007 Jul;46(7):1153-6.
308. Buch MH, Bingham SJ, Seto Y, et al. Lack of response to anakinra in rheumatoid arthritis following failure of tumor necrosis factor alpha blockade. *Arthritis Rheum*. 2004 Mar;50(3):725-8.
309. Buch MH, Boyle DL, Rosengren S, et al. Mode of action of abatacept in rheumatoid arthritis patients having failed tumour necrosis factor blockade: a histological, gene expression and dynamic magnetic resonance imaging pilot study. *Ann Rheum Dis*. 2009 Jul;68(7):1220-7.
310. Buch MH, Conaghan PG, Quinn MA, et al. True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? *Ann Rheum Dis*. 2004 Oct;63(10):1344-6.
311. Buch MH, Reece RJ, Quinn MA, et al. The value of synovial cytokine expression in predicting the clinical response to TNF antagonist therapy (infliximab). *Rheumatology (Oxford)*. 2008 Oct;47(10):1469-75.
312. Buch MH, Seto Y, Bingham SJ, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. *Arthritis Rheum*. 2005 Jan;52(1):42-8.
313. Buchbinder R, Barber M, Heuzenroeder L, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. *Arthritis Rheum*. 2008 Jun 15;59(6):794-9.
314. Buchs N, Silvestri T, di Giovine FS, et al. IL-4 VNTR gene polymorphism in chronic polyarthritis. The rare allele is associated with protection against destruction. *Rheumatology (Oxford)*. 2000 Oct;39(10):1126-31.
315. Buckland GT, 3rd, Carlson JA, Meyer DR. Persistent periorbital and facial lymphedema associated with Group A beta-hemolytic streptococcal infection (erysipelas). *Ophthalmol Plast Reconstr Surg*. 2007 Mar-Apr;23(2):161-3.
316. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. *J Rheumatol*. 1995 Jun;22(6):1055-9.
317. Buckley LM, Leib ES, Cartularo KS, et al. Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med*. 1996 Dec 15;125(12):961-8.
318. Buckley LM, Leib ES, Cartularo KS, et al. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. *J Rheumatol*. 1997 Aug;24(8):1489-94.
319. Buda-Okreglak EM, Drabick JJ, Delaney NR. Proinflammatory syndrome mimicking acute rheumatoid arthritis in a patient with Waldenstrom's macroglobulinemia treated with rituximab. *Ann Hematol*. 2004 Feb;83(2):117-9.
320. Bunescu A, Seideman P, Lenkei R, et al. Enhanced Fc gamma receptor I, alpha M beta 2 integrin receptor expression by monocytes and neutrophils in rheumatoid arthritis: interaction with platelets. *J Rheumatol*. 2004 Dec;31(12):2347-55.
321. Burge DJ, Bookbinder SA, Kivitz AJ, et al. Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study. *Clin Ther*. 2008 Oct;30(10):1806-16.
322. Burgos RA, Hancke JL, Bertoglio JC, et al. Efficacy of an *Andrographis paniculata* composition for the relief of rheumatoid arthritis symptoms: a prospective randomized placebo-controlled trial. *Clin Rheumatol*. 2009 Aug;28(8):931-46.
323. Burmester GR, Ferraccioli G, Flipo RM, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. *Arthritis Rheum*. 2008 Jan 15;59(1):32-41.

324. Burmester GR, Mariette X, Montecucco C, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. *Ann Rheum Dis* 2007;66(6):732-9.
325. Burnham JM, Shults J, Dubner SE, et al. Bone density, structure, and strength in juvenile idiopathic arthritis: importance of disease severity and muscle deficits. *Arthritis Rheum*. 2008 Aug;58(8):2518-27.
326. Buttgereit F, Doering G, Schaeffler A, et al. Efficacy of modified-release versus standard prednisone to reduce duration of morning stiffness of the joints in rheumatoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. *Lancet*. 2008 Jan 19;371(9608):205-14.
327. Buttgereit F, Doering G, Schaeffler A, et al. Targeting pathophysiological rhythms: prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. *Ann Rheum Dis*. 2010 Jul;69(7):1275-80.
328. Caballol Pons N, Montala N, Valverde J, et al. Isolated cerebral vasculitis associated with rheumatoid arthritis. *Joint Bone Spine*. 2010 Jul;77(4):361-3.
329. Cairns AP, Duncan MK, Hinder AE, et al. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. *Ann Rheum Dis*. 2002 Nov;61(11):1031-2.
330. Cairns AP, Taggart AJ. Anti-tumour necrosis factor therapy for severe inflammatory arthritis: two years of experience in Northern Ireland. *Ulster Med J*. 2002 Nov;71(2):101-5.
331. Calabrese LH. Rheumatoid arthritis and primary care: the case for early diagnosis and treatment. *J Am Osteopath Assoc*. 1999 Jun;99(6):313-21.
332. Calin A, Dijkmans BA, Emery P, et al. Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. *Ann Rheum Dis*. 2004 Dec;63(12):1594-600.
333. Callaly EL, FitzGerald O, Rogers S. Hydroxychloroquine-associated, photo-induced toxic epidermal necrolysis. *Clin Exp Dermatol*. 2008 Aug;33(5):572-4.
334. Cambridge G, Leandro MJ, Edwards JC, et al. Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. *Arthritis Rheum*. 2003 Aug;48(8):2146-54.
335. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationships with B cell depletion, circulating antibodies, and clinical relapse. *Arthritis Rheum*. 2006 Mar;54(3):723-32.
336. Champion GV, Lebsack ME, Lookabaugh J, et al. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. *Arthritis Rheum*. 1996 Jul;39(7):1092-101.
337. Campione E, Mazzotta A, Paterno EJ, et al. Effect of calcipotriol on etanercept partial responder psoriasis vulgaris and psoriatic arthritis patients. *Acta Derm Venereol*. 2009;89(3):288-91.
338. Cankaya H, Alpoz E, Karabulut G, et al. Effects of hydroxychloroquine on salivary flow rates and oral complaints of Sjogren patients: a prospective sample study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2010 Jul;110(1):62-7.
339. Cannon GW, Holden WL, Juhaeri J, et al. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. *J Rheumatol*. 2004 Oct;31(10):1906-11.
340. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. *J Rheumatol*. 2008 Mar;35(3):421-4.
341. Cantarini L, Tinazzi I, Biasi D, et al. Sulfasalazine-induced immune thrombocytopenia. *Postgrad Med J*. 2007 Jun;83(980):e1.

342. Cantini F, Niccoli L, Benucci M, et al. Switching from infliximab to once-weekly administration of 50 mg etanercept in resistant or intolerant patients with ankylosing spondylitis: results of a fifty-four-week study. *Arthritis Rheum.* 2006 Oct 15;55(5):812-6.
343. Cantini F, Niccoli L, Nannini C, et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. *Rheumatology (Oxford)* 2008;47(6):872-6.
344. Capell H. Longterm maintenance therapy with disease modifying antirheumatic drugs. *J Rheumatol Suppl.* 2002 Nov;66:38-43.
345. Capell HA, Madhok R, Hunter JA, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. *Ann Rheum Dis.* 2004 Jul;63(7):797-803.
346. Capell HA, Murphy EA, Hunter JA. Rheumatoid arthritis: workload and outcome over 10 years. *Q J Med.* 1991 Jun;79(290):461-76.
347. Caplan L, Wolfe F, Russell AS, et al. Corticosteroid use in rheumatoid arthritis: prevalence, predictors, correlates, and outcomes. *J Rheumatol.* 2007 Apr;34(4):696-705.
348. Capria A, De Nardo D, Baffetti FR, et al. Long-term anti-TNF-alpha treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. *Int J Immunopathol Pharmacol.* 2010 Jan-Mar;23(1):255-62.
349. Capsoni F, Sarzi-Puttini P, Atzeni F, et al. Effect of adalimumab on neutrophil function in patients with rheumatoid arthritis. *Arthritis Res Ther.* 2005;7(2):R250-5.
350. Caramaschi P, Biasi D, Carletto A, et al. A case of adult onset Still's disease treated with infliximab. *Clin Exp Rheumatol.* 2002 Jan-Feb;20(1):113.
351. Caramaschi P, Biasi D, Carletto A, et al. Orbital myositis in a rheumatoid arthritis patient during etanercept treatment. *Clin Exp Rheumatol.* 2003 Jan-Feb;21(1):136-7.
352. Caramaschi P, Ruzzenente O, Pieropan S, et al. Determination of ANA specificity using multiplexed fluorescent microsphere immunoassay in patients with ANA positivity at high titres after infliximab treatment: preliminary results. *Rheumatol Int.* 2007 May;27(7):649-54.
353. Caramella C, Avouac J, Sogni P, et al. Association between rheumatoid arthritis and primary biliary cirrhosis. *Joint Bone Spine.* 2007 May;74(3):279-81.
354. Cardillo C, Schinzari F, Mores N, et al. Intravascular tumor necrosis factor alpha blockade reverses endothelial dysfunction in rheumatoid arthritis. *Clin Pharmacol Ther.* 2006 Sep;80(3):275-81.
355. Carloni A, Piciocchi S, Giannakakis K, et al. Diffuse alveolar hemorrhage after leflunomide therapy in a patient with rheumatoid arthritis. *J Thorac Imaging.* 2008 Feb;23(1):57-9.
356. Carlson E, Rothfield N. Etanercept-induced lupus-like syndrome in a patient with rheumatoid arthritis. *Arthritis Rheum.* 2003 Apr;48(4):1165-6; author reply 6.
357. Carmona L, Gomez-Reino JJ, Rodriguez-Valverde V, et al. Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists. *Arthritis Rheum.* 2005 Jun;52(6):1766-72.
358. Caroyer JM, Manto MU, Steinfeld SD. Severe sensory neuronopathy responsive to infliximab in primary Sjogren's syndrome. *Neurology.* 2002 Oct 8;59(7):1113-4.
359. Carrasco R, Smith JA, Lovell D. Biologic agents for the treatment of juvenile rheumatoid arthritis: current status. *Paediatr Drugs.* 2004;6(3):137-46.
360. Carreira PE, Gonzalez-Crespo MR, Ciruelo E, et al. Polymorphism of the interleukin-1 receptor antagonist gene: a factor in susceptibility to rheumatoid arthritis in a Spanish population. *Arthritis Rheum.* 2005 Oct;52(10):3015-9.
361. Carrera C, Mascaro JM, Jr., Moreno-Romero JA, et al. Pyoderma vegetans associated with severe psoriatic arthritis: good response to etanercept. *Dermatology.* 2007;214(1):77-81.

362. Carroll MB, Bond MI. Use of tumor necrosis factor-alpha inhibitors in patients with chronic hepatitis B infection. *Semin Arthritis Rheum*. 2008 Dec;38(3):208-17.
363. Carter JD, Gerard HC, Hudson AP. Psoriasiform lesions induced by tumour necrosis factor antagonists: a skin-deep medical conundrum. *Ann Rheum Dis*. 2008 Aug;67(8):1181-3.
364. Carter JD, Valeriano J, Vasey FB. Tumor necrosis factor-alpha inhibition and VATER association: a causal relationship. *J Rheumatol*. 2006 May;33(5):1014-7.
365. Caselli RJ, Scheithauer BW, Bowles CA, et al. The treatable dementia of Sjogren's syndrome. *Ann Neurol*. 1991 Jul;30(1):98-101.
366. Caselli RJ, Scheithauer BW, O'Duffy JD, et al. Chronic inflammatory meningoencephalitis should not be mistaken for Alzheimer's disease. *Mayo Clin Proc*. 1993 Sep;68(9):846-53.
367. Cash JM, Crofford LJ, Gallucci WT, et al. Pituitary-adrenal axis responsiveness to ovine corticotropin releasing hormone in patients with rheumatoid arthritis treated with low dose prednisone. *J Rheumatol*. 1992 Nov;19(11):1692-6.
368. Casoli P, Tumiatì B. Rheumatoid arthritis, corticosteroid therapy and Kaposi's sarcoma: a coincidence? A case and review of literature. *Clin Rheumatol*. 1992 Sep;11(3):432-5.
369. Caspi D, Elkayam O, Eisinger M, et al. Clinical significance of low titer anti-nuclear antibodies in early rheumatoid arthritis: implications on the presentation and long-term course of the disease. *Rheumatol Int*. 2001 Feb;20(2):43-7.
370. Cassano N, Galluccio A, De Simone C, et al. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. *J Biol Regul Homeost Agents*. 2008 Oct-Dec;22(4):233-7.
371. Cassano N, Loconsole F, Amoroso A, et al. Infliximab monotherapy for refractory psoriasis: preliminary results. *Int J Immunopathol Pharmacol*. 2004 Sep-Dec;17(3):373-80.
372. Castagnetta LA, Carruba G, Granata OM, et al. Increased estrogen formation and estrogen to androgen ratio in the synovial fluid of patients with rheumatoid arthritis. *J Rheumatol*. 2003 Dec;30(12):2597-605.
373. Castaneda O, Nair MG. Controlled trial of methotrexate versus CH-1504 in the treatment of rheumatoid arthritis. *J Rheumatol*. 2006 May;33(5):862-4.
374. Catananti C, Mastropaolo S, Calabrese C, et al. A case of normal-pressure hydrocephalus associated with rheumatoid arthritis. *Aging Clin Exp Res*. 2010 Apr;22(2):189-91.
375. Catley D, Kaell AT, Kirschbaum C, et al. A naturalistic evaluation of cortisol secretion in persons with fibromyalgia and rheumatoid arthritis. *Arthritis Care Res*. 2000 Feb;13(1):51-61.
376. Catrina AI, af Klint E, Ernestam S, et al. Anti-tumor necrosis factor therapy increases synovial osteoprotegerin expression in rheumatoid arthritis. *Arthritis Rheum*. 2006 Jan;54(1):76-81.
377. Catrina AI, Lampa J, Ernestam S, et al. Anti-tumour necrosis factor (TNF)-alpha therapy (etanercept) down-regulates serum matrix metalloproteinase (MMP)-3 and MMP-1 in rheumatoid arthritis. *Rheumatology (Oxford)*. 2002 May;41(5):484-9.
378. Catrina AI, Trollmo C, af Klint E, et al. Evidence that anti-tumor necrosis factor therapy with both etanercept and infliximab induces apoptosis in macrophages, but not lymphocytes, in rheumatoid arthritis joints: extended report. *Arthritis Rheum*. 2005 Jan;52(1):61-72.
379. Catrina AI, Ulfgren AK, Lindblad S, et al. Low levels of apoptosis and high FLIP expression in early rheumatoid arthritis synovium. *Ann Rheum Dis*. 2002 Oct;61(10):934-6.
380. Cattalini M, Maduskuie V, Fawcett PT, et al. Predicting duration of beneficial effect of joint injection among children with chronic arthritis by measuring biomarkers concentration in synovial fluid at the time of injection. *Clin Exp Rheumatol*. 2008 Nov-Dec;26(6):1153-60.

381. Cauli A, Gianni G, Panayi GS. Interleukin-1, interleukin-1 receptor antagonist and macrophage populations in rheumatoid arthritis synovial membrane. *Br J Rheumatol.* 1997 Sep;36(9):935-40.
382. Cauza E, Cauza K, Hanusch-Enserer U, et al. Intravenous anti TNF-alpha antibody therapy leads to elevated triglyceride and reduced HDL-cholesterol levels in patients with rheumatoid and psoriatic arthritis. *Wien Klin Wochenschr.* 2002 Dec 30;114(23-24):1004-7.
383. Cauza E, Hanusch-Enserer U, Frischmuth K, et al. Short-term infliximab therapy improves symptoms of psoriatic arthritis and decreases concentrations of cartilage oligomeric matrix protein. *J Clin Pharm Ther.* 2006 Apr;31(2):149-52.
384. Cauza E, Spak M, Cauza K, et al. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. *Rheumatol Int.* 2002 Nov;22(6):227-32.
385. Cavagna L, Caporali R, Epis O, et al. Infliximab in the treatment of adult Still's disease refractory to conventional therapy. *Clin Exp Rheumatol.* 2001 May-Jun;19(3):329-32.
386. Cavallasca JA, Caubet M, Helling CA, et al. Cryptogenic organizing pneumonia (COP), as presentation of rheumatoid arthritis. *Rheumatol Int.* 2008 Nov;29(1):99-101.
387. Cavazzana I, Bobbio-Pallavicini F, Franceschini F, et al. Anti-TNF-alpha treatment in rheumatoid arthritis with anti-Ro/SSA antibodies. Analysis of 17 cases among a cohort of 322 treated patients. *Clin Exp Rheumatol.* 2007 Sep-Oct;25(5):676-83.
388. Cay HF, Gungor HA, Sezer I, et al. Adverse effect of TNF-alpha blocker? Demyelination in an ankylosing spondylitis patient: a case report. *J Clin Pharm Ther.* 2006 Dec;31(6):645-8.
389. Cefle A. Leflunomide and azathioprine combination in refractory adult-onset Still's disease. *Ann Pharmacother.* 2005 Apr;39(4):764-7.
390. Cepeda EJ, Williams FM, Ishimori ML, et al. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease. *Ann Rheum Dis.* 2008 May;67(5):710-2.
391. Chakraborty PP, Achar A. Spontaneous bleeding in a patient of rheumatoid arthritis: a complication after accidental overdose of methotrexate. *J Assoc Physicians India.* 2007 Jul;55:501.
392. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. *J Rheumatol.* 2003 Feb;30(2):241-6.
393. Chambers CD, Johnson DL, Robinson LK, et al. Birth outcomes in women who have taken leflunomide during pregnancy. *Arthritis Rheum* 2010;62(5):1494-503.
394. Chan AT, Cleeve V, Daymond TJ. Necrotising fasciitis in a patient receiving infliximab for rheumatoid arthritis. *Postgrad Med J.* 2002 Jan;78(915):47-8.
395. Chan JL, Davis-Reed L, Kimball AB. Counter-regulatory balance: atopic dermatitis in patients undergoing infliximab infusion therapy. *J Drugs Dermatol.* 2004 May-Jun;3(3):315-8.
396. Chandra PA, Margulis Y, Schiff C. Rituximab is useful in the treatment of Felty's syndrome. *Am J Ther.* 2008 Jul-Aug;15(4):321-2.
397. Chandran V, Schentag CT, Gladman DD. Reappraisal of the effectiveness of methotrexate in psoriatic arthritis: results from a longitudinal observational cohort. *J Rheumatol.* 2008 Mar;35(3):469-71.
398. Chandran V, Siannis F, Rahman P, et al. Folate pathway enzyme gene polymorphisms and the efficacy and toxicity of methotrexate in psoriatic arthritis. *J Rheumatol.* 2010 Jul;37(7):1508-12.
399. Chang DM, Chang SY, Yeh MK, et al. The pharmacokinetics of interleukin-1 receptor antagonist in Chinese subjects with rheumatoid arthritis. *Pharmacol Res.* 2004 Sep;50(3):371-6.



400. Chang DM, Weinblatt ME, Schur PH. The effects of methotrexate on interleukin 1 in patients with rheumatoid arthritis. *J Rheumatol*. 1992 Nov;19(11):1678-82.
401. Chang HK, Park W, Ryu DS. Successful treatment of progressive rheumatoid interstitial lung disease with cyclosporine: a case report. *J Korean Med Sci*. 2002 Apr;17(2):270-3.
402. Chang J, Girgis L. Clinical use of anti-TNF-alpha biological agents--a guide for GPs. *Aust Fam Physician*. 2007 Dec;36(12):1035-8.
403. Chang WH, Katz BJ, Warner JE, et al. A novel method for screening the multifocal electroretinogram in patients using hydroxychloroquine. *Retina*. 2008 Nov-Dec;28(10):1478-86.
404. Chantler IW, Davie MW, Evans SF, et al. Oral corticosteroid prescribing in women over 50, use of fracture prevention therapy, and bone densitometry service. *Ann Rheum Dis*. 2003 Apr;62(4):350-2.
405. Chapman PT, O'Donnell JL, Moller PW. Rheumatoid pleural effusion: response to intrapleural corticosteroid. *J Rheumatol*. 1992 Mar;19(3):478-80.
406. Charabaty S, Shanmugam V. A 65-year-old man with longstanding seropositive rheumatoid arthritis and lower extremity ulceration. *Arthritis Rheum*. 2009 Sep 15;61(9):1275-80.
407. Charles PJ, Smeenk RJ, De Jong J, et al. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor alpha: findings in open-label and randomized placebo-controlled trials. *Arthritis Rheum*. 2000 Nov;43(11):2383-90.
408. Charles-Schoeman C, Watanabe J, Lee YY, et al. Abnormal function of high-density lipoprotein is associated with poor disease control and an altered protein cargo in rheumatoid arthritis. *Arthritis Rheum*. 2009 Oct;60(10):2870-9.
409. Chatterjee S. Severe interstitial pneumonitis associated with infliximab therapy. *Scand J Rheumatol*. 2004;33(4):276-7.
410. Chatzikyriakidou A, Georgiou I, Voulgari PV, et al. Transcription regulatory polymorphism -43T>C in the 5'-flanking region of SLC19A1 gene could affect rheumatoid arthritis patient response to methotrexate therapy. *Rheumatol Int*. 2007 Sep;27(11):1057-61.
411. Chauhan A, Mikulik Z, Hackshaw KV. Multicentric reticulohistiocytosis with positive anticyclic citrullinated antibodies. *J Natl Med Assoc*. 2007 Jun;99(6):678-80.
412. Chaveiro MA, Vieira R, Cardoso J, et al. Cutaneous infection due to *Scedosporium apiospermum* in an immunosuppressed patient. *J Eur Acad Dermatol Venereol*. 2003 Jan;17(1):47-9.
413. Chavez-Lopez MA, Delgado-Villafana J, Gallaga A, et al. Severe anaphylactic reaction during the second infusion of infliximab in a patient with psoriatic arthritis. *Allergol Immunopathol (Madr)*. 2005 Sep-Oct;33(5):291-2.
414. Cheema GS, Quismorio FP, Jr. Pulmonary involvement in adult-onset Still's disease. *Curr Opin Pulm Med*. 1999 Sep;5(5):305-9.
415. Chen DY, Shen GH, Hsieh TY, et al. Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy. *Arthritis Rheum*. 2008 Jun 15;59(6):800-6.
416. Chen HA, Lin KC, Chen CH, et al. The effect of etanercept on anti-cyclic citrullinated peptide antibodies and rheumatoid factor in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2006 Jan;65(1):35-9.
417. Chen YC, Hsu SW. Tuberculous arthritis mimic arthritis of the Sjogren's syndrome: findings from sonography, computed tomography and magnetic resonance images. *Eur J Radiol*. 2001 Dec;40(3):232-5.
418. Chen YC, Yang WC, Yang AH, et al. Primary Sjogren's syndrome associated with Gitelman's syndrome presenting with muscular paralysis. *Am J Kidney Dis*. 2003 Sep;42(3):586-90.

419. Cheung KK, Chow KM, Szeto CC, et al. Fatal pancytopenia in a hemodialysis patient after treatment with low-dose methotrexate. *J Clin Rheumatol*. 2009 Jun;15(4):177-80.
420. Chevillotte-Maillard H, Ornetti P, Mistrih R, et al. Survival and safety of treatment with infliximab in the elderly population. *Rheumatology (Oxford)*. 2005 May;44(5):695-6.
421. Chew AL, Bennett A, Smith CH, et al. Successful treatment of severe psoriasis and psoriatic arthritis with adalimumab. *Br J Dermatol*. 2004 Aug;151(2):492-6.
422. Chikanza IC, Petrou P, Kingsley G, et al. Defective hypothalamic response to immune and inflammatory stimuli in patients with rheumatoid arthritis. *Arthritis Rheum*. 1992 Nov;35(11):1281-8.
423. Chikanza IC, Roux-Lombard P, Dayer JM, et al. Dysregulation of the in vivo production of interleukin-1 receptor antagonist in patients with rheumatoid arthritis. Pathogenetic implications. *Arthritis Rheum*. 1995 May;38(5):642-8.
424. Chikkamuniyappa S. Streptococcal toxic shock syndrome and sepsis manifesting in a patient with chronic rheumatoid arthritis. *Dermatol Online J*. 2004;10(1):7.
425. Chikura B, Sathi N, Lane S, et al. Variation of immunological response in methotrexate-induced pneumonitis. *Rheumatology (Oxford)*. 2008 Nov;47(11):1647-50.
426. Chilton F, Collett RA. Treatment choices, preferences and decision-making by patients with rheumatoid arthritis. *Musculoskeletal Care*. 2008 Mar;6(1):1-14.
427. Chim CS, Pang YY, Ooi GC, et al. EBV-associated synovial lymphoma in a chronically inflamed joint in rheumatoid arthritis receiving prolonged methotrexate treatment. *Haematologica*. 2006 Aug;91(8 Suppl):ECR31.
428. Chiou CF, Sherbourne CD, Cornelio I, et al. Revalidation of the original Cedars-Sinai health-related quality of life in rheumatoid arthritis questionnaire. *J Rheumatol*. 2006 Feb;33(2):256-62.
429. Cho I, Mori S, Imamura F, et al. Methotrexate pneumonia lacking dyspnea and radiographic interstitial patterns during treatment for early rheumatoid arthritis: bronchoalveolar lavage and transbronchial lung biopsy in a differential diagnosis. *Mod Rheumatol*. 2007;17(3):256-61.
430. Choi SW, Ahn JJ, Hwang YT, et al. A case of tuberculous arthritis following the use of etanercept. *Korean J Intern Med*. 2009 Dec;24(4):397-401.
431. Chomarat P, Vannier E, Dechanet J, et al. Balance of IL-1 receptor antagonist/IL-1 beta in rheumatoid synovium and its regulation by IL-4 and IL-10. *J Immunol*. 1995 Feb 1;154(3):1432-9.
432. Chopin F, Garnero P, le Henanff A, et al. Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2008 Mar;67(3):353-7.
433. Chopra A, Saluja M, Lagu-Joshi V, et al. Leflunomide (Arava) is a useful DMARD in Indian (Asian) patients: a clinic-based observational study of 1-year treatment. *Clin Rheumatol* 2008;27(8):1039-44.
434. Chou CT. The clinical application of etanercept in Chinese patients with rheumatic diseases. *Mod Rheumatol*. 2006;16(4):206-13.
435. Choy EH, Isenberg DA, Garrood T, et al. Therapeutic benefit of blocking interleukin-6 activity with an anti-interleukin-6 receptor monoclonal antibody in rheumatoid arthritis: a randomized, double-blind, placebo-controlled, dose-escalation trial. *Arthritis Rheum*. 2002 Dec;46(12):3143-50.
436. Choy EH, Smith CM, Farewell V, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. *Ann Rheum Dis* 2008;67(5):656-63.
437. Chung CP, Oeser A, Solus JF, et al. Inflammation-associated insulin resistance: differential effects in rheumatoid arthritis and systemic lupus erythematosus define potential mechanisms. *Arthritis Rheum*. 2008 Jul;58(7):2105-12.

438. Chung CP, Russell AS, Segami MI, et al. The effect of low-dose prednisone on bone mineral density in Peruvian rheumatoid arthritis patients. *Rheumatol Int.* 2005 Mar;25(2):114-7.
439. Ciboddo G, Idone C. Treatment of renal amyloidosis in rheumatoid arthritis requires further investigation: comment on the case report by Elkayam et al. *Arthritis Rheum.* 2003 Nov;48(11):3299; author reply -300.
440. Cisternas M, Gutierrez M, Jacobelli S. Successful rechallenge with anti-tumor necrosis factor alpha for psoriatic arthritis after development of demyelinating nervous system disease during initial treatment: comment on the article by Mohan et al. *Arthritis Rheum.* 2002 Nov;46(11):3107-8; author reply 8-9.
441. Clark W, Jobanputra P, Barton P, et al. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. *Health Technol Assess.* 2004 May;8(18):iii-iv, ix-x, 1-105.
442. Clarke LE, Junkins-Hopkins J, Seykora JT, et al. Methotrexate-associated lymphoproliferative disorder in a patient with rheumatoid arthritis presenting in the skin. *J Am Acad Dermatol.* 2007 Apr;56(4):686-90.
443. Cleland LG, Caughey GE, James MJ, et al. Reduction of cardiovascular risk factors with longterm fish oil treatment in early rheumatoid arthritis. *J Rheumatol.* 2006 Oct;33(10):1973-9.
444. Clelland S, Hunek JR. Etanercept injection site reaction. *Dermatol Nurs.* 2005 Oct;17(5):375-.
445. Clementine RR, Lyman J, Zakem J, et al. Tumor necrosis factor-alpha antagonist-induced sarcoidosis. *J Clin Rheumatol.* 2010 Sep;16(6):274-9.
446. Clifford LJ, Rossiter JD. Peripheral visual field loss following treatment with etanercept. *Br J Ophthalmol.* 2004 Jun;88(6):842.
447. Clunie G, Voules S, Watts R. Dose reduction of etanercept--can we treat more patients using a fixed budget? *Rheumatology (Oxford).* 2003 Apr;42(4):600-1.
448. Coates LC, Cawkwell LS, Ng NW, et al. Sustained response to long-term biologics and switching in psoriatic arthritis: results from real life experience. *Ann Rheum Dis.* 2008 May;67(5):717-9.
449. Cobo Ibanez T, Yehia Tayel M, Balsa Criado A, et al. Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis. *Rheumatology (Oxford).* 2005 Nov;44(11):1467-8.
450. Coca A, Sanz I. B cell depletion in lupus and Sjogren's syndrome: an update. *Curr Opin Rheumatol.* 2009 Sep;21(5):483-8.
451. Cocito D, Bergamasco B, Tavella A, et al. Multifocal motor neuropathy during treatment with infliximab. *J Peripher Nerv Syst.* 2005 Dec;10(4):386-7.
452. Cohen CD, Horster S, Sander CA, et al. Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy. *Ann Rheum Dis.* 2003 Jul;62(7):684.
453. Cohen G, Courvoisier N, Cohen JD, et al. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. *Clin Exp Rheumatol.* 2005 Nov-Dec;23(6):795-800.
454. Cohen J. Still looking for the cause of fever? *Crit Care Resusc.* 2006 Jun;8(2):155-6.
455. Cohen JD, Bournerias I, Buffard V, et al. Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. *J Rheumatol.* 2007 Feb;34(2):380-5.
456. Cohen JD, Zaltini S, Kaiser MJ, et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. *Ann Rheum Dis.* 2004 Feb;63(2):209-10.
457. Cohen MD, Conn DL. Benefits of low-dose corticosteroids in rheumatoid arthritis. *Bull Rheum Dis.* 1997 Jun;46(4):4-7.
458. Cohen S, Hurd E, Cush J, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 2002 Mar;46(3):614-24.

459. Cohen SB, Cheng TT, Chindalore V, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. *Arthritis Rheum.* 2009 Feb;60(2):335-44.
460. Cohen SB, Dore RK, Lane NE, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. *Arthritis Rheum.* 2008 May;58(5):1299-309.
461. Cohen SB, Keystone E, Genovese MC, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. *Ann Rheum Dis* 2010;69(6):1158-61.
462. Cohen SB, Moreland LW, Cush JJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. *Ann Rheum Dis.* 2004 Sep;63(9):1062-8.
463. Cohen SB, Strand V, Aguilar D, et al. Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapy. *Rheumatology (Oxford).* 2004 Jun;43(6):704-11.
464. Cohen SB, Woolley JM, Chan W. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. *J Rheumatol.* 2003 Feb;30(2):225-31.
465. Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. *Rheumatol Int* 2007;27(4):369-73.
466. Cole JC, Li T, Lin P, et al. Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept. *Rheumatology (Oxford).* 2008 Jul;47(7):1044-50.
467. Coluccia D, Wolf OT, Kollias S, et al. Glucocorticoid therapy-induced memory deficits: acute versus chronic effects. *J Neurosci.* 2008 Mar 26;28(13):3474-8.
468. Colwell CW, Jr., Robinson CA, Stevenson DD, et al. Osteonecrosis of the femoral head in patients with inflammatory arthritis or asthma receiving corticosteroid therapy. *Orthopedics.* 1996 Nov;19(11):941-6.
469. Combe B, Codreanu C, Fiocco U, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. *Ann Rheum Dis* 2009;68(7):1146-52.
470. Comby E, Tanaff P, Mariotte D, et al. Evolution of antinuclear antibodies and clinical patterns in patients with active rheumatoid arthritis with longterm infliximab therapy. *J Rheumatol.* 2006 Jan;33(1):24-30.
471. Conaghan PG, O'Connor P, McGonagle D, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. *Arthritis Rheum.* 2003 Jan;48(1):64-71.
472. Constantinescu F, Goucher S, Weinstein A, et al. Racial disparities in treatment preferences for rheumatoid arthritis. *Med Care.* 2009 Mar;47(3):350-5.
473. Constantinou M, Jhanji V, Tao LW, et al. Clinical review of corneal ulcers resulting in evisceration and enucleation in elderly population. *Graefes Arch Clin Exp Ophthalmol.* 2009 Oct;247(10):1389-93.
474. Conti A, Sartorio A, Ferrero S, et al. Modifications of biochemical markers of bone and collagen turnover during corticosteroid therapy. *J Endocrinol Invest.* 1996 Feb;19(2):127-30.

475. Conti F, Ceccarelli F, Marocchi E, et al. Switching tumour necrosis factor alpha antagonists in patients with ankylosing spondylitis and psoriatic arthritis: an observational study over a 5-year period. *Ann Rheum Dis*. 2007 Oct;66(10):1393-7.
476. Conti F, Priori R, Chimenti MS, et al. Successful treatment with intraarticular infliximab for resistant knee monoarthritis in a patient with spondylarthropathy: a role for scintigraphy with <sup>99m</sup>Tc-infliximab. *Arthritis Rheum*. 2005 Apr;52(4):1224-6.
477. Contreras-Yanez I, Ponce De Leon S, Cabiedes J, et al. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. *Am J Med Sci*. 2010 Oct;340(4):282-90.
478. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. *Ann Rheum Dis*. 1995 Jan;54(1):49-52.
479. Cordero-Coma M, Anzaar F, Sobrin L, et al. Systemic immunomodulatory therapy in severe dry eye secondary to inflammation. *Ocul Immunol Inflamm*. 2007 Mar-Apr;15(2):99-104.
480. Cordiali-Fei P, Trento E, D'Agosto G, et al. Effective therapy with anti-TNF-alpha in patients with psoriatic arthritis is associated with decreased levels of metalloproteinases and angiogenic cytokines in the sera and skin lesions. *Ann N Y Acad Sci*. 2007 Sep;1110:578-89.
481. Corrao S, Pistone G, Arnone S, et al. Safety of etanercept therapy in rheumatoid patients undergoing surgery: preliminary report. *Clin Rheumatol*. 2007 Sep;26(9):1513-5.
482. Corsi F, Previde P, Colombo F, et al. Two cases of intestinal perforation in patients on anti-rheumatic treatment with etanercept. *Clin Exp Rheumatol*. 2006 Jan-Feb;24(1):113.
483. Cortet B, Flipo RM, Pigny P, et al. How useful are bone turnover markers in rheumatoid arthritis? Influence of disease activity and corticosteroid therapy. *Rev Rhum Engl Ed*. 1997 Mar;64(3):153-9.
484. Cortet B, Guyot MH, Solau E, et al. Factors influencing bone loss in rheumatoid arthritis: a longitudinal study. *Clin Exp Rheumatol*. 2000 Nov-Dec;18(6):683-90.
485. Cortot AB, Cottin V, Miossec P, et al. Improvement of refractory rheumatoid arthritis-associated constrictive bronchiolitis with etanercept. *Respir Med*. 2005 Apr;99(4):511-4.
486. Courtney PA, Alderdice J, Whitehead EM. Comment on methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. *Arthritis Rheum*. 2003 Aug 15;49(4):617; author reply -8.
487. Coury F, Ferraro-Peyret C, Le Cam S, et al. Peripheral blood lymphocytes from patients with rheumatoid arthritis are differentially sensitive to apoptosis induced by anti-tumour necrosis factor-alpha therapy. *Clin Exp Rheumatol*. 2008 Mar-Apr;26(2):234-9.
488. Covelli M, Scioscia C, Iannone F, et al. Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab. *Clin Exp Rheumatol*. 2005 Mar-Apr;23(2):145-51.
489. Coyle CM, Weiss LM, Rhodes LV, 3rd, et al. Fatal myositis due to the microsporidian *Brachiola algerae*, a mosquito pathogen. *N Engl J Med*. 2004 Jul 1;351(1):42-7.
490. Cracchiolo A, 3rd, Severt R, Moreland J. Uncemented total hip arthroplasty in rheumatoid arthritis diseases. A two- to six-year follow-up study. *Clin Orthop Relat Res*. 1992 Apr(277):166-74.
491. Creamer P, Keen M, Zananiri F, et al. Quantitative magnetic resonance imaging of the knee: a method of measuring response to intra-articular treatments. *Ann Rheum Dis*. 1997 Jun;56(6):378-81.
492. Creemers MC, Franssen MJ, van de Putte LB, et al. Methotrexate in severe ankylosing spondylitis: an open study. *J Rheumatol*. 1995 Jun;22(6):1104-7.
493. Crellin AM, Shareef DS, Maher EJ. Opportunistic *Listeria* pericardial effusion. *Postgrad Med J*. 1990 Mar;66(773):203-4.
494. Crilly A, Maiden N, Capell HA, et al. Predictive value of interleukin 1 gene polymorphisms for surgery. *Ann Rheum Dis*. 2000 Sep;59(9):695-9.

495. Criswell LA, Lum RF, Turner KN, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. *Arthritis Rheum.* 2004 Sep;50(9):2750-6.
496. Crnkic M, Mansson B, Larsson L, et al. Serum cartilage oligomeric matrix protein (COMP) decreases in rheumatoid arthritis patients treated with infliximab or etanercept. *Arthritis Res Ther.* 2003;5(4):R181-5.
497. Croce A, Firuzi O, Altieri F, et al. Effect of infliximab on the glycosylation of IgG of patients with rheumatoid arthritis. *J Clin Lab Anal.* 2007;21(5):303-14.
498. Crofford LJ, Kalogeras KT, Mastorakos G, et al. Circadian relationships between interleukin (IL)-6 and hypothalamic-pituitary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid arthritis. *J Clin Endocrinol Metab.* 1997 Apr;82(4):1279-83.
499. Crowson CS, Rahman MU, Matteson EL. Which measure of inflammation to use? A comparison of erythrocyte sedimentation rate and C-reactive protein measurements from randomized clinical trials of golimumab in rheumatoid arthritis. *J Rheumatol.* 2009 Aug;36(8):1606-10.
500. Cruse LM, Valeriano J, Vasey FB, et al. Prevalence of evaluation and treatment of glucocorticoid-induced osteoporosis in men. *J Clin Rheumatol.* 2006 Oct;12(5):221-5.
501. Cuchacovich M, Catalan D, Wainstein E, et al. Basal anti-cyclic citrullinated peptide (anti-CCP) antibody levels and a decrease in anti-CCP titres are associated with clinical response to adalimumab in rheumatoid arthritis. *Clin Exp Rheumatol.* 2008 Nov-Dec;26(6):1067-73.
502. Cuchacovich M, Ferreira L, Aliste M, et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. *Scand J Rheumatol.* 2004;33(4):228-32.
503. Cuchacovich M, Soto L, Edwardes M, et al. Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis. *Scand J Rheumatol.* 2006 Nov-Dec;35(6):435-40.
504. Cuchacovich R, Espinoza CG, Virk Z, et al. Biologic therapy (TNF-alpha antagonists)-induced psoriasis: a cytokine imbalance between TNF-alpha and IFN-alpha? *J Clin Rheumatol.* 2008 Dec;14(6):353-6.
505. Cuchacovich R, Espinoza LR. Does TNF-alpha blockade play any role in cardiovascular risk among rheumatoid arthritis (RA) patients? *Clin Rheumatol.* 2009 Oct;28(10):1217-20.
506. Cui J, Saevarsdottir S, Thomson B, et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. *Arthritis Rheum* 2010;62(7):1849-61.
507. Culy CR, Keating GM. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis. *Drugs.* 2002;62(17):2493-537.
508. Cunnane G, Madigan A, Murphy E, et al. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. *Rheumatology (Oxford).* 2001 Jan;40(1):62-9.
509. Cunnane G, Warnock M, Fye KH, et al. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. *Arthritis Rheum.* 2002 Aug;47(4):445-9.
510. Curkendall S, Patel V, Gleeson M, et al. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? *Arthritis Rheum.* 2008 Oct 15;59(10):1519-26.
511. Cursiefen C, Grunke M, Dechant C, et al. Multiple bilateral eyelid molluscum contagiosum lesions associated with TNFalpha-antibody and methotrexate therapy. *Am J Ophthalmol.* 2002 Aug;134(2):270-1.

512. Curtis JR, Kramer JM, Martin C, et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. *Rheumatology (Oxford)* 2007;46(11):1688-93.
513. Curtis JR, Martin C, Saag KG, et al. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. *Arthritis Rheum.* 2007 Mar 15;57(2):343-6.
514. Curtis JR, Patkar N, Xie A, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. *Arthritis Rheum* 2007;56(4):1125-33.
515. Curtis JR, Xi J, Patkar N, et al. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. *Arthritis Rheum* 2007;56(12):4226-7.
516. Cutolo M, Balleari E, Giusti M, et al. Androgen replacement therapy in male patients with rheumatoid arthritis. *Arthritis Rheum.* 1991 Jan;34(1):1-5.
517. Cutolo M, Bisso A, Sulli A, et al. Antiproliferative and antiinflammatory effects of methotrexate on cultured differentiating myeloid monocytic cells (THP-1) but not on synovial macrophages from patients with rheumatoid arthritis. *J Rheumatol.* 2000 Nov;27(11):2551-7.
518. Cutolo M, Foppiani L, Minuto F. Hypothalamic-pituitary-adrenal axis impairment in the pathogenesis of rheumatoid arthritis and polymyalgia rheumatica. *J Endocrinol Invest.* 2002;25(10 Suppl):19-23.
519. Cutolo M, Foppiani L, Prete C, et al. Hypothalamic-pituitary-adrenocortical axis function in premenopausal women with rheumatoid arthritis not treated with glucocorticoids. *J Rheumatol.* 1999 Feb;26(2):282-8.
520. Cutolo M, Maestroni GJ, Otsa K, et al. Circadian melatonin and cortisol levels in rheumatoid arthritis patients in winter time: a north and south Europe comparison. *Ann Rheum Dis.* 2005 Feb;64(2):212-6.
521. Cutolo M, Villaggio B, Pizzorni C, et al. Inflammatory gene profile in early rheumatoid arthritis and modulation by leflunomide and prednisone treatment. *Ann N Y Acad Sci.* 2010 Apr;1193(1):15-21.
522. Cvetkovic JT, Wallberg-Jonsson S, Stegmayr B, et al. Susceptibility for and clinical manifestations of rheumatoid arthritis are associated with polymorphisms of the TNF-alpha, IL-1beta, and IL-1Ra genes. *J Rheumatol.* 2002 Feb;29(2):212-9.
523. Cypiene A, Laucevicius A, Venalis A, et al. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). *Proc West Pharmacol Soc.* 2007;50:119-22.
524. D'Acquisto F, Paschalidis N, Raza K, et al. Glucocorticoid treatment inhibits annexin-1 expression in rheumatoid arthritis CD4+ T cells. *Rheumatology (Oxford).* 2008 May;47(5):636-9.
525. Dagci H, Zeyrek F, Gerzile YK, et al. A case of myiasis in a patient with psoriasis from Turkey. *Parasitol Int.* 2008 Jun;57(2):239-41.
526. Dahlqvist SR, Engstrand S, Berglin E, et al. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. *Scand J Rheumatol.* 2006 Mar-Apr;35(2):107-11.
527. Dahlqvist SR, Olsson T. Interference with the cortisol axis by the microtubule antagonist, CPH82. *Br J Rheumatol.* 1993 Sep;32(9):804-6.
528. Dain L, Braun-Moscovici Y, Baum E, et al. Modification of neutrophil function by plasma of rheumatoid arthritis patients treated with infliximab. *Clin Exp Rheumatol.* 2006 Jan-Feb;24(1):38-44.
529. Dalrymple JM, Stamp LK, O'Donnell JL, et al. Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum.* 2008 Nov;58(11):3299-308.

530. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. *Arthritis Rheum.* 2009 May;60(5):1232-41.
531. Danko JR, Gilliland WR, Miller RS, et al. Disseminated *Mycobacterium marinum* infection in a patient with rheumatoid arthritis receiving infliximab therapy. *Scand J Infect Dis.* 2009;41(4):252-5.
532. Dans M, Hivnor C, van Voorhees AS. Psoriatic onychopachydermoperiostitis: improvement with etanercept. *Br J Dermatol.* 2005 Oct;153(4):858-9.
533. Darabi K, Jaiswal R, Hostetler S, et al. Infectious complications in patients with psoriasis and rheumatoid arthritis treated with antitumor necrosis factor agents and methotrexate. *J Drugs Dermatol.* 2009 Feb;8(2):175-8.
534. Darmawan J, Muirden KD, Valkenburg HA, et al. The epidemiology of rheumatoid arthritis in Indonesia. *Br J Rheumatol.* 1993 Jul;32(7):537-40.
535. Das P, Raghu P, Amit Kumar D, et al. Strongyloides hyperinfection in rheumatoid arthritis. *Int J Surg Pathol.* 2007 Oct;15(4):391-2.
536. Das SK, Pareek A, Mathur DS, et al. Efficacy and safety of hydroxychloroquine sulphate in rheumatoid arthritis: a randomized, double-blind, placebo controlled clinical trial--an Indian experience. *Curr Med Res Opin.* 2007 Sep;23(9):2227-34.
537. Dascalu C, Mrejen-Shakin K, Bandagi S. Adalimumab-induced acute pneumonitis in a patient with rheumatoid arthritis. *J Clin Rheumatol.* 2010 Jun;16(4):172-4.
538. Dass S, Bowman SJ, Vital EM, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. *Ann Rheum Dis.* 2008 Nov;67(11):1541-4.
539. Dauendorffer JN, Rivet J, Allard A, et al. Sezary syndrome in a patient receiving infliximab for ankylosing spondylitis. *Br J Dermatol.* 2007 Apr;156(4):742-3.
540. D'Auria F, Rovere-Querini P, Giazson M, et al. Accumulation of plasma nucleosomes upon treatment with anti-tumour necrosis factor-alpha antibodies. *J Intern Med.* 2004 Mar;255(3):409-18.
541. Davaine AC, Saraux A, Prigent S, et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. *J Eur Acad Dermatol Venereol.* 2008 Dec;22(12):1471-8.
542. Davey M, Buchbinder R. Glucocorticoids in early rheumatoid arthritis. *Aust Fam Physician.* 2008 Jan-Feb;37(1-2):31-2.
543. Davies K, Stiehm ER, Woo P, et al. Juvenile idiopathic polyarticular arthritis and IgA deficiency in the 22q11 deletion syndrome. *J Rheumatol.* 2001 Oct;28(10):2326-34.
544. Davis JC, Jr. The role of etanercept in ankylosing spondylitis. *Clin Exp Rheumatol.* 2002 Nov-Dec;20(6 Suppl 28):S111-5.
545. Davis JC, Jr., Van Der Heijde D, Braun J, et al. Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. *Arthritis Rheum.* 2003 Nov;48(11):3230-6.
546. Davis JC, van der Heijde D, Dougados M, et al. Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. *Arthritis Rheum.* 2005 Aug 15;53(4):494-501.
547. Davis JC, van der Heijde DM, Braun J, et al. Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. *Ann Rheum Dis.* 2005 Nov;64(11):1557-62.
548. Davis JC, Jr., Van der Heijde DM, Dougados M, et al. Baseline factors that influence ASAS 20 response in patients with ankylosing spondylitis treated with etanercept. *J Rheumatol.* 2005 Sep;32(9):1751-4.
549. Davis JM, 3rd, Maradit Kremers H, Crowson CS, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum.* 2007 Mar;56(3):820-30.



550. Davis MC, Zautra AJ, Younger J, et al. Chronic stress and regulation of cellular markers of inflammation in rheumatoid arthritis: implications for fatigue. *Brain Behav Immun*. 2008 Jan;22(1):24-32.
551. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. *Lancet*. 2002 Feb 16;359(9306):540-1.
552. Daza L, Martin-Jimenez R, De la Torre PX, et al. Improvement of ACTH response to insulin tolerance test in female patients with rheumatoid arthritis due to tumor necrosis factor inhibition. *Eur J Endocrinol*. 2007 Jul;157(1):47-51.
553. De A, Blotta HM, Mamoni RL, et al. Effects of dexamethasone on lymphocyte proliferation and cytokine production in rheumatoid arthritis. *J Rheumatol*. 2002 Jan;29(1):46-51.
554. De Bandt M, Kahn MF. Takayasu's arteritis associated with Still's disease in an adult. *Clin Exp Rheumatol*. 1991 Nov-Dec;9(6):639-40.
555. De Bandt M, Sibilia J, Le Loet X, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. *Arthritis Res Ther*. 2005;7(3):R545-51.
556. De Bandt M, Vittecoq O, Descamps V, et al. Anti-TNF-alpha-induced systemic lupus syndrome. *Clin Rheumatol*. 2003 Feb;22(1):56-61.
557. De Benedetti F. Targeting interleukin-6 in pediatric rheumatic diseases. *Curr Opin Rheumatol*. 2009 Sep;21(5):533-7.
558. De Benedetti F, Pignatti P, Gerloni V, et al. Differences in synovial fluid cytokine levels between juvenile and adult rheumatoid arthritis. *J Rheumatol*. 1997 Jul;24(7):1403-9.
559. de' Clari F, Salani I, Safwan E, et al. Sudden death in a patient without heart failure after a single infusion of 200 mg infliximab: does TNF-alpha have protective effects on the failing heart, or does infliximab have direct harmful cardiovascular effects? *Circulation*. 2002 May 28;105(21):E183.
560. De Felice C, Mazzotta A, Esposito M, et al. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. *J Dermatolog Treat*. 2006;17(6):355-8.
561. de Jong JW, van Altena R. Non-respiratory tuberculosis with Mycobacterium tuberculosis after penetrating lesions of the skin: five case histories. *Int J Tuberc Lung Dis*. 2000 Dec;4(12):1184-7.
562. de la Torre B, Hedman M, Nilsson E, et al. Relationship between blood and joint tissue DHEAS levels in rheumatoid arthritis and osteoarthritis. *Clin Exp Rheumatol*. 1993 Nov-Dec;11(6):597-601.
563. De Leonardis F, Govoni M, Lo Monaco A, et al. Visceral leishmaniasis and anti-TNF-alpha therapy: case report and review of the literature. *Clin Exp Rheumatol*. 2009 May-Jun;27(3):503-6.
564. De Miguel S, Jover JA, Vadillo C, et al. B cell activation in rheumatoid arthritis patients under infliximab treatment. *Clin Exp Rheumatol*. 2003 Nov-Dec;21(6):726-32.
565. de Nijs RN, Jacobs JW, Bijlsma JW, et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2001 Dec;40(12):1375-83.
566. de Paz B, Alperi-Lopez M, Ballina-Garcia FJ, et al. Interleukin 10 and tumor necrosis factor-alpha genotypes in rheumatoid arthritis--association with clinical response to glucocorticoids. *J Rheumatol*. 2010 Mar;37(3):503-11.
567. De Rosa FG, Shaz D, Campagna AC, et al. Invasive pulmonary aspergillosis soon after therapy with infliximab, a tumor necrosis factor-alpha-neutralizing antibody: a possible healthcare-associated case? *Infect Control Hosp Epidemiol*. 2003 Jul;24(7):477-82.
568. De Rycke L, Baeten D, Foell D, et al. Differential expression and response to anti-TNFalpha treatment of infiltrating versus resident tissue macrophage subsets in autoimmune arthritis. *J Pathol*. 2005 May;206(1):17-27.

569. De Rycke L, Baeten D, Kruithof E, et al. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. *Arthritis Rheum.* 2005 Jul;52(7):2192-201.
570. De Rycke L, Kruithof E, Van Damme N, et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. *Arthritis Rheum.* 2003 Apr;48(4):1015-23.
571. De Rycke L, Vandooren B, Kruithof E, et al. Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. *Arthritis Rheum.* 2005 Jul;52(7):2146-58.
572. De Rycke L, Verhelst X, Kruithof E, et al. Rheumatoid factor, but not anti-cyclic citrullinated peptide antibodies, is modulated by infliximab treatment in rheumatoid arthritis. *Ann Rheum Dis.* 2005 Feb;64(2):299-302.
573. de Seze J, Delalande S, Fauchais AL, et al. Myelopathies secondary to Sjogren's syndrome: treatment with monthly intravenous cyclophosphamide associated with corticosteroids. *J Rheumatol.* 2006 Apr;33(4):709-11.
574. De Stefano R, Frati E, Nargi F, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. *Clin Rheumatol* 2010;29(5):517-24.
575. de Thurah A, Norgaard M, Johansen M, et al. Time to methotrexate treatment in patients with rheumatoid arthritis referred to hospital. *Scand J Rheumatol.* 2010;39(1):19-25.
576. de Thurah A, Norgaard M, Johansen MB, et al. Methotrexate compliance among patients with rheumatoid arthritis: the influence of disease activity, disease duration, and comorbidity in a 10-year longitudinal study. *Scand J Rheumatol.* 2010 May;39(3):197-205.
577. De Vita S, Zaja F, Sacco S, et al. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis: evidence for a pathogenetic role of B cells. *Arthritis Rheum.* 2002 Aug;46(8):2029-33.
578. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. *Arthritis Rheum.* 2008 May;58(5):1293-8.
579. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Wesoly J, et al. Ex vivo interleukin 1 receptor antagonist production on lipopolysaccharide stimulation is associated with rheumatoid arthritis and with joint damage. *Ann Rheum Dis.* 2007 Aug;66(8):1033-7.
580. de Winter S, van Buchem MA, Vermeer MH. Annular erythema of Sjogren's syndrome. *Lancet.* 2006 May 13;367(9522):1604.
581. Debiais S, Maillot F, Luca L, et al. Efficacy of anakinra in a case of refractory Still disease. *J Clin Rheumatol.* 2008 Dec;14(6):357-8.
582. Deighton CM, Watson MJ, Walker DJ. Sex hormones in postmenopausal HLA-identical rheumatoid arthritis discordant sibling pairs. *J Rheumatol.* 1992 Nov;19(11):1663-7.
583. Dekkers JC, Geenen R, Godaert GL, et al. Experimentally challenged reactivity of the hypothalamic pituitary adrenal axis in patients with recently diagnosed rheumatoid arthritis. *J Rheumatol.* 2001 Jul;28(7):1496-504.
584. del Porto F, Aloe L, Lagana B, et al. Nerve growth factor and brain-derived neurotrophic factor levels in patients with rheumatoid arthritis treated with TNF-alpha blockers. *Ann N Y Acad Sci.* 2006 Jun;1069:438-43.
585. Del Porto F, Lagana B, Lai S, et al. Response to anti-tumour necrosis factor alpha blockade is associated with reduction of carotid intima-media thickness in patients with active rheumatoid arthritis. *Rheumatology (Oxford).* 2007 Jul;46(7):1111-5.

586. Delabaye I, De Keyser F. 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. *Arthritis Res Ther.* 2010;12(3):R121.
587. Delaunay C, Farrenq V, Marini-Portugal A, et al. Infliximab to etanercept switch in patients with spondyloarthropathies and psoriatic arthritis: preliminary data. *J Rheumatol.* 2005 Nov;32(11):2183-5.
588. Delmez JA, Dusso AS, Slatopolsky E, et al. Modulation of renal osteodystrophy by extrarenal production of calcitriol. *Am J Nephrol.* 1995;15(1):85-9.
589. Demir H, Kelestimur F, Tunc M, et al. Hypothalamo-pituitary-adrenal axis and growth hormone axis in patients with rheumatoid arthritis. *Scand J Rheumatol.* 1999;28(1):41-6.
590. den Broeder A, van de Putte L, Rau R, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. *J Rheumatol.* 2002 Nov;29(11):2288-98.
591. den Broeder AA, Assmann KJ, van Riel PL, et al. Nephrotic syndrome as a complication of anti-TNFalpha in a patient with rheumatoid arthritis. *Neth J Med.* 2003 Apr;61(4):137-41.
592. den Broeder AA, Creemers MC, Franssen J, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. *J Rheumatol* 2007;34(4):689-95.
593. Den Broeder AA, Creemers MC, van Gestel AM, et al. Dose titration using the Disease Activity Score (DAS28) in rheumatoid arthritis patients treated with anti-TNF-alpha. *Rheumatology (Oxford).* 2002 Jun;41(6):638-42.
594. den Broeder AA, Joosten LA, Saxne T, et al. Long term anti-tumour necrosis factor alpha monotherapy in rheumatoid arthritis: effect on radiological course and prognostic value of markers of cartilage turnover and endothelial activation. *Ann Rheum Dis.* 2002 Apr;61(4):311-8.
595. den Broeder AA, Wanten GJ, Oyen WJ, et al. Neutrophil migration and production of reactive oxygen species during treatment with a fully human anti-tumor necrosis factor-alpha monoclonal antibody in patients with rheumatoid arthritis. *J Rheumatol.* 2003 Feb;30(2):232-7.
596. Denault A, Dimopoulos MA, Fitzcharles MA. Meningoencephalitis and peripheral neuropathy complicating adult Still's disease. *J Rheumatol.* 1990 May;17(5):698-700.
597. Deng A, Harvey V, Sina B, et al. Interstitial granulomatous dermatitis associated with the use of tumor necrosis factor alpha inhibitors. *Arch Dermatol.* 2006 Feb;142(2):198-202.
598. Denis B, Lefort A, Flipo RM, et al. Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment. *Clin Microbiol Infect.* 2008 Feb;14(2):183-6.
599. Deodhar A, Allen E, Daoud K, et al. Vasculitis secondary to staphylococcal Protein A immunoabsorption (Proisorba column) treatment in rheumatoid arthritis. *Semin Arthritis Rheum.* 2002 Aug;32(1):3-9.
600. Dequeker J, Borghs H, Van Cleemput J, et al. Transplantation osteoporosis and corticosteroid-induced osteoporosis in autoimmune diseases: experience with alfacalcidol. *Z Rheumatol.* 2000;59 Suppl 1:53-7.
601. Dereure O, Guillot B, Jorgensen C, et al. Psoriatic lesions induced by antitumour necrosis factor-alpha treatment: two cases. *Br J Dermatol.* 2004 Aug;151(2):506-7.
602. Derot G, Marini-Portugal A, Maitre B, et al. Marked regression of pulmonary rheumatoid nodules under etanercept therapy. *J Rheumatol.* 2009 Feb;36(2):437-9.
603. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. *Arthritis Rheum.* 2006 Oct;54(10):3095-103.

604. Desai D, Goldbach-Mansky R, Milner JD, et al. Anaphylactic reaction to anakinra in a rheumatoid arthritis patient intolerant to multiple nonbiologic and biologic disease-modifying antirheumatic drugs. *Ann Pharmacother.* 2009 May;43(5):967-72.
605. Despaux J, Manzoni P, Toussiroit E, et al. Prospective study of the prevalence of bronchiectasis in rheumatoid arthritis using high-resolution computed tomography. *Rev Rhum Engl Ed.* 1998 Jul-Sep;65(7-9):453-61.
606. Dessein PH, Joffe BI. Suppression of circulating interleukin-6 concentrations is associated with decreased endothelial activation in rheumatoid arthritis. *Clin Exp Rheumatol.* 2006 Mar-Apr;24(2):161-7.
607. Dessein PH, Joffe BI, Stanwix AE, et al. Hyposecretion of the adrenal androgen dehydroepiandrosterone sulfate and its relation to clinical variables in inflammatory arthritis. *Arthritis Res.* 2001;3(3):183-8.
608. Dessein PH, Woodiwiss AJ, Joffe BI, et al. Aminotransferases are associated with insulin resistance and atherosclerosis in rheumatoid arthritis. *BMC Cardiovasc Disord.* 2007;7:31.
609. Devauchelle-Pensec V, Pennec Y, Morvan J, et al. Improvement of Sjogren's syndrome after two infusions of rituximab (anti-CD20). *Arthritis Rheum.* 2007 Mar 15;57(2):310-7.
610. Devos SA, Van Den Bossche N, De Vos M, et al. Adverse skin reactions to anti-TNF-alpha monoclonal antibody therapy. *Dermatology.* 2003;206(4):388-90.
611. Dhaille F, Viseux V, Caudron A, et al. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases. *Dermatology.* 2010;220(3):234-7.
612. di Comite G, Marinosci A, Di Matteo P, et al. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis. *Ann N Y Acad Sci.* 2006 Jun;1069:428-37.
613. Di Poi E, Perin A, Morassi MP, et al. Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab. *Clin Exp Rheumatol.* 2007 Jan-Feb;25(1):85-7.
614. Dichamp I, Bourgeois A, Dirand C, et al. Increased nuclear factor-kappaB activation in peripheral blood monocytes of patients with rheumatoid arthritis is mediated primarily by tumor necrosis factor-alpha. *J Rheumatol.* 2007 Oct;34(10):1976-83.
615. Dilek K, Ali I, Goksal K, et al. The effects of sulphasalazine on urinary excretion of the hydroxypyridinium crosslinks of collagen in patients with rheumatoid arthritis. *Yonsei Med J.* 2002 Aug;43(4):435-40.
616. Dilhuydy MS, Vatan R, Etienne G, et al. Prolonged efficacy of infliximab for refractory adult-onset Still's disease. *Clin Exp Rheumatol.* 2005 Jan-Feb;23(1):121-2.
617. Dimakou K, Papaioannides D, Latsi P, et al. Disseminated tuberculosis complicating anti-TNF-alpha treatment. *Int J Clin Pract.* 2004 Nov;58(11):1052-5.
618. Diskin CJ, Stokes TJ, Dansby LM, et al. Removal of methotrexate by peritoneal dialysis and hemodialysis in a single patient with end-stage renal disease. *Am J Med Sci.* 2006 Sep;332(3):156-8.
619. Dockery KM, Sismanis A, Abedi E. Rheumatoid arthritis of the larynx: the importance of early diagnosis and corticosteroid therapy. *South Med J.* 1991 Jan;84(1):95-6.
620. Doggrell SA. Triamcinolone: new and old indications. *Expert Opin Pharmacother.* 2001 Jul;2(7):1177-86.
621. Doggrell SA. Is tocilizumab an option for the treatment of arthritis? *Expert Opin Pharmacother.* 2008 Aug;9(11):2009-13.
622. Dohn UM, Skjodt H, Hetland ML, et al. No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation. *Clin Rheumatol.* 2007 Nov;26(11):1857-61.
623. Dombrecht EJ, Aerts NE, Schuerwegh AJ, et al. Influence of anti-tumor necrosis factor therapy (Adalimumab) on regulatory T cells and dendritic cells in rheumatoid arthritis. *Clin Exp Rheumatol.* 2006 Jan-Feb;24(1):31-7.

624. Domiciano DS, de Carvalho JF, Macedo AR, et al. Central diabetes insipidus induced by tuberculosis in a rheumatoid arthritis patient. *Acta Reumatol Port.* 2010 Apr-Jun;35(2):232-5.
625. Domm A. A patient's reaction to infliximab. *Ann Allergy Asthma Immunol.* 2003 Mar;90(3):298-301.
626. Donahue KE, Gartlehner G, Jonas DE, et al. Systematic review: comparative effectiveness and harms of disease-modifying medications for rheumatoid arthritis. *Ann Intern Med.* 2008 Jan 15;148(2):124-34.
627. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. *Arthritis Rheum.* 2002 Sep;46(9):2294-300.
628. Doran MF, Crowson CS, Pond GR, et al. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum.* 2002 Sep;46(9):2287-93.
629. Dore RK, Mathews S, Schechtman J, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. *Clin Exp Rheumatol.* 2007 Jan-Feb;25(1):40-6.
630. Doria AS, Kiss MH, Sallum AM, et al. Correlation between osteochondral changes depicted by magnetic resonance imaging and disease progression. *Rev Hosp Clin Fac Med Sao Paulo.* 2001 Jul-Aug;56(4):107-14.
631. Doshi JA, Li P, Puig A. Impact of the Medicare Modernization Act of 2003 on utilization and spending for medicare part B-covered biologics in rheumatoid arthritis. *Arthritis Care Res (Hoboken).* 2010 Mar;62(3):354-61.
632. Douglas G, Bird K, Flume P, et al. Wegener's granulomatosis in patients with rheumatoid arthritis. *J Rheumatol.* 2003 Sep;30(9):2064-9.
633. Doulton TW, Tucker B, Reardon J, et al. Antineutrophil cytoplasmic antibody-associated necrotizing crescentic glomerulonephritis in a patient receiving treatment with etanercept for severe rheumatoid arthritis. *Clin Nephrol.* 2004 Sep;62(3):234-8.
634. Drosos A. Methotrexate intolerance in elderly patients with rheumatoid arthritis: what are the alternatives? *Drugs Aging.* 2003;20(10):723-36.
635. Drouin J, Haraoui B. Predictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapy. *J Rheumatol.* 2010 Jul;37(7):1405-10.
636. Drozdziak M, Rudas T, Pawlik A, et al. Reduced folate carrier-1 80G>A polymorphism affects methotrexate treatment outcome in rheumatoid arthritis. *Pharmacogenomics J.* 2007 Dec;7(6):404-7.
637. Drozdziak M, Rudas T, Pawlik A, et al. The effect of 3435C>T MDR1 gene polymorphism on rheumatoid arthritis treatment with disease-modifying antirheumatic drugs. *Eur J Clin Pharmacol.* 2006 Nov;62(11):933-7.
638. Drynda S, Kuhne C, Kekow J. Soluble tumour necrosis factor receptor treatment does not affect raised transforming growth factor beta levels in rheumatoid arthritis. *Ann Rheum Dis.* 2002 Mar;61(3):254-6.
639. Dubois T, Bisagni-Faure A, Coste J, et al. High levels of antibodies to annexins V and VI in patients with rheumatoid arthritis. *J Rheumatol.* 1995 Jul;22(7):1230-4.
640. Ducharme J, Pelletier C, Zacharias R. The safety of infliximab infusions in the community setting. *Can J Gastroenterol.* 2010;24(5):307-11.
641. Duclos M, Gossec L, Ruysse-Witrand A, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. *J Rheumatol.* 2006;33(12):2433-8.
642. Ducoulombier V, Solau E, Coquerelle P, et al. Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network. *Joint Bone Spine.* 2007 Jan;74(1):56-9.
643. Duftner C, Dejaco C, Larcher H, et al. Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic. *Rheumatol Int.* 2008 Nov;29(1):69-73.

644. Dumont-Berset M, Laffitte E, Gerber C, et al. Eczematous drug eruption after infliximab. *Br J Dermatol.* 2004 Dec;151(6):1272-3.
645. Dunne CA, Moran CJ, Thompson PW. The effect of regular intramuscular corticosteroid therapy on bone mineral density in rheumatoid patients. *Scand J Rheumatol.* 1995;24(1):48-9.
646. Durez P, Malghem J, Nzeusseu Toukap A, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. *Arthritis Rheum* 2007;56(12):3919-27.
647. Durez P, Nzeusseu Toukap A, Lauwerys BR, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. *Ann Rheum Dis.* 2004 Sep;63(9):1069-74.
648. Durez P, Van den Bosch F, Corluy L, et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. *Rheumatology (Oxford).* 2005 Apr;44(4):465-8.
649. Dursun AB, Kalac N, Ozkan B, et al. Pulmonary tuberculosis in patients with rheumatoid arthritis (four case reports). *Rheumatol Int.* 2002 Jan;21(4):153-7.
650. Dweik M, Baethge BA, Duarte AG. Coccidioidomycosis pneumonia in a nonendemic area associated with infliximab. *South Med J.* 2007 May;100(5):517-8.
651. Eberhardt K, Rydgren L, Fex E, et al. D-penicillamine in early rheumatoid arthritis: experience from a 2-year double blind placebo controlled study. *Clin Exp Rheumatol.* 1996 Nov-Dec;14(6):625-31.
652. Eberhardt K, Sandqvist G, Geborek P. Hand function tests are important and sensitive tools for assessment of treatment response in patients with rheumatoid arthritis. *Scand J Rheumatol.* 2008 Mar-Apr;37(2):109-12.
653. Eberhardt R, Kruger K, Reiter W, et al. Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone. *Arzneimittelforschung.* 1994 May;44(5):642-7.
654. Eder L, Chandran V, Gladman DD. From ankylosis to pencil-in-cup deformity in psoriatic arthritis: a case report. *Clin Exp Rheumatol.* 2009 Jul-Aug;27(4):661-3.
655. Edwards CJ, Cooper C, Fisher D, et al. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. *Arthritis Rheum* 2007;57(7):1151-7.
656. Edwards JC, Szczepanski L, Szechinski J, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med.* 2004 Jun 17;350(25):2572-81.
657. Edwards KR, Mowad CM, Tyler WB. Worsening injection site reactions with continued use of etanercept. *J Drugs Dermatol.* 2003 Apr;2(2):184-7.
658. Efde MN, Houtman PM, Spoorenberg JP, et al. Tonsillar tuberculosis in a rheumatoid arthritis patient receiving anti-TNFalpha (adalimumab) treatment. *Neth J Med.* 2005 Mar;63(3):112-4.
659. Efthimiou P, Georgy S. Pathogenesis and management of adult-onset Still's disease. *Semin Arthritis Rheum.* 2006 Dec;36(3):144-52.
660. Eggert M, Kluter A, Rusch D, et al. Expression analysis of the glucocorticoid receptor and the nuclear factor-kB subunit p50 in lymphocytes from patients with rheumatoid arthritis. *J Rheumatol.* 2002 Dec;29(12):2500-6.
661. Egnatios G, Warthan MM, Pariser R, et al. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors. *J Drugs Dermatol.* 2008 Oct;7(10):975-7.
662. Eijsbouts AM, van den Hoogen FH, Laan RF, et al. Hypothalamic-pituitary-adrenal axis activity in patients with rheumatoid arthritis. *Clin Exp Rheumatol.* 2005 Sep-Oct;23(5):658-64.

663. Eklow C, Makrygiannakis D, Backdahl L, et al. Cellular distribution of the C-type II lectin dendritic cell immunoreceptor (DCIR) and its expression in the rheumatic joint: identification of a subpopulation of DCIR+ T cells. *Ann Rheum Dis*. 2008 Dec;67(12):1742-9.
664. Eklund KK, Leirisalo-Repo M, Ranta P, et al. Serum IL-1beta levels are associated with the presence of erosions in recent onset rheumatoid arthritis. *Clin Exp Rheumatol*. 2007 Sep-Oct;25(5):684-9.
665. Eklund KK, Peltomaa R, Leirisalo-Repo M. Occurrence of pulmonary thromboembolism during infliximab therapy. *Clin Exp Rheumatol*. 2003 Sep-Oct;21(5):679.
666. El Maghraoui A, Do Santos Zounon AA, Jroundi I, et al. Reproducibility of bone mineral density measurements using dual X-ray absorptiometry in daily clinical practice. *Osteoporos Int*. 2005 Dec;16(12):1742-8.
667. Elkayam O, Burke M, Vardinon N, et al. Autoantibodies profile of rheumatoid arthritis patients during treatment with infliximab. *Autoimmunity*. 2005 Mar;38(2):155-60.
668. Elkayam O, Caspi D. Infliximab induced lupus in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2004 Jul-Aug;22(4):502-3.
669. Elkayam O, Caspi D, Reitblatt T, et al. The effect of tumor necrosis factor blockade on the response to pneumococcal vaccination in patients with rheumatoid arthritis and ankylosing spondylitis. *Semin Arthritis Rheum*. 2004 Feb;33(4):283-8.
670. Elkayam O, Hawkins PN, Lachmann H, et al. Rapid and complete resolution of proteinuria due to renal amyloidosis in a patient with rheumatoid arthritis treated with infliximab. *Arthritis Rheum*. 2002 Oct;46(10):2571-3.
671. Elkayam O, Paran D, Flusser G, et al. Insufficiency fractures in rheumatic patients: misdiagnosis and underlying characteristics. *Clin Exp Rheumatol*. 2000 May-Jun;18(3):369-74.
672. Elkayam O, Yaron I, Shirazi I, et al. Serum levels of IL-10, IL-6, IL-1ra, and sIL-2R in patients with psoriatic arthritis. *Rheumatol Int*. 2000;19(3):101-5.
673. Elkayam O, Yaron M, Caspi D. From wheels to feet: a dramatic response of severe chronic psoriatic arthritis to etanercept. *Ann Rheum Dis*. 2000 Oct;59(10):839.
674. Ellerton ML. When parents and children disagree about care. *Can Nurse*. 2000 Aug;96(7):35-6.
675. Ellingsen T, Hornung N, Moller BK, et al. In active chronic rheumatoid arthritis, dipeptidyl peptidase IV density is increased on monocytes and CD4(+) T lymphocytes. *Scand J Immunol*. 2007 Oct;66(4):451-7.
676. Ellingsen T, Hornung N, Moller BK, et al. Differential effect of methotrexate on the increased CCR2 density on circulating CD4 T lymphocytes and monocytes in active chronic rheumatoid arthritis, with a down regulation only on monocytes in responders. *Ann Rheum Dis*. 2007 Feb;66(2):151-7.
677. Elliott MJ, Maini RN, Feldmann M, et al. Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis. *Lancet*. 1994 Oct 22;344(8930):1105-10.
678. Emery P, Breedveld F, van der Heijde D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. *Arthritis Rheum* 2010;62(3):674-82.
679. Emery P, Breedveld FC, Hall S, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. *Lancet* 2008;372(9636):375-82.
680. Emery P, Deodhar A, Rigby WF, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). *Ann Rheum Dis* 2010;69(9):1629-35.

681. Emery P, Fleischmann RM, Moreland LW, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naïve patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. *Arthritis Rheum* 2009;60(8):2272-83.
682. Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumor necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis* 2008;67(11):1516-23.
683. Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. *J Rheumatol*. 2006 Apr;33(4):681-9.
684. Emkey RD, Lindsay R, Lyssy J, et al. The systemic effect of intraarticular administration of corticosteroid on markers of bone formation and bone resorption in patients with rheumatoid arthritis. *Arthritis Rheum*. 1996 Feb;39(2):277-82.
685. Emlen W, Niebur J, Kadera R. Accelerated in vitro apoptosis of lymphocytes from patients with systemic lupus erythematosus. *J Immunol*. 1994 Apr 1;152(7):3685-92.
686. Engels EA, Cerhan JR, Linet MS, et al. Immune-related conditions and immune-modulating medications as risk factors for non-Hodgkin's lymphoma: a case-control study. *Am J Epidemiol*. 2005 Dec 15;162(12):1153-61.
687. Epler GR. Bronchiolitis obliterans organizing pneumonia. *Semin Respir Infect*. 1995 Jun;10(2):65-77.
688. Eriksson C, Engstrand S, Sundqvist KG, et al. Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha. *Ann Rheum Dis*. 2005 Mar;64(3):403-7.
689. Eriksson C, Rantapaa-Dahlqvist S, Sundqvist KG. T-cell expression of CD91 - a marker of unresponsiveness to anti-TNF therapy in rheumatoid arthritis. *APMIS*. 2010 Nov;118(11):837-45.
690. Ernestam S, Hafstrom I, Werner S, et al. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. *J Rheumatol*. 2007 Jul;34(7):1451-8.
691. Escalante A, Kaufman RL, Quismorio FP, Jr., et al. Cardiac compression in rheumatoid pericarditis. *Semin Arthritis Rheum*. 1990 Dec;20(3):148-63.
692. Esmailzadeh A, Yousefi P, Farhi D, et al. Predictive factors of eczema-like eruptions among patients without cutaneous psoriasis receiving infliximab: a cohort study of 92 patients. *Dermatology*. 2009;219(3):263-7.
693. Esser AC, Abril A, Fayne S, et al. Acute development of multiple keratoacanthomas and squamous cell carcinomas after treatment with infliximab. *J Am Acad Dermatol*. 2004 May;50(5 Suppl):S75-7.
694. Estradas J, Pascual-Ramos V, Martinez B, et al. Autoimmune hepatitis with giant-cell transformation. *Ann Hepatol*. 2009 Jan-Mar;8(1):68-70.
695. Etemad L, Yu EB, Wanke LA. Dose adjustment over time of etanercept and infliximab in patients with rheumatoid arthritis. *Manag Care Interface*. 2005 Apr;18(4):21-7.
696. Ettefagh L, Nedorost S, Mirmirani P. Alopecia areata in a patient using infliximab: new insights into the role of tumor necrosis factor on human hair follicles. *Arch Dermatol*. 2004 Aug;140(8):1012.
697. Evans CH, Robbins PD, Ghivizzani SC, et al. Gene transfer to human joints: progress toward a gene therapy of arthritis. *Proc Natl Acad Sci U S A*. 2005 Jun 14;102(24):8698-703.
698. Eyigor S, Karapolat H, Kirazli Y. Efficacy of etanercept and complete decongestive physical therapy in bilateral lower-limb lymphoedema associated with rheumatoid arthritis: a case report. *Adv Ther*. 2008 Jan;25(1):23-8.



699. Fabre S, Dupuy AM, Dossat N, et al. Protein biochip array technology for cytokine profiling predicts etanercept responsiveness in rheumatoid arthritis. *Clin Exp Immunol*. 2008 Aug;153(2):188-95.
700. Fabre S, Gibert C, Lechiche C, et al. Visceral leishmaniasis infection in a rheumatoid arthritis patient treated with infliximab. *Clin Exp Rheumatol*. 2005 Nov-Dec;23(6):891-2.
701. Fabre S, Gibert C, Lechiche C, et al. Primary cutaneous *Nocardia* otitidiscaviarum infection in a patient with rheumatoid arthritis treated with infliximab. *J Rheumatol*. 2005 Dec;32(12):2432-3.
702. Fabre S, Guisset C, Tatem L, et al. Protein biochip array technology to monitor rituximab in rheumatoid arthritis. *Clin Exp Immunol*. 2009 Mar;155(3):395-402.
703. Familian A, Voskuyl AE, van Mierlo GJ, et al. Infliximab treatment reduces complement activation in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2005 Jul;64(7):1003-8.
704. Fantasia JE. Bisphosphonates--what the dentist needs to know: practical considerations. *J Oral Maxillofac Surg*. 2009 May;67(5 Suppl):53-60.
705. Fantini F, Gallazzi M, Gattinara M, et al. Monitoring bone mineralization in chronic rheumatic children on steroid treatment. *Acta Univ Carol [Med] (Praha)*. 1994;40(1-4):17-22.
706. Fantini F, Gallazzi M, Gattinara M, et al. Monitoring osteopenia by dual-photon absorptiometry in chronically ill children treated with steroids. *Acta Univ Carol [Med] (Praha)*. 1991;37(1-2):68-72.
707. Farah RE, Shay MD. Pulmonary sarcoidosis associated with etanercept therapy. *Pharmacotherapy*. 2007 Oct;27(10):1446-8.
708. Farahani P, Levine M, Gaebel K, et al. Clinical data gap between phase III clinical trials (pre-marketing) and phase IV (post-marketing) studies: evaluation of etanercept in rheumatoid arthritis. *Can J Clin Pharmacol*. 2005 Fall;12(3):e254-63.
709. Farahani P, Levine M, Gaebel K, et al. Community-based evaluation of etanercept in patients with rheumatoid arthritis. *J Rheumatol*. 2006 Apr;33(4):665-70.
710. Farukhi FI, Bollinger K, Ruggieri P, et al. Infliximab-associated third nerve palsy. *Arch Ophthalmol*. 2006 Jul;124(7):1055-7.
711. Fautrel B, Borget C, Rozenberg S, et al. Corticosteroid sparing effect of low dose methotrexate treatment in adult Still's disease. *J Rheumatol*. 1999 Feb;26(2):373-8.
712. Fautrel B, Flipo RM, Saraux A. Eligibility of rheumatoid arthritis patients for anti-TNF-alpha therapy according to the 2005 recommendations of the French and British Societies for Rheumatology. *Rheumatology (Oxford)*. 2008 Nov;47(11):1698-703.
713. Fautrel B, Foltz V, Frances C, et al. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. *Arthritis Rheum*. 2002 May;46(5):1408-9; author reply 9.
714. Fautrel B, Sibilia J, Mariette X, et al. Tumor necrosis factor alpha blocking agents in refractory adult Still's disease: an observational study of 20 cases. *Ann Rheum Dis*. 2005 Feb;64(2):262-6.
715. Fautrel B, Woronoff-Lemsi MC, Ethgen M, et al. Impact of medical practices on the costs of management of rheumatoid arthritis by anti-TNFalpha biological therapy in France. *Joint Bone Spine*. 2005 Dec;72(6):550-6.
716. Favalli EG, Arreghini M, Arnoldi C, et al. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. *Arthritis Rheum*. 2004 Apr 15;51(2):301-2.
717. Favalli EG, Marchesoni A, Colombo GL, et al. Pattern of use, economic burden and vial optimization of infliximab for rheumatoid arthritis in Italy. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1):45-51.
718. Favalli EG, Sinigaglia L, Varenna M, et al. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. *Lupus*. 2002;11(11):753-5.
719. Favero M, Schiavon F, Riato L, et al. Rheumatoid arthritis is the major risk factor for septic arthritis in rheumatological settings. *Autoimmun Rev*. 2008 Oct;8(1):59-61.

720. Feijoo M, Tunes I, Tasset I, et al. Infliximab reduces myeloperoxidase concentration in chronic inflammatory joint diseases. *Pharmacology*. 2009;83(4):211-6.
721. Felder M, Ruegsegger P. Bone loss in patients with rheumatoid arthritis--effect of steroids measured by low dose quantitative computed tomography. *Rheumatol Int*. 1991;11(1):41-4.
722. Feldman SR, Gottlieb AB, Bala M, et al. Infliximab improves health-related quality of life in the presence of comorbidities among patients with moderate-to-severe psoriasis. *Br J Dermatol*. 2008 Sep;159(3):704-10.
723. Feldstein AC, Elmer PJ, Nichols GA, et al. Practice patterns in patients at risk for glucocorticoid-induced osteoporosis. *Osteoporos Int*. 2005 Dec;16(12):2168-74.
724. Feletar M, Brockbank JE, Schentag CT, et al. Treatment of refractory psoriatic arthritis with infliximab: a 12 month observational study of 16 patients. *Ann Rheum Dis*. 2004 Feb;63(2):156-61.
725. Feltelius N, Fored CM, Blomqvist P, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. *Ann Rheum Dis*. 2005 Feb;64(2):246-52.
726. Fernandes M, Vemuganti GK, Rao GN. Bilateral periocular psoriasis: an initial manifestation of acute generalized pustular psoriasis with coexistent Sjogren's syndrome. *Clin Experiment Ophthalmol*. 2007 Nov;35(8):763-6.
727. Fernandes NF, Martin RR, Schenker S. Trazodone-induced hepatotoxicity: a case report with comments on drug-induced hepatotoxicity. *Am J Gastroenterol*. 2000 Feb;95(2):532-5.
728. Fernandez-Castro M, Andreu JL, Munoz P, et al. Sepsis of a prosthetic joint and biological therapies. *Rheumatology (Oxford)*. 2005 Aug;44(8):1076-7; author reply 5.
729. Fernandez-Nebro A, Irigoyen MV, Urena I, et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. *J Rheumatol*. 2007;34(12):2334-42.
730. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. *Am J Med*. 2005 May;118(5):552-6.
731. Ferraccioli G, Casatta L, Bartoli E. Increase of bone mineral density and anabolic variables in patients with rheumatoid arthritis resistant to methotrexate after cyclosporin A therapy. *J Rheumatol*. 1996 Sep;23(9):1539-42.
732. Ferraccioli G, Guerra P, Rizzi V, et al. Cyclosporin A increases somatomedin C insulin-like growth factor I levels in chronic rheumatic diseases. *J Rheumatol*. 1995 Jun;22(6):1060-4.
733. Ferraccioli G, Mecchia F, Di Poi E, et al. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible association with infections. *Ann Rheum Dis*. 2002 Apr;61(4):358-61.
734. Ferraccioli G, Zoli A, Alivernini S, et al. Lupus anticoagulant and ischemic myocardial microangiopathy in rheumatoid arthritis. *Nat Clin Pract Cardiovasc Med*. 2006 Jun;3(6):339-43; quiz following 43.
735. Ferraccioli GF, Assaloni R, Di Poi E, et al. Rescue of combination therapy failures using infliximab, while maintaining the combination or monotherapy with methotrexate: results of an open trial. *Rheumatology (Oxford)*. 2002 Oct;41(10):1109-12.
736. Ferri C, Ferraccioli G, Ferrari D, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. *J Rheumatol*. 2008 Oct;35(10):1944-9.
737. Fidalgo A, Baptista J, Rocha Paris F, et al. Etanercept for psoriasis: two case reports. *Int J Clin Pharmacol Res*. 2005;25(4):159-63.
738. Fiedorczyk M, Klimiuk PA, Sierakowski S, et al. Serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with early rheumatoid arthritis. *J Rheumatol*. 2006 Aug;33(8):1523-9.

739. Fiehn C, Andrassy K. Case number 29: hitting three with one strike: rapid improvement of psoriatic arthritis, psoriatic erythroderma, and secondary renal amyloidosis by treatment with infliximab (Remicade). *Ann Rheum Dis*. 2004 Mar;63(3):232.
740. Fiehn C, Jacki S, Heilig B, et al. Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. *Rheumatol Int*. 2007 Aug;27(10):975-9.
741. Figueiredo IT, Morel J, Sany J, et al. Maintenance and tolerability of infliximab in a cohort of 152 patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1):18-23.
742. Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. *Arthritis Rheum* 2007;56(5):1417-23.
743. Finckh A, Ciurea A, Brulhart L, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? *Ann Rheum Dis* 2010;69(2):387-93.
744. Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. *Ann Rheum Dis* 2009;68(1):33-9.
745. Finckh A, Dudler J, Wermelinger F, et al. Influence of anti-infliximab antibodies and residual infliximab concentrations on the occurrence of acquired drug resistance to infliximab in rheumatoid arthritis patients. *Joint Bone Spine*. 2010 Jul;77(4):313-8.
746. Finckh A, Simard JF, Duryea J, et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. *Arthritis Rheum*. 2006 Jan;54(1):54-9.
747. Finlay DG, Szauter K, Raju GS, et al. Tuberculous peritonitis. *Am J Gastroenterol*. 2005 Jul;100(7):1624-5.
748. Fiocco U, Ferro F, Vezzu M, et al. Rheumatoid and psoriatic knee synovitis: clinical, grey scale, and power Doppler ultrasound assessment of the response to etanercept. *Ann Rheum Dis*. 2005 Jun;64(6):899-905.
749. Firestein GS, Paine MM, Littman BH. Gene expression (collagenase, tissue inhibitor of metalloproteinases, complement, and HLA-DR) in rheumatoid arthritis and osteoarthritis synovium. Quantitative analysis and effect of intraarticular corticosteroids. *Arthritis Rheum*. 1991 Sep;34(9):1094-105.
750. Firth J, Helliwell P, Hale C, et al. The predictors of foot ulceration in patients with rheumatoid arthritis: a preliminary investigation. *Clin Rheumatol*. 2008 Nov;27(11):1423-8.
751. Fischer P. Resolution of treatment-related arthralgias and serologic findings with a switch of TNF antagonist therapies in a patient with psoriatic arthritis. *J Clin Rheumatol*. 2007 Oct;13(5):294-5.
752. Fiter J, Nolla JM, Navarro MA, et al. Weak androgen levels, glucocorticoid therapy, and bone mineral density in postmenopausal women with rheumatoid arthritis. *Joint Bone Spine*. 2000;67(3):199-203.
753. Fitzgerald AA, Leclercq SA, Yan A, et al. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. *Arthritis Rheum*. 2005 Jun;52(6):1794-803.
754. Flaisler F, Hedon B, Sany J, et al. A study of ovarian function in rheumatoid arthritis. *Rev Rhum Engl Ed*. 1995 Oct;62(9):549-54.
755. Fleischmann R. The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. *Expert Opin Biol Ther*. 2010 May;10(5):773-86.
756. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. *Ann Rheum Dis* 2006;65(3):379-84.
757. Fleischmann R, Stern R, Iqbal I. Anakinra: an inhibitor of IL-1 for the treatment of rheumatoid arthritis. *Expert Opin Biol Ther*. 2004 Aug;4(8):1333-44.

758. Fleischmann R, Vencovsky J, van Vollenhoven RF, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Ann Rheum Dis*. 2009 Jun;68(6):805-11.
759. Fleischmann RM. Safety of anakinra, a recombinant interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis and comparison to anti-TNF-alpha agents. *Clin Exp Rheumatol*. 2002 Sep-Oct;20(5 Suppl 27):S35-41.
760. Fleischmann RM. Addressing the safety of anakinra in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2003 May;42 Suppl 2:ii29-35.
761. Fleischmann RM. Progressive multifocal leukoencephalopathy following rituximab treatment in a patient with rheumatoid arthritis. *Arthritis Rheum*. 2009 Nov;60(11):3225-8.
762. Fleischmann RM, Cohen SB, Moreland LW, et al. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. *Curr Med Res Opin*. 2005 Aug;21(8):1181-90.
763. Fleischmann RM, Schechtman J, Bennett R, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. *Arthritis Rheum*. 2003 Apr;48(4):927-34.
764. Flenaugh EL, Kolawole FO, Allen R. Dyspnea and dry cough in a patient with rheumatoid arthritis. *Am Fam Physician*. 2007 Jan 1;75(1):103-5.
765. Flendrie M, Creemers MC, van Riel PL. Titration of infliximab treatment in rheumatoid arthritis patients based on response patterns. *Rheumatology (Oxford)*. 2007 Jan;46(1):146-9.
766. Flendrie M, Creemers MC, Welsing PM, et al. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. *Ann Rheum Dis*. 2003 Nov;62 Suppl 2:ii30-3.
767. Flendrie M, Creemers MC, Welsing PM, et al. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis; a longitudinal observational study. *Rheumatology (Oxford)*. 2005 Apr;44(4):472-8.
768. Foell D, Wittkowski H, Hammerschmidt I, et al. Monitoring neutrophil activation in juvenile rheumatoid arthritis by S100A12 serum concentrations. *Arthritis Rheum*. 2004 Apr;50(4):1286-95.
769. Fomin I, Caspi D, Levy V, et al. Vaccination against influenza in rheumatoid arthritis: the effect of disease modifying drugs, including TNF alpha blockers. *Ann Rheum Dis*. 2006 Feb;65(2):191-4.
770. Fonollosa A, Segura A, Giralt J, et al. Tuberculous uveitis after treatment with etanercept. *Graefes Arch Clin Exp Ophthalmol*. 2007 Sep;245(9):1397-9.
771. Fonseca A, Wagner J, Yamaga LI, et al. (18) F-FDG PET imaging of rheumatoid articular and extraarticular synovitis. *J Clin Rheumatol*. 2008 Oct;14(5):307.
772. Fonseca JE, Canhao H, Tavares NJ, et al. Persistent low grade synovitis without erosive progression in magnetic resonance imaging of rheumatoid arthritis patients treated with infliximab over 1 year. *Clin Rheumatol*. 2009 Oct;28(10):1213-6.
773. Fonseca JE, Carvalho T, Cruz M, et al. Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics. *Ann Rheum Dis*. 2005 May;64(5):793-4.
774. Font J, Ramos-Casals M, de la Red G, et al. Pure sensory neuropathy in primary Sjogren's syndrome. Longterm prospective followup and review of the literature. *J Rheumatol*. 2003 Jul;30(7):1552-7.
775. Foppiani L, Cutolo M, Sessarego P, et al. Desmopressin and low-dose ACTH test in rheumatoid arthritis. *Eur J Endocrinol*. 1998 Mar;138(3):294-301.
776. Forsblad d'Elia H, Pullerits R, Carlsten H, et al. Resistin in serum is associated with higher levels of IL-1Ra in post-menopausal women with rheumatoid arthritis. *Rheumatology (Oxford)*. 2008 Jul;47(7):1082-7.

777. Forsblad-d'Elia H, Carlsten H, Labrie F, et al. Low serum levels of sex steroids are associated with disease characteristics in primary Sjogren's syndrome; supplementation with dehydroepiandrosterone restores the concentrations. *J Clin Endocrinol Metab.* 2009 Jun;94(6):2044-51.
778. Forslind K, Boonen A, Albertsson K, et al. Hand bone loss measured by digital X-ray radiogrammetry is a predictor of joint damage in early rheumatoid arthritis. *Scand J Rheumatol.* 2009 Nov-Dec;38(6):431-8.
779. Forslind K, Hafstrom I, Ahlmen M, et al. Sex: a major predictor of remission in early rheumatoid arthritis? *Ann Rheum Dis.* 2007 Jan;66(1):46-52.
780. Forslund T, Hannonen P, Reitamo S, et al. Hypertension in cyclosporin A-treated patients is independent of circulating endothelin levels. *J Intern Med.* 1995 Jul;238(1):71-5.
781. Fortna RR, Gudjonsson JE, Seidel G, et al. Persistent pruritic papules and plaques: a characteristic histopathologic presentation seen in a subset of patients with adult-onset and juvenile Still's disease. *J Cutan Pathol.* 2010 Sep;37(9):932-7.
782. Fossaluzza V, De Vita S. Clinical differences between ANA/anti-ENA positive or negative primary Sjogren's syndrome. *Clin Rheumatol.* 1992 Sep;11(3):385-7.
783. Foster CS, Barrett F. Cataract development and cataract surgery in patients with juvenile rheumatoid arthritis-associated iridocyclitis. *Ophthalmology.* 1993 Jun;100(6):809-17.
784. Foster EN, Nguyen KK, Sheikh RA, et al. Crohn's disease associated with Sweet's syndrome and Sjogren's syndrome treated with infliximab. *Clin Dev Immunol.* 2005 Jun;12(2):145-9.
785. Fox RI, Stern M, Michelson P. Update in Sjogren syndrome. *Curr Opin Rheumatol.* 2000 Sep;12(5):391-8.
786. Fraenkel L, Bogardus ST, Concato J, et al. Patient preferences for treatment of rheumatoid arthritis. *Ann Rheum Dis.* 2004 Nov;63(11):1372-8.
787. Franchini S, Dagna L, Salvo F, et al. Efficacy of traditional and biologic agents in different clinical phenotypes of adult-onset Still's disease. *Arthritis Rheum.* 2010 Aug;62(8):2530-5.
788. Franck H, Gottwalt J. Peripheral bone density in patients with rheumatoid arthritis. *Clin Rheumatol.* 2009 Oct;28(10):1141-5.
789. Franklin CM. Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis. *Semin Arthritis Rheum.* 1999 Dec;29(3):172-81.
790. Franklin J, Lunt M, Bunn D, et al. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. *Ann Rheum Dis.* 2007 Mar;66(3):308-12.
791. Fransen J, Moens HB, Speyer I, et al. Effectiveness of systematic monitoring of rheumatoid arthritis disease activity in daily practice: a multicentre, cluster randomised controlled trial. *Ann Rheum Dis.* 2005 Sep;64(9):1294-8.
792. Fransen J, Stucki G, Twisk J, et al. Effectiveness of a measurement feedback system on outcome in rheumatoid arthritis: a controlled clinical trial. *Ann Rheum Dis.* 2003 Jul;62(7):624-9.
793. Fraser DA, Thoen J, Djoseland O, et al. Serum levels of interleukin-6 and dehydroepiandrosterone sulphate in response to either fasting or a ketogenic diet in rheumatoid arthritis patients. *Clin Exp Rheumatol.* 2000 May-Jun;18(3):357-62.
794. Fraser DA, Thoen J, Selvaag AM, et al. A preliminary study of circadian serum cortisol concentrations in response to a 72-hour fast in rheumatoid arthritis patients not previously treated with corticosteroids. *Clin Rheumatol.* 2001;20(2):85-7.
795. Frediani B, Falsetti P, Baldi F, et al. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy X-ray absorptiometry and quantitative ultrasound. *Bone.* 2003 Oct;33(4):575-81.

796. Frediani B, Falsetti P, Bisogno S, et al. Effects of high dose methylprednisolone pulse therapy on bone mass and biochemical markers of bone metabolism in patients with active rheumatoid arthritis: a 12-month randomized prospective controlled study. *J Rheumatol*. 2004 Jun;31(6):1083-7.
797. Fries JF, Bruce B. Rates of serious gastrointestinal events from low dose use of acetylsalicylic acid, acetaminophen, and ibuprofen in patients with osteoarthritis and rheumatoid arthritis. *J Rheumatol*. 2003 Oct;30(10):2226-33.
798. Fries JF, Miller SR, Spitz PW, et al. Identification of patients at risk for gastropathy associated with NSAID use. *J Rheumatol Suppl*. 1990 Feb;20:12-9.
799. Fries W, Giofre MR, Catanoso M, et al. Treatment of acute uveitis associated with Crohn's disease and sacroileitis with infliximab. *Am J Gastroenterol*. 2002 Feb;97(2):499-500.
800. Fu A, Bertouch JV, McNeil HP. Disseminated Salmonella typhimurium infection secondary to infliximab treatment. *Arthritis Rheum*. 2004 Sep;50(9):3049.
801. Fucci JC, Nightengale ML. Primary esophageal histoplasmosis. *Am J Gastroenterol*. 1997 Mar;92(3):530-1.
802. Fuchs I, Avnon L, Freud T, et al. Repeated tuberculin skin testing following therapy with TNF-alpha inhibitors. *Clin Rheumatol*. 2009 Feb;28(2):167-72.
803. Fuerst M, Mohl H, Baumgartel K, et al. Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. *Rheumatol Int* 2006;26(12):1138-42.
804. Fujikawa S. Non-steroidal anti-inflammatory drugs and slow-acting anti-rheumatic drugs in juvenile rheumatoid arthritis. *Acta Paediatr Jpn*. 1993 Oct;35(5):447-53.
805. Fujita K, Tanaka E, Hatta K, et al. An autopsy case of Mycobacterium abscessus pulmonary infection complicated with rheumatoid arthritis. *Intern Med*. 2008;47(13):1273-6.
806. Fujita Y, Fujii T, Takeda N, et al. Successful treatment of primary Sjogren's syndrome with chronic natural killer lymphocytosis by high-dose prednisolone and indomethacin farnesil. *Intern Med*. 2007;46(5):251-4.
807. Fujiwara H, Nishimoto N, Hamano Y, et al. Masked early symptoms of pneumonia in patients with rheumatoid arthritis during tocilizumab treatment: a report of two cases. *Mod Rheumatol*. 2009;19(1):64-8.
808. Fukino K, Kawashima T, Suzuki M, et al. Methylenetetrahydrofolate reductase and reduced folate carrier-1 genotypes and methotrexate serum concentrations in patients with rheumatoid arthritis. *J Toxicol Sci*. 2007 Oct;32(4):449-52.
809. Fukuchi M, Mizushima Y, Hori T, et al. Cryptococcal pleural effusion in a patient with chronic renal failure receiving long-term corticosteroid therapy for rheumatoid arthritis. *Intern Med*. 1998 Jun;37(6):534-7.
810. Fulchiero GJ, Jr., Salvaggio H, Drabick JJ, et al. Eruptive latent metastatic melanomas after initiation of antitumor necrosis factor therapies. *J Am Acad Dermatol*. 2007 May;56(5 Suppl):S65-7.
811. Fumagalli M, Incorvaia C, Nitti F, et al. The assessment of quality of life as a measure of gold salts treatment efficacy in rheumatoid arthritis. *Minerva Med*. 2002 Jun;93(3):199-202.
812. Funahashi K, Koyano S, Miura T, et al. Efficacy of tocilizumab and evaluation of clinical remission as determined by CDAI and MMP-3 level. *Mod Rheumatol*. 2009;19(5):507-12.
813. Funovits J, Aletaha D, Bykerk V, et al. The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: methodological report phase I. *Ann Rheum Dis*. 2010 Sep;69(9):1589-95.
814. Furfaro N, Mease PJ. Nursing considerations for infusion therapy in rheumatoid arthritis versus malignancy. *J Infus Nurs*. 2008 Nov-Dec;31(6):350-60.

815. Furse RK, Rossetti RG, Seiler CM, et al. Oral administration of gammalinolenic acid, an unsaturated fatty acid with anti-inflammatory properties, modulates interleukin-1beta production by human monocytes. *J Clin Immunol*. 2002 Mar;22(2):83-91.
816. Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. *Clin Ther*. 2004 Dec;26(12):1960-75.
817. Furst DE, Gaylis N, Bray V, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. *Ann Rheum Dis* 2007;66(7):893-9.
818. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). *J Rheumatol*. 2003 Dec;30(12):2563-71.
819. Furtado RN, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. *J Rheumatol*. 2005 Sep;32(9):1691-8.
820. Furukawa K, Ohtani T, Furukawa F, et al. Infectious mononucleosis-like syndrome induced by salazosulfapyridine in a patient with rheumatoid arthritis. *Mod Rheumatol*. 2007;17(6):492-5.
821. Gadadhar H, Hawkins S, Huffstutter JE, et al. Cutaneous mucormycosis complicating methotrexate, prednisone, and infliximab therapy. *J Clin Rheumatol*. 2007 Dec;13(6):361-2.
822. Gadsby K, Deighton C. Characteristics and treatment responses of patients satisfying the BSR guidelines for anti-TNF in ankylosing spondylitis. *Rheumatology (Oxford)*. 2007 Mar;46(3):439-41.
823. Gal I, Toth L, Szegedi L, et al. Gastric bleeding in a patient with rheumatoid arthritis complicated by immune thrombocytopenic purpura. *Joint Bone Spine*. 2008 May;75(3):350-2.
824. Galaria NA, Werth VP, Schumacher HR. Leukocytoclastic vasculitis due to etanercept. *J Rheumatol*. 2000 Aug;27(8):2041-4.
825. Galarraga B, Belch JJ, Pullar T, et al. Clinical improvement in rheumatoid arthritis is associated with healthier microvascular function in patients who respond to antirheumatic therapy. *J Rheumatol*. 2010 Mar;37(3):521-8.
826. Galarraga B, Khan F, Kumar P, et al. Etanercept improves inflammation-associated arterial stiffness in rheumatoid arthritis. *Rheumatology (Oxford)*. 2009 Nov;48(11):1418-23.
827. Galindo M, Pablos JL, Gomez-Reino JJ. Internuclear ophthalmoplegia in systemic lupus erythematosus. *Semin Arthritis Rheum*. 1998 Dec;28(3):179-86.
828. Ganeshan A, Quen L, Smith D. Occurrence of vesicocolic fistula with a use of etanercept: a cautionary tale. *J Clin Rheumatol*. 2005 Oct;11(5):290-1.
829. Garcia-Gomez C, Nolla JM, Valverde J, et al. High HDL-cholesterol in women with rheumatoid arthritis on low-dose glucocorticoid therapy. *Eur J Clin Invest*. 2008 Sep;38(9):686-92.
830. Garcia-Porrua C, Gonzalez-Gay MA. Successful treatment of refractory mononeuritis multiplex secondary to rheumatoid arthritis with the anti-tumour necrosis factor alpha monoclonal antibody infliximab. *Rheumatology (Oxford)*. 2002 Feb;41(2):234-5.
831. Garcia-Porrua C, Gonzalez-Gay MA, Quevedo V. Should anti-tumor necrosis factor-alpha be the first therapy for rheumatoid vasculitis? *J Rheumatol*. 2006 Feb;33(2):433; author reply -4.
832. Gardiner PV, Bell AL, Taggart AJ, et al. A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritis. *Ann Rheum Dis*. 2005 Mar;64(3):506-7.
833. Garfield BE, Krahl T, Appel S, et al. Regulation of p38 MAP kinase in CD4+ lymphocytes by infliximab therapy in patients with rheumatoid arthritis. *Clin Immunol*. 2005 Aug;116(2):101-7.

834. Garnero P, Gineyts E, Christgau S, et al. Association of baseline levels of urinary glucosyl-galactosyl-pyridinoline and type II collagen C-telopeptide with progression of joint destruction in patients with early rheumatoid arthritis. *Arthritis Rheum.* 2002 Jan;46(1):21-30.
835. Garnero P, Tabassi NC, Voorzanger-Rousselot N. Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. *J Rheumatol.* 2008 Dec;35(12):2313-5.
836. Gartlehner G, Hansen RA, Nissman D, et al. A simple and valid tool distinguished efficacy from effectiveness studies. *J of Clinical Epidemiology.* 2006 Aug 4;59(10):1040-8.
837. Garton MJ, Reid DM. Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis. Effects of low-dose corticosteroids. *Arthritis Rheum.* 1993 Feb;36(2):222-8.
838. Gaujoux-Viala C, Smolen JS, Landewe R, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis.* 2010 Jun;69(6):1004-9.
839. Gaylis NB, Needell SD, Rudensky D. Comparison of in-office magnetic resonance imaging versus conventional radiography in detecting changes in erosions after one year of infliximab therapy in patients with rheumatoid arthritis. *Mod Rheumatol.* 2007;17(4):273-8.
840. Geborek P, Bladstrom A, Turesson C, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. *Ann Rheum Dis.* 2005 May;64(5):699-703.
841. Geborek P, Crnkic M, Petersson IF, et al. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. *Ann Rheum Dis.* 2002 Sep;61(9):793-8.
842. Geborek P, Mansson B, Wollheim FA, et al. Intraarticular corticosteroid injection into rheumatoid arthritis knees improves extensor muscles strength. *Rheumatol Int.* 1990;9(6):265-70.
843. Geenen R, Godaert GL, Heijnen CJ, et al. Experimentally induced stress in rheumatoid arthritis of recent onset: effects on peripheral blood lymphocytes. *Clin Exp Rheumatol.* 1998 Sep-Oct;16(5):553-9.
844. Gelinck LB, van der Bijl AE, Beyer WE, et al. The effect of anti-tumour necrosis factor alpha treatment on the antibody response to influenza vaccination. *Ann Rheum Dis.* 2008 May;67(5):713-6.
845. Genc H, Duyur Cakit B, Nacir B, et al. The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. *Clin Rheumatol.* 2007 Jul;26(7):1104-10.
846. Gengenbacher M, Sebald HJ, Villiger PM, et al. Infliximab inhibits bone resorption by circulating osteoclast precursor cells in patients with rheumatoid arthritis and ankylosing spondylitis. *Ann Rheum Dis.* 2008 May;67(5):620-4.
847. Genovese MC, Bathon JM, Fleischmann RM, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. *J Rheumatol.* 2005 Jul;32(7):1232-42.
848. Genovese MC, Bathon JM, Martin RW, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. *Arthritis Rheum.* 2002 Jun;46(6):1443-50.
849. Genovese MC, Becker JC, Schiff M, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med.* 2005 Sep 15;353(11):1114-23.
850. Genovese MC, Cohen S, Moreland L, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. *Arthritis Rheum.* 2004 May;50(5):1412-9.



851. Genovese MC, Schiff M, Luggen M, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. *Ann Rheum Dis.* 2008 Apr;67(4):547-54.
852. Genovese MC, Van den Bosch F, Roberson SA, et al. LY2439821, a humanized anti-interleukin-17 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: A phase I randomized, double-blind, placebo-controlled, proof-of-concept study. *Arthritis Rheum.* 2010 Apr;62(4):929-39.
853. Geoghegan JM, Clark DI, Bainbridge LC, et al. Risk factors in carpal tunnel syndrome. *J Hand Surg [Br].* 2004 Aug;29(4):315-20.
854. George D, Kadlubek P, Batra D, et al. Infliximab dose and charge escalation patterns in managed care. *Manag Care Interface.* 2004;Suppl A:5-8.
855. Georgescu C. Sulphasalazine therapy in rheumatoid arthritis. A two-year study and follow-up of clinical results. *Rom J Intern Med.* 1992 Apr-Jun;30(2):127-32.
856. Georgiadis AN, Papavasiliou EC, Lourida ES, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. *Arthritis Res Ther.* 2006;8(3):R82.
857. Georgiadis AN, Voulgari PV, Argyropoulou MI, et al. Early treatment reduces the cardiovascular risk factors in newly diagnosed rheumatoid arthritis patients. *Semin Arthritis Rheum.* 2008 Aug;38(1):13-9.
858. Geraghty EM, Ristow B, Gordon SM, et al. Overwhelming parasitemia with *Plasmodium falciparum* infection in a patient receiving infliximab therapy for rheumatoid arthritis. *Clin Infect Dis.* 2007 May 15;44(10):e82-4.
859. Gergely P, Jr., Blazsek A, Danko K, et al. Detection of TT virus in patients with idiopathic inflammatory myopathies. *Ann N Y Acad Sci.* 2005 Jun;1050:304-13.
860. Gerlag DM, Boyle DL, Rosengren S, et al. Real-time quantitative PCR to detect changes in synovial gene expression in rheumatoid arthritis after corticosteroid treatment. *Ann Rheum Dis.* 2007 Apr;66(4):545-7.
861. Gerli R, Bertotto A, Agea E, et al. Basis for defective proliferation of peripheral blood T cells to anti-CD2 antibodies in primary Sjogren's syndrome. *J Clin Invest.* 1990 Dec;86(6):1870-7.
862. Gerli R, Lunardi C, Bocci EB, et al. Anti-tumor necrosis factor-alpha response in rheumatoid arthritis is associated with an increase in serum soluble CD30. *J Rheumatol.* 2008 Jan;35(1):14-9.
863. Gerli R, Schillaci G, Giordano A, et al. CD4+CD28- T lymphocytes contribute to early atherosclerotic damage in rheumatoid arthritis patients. *Circulation.* 2004 Jun 8;109(22):2744-8.
864. Gerloni V, Pontikaki I, Gattinara M, et al. Focus on adverse events of tumour necrosis factor alpha blockade in juvenile idiopathic arthritis in an open monocentric long-term prospective study of 163 patients. *Ann Rheum Dis.* 2008 Aug;67(8):1145-52.
865. Germano V, Picchianti Diamanti A, Baccano G, et al. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. *Ann Rheum Dis.* 2005 Oct;64(10):1519-20.
866. Gerster JC, Dudler J. Cellulitis caused by *Capnocytophaga cynodegmi* associated with etanercept treatment in a patient with rheumatoid arthritis. *Clin Rheumatol.* 2004 Dec;23(6):570-1.
867. Geusens P, Dequeker J, Vanhoof J, et al. Cyclical etidronate increases bone density in the spine and hip of postmenopausal women receiving long term corticosteroid treatment. A double blind, randomised placebo controlled study. *Ann Rheum Dis.* 1998 Dec;57(12):724-7.
868. Gevers G, Dequeker J, van Holsbeeck M, et al. A high dose (up to 200 mg) tolerance and efficacy study of intra-articular rimexolone (Org 6216) in rheumatoid synovitis of the knee. *Clin Rheumatol.* 1994 Mar;13(1):103-9.

869. Ghavami A, Genevay S, Fulpius T, et al. Etanercept in treatment of Felty's syndrome. *Ann Rheum Dis*. 2005 Jul;64(7):1090-1.
870. Giagounidis AA, Haase S, Germing U, et al. Autoimmune disorders in two patients with myelodysplastic syndrome and 5q deletion. *Acta Haematol*. 2005;113(2):146-9.
871. Gianella S, Schaer DJ, Schwarz U, et al. Retinal microangiopathy and rapidly fatal cerebral edema in a patient with adult-onset Still's disease and concurrent macrophage activation syndrome. *Am J Hematol*. 2008 May;83(5):424-7.
872. Giannelli G, Iannone F, Marinosci F, et al. Infliximab therapy does not modify MMP-2 and MMP-9 serum concentrations in chronic arthritis. *Clin Exp Rheumatol*. 2005 Nov-Dec;23(6):867-72.
873. Giardina AR, Accardo-Palumbo A, Ciccia F, et al. Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vgamma9/Vdelta2 T lymphocytes from patients with active rheumatoid arthritis. A role in the susceptibility to tuberculosis? *Reumatismo*. 2009 Jan-Mar;61(1):21-6.
874. Gibofsky A, Palmer WR, Goldman JA, et al. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. *Curr Med Res Opin*. 2006 Jan;22(1):169-83.
875. Gibson JN, Poyser NL, Morrison WL, et al. Muscle protein synthesis in patients with rheumatoid arthritis: effect of chronic corticosteroid therapy on prostaglandin F2 alpha availability. *Eur J Clin Invest*. 1991 Aug;21(4):406-12.
876. Gilbert ME, Savino PJ. Missing the bull's eye. *Surv Ophthalmol*. 2007 Jul-Aug;52(4):440-2.
877. Gilbert TD, Jr., Smith D, Ollendorf DA. Patterns of use, dosing, and economic impact of biologic agent use in patients with rheumatoid arthritis: a retrospective cohort study. *BMC Musculoskelet Disord*. 2004 Oct 14;5(1):36.
878. Gilboe IM, Kvien TK, Haugeberg G, et al. Bone mineral density in systemic lupus erythematosus: comparison with rheumatoid arthritis and healthy controls. *Ann Rheum Dis*. 2000 Feb;59(2):110-5.
879. Giles JT, Bartlett SJ, Gelber AC, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. *Arthritis Rheum*. 2006 Apr 15;55(2):333-7.
880. Giles JT, Fernandes V, Lima JA, et al. Myocardial dysfunction in rheumatoid arthritis: epidemiology and pathogenesis. *Arthritis Res Ther*. 2005;7(5):195-207.
881. Gill JB. Fat suppression imaging in epidural lipomatosis: case report. *J Surg Orthop Adv*. 2007 Fall;16(3):144-7.
882. Giltay EJ, Popp-Snijders C, van Schaardenburg D, et al. Serum testosterone levels are not elevated in patients with ankylosing spondylitis. *J Rheumatol*. 1998 Dec;25(12):2389-94.
883. Gladman DD, Mease PJ, Choy EH, et al. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. *Arthritis Res Ther*. 2010;12(3):R113.
884. Glass GE, Greig AV, Weir J, et al. Nasal tip necrosis--an unusual presentation of rheumatoid vasculitis. *Clin Rheumatol*. 2007 Nov;26(11):1943-5.
885. Gleissner C, Willershausen B, Kaesser U, et al. The role of risk factors for periodontal disease in patients with rheumatoid arthritis. *Eur J Med Res*. 1998 Aug 18;3(8):387-92.
886. Gluck T, Linde HJ, Scholmerich J, et al. Anti-tumor necrosis factor therapy and *Listeria monocytogenes* infection: report of two cases. *Arthritis Rheum*. 2002 Aug;46(8):2255-7; author reply 7.
887. Go RS, Li CY, Tefferi A, et al. Acquired pure red cell aplasia associated with lymphoproliferative disease of granular T lymphocytes. *Blood*. 2001 Jul 15;98(2):483-5.
888. Godaert GL, Hartkamp A, Geenen R, et al. Fatigue in daily life in patients with primary Sjogren's syndrome and systemic lupus erythematosus. *Ann N Y Acad Sci*. 2002 Jun;966:320-6.

889. Godinho F, Godfrin B, El Mahou S, et al. Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. *Clin Exp Rheumatol*. 2004 May-Jun;22(3):328-30.
890. Goeb V, Buch MH, Vital EM, et al. Costimulation blockade in rheumatic diseases: where we are? *Curr Opin Rheumatol*. 2009 May;21(3):244-50.
891. Goedkoop AY, Kraan MC, Picavet DI, et al. Deactivation of endothelium and reduction in angiogenesis in psoriatic skin and synovium by low dose infliximab therapy in combination with stable methotrexate therapy: a prospective single-centre study. *Arthritis Res Ther*. 2004;6(4):R326-34.
892. Goedkoop AY, Kraan MC, Teunissen MB, et al. Early effects of tumour necrosis factor alpha blockade on skin and synovial tissue in patients with active psoriasis and psoriatic arthritis. *Ann Rheum Dis*. 2004 Jul;63(7):769-73.
893. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). *Ann Rheum Dis*. 2007 Sep;66(9):1227-32.
894. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum*. 2005 Nov;52(11):3381-90.
895. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. *Arthritis Rheum*. 2008 Feb;58(2 Suppl):S126-35.
896. Goerres GW, Forster A, Uebelhart D, et al. F-18 FDG whole-body PET for the assessment of disease activity in patients with rheumatoid arthritis. *Clin Nucl Med*. 2006 Jul;31(7):386-90.
897. Goerttler E, Kutzner H, Peter HH, et al. Methotrexate-induced papular eruption in patients with rheumatic diseases: a distinctive adverse cutaneous reaction produced by methotrexate in patients with collagen vascular diseases. *J Am Acad Dermatol*. 1999 May;40(5 Pt 1):702-7.
898. Goksugur N, Yilmaz F. Medical image. Extensive oral ulcerations. *N Z Med J*. 2006;119(1242):U2236.
899. Golan TD, Keren D, Elias N, et al. Severe reversible cardiomyopathy associated with systemic vasculitis in primary Sjogren's syndrome. *Lupus*. 1997;6(6):505-8.
900. Golda N, Feldman M. Histoplasmosis clinically imitating cutaneous malignancy. *J Cutan Pathol*. 2008 Oct;35 Suppl 1:26-8.
901. Goldbach-Mansky R, Wilson M, Fleischmann R, et al. Comparison of Tripterygium wilfordii Hook F versus sulfasalazine in the treatment of rheumatoid arthritis: a randomized trial. *Ann Intern Med*. 2009 Aug 18;151(4):229-40, W49-51.
902. Goldberger C, Dulak J, Duftner C, et al. Vascular endothelial growth factor (VEGF) in ankylosing spondylitis--a pilot study. *Wien Med Wochenschr*. 2002;152(9-10):223-5.
903. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. *Clin Ther*. 1999 Jan;21(1):75-87; discussion 1-2.
904. Gomez-Reino JJ, Carmona L, Valverde VR, et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. *Arthritis Rheum*. 2003 Aug;48(8):2122-7.
905. Gonnet-Gracia C, Barnetche T, Richez C, et al. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. *Clin Exp Rheumatol*. 2008 May-Jun;26(3):401-7.
906. Gonzalez-Alvaro I, Ortiz AM, Tomero EG, et al. Baseline serum RANKL levels may serve to predict remission in rheumatoid arthritis patients treated with TNF antagonists. *Ann Rheum Dis*. 2007 Dec;66(12):1675-8.

907. Gonzalez-Chavez JR, Berlingeri-Ramos AC, Sanchez Casiano MA. Puerto Rico psoriasis study group: efficacy and safety of etanercept. *J Drugs Dermatol.* 2005 Nov-Dec;4(6):735-9.
908. Gonzalez-Gay MA, De Matias JM, Gonzalez-Juanatey C, et al. Anti-tumor necrosis factor-alpha blockade improves insulin resistance in patients with rheumatoid arthritis. *Clin Exp Rheumatol.* 2006 Jan-Feb;24(1):83-6.
909. Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, et al. Anti-TNF-alpha therapy does not modulate leptin in patients with severe rheumatoid arthritis. *Clin Exp Rheumatol.* 2009 Mar-Apr;27(2):222-8.
910. Gonzalez-Gay MA, Garcia-Unzueta MT, Berja A, et al. Short-term effect of anti-TNF-alpha therapy on nitric oxide production in patients with severe rheumatoid arthritis. *Clin Exp Rheumatol.* 2009 May-Jun;27(3):452-8.
911. Gonzalez-Gay MA, Garcia-Unzueta MT, De Matias JM, et al. Influence of anti-TNF-alpha infliximab therapy on adhesion molecules associated with atherogenesis in patients with rheumatoid arthritis. *Clin Exp Rheumatol.* 2006 Jul-Aug;24(4):373-9.
912. Gonzalez-Gay MA, Garcia-Unzueta MT, Gonzalez-Juanatey C, et al. Anti-TNF-alpha therapy modulates resistin in patients with rheumatoid arthritis. *Clin Exp Rheumatol.* 2008 Mar-Apr;26(2):311-6.
913. Gonzalez-Gay MA, Llorca J, Garcia-Unzueta MT, et al. High-grade inflammation, circulating adiponectin concentrations and cardiovascular risk factors in severe rheumatoid arthritis. *Clin Exp Rheumatol.* 2008 Jul-Aug;26(4):596-603.
914. Gonzalez-Gay MA, Vazquez-Rodriguez TR, Garcia-Unzueta MT, et al. Visfatin is not associated with inflammation or metabolic syndrome in patients with severe rheumatoid arthritis undergoing anti-TNF-alpha therapy. *Clin Exp Rheumatol.* 2010 Jan-Feb;28(1):56-62.
915. Gonzalez-Juanatey C, Llorca J, Sanchez-Andrade A, et al. Short-term adalimumab therapy improves endo-thelial function in patients with rheumatoid arthritis refractory to infliximab. *Clin Exp Rheumatol.* 2006 May-Jun;24(3):309-12.
916. Gonzalez-Juanatey C, Llorca J, Vazquez-Rodriguez TR, et al. Short-term improvement of endothelial function in rituximab-treated rheumatoid arthritis patients refractory to tumor necrosis factor alpha blocker therapy. *Arthritis Rheum.* 2008 Dec 15;59(12):1821-4.
917. Gonzalez-Juanatey C, Testa A, Garcia-Castelo A, et al. Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody. *Arthritis Rheum.* 2004 Jun 15;51(3):447-50.
918. Gonzalez-Lopez MA, Martinez-Taboada VM, Gonzalez-Vela MC, et al. Recall injection-site reactions associated with etanercept therapy: report of two new cases with immunohistochemical analysis. *Clin Exp Dermatol.* 2007 Nov;32(6):672-4.
919. Goossens PH, Heemskerk B, van Tongeren J, et al. Reliability and sensitivity to change of various measures of hand function in relation to treatment of synovitis of the metacarpophalangeal joint in rheumatoid arthritis. *Rheumatology (Oxford).* 2000 Aug;39(8):909-13.
920. Gorman JD, Sack KE, Davis JC, Jr. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. *N Engl J Med.* 2002 May 2;346(18):1349-56.
921. Gosset P, Perez T, Lassalle P, et al. Increased TNF-alpha secretion by alveolar macrophages from patients with rheumatoid arthritis. *Am Rev Respir Dis.* 1991 Mar;143(3):593-7.
922. Gottenberg JE, Guillevin L, Lambotte O, et al. Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases. *Ann Rheum Dis.* 2005 Jun;64(6):913-20.

923. Gottenberg JE, Miceli-Richard C, Ducot B, et al. Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort. *Arthritis Res Ther.* 2009;11(4):R114.
924. Gottenberg JE, Ravaud P, Bardin T, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. *Arthritis Rheum.* 2010 Sep;62(9):2625-32.
925. Gottlieb AB, Kircik L, Eisen D, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. *J Dermatolog Treat.* 2006;17(6):343-52.
926. Gottlieb AB, Mease PJ, Mark Jackson J, et al. Clinical characteristics of psoriatic arthritis and psoriasis in dermatologists' offices. *J Dermatolog Treat.* 2006;17(5):279-87.
927. Gough A, Sheeran T, Arthur V, et al. Adverse interaction between intramuscular methylprednisolone and sulphasalazine in patients with early rheumatoid arthritis. A pilot study. *Scand J Rheumatol.* 1994;23(1):46-8.
928. Graf C, Cardoso G, Silva MB, et al. Intra ocular pressure in chronic users of oral glucocorticoids for rheumatoid arthritis. *Acta Reumatol Port.* 2006 Apr-Jun;31(2):151-5, 83.
929. Gran JT, Myklebust G. Toxicity of sulphasalazine in rheumatoid arthritis. Possible protective effect of rheumatoid factors and corticosteroids. *Scand J Rheumatol.* 1993;22(5):229-32.
930. Grange L, Nissen MJ, Garambois K, et al. Infliximab-induced cerebral thrombophlebitis. *Rheumatology (Oxford).* 2005 Feb;44(2):260-1.
931. Granjo E, Lima M, Correia T, et al. Cd8(+)/V beta 5.1(+) large granular lymphocyte leukemia associated with autoimmune cytopenias, rheumatoid arthritis and vascular mammary skin lesions: successful response to 2-deoxycoformycin. *Hematol Oncol.* 2002 Jun;20(2):87-93.
932. Grassi W, De Angelis R, Cervini C. Corticosteroid prescribing in rheumatoid arthritis and psoriatic arthritis. *Clin Rheumatol.* 1998;17(3):223-6.
933. Grassi W, Lamanna G, Farina A, et al. Synovitis of small joints: sonographic guided diagnostic and therapeutic approach. *Ann Rheum Dis.* 1999 Oct;58(10):595-7.
934. Gratacos J, Casado E, Real J, et al. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. *Ann Rheum Dis.* 2007 Apr;66(4):493-7.
935. Gray RE, Doherty SM, Galloway J, et al. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. *Arthritis Rheum.* 1991 Mar;34(3):287-95.
936. Greenberg JD, Kishimoto M, Strand V, et al. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. *Am J Med.* 2008 Jun;121(6):532-8.
937. Greenwood MC, Hakim AJ, Doyle DV. A simple extension to the Rheumatoid Arthritis Quality of Life Questionnaire (RAQol) to explore individual patient concerns and monitor group outcome in clinical practice. *Rheumatology (Oxford).* 2006 Jan;45(1):61-5.
938. Grijalva CG, Chung CP, Arbogast PG, et al. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. *Med Care* 2007;45(10 Supl 2):S66-76.
939. Grijalva CG, Chung CP, Stein CM, et al. Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. *Rheumatology (Oxford).* 2008 Jul;47(7):1061-4.
940. Grijalva CG, Kaltenbach L, Arbogast PG, et al. Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. *Arthritis Care Res (Hoboken)* 2010;62(5):730-4.

941. Grinblat B, Scheinberg M. Unexpected onset of psoriasis during infliximab treatment: comment on the article by Beuthien et al. *Arthritis Rheum.* 2005 Apr;52(4):1333-4; author reply 4.
942. Grinblat B, Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. *Semin Arthritis Rheum.* 2008 Feb;37(4):251-5.
943. Grisar J, Aletaha D, Steiner CW, et al. Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. *Ann Rheum Dis.* 2007 Oct;66(10):1284-8.
944. Guarneri C, Polimeni G. Nicolau syndrome following etanercept administration. *Am J Clin Dermatol.* 2010;11 Suppl 1:51-2.
945. Guarneri C, Polimeni G, Nunnari G. Pityriasis rosea during etanercept therapy. *Eur Rev Med Pharmacol Sci.* 2009 Sep-Oct;13(5):383-7.
946. Guarnieri MV, Rosenberg L, Scheinberg MA. Intractable pain in a rheumatoid wrist. *J Rheumatol.* 2003 Dec;30(12):2718-9.
947. Gubinelli E, Angelo C, Pacifico V. A case of dystrophic epidermolysis bullosa improved with etanercept for concomitant psoriatic arthritis. *Am J Clin Dermatol.* 2010;11 Suppl 1:53-4.
948. Gudbjornsson B, Skogseid B, Oberg K, et al. Intact adrenocorticotrophic hormone secretion but impaired cortisol response in patients with active rheumatoid arthritis. Effect of glucocorticoids. *J Rheumatol.* 1996 Apr;23(4):596-602.
949. Gudbrandsdottir S, Bliddal H, Petri A, et al. Plasma TNF binding capacity profiles during treatment with etanercept in rheumatoid arthritis. *Scand J Rheumatol.* 2004;33(6):385-8.
950. Guignard S, Dien G, Dougados M. Severe systemic inflammatory response syndrome in a patient with adult onset Still's disease treated with the anti-IL1 drug anakinra: a case report. *Clin Exp Rheumatol.* 2007 Sep-Oct;25(5):758-9.
951. Guignard S, Gossec L, Bandinelli F, et al. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. *Clin Exp Rheumatol* 2008;26(3 Suppl 49):S23-9.
952. Guillot X, Solau-Gervais E, Coulon A, et al. Sjogren's syndrome with ANCA-associated crescentic extramembranous glomerulonephritis. *Joint Bone Spine.* 2009 Mar;76(2):188-9.
953. Guion TL, Sculco TP. *Pasteurella multocida* infection in total knee arthroplasty. Case report and literature review. *J Arthroplasty.* 1992 Jun;7(2):157-60.
954. Guis S, Balandraud N, Bouvenot J, et al. Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis. *Arthritis Rheum.* 2007 Dec 15;57(8):1426-30.
955. Gul U, Gonul M, Kilic A, et al. Treatment of psoriatic arthritis with etanercept, methotrexate, and cyclosporin A. *Clin Ther.* 2006 Feb;28(2):251-4.
956. Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. *Ann Rheum Dis.* 2009 Mar;68(3):330-6.
957. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. *Ann Rheum Dis.* 2008 Jun;67(6):823-8.
958. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, et al. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. *Ann Rheum Dis.* 2007 Nov;66(11):1508-12.
959. Guler-Yuksel M, Klarenbeek NB, Goekoop-Ruiterman YP, et al. Accelerated hand bone mineral density loss is associated with progressive joint damage in hands and feet in recent-onset rheumatoid arthritis. *Arthritis Res Ther.* 2010;12(3):R96.
960. Gupta A, Bansal RK, Bamberg P. Posterior scleritis related fundal mass in a patient with rheumatoid arthritis. *Scand J Rheumatol.* 1992;21(5):254-6.

961. Gupta N, Fox CM, Grisolano SW. Disseminated histoplasmosis with colonic ulcers in a patient receiving infliximab. *Gastrointest Endosc.* 2009 Sep;70(3):597-8.
962. Gutierrez MA, Garcia ME, Rodriguez JA, et al. Hypothalamic-pituitary-adrenal axis function in patients with active rheumatoid arthritis: a controlled study using insulin hypoglycemia stress test and prolactin stimulation. *J Rheumatol.* 1999 Feb;26(2):277-81.
963. Guzman-Clark JR, Fang MA, Sehl ME, et al. Barriers in the management of glucocorticoid-induced osteoporosis. *Arthritis Rheum.* 2007 Feb 15;57(1):140-6.
964. Gwak GY, Koh KC, Kim HY. Fatal hepatic failure associated with hepatitis B virus reactivation in a hepatitis B surface antigen-negative patient with rheumatoid arthritis receiving low dose methotrexate. *Clin Exp Rheumatol.* 2007 Nov-Dec;25(6):888-9.
965. Habib GS, Haj S. Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids. *Clin Rheumatol.* 2005 Apr;24(2):129-33.
966. Hadi A, Hickling P, Brown M, et al. Scintigraphic evidence of effect of infliximab on disease activity in ankylosing spondylitis. *Rheumatology (Oxford).* 2002 Jan;41(1):114-6.
967. Hadj Kacem H, Kaddour N, Adyel FZ, et al. HLA-DQB1 CARI/CAR2, TNFa IR2/IR4 and CTLA-4 polymorphisms in Tunisian patients with rheumatoid arthritis and Sjogren's syndrome. *Rheumatology (Oxford).* 2001 Dec;40(12):1370-4.
968. Haerden J, Coolen L, Dequeker J. The effect of D-penicillamine on lung function parameters (diffusion capacity) in rheumatoid arthritis. *Clin Exp Rheumatol.* 1993 Sep-Oct;11(5):509-13.
969. Hafstrom I, Albertsson K, Boonen A, et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. *Ann Rheum Dis.* 2009 Apr;68(4):508-13.
970. Hafstrom I, Rohani M, Deneberg S, et al. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. *J Rheumatol.* 2007 Sep;34(9):1810-6.
971. Hage CA, Wood KL, Winer-Muram HT, et al. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. *Chest.* 2003 Dec;124(6):2395-7.
972. Hagiwara K, Sato T, Takagi-Kobayashi S, et al. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. *J Rheumatol.* 2007 May;34(5):1151-4.
973. Hahtola PA, Jarvenpaa RE, Lounatmaa K, et al. Hard metal alveolitis accompanied by rheumatoid arthritis. *Respiration.* 2000;67(2):209-12.
974. Haibel H, Rudwaleit M, Brandt HC, et al. Adalimumab reduces spinal symptoms in active ankylosing spondylitis: clinical and magnetic resonance imaging results of a fifty-two-week open-label trial. *Arthritis Rheum.* 2006 Feb;54(2):678-81.
975. Haibel H, Rudwaleit M, Listing J, et al. Open label trial of anakinra in active ankylosing spondylitis over 24 weeks. *Ann Rheum Dis.* 2005 Feb;64(2):296-8.
976. Haigh RC, McCabe CS, Halligan PW, et al. Joint stiffness in a phantom limb: evidence of central nervous system involvement in rheumatoid arthritis. *Rheumatology (Oxford).* 2003 Jul;42(7):888-92.
977. Hall GM, Daniels M, Doyle DV, et al. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. *Arthritis Rheum.* 1994 Oct;37(10):1499-505.
978. Hall GM, Peerbhoy D, Shenkin A, et al. Hip and knee arthroplasty: a comparison and the endocrine, metabolic and inflammatory responses. *Clin Sci (Lond).* 2000 Jan;98(1):71-9.
979. Hall GM, Perry LA, Spector TD. Depressed levels of dehydroepiandrosterone sulphate in postmenopausal women with rheumatoid arthritis but no relation with axial bone density. *Ann Rheum Dis.* 1993 Mar;52(3):211-4.

980. Hall GM, Spector TD, Delmas PD. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. *Arthritis Rheum.* 1995 Jul;38(7):902-6.
981. Hall GM, Spector TD, Griffin AJ, et al. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. *Arthritis Rheum.* 1993 Nov;36(11):1510-6.
982. Hall HA, Zimmermann B. Evolution of dermatomyositis during therapy with a tumor necrosis factor alpha inhibitor. *Arthritis Rheum.* 2006 Dec 15;55(6):982-4.
983. Hall J, Morand EF, Medbak S, et al. Abnormal hypothalamic-pituitary-adrenal axis function in rheumatoid arthritis. Effects of nonsteroidal antiinflammatory drugs and water immersion. *Arthritis Rheum.* 1994 Aug;37(8):1132-7.
984. Hall SJ, Hickling P. Failure of etanercept to control extra-articular manifestations of rheumatoid arthritis. *J Clin Rheumatol.* 2007 Feb;13(1):54.
985. Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. *Ann Rheum Dis.* 2009 Jun;68(6):930-7.
986. Halvorsen EH, Haavardsholm EA, Pollmann S, et al. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents. *Ann Rheum Dis.* 2009 Feb;68(2):249-52.
987. Hamada H, Kohno N, Yokoyama A, et al. KL-6 as a serologic indicator of *Pneumocystis carinii* pneumonia in immunocompromised hosts. *Intern Med.* 1998 Mar;37(3):307-10.
988. Hamadeh MA, Atkinson J, Smith LJ. Sulfasalazine-induced pulmonary disease. *Chest.* 1992 Apr;101(4):1033-7.
989. Hamalainen H, Arkela-Kautiainen M, Kautiainen H, et al. Bone mineral content in young adults with active or inactive juvenile idiopathic arthritis and in controls. *Scand J Rheumatol.* 2010 May;39(3):219-22.
990. Hamilton TK. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy. *J Drugs Dermatol.* 2008 Nov;7(11):1089-93.
991. Hammer HB, Sveinsson M, Kongtorp AK, et al. A 78-joints ultrasonographic assessment is associated with clinical assessments and is highly responsive to improvement in a longitudinal study of patients with rheumatoid arthritis starting adalimumab treatment. *Ann Rheum Dis.* 2010 Jul;69(7):1349-51.
992. Hammoudeh M. Influximab treatment in a patient with rheumatoid arthritis on haemodialysis. *Rheumatology (Oxford).* 2006 Mar;45(3):357-9.
993. Hammoudeh M. Recurrent postpartum episodic rheumatoid arthritis. *J Clin Rheumatol.* 2006 Aug;12(4):196-8.
994. Han C, Rahman MU, Doyle MK, et al. Association of anemia and physical disability among patients with rheumatoid arthritis. *J Rheumatol.* 2007 Nov;34(11):2177-82.
995. Han C, Smolen J, Kavanaugh A, et al. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. *Arthritis Rheum.* 2008 Apr 15;59(4):510-4.
996. Hanauer SB. Review article: safety of infliximab in clinical trials. *Aliment Pharmacol Ther.* 1999 Sep;13 Suppl 4:16-22; discussion 38.
997. Hanna B, Holdeman NR, Tang RA, et al. Retinal toxicity secondary to Plaquenil therapy. *Optometry.* 2008 Feb;79(2):90-4.
998. Hansel S, Lassig G, Pistrosch F, et al. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. *Atherosclerosis.* 2003 Sep;170(1):177-80.
999. Hansen IB, Ellingsen T, Hornung N, et al. Plasma level of CXC-chemokine CXCL12 is increased in rheumatoid arthritis and is independent of disease activity and methotrexate treatment. *J Rheumatol.* 2006 Sep;33(9):1754-9.



1000. Hansen KE, Cush J, Singhal A, et al. The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. *Arthritis Rheum.* 2004 Apr 15;51(2):228-32.
1001. Hansen KE, Hildebrand JP, Genovese MC, et al. The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. *J Rheumatol.* 2004 Jun;31(6):1098-102.
1002. Hansen M, Florescu A, Stoltenberg M, et al. Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment. *Scand J Rheumatol.* 1996;25(6):367-76.
1003. Harada K, Akai Y, Koyama S, et al. A case of autoimmune hepatitis exacerbated by the administration of etanercept in the patient with rheumatoid arthritis. *Clin Rheumatol.* 2008 Aug;27(8):1063-6.
1004. Harada S, Mitsunobu F, Kodama F, et al. Giant cell arteritis associated with rheumatoid arthritis monitored by magnetic resonance angiography. *Intern Med.* 1999 Aug;38(8):675-8.
1005. Haraoui B, Cameron L, Ouellet M, et al. Anti-infliximab antibodies in patients with rheumatoid arthritis who require higher doses of infliximab to achieve or maintain a clinical response. *J Rheumatol.* 2006 Jan;33(1):31-6.
1006. Haraoui B, Keystone EC, Thorne JC, et al. Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. *J Rheumatol.* 2004 Dec;31(12):2356-9.
1007. Harboe E, Tjensvoll AB, Vefring HK, et al. Fatigue in primary Sjogren's syndrome--a link to sickness behaviour in animals? *Brain Behav Immun.* 2009 Nov;23(8):1104-8.
1008. Harbuz MS, Korendowych E, Jessop DS, et al. Hypothalamo-pituitary-adrenal axis dysregulation in patients with rheumatoid arthritis after the dexamethasone/corticotrophin releasing factor test. *J Endocrinol.* 2003 Jul;178(1):55-60.
1009. Hardy R, Rabbitt EH, Filer A, et al. Local and systemic glucocorticoid metabolism in inflammatory arthritis. *Ann Rheum Dis.* 2008 Sep;67(9):1204-10.
1010. Hargreaves MR, Mowat AG, Benson MK. Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. *Thorax.* 1992 Aug;47(8):628-33.
1011. Harle P, Pongratz G, Weidler C, et al. Possible role of leptin in hypoandrogenicity in patients with systemic lupus erythematosus and rheumatoid arthritis. *Ann Rheum Dis.* 2004 Jul;63(7):809-16.
1012. Harle P, Straub RH, Wiest R, et al. Increase of sympathetic outflow measured by neuropeptide Y and decrease of the hypothalamic-pituitary-adrenal axis tone in patients with systemic lupus erythematosus and rheumatoid arthritis: another example of uncoupling of response systems. *Ann Rheum Dis.* 2006 Jan;65(1):51-6.
1013. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. *Am J Manag Care.* 2003 Oct;9(6 Suppl):S136-43.
1014. Harner KC, Jackson LW, Drabick JJ. Normalization of anticardiolipin antibodies following rituximab therapy for marginal zone lymphoma in a patient with Sjogren's syndrome. *Rheumatology (Oxford).* 2004 Oct;43(10):1309-10.
1015. Harney S, O'Shea FD, FitzGerald O. Peptostreptococcal pericarditis complicating anti-tumour necrosis factor alpha treatment in rheumatoid arthritis. *Ann Rheum Dis.* 2002 Jul;61(7):653-4.
1016. Haroon M, Bond U, Phelan M. Sinusitis: a possible link with adalimumab. *Clin Rheumatol.* 2008 Sep;27(9):1189-90.
1017. Haroon N, Srivastava R, Misra R, et al. A novel predictor of clinical response to methotrexate in patients with rheumatoid arthritis: a pilot study of in vitro T cell cytokine suppression. *J Rheumatol.* 2008 Jun;35(6):975-8.

1018. Harrison DJ, Huang X, Globe D. Dosing patterns and costs of tumor necrosis factor inhibitor use for rheumatoid arthritis. *Am J Health Syst Pharm.* 2010 Aug;67(15):1281-7.
1019. Harrison MJ, Dixon WG, Watson KD, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis* 2009;68(2):209-15.
1020. Harrison MJ, Kim CA, Silverberg M, et al. Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis? *J Rheumatol.* 2005 Jul;32(7):1243-8.
1021. Hartkamp A, Geenen R, Godaert GL, et al. Effect of dehydroepiandrosterone administration on fatigue, well-being, and functioning in women with primary Sjogren syndrome: a randomised controlled trial. *Ann Rheum Dis.* 2008 Jan;67(1):91-7.
1022. Hashiramoto A, Shiozawa K, Tanaka Y, et al. Prospective study of methotrexate treatment for rheumatoid arthritis treated legitimately according to the government recommended 8 mg/week dose. *Mod Rheumatol.* 2009;19(6):637-42.
1023. Hassell AB, Davis MJ, Fowler PD, et al. The relationship between serial measures of disease activity and outcome in rheumatoid arthritis. *Q J Med.* 1993 Sep;86(9):601-7.
1024. Hassett AL, Li T, Buyske S, et al. The multi-faceted assessment of independence in patients with rheumatoid arthritis: preliminary validation from the ATTAIn study. *Curr Med Res Opin* 2008;24(5):1443-53.
1025. Hassikou H, El Haouri M, Tabache F, et al. Leflunomide-induced toxic epidermal necrolysis in a patient with rheumatoid arthritis. *Joint Bone Spine.* 2008 Oct;75(5):597-9.
1026. Hatemi G, Melikoglu M, Fresko I, et al. Infliximab does not suppress the tuberculin skin test (purified protein derivative). *J Rheumatol.* 2007 Mar;34(3):474-80.
1027. Hau M, Kneitz C, Tony HP, et al. High resolution ultrasound detects a decrease in pannus vascularisation of small finger joints in patients with rheumatoid arthritis receiving treatment with soluble tumour necrosis factor alpha receptor (etanercept). *Ann Rheum Dis.* 2002 Jan;61(1):55-8.
1028. Haugeberg G, Orstavik RE, Uhlig T, et al. Clinical decision rules in rheumatoid arthritis: do they identify patients at high risk for osteoporosis? Testing clinical criteria in a population based cohort of patients with rheumatoid arthritis recruited from the Oslo Rheumatoid Arthritis Register. *Ann Rheum Dis.* 2002 Dec;61(12):1085-9.
1029. Haugeberg G, Orstavik RE, Uhlig T, et al. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. *Arthritis Rheum.* 2002 Jul;46(7):1720-8.
1030. Haugeberg G, Orstavik RE, Uhlig T, et al. Comparison of ultrasound and X-ray absorptiometry bone measurements in a case control study of female rheumatoid arthritis patients and randomly selected subjects in the population. *Osteoporos Int.* 2003 Jun;14(4):312-9.
1031. Haugeberg G, Uhlig T, Falch JA, et al. Bone mineral density and frequency of osteoporosis in female patients with rheumatoid arthritis: results from 394 patients in the Oslo County Rheumatoid Arthritis register. *Arthritis Rheum.* 2000 Mar;43(3):522-30.
1032. Haugen M, Lien G, Flato B, et al. Young adults with juvenile arthritis in remission attain normal peak bone mass at the lumbar spine and forearm. *Arthritis Rheum.* 2000 Jul;43(7):1504-10.
1033. Haugen MA, Lien G, Flato B, et al. Minor impact of juvenile arthritis on nutritional status in young adult patients. *Arthritis Rheum.* 2002 Dec 15;47(6):623-9.
1034. Hauselmann HJ, Caravatti M, Seifert B, et al. Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind, randomized trial. *Br J Rheumatol.* 1998 Oct;37(10):1110-7.

1035. Havel J, Aboutalebi S, Doughty L, et al. Development of systemic lupus erythematosus in a patient with rheumatoid arthritis following treatment conversion of infliximab to adalimumab. *J Drugs Dermatol*. 2008 Aug;7(8):796-8.
1036. Havelka S, Vavrincova P, Stepan J. Metabolic bone status in young women with juvenile chronic arthritis. *J Rheumatol Suppl*. 1993 Apr;37:14-6.
1037. Havelka S, Vavrincova P, Stepan J, et al. Metabolic bone status in young women with JCA. *Acta Univ Carol [Med] (Praha)*. 1994;40(1-4):65-7.
1038. Hawboldt J, Bader M. Intramuscular methotrexate-induced aseptic meningitis. *Ann Pharmacother*. 2007 Nov;41(11):1906-11.
1039. Hayashi H, Fujimaki C, Daimon T, et al. Genetic polymorphisms in folate pathway enzymes as a possible marker for predicting the outcome of methotrexate therapy in Japanese patients with rheumatoid arthritis. *J Clin Pharm Ther*. 2009 Jun;34(3):355-61.
1040. He Y, Lu A, Zha Y, et al. Differential effect on symptoms treated with traditional Chinese medicine and western combination therapy in RA patients. *Complement Ther Med*. 2008 Aug;16(4):206-11.
1041. He Y, Lu A, Zha Y, et al. Correlations between symptoms as assessed in traditional chinese medicine (TCM) and ACR20 efficacy response: a comparison study in 396 patients with rheumatoid arthritis treated with TCM or Western medicine. *J Clin Rheumatol*. 2007 Dec;13(6):317-21.
1042. Healy PJ, Groves C, Chandramohan M, et al. MRI changes in psoriatic dactylitis--extent of pathology, relationship to tenderness and correlation with clinical indices. *Rheumatology (Oxford)*. 2008 Jan;47(1):92-5.
1043. Healy PJ, Helliwell PS. Measuring dactylitis in clinical trials: which is the best instrument to use? *J Rheumatol*. 2007 Jun;34(6):1302-6.
1044. Healy PJ, Helliwell PS. Measuring clinical enthesitis in psoriatic arthritis: assessment of existing measures and development of an instrument specific to psoriatic arthritis. *Arthritis Rheum*. 2008 May 15;59(5):686-91.
1045. Hebbar M, Hebbar-Savean K, Hachulla E, et al. Participation of cryoglobulinaemia in the severe peripheral neuropathies of primary Sjogren's syndrome. *Ann Med Interne (Paris)*. 1995;146(4):235-8.
1046. Hedman M, Nilsson E, de la Torre B. Low blood and synovial fluid levels of sulpho-conjugated steroids in rheumatoid arthritis. *Clin Exp Rheumatol*. 1992 Jan-Feb;10(1):25-30.
1047. Heiberg MS, Koldingsnes W, Mikkelsen K, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. *Arthritis Rheum*. 2008 Feb 15;59(2):234-40.
1048. Heiberg MS, Nordvag BY, Mikkelsen K, et al. The comparative effectiveness of tumor necrosis factor-blocking agents in patients with rheumatoid arthritis and patients with ankylosing spondylitis: a six-month, longitudinal, observational, multicenter study. *Arthritis Rheum*. 2005 Aug;52(8):2506-12.
1049. Heikkila R, Aho K, Heliovaara M, et al. Serum androgen-anabolic hormones and the risk of rheumatoid arthritis. *Ann Rheum Dis*. 1998 May;57(5):281-5.
1050. Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions. *J Rheumatol*. 2008 Mar;35(3):472-6.
1051. Henke PK, Sukheepod P, Proctor MC, et al. Clinical relevance of peripheral vascular occlusive disease in patients with rheumatoid arthritis and systemic lupus erythematosus. *J Vasc Surg*. 2003 Jul;38(1):111-5.
1052. Henrickson M, Reiff A. Prolonged efficacy of etanercept in refractory enthesitis-related arthritis. *J Rheumatol*. 2004 Oct;31(10):2055-61.

1053. Hepburn AL, Mason JC, Davies KA. Expression of Fcγ and complement receptors on peripheral blood monocytes in systemic lupus erythematosus and rheumatoid arthritis. *Rheumatology (Oxford)*. 2004 May;43(5):547-54.
1054. Herenius MM, Hoving JL, Sluiter JK, et al. Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab. *J Occup Environ Med*. 2010 Jun;52(6):618-21.
1055. Hermann J, Mueller T, Fahrleitner A, et al. Early onset and effective inhibition of bone resorption in patients with rheumatoid arthritis treated with the tumour necrosis factor alpha antibody infliximab. *Clin Exp Rheumatol*. 2003 Jul-Aug;21(4):473-6.
1056. Herrera-Esparza R, Avalos-Diaz E. Infliximab treatment in a case of rheumatoid scleromalacia perforans. *Reumatismo*. 2009 Jul-Sep;61(3):212-5.
1057. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. *Arthritis Rheum*. 2006 May;54(5):1401-9.
1058. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTR study. *Ann Rheum Dis*. 2008 Jun;67(6):815-22.
1059. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTR trial. *Ann Rheum Dis*. 2010 Oct;69(10):1789-95.
1060. Heytman M, Ahern MJ, Smith MD, et al. The longterm effect of pulsed corticosteroids on the efficacy and toxicity of chrysotherapy in rheumatoid arthritis. *J Rheumatol*. 1994 Mar;21(3):435-41.
1061. Hider SL, Thomson W, Mack LF, et al. Polymorphisms within the adenosine receptor 2a gene are associated with adverse events in RA patients treated with MTX. *Rheumatology (Oxford)*. 2008 Aug;47(8):1156-9.
1062. Higashida J, Wun T, Schmidt S, et al. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. *J Rheumatol*. 2005 Nov;32(11):2109-15.
1063. High WA, Muldrow ME, Fitzpatrick JE. Cutaneous lupus erythematosus induced by infliximab. *J Am Acad Dermatol*. 2005 Apr;52(4):E5.
1064. Hilliquin P, Houbaba H, Aissa J, et al. Correlations between PAF-acether and tumor necrosis factor in rheumatoid arthritis. Influence of parenteral corticosteroids. *Scand J Rheumatol*. 1995;24(3):169-73.
1065. Hirabayashi Y, Shimizu H, Kobayashi N, et al. Leflunomide-induced pneumonitis in a patient with rheumatoid arthritis. *Intern Med*. 2006;45(10):689-91.
1066. Hirano D, Nagashima M, Ogawa R, et al. Serum levels of interleukin 6 and stress related substances indicate mental stress condition in patients with rheumatoid arthritis. *J Rheumatol*. 2001 Mar;28(3):490-5.
1067. Hirano Y, Kishimoto H, Hagino H, et al. The change of bone mineral density in secondary osteoporosis and vertebral fracture incidence. *J Bone Miner Metab*. 1999;17(2):119-24.
1068. Hirano Y, Kojima T, Kanayama Y, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. *Clin Rheumatol* 2010;29(5):495-500.
1069. Hirayama T, Danks L, Sabokbar A, et al. Osteoclast formation and activity in the pathogenesis of osteoporosis in rheumatoid arthritis. *Rheumatology (Oxford)*. 2002 Nov;41(11):1232-9.

1070. Hirche D, Rubbert A, Lunau L, et al. Successful treatment of refractory rheumatoid arthritis-associated leg ulcerations with adalimumab. *Br J Dermatol*. 2005 May;152(5):1062-4.
1071. Hirohata M, Yasukawa Y, Ishida C, et al. Reversible cortical lesions in primary Sjogren's syndrome presenting with meningoencephalitis as an initial manifestation. *J Neurol Sci*. 2005 May 15;232(1-2):111-3.
1072. Hirohata S, Yanagida T, Tomita T, et al. Differential influences of bucillamine and methotrexate on the generation of fibroblast-like cells from bone marrow CD34+ cells of rheumatoid arthritis patients. *Int Immunopharmacol*. 2009 Jan;9(1):86-90.
1073. Hirose W, Nishikawa K, Hirose M, et al. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging. *Mod Rheumatol*. 2009;19(1):20-6.
1074. Hjardem E, Ostergaard M, Podenphant J, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? *Ann Rheum Dis* 2007;66(9):1184-9.
1075. Ho YV, Briganti EM, Duan Y, et al. Polymorphism of the vitamin D receptor gene and corticosteroid-related osteoporosis. *Osteoporos Int*. 1999;9(2):134-8.
1076. Hochberg MC, Johnston SS, John AK. The incidence and prevalence of extra-articular and systemic manifestations in a cohort of newly-diagnosed patients with rheumatoid arthritis between 1999 and 2006. *Curr Med Res Opin*. 2008 Feb;24(2):469-80.
1077. Hoff M, Kvien TK, Kalvesten J, et al. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. *Ann Rheum Dis* 2009;68(7):1171-6.
1078. Holman AJ, Ng E. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis. *Auton Neurosci*. 2008 Dec 5;143(1-2):58-67.
1079. Homsy S, Alexandrescu DT, Milojkovic N, et al. Diffuse large B-cell lymphoma with lung involvement in a psoriatic arthritis patient treated with methotrexate. *Dermatol Online J*. 2010;16(5):1.
1080. Hong BK, Kumar C, Marottoli RA. "MAC" attack. *Am J Med*. 2009 Dec;122(12):1096-8.
1081. Hong S, Kim T, Chung SH, et al. Recurrence after topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren's syndrome. *J Ocul Pharmacol Ther*. 2007 Feb;23(1):78-82.
1082. Hooper DR, Tarnopolsky MA, Baker SK. Lewis-Sumner syndrome associated with infliximab therapy in rheumatoid arthritis. *Muscle Nerve*. 2008 Oct;38(4):1318-25.
1083. Hoppe E, Masson C, Audran M, et al. Whipple's disease diagnosed during biological treatment for joint disease. *Joint Bone Spine*. 2010 Jul;77(4):335-9.
1084. Hornung N, Ellingsen T, Attermann J, et al. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. *J Rheumatol*. 2008 Sep;35(9):1709-15.
1085. Hosaka K, Ryu J, Saitoh S, et al. The combined effects of anti-TNFalpha antibody and IL-1 receptor antagonist in human rheumatoid arthritis synovial membrane. *Cytokine*. 2005 Dec 21;32(6):263-9.
1086. Hoshida Y, Xu JX, Fujita S, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. *J Rheumatol*. 2007 Feb;34(2):322-31.
1087. Hoshida Y, Yamamoto S, Wada N, et al. Infliximab-associated lymphoproliferative disorders. *Int J Hematol*. 2005 May;81(4):356-7.
1088. Hot A, Toh ML, Coppere B, et al. Reactive hemophagocytic syndrome in adult-onset Still disease: clinical features and long-term outcome: a case-control study of 8 patients. *Medicine (Baltimore)*. 2010 Jan;89(1):37-46.

1089. Housden MM, Bell G, Heycock CR, et al. How to reduce morbidity and mortality from chest infections in rheumatoid arthritis. *Clin Med*. 2010 Aug;10(4):326-9.
1090. Houtman PM. Septic monoarthritis due to *Pasteurella multocida* after a cat scratch in a patient with rheumatoid arthritis. *Neth J Med*. 1990 Apr;36(3-4):207-8.
1091. Hrycaj P, Korczowska I, Lacki JK. Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab. *Rheumatology (Oxford)*. 2003 May;42(5):702-3.
1092. Hrycaj P, Lacki JK. Treatment resistant ankylosing spondylitis with peripheral joint involvement - a case for infliximab? *J Rheumatol*. 2003 Jan;30(1):204-6; author reply 6.
1093. Hsieh TY, Lan JL, Chen DY. Primary Sjogren's syndrome with protein-losing gastroenteropathy: report of two cases. *J Formos Med Assoc*. 2002 Jul;101(7):519-22.
1094. Hsu CT, Lin YT, Yang YH, et al. Factors affecting clinical and therapeutic outcomes of patients with juvenile rheumatoid arthritis. *Scand J Rheumatol*. 2004;33(5):312-7.
1095. Hsu PC, Lan JL, Hsieh TY, et al. Methotrexate pneumonitis in a patient with rheumatoid arthritis. *J Microbiol Immunol Infect*. 2003 Jun;36(2):137-40.
1096. Hu D, Bao C, Chen S, et al. A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China. *Rheumatol Int*. 2009 Jan;29(3):297-303.
1097. Hu S, Cohen D, Murphy G, et al. Interstitial granulomatous dermatitis in a patient with rheumatoid arthritis on etanercept. *Cutis*. 2008 Apr;81(4):336-8.
1098. Huang F, Zhu J, Zhang L, et al. Response to one infusion predicts subsequent improvement as well as the rate of relapse of ankylosing spondylitis infused with three pulses of infliximab. *Clin Rheumatol*. 2007 Jun;26(6):920-6.
1099. Huang X, Gu NY, Fox KM, et al. Comparison of methods for measuring dose escalation of the subcutaneous TNF antagonists for rheumatoid arthritis patients treated in routine clinical practice. *Curr Med Res Opin*. 2010 Jul;26(7):1637-45.
1100. Hubscher O, Re R, Iotti R. Pulmonary rheumatoid nodules in an etanercept-treated patient. *Arthritis Rheum*. 2003 Jul;48(7):2077-8.
1101. Hughes LB, Criswell LA, Beasley TM, et al. Genetic risk factors for infection in patients with early rheumatoid arthritis. *Genes Immun*. 2004 Dec;5(8):641-7.
1102. Hurlimann D, Forster A, Noll G, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. *Circulation*. 2002 Oct 22;106(17):2184-7.
1103. Huscher D, Thiele K, Gromnica-Ihle E, et al. Dose-related patterns of glucocorticoid-induced side effects. *Ann Rheum Dis*. 2009 Jul;68(7):1119-24.
1104. Husni ME, Maier AL, Mease PJ, et al. Etanercept in the treatment of adult patients with Still's disease. *Arthritis Rheum*. 2002 May;46(5):1171-6.
1105. Hussar DA. New drugs: abatacept, sorafenib, and nelarabine. *J Am Pharm Assoc (Wash DC)*. 2006 Mar-Apr;46(2):300-3.
1106. Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. *Curr Opin Mol Ther*. 2008 Aug;10(4):393-406.
1107. Huwait H, Wang B, Shustik C, et al. Composite cutaneous lymphoma in a patient with rheumatoid arthritis treated with methotrexate. *Am J Dermatopathol*. 2010 Feb;32(1):65-70.
1108. Hyon JY, Lee YJ, Yun PY. Management of ocular surface inflammation in Sjogren syndrome. *Cornea*. 2007 Oct;26(9 Suppl 1):S13-5.
1109. Hyrich KL, Deighton C, Watson KD, et al. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. *Rheumatology (Oxford)*. 2009;48(10):1323-7.

1110. Hyrich KL, Lunt M, Dixon WG, et al. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. *Rheumatology (Oxford)*. 2008 Jul;47(7):1000-5.
1111. Hyrich KL, Lunt M, Watson KD, et al. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. *Arthritis Rheum* 2007;56(1):13-20.
1112. Iagnocco A, Filippucci E, Perella C, et al. Clinical and ultrasonographic monitoring of response to adalimumab treatment in rheumatoid arthritis. *J Rheumatol*. 2008 Jan;35(1):35-40.
1113. Iagnocco A, Perella C, Naredo E, et al. Etanercept in the treatment of rheumatoid arthritis: clinical follow-up over one year by ultrasonography. *Clin Rheumatol*. 2008 Apr;27(4):491-6.
1114. Iannone F, Trotta F, Montecucco C, et al. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects. *Ann Rheum Dis*. 2007 Feb;66(2):249-52.
1115. Ichikawa T, Kageyama Y, Kobayashi H, et al. Etanercept treatment reduces the serum levels of interleukin-15 and interferon-gamma inducible protein-10 in patients with rheumatoid arthritis. *Rheumatol Int*. 2010 Apr;30(6):725-30.
1116. Ideguchi H, Ohno S, Ishigatsubo Y. Risk factors associated with the cumulative survival of low-dose methotrexate in 273 Japanese patients with rheumatoid arthritis. *J Clin Rheumatol*. 2007 Apr;13(2):73-8.
1117. Iglesias J, Sathiraju S, Marik PE. Severe systemic inflammatory response syndrome with shock and ARDS resulting from Still's disease: clinical response with high-dose pulse methylprednisolone therapy. *Chest*. 1999 Jun;115(6):1738-40.
1118. Iikuni N, Inoue E, Tanaka E, et al. Low disease activity state with corticosteroid may not represent 'true' low disease activity state in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2008 Apr;47(4):519-21.
1119. Ikegawa S, Urano F, Suzuki S, et al. Three cases of pustulotic arthro-osteitis associated with episcleritis. *J Am Acad Dermatol*. 1999 Nov;41(5 Pt 2):845-6.
1120. Ikonomidis I, Lekakis JP, Nikolaou M, et al. Inhibition of interleukin-1 by anakinra improves vascular and left ventricular function in patients with rheumatoid arthritis. *Circulation*. 2008 May 20;117(20):2662-9.
1121. Ikonomidis I, Tzortzis S, Lekakis J, et al. Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. *Heart*. 2009 Sep;95(18):1502-7.
1122. Ilias I, Mastorakos G, Mavrikakis M, et al. Thyroid disease associated with rheumatoid arthritis is not adequately screened with a sensitive chemiluminescence thyrotrophin assay. *Acta Med Austriaca*. 1999;26(1):26-8.
1123. Imaizumi K, Sugishita M, Usui M, et al. Pulmonary infectious complications associated with anti-TNFalpha therapy (infliximab) for rheumatoid arthritis. *Intern Med*. 2006;45(10):685-8.
1124. Imrich R, Rovensky J, Malis F, et al. Low levels of dehydroepiandrosterone sulphate in plasma, and reduced sympathoadrenal response to hypoglycaemia in premenopausal women with rheumatoid arthritis. *Ann Rheum Dis*. 2005 Feb;64(2):202-6.
1125. Imrich R, Rovensky J, Zlnay M, et al. Hypothalamic-pituitary-adrenal axis function in ankylosing spondylitis. *Ann Rheum Dis*. 2004 Jun;63(6):671-4.
1126. Imrich R, Vigeas M, Rovensky J, et al. Adrenal plasma steroid relations in glucocorticoid-naive premenopausal rheumatoid arthritis patients during insulin-induced hypoglycemia test compared to matched normal control females. *Endocr Regul*. 2009 Apr;43(2):65-73.
1127. Imrich R, Vlcek M, Aldag JC, et al. An endocrinologist's view on relative adrenocortical insufficiency in rheumatoid arthritis. *Ann N Y Acad Sci*. 2010 Apr;1193(1):134-8.

1128. Inanc N, Direskeneli H. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. *Rheumatol Int.* 2006 Nov;27(1):67-71.
1129. Infante R, Lahita RG. Rheumatoid arthritis. New disease-modifying and anti-inflammatory drugs. *Geriatrics.* 2000 Mar;55(3):30-2, 5-6, 9-40.
1130. Ingegnoli F, Fantini F, Favalli EG, et al. Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. *J Autoimmun.* 2008 Sep;31(2):175-9.
1131. Ingegnoli F, Fantini F, Griffini S, et al. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. *Clin Exp Rheumatol.* 2010 Mar-Apr;28(2):254-7.
1132. Ingegnoli F, Sciascera A, Galbiati V, et al. Bronchus-associated lymphoid tissue lymphoma in a patient with primary Sjogren's syndrome. *Rheumatol Int.* 2008 Dec;29(2):207-9.
1133. Inokuma S, Sato T, Sagawa A, et al. Proposals for leflunomide use to avoid lung injury in patients with rheumatoid arthritis. *Mod Rheumatol.* 2008;18(5):442-6.
1134. Inoue K, Takano H, Yanagisawa R, et al. Effects of tumor necrosis factor-alpha inhibitors on lung lesions with rheumatoid arthritis. *Chest.* 2003 Jul;124(1):413-4; author reply 4.
1135. Inoue S, Hashiguchi M, Kawai S, et al. Erythrocyte methotrexate-polyglutamate assay using fluorescence polarization immunoassay technique: application to the monitoring of patients with rheumatoid arthritis. *Yakugaku Zasshi.* 2009 Aug;129(8):1001-5.
1136. Inoue S, Hashiguchi M, Takagi K, et al. Preliminary study to identify the predictive factors for the response to methotrexate therapy in patients with rheumatoid arthritis. *Yakugaku Zasshi.* 2009 Jul;129(7):843-9.
1137. Iobst W, Ingraham K. Sneddon-Wilkinson disease in a patient with rheumatoid arthritis. *Arthritis Rheum.* 2005 Dec;52(12):3771.
1138. Ippolito JA, Palmer L, Spector S, et al. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. *Semin Arthritis Rheum.* 1993 Aug;23(1):70-8.
1139. Irwin LR, Beckett R, Suman RK. Steroid injection for carpal tunnel syndrome. *J Hand Surg [Br].* 1996 Jun;21(3):355-7.
1140. Ishiguro T, Takayanagi N, Kurashima K, et al. Development of sarcoidosis during etanercept therapy. *Intern Med.* 2008;47(11):1021-5.
1141. Ishii H, Nagashima M, Tanno M, et al. Does being easily moved to tears as a response to psychological stress reflect response to treatment and the general prognosis in patients with rheumatoid arthritis? *Clin Exp Rheumatol.* 2003 Sep-Oct;21(5):611-6.
1142. Ishikawa Y, Yukawa N, Ohmura K, et al. Etanercept-induced anti-Jo-1-antibody-positive polymyositis in a patient with rheumatoid arthritis: a case report and review of the literature. *Clin Rheumatol.* 2010 May;29(5):563-6.
1143. Itonaga I, Fujikawa Y, Sabokbar A, et al. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. *J Pathol.* 2000 Sep;192(1):97-104.
1144. Iwamoto N, Kawakami A, Fujikawa K, et al. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. *Mod Rheumatol* 2009;19(5):488-92.
1145. Iwatani M, Inoue E, Nakamura T, et al. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. *Mod Rheumatol* 2006;16(6):376-80.
1146. Iyer S, Yamauchi P, Lowe NJ. Etanercept for severe psoriasis and psoriatic arthritis: observations on combination therapy. *Br J Dermatol.* 2002 Jan;146(1):118-21.
1147. Izumi A. Varicella zoster virus infection in patients taking the TNF-alpha inhibitor, etanercept: coincidence or causal? *Hawaii Med J.* 2009 Dec;68(11):277-8.



1148. Izumi M, Eguchi K, Nakamura H, et al. Corticosteroid irrigation of parotid gland for treatment of xerostomia in patients with Sjogren's syndrome. *Ann Rheum Dis*. 1998 Aug;57(8):464-9.
1149. Jacobs JW, Geenen R, Evers AW, et al. Short term effects of corticosteroid pulse treatment on disease activity and the wellbeing of patients with active rheumatoid arthritis. *Ann Rheum Dis*. 2001 Jan;60(1):61-4.
1150. Jacobsson LT, Turesson C, Gulfe A, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. *J Rheumatol*. 2005 Jul;32(7):1213-8.
1151. James HM, Gillis D, Hissaria P, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. *J Rheumatol*. 2008 Apr;35(4):562-71.
1152. Jamnitski A, Visman IM, Peters MJ, et al. Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study. *Ann Rheum Dis*. 2010 Nov;69(11):1929-33.
1153. Jarrett SJ, Cunnane G, Conaghan PG, et al. Anti-tumor necrosis factor-alpha therapy-induced vasculitis: case series. *J Rheumatol*. 2003 Oct;30(10):2287-91.
1154. Jenkins EA, Walker-Bone KE, Wood A, et al. The prevention of corticosteroid-induced bone loss with intermittent cyclical etidronate. *Scand J Rheumatol*. 1999;28(3):152-6.
1155. Jenks KA, Stamp LK, O'Donnell JL, et al. Leflunomide-associated infections in rheumatoid arthritis. *J Rheumatol*. 2007 Nov;34(11):2201-3.
1156. Jeurissen ME, Boerbooms AM, van de Putte LB, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. *Arthritis Rheum*. 1991 Aug;34(8):961-72.
1157. Jia J, Wang Q, Zhang T, et al. Treatment of ankylosing spondylitis with medicated moxibustion plus salicylazosulfapyridine and methotrexate--a report of 30 cases. *J Tradit Chin Med*. 2006 Mar;26(1):26-8.
1158. Jian X, Guo G, Ruan Y, et al. Severe cutaneous adverse drug reaction to leflunomide: a report of two cases. *Cutan Ocul Toxicol*. 2008;27(1):5-9.
1159. Jiang Y, Genant HK, Watt I, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. *Arthritis Rheum*. 2000 May;43(5):1001-9.
1160. Jimenez FG, Colmenero JD, Irigoyen MV. Reactivation of brucellosis after treatment with infliximab in a patient with rheumatoid arthritis. *J Infect*. 2005 May;50(4):370-1.
1161. Jin T, Bokarewa M, Amu S, et al. Impact of short-term therapies with biologics on prothrombotic biomarkers in rheumatoid arthritis. *Clin Exp Rheumatol*. 2009 May-Jun;27(3):491-4.
1162. Jinno S, Pulido S, Pien BC. First reported United States case of Legionella pneumophila serogroup 1 pneumonia in a patient receiving anti-tumor necrosis factor-alpha therapy. *Hawaii Med J*. 2009 Jun;68(5):109-12.
1163. Jo SJ, Park JY, Yoon HS, et al. Case of acrodermatitis continua accompanied by psoriatic arthritis. *J Dermatol*. 2006 Nov;33(11):787-91.
1164. Jobanputra P, Amarasena R, Maggs F, et al. Hepatotoxicity associated with sulfasalazine in inflammatory arthritis: A case series from a local surveillance of serious adverse events. *BMC Musculoskelet Disord*. 2008;9:48.
1165. Johns KR, Littlejohn GO. The safety and efficacy of cyclosporine (Neoral) in rheumatoid arthritis. *J Rheumatol*. 1999 Oct;26(10):2110-3.
1166. Johnsen AK, Schiff MH, Mease PJ, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. *J Rheumatol*. 2006 Apr;33(4):659-64.

1167. Johnson EO, Vlachoyiannopoulos PG, Skopouli FN, et al. Hypofunction of the stress axis in Sjogren's syndrome. *J Rheumatol.* 1998 Aug;25(8):1508-14.
1168. Jois RN, Masding A, Somerville M, et al. Rituximab therapy in patients with resistant rheumatoid arthritis: real-life experience. *Rheumatology (Oxford).* 2007 Jun;46(6):980-2.
1169. Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. *Expert Rev Clin Immunol* 2010;6(2):189-95.
1170. Jones SM, Bhalla AK. Osteoporosis in rheumatoid arthritis. *Clin Exp Rheumatol.* 1993 Sep-Oct;11(5):557-62.
1171. Jonsdottir T, Forslid J, van Vollenhoven A, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. *Ann Rheum Dis.* 2004 Sep;63(9):1075-8.
1172. Jorgensen C, Bressot N, Bologna C, et al. Dysregulation of the hypothalamo-pituitary axis in rheumatoid arthritis. *J Rheumatol.* 1995 Oct;22(10):1829-33.
1173. Josefina M, Ana CJ, Ariel V, et al. Development of pseudogout during etanercept treatment. *J Clin Rheumatol.* 2007 Jun;13(3):177.
1174. Josipovic B. Levels of dehydroepiandrosterone sulfate in female patients with early stage of rheumatoid arthritis. *Ann N Y Acad Sci.* 1999 Jun 22;876:145-7.
1175. Josipovic B. Adrenal secretion of cortisol in patients with short-lasting rheumatoid arthritis. *Z Rheumatol.* 2000;59 Suppl 2:II/136.
1176. Ju JH, Kim SI, Lee JH, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. *Arthritis Rheum* 2007;56(6):2094-6.
1177. Juillard-Condât B, Constantin A, Cambon-Thomsen A, et al. Impact of etanercept on the costs of rheumatoid arthritis (RA): results from a French observational study. *Joint Bone Spine.* 2008 Jan;75(1):25-8.
1178. Julkunen H. Hormone replacement therapy in women with rheumatic diseases. *Scand J Rheumatol.* 2000;29(3):146-53.
1179. Jung N, Hellmann M, Hoheisel R, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). *Clin Rheumatol.* 2010 Oct;29(10):1169-73.
1180. Kaaja R, Julkunen H, Ammala P, et al. Congenital heart block: successful prophylactic treatment with intravenous gamma globulin and corticosteroid therapy. *Am J Obstet Gynecol.* 1991 Nov;165(5 Pt 1):1333-4.
1181. Kadar J, Petrovicz E. Adult-onset Still's disease. *Best Pract Res Clin Rheumatol.* 2004 Oct;18(5):663-76.
1182. Kadota J, Kusano S, Kawakami K, et al. Usual interstitial pneumonia associated with primary Sjogren's syndrome. *Chest.* 1995 Dec;108(6):1756-8.
1183. Kageyama Y, Kobayashi H, Kato N. Infliximab treatment reduces the serum levels of interleukin-23 in patients with rheumatoid arthritis. *Mod Rheumatol.* 2009;19(6):657-62.
1184. Kageyama Y, Kobayashi H, Kato N, et al. Etanercept reduces the serum levels of macrophage chemotactic protein-1 in patients with rheumatoid arthritis. *Mod Rheumatol.* 2009;19(4):372-8.
1185. Kageyama Y, Takahashi M, Ichikawa T, et al. Reduction of oxidative stress marker levels by anti-TNF-alpha antibody, infliximab, in patients with rheumatoid arthritis. *Clin Exp Rheumatol.* 2008 Jan-Feb;26(1):73-80.
1186. Kageyama Y, Torikai E, Nagano A. Anti-tumor necrosis factor-alpha antibody treatment reduces serum CXCL16 levels in patients with rheumatoid arthritis. *Rheumatol Int.* 2007 Mar;27(5):467-72.
1187. Kahan A, Modder G, Menkes CJ, et al. 169Erbium-citrate synoviorthesis after failure of local corticosteroid injections to treat rheumatoid arthritis-affected finger joints. *Clin Exp Rheumatol.* 2004 Nov-Dec;22(6):722-6.

1188. Kahn KL, MacLean CH, Liu H, et al. Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice. *Arthritis Rheum*. 2006 Dec 15;55(6):884-91.
1189. Kahn P, Weiss M, Imundo LF, et al. Favorable response to high-dose infliximab for refractory childhood uveitis. *Ophthalmology*. 2006 May;113(5):864 e1-2.
1190. Kaipainen-Seppanen O, Leino M. Recurrent uveitis in a patient with juvenile spondyloarthritis associated with tumour necrosis factor alpha inhibitors. *Ann Rheum Dis*. 2003 Jan;62(1):88-9.
1191. Kaiser J. Clinical trials. Gene transfer an unlikely contributor to patient's death. *Science*. 2007 Dec 7;318(5856):1535.
1192. Kaiser J. Gene therapy. Questions remain on cause of death in arthritis trial. *Science*. 2007 Sep 21;317(5845):1665.
1193. Kaiser MJ, Bozonnet MC, Jorgensen C, et al. Effect of etanercept on tenosynovitis and nodules in rheumatoid arthritis. *Arthritis Rheum*. 2002 Feb;46(2):559-60.
1194. Kaiser MJ, Sany J. Efficacy of infliximab (Remicade) in the treatment of spondyloarthropathies. two case reports. *Joint Bone Spine*. 2001 Dec;68(6):525-7.
1195. Kakkassery V, Mergler S, Pleyer U. Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. *Curr Eye Res*. 2010 Aug;35(8):751-6.
1196. Kalden JR, Nusslein HG, Wollenhaupt J, et al. Combination treatment with infliximab and leflunomide in patients with active rheumatoid arthritis: safety and efficacy in an open-label clinical trial. *Clin Exp Rheumatol*. 2008 Sep-Oct;26(5):834-40.
1197. Kalla AA, Bewerunge L, Langley A, et al. Trabecular bone density in premenopausal rheumatoid arthritis patients. *S Afr Med J*. 2002 Jan;92(1):62-8.
1198. Kalla AA, Brown GM, Meyers OL. Nutritional status in rheumatoid arthritis. Effects of disease activity, corticosteroid therapy and functional impairment. *S Afr Med J*. 1992 Dec;82(6):411-4.
1199. Kalla AA, Meyers OL, Kotze TJ, et al. Corticosteroid therapy and bone mass--comparison of rheumatoid arthritis and systemic lupus erythematosus. *S Afr Med J*. 1994 Jul;84(7):404-9.
1200. Kalyoncu U, Karadag O, Akdogan A, et al. *Pneumocystis carinii* pneumonia in a rheumatoid arthritis patient treated with adalimumab. *Scand J Infect Dis*. 2007;39(5):475-8.
1201. Kamal KM, Madhavan SS, Hornsby JA, et al. Use of tumor necrosis factor inhibitors in rheumatoid arthritis: a national survey of practicing United States rheumatologists. *Joint Bone Spine*. 2006 Dec;73(6):718-24.
1202. Kamarashev J, Lor P, Forster A, et al. Generalised pustular psoriasis induced by cyclosporin a withdrawal responding to the tumour necrosis factor alpha inhibitor etanercept. *Dermatology*. 2002;205(2):213-6.
1203. Kameda H, Okuyama A, Tamaru J, et al. Lymphomatoid granulomatosis and diffuse alveolar damage associated with methotrexate therapy in a patient with rheumatoid arthritis. *Clin Rheumatol*. 2007 Sep;26(9):1585-9.
1204. Kameda T, Dobashi H, Kittaka K, et al. A case of rheumatoid arthritis complicated by demyelination in both cerebral cortex and spinal cord during etanercept therapy. *Mod Rheumatol*. 2008;18(4):399-402.
1205. Kamili QA, Menter A. Atypical presentation of histoplasmosis in a patient with psoriasis and psoriatic arthritis on infliximab therapy. *J Drugs Dermatol*. 2010 Jan;9(1):57-60.
1206. Kamper AM, Malbrain M, Zachee P, et al. Parvovirus infection causing red cell aplasia and leukopenia in rheumatoid arthritis. *Clin Rheumatol*. 1994 Mar;13(1):129-31.
1207. Kanakoudi-Tsakalidou F, Tzimouli V, Pratsidou-Gertsi P, et al. The significance of persistent newly developed autoantibodies in JIA patients under long-term anti-TNF treatment. *Cytokine*. 2008 Jun;42(3):293-7.
1208. Kanbe K, Inoue K, Inoue Y, et al. Histological analysis of synovium in cases of effect attenuation associated with infliximab therapy in rheumatoid arthritis. *Clin Rheumatol*. 2008 Jun;27(6):777-81.

1209. Kanbe K, Inoue K, Inoue Y, et al. Histological changes in bone marrow after treatment of infliximab for rheumatoid arthritis. *Clin Rheumatol*. 2008 Apr;27(4):497-501.
1210. Kaneko K, Nonomura Y, Watanabe K, et al. Infected abdominal aortic aneurysm caused by nontyphoid Salmonella in an immunocompromised patient with rheumatoid arthritis. *J Infect Chemother*. 2009 Oct;15(5):312-5.
1211. Kaneko Y, Suwa A, Ikeda Y, et al. Pneumocystis jiroveci pneumonia associated with low-dose methotrexate treatment for rheumatoid arthritis: report of two cases and review of the literature. *Mod Rheumatol*. 2006;16(1):36-8.
1212. Kanekura T, Terasaki K, Higashi Y, et al. Improvement of adult Still's disease with granulocyte and monocyte adsorption apheresis. *Clin Exp Dermatol*. 2004 Jul;29(4):410-2.
1213. Kang CP, Lee KW, Yoo DH, et al. The influence of a polymorphism at position -857 of the tumour necrosis factor alpha gene on clinical response to etanercept therapy in rheumatoid arthritis. *Rheumatology (Oxford)*. 2005 Apr;44(4):547-52.
1214. Kang MJ, Kim MS, Choi EH, et al. Adenoviral pneumonia during etanercept treatment in a patient with rheumatoid arthritis. *Korean J Intern Med*. 2007 Mar;22(1):63-6.
1215. Kang MJ, Lee YH, Lee J. Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis. *J Korean Med Sci*. 2006 Oct;21(5):946-9.
1216. Kanik KS, Chrousos GP, Schumacher HR, et al. Adrenocorticotropin, glucocorticoid, and androgen secretion in patients with new onset synovitis/rheumatoid arthritis: relations with indices of inflammation. *J Clin Endocrinol Metab*. 2000 Apr;85(4):1461-6.
1217. Kanis JA, Borgstrom F, De Laet C, et al. Assessment of fracture risk. *Osteoporos Int*. 2005 Jun;16(6):581-9.
1218. Kao CD, Liao KK. A flow chart proposed for early diagnosis of cryptococcal infection as a cause of stroke. *Acta Neurol Taiwan*. 2009 Mar;18(1):30-3.
1219. Kapetanovic MC, Larsson L, Truedsson L, et al. Predictors of infusion reactions during infliximab treatment in patients with arthritis. *Arthritis Res Ther*. 2006;8(4):R131.
1220. Kapetanovic MC, Saxne T, Sjöholm A, et al. Influence of methotrexate, TNF blockers and prednisolone on antibody responses to pneumococcal polysaccharide vaccine in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2006 Jan;45(1):106-11.
1221. Kaplan MJ. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis? *Nat Clin Pract Rheumatol*. 2005 Dec;1(2):74-5.
1222. Kaplan RM, Groessl EJ, Sengupta N, et al. Comparison of measured utility scores and imputed scores from the SF-36 in patients with rheumatoid arthritis. *Med Care*. 2005 Jan;43(1):79-87.
1223. Karabacakoglu A, Karakose S, Ozerbil OM, et al. Fluoroscopy-guided intraarticular corticosteroid injection into the sacroiliac joints in patients with ankylosing spondylitis. *Acta Radiol*. 2002 Jul;43(4):425-7.
1224. Karaca-Mandic P, Joyce GF, Goldman DP, et al. Cost sharing, family health care burden, and the use of specialty drugs for rheumatoid arthritis. *Health Serv Res*. 2010 Oct;45(5 Pt 1):1227-50.
1225. Karagiannis S, Papaioannou D, Goulas S, et al. Intestinal tuberculosis in a patient on infliximab treatment. *Gastrointest Endosc*. 2008 Jun;67(7):1178-9; discussion 9.
1226. Karanikolas G, Charalambopoulos D, Vaiopoulos G, et al. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. *Rheumatology (Oxford)* 2008;47(9):1384-8.
1227. Karie S, Gandjbakhch F, Janus N, et al. Kidney disease in RA patients: prevalence and implication on RA-related drugs management: the MATRIX study. *Rheumatology (Oxford)*. 2008 Mar;47(3):350-4.

1228. Karlsson JA, Kristensen LE, Kapetanovic MC, et al. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. *Rheumatology (Oxford)* 2008;47(4):507-13.
1229. Karstila KL, Rantalaiho VM, Mustonen JT, et al. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. *Clin Exp Rheumatol* 2010;28(1):73-8.
1230. Kary S, Worm M, Audring H, et al. New onset or exacerbation of psoriatic skin lesions in patients with definite rheumatoid arthritis receiving tumour necrosis factor alpha antagonists. *Ann Rheum Dis*. 2006 Mar;65(3):405-7.
1231. Kasama T, Wakabayashi K, Odai T, et al. Effects of low-dose mizoribine pulse therapy in combination with methotrexate in rheumatoid arthritis patients with an insufficient response to methotrexate. *Mod Rheumatol*. 2009;19(4):395-400.
1232. Kasser UR, Gleissner C, Dehne F, et al. Risk for periodontal disease in patients with longstanding rheumatoid arthritis. *Arthritis Rheum*. 1997 Dec;40(12):2248-51.
1233. Kassimos D, Choy EH, Grossman AB, et al. Endogenous opioid tone in patients with rheumatoid arthritis. *Br J Rheumatol*. 1996 May;35(5):436-40.
1234. Kastanek L. Using anakinra for adult rheumatoid arthritis. *Nurse Pract*. 2002 Apr;27(4):62-5.
1235. Kastbom A, Bratt J, Ernestam S, et al. Fcγ receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. *Arthritis Rheum*. 2007 Feb;56(2):448-52.
1236. Kastrinaki MC, Sidiropoulos P, Roche S, et al. Functional, molecular and proteomic characterisation of bone marrow mesenchymal stem cells in rheumatoid arthritis. *Ann Rheum Dis*. 2008 Jun;67(6):741-9.
1237. Kasukawa R, Shio K, Kanno Y, et al. Doppler ultrasound measurements of knee joint synovitis in rheumatoid arthritis patients treated with infliximab. *Mod Rheumatol*. 2007;17(5):376-9.
1238. Katayama K, Matsuno T. Effects of bisphosphonates on fracture incidence and bone metabolism in rheumatoid arthritis patients in general practice taking long-term corticosteroid therapy: a retrospective study. *Clin Drug Investig*. 2008;28(3):149-58.
1239. Katayama K, Matsuno T. Long-term efficacy of leflunomide on disease activity and inhibition of joint damage: retrospective comparison with methotrexate for Japanese rheumatoid arthritis patients. *Mod Rheumatol*. 2009;19(5):513-21.
1240. Katayama Y, Kohriyama K, Kirizuka K, et al. Sjogren's syndrome complicated with autoimmune hepatitis and antiphospholipid antibody syndrome. *Intern Med*. 2000 Jan;39(1):73-6.
1241. Katchamart W, Trudeau J, Phumethum V, et al. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. *Cochrane Database Syst Rev*. 2010;4:CD008495.
1242. Kato T, Hoshi K, Sekijima Y, et al. Rheumatoid meningitis: an autopsy report and review of the literature. *Clin Rheumatol*. 2003 Dec;22(6):475-80.
1243. Kato T, Kiire A, Yamagata H, et al. Hypersensitivity reaction against influenza vaccine in a patient with rheumatoid arthritis after the initiation of etanercept injections. *Mod Rheumatol*. 2006;16(5):327-9.
1244. Katoulis AC, Kanelleas A, Zambacos G, et al. Development of two primary malignant melanomas after treatment with adalimumab: a case report and review of the possible link between biological therapy with TNF-alpha antagonists and melanocytic proliferation. *Dermatology*. 2010 Aug;221(1):9-12.
1245. Katz JA, Antoni C, Keenan GF, et al. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. *Am J Gastroenterol*. 2004 Dec;99(12):2385-92.

1246. Katz P, Yelin E, Patel V, et al. Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists. *Arthritis Rheum*. 2009 May 15;61(5):593-9.
1247. Kaufman I, Schwartz D, Caspi D, et al. Sjogren's syndrome - not just Sicca: renal involvement in Sjogren's syndrome. *Scand J Rheumatol*. 2008 May-Jun;37(3):213-8.
1248. Kaufman KR. Etanercept, anticytokines and mania. *Int Clin Psychopharmacol*. 2005 Jul;20(4):239-41.
1249. Kaur N, Mahl TC. *Pneumocystis jirovecii* (carinii) pneumonia after infliximab therapy: a review of 84 cases. *Dig Dis Sci*. 2007 Jun;52(6):1481-4.
1250. Kaur PP, Chan VC, Berney SN. Successful etanercept use in an HIV-positive patient with rheumatoid arthritis. *J Clin Rheumatol*. 2007 Apr;13(2):79-80.
1251. Kaur PP, Chan VC, Berney SN. Histological evaluation of liver in two rheumatoid arthritis patients with chronic hepatitis B and C treated with TNF-alpha blockade: case reports. *Clin Rheumatol*. 2008 Aug;27(8):1069-71.
1252. Kaur PP, Derk CT, Chatterji M, et al. Septic arthritis caused by *Actinobacillus ureae* in a patient with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha therapy. *J Rheumatol*. 2004 Aug;31(8):1663-5.
1253. Kaushik P, Cooper ES, Banda VR, et al. Bronchiolitis obliterans with organizing pneumonia in rheumatoid arthritis--a fatal case and short review of literature. *Rheumatol Int*. 2005 Jun;25(5):391-3.
1254. Kavalari R, Skok P, Kramberger KG. Phlegmonous gastritis in a patient with rheumatoid arthritis. *Wien Klin Wochenschr*. 2005 May;117(9-10):364-8.
1255. Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. *Ann Rheum Dis*. 2006 Apr;65(4):471-7.
1256. Kavanaugh A, Klareskog L, van der Heijde D, et al. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. *Ann Rheum Dis* 2008;67(10):1444-7.
1257. Kavanaugh A, Lee SJ, Weng HH, et al. Patient-derived joint counts are a potential alternative for determining Disease Activity Score. *J Rheumatol* 2010;37(5):1035-41.
1258. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. *Arthritis Rheum* 2009;60(4):976-86.
1259. Kavanaugh A, Rosengren S, Lee SJ, et al. Assessment of rituximab's immunomodulatory synovial effects (ARISE trial). 1: clinical and synovial biomarker results. *Ann Rheum Dis*. 2008 Mar;67(3):402-8.
1260. Kavanaugh A, Smolen JS, Emery P, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. *Arthritis Rheum* 2009;61(11):1592-600.
1261. Kavanaugh A, St Clair EW, McCune WJ, et al. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. *J Rheumatol*. 2000 Apr;27(4):841-50.
1262. Kawano M, Okada K, Muramoto H, et al. Simultaneous, clonally identical T cell expansion in tonsil and synovium in a patient with rheumatoid arthritis and chronic tonsillitis. *Arthritis Rheum*. 2003 Sep;48(9):2483-8.
1263. Kawano M, Seya T, Koni I, et al. Elevated serum levels of soluble membrane cofactor protein (CD46, MCP) in patients with systemic lupus erythematosus (SLE). *Clin Exp Immunol*. 1999 Jun;116(3):542-6.

1264. Kawashima M, Miossec P. Effect of treatment of rheumatoid arthritis with infliximab on IFN gamma, IL4, T-bet, and GATA-3 expression: link with improvement of systemic inflammation and disease activity. *Ann Rheum Dis.* 2005 Mar;64(3):415-8.
1265. Kawashima N, Shindo R, Kohno M. Primary Sjogren's syndrome with subcortical dementia. *Intern Med.* 1993 Jul;32(7):561-4.
1266. Kawashiri SY, Kawakami A, Iwamoto N, et al. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs. *J Rheumatol.* 2009 Nov;36(11):2397-402.
1267. Kay J, Matteson EL, Dasgupta B, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. *Arthritis Rheum* 2008;58(4):964-75.
1268. Kay LJ, Holland TM, Platt PN. Stress fractures in rheumatoid arthritis: a case series and case-control study. *Ann Rheum Dis.* 2004 Dec;63(12):1690-2.
1269. Kaya S, Kaptanoglu E, Elden H, et al. Coexistence of familial Mediterranean fever and juvenile idiopathic arthritis with osteoporosis successfully treated with etanercept. *Intern Med.* 2010;49(6):619-22.
1270. Kazkaz L, Marotte H, Hamwi M, et al. Rheumatoid arthritis and genetic markers in Syrian and French populations: different effect of the shared epitope. *Ann Rheum Dis.* 2007 Feb;66(2):195-201.
1271. Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med.* 2001 Oct 11;345(15):1098-104.
1272. Kedzia A, Boldys A, Krysiak R, et al. Potential benefit of paracetamol administration in adult-onset Still's disease. *Pol Arch Med Wewn.* 2009 Sep;119(9):595-8.
1273. Kekow J, Welte T, Kellner U, et al. Development of rheumatoid nodules during anti-tumor necrosis factor alpha therapy with etanercept. *Arthritis Rheum.* 2002 Mar;46(3):843-4.
1274. Kelaidi C, Tulliez M, Lecoq-Lafon C, et al. Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy. *Leukemia.* 2002 Oct;16(10):2173-4.
1275. Kelesidis T, Salhotra A, Fleisher J, et al. Listeria endocarditis in a patient with psoriatic arthritis on infliximab: are biologic agents as treatment for inflammatory arthritis increasing the incidence of Listeria infections? *J Infect.* 2010 May;60(5):386-96.
1276. Kellner H, Bornholdt K, Hein G. Leflunomide in the treatment of patients with early rheumatoid arthritis--results of a prospective non-interventional study. *Clin Rheumatol.* 2010 Aug;29(8):913-20.
1277. Kelsey JL, Lamster IB. Influence of musculoskeletal conditions on oral health among older adults. *Am J Public Health.* 2008 Jul;98(7):1177-83.
1278. Kemp E, Nielsen H, Petersen LJ, et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. *Clin Nephrol.* 2001 Jan;55(1):87-8.
1279. Kennedy JW, Wong LK, Kalantarian B, et al. An unusual presentation of methotrexate-induced B-cell lymphoma of the metacarpophalangeal joint: a case report and literature review. *J Hand Surg Am.* 2006 Sep;31(7):1193-6.
1280. Kent PD, Davis JM, 3rd, Davis MD, et al. Bullous skin lesions following infliximab infusion in a patient with rheumatoid arthritis. *Arthritis Rheum.* 2002 Aug;46(8):2257-8; author reply 9.
1281. Keren Z, Braun-Moscovici Y, Markovits D, et al. Depletion of B lymphocytes in rheumatoid arthritis patients modifies IL-8-anti-IL-8 autoantibody network. *Clin Immunol.* 2009 Oct;133(1):108-16.

1282. Kesteman T, Yombi JC, Gigi J, et al. Listeria infections associated with infliximab: case reports. *Clin Rheumatol*. 2007 Dec;26(12):2173-5.
1283. Keystone E, Burmester GR, Furie R, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. *Arthritis Rheum* 2008;59(6):785-93.
1284. Keystone E, Emery P, Peterfy CG, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. *Ann Rheum Dis* 2009;68(2):216-21.
1285. Keystone E, Fleischmann R, Emery P, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. *Arthritis Rheum*. 2007 Dec;56(12):3896-908.
1286. Keystone E, Freundlich B, Schiff M, et al. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. *J Rheumatol* 2009;36(3):522-31.
1287. Keystone E, Heijde D, Mason D, Jr., et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum* 2008;58(11):3319-29.
1288. Keystone EC, Genovese MC, Klareskog L, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Ann Rheum Dis* 2009;68(6):789-96.
1289. Keystone EC, Kavanaugh AF, Sharp JT, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum*. 2004 May;50(5):1400-11.
1290. Keystone EC, Schiff MH, Kremer JM, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2004 Feb;50(2):353-63.
1291. Khan IH, Krishnan VV, Ziman M, et al. A comparison of multiplex suspension array large-panel kits for profiling cytokines and chemokines in rheumatoid arthritis patients. *Cytometry B Clin Cytom*. 2009 May;76(3):159-68.
1292. Khanna M, Shirodkar MA, Gottlieb AB. Etanercept therapy in patients with autoimmunity and hepatitis C. *J Dermatolog Treat*. 2003 Dec;14(4):229-32.
1293. Kho LK, Kermodé AG. Leflunomide-induced peripheral neuropathy. *J Clin Neurosci*. 2007 Feb;14(2):179-81.
1294. Khosla P, Aroaa N, Jain S. Tubercular pyomyositis in a case of rheumatoid arthritis being treated with infliximab. *Int J Rheum Dis*. 2010 Feb 1;13(1):82-5.
1295. Kielhorn A, Porter D, Diamantopoulos A, et al. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. *Curr Med Res Opin*. 2008 Sep;24(9):2639-50.
1296. Kiely PD, Johnson DM. Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. *Rheumatology (Oxford)*. 2002 Jun;41(6):631-7.
1297. Kietz DA, Pepmueller PH, Moore TL. Clinical response to etanercept in polyarticular course juvenile rheumatoid arthritis. *J Rheumatol*. 2001 Feb;28(2):360-2.
1298. Kietz DA, Pepmueller PH, Moore TL. Therapeutic use of etanercept in polyarticular course juvenile idiopathic arthritis over a two year period. *Ann Rheum Dis*. 2002 Feb;61(2):171-3.
1299. Kievit W, Adang EM, Fransen J, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. *Ann Rheum Dis* 2008;67(9):1229-34.



1300. Kievit W, Fransen J, Oerlemans AJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. *Ann Rheum Dis*. 2007 Nov;66(11):1473-8.
1301. Kim SK, Jun JB, El-Sohemy A, et al. Cost-effectiveness analysis of MTHFR polymorphism screening by polymerase chain reaction in Korean patients with rheumatoid arthritis receiving methotrexate. *J Rheumatol*. 2006 Jul;33(7):1266-74.
1302. Kim TH, Stone M, Payne U, et al. Cartilage biomarkers in ankylosing spondylitis: relationship to clinical variables and treatment response. *Arthritis Rheum*. 2005 Mar;52(3):885-91.
1303. Kimball AB, Jackson JM, Sobell JM, et al. Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. *J Drugs Dermatol*. 2007 Mar;6(3):299-306.
1304. Kimel M, Cifaldi M, Chen N, et al. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. *J Rheumatol* 2008;35(2):206-15.
1305. Kimura E, Oga S, Pereira RM. Comparative study of the pharmacokinetics of MTX in juvenile idiopathic arthritis patients receiving long-term MTX monotherapy or MTX plus chloroquine. *J Clin Pharm Ther*. 2007 Dec;32(6):579-84.
1306. Kimura Y, Fieldston E, Devries-Vandervlugt B, et al. High dose, alternate day corticosteroids for systemic onset juvenile rheumatoid arthritis. *J Rheumatol*. 2000 Aug;27(8):2018-24.
1307. Kimura Y, Pinho P, Walco G, et al. Etanercept treatment in patients with refractory systemic onset juvenile rheumatoid arthritis. *J Rheumatol*. 2005 May;32(5):935-42.
1308. Kinder A, Stephens S, Mortimer N, et al. Severe herpes zoster after infliximab infusion. *Postgrad Med J*. 2004 Jan;80(939):26.
1309. Kinder AJ, Edwards J, Samanta A, et al. Pregnancy in a rheumatoid arthritis patient on infliximab and methotrexate. *Rheumatology (Oxford)*. 2004 Sep;43(9):1195-6.
1310. Kinjo M, Setoguchi S, Solomon DH. Bone mineral density in older adult patients with rheumatoid arthritis: an analysis of NHANES III. *J Rheumatol*. 2007 Oct;34(10):1971-5.
1311. Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on insulin resistance in patients with rheumatoid arthritis and ankylosing spondylitis. *Ann Rheum Dis*. 2005 May;64(5):765-6.
1312. Kiortsis DN, Mavridis AK, Vasakos S, et al. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. *J Rheumatol*. 2006 May;33(5):921-3.
1313. Kirchgatterer A, Weber T, Hinterreiter M, et al. Haemorrhagic colitis due to *Escherichia coli* O103:H2 associated with infliximab therapy in a patient with rheumatoid arthritis. *Rheumatology (Oxford)*. 2002 Mar;41(3):355-6.
1314. Kirino Y, Takeno M, Murakami S, et al. Tumor necrosis factor alpha acceleration of inflammatory responses by down-regulating heme oxygenase 1 in human peripheral monocytes. *Arthritis Rheum*. 2007 Feb;56(2):464-75.
1315. Kirshen C, Kanigsberg N. Alopecia areata following adalimumab. *J Cutan Med Surg*. 2009 Jan-Feb;13(1):48-50.
1316. Kirwan J. Early rheumatoid arthritis: combination therapy with disease-modifying antirheumatic drugs and low-dose glucocorticoids? *Nat Clin Pract Rheumatol*. 2006 Apr;2(4):182-3.
1317. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. *N Engl J Med*. 1995 Jul 20;333(3):142-6.

1318. Klaasen R, Thurlings RM, Wijbrandts CA, et al. The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study. *Arthritis Rheum.* 2009 Nov;60(11):3217-24.
1319. Klareskog L, van der Heijde D, de Jager JP, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet.* 2004 Feb 28;363(9410):675-81.
1320. Klein A, Buskila D, Gladman D, et al. Cortisol catabolism by lymphocytes of patients with systemic lupus erythematosus and rheumatoid arthritis. *J Rheumatol.* 1990 Jan;17(1):30-3.
1321. Klein R, Rosenbach M, Kim EJ, et al. Tumor necrosis factor inhibitor-associated dermatomyositis. *Arch Dermatol.* 2010 Jul;146(7):780-4.
1322. Klimiuk PA, Kita J, Chwiecko J, et al. The changes in serum chemokines following leflunomide therapy in patients with rheumatoid arthritis. *Clin Rheumatol.* 2009 Jan;28(1):17-21.
1323. Klimiuk PA, Sierakowski S, Domyslawska I, et al. Effect of repeated infliximab therapy on serum matrix metalloproteinases and tissue inhibitors of metalloproteinases in patients with rheumatoid arthritis. *J Rheumatol.* 2004 Feb;31(2):238-42.
1324. Klimiuk PA, Sierakowski S, Domyslawska I, et al. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. *Clin Exp Rheumatol.* 2006 Sep-Oct;24(5):529-33.
1325. Klimiuk PA, Sierakowski S, Domyslawska I, et al. Effect of etanercept on serum levels of soluble cell adhesion molecules (sICAM-1, sVCAM-1, and sE-selectin) and vascular endothelial growth factor in patients with rheumatoid arthritis. *Scand J Rheumatol.* 2009 Nov-Dec;38(6):439-44.
1326. Kneitz C, Suerbaum S, Beer M, et al. Exacerbation of Whipple's disease associated with infliximab treatment. *Scand J Rheumatol.* 2005 Mar-Apr;34(2):148-51.
1327. Kneitz C, Wilhelm M, Tony HP. Improvement of refractory rheumatoid arthritis after depletion of B cells. *Scand J Rheumatol.* 2004;33(2):82-6.
1328. Kobak S. Osteonecrosis and monoarticular rheumatoid arthritis treated with intra-articular adalimumab. *Mod Rheumatol.* 2008;18(3):290-2.
1329. Kobak S, Deveci H. Retinopathy due to antimalarial drugs in patients with connective tissue diseases: are they so innocent? A single center retrospective study. *Int J Rheum Dis.* 2010 Aug;13(3):e11-5.
1330. Kobayashi K, Okamoto Y, Inoue H, et al. Leukoencephalopathy with cognitive impairment following tocilizumab for the treatment of rheumatoid arthritis (RA). *Intern Med.* 2009;48(15):1307-9.
1331. Kobelt G, Andlin-Sobocki P, Brophy S, et al. The burden of ankylosing spondylitis and the cost-effectiveness of treatment with infliximab (Remicade). *Rheumatology (Oxford).* 2004 Sep;43(9):1158-66.
1332. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. *Ann Rheum Dis.* 2004 Jan;63(1):4-10.
1333. Kobelt G, Jonsson L, Young A, et al. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study. *Rheumatology (Oxford).* 2003 Feb;42(2):326-35.
1334. Kobelt G, Lindgren P, Singh A, et al. Cost effectiveness of etanercept (Enbrel) in combination with methotrexate in the treatment of active rheumatoid arthritis based on the TEMPO trial. *Ann Rheum Dis.* 2005 Aug;64(8):1174-9.
1335. Kobelt G, Sobocki P, Sieper J, et al. Comparison of the cost-effectiveness of infliximab in the treatment of ankylosing spondylitis in the United Kingdom based on two different clinical trials. *Int J Technol Assess Health Care.* 2007 Summer;23(3):368-75.

1336. Koch AE, Kunkel SL, Chensue SW, et al. Expression of interleukin-1 and interleukin-1 receptor antagonist by human rheumatoid synovial tissue macrophages. *Clin Immunol Immunopathol.* 1992 Oct;65(1):23-9.
1337. Kocharla L, Taylor J, Weiler T, et al. Monitoring methotrexate toxicity in juvenile idiopathic arthritis. *J Rheumatol.* 2009 Dec;36(12):2813-8.
1338. Koczan D, Drynda S, Hecker M, et al. Molecular discrimination of responders and nonresponders to anti-TNF alpha therapy in rheumatoid arthritis by etanercept. *Arthritis Res Ther.* 2008;10(3):R50.
1339. Koffeman EC, Genovese M, Amox D, et al. Epitope-specific immunotherapy of rheumatoid arthritis: clinical responsiveness occurs with immune deviation and relies on the expression of a cluster of molecules associated with T cell tolerance in a double-blind, placebo-controlled, pilot phase II trial. *Arthritis Rheum.* 2009 Nov;60(11):3207-16.
1340. Kogure T, Tatsumi T, Sato H, et al. Traditional herbal medicines (Kampo) for patients with rheumatoid arthritis receiving concomitant methotrexate: a preliminary study. *Altern Ther Health Med.* 2010 Jan-Feb;16(1):46-51.
1341. Koh ET. New disease modifying agents in adult rheumatoid arthritis. *Ann Acad Med Singapore.* 2001 Mar;30(2):170-3.
1342. Koh MS, Leng PH, Eng P, et al. An unusual cause of pulmonary haemorrhage in a patient with rheumatoid arthritis. *Ann Acad Med Singapore.* 2004 May;33(3):365-7.
1343. Kohno M, Tsutsumi A, Matsui H, et al. Interleukin-17 gene expression in patients with rheumatoid arthritis. *Mod Rheumatol.* 2008;18(1):15-22.
1344. Koide R, Isoo A, Ishii K, et al. Rheumatoid leptomeningitis: rare complication of rheumatoid arthritis. *Clin Rheumatol.* 2009 Sep;28(9):1117-9.
1345. Koike T, Harigai M, Inokuma S, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. *J Rheumatol.* 2009 May;36(5):898-906.
1346. Kojima M, Itoh H, Hirabayashi K, et al. Methotrexate-associated lymphoproliferative disorders. A clinicopathological study of 13 Japanese cases. *Pathol Res Pract.* 2006;202(9):679-85.
1347. Kokkinos A, Iliopoulos A, Greka P, et al. Successful treatment of refractory adult-onset Still's disease with infliximab. A prospective, non-comparative series of four patients. *Clin Rheumatol.* 2004 Feb;23(1):45-9.
1348. Kolokotronis A, Avramidou E, Zaraboukas T, et al. Oral tuberculosis associated with a treatment with anti-rheumatic drugs. *J Oral Pathol Med.* 2006 Feb;35(2):123-5.
1349. Komai N, Morita Y, Sakuta T, et al. Anti-tumor necrosis factor therapy increases serum adiponectin levels with the improvement of endothelial dysfunction in patients with rheumatoid arthritis. *Mod Rheumatol.* 2007;17(5):385-90.
1350. Komano Y, Harigai M, Koike R, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. *Arthritis Rheum.* 2009 Mar 15;61(3):305-12.
1351. Komatsuda A, Okamoto Y, Hatakeyama T, et al. Sulfasalazine-induced hypersensitivity syndrome and hemophagocytic syndrome associated with reactivation of Epstein-Barr virus. *Clin Rheumatol.* 2008 Mar;27(3):395-7.
1352. Komatsuda A, Wakui H, Nimura T, et al. Reversible infliximab-related lymphoproliferative disorder associated with Epstein-Barr virus in a patient with rheumatoid arthritis. *Mod Rheumatol.* 2008;18(3):315-8.
1353. Konai MS, Vilar Furtado RN, Dos Santos MF, et al. Monoarticular corticosteroid injection versus systemic administration in the treatment of rheumatoid arthritis patients: a randomized double-blind controlled study. *Clin Exp Rheumatol.* 2009 Mar-Apr;27(2):214-21.
1354. Kong XD, Xu D, Zhang W, et al. Clinical features and prognosis in adult-onset Still's disease: a study of 104 cases. *Clin Rheumatol.* 2010 Sep;29(9):1015-9.

1355. Kononoff A, Heiskanen J, Lumiaho J, et al. Intensifying treatment of rheumatoid arthritis with combinations of traditional disease-modifying anti-rheumatic drugs among patients with persistent disease did not reduce the need for large joint surgery. *Scand J Rheumatol*. 2007 Nov-Dec;36(6):424-7.
1356. Konttinen YT, Ramsay H, Hietanen J, et al. Otitis externa sicca/fibrotising external otitis (FEO) as a complication of Sjogren's syndrome. *Clin Exp Rheumatol*. 2000 Nov-Dec;18(6):746-8.
1357. Kontzias A, Efthimiou P. Adult-onset Still's disease: pathogenesis, clinical manifestations and therapeutic advances. *Drugs*. 2008;68(3):319-37.
1358. Kopp S, Alstergren P, Ernestam S, et al. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis. *Scand J Rheumatol*. 2006 May-Jun;35(3):182-8.
1359. Kopp S, Alstergren P, Ernestam S, et al. Reduction of temporomandibular joint pain after treatment with a combination of methotrexate and infliximab is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis. *Cells Tissues Organs*. 2005;180(1):22-30.
1360. Korah S, Kuriakose T. Optical coherence tomography in a patient with chloroquine-induced maculopathy. *Indian J Ophthalmol*. 2008 Nov-Dec;56(6):511-3.
1361. Korczowska I, Olewicz-Gawlik A, Trefler J, et al. Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients? *Clin Rheumatol*. 2008 May;27(5):565-72.
1362. Korkmaz C, Kasifoglu T, Yasar B. Acceleration of left-ventricular diastolic dysfunction and pulmonary hypertension after TNF-alpha blocker. *Ann Pharmacother*. 2005 Jun;39(6):1138-9.
1363. Kosinski M, Kujawski SC, Martin R, et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. *Am J Manag Care*. 2002 Mar;8(3):231-40.
1364. Kotaniemi K, Penttila H. Intraocular lens implantation in patients with juvenile idiopathic arthritis-associated uveitis. *Ophthalmic Res*. 2006;38(6):318-23.
1365. Kotha P, McGreevy MJ, Kotha A, et al. Early deaths with thrombolytic therapy for acute myocardial infarction in corticosteroid-dependent rheumatoid arthritis. *Clin Cardiol*. 1998 Nov;21(11):853-6.
1366. Kothapalli R, Nyland SB, Kusmartseva I, et al. Constitutive production of proinflammatory cytokines RANTES, MIP-1beta and IL-18 characterizes LGL leukemia. *Int J Oncol*. 2005 Feb;26(2):529-35.
1367. Kotter I, Wacker A, Koch S, et al. Anakinra in patients with treatment-resistant adult-onset Still's disease: four case reports with serial cytokine measurements and a review of the literature. *Semin Arthritis Rheum*. 2007 Dec;37(3):189-97.
1368. Kovacs A, Szekeres E, Berek L, et al. Relationship between the occurrence of anti-SSA, anti-SSB autoantibodies and HLA class II alleles from the aspect of in vitro inhibitory effect of glucocorticosteroid on the antibody-dependent cellular cytotoxicity in patients with primary Sjogren's syndrome. *Acta Microbiol Immunol Hung*. 2000;47(4):421-31.
1369. Kozaci DL, Chernajovsky Y, Chikanza IC. The differential expression of corticosteroid receptor isoforms in corticosteroid-resistant and -sensitive patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2007 Apr;46(4):579-85.
1370. Kozora E, Laudenslager M, Lemieux A, et al. Inflammatory and hormonal measures predict neuropsychological functioning in systemic lupus erythematosus and rheumatoid arthritis patients. *J Int Neuropsychol Soc*. 2001 Sep;7(6):745-54.
1371. Kraetsch HG, Antoni C, Kalden JR, et al. Successful treatment of a small cohort of patients with adult onset of Still's disease with infliximab: first experiences. *Ann Rheum Dis*. 2001 Nov;60 Suppl 3:iii55-7.
1372. Kramer N, Chuzhin Y, Kaufman LD, et al. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. *Arthritis Rheum*. 2002 Dec 15;47(6):670-1.

1373. Kreitzer T, Saoud A. Bacillary angiomatosis following the use of long-term methotrexate therapy: a case report. *W V Med J*. 2006 Jan-Feb;102(1):317-8.
1374. Kremer J, Ritchlin C, Mendelsohn A, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. *Arthritis Rheum* 2010;62(4):917-28.
1375. Kremer JM, Bloom BJ, Breedveld FC, et al. The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo. *Arthritis Rheum*. 2009 Jul;60(7):1895-905.
1376. Kremer JM, Genant HK, Moreland LW, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. *Arthritis Rheum*. 2008 Apr;58(4):953-63.
1377. Kremer JM, Habros JS, Kolba KS, et al. Tacrolimus in rheumatoid arthritis patients receiving concomitant methotrexate: a six-month, open-label study. *Arthritis Rheum*. 2003 Oct;48(10):2763-8.
1378. Kremer JM, Weinblatt ME, Bankhurst AD, et al. Etanercept added to background methotrexate therapy in patients with rheumatoid arthritis: continued observations. *Arthritis Rheum*. 2003 Jun;48(6):1493-9.
1379. Kremer JM, Westhovens R, Leon M, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. *N Engl J Med* 2003;349(20):1907-15.
1380. Kremers HM, Nicola P, Crowson CS, et al. Therapeutic strategies in rheumatoid arthritis over a 40-year period. *J Rheumatol*. 2004 Dec;31(12):2366-73.
1381. Kreuter A, Rose C, Zillikens D, et al. Bullous rheumatoid neutrophilic dermatosis. *J Am Acad Dermatol*. 2005 May;52(5):916-8.
1382. Krishnamurthy R, Dincer HE, Whittemore D. *Strongyloides stercoralis* hyperinfection in a patient with rheumatoid arthritis after anti-TNF-alpha therapy. *J Clin Rheumatol*. 2007 Jun;13(3):150-2.
1383. Kriss TC, Kriss VM. Neck pain. Primary care work-up of acute and chronic symptoms. *Geriatrics*. 2000 Jan;55(1):47-8, 51-4, 7.
1384. Kristensen LE, Gulfe A, Saxne T, et al. Efficacy and tolerability of anti-tumor necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. *Ann Rheum Dis* 2008;67(3):364-9.
1385. Kristensen LE, Kapetanovic MC, Gulfe A, et al. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. *Rheumatology (Oxford)*. 2008 Apr;47(4):495-9.
1386. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. *Arthritis Rheum*. 2006 Feb;54(2):600-6.
1387. Kristensen LE, Saxne T, Nilsson JA, et al. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. *Arthritis Res Ther* 2006;8(6):R174.
1388. Kritikos K, Haritatos E, Tsigkos S, et al. An atypical presentation of visceral leishmaniasis infection in a patient with rheumatoid arthritis treated with infliximab. *J Clin Rheumatol*. 2010 Jan;16(1):38-9.
1389. Kroesen S, Widmer AF, Tyndall A, et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. *Rheumatology (Oxford)*. 2003 May;42(5):617-21.
1390. Kroger H, Honkanen R, Saarikoski S, et al. Decreased axial bone mineral density in perimenopausal women with rheumatoid arthritis--a population based study. *Ann Rheum Dis*. 1994 Jan;53(1):18-23.

1391. Kroot EJ, van Gestel AM, Swinkels HL, et al. Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. *J Rheumatol*. 2001 Jul;28(7):1511-7.
1392. Kruithof E, Baeten D, De Rycke L, et al. Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. *Arthritis Res Ther*. 2005;7(3):R569-80.
1393. Kruize AA, Hene RJ, van der Heide A, et al. Long-term followup of patients with Sjogren's syndrome. *Arthritis Rheum*. 1996 Feb;39(2):297-303.
1394. Kucharekova M, Winnepeninckx V, Frank J, et al. Generalized pustulosis induced by adalimumab in a patient with rheumatoid arthritis - a therapeutic challenge. *Int J Dermatol*. 2008 Nov;47 Suppl 1:25-8.
1395. Kucharz EJ, Gozdzik J, Kopec M, et al. A single infusion of infliximab increases the serum endostatin level in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2003 Mar-Apr;21(2):273-4.
1396. Kuek A, Hazleman BL, Gaston JH, et al. Successful treatment of refractory polyarticular juvenile idiopathic arthritis with rituximab. *Rheumatology (Oxford)*. 2006 Nov;45(11):1448-9.
1397. Kumar D, Bouldin TW, Berger RG. A case of progressive multifocal leukoencephalopathy in a patient treated with infliximab. *Arthritis Rheum*. 2010 Nov;62(11):3191-5.
1398. Kumar N, Sandroni P, Steensma DP, et al. Polyradiculopathy due to methotrexate-induced ebv-associated lymphoproliferative disorder. *Neurology*. 2008 Nov 11;71(20):1644-5.
1399. Kumar S, Gupta N, Jhamb R, et al. Celiac disease: association with adult-onset Still's disease: apropos of a clinical case. *Indian J Med Sci*. 2007 Jul;61(7):414-7.
1400. Kumari R, Uppal SS. Prolonged remission in adult-onset Still's disease with etanercept. *Clin Rheumatol*. 2006 Feb;25(1):106-8.
1401. Kumeda Y, Inaba M, Goto H, et al. Increased thickness of the arterial intima-media detected by ultrasonography in patients with rheumatoid arthritis. *Arthritis Rheum*. 2002 Jun;46(6):1489-97.
1402. Kumon Y, Kakigi A, Sugiura T. Clinical images: Otagia, an unusual complication of Sjogren's syndrome. *Arthritis Rheum*. 2009 Aug;60(8):2542.
1403. Kurasawa M, Kotani K, Kurasawa G, et al. Adult-onset Still's disease in a patient over 80 years old successfully treated with low-dose methotrexate therapy. *Age Ageing*. 2007 Jan;36(1):104-6.
1404. Kuriya B, Arkema EV, Bykerk VP, et al. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. *Ann Rheum Dis* 2010;69(7):1298-304.
1405. Kurmann PT, Van Linthoudt D, So AK. Miller-Fisher syndrome in a patient with rheumatoid arthritis treated with adalimumab. *Clin Rheumatol*. 2009 Jan;28(1):93-4.
1406. Kuroda T, Otaki Y, Sato H, et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab. *Rheumatol Int*. 2008 Sep;28(11):1155-9.
1407. Kuroda T, Wada Y, Kobayashi D, et al. Effective anti-TNF-alpha therapy can induce rapid resolution and sustained decrease of gastroduodenal mucosal amyloid deposits in reactive amyloidosis associated with rheumatoid arthritis. *J Rheumatol*. 2009 Nov;36(11):2409-15.
1408. Kurschat P, Rubbert A, Poswig A, et al. Treatment of psoriatic arthritis with etanercept. *J Am Acad Dermatol*. 2001 Jun;44(6):1052.
1409. Kurtais Y, Tur BS, Elhan AH, et al. Hypothalamic-pituitary-adrenal hormonal responses to exercise stress test in patients with rheumatoid arthritis compared to healthy controls. *J Rheumatol*. 2006 Aug;33(8):1530-7.
1410. Kuruvilla J, Leitch HA, Vickars LM, et al. Aplastic anemia following administration of a tumor necrosis factor-alpha inhibitor. *Eur J Haematol*. 2003 Nov;71(5):396-8.

1411. Kur-Zalewska J, Swarowska-Knap J, Tlustochowicz W. Neurological disorders with demyelinating brain white matter lesions in a patient with rheumatoid arthritis treated with etanercept. *Pol Arch Med Wewn.* 2008 Apr;118(4):234-7.
1412. Kurzawski M, Pawlik A, Safranow K, et al. 677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis. *Pharmacogenomics.* 2007 Nov;8(11):1551-9.
1413. Kusabe T, Waguri-Nagaya Y, Tanikawa T, et al. The inhibitory effect of disease-modifying anti-rheumatic drugs and steroids on gliostatin/platelet-derived endothelial cell growth factor production in human fibroblast-like synoviocytes. *Rheumatol Int.* 2005 Oct;25(8):625-30.
1414. Kuuliala A, Nissinen R, Kautiainen H, et al. Low circulating soluble interleukin 2 receptor level predicts rapid response in patients with refractory rheumatoid arthritis treated with infliximab. *Ann Rheum Dis.* 2006 Jan;65(1):26-9.
1415. Kuzmanova SI. Arthroscopic treatment of rheumatoid synovitis. *Folia Med (Plovdiv).* 2003;45(3):48-54.
1416. Kvalvik AG, Aadland HA, Hoyeraal HM, et al. Were the patterns of treatment for rheumatoid arthritis during 1977-1992 consistent with modern clinical guidelines? *Scand J Rheumatol.* 2001;30(2):61-8.
1417. Kvalvik AG, Lefsaker L, Dyvik S, et al. Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis. *Joint Bone Spine.* 2007 Dec;74(6):606-11.
1418. Kvien TK, Haugeberg G, Uhlig T, et al. Data driven attempt to create a clinical algorithm for identification of women with rheumatoid arthritis at high risk of osteoporosis. *Ann Rheum Dis.* 2000 Oct;59(10):805-11.
1419. Kwak JJ, Chang JE, Lee J, et al. Chronic eosinophilic pneumonia associated with an initiation of rheumatoid arthritis. *Clin Rheumatol.* 2003 Sep;22(3):240-3.
1420. Kwon HH, Baek SH, Park SH. Miliary tuberculosis and necrotizing tuberculous fasciitis--an unusual coexistence in a rheumatoid arthritis patient. *Int J Rheum Dis.* 2010 May;13(2):171-4.
1421. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. *Ann Intern Med.* 2003 May 20;138(10):807-11.
1422. La Montagna G, Cacciapuoti F, Buono R, et al. Insulin resistance is an independent risk factor for atherosclerosis in rheumatoid arthritis. *Diab Vasc Dis Res.* 2007 Jun;4(2):130-5.
1423. La Montagna G, Valentini G. *Listeria monocytogenes* meningitis in a patient receiving etanercept for Still's disease. *Clin Exp Rheumatol.* 2005 Jan-Feb;23(1):121.
1424. Laas K, Peltomaa R, Kautiainen H, et al. Clinical impact of switching from infliximab to etanercept in patients with rheumatoid arthritis. *Clin Rheumatol.* 2008 Jul;27(7):927-32.
1425. Labbe P, Hardouin P. Epidemiology and optimal management of polymyalgia rheumatica. *Drugs Aging.* 1998 Aug;13(2):109-18.
1426. Lacaille D, Guh DP, Abrahamowicz M, et al. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. *Arthritis Rheum* 2008;59(8):1074-81.
1427. Lacroix BD, Lovern MR, Stockis A, et al. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. *Clin Pharmacol Ther.* 2009 Oct;86(4):387-95.
1428. Lafforgue P, Monjanel-Mouterde S, Durand A, et al. Is there an interaction between low doses of corticosteroids and methotrexate in patients with rheumatoid arthritis? A pharmacokinetic study in 33 patients. *J Rheumatol.* 1993 Feb;20(2):263-7.
1429. Lafforgue P, Toussirot E, Bille F, et al. Astasia-abasia revealing a primary Sjogren's syndrome. *Clin Rheumatol.* 1993 Jun;12(2):261-4.

1430. Lagana B, Picchianti Diamanti A, Ferlito C, et al. Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption. *Int J Immunopathol Pharmacol*. 2009 Apr-Jun;22(2):447-54.
1431. Lahiff C, Khiaron OB, Nolan N, et al. Pneumocystis carinii pneumonia in a patient on etanercept for psoriatic arthritis. *Ir J Med Sci*. 2007 Dec;176(4):309-11.
1432. Lahiri M, Teng GG. A case of refractory adult-onset Still's disease treated with anakinra. *Int J Rheum Dis*. 2010 Aug;13(3):e36-41.
1433. Lahners WJ, Hardten DR, Lindstrom RL. Peripheral keratitis following laser in situ keratomileusis. *J Refract Surg*. 2003 Nov-Dec;19(6):671-5.
1434. Lai TY, Ngai JW, Chan WM, et al. Visual field and multifocal electroretinography and their correlations in patients on hydroxychloroquine therapy. *Doc Ophthalmol*. 2006 May;112(3):177-87.
1435. Laine L, Bombardier C, Hawkey CJ, et al. Stratifying the risk of NSAID-related upper gastrointestinal clinical events: results of a double-blind outcomes study in patients with rheumatoid arthritis. *Gastroenterology*. 2002 Oct;123(4):1006-12.
1436. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. *Gastroenterology*. 2003 Feb;124(2):288-92.
1437. Laine M, Porola P, Udby L, et al. Low salivary dehydroepiandrosterone and androgen-regulated cysteine-rich secretory protein 3 levels in Sjogren's syndrome. *Arthritis Rheum*. 2007 Aug;56(8):2575-84.
1438. Lainez B, Fernandez-Real JM, Romero X, et al. Identification and characterization of a novel spliced variant that encodes human soluble tumor necrosis factor receptor 2. *Int Immunol*. 2004 Jan;16(1):169-77.
1439. Lakatos P, Nagy Z, Kiss L, et al. Prevention of corticosteroid-induced osteoporosis by alfacalcidol. *Z Rheumatol*. 2000;59 Suppl 1:48-52.
1440. Lam A, Toma W, Schlesinger N. Mycobacterium marinum arthritis mimicking rheumatoid arthritis. *J Rheumatol*. 2006 Apr;33(4):817-9.
1441. Lamazza L, Guerra F, Pezza M, et al. The use of etanercept as a non-surgical treatment for temporomandibular joint psoriatic arthritis: a case report. *Aust Dent J*. 2009 Jun;54(2):161-5.
1442. Lan JL, Chou SJ, Chen DY, et al. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. *J Formos Med Assoc*. 2004 Aug;103(8):618-23.
1443. Landewe RB, Boers M, Verhoeven AC, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. *Arthritis Rheum*. 2002 Feb;46(2):347-56.
1444. Lane NE, Pressman AR, Star VL, et al. Rheumatoid arthritis and bone mineral density in elderly women. The Study of Osteoporotic Fractures Research Group. *J Bone Miner Res*. 1995 Feb;10(2):257-63.
1445. Lange U, Boss B, Teichmann J, et al. Bone mineral density and biochemical markers of bone metabolism in late onset rheumatoid arthritis and polymyalgia rheumatica--a prospective study on the influence of glucocorticoid therapy. *Z Rheumatol*. 2000;59 Suppl 2:II/137-41.
1446. Lange U, Teichmann J, Muller-Ladner U, et al. Increase in bone mineral density of patients with rheumatoid arthritis treated with anti-TNF-alpha antibody: a prospective open-label pilot study. *Rheumatology (Oxford)*. 2005 Dec;44(12):1546-8.
1447. Langer HE, Missler-Karger B. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol. *Int J Clin Pharmacol Res*. 2003;23(4):119-28.
1448. Lassoued S, Sire S, Farny M, et al. Pulmonary aspergillosis in a patient with rheumatoid arthritis treated by etanercept. *Clin Exp Rheumatol*. 2004 Mar-Apr;22(2):267-8.
1449. Lassoued S, Zabraniecki L, Marin F, et al. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis. *Semin Arthritis Rheum*. 2007 Feb;36(4):262-3.



1450. Laurberg TB, Frystyk J, Ellingsen T, et al. Plasma adiponectin in patients with active, early, and chronic rheumatoid arthritis who are steroid- and disease-modifying antirheumatic drug-naïve compared with patients with osteoarthritis and controls. *J Rheumatol*. 2009 Sep;36(9):1885-91.
1451. Lavie F, Miceli-Richard C, Ittah M, et al. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. *Ann Rheum Dis*. 2007 May;66(5):700-3.
1452. Lazzarini PE, Acampa M, Hammoud M, et al. Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. *J Rheumatol*. 2008 Oct;35(10):1958-65.
1453. Le Loet X, Nordstrom D, Rodriguez M, et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. *J Rheumatol*. 2008 Aug;35(8):1538-44.
1454. Leandro MJ, Cambridge G, Ehrenstein MR, et al. Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis. *Arthritis Rheum*. 2006 Feb;54(2):613-20.
1455. Leandro MJ, Cooper N, Cambridge G, et al. Bone marrow B-lineage cells in patients with rheumatoid arthritis following rituximab therapy. *Rheumatology (Oxford)*. 2007 Jan;46(1):29-36.
1456. Leandro MJ, Edwards JC, Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. *Ann Rheum Dis*. 2002 Oct;61(10):883-8.
1457. Lebwohl M, Blum R, Berkowitz E, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. *Arch Dermatol*. 2005 Jul;141(7):861-4.
1458. Ledingham J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFalpha blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). *Rheumatology (Oxford)*. 2005 Feb;44(2):157-63.
1459. Ledwich LJ, Clarke K. Screening and treatment of glucocorticoid-induced osteoporosis in rheumatoid arthritis patients in an urban multispecialty practice. *J Clin Rheumatol*. 2009 Mar;15(2):61-4.
1460. Lee CK, Lee EY, Cho YS, et al. Increased expression of glucocorticoid receptor beta messenger RNA in patients with ankylosing spondylitis. *Korean J Intern Med*. 2005 Jun;20(2):146-51.
1461. Lee EB, Shin KC, Lee YJ, et al. 188Re-tincolloid as a new therapeutic agent for rheumatoid arthritis. *Nucl Med Commun*. 2003 Jun;24(6):689-96.
1462. Lee H, Kimko HC, Rogge M, et al. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. *Clin Pharmacol Ther*. 2003 Apr;73(4):348-65.
1463. Lee HJ, Waller RD, Stebbings S, et al. The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study. *Int J Rheum Dis*. 2010 Feb 1;13(1):48-54.
1464. Lee J, Noh JW, Hwang JW, et al. Extended dosing of etanercept 25 mg can be effective in patients with ankylosing spondylitis: a retrospective analysis. *Clin Rheumatol*. 2010 Oct;29(10):1149-54.
1465. Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. *Arthritis Rheum*. 2002 Oct;46(10):2565-70.
1466. Lee SS, Park YW, Park JJ, et al. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. *Scand J Rheumatol*. 2009 Jan-Feb;38(1):11-4.

1467. Lee YC, Cui J, Costenbader KH, et al. Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate. *Rheumatology (Oxford)*. 2009 Jun;48(6):613-7.
1468. Lee YH, Choi SJ, Ji JD, et al. No association of polymorphisms of the CTLA-4 exon 1(+49) and promoter(-318) genes with rheumatoid arthritis in the Korean population. *Scand J Rheumatol*. 2002;31(5):266-70.
1469. Lee YH, Kim HJ, Rho YH, et al. Interleukin-1 receptor antagonist gene polymorphism and rheumatoid arthritis. *Rheumatol Int*. 2004 May;24(3):133-6.
1470. Lehman TJ. Clinical trials for the treatment of systemic onset juvenile rheumatoid arthritis-juvenile idiopathic arthritis. *Curr Rheumatol Rep*. 2000 Aug;2(4):313-5.
1471. Lehnen M, Franckson T, Knab J, et al. Successful infliximab therapy of psoriasis vulgaris and psoriatic arthritis in a patient with cirrhosis. *Br J Dermatol*. 2005 Jul;153(1):212-4.
1472. Lehnen M, Franckson T, Korber A, et al. Etanercept therapy of psoriatic arthritis in a patient with liver cirrhosis. *Acta Derm Venereol*. 2005;85(4):351-2.
1473. Leitch R, Walker SE, Hillard AE. The rheumatoid knee before and after arthrocentesis and prednisolone injection: evaluation by Gd-enhanced MRI. *Clin Rheumatol*. 1996 Jul;15(4):358-66.
1474. Lems WF, Gerrits MI, Jacobs JW, et al. Changes in (markers of) bone metabolism during high dose corticosteroid pulse treatment in patients with rheumatoid arthritis. *Ann Rheum Dis*. 1996 May;55(5):288-93.
1475. Lems WF, Jacobs JW, van den Brink HR, et al. Transient decrease in osteocalcin and markers of type 1 collagen turnover during high-dose corticosteroid pulse therapy in rheumatoid arthritis. *Br J Rheumatol*. 1993 Sep;32(9):787-9.
1476. Lems WF, Jahangier ZN, Jacobs JW, et al. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. *Clin Exp Rheumatol*. 1995 May-Jun;13(3):293-7.
1477. Lems WF, Jahangier ZN, Raymakers JA, et al. Methods to score vertebral deformities in patients with rheumatoid arthritis. *Br J Rheumatol*. 1997 Feb;36(2):220-4.
1478. Leonardou A, Giali S, Daoussis D, et al. *Moraxella catarrhalis*-induced septic arthritis of a prosthetic knee joint in a patient with rheumatoid arthritis treated with anakinra: comment on the article by Schiff et al. *Arthritis Rheum*. 2005 Apr;52(4):1337; author reply 8.
1479. Lequerre T, Gauthier-Jauneau AC, Bansard C, et al. Gene profiling in white blood cells predicts infliximab responsiveness in rheumatoid arthritis. *Arthritis Res Ther*. 2006;8(4):R105.
1480. Lequerre T, Jouen F, Brazier M, et al. Autoantibodies, metalloproteinases and bone markers in rheumatoid arthritis patients are unable to predict their responses to infliximab. *Rheumatology (Oxford)*. 2007 Mar;46(3):446-53.
1481. Lequerre T, Quartier P, Rosellini D, et al. Interleukin-1 receptor antagonist (anakinra) treatment in patients with systemic-onset juvenile idiopathic arthritis or adult onset Still disease: preliminary experience in France. *Ann Rheum Dis*. 2008 Mar;67(3):302-8.
1482. Lesnik A, Bolivar J, Morel J, et al. On the AJR viewbox. Pseudotumoral colonic tuberculosis complicating rheumatoid arthritis treated with a tumor necrosis factor antagonist. *AJR Am J Roentgenol*. 2006 Jun;186(6):1799-800.
1483. Levalampi T, Korpela M, Vuolteenaho K, et al. Infliximab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: adverse events and other reasons for discontinuation of treatment. *Scand J Rheumatol*. 2008 Jan-Feb;37(1):6-12.
1484. Levy Y, Uziel Y, Zandman GG, et al. Intravenous immunoglobulins in peripheral neuropathy associated with vasculitis. *Ann Rheum Dis*. 2003 Dec;62(12):1221-3.
1485. Lewiecki EM. Denosumab for joints and bones. *Curr Rheumatol Rep*. 2009 Jul;11(3):196-201.

1486. Li Gobbi F, Benucci M, Del Rosso A. Pneumonitis caused by Legionella pneumoniae in a patient with rheumatoid arthritis treated with anti-TNF-alpha therapy (infliximab). *J Clin Rheumatol*. 2005 Apr;11(2):119-20.
1487. Li JY, Lai PH, Lam HC, et al. Hypertrophic cranial pachymeningitis and lymphocytic hypophysitis in Sjogren's syndrome. *Neurology*. 1999 Jan 15;52(2):420-3.
1488. Li P, Blum MA, Von Feldt J, et al. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. *Value Health* 2010;13(6):805-12.
1489. Li St, Kaur PP, Berney SN. Effects of methotrexate use in a patient with rheumatoid arthritis and multiple sclerosis. *J Clin Rheumatol*. 2008 Aug;14(4):241-2.
1490. Li T, Gignac M, Wells G, et al. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. *Clin Ther* 2008;30(4):734-48.
1491. Lian EC, Tzakis AG, Andrews D. Response of factor V inhibitor to rituximab in a patient who received liver transplantation for primary biliary cirrhosis. *Am J Hematol*. 2004 Dec;77(4):363-5.
1492. Liberopoulos EN, Drosos AA, Elisaf MS. Exacerbation of tuberculosis enteritis after treatment with infliximab. *Am J Med*. 2002 Nov;113(7):615.
1493. Lieberman-Maran L, Orzano IM, Passero MA, et al. Bronchiectasis in rheumatoid arthritis: report of four cases and a review of the literature--implications for management with biologic response modifiers. *Semin Arthritis Rheum*. 2006 Jun;35(6):379-87.
1494. Lin YT, Tsai MJ, Wang LH, et al. Efficacy and safety of methotrexate therapy for juvenile rheumatoid arthritis. *J Formos Med Assoc*. 2000 Aug;99(8):623-9.
1495. Linardaki G, Katsarou O, Ioannidou P, et al. Effective etanercept treatment for psoriatic arthritis complicating concomitant human immunodeficiency virus and hepatitis C virus infection. *J Rheumatol*. 2007 Jun;34(6):1353-5.
1496. Lindberg J, af Klint E, Catrina AI, et al. Effect of infliximab on mRNA expression profiles in synovial tissue of rheumatoid arthritis patients. *Arthritis Res Ther*. 2006;8(6):R179.
1497. Lindberg J, Wijbrandts CA, van Baarsen LG, et al. The gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritis. *PLoS One*. 2010;5(6):e11310.
1498. Linde L, Hetland ML, Ostergaard M. Drug survival and reasons for discontinuation of intramuscular methotrexate: a study of 212 consecutive patients switching from oral methotrexate. *Scand J Rheumatol*. 2006 Mar-Apr;35(2):102-6.
1499. Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. *Int J Technol Assess Health Care*. 2009 Apr;25(2):181-9.
1500. Lindsay K, Fraser AD, Layton A, et al. Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. *Rheumatology (Oxford)*. 2009 May;48(5):569-72.
1501. Ling S, Lewanczuk RZ, Russell AS, et al. Influence of controlled rheumatoid arthritis on the action and disposition of verapamil: focus on infliximab. *J Clin Pharmacol*. 2009 Mar;49(3):301-11.
1502. Lingg GM, Soltesz I, Kessler S, et al. Insufficiency and stress fractures of the long bones occurring in patients with rheumatoid arthritis and other inflammatory diseases, with a contribution on the possibilities of computed tomography. *Eur J Radiol*. 1997 Dec;26(1):54-63.
1503. Liote H, Liote F, Lenique F, et al. Adult-onset Still's disease revealed by a pleuropericarditis. *Eur Respir J*. 1990 Oct;3(9):1064-6.
1504. Liou LB. Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients. *Clin Exp Rheumatol*. 2001 Sep-Oct;19(5):515-23.

1505. Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. *N Engl J Med.* 2000 Nov 30;343(22):1594-602.
1506. Lisbona MP, Maymo J, Perich J, et al. Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. *Ann Rheum Dis* 2010;69(6):1117-22.
1507. Lisbona MP, Maymo J, Perich J, et al. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks. *J Rheumatol* 2008;35(3):394-7.
1508. Listing J, Brandt J, Rudwaleit M, et al. Impact of anti-tumour necrosis factor alpha treatment on admissions to hospital and days of sick leave in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2004 Dec;63(12):1670-2.
1509. Listing J, Strangfeld A, Kary S, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. *Arthritis Rheum.* 2005 Nov;52(11):3403-12.
1510. Listing J, Strangfeld A, Kekow J, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? *Arthritis Rheum* 2008;58(3):667-77.
1511. Liu FC, Chiang SY, Chang DM, et al. Purtscher's-like retinopathy as an initial presentation of adult-onset Still's disease: a case report and review of the literature. *Clin Rheumatol.* 2007 Jul;26(7):1204-6.
1512. Liu MF, Yang CY, Li JS, et al. Increased expression of down-regulatory CTLA-4 molecule on T lymphocytes from rheumatoid synovial compartment. *Scand J Immunol.* 1999 Jul;50(1):68-72.
1513. Li-Yu J, Clayburne GM, Sieck MS, et al. Calcium apatite crystals in synovial fluid rice bodies. *Ann Rheum Dis.* 2002 May;61(5):387-90.
1514. Ljung L, Olsson T, Engstrand S, et al. Interleukin-1 receptor antagonist is associated with both lipid metabolism and inflammation in rheumatoid arthritis. *Clin Exp Rheumatol.* 2007 Jul-Aug;25(4):617-20.
1515. Lloyd ME, Davitt S, Hall JR. Bilateral tibia and fibula fractures in a patient with rheumatoid arthritis. *Clin Rheumatol.* 2001;20(4):270-2.
1516. Lodder MC, de Jong Z, Kostense PJ, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. *Ann Rheum Dis.* 2004 Dec;63(12):1576-80.
1517. Lodder MC, Haugeberg G, Lems WF, et al. Radiographic damage associated with low bone mineral density and vertebral deformities in rheumatoid arthritis: the Oslo-Truro-Amsterdam (OSTRA) collaborative study. *Arthritis Rheum.* 2003 Apr 15;49(2):209-15.
1518. Lonardo A, Neri P, Mascia MT, et al. Hereditary hemochromatosis masquerading as rheumatoid arthritis. *Ann Ital Med Int.* 2001 Jan-Mar;16(1):46-9.
1519. Long JA, Husted JA, Gladman DD, et al. The relationship between patient satisfaction with health and clinical measures of function and disease status in patients with psoriatic arthritis. *J Rheumatol.* 2000 Apr;27(4):958-66.
1520. Loos T, Dekeyser L, Struyf S, et al. TLR ligands and cytokines induce CXCR3 ligands in endothelial cells: enhanced CXCL9 in autoimmune arthritis. *Lab Invest.* 2006 Sep;86(9):902-16.
1521. Lopes RV, Furtado RN, Parmigiani L, et al. Accuracy of intra-articular injections in peripheral joints performed blindly in patients with rheumatoid arthritis. *Rheumatology (Oxford).* 2008 Dec;47(12):1792-4.
1522. Lopez-Hoyos M, Rodrigo E, Fernandez-Fresnedo G, et al. Lack of effect of rapamycin in anti-CCP antibody production in a rheumatoid arthritis kidney allograft recipient. *Clin Exp Rheumatol.* 2005 Jul-Aug;23(4):529-31.

1523. Lorenzi AR, Morgan TA, Anderson A, et al. Thymic function in juvenile idiopathic arthritis. *Ann Rheum Dis*. 2009 Jun;68(6):983-90.
1524. Lories RJ, Derese I, Luyten FP, et al. Activation of nuclear factor kappa B and mitogen activated protein kinases in psoriatic arthritis before and after etanercept treatment. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1):96-102.
1525. Louis M, Rauch J, Armstrong M, et al. Induction of autoantibodies during prolonged treatment with infliximab. *J Rheumatol*. 2003 Dec;30(12):2557-62.
1526. Louthrenoo W, Kongtawelert P, Sivasomboon C, et al. Correlation between serum hyaluronan and disease activity and severity in Thai patients with rheumatoid arthritis. *J Med Assoc Thai*. 2001 May;84(5):622-7.
1527. Louthrenoo W, Zager EL, Freundlich B, et al. Intravenous corticosteroid therapy of cervical cord compression in rheumatoid arthritis. *Clin Exp Rheumatol*. 1992 Mar-Apr;10(2):173-5.
1528. Lozeron P, Denier C, Lacroix C, et al. Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy. *Arch Neurol*. 2009 Apr;66(4):490-7.
1529. Lu LJ, Bao CD, Dai M, et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. *Arthritis Rheum*. 2009 Jul 15;61(7):979-87.
1530. Lubbe S, Tikly M, van der Merwe L, et al. Interleukin-1 receptor antagonist gene polymorphisms are associated with disease severity in Black South Africans with rheumatoid arthritis. *Joint Bone Spine*. 2008 Jul;75(4):422-5.
1531. Lubrano E, D'Angelo S, Parsons WJ, et al. Effects of a combination treatment of an intensive rehabilitation program and etanercept in patients with ankylosing spondylitis: a pilot study. *J Rheumatol*. 2006 Oct;33(10):2029-34.
1532. Luessenhop CP, Higgins LD, Brause BD, et al. Multiple prosthetic infections after total joint arthroplasty. Risk factor analysis. *J Arthroplasty*. 1996 Oct;11(7):862-8.
1533. Lun SW, Wong CK, Tam LS, et al. Decreased ex vivo production of TNF-alpha and IL-8 by peripheral blood cells of patients with rheumatoid arthritis after infliximab therapy. *Int Immunopharmacol*. 2007 Dec 15;7(13):1668-77.
1534. Lurati A, Pontikaki I, Teruzzi B, et al. A comparison of response criteria to evaluate therapeutic response in patients with juvenile idiopathic arthritis treated with methotrexate and/or anti-tumor necrosis factor alpha agents. *Arthritis Rheum*. 2006 May;54(5):1602-7.
1535. Luukkainen R, Hakala M, Sajanti E, et al. Predictive value of synovial fluid analysis in estimating the efficacy of intra-articular corticosteroid injections in patients with rheumatoid arthritis. *Ann Rheum Dis*. 1992 Jul;51(7):874-6.
1536. Luzi G, Lagana B, Salemi S, et al. Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept? *Clin Ter*. 2009 Mar-Apr;160(2):121-3.
1537. Lyman J, Serebro L. Efalizumab-induced inflammatory polyarthritis: what are the implications? *South Med J*. 2010 Apr;103(4):357-60.
1538. Lyngberg KK, Harreby M, Bentzen H, et al. Elderly rheumatoid arthritis patients on steroid treatment tolerate physical training without an increase in disease activity. *Arch Phys Med Rehabil*. 1994 Nov;75(11):1189-95.
1539. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. *Am J Ophthalmol*. 2007 May;143(5):801-9.
1540. Ma Y, Lin BR, Lin B, et al. Pharmacokinetics of CTLA4Ig fusion protein in healthy volunteers and patients with rheumatoid arthritis. *Acta Pharmacol Sin*. 2009 Mar;30(3):364-71.
1541. Machado P, Santos A, Pereira C, et al. Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNFalpha. *Joint Bone Spine* 2009;76(5):508-13.

1542. Macias I, Garcia-Perez S, Ruiz-Tudela M, et al. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor- $\alpha$  blockade in patients with rheumatoid arthritis. *J Rheumatol*. 2005 Nov;32(11):2102-8.
1543. Mackie GC, Pohlen JM. Methotrexate-induced pulmonary non-Hodgkin lymphoma. *Clin Nucl Med*. 2006 May;31(5):272-4.
1544. MacLean CH, Mojica WA, Morton SC, et al. Effects of omega-3 fatty acids on lipids and glycemic control in type II diabetes and the metabolic syndrome and on inflammatory bowel disease, rheumatoid arthritis, renal disease, systemic lupus erythematosus, and osteoporosis. *Evid Rep Technol Assess (Summ)*. 2004 Mar(89):1-4.
1545. Maenpaa HM, Soini I, Lehto MU, et al. Insufficiency fractures in patients with chronic inflammatory joint diseases. *Clin Exp Rheumatol*. 2002 Jan-Feb;20(1):77-9.
1546. Magaro M, Tricerri A, Piane D, et al. Generalized osteoporosis in non-steroid treated rheumatoid arthritis. *Rheumatol Int*. 1991;11(2):73-6.
1547. Magliocco MA, Gottlieb AB. Etanercept therapy for patients with psoriatic arthritis and concurrent hepatitis C virus infection: report of 3 cases. *J Am Acad Dermatol*. 2004 Oct;51(4):580-4.
1548. Magnusson SE, Engstrom M, Jacob U, et al. High synovial expression of the inhibitory Fc $\gamma$ RIIb in rheumatoid arthritis. *Arthritis Res Ther*. 2007;9(3):R51.
1549. Maillard H, Ornetti P, Grimault L, et al. Severe pyogenic infections in patients taking infliximab: a regional cohort study. *Joint Bone Spine*. 2005 Jul;72(4):330-4.
1550. Maimon N, Brunton J, Chan AK, et al. Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept. *Thorax*. 2007 Aug;62(8):739-40.
1551. Maini R, St Clair EW, Breedveld F, et al. Infliximab (chimeric anti-tumor necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet*. 1999 Dec 4;354(9194):1932-9.
1552. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum*. 1998 Sep;41(9):1552-63.
1553. Maini RN, Breedveld FC, Kalden JR, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum*. 2004 Apr;50(4):1051-65.
1554. Maini RN, Taylor PC, Szechinski J, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis Rheum* 2006;54(9):2817-29.
1555. Mainman H, McClaren E, Heycock C, et al. When should we use parenteral methotrexate? *Clin Rheumatol*. 2010 Oct;29(10):1093-8.
1556. Maki-Petaja KM, Hall FC, Booth AD, et al. Rheumatoid arthritis is associated with increased aortic pulse-wave velocity, which is reduced by anti-tumor necrosis factor- $\alpha$  therapy. *Circulation*. 2006 Sep 12;114(11):1185-92.
1557. Maksymowych WP. Ankylosing spondylitis. Not just another pain in the back. *Can Fam Physician*. 2004 Feb;50:257-62.
1558. Maksymowych WP, Blackburn WD, Jr., Tami JA, et al. A randomized, placebo controlled trial of an antisense oligodeoxynucleotide to intercellular adhesion molecule-1 in the treatment of severe rheumatoid arthritis. *J Rheumatol*. 2002 Mar;29(3):447-53.

1559. Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of spinal inflammation in ankylosing spondylitis. *Arthritis Rheum.* 2005 Aug 15;53(4):502-9.
1560. Maksymowych WP, Inman RD, Salonen D, et al. Spondyloarthritis research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. *Arthritis Rheum.* 2005 Oct 15;53(5):703-9.
1561. Maksymowych WP, Jhangri GS, Lambert RG, et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. *J Rheumatol.* 2002 May;29(5):959-65.
1562. Maksymowych WP, Poole AR, Hiebert L, et al. Etanercept exerts beneficial effects on articular cartilage biomarkers of degradation and turnover in patients with ankylosing spondylitis. *J Rheumatol.* 2005 Oct;32(10):1911-7.
1563. Maksymowych WP, Reeve JP, Reveille JD, et al. High-throughput single-nucleotide polymorphism analysis of the IL1RN locus in patients with ankylosing spondylitis by matrix-assisted laser desorption ionization-time-of-flight mass spectrometry. *Arthritis Rheum.* 2003 Jul;48(7):2011-8.
1564. Malaviya AN, Kapoor S, Garg S, et al. A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. *J Assoc Physicians India.* 2007 Mar;55:193-7.
1565. Malesci D, Tirri R, Buono R, et al. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. *Clin Exp Rheumatol.* 2007 Nov-Dec;25(6):881-4.
1566. Malfait AM, Verbruggen G, Almqvist KF, et al. Coculture of human articular chondrocytes with peripheral blood mononuclear cells as a model to study cytokine-mediated interactions between inflammatory cells and target cells in the rheumatoid joint. *In Vitro Cell Dev Biol Anim.* 1994 Nov;30A(11):747-52.
1567. Malipeddi AS, Rajendran R, Kallarackal G. Disseminated tuberculosis after anti-TNFalpha treatment. *Lancet.* 2007 Jan 13;369(9556):162.
1568. Malysheva OA, Wahle M, Wagner U, et al. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. *J Rheumatol* 2008;35(6):979-85.
1569. Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. *Clin Exp Rheumatol.* 2003 Jul-Aug;21(4):526.
1570. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. *J Rheumatol.* 2007 Aug;34(8):1670-3.
1571. Manda G, Neagu M, Constantin C, et al. Patterns of peripheral cellular immune disorders in severe rheumatoid arthritis. *Roum Arch Microbiol Immunol.* 2005 Jan-Dec;64(1-4):17-26.
1572. Mang R, Stege H, Ruzicka T, et al. Response of severe psoriasis to infliximab. *Dermatology.* 2002;204(2):156-7.
1573. Mangat P, Whittle S, Cleland L, et al. Digital vasculitis: a late complication of anti-tumour necrosis factor alpha therapy. *Clin Rheumatol.* 2008 Dec;27(12):1593-5.
1574. Manger B, Rech J, Schett G. Use of methotrexate in adult-onset Still's disease. *Clin Exp Rheumatol.* 2010 Sep-Oct;28(5 Suppl 61):S168-71.
1575. Marchesoni A, Arreghini M, Panni B, et al. Life-threatening reversible bone marrow toxicity in a rheumatoid arthritis patient switched from leflunomide to infliximab. *Rheumatology (Oxford).* 2003 Jan;42(1):193-4.

1576. Marchesoni A, Ceravolo GP, Battafarano N, et al. Cyclosporin A in the treatment of adult onset Still's disease. *J Rheumatol.* 1997 Aug;24(8):1582-7.
1577. Marchesoni A, Puttini PS, Gorla R, et al. Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis. *Clin Exp Rheumatol.* 2005 Nov-Dec;23(6):916-7.
1578. Marchesoni A, Zaccara E, Gorla R, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. *Ann N Y Acad Sci* 2009;1173837-46.
1579. Mariette X, Ravaud P, Steinfeld S, et al. Inefficacy of infliximab in primary Sjogren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjogren's Syndrome (TRIPSS). *Arthritis Rheum.* 2004 Apr;50(4):1270-6.
1580. Maripuri S, Grande JP, Osborn TG, et al. Renal involvement in primary Sjogren's syndrome: a clinicopathologic study. *Clin J Am Soc Nephrol.* 2009 Sep;4(9):1423-31.
1581. Markatseli TE, Kaltsonoudis ES, Voulgari PV, et al. Induction of psoriatic skin lesions in a patient with rheumatoid arthritis treated with rituximab. *Clin Exp Rheumatol.* 2009 Nov-Dec;27(6):996-8.
1582. Marotte H, Arnaud B, Diasparra J, et al. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. *Arthritis Rheum.* 2008 May;58(5):1258-63.
1583. Marotte H, Gineyts E, Miossec P, et al. Effects of infliximab therapy on biological markers of synovium activity and cartilage breakdown in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2009 Jul;68(7):1197-200.
1584. Marotte H, Maslinski W, Miossec P. Circulating tumour necrosis factor-alpha bioactivity in rheumatoid arthritis patients treated with infliximab: link to clinical response. *Arthritis Res Ther.* 2005;7(1):R149-55.
1585. Marotte H, Pallot-Prades B, Grange L, et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. *Ann Rheum Dis.* 2006 Mar;65(3):342-7.
1586. Marsh P, Pflugfelder SC. Topical nonpreserved methylprednisolone therapy for keratoconjunctivitis sicca in Sjogren syndrome. *Ophthalmology.* 1999 Apr;106(4):811-6.
1587. Marshall NJ, Wilson G, Lapworth K, et al. Patients' perceptions of treatment with anti-TNF therapy for rheumatoid arthritis: a qualitative study. *Rheumatology (Oxford).* 2004 Aug;43(8):1034-8.
1588. Marti L, Golmia R, Golmia AP, et al. Alterations in cytokine profile and dendritic cells subsets in peripheral blood of rheumatoid arthritis patients before and after biologic therapy. *Ann N Y Acad Sci.* 2009 Sep;1173:334-42.
1589. Martin JA, Jarrett P. Rheumatoid papules treated with dapsone. *Clin Exp Dermatol.* 2004 Jul;29(4):387-9.
1590. Martin JC, Munro R, Campbell MK, et al. Effects of disease and corticosteroids on appendicular bone mass in postmenopausal women with rheumatoid arthritis: comparison with axial measurements. *Br J Rheumatol.* 1997 Jan;36(1):43-9.
1591. Martin JM, Ricart JM, Alcaccer J, et al. Adalimumab-induced lupus erythematosus. *Lupus.* 2008 Jul;17(7):676-8.
1592. Martin K, Bentaberry F, Dumoulin C, et al. Peripheral neuropathy associated with leflunomide: is there a risk patient profile? *Pharmacoepidemiol Drug Saf.* 2007 Jan;16(1):74-8.
1593. Martin LS, Migliore A, Todino V, et al. Infliximab therapy in patients with secondary Sjogren's syndrome: functional evaluation. *Clin Exp Rheumatol.* 2003 May-Jun;21(3):412.
1594. Martin N, Innes JA, Lambert CM, et al. Hypersensitivity pneumonitis associated with leflunomide therapy. *J Rheumatol.* 2007 Sep;34(9):1934-7.



1595. Martinez A, Salido M, Bonilla G, et al. Association of the major histocompatibility complex with response to infliximab therapy in rheumatoid arthritis patients. *Arthritis Rheum*. 2004 Apr;50(4):1077-82.
1596. Martinez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). *Clin Exp Rheumatol* 2009;27(4):678-84.
1597. Maruani A, Wierzbicka E, Machet MC, et al. Reversal of multifocal cutaneous lymphoproliferative disease associated with Epstein-Barr virus after withdrawal of methotrexate therapy for rheumatoid arthritis. *J Am Acad Dermatol*. 2007 Nov;57(5 Suppl):S69-71.
1598. Marzo-Ortega H, McGonagle D, Jarrett S, et al. Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. *Ann Rheum Dis*. 2005 Nov;64(11):1568-75.
1599. Marzo-Ortega H, McGonagle D, O'Connor P, et al. Efficacy of etanercept in the treatment of the enthesal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study. *Arthritis Rheum*. 2001 Sep;44(9):2112-7.
1600. Marzo-Ortega H, McGonagle D, Rhodes LA, et al. Efficacy of infliximab on MRI-determined bone oedema in psoriatic arthritis. *Ann Rheum Dis*. 2007 Jun;66(6):778-81.
1601. Marzo-Ortega H, Misbah S, Emery P. Minocycline induced autoimmune disease in rheumatoid arthritis: a missed diagnosis? *J Rheumatol*. 2001 Feb;28(2):377-8.
1602. Masera RG, Carignola R, Sartori ML, et al. Circadian abnormalities of natural killer cell activity in rheumatoid arthritis. *Ann N Y Acad Sci*. 1999 Jun 22;876:88-90.
1603. Masi AT, Aldag JC, Chatterton RT, et al. Adrenal androgen and glucocorticoid dissociation in premenopausal rheumatoid arthritis: a significant correlate or precursor to onset? *Z Rheumatol*. 2000;59 Suppl 2:II/54-61.
1604. Masi AT, Chatterton RT, Aldag JC, et al. Perspectives on the relationship of adrenal steroids to rheumatoid arthritis. *Ann N Y Acad Sci*. 2002 Jun;966:1-12.
1605. Masiero S, Boniolo A, Wassermann L, et al. Effects of an educational-behavioral joint protection program on people with moderate to severe rheumatoid arthritis: a randomized controlled trial. *Clin Rheumatol*. 2007 Dec;26(12):2043-50.
1606. Massarotti EM. Medical aspects of rheumatoid arthritis. Diagnosis and treatment. *Hand Clin*. 1996 Aug;12(3):463-75.
1607. Mastroianni A, Minutilli E, Mussi A, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. *Br J Dermatol*. 2005 Sep;153(3):531-6.
1608. Masuda K, Mochida Y, Fujii J, et al. Primary cervical epidural malignant lymphoma with rheumatoid arthritis: a case report. *Mod Rheumatol*. 2007;17(3):239-42.
1609. Mateo L, Nolla JM, Bonnin MR, et al. Sex hormone status and bone mineral density in men with rheumatoid arthritis. *J Rheumatol*. 1995 Aug;22(8):1455-60.
1610. Mathias SD, Colwell HH, Miller DP, et al. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. *Clin Ther*. 2000 Jan;22(1):128-39.
1611. Mathieu S, Vellin JF, Poujol D, et al. Cat scratch disease during etanercept therapy. *Joint Bone Spine*. 2007 Mar;74(2):184-6.
1612. Matsuda M, Morita H, Ikeda S. Long-term follow-up of systemic reactive AA amyloidosis secondary to rheumatoid arthritis: successful treatment with intermediate-dose corticosteroid. *Intern Med*. 2002 May;41(5):403-7.
1613. Matsui T, Komiya A, Shimada K, et al. Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. *Mod Rheumatol*. 2009;19(6):696-7.

1614. Matsui T, Kuga Y, Kaneko A, et al. Disease Activity Score 28 (DAS28) using C-reactive protein underestimates disease activity and overestimates EULAR response criteria compared with DAS28 using erythrocyte sedimentation rate in a large observational cohort of rheumatoid arthritis patients in Japan. *Ann Rheum Dis*. 2007 Sep;66(9):1221-6.
1615. Matsui T, Ohsumi K, Ozawa N, et al. CD64 on neutrophils is a sensitive and specific marker for detection of infection in patients with rheumatoid arthritis. *J Rheumatol*. 2006 Dec;33(12):2416-24.
1616. Matsumoto K, Hukuda S, Nishioka J, et al. Rupture of the Achilles tendon in rheumatoid arthritis with histologic evidence of enthesitis. A case report. *Clin Orthop Relat Res*. 1992 Jul(280):235-40.
1617. Matsumoto T, Kaneko T, Seto M, et al. The membrane proteinase 3 expression on neutrophils was downregulated after treatment with infliximab in patients with rheumatoid arthritis. *Clin Appl Thromb Hemost*. 2008 Apr;14(2):186-92.
1618. Matsuo T, Koyama T, Morimoto N, et al. Retinal vasculitis as a complication of rheumatoid arthritis. *Ophthalmologica*. 1990;201(4):196-200.
1619. Matsushita I, Uzuki M, Matsuno H, et al. Rheumatoid nodulosis during methotrexate therapy in a patient with rheumatoid arthritis. *Mod Rheumatol*. 2006;16(6):401-3.
1620. Matthey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. *J Rheumatol* 2009;36(6):1180-7.
1621. Matthews C, Fitzgerald O. Seropositive erosive rheumatoid arthritis (RA). *Rheumatology (Oxford)*. 2006 Sep;45(9):1100.
1622. Maugars Y, Mathis C, Berthelot JM, et al. Assessment of the efficacy of sacroiliac corticosteroid injections in spondylarthropathies: a double-blind study. *Br J Rheumatol*. 1996 Aug;35(8):767-70.
1623. Mavragani CP, La DT, Stohl W, et al. Association of the response to tumor necrosis factor antagonists with plasma type I interferon activity and interferon-beta/alpha ratios in rheumatoid arthritis patients: a post hoc analysis of a predominantly Hispanic cohort. *Arthritis Rheum*. 2010 Feb;62(2):392-401.
1624. Mavropoulos JC, Cuchacovich M, Llanos C, et al. Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis. *J Rheumatol*. 2005 Nov;32(11):2116-24.
1625. Maxwell JR, Potter C, Hyrich KL, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. *Hum Mol Genet*. 2008 Nov 15;17(22):3532-8.
1626. Mayer DF, Matteson EL. Testicular involvement in rheumatoid vasculitis. *Clin Exp Rheumatol*. 2004;22(6 Suppl 36):S62-4.
1627. Mayer Y, Balbir-Gurman A, Machtei EE. Anti-tumor necrosis factor-alpha therapy and periodontal parameters in patients with rheumatoid arthritis. *J Periodontol*. 2009 Sep;80(9):1414-20.
1628. Mazokopakis E, Katsogridakis K, Koutsopoulos A, et al. Fatal methotrexate-induced pneumonitis in a psoriatic patient. *Mil Med*. 2004 Apr;169(4):298-300.
1629. Mazzotta A, Esposito M, Costanzo A, et al. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. *Am J Clin Dermatol*. 2009;10(5):319-24.
1630. Mazzotta A, Esposito M, Schipani C, et al. Long-term experience with etanercept in psoriatic arthritis patients: a 3-year observational study. *J Dermatolog Treat*. 2009;20(6):354-8.
1631. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. *Rheumatology (Oxford)*. 2002 Jan;41(1):116-7.
1632. McCarthy CJ, Regan M, Coughlan RJ. Treatment of rheumatoid hand synovitis with a regional block technique. *Ir J Med Sci*. 1993 Apr;162(4):143-4.

1633. McCombe PA, Klestov AC, Tannenberg AE, et al. Sensorimotor peripheral neuropathy in rheumatoid arthritis. *Clin Exp Neurol*. 1991;28:146-53.
1634. McDonald JR, Zeringue AL, Caplan L, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. *Clin Infect Dis* 2009;48(10):1364-71.
1635. McGarry F, Neilly J, Anderson N, et al. A polymorphism within the interleukin 1 receptor antagonist (IL-1Ra) gene is associated with ankylosing spondylitis. *Rheumatology (Oxford)*. 2001 Dec;40(12):1359-64.
1636. McGonagle D, Tan AL, Madden J, et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. *Rheumatology (Oxford)*. 2008 Jun;47(6):865-7.
1637. McMinn JR, Jr., Cohen S, Moore J, et al. Complete recovery from refractory immune thrombocytopenic purpura in three patients treated with etanercept. *Am J Hematol*. 2003 Jun;73(2):135-40.
1638. Mease PJ, Cohen S, Gaylis NB, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. *J Rheumatol* 2010;37(5):917-27.
1639. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum* 2005;52(10):3279-89.
1640. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet*. 2000 Jul 29;356(9227):385-90.
1641. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. *J Rheumatol* 2006;33(4):712-21.
1642. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis Rheum* 2004;50(7):2264-72.
1643. Mease PJ, Ory P, Sharp JT, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). *Ann Rheum Dis*. 2009 May;68(5):702-9.
1644. Mease PJ, Reich K. Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. *J Am Acad Dermatol*. 2009 Mar;60(3):402-11.
1645. Mease PJ, Revicki DA, Szechinski J, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. *J Rheumatol* 2008;35(1):20-30.
1646. Mease PJ, Ritchlin CT, Martin RW, et al. Pneumococcal vaccine response in psoriatic arthritis patients during treatment with etanercept. *J Rheumatol*. 2004 Jul;31(7):1356-61.
1647. Mease PJ, Woolley JM, Singh A, et al. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. *J Rheumatol* 2010;37(6):1221-7.
1648. Mehta BM, Hashkes PJ, Avery R, et al. A 21-year-old man with Still's disease with fever, rash, and pancytopenia. *Arthritis Care Res (Hoboken)*. 2010 Apr;62(4):575-9.
1649. Meijer JM, Meiners PM, Vissink A, et al. Effectiveness of rituximab treatment in primary Sjogren's syndrome: a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2010 Apr;62(4):960-8.
1650. Meirer R, Muller-Gerbl M, Huemer GM, et al. Quantitative assessment of periarticular osteopenia in patients with early rheumatoid arthritis: a preliminary report. *Scand J Rheumatol*. 2004;33(5):307-11.
1651. Melikoglu MA, Melikoglu M, Gurbuz U, et al. Hydroxychloroquine-induced hyperpigmentation: a case report. *J Clin Pharm Ther*. 2008 Dec;33(6):699-701.

1652. Menard O, Petit N, Gillet P, et al. Association of histologically proven rheumatoid arthritis with pulmonary sarcoidosis. *Eur Respir J*. 1995 Mar;8(3):472-3.
1653. Menninger H, Herborn G, Sander O, et al. A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active and erosive rheumatoid arthritis. *Br J Rheumatol*. 1998 Oct;37(10):1060-8.
1654. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. *Cochrane Database Syst Rev* 2009(1):CD005121.
1655. Mertz LE, Blair JE. Coccidioidomycosis in rheumatology patients: incidence and potential risk factors. *Ann N Y Acad Sci* 2007;1111343-57.
1656. Messina OD, Barreira JC, Zanchetta JR, et al. Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. *J Rheumatol*. 1992 Oct;19(10):1520-6.
1657. Meusch U, Rossol M, Baerwald C, et al. Outside-to-inside signaling through transmembrane tumor necrosis factor reverses pathologic interleukin-1beta production and deficient apoptosis of rheumatoid arthritis monocytes. *Arthritis Rheum*. 2009 Sep;60(9):2612-21.
1658. Miceli-Richard C, Comets E, Verstuyft C, et al. A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis. *Ann Rheum Dis*. 2008 Apr;67(4):478-84.
1659. Michaelsson G, Kajermo U, Michaelsson A, et al. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? *Br J Dermatol*. 2005 Dec;153(6):1243-4.
1660. Michaud K, Wolfe F. The association of rheumatoid arthritis and its treatment with sinus disease. *J Rheumatol* 2006;33(12):2412-5.
1661. Michel BA, Bloch DA, Fries JF. Predictors of fractures in early rheumatoid arthritis. *J Rheumatol*. 1991 Jun;18(6):804-8.
1662. Michel BA, Bloch DA, Wolfe F, et al. Fractures in rheumatoid arthritis: an evaluation of associated risk factors. *J Rheumatol*. 1993 Oct;20(10):1666-9.
1663. Michel M, Duvoux C, Hezode C, et al. Fulminant hepatitis after infliximab in a patient with hepatitis B virus treated for an adult onset still's disease. *J Rheumatol*. 2003 Jul;30(7):1624-5.
1664. Michel M, Habibi A, Godeau B, et al. Characteristics and outcome of connective tissue diseases in patients with sickle-cell disease: report of 30 cases. *Semin Arthritis Rheum*. 2008 Dec;38(3):228-40.
1665. Mielants H, Goemaere S, De Vos M, et al. Intestinal mucosal permeability in inflammatory rheumatic diseases. I. Role of antiinflammatory drugs. *J Rheumatol*. 1991 Mar;18(3):389-93.
1666. Mielke F, Schweigert M. Safe adalimumab therapy for rheumatoid arthritis in a patient with pre-existing multiple myeloma. *Nat Clin Pract Rheumatol*. 2008 Apr;4(4):218-21.
1667. Migliore A, Bizzi E, Massafra U, et al. Can Cyclosporine-A associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid arthritis patients? (Cynar pilot study). *Int J Immunopathol Pharmacol*. 2010 Jul-Sep;23(3):783-90.
1668. Migliore A, Massafra U, Capuano A, et al. Combined use of teriparatide and TNFalpha blockade: safety. *Aging Clin Exp Res*. 2007 Jun;19(3 Suppl):18-20.
1669. Migliore A, Signore A, Capuano A, et al. Relevance of 99mTc-HYNIC-tir-octreotide scintigraphy in a patient affected by sarcoidosis with lung and joints involvement and secondary Sjogren's syndrome treated with infliximab: case report. *Eur Rev Med Pharmacol Sci*. 2008 Mar-Apr;12(2):127-30.
1670. Mikashima Y, Kawamura K, Miyawaki M, et al. Neglected spontaneous rupture of the Achilles tendon in elderly patients with rheumatoid arthritis. *J Clin Rheumatol*. 2010 Aug;16(5):221-4.
1671. Mikhail M, Weinberg JM, Smith BL. Successful treatment with etanercept of von Zumbusch pustular psoriasis in a patient with human immunodeficiency virus. *Arch Dermatol*. 2008 Apr;144(4):453-6.

1672. Miller KL, Sawitzke AD, Doane J. Abatacept and serious respiratory infections in patients with previous lung disease. *Clin Rheumatol*. 2008 Dec;27(12):1569-71.
1673. Miller-Blair DJ, Robbins DL. Rheumatoid arthritis: new science, new treatment. *Geriatrics*. 1993 Jun;48(6):28-31, 5-8.
1674. Mima T, Nishimoto N. Clinical value of blocking IL-6 receptor. *Curr Opin Rheumatol*. 2009 May;21(3):224-30.
1675. Min JK, Han NI, Kim JA, et al. A case of cholestatic autoimmune hepatitis and acute liver failure: an unusual hepatic manifestation of mixed connective tissue disease and Sjogren's syndrome. *J Korean Med Sci*. 2001 Aug;16(4):512-5.
1676. Mirone L, Altomonte L, D'Agostino P, et al. A study of serum androgen and cortisol levels in female patients with rheumatoid arthritis. Correlation with disease activity. *Clin Rheumatol*. 1996 Jan;15(1):15-9.
1677. Misery L, Perrot JL, Gentil-Perret A, et al. Dermatological complications of etanercept therapy for rheumatoid arthritis. *Br J Dermatol*. 2002 Feb;146(2):334-5.
1678. Mishra KK, Pandey HP. A study on physiological changes in essential hypertension and rheumatoid arthritis with reference to the levels of cortisol, blood glucose, triglycerides and cholesterol. *Indian J Physiol Pharmacol*. 1995 Jan;39(1):68-70.
1679. Mishra KK, Pandey HP. A study on physiological changes in certain psychosomatic disorders with reference to cortisol, blood glucose and lipid profile. *Indian J Physiol Pharmacol*. 1996 Apr;40(2):151-4.
1680. Mitamura M, Tada Y, Koarada S, et al. Cyclosporin A treatment for Japanese patients with severe adult-onset Still's disease. *Mod Rheumatol*. 2009;19(1):57-63.
1681. Mittendorf T, Dietz B, Sterz R, et al. Personal and economic burden of late-stage rheumatoid arthritis among patients treated with adalimumab: an evaluation from a patient's perspective. *Rheumatology (Oxford)*. 2008 Feb;47(2):188-93.
1682. Mittendorf T, Dietz B, Sterz R, et al. Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. *J Rheumatol*. 2007 Dec;34(12):2343-50.
1683. Miyagawa Y, Nagata N, Nakanishi Y, et al. A case of steroid-responsive organizing pneumonia in a patient with rheumatoid arthritis showing migratory infiltration and normal glucose levels in pleural effusions. *Br J Rheumatol*. 1993 Sep;32(9):829-31.
1684. Miyamoto S, Kageyama Y, Ozeki T, et al. Bone mineral density after total joint arthroplasty of lower extremities in rheumatoid arthritis patients. *Arch Orthop Trauma Surg*. 2001;121(3):127-30.
1685. Miyanishi K, Hara T, Hamada T, et al. Co-occurrence of subchondral insufficiency fracture of the femoral head and contralateral femoral neck fracture in a rheumatic patient receiving steroid treatment. *Mod Rheumatol*. 2008;18(6):619-22.
1686. Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. *Mod Rheumatol* 2008;18(3):252-62.
1687. Miyazaki T, Fujimaki K, Shirasugi Y, et al. Remission of lymphoma after withdrawal of methotrexate in rheumatoid arthritis: relationship with type of latent Epstein-Barr virus infection. *Am J Hematol*. 2007 Dec;82(12):1106-9.
1688. Moccia F, Mazzarello GP, Morra L. Effect of corticosteroid treatment on hemopoiesis in vivo and in vitro in a patient with Felty's syndrome. *Biomed Pharmacother*. 1991;45(9):403-8.
1689. Mochizuki T, Momohara S, Ikari K, et al. Spontaneous multiple insufficiency fractures after pelvic abscess and sepsis in a rheumatoid arthritis patient treated with high-load corticosteroid therapy: a case report. *Clin Rheumatol*. 2007 Nov;26(11):1925-8.
1690. Mochizuki T, Momohara S, Ikari K, et al. The serum concentration of infliximab in cases of autologous blood donation for patients with rheumatoid arthritis. *Mod Rheumatol*. 2007;17(1):24-7.

1691. Mody GM, Meyers OL. Therapeutic requirements in rheumatoid arthritis. *S Afr Med J*. 1990 May 19;77(10):497-9.
1692. Moen K, Kvalvik AG, Hellem S, et al. The long-term effect of anti TNF-alpha treatment on temporomandibular joints, oral mucosa, and salivary flow in patients with active rheumatoid arthritis: a pilot study. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod*. 2005 Oct;100(4):433-40.
1693. Mogosan C, Stoica V, Mihai C, et al. Rheumatoid arthritis: travelling biological era a Romanian X-ray population. *J Med Life*. 2009 Oct-Dec;2(4):414-25.
1694. Mohammad A, Kilcoyne A, Bond U, et al. Methotrexate information booklet study 2008. *Clin Exp Rheumatol*. 2009 Jul-Aug;27(4):649-50.
1695. Mohan AK, Cote TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. *Clin Infect Dis*. 2004 Aug 1;39(3):295-9.
1696. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. *Arthritis Rheum*. 2001 Dec;44(12):2862-9.
1697. Mohyuddin T, Elyan M, Kushner I. Pericarditis: a rare complication of methotrexate therapy. *Clin Rheumatol*. 2007 Dec;26(12):2157-8.
1698. Mok CC, Lau CS, Wong RW. Clinical characteristics, treatment, and outcome of adult onset Still's disease in southern Chinese. *J Rheumatol*. 1998 Dec;25(12):2345-51.
1699. Mok MY, Lo Y, Leung PY, et al. Pregnancy outcome in patients with adult onset Still's disease. *J Rheumatol*. 2004 Nov;31(11):2307-9.
1700. Mok MY, Wong SY, Chan TM, et al. Necrotizing fasciitis in rheumatic diseases. *Lupus*. 2006;15(6):380-3.
1701. Molenaar ET, Bultink IE, Dijkmans BA, et al. Development of fatal tuberculosis in a patient with rheumatoid arthritis after three years of treatment with infliximab: comment on the article by Wolfe et al. *Arthritis Rheum*. 2005 Apr;52(4):1334-6.
1702. Moller B, Kukoc-Zivojnov N, Koyama N, et al. Prednisolone induces interleukin-18 expression in mononuclear blood and myeloid progenitor cells. *Inflamm Res*. 2002 Sep;51(9):457-63.
1703. Molloy E, Ramakrishnan S, Murphy E, et al. Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab. *Rheumatology (Oxford)*. 2004 Apr;43(4):522-3.
1704. Momeni M, Mehta AP, Katz JD. Anti-tumor necrosis factor therapy is tolerated in an individual with homozygous complement C2 deficiency. *J Clin Rheumatol*. 2005 Jun;11(3):180-2.
1705. Montagna GL, Malesci D, Buono R, et al. Asthenozoospermia in patients receiving anti-tumour necrosis factor {alpha} agents. *Ann Rheum Dis*. 2005 Nov;64(11):1667.
1706. Montecucco C, Caporali R, Caprotti P, et al. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. *J Rheumatol*. 1992 Dec;19(12):1895-900.
1707. Montero JA, Ruiz-Moreno JM, Rodriguez AE, et al. Endogenous endophthalmitis by *Propionibacterium acnes* associated with leflunomide and adalimumab therapy. *Eur J Ophthalmol*. 2006 Mar-Apr;16(2):343-5.
1708. Moore A, Phillips C, Hunsche E, et al. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK. *Pharmacoeconomics*. 2004;22(10):643-60.
1709. Moore J, Ma D, Will R, et al. A phase II study of Rituximab in rheumatoid arthritis patients with recurrent disease following haematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2004 Aug;34(3):241-7.
1710. Mor A, Bingham C, 3rd, Barisoni L, et al. Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept. *J Rheumatol*. 2005 Apr;32(4):740-3.

1711. Mor A, Bingham CO, 3rd, Kishimoto M, et al. Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic. *Ann Rheum Dis.* 2008 Apr;67(4):462-5.
1712. Morand EF, Jefferiss CM, Dixey J, et al. Impaired glucocorticoid induction of mononuclear leukocyte lipocortin-1 in rheumatoid arthritis. *Arthritis Rheum.* 1994 Feb;37(2):207-11.
1713. Moreland LW. Inhibitors of tumor necrosis factor: new treatment options for rheumatoid arthritis. *Cleve Clin J Med.* 1999 Jun;66(6):367-74.
1714. Moreland LW, Alten R, Van den Bosch F, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. *Arthritis Rheum.* 2002 Jun;46(6):1470-9.
1715. Moreland LW, Bucy RP, Weinblatt ME, et al. Immune function in patients with rheumatoid arthritis treated with etanercept. *Clin Immunol.* 2002 Apr;103(1):13-21.
1716. Moreland LW, Cohen SB, Baumgartner SW, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. *J Rheumatol.* 2001 Jun;28(6):1238-44.
1717. Moreland LW, Schiff MH, Baumgartner SW, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann Intern Med.* 1999 Mar 16;130(6):478-86.
1718. Morelli S, Sgreccia A, Bernardo ML, et al. Primary aspergillosis of the larynx in a patient with Felty's syndrome. *Clin Exp Rheumatol.* 2000 Jul-Aug;18(4):523-4.
1719. Mori K, Iijima M, Koike H, et al. The wide spectrum of clinical manifestations in Sjogren's syndrome-associated neuropathy. *Brain.* 2005 Nov;128(Pt 11):2518-34.
1720. Mori S. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. *Mod Rheumatol.* 2007;17(2):83-91.
1721. Mori S, Cho I, Ichiyasu H, et al. Asymptomatic carriage of *Pneumocystis jiroveci* in elderly patients with rheumatoid arthritis in Japan: a possible association between colonization and development of *Pneumocystis jiroveci* pneumonia during low-dose MTX therapy. *Mod Rheumatol.* 2008;18(3):240-6.
1722. Mori S, Cho I, Sugimoto M. A followup study of asymptomatic carriers of *Pneumocystis jiroveci* during immunosuppressive therapy for rheumatoid arthritis. *J Rheumatol.* 2009 Aug;36(8):1600-5.
1723. Mori S, Ebihara K. A sudden onset of diabetic ketoacidosis and acute pancreatitis after introduction of mizoribine therapy in a patient with rheumatoid arthritis. *Mod Rheumatol.* 2008;18(6):634-8.
1724. Mori S, Imamura F, Kiyofuji C, et al. *Pneumocystis jiroveci* pneumonia in a patient with rheumatoid arthritis as a complication of treatment with infliximab, anti-tumor necrosis factor alpha neutralizing antibody. *Mod Rheumatol.* 2006;16(1):58-62.
1725. Mori S, Imamura F, Kiyofuji C, et al. Development of interstitial pneumonia in a rheumatoid arthritis patient treated with infliximab, an anti-tumor necrosis factor alpha-neutralizing antibody. *Mod Rheumatol.* 2006;16(4):251-5.
1726. Mori S, Koga Y, Imamura F, et al. Early rheumatoid arthritis in a patient with Sjogren's syndrome and pulmonary nodular amyloidosis: clinical implication of early limited use of infliximab. *Mod Rheumatol.* 2007;17(6):500-6.
1727. Mori S, Tomita Y, Horikawa T, et al. Delayed spinal infection after laminectomy in a patient with rheumatoid arthritis interruptedly exposed to anti-tumor necrosis factor alpha agents. *Clin Rheumatol.* 2008 Jul;27(7):937-9.
1728. Morita Y, Fukazawa T, Hirashima M, et al. The effect of methotrexate (MTX) on expression of signalling lymphocytic activation molecule (SLAM) in patients with rheumatoid arthritis (RA) and its role in the regulation of cytokine production. *Scand J Rheumatol.* 2006 Jul-Aug;35(4):268-72.

1729. Morita Y, Sasae Y, Sakuta T, et al. Efficacy of low-dose tacrolimus added to methotrexate in patients with rheumatoid arthritis in Japan: a retrospective study. *Mod Rheumatol*. 2008;18(4):379-84.
1730. Morozzi G, Fabbroni M, Bellisai F, et al. Low serum level of COMP, a cartilage turnover marker, predicts rapid and high ACR70 response to adalimumab therapy in rheumatoid arthritis. *Clin Rheumatol*. 2007 Aug;26(8):1335-8.
1731. Morrison E, Crosbie D, Capell HA. Attitude of rheumatoid arthritis patients to treatment with oral corticosteroids. *Rheumatology (Oxford)*. 2003 Oct;42(10):1247-50.
1732. Moszyk DJ, Sulit DJ. Rheumatoid arthritis in a military aviator. *Aviat Space Environ Med*. 2007 Jan;78(1):63-6.
1733. Motivala SJ, Khanna D, FitzGerald J, et al. Stress activation of cellular markers of inflammation in rheumatoid arthritis: protective effects of tumor necrosis factor alpha antagonists. *Arthritis Rheum*. 2008 Feb;58(2):376-83.
1734. Mourao AF, Rustin M, Isenberg D. Exacerbation of psoriatic skin lesions in patients with psoriatic arthritis receiving anti-tumour necrosis factor-alpha therapy: description of 3 cases and review of the literature. *Clin Exp Rheumatol*. 2010 May-Jun;28(3):408-10.
1735. Mrabet D, Meddeb N, Ajlani H, et al. Cerebral vasculitis in a patient with rheumatoid arthritis. *Joint Bone Spine*. 2007 Mar;74(2):201-4.
1736. Mufti AH, Toye BW, McKendry RR, et al. Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. *Diagn Microbiol Infect Dis*. 2005 Nov;53(3):233-8.
1737. Mugnier B, Balandraud N, Darque A, et al. Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis. *Arthritis Rheum*. 2003 Jul;48(7):1849-52.
1738. Mulherin D, Sheeran TP. Clinical image: hidden costs of anti-tumor necrosis factor alpha therapy. *Arthritis Rheum*. 2003 Mar;48(3):868.
1739. Mullan RH, Bresnihan B. Disease-modifying anti-rheumatic drug therapy and structural damage in early rheumatoid arthritis. *Clin Exp Rheumatol*. 2003 Sep-Oct;21(5 Suppl 31):S158-64.
1740. Muller K, Zak M, Nielsen S, et al. Interleukin-1 receptor antagonist in neonates, children and adults, and in patients with pauci- and polyarticular onset juvenile chronic arthritis. *Clin Exp Rheumatol*. 1997 Jul-Aug;15(4):439-44.
1741. Muntinghe FL, de Filippi JP, Breedveld RW, et al. A young woman with fever and a pericardial effusion. *Neth J Med*. 2002 Nov;60(10):414-5.
1742. Murata K, Yasuda T, Ito H, et al. Lack of increase in postoperative complications with low-dose methotrexate therapy in patients with rheumatoid arthritis undergoing elective orthopedic surgery. *Mod Rheumatol*. 2006;16(1):14-9.
1743. Murphy FT, Enzenauer RJ, Battafarano DF, et al. Etanercept-associated injection-site reactions. *Arch Dermatol*. 2000 Apr;136(4):556-7.
1744. Murphy NG. Current concepts in the management of rheumatoid arthritis. *Del Med J*. 1992 Apr;64(4):257-64.
1745. Murray RP, Bourne MH, Fitzgerald RH, Jr. Metachronous infections in patients who have had more than one total joint arthroplasty. *J Bone Joint Surg Am*. 1991 Dec;73(10):1469-74.
1746. Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. *Rheumatology (Oxford)*. 2003 Dec;42(12):1566-8.
1747. Muto S, Asano Y, Okazaki H, et al. Renal potassium wasting in distal renal tubular acidosis: role of aldosterone. *Intern Med*. 1992 Aug;31(8):1047-51.
1748. Mutsukura K, Nakamura H, Iwanaga N, et al. Successful treatment of a patient with primary Sjogren's syndrome complicated with pericarditis during pregnancy. *Intern Med*. 2007;46(14):1143-7.



1749. Muzaffer MA, Dayer JM, Feldman BM, et al. Differences in the profiles of circulating levels of soluble tumor necrosis factor receptors and interleukin 1 receptor antagonist reflect the heterogeneity of the subgroups of juvenile rheumatoid arthritis. *J Rheumatol.* 2002 May;29(5):1071-8.
1750. Myers WA, Najarian D, Gottlieb AB. New-onset, debilitating arthritis in psoriasis patients receiving efalizumab. *J Dermatolog Treat.* 2006;17(6):353-4.
1751. Mylona E, Golfopoulou S, Samarkos M, et al. Acute hepatitis in adult Still's disease during corticosteroid treatment successfully treated with anakinra. *Clin Rheumatol.* 2008 May;27(5):659-61.
1752. Mylona E, Vadala C, Papadakis V, et al. Cutaneous polyarteritis nodosa in adult onset Still's disease. *Eur J Dermatol.* 2009 Nov-Dec;19(6):621-2.
1753. Nabae M, Inoue K, Ushiyama T, et al. Gene expressions of antiinflammatory mediators in THR retrieved interfacial membranes. *Acta Orthop Scand.* 1999 Apr;70(2):149-54.
1754. Nadarajah K, Pritchard C. *Listeria monocytogenes* septic arthritis in a patient treated with etanercept for rheumatoid arthritis. *J Clin Rheumatol.* 2005 Apr;11(2):120-2.
1755. Nadareishvili Z, Michaud K, Hallenbeck JM, et al. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. *Arthritis Rheum* 2008;59(8):1090-6.
1756. Nagasawa H, Kameda H, Sekiguchi N, et al. Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical function. *Clin Exp Rheumatol.* 2010 May-Jun;28(3):365-72.
1757. Nagashima M, Matsuoka T, Saitoh K, et al. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. *Clin Exp Rheumatol* 2006;24(3):260-7.
1758. Nair B, Raval G, Mehta P. TNF-alpha inhibitor etanercept and hematologic malignancies: report of a case and review of the literature. *Am J Hematol.* 2007 Nov;82(11):1022-4.
1759. Nakahara H, Mima T, Yoshio-Hoshino N, et al. A case report of a patient with refractory adult-onset Still's disease who was successfully treated with tocilizumab over 6 years. *Mod Rheumatol.* 2009;19(1):69-72.
1760. Nakajima A, Inoue E, Tanaka E, et al. Mortality and cause of death in Japanese patients with rheumatoid arthritis based on a large observational cohort, IORRA. *Scand J Rheumatol.* 2010;39(5):360-7.
1761. Nakamura T, Higashi S, Tomoda K, et al. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. *Clin Exp Rheumatol.* 2007 Jul-Aug;25(4):518-22.
1762. Nakashima C, Tanioka M, Takahashi K, et al. Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate. *Clin Exp Dermatol.* 2008 Jul;33(4):437-9.
1763. Nakashima Y, Kondo M, Harada H, et al. Clinical evaluation of tocilizumab for patients with active rheumatoid arthritis refractory to anti-TNF biologics: tocilizumab in combination with methotrexate. *Mod Rheumatol.* 2010 Aug;20(4):343-52.
1764. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. *Am J Med.* 2002 Jan;112(1):78.
1765. Nakou M, Katsikas G, Sidiropoulos P, et al. Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. *Arthritis Res Ther.* 2009;11(4):R131.
1766. Nampei A, Hashimoto J, Koyanagi J, et al. Characteristics of fracture and related factors in patients with rheumatoid arthritis. *Mod Rheumatol.* 2008;18(2):170-6.
1767. Nanke Y, Kotake S, Yonemoto K, et al. Cricoarytenoid arthritis with rheumatoid arthritis and systemic lupus erythematosus. *J Rheumatol.* 2001 Mar;28(3):624-6.

1768. Naranjo A, Sokka T, Descalzo MA, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. *Arthritis Res Ther* 2008;10(2):R30.
1769. Naredo E, Moller I, Cruz A, et al. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. *Arthritis Rheum*. 2008 Aug;58(8):2248-56.
1770. Narushima M, Suzuki H, Kasai T, et al. Pulmonary nocardiosis in a patient treated with corticosteroid therapy. *Respirology*. 2002 Mar;7(1):87-9.
1771. Narvaez J, Montala N, Busquets-Perez N, et al. Collagenous colitis and spondylarthropathy. *Arthritis Rheum*. 2006 Jun 15;55(3):507-12.
1772. Nash P, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. *Dermatology*. 2006;212(3):238-49.
1773. Nast A, Reytan N, Rosumeck S, et al. Low prescription rate for systemic treatments in the management of severe psoriasis vulgaris and psoriatic arthritis in dermatological practices in Berlin and Brandenburg, Germany: results from a patient registry. *J Eur Acad Dermatol Venereol*. 2008 Nov;22(11):1337-42.
1774. Natsuga K, Sawamura D, Homma E, et al. Amicrobial pustulosis associated with IgA nephropathy and Sjogren's syndrome. *J Am Acad Dermatol*. 2007 Sep;57(3):523-6.
1775. Nawata M, Saito K, Nakayamada S, et al. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. *Mod Rheumatol*. 2008;18(5):460-4.
1776. Ndongo S, Lekpa FK, Ka MM, et al. Presentation and severity of rheumatoid arthritis at diagnosis in Senegal. *Rheumatology (Oxford)*. 2009 Sep;48(9):1111-3.
1777. Neeck G, Federlin K, Graef V, et al. Adrenal secretion of cortisol in patients with rheumatoid arthritis. *J Rheumatol*. 1990 Jan;17(1):24-9.
1778. Neeman N, Aronson MD, Schulze JE, et al. Improving pregnancy counseling for women with rheumatoid arthritis taking methotrexate. *Am J Med*. 2009 Nov;122(11):998-1000.
1779. Neff K, Stack J, Harney S, et al. The use of abatacept in debilitating cavitating lung disease associated with rheumatoid arthritis, bronchocentric granulomatosis and aspergillosis. *Thorax*. 2010 Jun;65(6):545-6.
1780. Neidel J, Schulze M, Lindschau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. *Inflamm Res*. 1995 May;44(5):217-21.
1781. Nemoto Y, Taniguchi A, Kamioka M, et al. Epstein-Barr virus-infected subcutaneous panniculitis-like T-cell lymphoma associated with methotrexate treatment. *Int J Hematol*. 2010 Sep;92(2):364-8.
1782. Nerome Y, Imanaka H, Nonaka Y, et al. A case of planned pregnancy with an interruption in infliximab administration in a 27-year-old female patient with rheumatoid-factor-positive polyarthritis juvenile idiopathic arthritis which improved after restarting infliximab and methotrexate. *Mod Rheumatol*. 2008;18(2):189-92.
1783. Nesheiwat JP, Dillon K, McGlothan K, et al. An elderly man with rheumatoid arthritis and dyspnea. *Chest*. 2009 Apr;135(4):1090-3.
1784. Netea MG, Radstake T, Joosten LA, et al. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: association with decreased interferon-gamma production and Toll-like receptor 4 expression. *Arthritis Rheum*. 2003 Jul;48(7):1853-7.
1785. Neustadt DH. Double blind evaluation of the long-term effects of etodolac versus ibuprofen in patients with rheumatoid arthritis. *J Rheumatol Suppl*. 1997 Feb;47:17-22.
1786. Newman DK, Isaacs JD, Watson PG, et al. Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H. *Eye*. 1995;9 (Pt 5):564-9.

1787. Newton SM, Mackie SL, Martineau AR, et al. Reduction of chemokine secretion in response to mycobacteria in infliximab-treated patients. *Clin Vaccine Immunol.* 2008 Mar;15(3):506-12.
1788. Ng CM, Bruno R, Combs D, et al. Population pharmacokinetics of rituximab (anti-CD20 monoclonal antibody) in rheumatoid arthritis patients during a phase II clinical trial. *J Clin Pharmacol.* 2005 Jul;45(7):792-801.
1789. Niemela RK, Hakala M. Primary Sjogren's syndrome with severe central nervous system disease. *Semin Arthritis Rheum.* 1999 Aug;29(1):4-13.
1790. Niemela RK, Hakala M, Huikuri HV, et al. Comprehensive study of autonomic function in a population with primary Sjogren's syndrome. No evidence of autonomic involvement. *J Rheumatol.* 2003 Jan;30(1):74-9.
1791. Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. *Arthritis Rheum.* 2006 Jul;54(7):2335-7.
1792. Niitsu N, Okamoto M, Nakamine H, et al. Clinicopathologic correlations of diffuse large B-cell lymphoma in rheumatoid arthritis patients treated with methotrexate. *Cancer Sci.* 2010 May;101(5):1309-13.
1793. Nikas SN, Alamanos Y, Voulgari PV, et al. Infliximab treatment in ankylosing spondylitis: an observational study. *Ann Rheum Dis.* 2005 Jun;64(6):940-2.
1794. Nikas SN, Temekonidis TI, Zikou AK, et al. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. *Ann Rheum Dis.* 2004 Jan;63(1):102-3.
1795. Nikas SN, Voulgari PV, Alamanos Y, et al. Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study. *Ann Rheum Dis.* 2006 Feb;65(2):257-60.
1796. Nikas SN, Voulgari PV, Takalou IP, et al. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment. *Ann Rheum Dis.* 2005 Nov;64(11):1665-7.
1797. Nishida K, Okada Y, Nawata M, et al. Induction of hyperadiponectinemia following long-term treatment of patients with rheumatoid arthritis with infliximab (IFX), an anti-TNF-alpha antibody. *Endocr J.* 2008 Mar;55(1):213-6.
1798. Nishie W, Sawamura D, Iitoyo M, et al. Intravascular histiocytosis associated with rheumatoid arthritis. *Dermatology.* 2008;217(2):144-5.
1799. Nishimoto N, Hashimoto J, Miyasaka N, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. *Ann Rheum Dis* 2007;66(9):1162-7.
1800. Nishimoto N, Miyasaka N, Yamamoto K, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. *Mod Rheumatol* 2009;19(1):12-9.
1801. Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. *Blood.* 2008 Nov 15;112(10):3959-64.
1802. Nishimura H, Tachibana H, Makiura N, et al. Corticosteroid-responsive parkinsonism associated with primary Sjogren's syndrome. *Clin Neurol Neurosurg.* 1994 Nov;96(4):327-31.
1803. Nissinen R, Leirisalo-Repo M, Peltomaa R, et al. Cytokine and chemokine receptor profile of peripheral blood mononuclear cells during treatment with infliximab in patients with active rheumatoid arthritis. *Ann Rheum Dis.* 2004 Jun;63(6):681-7.
1804. Niwa Y, Iio A, Niwa G, et al. Serum albumin metabolism in rheumatic diseases: relationship to corticosteroids and peptic ulcer. *J Clin Lab Immunol.* 1990 Jan;31(1):11-6.

1805. Nizam S, Johnstone A, Green M, et al. Necrotising scleritis and connective tissue disease--three cases and a review. *Clin Rheumatol*. 2009 Mar;28(3):339-41.
1806. Noguera-Pons R, Borrás-Blasco J, Romero-Crespo I, et al. Optic neuritis with concurrent etanercept and isoniazid therapy. *Ann Pharmacother*. 2005 Dec;39(12):2131-5.
1807. Nonaka T, Nishisaka F, Fukuda K, et al. Relationship between bone mineral density and urine level of NTx in rheumatoid arthritis. *J Bone Miner Metab*. 2005;23(4):314-7.
1808. Novak S, Cikes N. Infliximab-induced lupus or rheumatoid arthritis (RA) overlapping with systemic lupus erythematosus (SLE) unmasked by infliximab. *Clin Exp Rheumatol*. 2004 Mar-Apr;22(2):268.
1809. Nozaki Y, Nagare Y, Hino S, et al. Therapeutic strategy and significance of serum rheumatoid factor in patients with rheumatoid arthritis during infliximab treatment. *Nihon Rinsho Meneki Gakkai Kaishi*. 2010;33(3):135-41.
1810. Nozaki Y, Nagare Y, Kinoshita K, et al. Successful treatment using tacrolimus plus corticosteroid in a patient with RA associated with MDS. *Rheumatol Int*. 2008 Mar;28(5):487-90.
1811. Nuijten MJ, Engelfriet P, Duijn K, et al. A cost-cost study comparing etanercept with infliximab in rheumatoid arthritis. *Pharmacoeconomics*. 2001;19(10):1051-64.
1812. Nuki G, Bresnihan B, Bear MB, et al. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2002 Nov;46(11):2838-46.
1813. Nunez-Cornejo C, Borrás-Blasco J, Gracia-Perez A, et al. Septic shock and community-acquired pneumonia associated with etanercept therapy. *Int J Clin Pharmacol Ther*. 2008 Apr;46(4):193-7.
1814. Nyhall-Wahlin BM, Petersson IF, Nilsson JA, et al. High disease activity disability burden and smoking predict severe extra-articular manifestations in early rheumatoid arthritis. *Rheumatology (Oxford)*. 2009 Apr;48(4):416-20.
1815. Oberstein EM, Kromo O, Tozman EC. Type I reaction of Hansen's disease with exposure to adalimumab: a case report. *Arthritis Rheum*. 2008 Jul 15;59(7):1040-3.
1816. Ochi S, Harigai M, Mizoguchi F, et al. Leflunomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy findings with a mosaic pattern of acute and organizing diffuse alveolar damage. *Mod Rheumatol*. 2006;16(5):316-20.
1817. Ochi S, Taniguchi K, Nagashima M. Leflunomide-induced polymyositis in a patient with rheumatoid arthritis. *Mod Rheumatol*. 2009;19(4):443-6.
1818. Ochiai T, Washio H, Shiraiwa H, et al. Psoriatic onycho-pachydermo-periostitis successfully treated with low-dose methotrexate. *Med Sci Monit*. 2006 Apr;12(4):CS27-30.
1819. O'Connor PA, Eustace S, O'Byrne J. Spinal cord injury following osteoporotic vertebral fracture: case report. *Spine*. 2002 Sep 15;27(18):E413-5.
1820. Oda S, Fujinaga H, Takahashi K. Infectious myositis involving the piriformis in a patient with rheumatoid arthritis. *Mod Rheumatol*. 2006;16(4):260-3.
1821. O'Dell J. Conventional DMARD options for patients with a suboptimal response to methotrexate. *J Rheumatol Suppl*. 2001 Jun;62:21-6.
1822. O'Dell JR, Petersen K, Leff R, et al. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. *J Rheumatol*. 2006 Feb;33(2):213-8.
1823. Odessey E, Cohn A, Beaman K, et al. Invasive mucormycosis of the maxillary sinus: extensive destruction with an indolent presentation. *Surg Infect (Larchmt)*. 2008 Feb;9(1):91-8.

1824. Oei HB, Hooker RS, Cipher DJ, et al. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. *Clin Exp Rheumatol* 2009;27(6):926-34.
1825. Oelzner P, Schwabe A, Lehmann G, et al. Significance of risk factors for osteoporosis is dependent on gender and menopause in rheumatoid arthritis. *Rheumatol Int*. 2008 Sep;28(11):1143-50.
1826. Ogawa H, Itokazu M, Ito Y, et al. Quality of life evaluated by Short Form-8 in patients with rheumatoid arthritis who were receiving infusion of infliximab. *Mod Rheumatol*. 2009;19(1):27-32.
1827. Ogiwara Y, Mochizuki H, Morioka T, et al. A case with life-threatening interstitial pneumonia associated with bucillamine treatment. *Mod Rheumatol*. 2008;18(5):522-5.
1828. Oguz FM, Oguz A, Uzunlulu M. The effect of infliximab treatment on insulin resistance in patients with rheumatoid arthritis. *Acta Clin Belg*. 2007 Jul-Aug;62(4):218-22.
1829. Oh J, Arkfeld DG, Horwitz DA. Development of Crohn's disease in a patient taking etanercept. *J Rheumatol*. 2005 Apr;32(4):752-3.
1830. Oh WM, Hwang IN, Son HH, et al. Rapid periapical bone destruction during endodontic treatment of a patient with rheumatoid arthritis. *J Endod*. 2008 Oct;34(10):1261-3.
1831. Ohshima S, Mima T, Sasai M, et al. Tumour necrosis factor alpha (TNF-alpha) interferes with Fas-mediated apoptotic cell death on rheumatoid arthritis (RA) synovial cells: a possible mechanism of rheumatoid synovial hyperplasia and a clinical benefit of anti-TNF-alpha therapy for RA. *Cytokine*. 2000 Mar;12(3):281-8.
1832. Ohsugi Y, Kishimoto T. The recombinant humanized anti-IL-6 receptor antibody tocilizumab, an innovative drug for the treatment of rheumatoid arthritis. *Expert Opin Biol Ther*. 2008 May;8(5):669-81.
1833. Oili KS, Niinisalo H, Korpilahde T, et al. Treatment of reactive arthritis with infliximab. *Scand J Rheumatol*. 2003;32(2):122-4.
1834. Okamoto H, Koizumi K, Kamitsuji S, et al. Beneficial action of statins in patients with rheumatoid arthritis in a large observational cohort. *J Rheumatol*. 2007 May;34(5):964-8.
1835. Okamoto O, Oishi M, Fujiwara S. Steroid-resistant adult-onset Still's disease which showed a quick response to methotrexate. *J Dermatol*. 2008 Feb;35(2):106-10.
1836. Okuda Y, Takasugi K. Successful use of a humanized anti-interleukin-6 receptor antibody, tocilizumab, to treat amyloid A amyloidosis complicating juvenile idiopathic arthritis. *Arthritis Rheum*. 2006 Sep;54(9):2997-3000.
1837. Okuda Y, Takasugi K, Oyama T, et al. Intractable diarrhoea associated with secondary amyloidosis in rheumatoid arthritis. *Ann Rheum Dis*. 1997 Sep;56(9):535-41.
1838. Olewicz-Gawlik A, Korczowska-Lacka I, Lacki JK, et al. Fucosylation of serum alpha1-acid glycoprotein in rheumatoid arthritis patients treated with infliximab. *Clin Rheumatol*. 2007 Oct;26(10):1679-84.
1839. Olive A, del Blanco J, Pons M, et al. The clinical spectrum of remitting seronegative symmetrical synovitis with pitting edema. The Catalan Group for the Study of RS3PE. *J Rheumatol*. 1997 Feb;24(2):333-6.
1840. Oliveira B, Arkfeld DG, Weitz IC, et al. Successful rituximab therapy of acquired factor VIII inhibitor in a patient with rheumatoid arthritis. *J Clin Rheumatol*. 2007 Apr;13(2):89-91.
1841. Olivieri I, de Portu S, Salvarani C, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. *Rheumatology (Oxford)*. 2008 Nov;47(11):1664-70.
1842. Olivieri I, de Stefano G, Padula A, et al. Infliximab in a case of early adult-onset Still's disease. *Clin Rheumatol*. 2003 Oct;22(4-5):369-70.
1843. Olivieri I, Palazzi C, Peruz G, et al. Management issues with elderly-onset rheumatoid arthritis: an update. *Drugs Aging*. 2005;22(10):809-22.

1844. Ollendorf DA, Massarotti E, Birbara C, et al. Frequency, predictors, and economic impact of upward dose adjustment of infliximab in managed care patients with rheumatoid arthritis. *J Manag Care Pharm.* 2005 Jun;11(5):383-93.
1845. Ollendorf DA, Peterson AN, Doyle J, et al. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. *Am J Manag Care.* 2002 May;8(7 Suppl):S203-13.
1846. Omdal R, Gunnarsson R. The effect of interleukin-1 blockade on fatigue in rheumatoid arthritis--a pilot study. *Rheumatol Int.* 2005 Aug;25(6):481-4.
1847. Ongaro A, De Mattei M, Pellati A, et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? *Rheumatol Int.* 2008 Jul;28(9):901-8.
1848. Onuma S, Yamaji K, Kempe K, et al. Investigation of the clinical effect of large volume leukocytapheresis on methotrexate-resistant rheumatoid arthritis. *Ther Apher Dial.* 2006 Oct;10(5):404-11.
1849. Ooi KG, Wingate R, Adler PA. Necrotising anterior scleritis in a late-onset rheumatoid arthritis (LORA) patient. *Ocul Immunol Inflamm.* 2007 Jan-Feb;15(1):33-6.
1850. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. *Ann Rheum Dis.* 2008 Jul;67(7):937-41.
1851. Ornetti P, Solau E, Gaudin P, et al. Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab. *Ann Rheum Dis.* 2005 Sep;64(9):1379-80.
1852. Orstavik RE, Haugeberg G, Mowinckel P, et al. Vertebral deformities in rheumatoid arthritis: a comparison with population-based controls. *Arch Intern Med.* 2004 Feb 23;164(4):420-5.
1853. Orstavik RE, Haugeberg G, Uhlig T, et al. Vertebral deformities in 229 female patients with rheumatoid arthritis: associations with clinical variables and bone mineral density. *Arthritis Rheum.* 2003 Jun 15;49(3):355-60.
1854. Orstavik RE, Haugeberg G, Uhlig T, et al. Incidence of vertebral deformities in 255 female rheumatoid arthritis patients measured by morphometric X-ray absorptiometry. *Osteoporos Int.* 2005 Jan;16(1):35-42.
1855. Orstavik RE, Haugeberg G, Uhlig T, et al. Quantitative ultrasound and bone mineral density: discriminatory ability in patients with rheumatoid arthritis and controls with and without vertebral deformities. *Ann Rheum Dis.* 2004 Aug;63(8):945-51.
1856. Ortiz-Santamaria V, Valls-Roc M, Sanmarti M, et al. Anti-TNF treatment in secondary amyloidosis. *Rheumatology (Oxford).* 2003 Nov;42(11):1425-6.
1857. Osawa H, Yamabe H, Seino S, et al. A case of Sjogren's syndrome associated with Sweet's syndrome. *Clin Rheumatol.* 1997 Jan;16(1):101-5.
1858. Ostanek L, Pawlik A, Brzosko I, et al. The urinary excretion of pyridinoline and deoxypyridinoline during rheumatoid arthritis therapy with infliximab. *Clin Rheumatol.* 2004 Jun;23(3):214-7.
1859. Ostensen M, Eigenmann GO. Etanercept in breast milk. *J Rheumatol.* 2004 May;31(5):1017-8.
1860. Ostensen M, Forger F. Management of RA medications in pregnant patients. *Nat Rev Rheumatol.* 2009 Jul;5(7):382-90.
1861. Ostensen M, Raio L. A woman with rheumatoid arthritis whose condition did not improve during pregnancy. *Nat Clin Pract Rheumatol.* 2005 Dec;1(2):111-4; quiz 1 p following 4.
1862. Ostergaard M, Duer A, Nielsen H, et al. Magnetic resonance imaging for accelerated assessment of drug effect and prediction of subsequent radiographic progression in rheumatoid arthritis: a study of patients receiving combined anakinra and methotrexate treatment. *Ann Rheum Dis.* 2005 Oct;64(10):1503-6.
1863. Ostor AJ, Crisp AJ, Somerville MF, et al. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. *BMJ.* 2004 Nov 27;329(7477):1266.

1864. Ostrov BE. Beneficial effect of etanercept on rheumatoid lymphedema. *Arthritis Rheum.* 2001 Jan;44(1):240-1.
1865. Ostuni P, Botsios C, Punzi L, et al. Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate. *Ann Rheum Dis.* 2003 Jul;62(7):686-7.
1866. O'Sullivan MM, Amos N, Bedwell A, et al. Complement-mediated inhibition of immune precipitation in rheumatoid vasculitis. *Rheumatol Int.* 1990;10(4):159-63.
1867. Otabe S, Muto S, Asano Y, et al. Selective hypoaldosteronism in a patient with Sjogren's syndrome: insensitivity to angiotensin II. *Nephron.* 1991;59(3):466-70.
1868. Otsuka T, Koyama T, Ohtani R, et al. Leflunomide-induced lung injury that developed after its withdrawal, coinciding with peripheral blood lymphocyte count decrease. *Mod Rheumatol.* 2008;18(1):96-9.
1869. Ott SJ, Baron A, Berghaus T, et al. Liver failure in adult Still's disease during corticosteroid treatment. *Eur J Gastroenterol Hepatol.* 2003 Jan;15(1):87-90.
1870. Ouedraogo DD, Palazzo E, Nlome-Nze M, et al. Predominant cervical involvement in patients with psoriatic arthritis: report of two cases. *Joint Bone Spine.* 2007 Mar;74(2):175-8.
1871. Owino BO, Oyoo GO, Otieno CF. Socio-demographic and clinical aspects of rheumatoid arthritis. *East Afr Med J.* 2009 May;86(5):204-11.
1872. Ozaki D, Shirai Y, Nakayama Y, et al. A case report of insufficiency fracture of the Fossa acetabuli in a patient with rheumatoid arthritis. *J Nippon Med Sch.* 2000 Aug;67(4):267-70.
1873. Ozgocmen S, Godekmerdan A, Ozkurt-Zengin F. Acute-phase response, clinical measures and disease activity in ankylosing spondylitis. *Joint Bone Spine.* 2007 May;74(3):249-53.
1874. Ozgocmen S, Ozdemir H, Kiris A, et al. Clinical evaluation and power Doppler sonography in rheumatoid arthritis: evidence for ongoing synovial inflammation in clinical remission. *South Med J.* 2008 Mar;101(3):240-5.
1875. Pace J, Adami JZ, Mallia C, et al. Toxic epidermal necrolysis in a patient with psoriatic arthritis. *Adv Exp Med Biol.* 1999;455:557-60.
1876. Pachot A, Arnaud B, Marrote H, et al. Increased tumor necrosis factor-alpha mRNA expression in whole blood from patients with rheumatoid arthritis: reduction after infliximab treatment does not predict response. *J Rheumatol.* 2007 Nov;34(11):2158-61.
1877. Padyukov L, Lampa J, Heimbürger M, et al. Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis. *Ann Rheum Dis.* 2003 Jun;62(6):526-9.
1878. Pagliano P, Attanasio V, Fusco U, et al. Does etanercept monotherapy enhance the risk of *Listeria monocytogenes* meningitis? *Ann Rheum Dis.* 2004 Apr;63(4):462-3.
1879. Paira S, Caliani L, Luraquiz N. Distal extremity swelling with pitting oedema in rheumatoid arthritis. *Clin Rheumatol.* 2001;20(1):76-9.
1880. Palanichamy A, Roll P, Theiss R, et al. Modulation of molecular imprints in the antigen-experienced B cell repertoire by rituximab. *Arthritis Rheum.* 2008 Dec;58(12):3665-74.
1881. Palazzi C, D'Amico E, Pennese E, et al. Purpura and serum mixed cryoglobulinemia in psoriatic arthritis. *Rheumatol Int.* 2006 Dec;27(2):187-9.
1882. Palkonyai E, Kolarz G, Kopp M, et al. Depressive symptoms in early rheumatoid arthritis: a comparative longitudinal study. *Clin Rheumatol.* 2007 May;26(5):753-8.
1883. Pallinti V, Ganesan N, Anbazhagan M, et al. Serum biochemical markers in rheumatoid arthritis. *Indian J Biochem Biophys.* 2009 Aug;46(4):342-4.
1884. Pallotta P, Cianchini G, Ruffelli M, et al. Infliximab-induced lupus-like reaction in a patient with psoriatic arthritis. *Rheumatology (Oxford).* 2006 Jan;45(1):116-7.
1885. Palm S, Hinrichsen H, Barth J, et al. Modulation of lymphocyte subsets due to psychological stress in patients with rheumatoid arthritis. *Eur J Clin Invest.* 1992 Oct;22 Suppl 1:26-9.

1886. Pamuk ON, Harmandar F. A case of cervical spine meningioma following etanercept use in a patient with RA. *Nat Rev Rheumatol*. 2009 Aug;5(8):457-60.
1887. Pamuk ON, Harmandar F, Cakir N. The development of trigeminal neuralgia related to auricular chondritis in a patient with rheumatoid arthritis-relapsing polychondritis and its treatment with etanercept. Description of the first case. *Clin Exp Rheumatol*. 2009 Jan-Feb;27(1):128-9.
1888. Pan SM, Dehler S, Ciurea A, et al. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. *Arthritis Rheum* 2009;61(5):560-8.
1889. Panfilio CB, Hernandez-Cossio O, Hernandez-Fustes OJ. Orbital myositis and rheumatoid arthritis: case report. *Arq Neuropsiquiatr*. 2000 Mar;58(1):174-7.
1890. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2008 Jan;47(1):72-5.
1891. Panthakalam S, Bhatnagar D, Klimiuk P. The prevalence and management of hyperglycaemia in patients with rheumatoid arthritis on corticosteroid therapy. *Scott Med J*. 2004 Nov;49(4):139-41.
1892. Papadaki HA, Kritikos HD, Valatas V, et al. Anemia of chronic disease in rheumatoid arthritis is associated with increased apoptosis of bone marrow erythroid cells: improvement following anti-tumor necrosis factor-alpha antibody therapy. *Blood*. 2002 Jul 15;100(2):474-82.
1893. Papadopoulos IA, Katsimbri P, Alamanos Y, et al. Early rheumatoid arthritis patients: relationship of age. *Rheumatol Int*. 2003 Mar;23(2):70-4.
1894. Papageorgiou SG, Kontaxis T, Bonakis A, et al. Orofacial dystonia related to Sjogren's syndrome. *Clin Rheumatol*. 2007 Oct;26(10):1779-81.
1895. Papagoras CE, Argyropoulou MI, Voulgari PV, et al. A case of Brucella spondylitis in a patient with psoriatic arthritis receiving infliximab. *Clin Exp Rheumatol*. 2009 Jan-Feb;27(1):124-7.
1896. Papanikolaou IC, Sharma OP. A 47-year-old woman with rheumatoid arthritis and dyspnea on exertion. *Chest*. 2009 Dec;136(6):1694-7.
1897. Papoutsaki M, Chimenti MS, Costanzo A, et al. Adalimumab for severe psoriasis and psoriatic arthritis: an open-label study in 30 patients previously treated with other biologics. *J Am Acad Dermatol*. 2007 Aug;57(2):269-75.
1898. Parambil JG, Myers JL, Lindell RM, et al. Interstitial lung disease in primary Sjogren syndrome. *Chest*. 2006 Nov;130(5):1489-95.
1899. Parambil JG, Yi ES, Ryu JH. Obstructive bronchiolar disease identified by CT in the non-transplant population: analysis of 29 consecutive cases. *Respirology*. 2009 Apr;14(3):443-8.
1900. Park IN, Kim DS, Shim TS, et al. Acute exacerbation of interstitial pneumonia other than idiopathic pulmonary fibrosis. *Chest*. 2007 Jul;132(1):214-20.
1901. Park JH, Seo GY, Lee JS, et al. Positive conversion of tuberculin skin test and performance of interferon release assay to detect hidden tuberculosis infection during anti-tumor necrosis factor agent trial. *J Rheumatol*. 2009 Oct;36(10):2158-63.
1902. Park MC, Chung SJ, Park YB, et al. Relationship of serum TWEAK level to cytokine level, disease activity, and response to anti-TNF treatment in patients with rheumatoid arthritis. *Scand J Rheumatol*. 2008 May-Jun;37(3):173-8.
1903. Park SH, Kim CG, Kim JY, et al. Spontaneous regression of EBV-associated diffuse lymphoproliferative disease in a patient with rheumatoid arthritis after discontinuation of etanercept treatment. *Rheumatol Int*. 2008 Mar;28(5):475-7.
1904. Park YB, Ahn CW, Choi HK, et al. Atherosclerosis in rheumatoid arthritis: morphologic evidence obtained by carotid ultrasound. *Arthritis Rheum*. 2002 Jul;46(7):1714-9.
1905. Park YB, Choi HK, Kim MY, et al. Effects of antirheumatic therapy on serum lipid levels in patients with rheumatoid arthritis: a prospective study. *Am J Med*. 2002 Aug 15;113(3):188-93.



1906. Park YB, Lee SK, Lee WK, et al. Lipid profiles in untreated patients with rheumatoid arthritis. *J Rheumatol.* 1999 Aug;26(8):1701-4.
1907. Parke FA, Reveille JD. Anti-tumor necrosis factor agents for rheumatoid arthritis in the setting of chronic hepatitis C infection. *Arthritis Rheum.* 2004 Oct 15;51(5):800-4.
1908. Parker A, Izmailova ES, Narang J, et al. Peripheral blood expression of nuclear factor-kappaB-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate. *J Rheumatol.* 2007 Sep;34(9):1817-22.
1909. Parker SR, Solomon AR, Lane JE. A report of Epstein-Barr virus-positive primary cutaneous natural killer-/T-cell lymphoma. *J Am Acad Dermatol.* 2008 Jul;59(1):157-61.
1910. Paroli MP, Bruscolini A, De Carlo L, et al. Ring keratopathy in a patient with psoriatic arthritis and ulcerative colitis. *Ocul Immunol Inflamm.* 2007 Jan-Feb;15(1):51-6.
1911. Parra Ruiz J, Ortego Centeno N, Raya Alvarez E. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. *J Rheumatol.* 2003 Jul;30(7):1657-8.
1912. Pasek M, Duk M, Podbielska M, et al. Galactosylation of IgG from rheumatoid arthritis (RA) patients--changes during therapy. *Glycoconj J.* 2006 Nov;23(7-8):463-71.
1913. Patel A, Kesler B, Wise RA. Persistent pneumomediastinum in interstitial fibrosis associated with rheumatoid arthritis: treatment with high-concentration oxygen. *Chest.* 2000 Jun;117(6):1809-13.
1914. Patel NK, Salathe C, Vu C, et al. Esophagitis dissecans: a rare cause of odynophagia. *Endoscopy.* 2007 Feb;39 Suppl 1:E127.
1915. Paulus HE, Di Primeo D, Sanda M, et al. Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. *J Rheumatol.* 2000 Jul;27(7):1632-7.
1916. Paulus HE, Di Primeo D, Sharp JT, et al. Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs. *J Rheumatol.* 2004 Mar;31(3):470-81.
1917. Pavelka K, Gatterova J, Tegzova D, et al. Radiographic progression of rheumatoid arthritis in patients from the Czech National Registry receiving infliximab treatment. *Clin Exp Rheumatol.* 2007 Jul-Aug;25(4):540-5.
1918. Pavletic SZ, Klassen LW, Pope R, et al. Treatment of relapse after autologous blood stem cell transplantation for severe rheumatoid arthritis. *J Rheumatol Suppl.* 2001 Oct;64:28-31.
1919. Pavlica L, Peric-Hajzler Z, Jovelic A, et al. Psoriatic arthritis: a retrospective study of 162 patients. *Vojnosanit Pregl.* 2005 Sep;62(9):613-20.
1920. Pawlik A, Herczynska M, Kurzawski M, et al. The effect of exon (19C>A) dihydroorotate dehydrogenase gene polymorphism on rheumatoid arthritis treatment with leflunomide. *Pharmacogenomics.* 2009 Feb;10(2):303-9.
1921. Pawlik A, Herczynska M, Kurzawski M, et al. IL-1beta, IL-6, and TNF gene polymorphisms do not affect the treatment outcome of rheumatoid arthritis patients with leflunomide. *Pharmacol Rep.* 2009 Mar-Apr;61(2):281-7.
1922. Pawlik A, Ostanek L, Brzosko I, et al. Therapy with infliximab decreases the CD4+CD28- T cell compartment in peripheral blood in patients with rheumatoid arthritis. *Rheumatol Int.* 2004 Nov;24(6):351-4.
1923. Peddle L, Butt C, Snelgrove T, et al. Interleukin (IL) 1alpha, IL1beta, IL receptor antagonist, and IL10 polymorphisms in psoriatic arthritis. *Ann Rheum Dis.* 2005 Jul;64(7):1093-4.
1924. Pelivani N, Hassan AS, Braathen LR, et al. Alopecia areata universalis elicited during treatment with adalimumab. *Dermatology.* 2008;216(4):320-3.

1925. Penn SK, Kao AH, Schott LL, et al. Hydroxychloroquine and glycemia in women with rheumatoid arthritis and systemic lupus erythematosus. *J Rheumatol*. 2010 Jun;37(6):1136-42.
1926. Perdriger A, Mariette X, Kuntz JL, et al. Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. *J Rheumatol*. 2006 May;33(5):865-9.
1927. Perera LC, Tymms KE, Wilson BJ, et al. Etanercept in severe active rheumatoid arthritis: first Australian experience. *Intern Med J*. 2006 Oct;36(10):625-31.
1928. Perez-De-Lis M, Akasbi M, Siso A, et al. Cardiovascular risk factors in primary Sjogren's syndrome: a case-control study in 624 patients. *Lupus*. 2010;19(8):941-8.
1929. Perez-Ezquerria PR, de Barrio Fernandez M, de Castro Martinez FJ, et al. Delayed hypersensitivity to hydroxychloroquine manifested by two different types of cutaneous eruptions in the same patient. *Allergol Immunopathol (Madr)*. 2006 Jul-Aug;34(4):174-5.
1930. Perez-Garcia C, Maymo J, Lisbona Perez MP, et al. Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab. *Rheumatology (Oxford)*. 2006 Jan;45(1):114-6.
1931. Perez-Guijo VC, Cravo AR, Castro Mdel C, et al. Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. *Joint Bone Spine*. 2007 May;74(3):254-8.
1932. Perhala RS, Wilke WS, Clough JD, et al. Local infectious complications following large joint replacement in rheumatoid arthritis patients treated with methotrexate versus those not treated with methotrexate. *Arthritis Rheum*. 1991 Feb;34(2):146-52.
1933. Peris P, Font J, Grau JM, et al. Calcitriol-mediated hypercalcaemia and increased interleukins in a patient with sarcoid myopathy. *Clin Rheumatol*. 1999;18(6):488-91.
1934. Perkins DJ, St Clair EW, Misukonis MA, et al. Reduction of NOS2 overexpression in rheumatoid arthritis patients treated with anti-tumor necrosis factor alpha monoclonal antibody (cA2). *Arthritis Rheum*. 1998 Dec;41(12):2205-10.
1935. Perlmutter A, Mittal A, Menter A. Tuberculosis and tumour necrosis factor-alpha inhibitor therapy: a report of three cases in patients with psoriasis. Comprehensive screening and therapeutic guidelines for clinicians. *Br J Dermatol*. 2009 Jan;160(1):8-15.
1936. Perotti LA, Peretti L, Lovino C, et al. Concentration of cortisol in the synovial fluid of patients with untreated rheumatoid arthritis. Relation to in vitro IL-8 production by synovial mononuclear cells. *Ann N Y Acad Sci*. 1999 Jun 22;876:255-8.
1937. Perry MG, Kirwan JR, Jessop DS, et al. Overnight variations in cortisol, interleukin 6, tumour necrosis factor alpha and other cytokines in people with rheumatoid arthritis. *Ann Rheum Dis*. 2009 Jan;68(1):63-8.
1938. Pers JO, Saraux A, Pierre R, et al. Anti-TNF-alpha immunotherapy is associated with increased gingival inflammation without clinical attachment loss in subjects with rheumatoid arthritis. *J Periodontol*. 2008 Sep;79(9):1645-51.
1939. Peters MJ, Vis M, van Halm VP, et al. Changes in lipid profile during infliximab and corticosteroid treatment in rheumatoid arthritis. *Ann Rheum Dis*. 2007 Jul;66(7):958-61.
1940. Peterson JR, Hsu FC, Simkin PA, et al. Effect of tumour necrosis factor alpha antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection. *Ann Rheum Dis*. 2003 Nov;62(11):1078-82.
1941. Peyrou J, Saxer-Sekulic N, Lerch R, et al. Fast progression of aortic stenosis in rheumatoid arthritis. *Arch Cardiovasc Dis*. 2009 Mar;102(3):251-2.
1942. Pfeil A, Lippold J, Eidner T, et al. Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis. *Rheumatol Int*. 2009 Jan;29(3):287-95.

1943. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjogren's syndrome keratoconjunctivitis sicca. *Curr Eye Res.* 1999 Sep;19(3):201-11.
1944. Pham TN, Rahman P, Richardson VJ. Divergent effects of infliximab and anakinra therapies on macrophage phenotype from patients with refractory rheumatoid arthritis. *Int J Immunopathol Pharmacol.* 2010 Apr-Jun;23(2):491-501.
1945. Phillips K, Aliprantis A, Coblyn J. Strategies for the prevention and treatment of osteoporosis in patients with rheumatoid arthritis. *Drugs Aging.* 2006;23(10):773-9.
1946. Phillips K, Weinblatt M. Granulomatous lung disease occurring during etanercept treatment. *Arthritis Rheum.* 2005 Aug 15;53(4):618-20.
1947. Pickartz T, Pickartz H, Lochs H, et al. Overlap syndrome of autoimmune pancreatitis and cholangitis associated with secondary Sjogren's syndrome. *Eur J Gastroenterol Hepatol.* 2004 Nov;16(12):1295-9.
1948. Pijpe J, Meijer JM, Bootsma H, et al. Clinical and histologic evidence of salivary gland restoration supports the efficacy of rituximab treatment in Sjogren's syndrome. *Arthritis Rheum.* 2009 Nov;60(11):3251-6.
1949. Pijpe J, van Imhoff GW, Spijkervet FK, et al. Rituximab treatment in patients with primary Sjogren's syndrome: an open-label phase II study. *Arthritis Rheum.* 2005 Sep;52(9):2740-50.
1950. Pijpe J, van Imhoff GW, Vissink A, et al. Changes in salivary gland immunohistology and function after rituximab monotherapy in a patient with Sjogren's syndrome and associated MALT lymphoma. *Ann Rheum Dis.* 2005 Jun;64(6):958-60.
1951. Pileggi GS, de Souza CB, Ferriani VP. Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids. *Arthritis Care Res (Hoboken).* 2010 Jul;62(7):1034-9.
1952. Pillemer SR, Brennan MT, Sankar V, et al. Pilot clinical trial of dehydroepiandrosterone (DHEA) versus placebo for Sjogren's syndrome. *Arthritis Rheum.* 2004 Aug 15;51(4):601-4.
1953. Pincus T, Ferraccioli G, Sokka T, et al. Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. *Rheumatology (Oxford).* 2002 Dec;41(12):1346-56.
1954. Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. *Am J Med.* 1990 Aug;89(2):161-8.
1955. Pincus T, Swearingen CJ, Bergman M, et al. RAPID3 (Routine Assessment of Patient Index Data 3), a rheumatoid arthritis index without formal joint counts for routine care: proposed severity categories compared to disease activity score and clinical disease activity index categories. *J Rheumatol.* 2008 Nov;35(11):2136-47.
1956. Pisitkun P, Pattarowas C, Siriwongpairat P, et al. Reappraisal of cervical spine subluxation in Thai patients with rheumatoid arthritis. *Clin Rheumatol.* 2004 Feb;23(1):14-8.
1957. Pitsillides AA, Will RK, Bayliss MT, et al. Circulating and synovial fluid hyaluronan levels. Effects of intraarticular corticosteroid on the concentration and the rate of turnover. *Arthritis Rheum.* 1994 Jul;37(7):1030-8.
1958. Pittoni V, Bombardieri M, Spinelli FR, et al. Anti-tumour necrosis factor (TNF) alpha treatment of rheumatoid arthritis (infliximab) selectively down regulates the production of interleukin (IL) 18 but not of IL12 and IL13. *Ann Rheum Dis.* 2002 Aug;61(8):723-5.
1959. Pizzuti P, Liote F, Cerf-Payraastre I, et al. Hypersensitivity to glucocorticoids: does it exist? *Rev Rhum Engl Ed.* 1996 Mar;63(3):223-6.
1960. Plant MJ, Borg AA, Dziedzic K, et al. Radiographic patterns and response to corticosteroid hip injection. *Ann Rheum Dis.* 1997 Aug;56(8):476-80.

1961. Podgorski MR, Goulding NJ, Hall ND, et al. Autoantibodies to lipocortin-1 are associated with impaired glucocorticoid responsiveness in rheumatoid arthritis. *J Rheumatol.* 1992 Nov;19(11):1668-71.
1962. Pollet SM, Vogt PJ, Leek JC. Serous peritonitis in adult Still's syndrome. *J Rheumatol.* 1990 Jan;17(1):98-101.
1963. Polzer K, Baeten D, Soleiman A, et al. Tumour necrosis factor blockade increases lymphangiogenesis in murine and human arthritic joints. *Ann Rheum Dis.* 2008 Nov;67(11):1610-6.
1964. Pomerantz RG, Mody E, Husni ME, et al. Follow-up of psoriatic arthritis mutilans patients treated with anti-TNF-alpha therapy. *J Drugs Dermatol.* 2009 Apr;8(4):406-12.
1965. Pool AJ, Whipp BJ, Skasick AJ, et al. Serum cortisol reduction and abnormal prolactin and CD4+/CD8+ T-cell response as a result of controlled exercise in patients with rheumatoid arthritis and systemic lupus erythematosus despite unaltered muscle energetics. *Rheumatology (Oxford).* 2004 Jan;43(1):43-8.
1966. Poor G, Strand V. Efficacy and safety of leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoid arthritis: multinational double-blind, randomized trial. *Rheumatology (Oxford).* 2004 Jun;43(6):744-9.
1967. Popa C, Leandro MJ, Cambridge G, et al. Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs. *Rheumatology (Oxford).* 2007 Apr;46(4):626-30.
1968. Popa C, Netea MG, de Graaf J, et al. Circulating leptin and adiponectin concentrations during tumor necrosis factor blockade in patients with active rheumatoid arthritis. *J Rheumatol.* 2009 Apr;36(4):724-30.
1969. Popa C, Netea MG, Radstake TR, et al. Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis. *Ann Rheum Dis.* 2005 Aug;64(8):1195-8.
1970. Popa C, van den Hoogen FH, Radstake TR, et al. Modulation of lipoprotein plasma concentrations during long-term anti-TNF therapy in patients with active rheumatoid arthritis. *Ann Rheum Dis.* 2007 Nov;66(11):1503-7.
1971. Popa C, van Tits LJ, Barrera P, et al. Anti-inflammatory therapy with tumour necrosis factor alpha inhibitors improves high-density lipoprotein cholesterol antioxidative capacity in rheumatoid arthritis patients. *Ann Rheum Dis.* 2009 Jun;68(6):868-72.
1972. Pope RM, Kniker WT, Talal N, et al. Delayed type hypersensitivity in patients with rheumatoid arthritis. *J Rheumatol.* 1993 Jan;20(1):17-20.
1973. Porola P, Laine M, Virtanen I, et al. Androgens and integrins in salivary glands in Sjogren's syndrome. *J Rheumatol.* 2010 Jun;37(6):1181-7.
1974. Porola P, Virkki L, Przybyla BD, et al. Androgen deficiency and defective intracrine processing of dehydroepiandrosterone in salivary glands in Sjogren's syndrome. *J Rheumatol.* 2008 Nov;35(11):2229-35.
1975. Portales P, Fabre S, Vincent T, et al. Peripheral blood T4 cell surface CCR5 density as a marker of activity in rheumatoid arthritis treated with anti-CD20 monoclonal antibody. *Immunology.* 2009 Sep;128(1 Suppl):e738-45.
1976. Porterfield LM. Why has this patient developed sepsis? *Rn.* 1999 Aug;62(8):89.
1977. Porterfield LM. Rheumatoid arthritis patient's respiratory distress. *Rn.* 2009 Jan;72(1):21.
1978. Posten W, Swan J. Recurrence of alopecia areata in a patient receiving etanercept injections. *Arch Dermatol.* 2005 Jun;141(6):759-60.
1979. Potter C, Cordell HJ, Barton A, et al. Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF{ $\kappa$ }B signalling pathways. *Ann Rheum Dis.* 2010 Jul;69(7):1315-20.

1980. Potter C, Hyrich KL, Tracey A, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. *Ann Rheum Dis* 2009;68(1):69-74.
1981. Pou MA, Diaz-Torne C, Vidal S, et al. Development of autoimmune diseases after vaccination. *J Clin Rheumatol*. 2008 Aug;14(4):243-4.
1982. Price-Forbes AN, Callaghan R, Allen ME, et al. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines. *Rheumatology (Oxford)*. 2005 Jul;44(7):921-4.
1983. Priori R, Ceccarelli F, Barone F, et al. Clinical, biological and sonographic response to IL-1 blockade in adult-onset Still's disease. *Clin Exp Rheumatol*. 2008 Sep-Oct;26(5):933-7.
1984. Probst C, Pongratz G, Capellino S, et al. Cryptococcosis mimicking cutaneous cellulitis in a patient suffering from rheumatoid arthritis: a case report. *BMC Infect Dis*. 2010;10:239.
1985. Probst LE, Holland EJ. Intraocular lens implantation in patients with juvenile rheumatoid arthritis. *Am J Ophthalmol*. 1996 Aug;122(2):161-70.
1986. Proudman SM, Keen HI, Stamp LK, et al. Response-driven combination therapy with conventional disease-modifying antirheumatic drugs can achieve high response rates in early rheumatoid arthritis with minimal glucocorticoid and nonsteroidal anti-inflammatory drug use. *Semin Arthritis Rheum*. 2007 Oct;37(2):99-111.
1987. Provenzano G, Termini A, Le Moli C, et al. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study. *Ann Rheum Dis*. 2003 Jul;62(7):680-1.
1988. Puechal X, Miceli-Richard C, Mejjad O, et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. *Ann Rheum Dis*. 2008 Jun;67(6):880-4.
1989. Pullerits R, Bokarewa M, Dahlberg L, et al. Synovial fluid expression of autoantibodies specific for RAGE relates to less erosive course of rheumatoid arthritis. *Rheumatology (Oxford)*. 2007 Aug;46(8):1367-71.
1990. Pulsatelli L, Dolzani P, Silvestri T, et al. Synovial expression of vasoactive intestinal peptide in polymyalgia rheumatica. *Clin Exp Rheumatol*. 2006 Sep-Oct;24(5):562-6.
1991. Pun YL, Barraclough DR, Muirden KD. Leg ulcers in rheumatoid arthritis. *Med J Aust*. 1990 Nov 19;153(10):585-7.
1992. Puri PK, Lountzis NI, Tyler W, et al. Hydroxychloroquine-induced hyperpigmentation: the staining pattern. *J Cutan Pathol*. 2008 Dec;35(12):1134-7.
1993. Pyrpasopoulou A, Douma S, Triantafyllou A, et al. Response to rituximab and timeframe to relapse in rheumatoid arthritis patients: association with B-cell markers. *Mol Diagn Ther*. 2010 Feb 1;14(1):43-8.
1994. Qallich LG, Greenson J, Haftel HM, et al. Is it Crohn's disease? A severe systemic granulomatous reaction to sulfasalazine in patient with rheumatoid arthritis. *BMC Gastroenterol*. 2001;1:8.
1995. Quartier P, Taupin P, Bourdeaut F, et al. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type. *Arthritis Rheum*. 2003 Apr;48(4):1093-101.
1996. Quartuccio L, De Re V, Fabris M, et al. Atypical lymphoproliferation progressing into B-cell lymphoma in rheumatoid arthritis treated with different biological agents: clinical course and molecular characterization. *Haematologica*. 2006 May;91(5):691-4.
1997. Quartuccio L, Maset M, De Vita S. Efficacy of abatacept in a refractory case of adult-onset Still's disease. *Clin Exp Rheumatol*. 2010 Mar-Apr;28(2):265-7.
1998. Queiro R, Torre JC, Belzunegui J, et al. Clinical features and predictive factors in psoriatic arthritis-related uveitis. *Semin Arthritis Rheum*. 2002 Feb;31(4):264-70.

1999. Quinn MA, Conaghan PG, O'Connor PJ, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 2005 Jan;52(1):27-35.
2000. Rachapalli S, O'Daunt S. Septic arthritis due to *Listeria monocytogenes* in a patient receiving etanercept. *Arthritis Rheum.* 2005 Mar;52(3):987.
2001. Racunica T, Cassidy D, Cicuttini F, et al. Trouble with tumor necrosis factor alpha inhibitors, not just tuberculosis. *Arthritis Care Res (Hoboken)* 2010;62(6):770-4.
2002. Radikova Z, Rovensky J, Vlcek M, et al. Adrenocortical response to low-dose ACTH test in female patients with rheumatoid arthritis. *Ann N Y Acad Sci.* 2008 Dec;1148:562-6.
2003. Radovits BJ, Kievit W, Laan RF. Tumor necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety. *Drugs Aging.* 2009;26(8):647-64.
2004. Radstake TR, Franssen J, Toonen EJ, et al. Macrophage migration inhibitory factor polymorphisms do not predict therapeutic response to glucocorticoids or to tumor necrosis factor alpha-neutralising treatments in rheumatoid arthritis. *Ann Rheum Dis.* 2007 Nov;66(11):1525-30.
2005. Raghavendra S, Nair MD, Chemmanam T, et al. Disseminated necrotizing leukoencephalopathy following low-dose oral methotrexate. *Eur J Neurol.* 2007 Mar;14(3):309-14.
2006. Rahman MU, Strusberg I, Geusens P, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2007 Sep;66(9):1233-8.
2007. Rahman N, Healy C, Flint SR, et al. Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening. *J Clin Rheumatol.* 2010 Jun;16(4):197-9.
2008. Rahmlow M, Shuster EA, Dominik J, et al. Leflunomide-associated progressive multifocal leukoencephalopathy. *Arch Neurol.* 2008 Nov;65(11):1538-9.
2009. Rajagopala S, Singh N, Gupta K, et al. Pulmonary amyloidosis in Sjogren's syndrome: a case report and systematic review of the literature. *Respirology.* 2010 Jul;15(5):860-6.
2010. Rajakulendran S, Deighton C. Delayed multiple injection site reaction in a rheumatoid arthritis patient treated with etanercept. *Rheumatology (Oxford).* 2004 Dec;43(12):1588-9.
2011. Rajakulendran S, Deighton C. Adverse dermatological reactions in rheumatoid arthritis patients treated with etanercept, an anti-TNFalpha drug. *Curr Drug Saf.* 2006 Aug;1(3):259-64.
2012. Rajakulendran S, Gadsby K, Deighton C. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified? *Musculoskeletal Care.* 2008 Dec;6(4):233-45.
2013. Rajaraman RT, Kimura Y, Li S, et al. Retrospective case review of pediatric patients with uveitis treated with infliximab. *Ophthalmology.* 2006 Feb;113(2):308-14.
2014. Ramirez-Hernandez M, Marras C, Martinez-Escribano JA. Infliximab-induced vitiligo. *Dermatology.* 2005;210(1):79-80.
2015. Ramos-Casals M, Brito-Zeron P, Siso A, et al. High prevalence of serum metabolic alterations in primary Sjogren's syndrome: influence on clinical and immunological expression. *J Rheumatol.* 2007 Apr;34(4):754-61.
2016. Ramos-Casals M, Garcia-Hernandez FJ, de Ramon E, et al. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases. *Clin Exp Rheumatol.* 2010 Jul-Aug;28(4):468-76.
2017. Ramos-Casals M, Lopez-Guillermo A, Brito-Zeron P, et al. Treatment of B-cell lymphoma with rituximab in two patients with Sjogren's syndrome associated with hepatitis C virus infection. *Lupus.* 2004;13(12):969-71.

2018. Ranganathan P. Infliximab-induced scleredema in a patient with rheumatoid arthritis. *J Clin Rheumatol*. 2005 Dec;11(6):319-22.
2019. Rantalaiho V, Korpela M, Hannonen P, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. *Arthritis Rheum*. 2009 May;60(5):1222-31.
2020. Raterman HG, Hoving JL, Nurmohamed MT, et al. Work ability: a new outcome measure in rheumatoid arthritis? *Scand J Rheumatol*. 2010 Mar;39(2):127-31.
2021. Rau R, Sander O, van Riel P, et al. Intravenous human recombinant tumor necrosis factor receptor p55-Fc IgG1 fusion protein Ro 45-2081 (lenercept): a double blind, placebo controlled dose-finding study in rheumatoid arthritis. *J Rheumatol*. 2003 Apr;30(4):680-90.
2022. Rau R, Sander O, Wassenberg S. Erosion healing in rheumatoid arthritis after anakinra treatment. *Ann Rheum Dis*. 2003 Jul;62(7):671-3.
2023. Rau R, Simianer S, van Riel PL, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. *Scand J Rheumatol*. 2004;33(3):145-53.
2024. Ravindran J, Shenker N, Bhalla AK, et al. Case report: Response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade. *Rheumatology (Oxford)*. 2004 May;43(5):669-72.
2025. Raza N, Hameed A, Ali MK. Detection of subclinical joint involvement in psoriasis with bone scintigraphy and its response to oral methotrexate. *Clin Exp Dermatol*. 2008 Jan;33(1):70-3.
2026. Reddy AR, Backhouse OC. Does etanercept induce uveitis? *Br J Ophthalmol*. 2003 Jul;87(7):925.
2027. Reed A, Haugen M, Pachman LM, et al. Abnormalities in serum osteocalcin values in children with chronic rheumatic diseases. *J Pediatr*. 1990 Apr;116(4):574-80.
2028. Regula CG, Hennessy J, Clarke LE, et al. Interstitial granulomatous drug reaction to anakinra. *J Am Acad Dermatol*. 2008 Aug;59(2 Suppl 1):S25-7.
2029. Rehnberg M, Amu S, Tarkowski A, et al. Short- and long-term effects of anti-CD20 treatment on B cell ontogeny in bone marrow of patients with rheumatoid arthritis. *Arthritis Res Ther*. 2009;11(4):R123.
2030. Rehnberg M, Brisslert M, Amu S, et al. Vaccination response to protein and carbohydrate antigens in patients with rheumatoid arthritis after rituximab treatment. *Arthritis Res Ther*. 2010;12(3):R111.
2031. Reitman CA, Lidsky MD, Heggeness MH. Neurologic and morphologic features of dural ectasia in ankylosing spondylitis and rheumatoid arthritis: a case report. *Am J Orthop*. 2006 Nov;35(11):530-1.
2032. Rejon E, Gimenez MD, Mayordomo L, et al. Therapeutic efficacy and safety of multiple intravenous infusions of infliximab in refractory ankylosing spondylitis patients with axial involvement. *Scand J Rheumatol*. 2004;33(5):323-6.
2033. Ren H, Wang WM, Chen XN, et al. Renal involvement and followup of 130 patients with primary Sjogren's syndrome. *J Rheumatol*. 2008 Feb;35(2):278-84.
2034. Renato GM. B cell depletion in early rheumatoid arthritis: a new concept in therapeutics. *Ann N Y Acad Sci*. 2009 Sep;1173:729-35.
2035. Resmini E, Farkas C, Murillo B, et al. Body composition after endogenous (Cushing's syndrome) and exogenous (rheumatoid arthritis) exposure to glucocorticoids. *Horm Metab Res*. 2010 Jul;42(8):613-8.
2036. Ribbens C, Andre B, Marcelis S, et al. Rheumatoid hand joint synovitis: gray-scale and power Doppler US quantifications following anti-tumor necrosis factor-alpha treatment: pilot study. *Radiology*. 2003 Nov;229(2):562-9.
2037. Ribbens C, Martin y Porras M, Franchimont N, et al. Increased matrix metalloproteinase-3 serum levels in rheumatic diseases: relationship with synovitis and steroid treatment. *Ann Rheum Dis*. 2002 Feb;61(2):161-6.

2038. Richards BL, Spies J, McGill N, et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. *Intern Med J.* 2007 Feb;37(2):101-7.
2039. Rchette P, Dieude P, Damiano J, et al. Sensory neuropathy revealing necrotizing vasculitis during infliximab therapy for rheumatoid arthritis. *J Rheumatol.* 2004 Oct;31(10):2079-81.
2040. Rchette P, Francois M, Vicaut E, et al. A high interleukin 1 receptor antagonist/IL-1beta ratio occurs naturally in knee osteoarthritis. *J Rheumatol.* 2008 Aug;35(8):1650-4.
2041. Richez C, Blanco P, Lagueny A, et al. Neuropathy resembling CIDP in patients receiving tumor necrosis factor-alpha blockers. *Neurology.* 2005 Apr 26;64(8):1468-70.
2042. Richez C, Dumoulin C, Schaefferbeke T. Infliximab induced chilblain lupus in a patient with rheumatoid arthritis. *J Rheumatol.* 2005 Apr;32(4):760-1.
2043. Richter C, Wanke L, Steinmetz J, et al. Mononeuritis secondary to rheumatoid arthritis responds to etanercept. *Rheumatology (Oxford).* 2000 Dec;39(12):1436-7.
2044. Richter J, Benson V, Grobarova V, et al. CD161 receptor participates in both impairing NK cell cytotoxicity and the response to glycans and vimentin in patients with rheumatoid arthritis. *Clin Immunol.* 2010 Jul;136(1):139-47.
2045. Riepl B, Grassel S, Wiest R, et al. Tumor necrosis factor and norepinephrine lower the levels of human neutrophil peptides 1-3 secretion by mixed synovial tissue cultures in osteoarthritis and rheumatoid arthritis. *Arthritis Res Ther.* 2010;12(3):R110.
2046. Rihl M, Kruihof E, Barthel C, et al. Involvement of neurotrophins and their receptors in spondyloarthritis synovitis: relation to inflammation and response to treatment. *Ann Rheum Dis.* 2005 Nov;64(11):1542-9.
2047. Rihl M, Ulbricht K, Schmidt RE, et al. Treatment of sicca symptoms with hydroxychloroquine in patients with Sjogren's syndrome. *Rheumatology (Oxford).* 2009 Jul;48(7):796-9.
2048. Riise T, Jacobsen BK, Gran JT. Changes in therapy of rheumatoid arthritis during the period 1979 to 1996. *Scand J Rheumatol.* 2001;30(4):199-202.
2049. Rijkeboer A, Voskuyl A, Van Agtmael M. Fatal Salmonella enteritidis septicaemia in a rheumatoid arthritis patient treated with a TNF-alpha antagonist. *Scand J Infect Dis.* 2007;39(1):80-3.
2050. Rimar D, Rozenbaum M, Slobodin G, et al. Etanercept related pseudo-empyema in rheumatoid arthritis. *Clin Rheumatol* 2010;29(5):547-9.
2051. Rinaldi F, Provenzano G, Termini A, et al. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response. *Ann Rheum Dis.* 2005 Sep;64(9):1375-6.
2052. Rindfleisch JA, Muller D. Diagnosis and management of rheumatoid arthritis. *Am Fam Physician.* 2005 Sep 15;72(6):1037-47.
2053. Rivers JK, Podgorski MR, Goulding NJ, et al. The presence of autoantibody to recombinant lipocortin-I in patients with psoriasis and psoriatic arthritis. *Br J Dermatol.* 1990 Nov;123(5):569-72.
2054. Rizzo R, Rubini M, Govoni M, et al. HLA-G 14-bp polymorphism regulates the methotrexate response in rheumatoid arthritis. *Pharmacogenet Genomics.* 2006 Sep;16(9):615-23.
2055. Rodrigues K, Neves FS, Stoeterau KB, et al. Pulmonary amyloidosis in Sjogren's syndrome: a rare diagnosis for nodular lung lesions. *Int J Rheum Dis.* 2009 Dec;12(4):358-60.
2056. Rodriguez-Escalera C, Belzunegui J, Lopez-Dominguez L, et al. Multifocal motor neuropathy with conduction block in a patient with rheumatoid arthritis on infliximab therapy. *Rheumatology (Oxford).* 2005 Jan;44(1):132-3.
2057. Rodriguez-Padilla JA, Hedges TR, 3rd, Monson B, et al. High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathy. *Arch Ophthalmol.* 2007 Jun;125(6):775-80.



2058. Rokhsar C, Rabhan N, Cohen SR. Etanercept monotherapy for a patient with psoriasis, psoriatic arthritis, and concomitant hepatitis C infection. *J Am Acad Dermatol*. 2006 Feb;54(2):361-2.
2059. Roll P, Dorner T, Tony HP. Anti-CD20 therapy in patients with rheumatoid arthritis: predictors of response and B cell subset regeneration after repeated treatment. *Arthritis Rheum*. 2008 Jun;58(6):1566-75.
2060. Roll P, Palanichamy A, Kneitz C, et al. Regeneration of B cell subsets after transient B cell depletion using anti-CD20 antibodies in rheumatoid arthritis. *Arthritis Rheum*. 2006 Aug;54(8):2377-86.
2061. Rooryck C, Barnette T, Richez C, et al. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. *Clin Exp Rheumatol*. 2008 Mar-Apr;26(2):340-2.
2062. Roos JC, Ostor AJ. Orbital cellulitis in a patient receiving infliximab for Ankylosing spondylitis. *Am J Ophthalmol*. 2006 Apr;141(4):767-9.
2063. Rosenvinge A, Krogh-Madsen R, Baslund B, et al. Insulin resistance in patients with rheumatoid arthritis: effect of anti-TNFalpha therapy. *Scand J Rheumatol*. 2007 Mar-Apr;36(2):91-6.
2064. Rosmarin D, Bush M, Scheinman PL. Patch testing a patient with allergic contact hand dermatitis who is taking infliximab. *J Am Acad Dermatol*. 2008 Jul;59(1):145-7.
2065. Roth EB, Stenberg P, Book C, et al. Antibodies against transglutaminases, peptidylarginine deiminase and citrulline in rheumatoid arthritis--new pathways to epitope spreading. *Clin Exp Rheumatol*. 2006 Jan-Feb;24(1):12-8.
2066. Roth S. Effects of Proserba column apheresis in patients with chronic refractory rheumatoid arthritis. *J Rheumatol*. 2004 Nov;31(11):2131-5.
2067. Roubenoff R, Roubenoff RA, Ward LM, et al. Catabolic effects of high-dose corticosteroids persist despite therapeutic benefit in rheumatoid arthritis. *Am J Clin Nutr*. 1990 Dec;52(6):1113-7.
2068. Roux CH, Brocq O, Albert CBV, et al. Cutaneous vasculitis and glomerulonephritis in a patient taking the anti-TNF alpha agent etanercept for rheumatoid arthritis. *Joint Bone Spine*. 2004 Sep;71(5):444-5.
2069. Roux N, Flipo RM, Cortet B, et al. Pneumocystis carinii pneumonia in rheumatoid arthritis patients treated with methotrexate. A report of two cases. *Rev Rhum Engl Ed*. 1996 Jun;63(6):453-6.
2070. Roux-Lombard P, Eberhardt K, Saxne T, et al. Cytokines, metalloproteinases, their inhibitors and cartilage oligomeric matrix protein: relationship to radiological progression and inflammation in early rheumatoid arthritis. A prospective 5-year study. *Rheumatology (Oxford)*. 2001 May;40(5):544-51.
2071. Rovensky J, Bakosova J, Koska J, et al. Somatotropic, lactotropic and adrenocortical responses to insulin-induced hypoglycemia in patients with rheumatoid arthritis. *Ann N Y Acad Sci*. 2002 Jun;966:263-70.
2072. Rovensky J, Bakosova J, Payer J, et al. Increased demand for steroid therapy in hyperprolactinemic patients with rheumatoid arthritis. *Int J Tissue React*. 2001;23(4):145-9.
2073. Rovensky J, Imrich R, Koska J, et al. Cortisol elimination from plasma in premenopausal women with rheumatoid arthritis. *Ann Rheum Dis*. 2003 Jul;62(7):674-6.
2074. Rovensky J, Radikova Z, Imrich R, et al. Gonadal and adrenal steroid hormones in plasma and synovial fluid of patients with rheumatoid arthritis. *Endocr Regul*. 2004 Dec;38(4):143-9.
2075. Rovensky J, Simorova E, Radikova Z, et al. Comparison of hormone transfer to pleural and synovial exudates. *Endocr Regul*. 2006 Jun;40(2):29-36.
2076. Rovere Querini P, Vecellio M, Sabbadini MG, et al. Miliary tuberculosis after biological therapy for rheumatoid arthritis. *Rheumatology (Oxford)*. 2002 Feb;41(2):231.

2077. Roy A, Mould DR, Wang XF, et al. Modeling and simulation of abatacept exposure and interleukin-6 response in support of recommended doses for rheumatoid arthritis. *J Clin Pharmacol*. 2007 Nov;47(11):1408-20.
2078. Roy DB, Conte ET, Cohen DJ. The treatment of pyoderma gangrenosum using etanercept. *J Am Acad Dermatol*. 2006 Mar;54(3 Suppl 2):S128-34.
2079. Rozenbaum M, Boulman N, Slobodin G, et al. Polyarthritis flare complicating rheumatoid arthritis infliximab therapy: a paradoxical adverse reaction. *J Clin Rheumatol*. 2006 Dec;12(6):269-71.
2080. Rozenbaum M, Rosner I, Portnoy E. Remission of Behcet's syndrome with TNFalpha blocking treatment. *Ann Rheum Dis*. 2002 Mar;61(3):283-4.
2081. Ruderman EM, Pope RM. The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. *Arthritis Res Ther*. 2005;7 Suppl 2:S21-5.
2082. Rudwaleit M, Baraliakos X, Listing J, et al. Magnetic resonance imaging of the spine and the sacroiliac joints in ankylosing spondylitis and undifferentiated spondyloarthritis during treatment with etanercept. *Ann Rheum Dis*. 2005 Sep;64(9):1305-10.
2083. Rudwaleit M, Listing J, Brandt J, et al. Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor alpha blockers in ankylosing spondylitis. *Ann Rheum Dis*. 2004 Jun;63(6):665-70.
2084. Rudwaleit M, Van den Bosch F, Kron M, et al. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. *Arthritis Res Ther*. 2010;12(3):R117.
2085. Ruppert M, De Clerck L, van Offel J, et al. Intestinal necrosis in a patient with rheumatoid arthritis receiving anti-TNF treatment. *Acta Chir Belg*. 2006 Mar-Apr;106(2):225-7.
2086. Russell A, Haraoui B, Keystone E, et al. Current and emerging therapies for rheumatoid arthritis, with a focus on infliximab: clinical impact on joint damage and cost of care in Canada. *Clin Ther*. 2001 Nov;23(11):1824-38; discussion 791.
2087. Russell E, Zeihen M, Wergin S, et al. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays. *Arthritis Rheum*. 2000 Apr;43(4):944.
2088. Ruysse-Witrand A, Gossec L, Salliot C, et al. Complication rates of 127 surgical procedures performed in rheumatic patients receiving tumor necrosis factor alpha blockers. *Clin Exp Rheumatol*. 2007 May-Jun;25(3):430-6.
2089. Saad AA, Ashcroft DM, Watson KD, et al. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. *Arthritis Care Res (Hoboken)* 2010;62(3):345-53.
2090. Saad AA, Symmons DP, Noyce PR, et al. Risks and benefits of tumor necrosis factor-alpha inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. *J Rheumatol*. 2008 May;35(5):883-90.
2091. Saadeh C, Saadeh C. Asthma remission in a patient with rheumatoid arthritis while on antiangiogenesis therapy during a rheumatoid arthritis trial demonstrated by forced oscillation and spirometry. *J Asthma*. 2007 May;44(4):281-3.
2092. Saag KG, Koehnke R, Caldwell JR, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. *Am J Med*. 1994 Feb;96(2):115-23.
2093. Saario R, Sonninen P, Mottonen T, et al. Bone mineral density of the lumbar spine in patients with advanced rheumatoid arthritis. Influence of functional capacity and corticosteroid use. *Scand J Rheumatol*. 1999;28(6):363-7.
2094. Saba NS, Kousseifi SG, Charaf EA, et al. Adalimumab-induced acute myelogenous leukemia. *South Med J*. 2008 Dec;101(12):1261-2.

2095. Saber TP, Ng CT, Renard G, et al. Remission in psoriatic arthritis: is it possible and how can it be predicted? *Arthritis Res Ther.* 2010;12(3):R94.
2096. Saeki Y, Ohshima S, Ishida T, et al. Remission of the renal involvement in a patient with primary Sjogren's syndrome (SS) after pulse high-dose corticosteroid infusion therapy. *Clin Rheumatol.* 2001;20(3):225-8.
2097. Saeki Y, Ohshima S, Mima T, et al. Suboptimal clinical response to anti-tumor necrosis factor alpha (TNFalpha) antibody therapy in a patient with severe rheumatoid arthritis and lymphadenopathy. *Scand J Rheumatol.* 1998;27(4):303-5.
2098. Sahin M, Keskin M, Tunc SE, et al. Kaposi's sarcoma complicating rheumatoid arthritis treated with corticosteroid Kaposi's sarcoma and rheumatoid arthritis. *Saudi Med J.* 2007 Jul;28(7):1133-4.
2099. Saiki O, Takao R, Naruse Y, et al. Infliximab but not methotrexate induces extra-high levels of VLDL-triglyceride in patients with rheumatoid arthritis. *J Rheumatol.* 2007 Oct;34(10):1997-2004.
2100. Saint Marcoux B, De Bandt M. Vasculitides induced by TNFalpha antagonists: a study in 39 patients in France. *Joint Bone Spine.* 2006 Dec;73(6):710-3.
2101. Saito S, Momohara S, Taniguchi A, et al. The intra-articular efficacy of hyaluronate injections in the treatment of rheumatoid arthritis. *Mod Rheumatol.* 2009;19(6):643-51.
2102. Sakai K, Hamaguchi T, Yamada M. Multiple cranial nerve enhancement on MRI in primary Sjogren's syndrome. *Intern Med.* 2010;49(9):857-9.
2103. Sakai Y, Sakai S, Otsuka T, et al. Efficacy of high-throughput leukocytapheresis for rheumatoid arthritis with a reduced response to infliximab. *Ther Apher Dial.* 2009 Jun;13(3):179-85.
2104. Sakamoto O, Saita N, Ando M, et al. Two cases of Sjogren's syndrome with multiple bullae. *Intern Med.* 2002 Feb;41(2):124-8.
2105. Sakaura H, Hosono N, Mukai Y, et al. Paraparesis due to exacerbation of preexisting spinal pseudoarthrosis following infliximab therapy for advanced ankylosing spondylitis. *Spine J.* 2006 May-Jun;6(3):325-9.
2106. Sakellariou GT, Vounotrypidis P, Berberidis C. Infliximab treatment in two patients with psoriatic arthritis and secondary IgA nephropathy. *Clin Rheumatol.* 2007 Jul;26(7):1132-3.
2107. Salamon L, Salamon T, Morovic-Vergles J. Thrombotic microangiopathy in adult-onset Still's disease: case report and review of the literature. *Wien Klin Wochenschr.* 2009;121(17-18):583-8.
2108. Saleem B, Brown AK, Keen H, et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study. *Arthritis Rheum* 2009;60(7):1915-22.
2109. Saleem B, Mackie S, Quinn M, et al. Does the use of tumour necrosis factor antagonist therapy in poor prognosis, undifferentiated arthritis prevent progression to rheumatoid arthritis? *Ann Rheum Dis.* 2008 Aug;67(8):1178-80.
2110. Saleem G, Li SC, MacPherson BR, et al. Hepatitis with interface inflammation and IgG, IgM, and IgA anti-double-stranded DNA antibodies following infliximab therapy: comment on the article by Charles et al. *Arthritis Rheum.* 2001 Aug;44(8):1966-8.
2111. Salli A, Sahin N, Paksoy Y, et al. Treatment of periodontoid pannus with infliximab in a patient with rheumatoid arthritis. *J Clin Rheumatol.* 2009 Aug;15(5):250-1.
2112. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. *Ann Rheum Dis* 2009;68(1):25-32.
2113. Salliot C, van der Heijde D. Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. *Ann Rheum Dis.* 2009 Jul;68(7):1100-4.

2114. Salloum E, Cooper DL, Howe G, et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. *J Clin Oncol*. 1996 Jun;14(6):1943-9.
2115. Salvarani C, Cantini F, Olivieri I, et al. Efficacy of infliximab in resistant psoriatic arthritis. *Arthritis Rheum*. 2003 Aug 15;49(4):541-5.
2116. Salvarani C, Cantini F, Olivieri I, et al. Distal extremity swelling with pitting edema in psoriatic arthritis: evidence of 2 pathological mechanisms. *J Rheumatol*. 1999 Aug;26(8):1831-4.
2117. Samanta J, Kendall J, Samanta A. Polyarthralgia. *BMJ*. 2003 Apr 19;326(7394):859.
2118. Sambrook P, Birmingham J, Champion D, et al. Postmenopausal bone loss in rheumatoid arthritis: effect of estrogens and androgens. *J Rheumatol*. 1992 Mar;19(3):357-61.
2119. Sanchez A, Maximiano C, Cantos B, et al. Neurological symptoms simulating cord compression in breast cancer patient. *J Neurooncol*. 2005 Apr;72(2):149-50.
2120. Sanchez G, Castro JS, Snih SA, et al. Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. *Rheumatol Int*. 2007 Apr;27(6):531-6.
2121. Sandler C, Lindstedt KA, Joutsiniemi S, et al. Selective activation of mast cells in rheumatoid synovial tissue results in production of TNF-alpha, IL-1beta and IL-1Ra. *Inflamm Res*. 2007 Jun;56(6):230-9.
2122. Sankar V, Brennan MT, Kok MR, et al. Etanercept in Sjogren's syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. *Arthritis Rheum*. 2004 Jul;50(7):2240-5.
2123. Sanmarti R, Gomez-Centeno A, Ercilla G, et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. *Clin Rheumatol*. 2007 Jul;26(7):1111-8.
2124. Sano H, Arai K, Murai T, et al. Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1 year. *Mod Rheumatol*. 2009;19(4):390-4.
2125. Santiago-Casas Y, Gonzalez-Rivera TC, Castro-Santana LE, et al. Impact of age on clinical manifestations and outcome in Puerto Ricans with rheumatoid arthritis. *Ethn Dis*. 2010 Winter;20(1 Suppl 1):S1-191-5.
2126. Santos-Ocampo AS, Santos-Ocampo RS. Non-contrast computed tomography-guided intra-articular corticosteroid injections of severe bilateral hip arthritis in a patient with ankylosing spondylitis. *Clin Exp Rheumatol*. 2003 Mar-Apr;21(2):239-40.
2127. Sany J, Bourgeois P, Saraux A, et al. Characteristics of patients with rheumatoid arthritis in France: a study of 1109 patients managed by hospital based rheumatologists. *Ann Rheum Dis*. 2004 Oct;63(10):1235-40.
2128. Sany J, Cohen JD, Combescure C, et al. Medico-economic evaluation of infliximab in rheumatoid arthritis--prospective French study of a cohort of 635 patients monitored for two years. *Rheumatology (Oxford)*. 2009 Oct;48(10):1236-41.
2129. Sany J, Kaiser MJ, Jorgensen C, et al. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. *Ann Rheum Dis*. 2005 Nov;64(11):1647-9.
2130. Sanz I, Anolik J. Reconstitution of the adult B cell repertoire after treatment with rituximab. *Arthritis Res Ther*. 2005;7(5):175-6.
2131. Saraux A, Devauchelle-Pensec V, Engerran L, et al. Most rheumatologists are conservative in active rheumatoid arthritis despite methotrexate therapy: results of the PRISME survey. *J Rheumatol*. 2006 Jul;33(7):1258-65.
2132. Sari I, Akar S, Birlik M, et al. Anti-tumor necrosis factor-alpha-induced psoriasis. *J Rheumatol*. 2006 Jul;33(7):1411-4.

2133. Saruhan-Direskeneli G, Inanc M, Fresko I, et al. The role of HLA-DRB1 shared epitope alleles in predicting short-term response to leflunomide in rheumatoid arthritis. *Rheumatology (Oxford)*. 2007 Dec;46(12):1842-4.
2134. Sarzi-Puttini P, Antivalle M, Marchesoni A, et al. Efficacy and safety of anti-TNF agents in the Lombardy rheumatoid arthritis network (LORHEN). *Reumatismo*. 2008 Oct-Dec;60(4):290-5.
2135. Sarzi-Puttini P, Atzeni F, Scholmerich J, et al. Anti-TNF antibody treatment improves glucocorticoid induced insulin-like growth factor 1 (IGF1) resistance without influencing myoglobin and IGF1 binding proteins 1 and 3. *Ann Rheum Dis*. 2006 Mar;65(3):301-5.
2136. Sato H, Kazama JJ, Wada Y, et al. Decreased levels of circulating alpha2-Heremans-Schmid glycoprotein/Fetuin-A (AHSG) in patients with rheumatoid arthritis. *Intern Med*. 2007;46(20):1685-91.
2137. Sato H, Sakai T, Sugaya T, et al. Tocilizumab dramatically ameliorated life-threatening diarrhea due to secondary amyloidosis associated with rheumatoid arthritis. *Clin Rheumatol*. 2009 Sep;28(9):1113-6.
2138. Sato M, Takeda A, Honzu H, et al. Adult Still's disease with Sjogren's syndrome successfully treated with intravenous pulse methylprednisolone and oral cyclophosphamide. *Intern Med*. 1993 Sep;32(9):730-2.
2139. Sato T, Inokuma S, Sagawa A, et al. Factors associated with fatal outcome of leflunomide-induced lung injury in Japanese patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2009 Oct;48(10):1265-8.
2140. Satoh K, Yoshida N, Imaizumi K, et al. Reversible methotrexate-associated lymphoproliferative disorder resembling advanced gastric cancer in a patient with rheumatoid arthritis. *Am J Med Sci*. 2009 Oct;338(4):334-5.
2141. Saunders SA, Capell HA, Stirling A, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. *Arthritis Rheum* 2008;58(5):1310-7.
2142. Saviola G, Abdi Ali L, Shams Eddin S, et al. Compared clinical efficacy and bone metabolic effects of low-dose deflazacort and methyl prednisolone in male inflammatory arthropathies: a 12-month open randomized pilot study. *Rheumatology (Oxford)*. 2007 Jun;46(6):994-8.
2143. Saxne T, Larsson L, Geborek P. Results of anakinra treatment in rheumatoid arthritis patients previously treated with tumor necrosis factor alpha blockade: comment on the article by Buch et al. *Arthritis Rheum*. 2004 Sep;50(9):3049-50; author reply 50-1.
2144. Scali JJ, Visentini S, Salomon J, et al. Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants. *Ann N Y Acad Sci*. 2007 Sep;1110:389-401.
2145. Scarpa R, Peluso R, Attenu M, et al. The effectiveness of a traditional therapeutical approach in early psoriatic arthritis: results of a pilot randomised 6-month trial with methotrexate. *Clin Rheumatol*. 2008 Jul;27(7):823-6.
2146. Scarsi M, Ziglioli T, Airo P. Decreased circulating CD28-negative T cells in patients with rheumatoid arthritis treated with abatacept are correlated with clinical response. *J Rheumatol*. 2010 May;37(5):911-6.
2147. Schafer JA, Kjesbo NK, Gleason PP. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. *J Manag Care Pharm*. 2010 Jul-Aug;16(6):402-16.
2148. Schalk E, Krogel C, Scheinpflug K, et al. Lymphomatoid granulomatosis in a patient with rheumatoid arthritis receiving methotrexate: successful treatment with the anti-CD20 antibody mabthera. *Onkologie*. 2009 Jul;32(7):440-1.
2149. Schapira D, Militeanu D, Israel O, et al. Insufficiency fractures of the pubic ramus. *Semin Arthritis Rheum*. 1996 Jun;25(6):373-82.

2150. Scharf SL, Christophidis N. Second-line agents for rheumatoid arthritis. *Med J Aust.* 1995 Aug 21;163(4):215-8.
2151. Schatteman L, Gyselbrecht L, De Clercq L, et al. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab. *J Rheumatol.* 2006 Jan;33(1):82-5.
2152. Scheinberg M, Guedes-Barbosa LS, Mangueira C, et al. Yellow fever revaccination during infliximab therapy. *Arthritis Care Res (Hoboken)* 2010;62(6):896-8.
2153. Scheinberg M, Hamerschlak N, Kutner JM, et al. Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004). *Clin Exp Rheumatol.* 2006 Jan-Feb;24(1):65-9.
2154. Scheinfeld N. Menorrhagia and severe menstrual pain related to the use of adalimumab in a psoriatic. *J Dermatolog Treat.* 2008;19(3):188-9.
2155. Scherak O, Popp W, Kolarz G, et al. Bronchoalveolar lavage and lung biopsy in rheumatoid arthritis. In vivo effects of disease modifying antirheumatic drugs. *J Rheumatol.* 1993 Jun;20(6):944-9.
2156. Schett G, Herak P, Graninger W, et al. Listeria-associated arthritis in a patient undergoing etanercept therapy: case report and review of the literature. *J Clin Microbiol.* 2005 May;43(5):2537-41.
2157. Schiff M, Keiserman M, Codding C, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Ann Rheum Dis* 2008;67(8):1096-103.
2158. Schiff MH, DiVittorio G, Tesser J, et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. *Arthritis Rheum.* 2004 Jun;50(6):1752-60.
2159. Schipper LG, Fransen J, Barrera P, et al. Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add? *Rheumatology (Oxford)* 2009;48(10):1247-53.
2160. Schipper LG, Fransen J, Barrera P, et al. Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs. *Rheumatology (Oxford)* 2009;48(7):828-33.
2161. Schirren CA, Zchoval R, Schirren CG, et al. A role for chronic hepatitis C virus infection in a patient with cutaneous vasculitis, cryoglobulinemia, and chronic liver disease. Effective therapy with interferon-alpha. *Dig Dis Sci.* 1995 Jun;40(6):1221-5.
2162. Schlaghecke R, Beuscher D, Kornely E, et al. Effects of glucocorticoids in rheumatoid arthritis. Diminished glucocorticoid receptors do not result in glucocorticoid resistance. *Arthritis Rheum.* 1994 Aug;37(8):1127-31.
2163. Schlaghecke R, Kornely E, Wollenhaupt J, et al. Glucocorticoid receptors in rheumatoid arthritis. *Arthritis Rheum.* 1992 Jul;35(7):740-4.
2164. Schmeling H, Horneff G. Infliximab in two patients with juvenile ankylosing spondylitis. *Rheumatol Int.* 2004 May;24(3):173-6.
2165. Schmeling H, Horneff G. Etanercept and uveitis in patients with juvenile idiopathic arthritis. *Rheumatology (Oxford).* 2005 Aug;44(8):1008-11.
2166. Schmid L, Muller M, Treumann T, et al. Induction of complete and sustained remission of rheumatoid pachymeningitis by rituximab. *Arthritis Rheum.* 2009 Jun;60(6):1632-4.
2167. Schmidt M, Hartung R, Capellino S, et al. Estrone/17beta-estradiol conversion to, and tumor necrosis factor inhibition by, estrogen metabolites in synovial cells of patients with rheumatoid arthritis and patients with osteoarthritis. *Arthritis Rheum.* 2009 Oct;60(10):2913-22.
2168. Schmidt M, Weidler C, Naumann H, et al. Reduced capacity for the reactivation of glucocorticoids in rheumatoid arthritis synovial cells: possible role of the sympathetic nervous system? *Arthritis Rheum.* 2005 Jun;52(6):1711-20.

2169. Schneeweiss S, Setoguchi S, Weinblatt ME, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. *Arthritis Rheum* 2007;56(6):1754-64.
2170. Schneider SW, Staender S, Schluter B, et al. Infliximab-induced lupus erythematosus tumidus in a patient with rheumatoid arthritis. *Arch Dermatol*. 2006 Jan;142(1):115-6.
2171. Schoels M, Aletaha D, Funovits J, et al. Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. *Ann Rheum Dis*. 2010 Aug;69(8):1441-7.
2172. Schoels M, Kapral T, Stamm T, et al. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study. *Ann Rheum Dis* 2007;66(8):1059-65.
2173. Schotte H, Schluter B, Drynda S, et al. Interleukin 10 promoter microsatellite polymorphisms are associated with response to long term treatment with etanercept in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2005 Apr;64(4):575-81.
2174. Schotte H, Schluter B, Willeke P, et al. Long-term treatment with etanercept significantly reduces the number of proinflammatory cytokine-secreting peripheral blood mononuclear cells in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2004 Aug;43(8):960-4.
2175. Schramm C, Schneider A, Marx A, et al. Adalimumab could suppress the activity of non alcoholic steatohepatitis (NASH). *Z Gastroenterol*. 2008 Dec;46(12):1369-71.
2176. Schuh A, Zeiler G, Holzwarth U, et al. Malignant fibrous histiocytoma at the site of a total hip arthroplasty. *Clin Orthop Relat Res*. 2004 Aug;425:218-22.
2177. Schumacher HR, Chen LX. Injectable corticosteroids in treatment of arthritis of the knee. *Am J Med*. 2005 Nov;118(11):1208-14.
2178. Schwartz JI, Agrawal NG, Wong PH, et al. Examination of the effect of increasing doses of etoricoxib on oral methotrexate pharmacokinetics in patients with rheumatoid arthritis. *J Clin Pharmacol*. 2009 Oct;49(10):1202-9.
2179. Schwetz BA. From the Food and Drug Administration. *JAMA*. 2002 Mar 6;287(9):1103.
2180. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. *N Engl J Med*. 2006 Aug 17;355(7):704-12.
2181. Scrivo R, Conti F, Spinelli FR, et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. *Reumatismo*. 2009 Apr-Jun;61(2):107-17.
2182. Scuderi F, Convertino R, Molino N, et al. Effect of pro-inflammatory/anti-inflammatory agents on cytokine secretion by peripheral blood mononuclear cells in rheumatoid arthritis and systemic lupus erythematosus. *Autoimmunity*. 2003 Mar;36(2):71-7.
2183. Seidl C, Donner H, Fischer B, et al. CTLA4 codon 17 dimorphism in patients with rheumatoid arthritis. *Tissue Antigens*. 1998 Jan;51(1):62-6.
2184. Seitz CS, Berens N, Brocker EB, et al. Leg ulceration in rheumatoid arthritis--an underreported multicausal complication with considerable morbidity: analysis of thirty-six patients and review of the literature. *Dermatology*. 2010;220(3):268-73.
2185. Seitz M, Loetscher P, Dewald B, et al. Production of interleukin-1 receptor antagonist, inflammatory chemotactic proteins, and prostaglandin E by rheumatoid and osteoarthritic synoviocytes--regulation by IFN-gamma and IL-4. *J Immunol*. 1994 Feb 15;152(4):2060-5.
2186. Seitz M, Zwicker M, Villiger PM. Pretreatment cytokine profiles of peripheral blood mononuclear cells and serum from patients with rheumatoid arthritis in different american college of rheumatology response groups to methotrexate. *J Rheumatol*. 2003 Jan;30(1):28-35.

2187. Sekigawa I, Yanagida M, Iwabuchi K, et al. Protein biomarker analysis by mass spectrometry in patients with rheumatoid arthritis receiving anti-tumor necrosis factor-alpha antibody therapy. *Clin Exp Rheumatol*. 2008 Mar-Apr;26(2):261-7.
2188. Sekiguchi N, Kawauchi S, Furuya T, et al. Messenger ribonucleic acid expression profile in peripheral blood cells from RA patients following treatment with an anti-TNF-alpha monoclonal antibody, infliximab. *Rheumatology (Oxford)*. 2008 Jun;47(6):780-8.
2189. Sekiya H, Horii T, Kariya Y, et al. Arthroscopic-assisted tibiototalcaneal arthrodesis using an intramedullary nail with fins: a case report. *J Foot Ankle Surg*. 2006 Jul-Aug;45(4):266-70.
2190. Sellam J, Bouvard B, Masson C, et al. Use of infliximab to treat psoriatic arthritis in HIV-positive patients. *Joint Bone Spine*. 2007 Mar;74(2):197-200.
2191. Semmler M, Seeck U, Neustadt B, et al. No effects of adalimumab therapy on the activation of NF-kappaB in lymphocytes from patients with severe rheumatoid arthritis. *Clin Rheumatol*. 2007 Sep;26(9):1499-504.
2192. Sennels H, Sorensen S, Ostergaard M, et al. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. *Scand J Rheumatol*. 2008 Jul-Aug;37(4):241-7.
2193. Seong SS, Choi CB, Woo JH, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. *J Rheumatol*. 2007 Apr;34(4):706-11.
2194. Serelis J, Kontogianni MD, Katsiogiannis S, et al. Effect of anti-TNF treatment on body composition and serum adiponectin levels of women with rheumatoid arthritis. *Clin Rheumatol*. 2008 Jun;27(6):795-7.
2195. Seriola B, Ferretti V, Sulli A, et al. Serum prolactin concentrations in male patients with rheumatoid arthritis. *Ann N Y Acad Sci*. 2002 Jun;966:258-62.
2196. Seriola B, Paolino S, Sulli A, et al. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. *Ann N Y Acad Sci*. 2006 Jun;1069:414-9.
2197. Seriola B, Paolino S, Sulli A, et al. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. *Ann N Y Acad Sci*. 2006 Jun;1069:420-7.
2198. Seror P, Pluvinage P, d'Andre FL, et al. Frequency of sepsis after local corticosteroid injection (an inquiry on 1160000 injections in rheumatological private practice in France). *Rheumatology (Oxford)*. 1999 Dec;38(12):1272-4.
2199. Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and changes in serum B cell biomarkers in patients with systemic complications of primary Sjogren's syndrome. *Ann Rheum Dis*. 2007 Mar;66(3):351-7.
2200. Serratrice J, Granel B, Disdier P, et al. Resolution with etanercept of nephrotic syndrome due to renal AA amyloidosis in adult Still's disease. *Am J Med*. 2003 Nov;115(7):589-90.
2201. Setoguchi S, Schneeweiss S, Avorn J, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. *Am Heart J* 2008;156(2):336-41.
2202. Seton M. Giant cell arteritis in a patient taking etanercept and methotrexate. *J Rheumatol*. 2004 Jul;31(7):1467.
2203. Settas LD, Tsimirikas G, Vosvotekas G, et al. Reactivation of pulmonary tuberculosis in a patient with rheumatoid arthritis during treatment with IL-1 receptor antagonists (anakinra). *J Clin Rheumatol*. 2007 Aug;13(4):219-20.
2204. Settergren M, Tornvall P. Does TNF-alpha blockade cause plaque rupture? *Atherosclerosis*. 2004 Mar;173(1):149.
2205. Sfikakis PP. The first decade of biologic TNF antagonists in clinical practice: lessons learned, unresolved issues and future directions. *Curr Dir Autoimmun*. 2010;11:180-210.



2206. Sfikakis PP, Iliopoulos A, Elezoglou A, et al. Psoriasis induced by anti-tumor necrosis factor therapy: a paradoxical adverse reaction. *Arthritis Rheum.* 2005 Aug;52(8):2513-8.
2207. Shadick NA, Fanta CH, Weinblatt ME, et al. Bronchiectasis. A late feature of severe rheumatoid arthritis. *Medicine (Baltimore).* 1994 May;73(3):161-70.
2208. Shakiba K, Falcone T. Tumour necrosis factor-alpha blockers: potential limitations in the management of advanced endometriosis? A case report. *Hum Reprod.* 2006 Sep;21(9):2417-20.
2209. Shakoor N, Michalska M, Harris CA, et al. Drug-induced systemic lupus erythematosus associated with etanercept therapy. *Lancet.* 2002 Feb 16;359(9306):579-80.
2210. Shan SJ, Wu EI, Akpek EK. Sterile corneal melt after descemet stripping endothelial keratoplasty in patients with previously undiagnosed Sjogren syndrome. *Arch Ophthalmol.* 2009 Feb;127(2):219-20.
2211. Sharma A, Baethge BA, Acebes JC, et al. Arthroscopic lavage treatment in rheumatoid arthritis of the knee. *J Rheumatol.* 1996 Nov;23(11):1872-4.
2212. Sharma S, Das M, Kumar A, et al. Interaction of genes from influx-metabolism-efflux pathway and their influence on methotrexate efficacy in rheumatoid arthritis patients among Indians. *Pharmacogenet Genomics.* 2008 Dec;18(12):1041-9.
2213. Sharma S, Das M, Kumar A, et al. Purine biosynthetic pathway genes and methotrexate response in rheumatoid arthritis patients among north Indians. *Pharmacogenet Genomics.* 2009 Oct;19(10):823-8.
2214. Shastri V, Betkerur J, Kushalappa PA, et al. Severe cutaneous adverse drug reaction to leflunomide: a report of five cases. *Indian J Dermatol Venereol Leprol.* 2006 Jul-Aug;72(4):286-9.
2215. Shawe D, Hesp R, Gumpel JM, et al. Physical activity as a determinant of bone conservation in the radial diaphysis in rheumatoid arthritis. *Ann Rheum Dis.* 1993 Aug;52(8):579-81.
2216. Shbeeb M, Uramoto KM, Gibson LE, et al. The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982-1991. *J Rheumatol.* 2000 May;27(5):1247-50.
2217. Shedd AD, Reddy SG, Meffert JJ, et al. Acute onset of rash and oligoarthritis. *J Fam Pract.* 2007 Oct;56(10):811-4.
2218. Shehan JM, Sarma DP. *Mycobacterium mucogenicum*: report of a skin infection associated with etanercept. *Dermatol Online J.* 2008;14(1):5.
2219. Shergy WJ, Isern RA, Cooley DA, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. *J Rheumatol.* 2002 Apr;29(4):667-77.
2220. Sherrer Y. Abatacept in biologic-naive patients and TNF inadequate responders: clinical data in focus. *Curr Med Res Opin.* 2008 Aug;24(8):2283-94.
2221. Shibata S, Ubara Y, Sawa N, et al. Severe interstitial cystitis associated with Sjogren's syndrome. *Intern Med.* 2004 Mar;43(3):248-52.
2222. Shih WJ, Ghesani N, Hongming Z, et al. F-18 FDG positron emission tomography demonstrates resolution of non-Hodgkin's lymphoma of the parotid gland in a patient with Sjogren's syndrome: before and after anti-CD20 antibody rituximab therapy. *Clin Nucl Med.* 2002 Feb;27(2):142-3.
2223. Shimada K, Matsui T, Kawakami M, et al. Methotrexate-related lymphomatoid granulomatosis: a case report of spontaneous regression of large tumours in multiple organs after cessation of methotrexate therapy in rheumatoid arthritis. *Scand J Rheumatol.* 2007 Jan-Feb;36(1):64-7.
2224. Shimizu H, Miyashita N, Obase Y, et al. An asymptomatic case of pulmonary cryptococcosis with endobronchial polypoid lesions and bilateral infiltrative shadow. *J Infect Chemother.* 2008 Aug;14(4):315-8.
2225. Shimojima Y, Ishii W, Matsuda M, et al. Cytomegalovirus-induced infectious mononucleosis-like syndrome in a rheumatoid arthritis patient treated with methotrexate and infliximab. *Intern Med.* 2010;49(10):937-40.

2226. Shimoyama M, Ohtahara A, Fukui H, et al. Acute secondary gastrointestinal amyloidosis in a patient with rheumatoid arthritis. *Am J Med Sci.* 2003 Sep;326(3):145-7.
2227. Shimura C, Satoh T, Takayama K, et al. Methotrexate-related lymphoproliferative disorder with extensive vascular involvement in a patient with rheumatoid arthritis. *J Am Acad Dermatol.* 2009 Jul;61(1):126-9.
2228. Shin IS, Baer AN, Kwon HJ, et al. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. *Arthritis Rheum.* 2006 May;54(5):1429-34.
2229. Shin K, Lee JC, Choi HJ, et al. Radiation synovectomy using 188Re-tin colloid improves knee synovitis as shown by MRI in refractory rheumatoid arthritis. *Nucl Med Commun.* 2007 Apr;28(4):239-44.
2230. Shin SJ, Na KS, Jung SS, et al. Acute acalculous cholecystitis associated with systemic lupus erythematosus with Sjogren's syndrome. *Korean J Intern Med.* 2002 Mar;17(1):61-4.
2231. Shingu M, Fujikawa Y, Wada T, et al. Increased IL-1 receptor antagonist (IL-1ra) production and decreased IL-1 beta/IL-1ra ratio in mononuclear cells from rheumatoid arthritis patients. *Br J Rheumatol.* 1995 Jan;34(1):24-30.
2232. Shinoda K, Taki H, Hounoki H, et al. Severe autoimmune hemolytic anemia associated with IgM warm auto-antibodies in primary Sjogren's syndrome. *Int J Rheum Dis.* 2010 Feb 1;13(1):94-6.
2233. Shinozaki M, Inoue E, Nakajima A, et al. Elevation of serum matrix metalloproteinase-3 as a predictive marker for the long-term disability of rheumatoid arthritis patients in a prospective observational cohort IORRA. *Mod Rheumatol.* 2007;17(5):403-8.
2234. Shio K, Homma F, Kanno Y, et al. Doppler sonographic comparative study on usefulness of synovial vascularity between knee and metacarpophalangeal joints for evaluation of articular inflammation in patients with rheumatoid arthritis treated by infliximab. *Mod Rheumatol.* 2006;16(4):220-5.
2235. Shoda H, Inokuma S, Yajima N, et al. Higher maximal serum concentration of methotrexate predicts the incidence of adverse reactions in Japanese rheumatoid arthritis patients. *Mod Rheumatol.* 2007;17(4):311-6.
2236. Sholsberg J, Jackson R. Best evidence topic report. Intra-articular corticosteroid injections in acute rheumatoid monoarthritis. *Emerg Med J.* 2004 Mar;21(2):204.
2237. Shovman O, Anouk M, Vinnitsky N, et al. QuantiFERON-TB Gold in the identification of latent tuberculosis infection in rheumatoid arthritis: a pilot study. *Int J Tuberc Lung Dis.* 2009 Nov;13(11):1427-32.
2238. Shrestha RK, Stoller JK, Honari G, et al. Pneumonia due to *Cryptococcus neoformans* in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. *Respir Care.* 2004 Jun;49(6):606-8.
2239. Shrim A, Koren G. Tumor necrosis factor alpha and use of infliximab. Safety during pregnancy. *Can Fam Physician.* 2005 May;51:667-8.
2240. Sibbitt WL, Jr., Peisajovich A, Michael AA, et al. Does sonographic needle guidance affect the clinical outcome of intraarticular injections? *J Rheumatol.* 2009 Sep;36(9):1892-902.
2241. Sibia J, Javier RM, Albert A, et al. Pancytopenia secondary to hemophagocytic syndrome in rheumatoid arthritis treated with methotrexate and sulfasalazine. *J Rheumatol.* 1998 Jun;25(6):1218-20.
2242. Sichletidis L, Settas L, Spyrtos D, et al. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. *Int J Tuberc Lung Dis.* 2006 Oct;10(10):1127-32.
2243. Sicotte NL, Voskuhl RR. Onset of multiple sclerosis associated with anti-TNF therapy. *Neurology.* 2001 Nov 27;57(10):1885-8.
2244. Sidiropoulos P, Bertsias G, Kritikos HD, et al. Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. *Ann Rheum Dis.* 2004 Feb;63(2):144-8.

2245. Sidiropoulos P, Kritikos HD, Siakka P, et al. Low dose of infliximab is inadequate in most patients with spondylarthropathies. *Clin Exp Rheumatol*. 2005 Jul-Aug;23(4):513-6.
2246. Sidiropoulos PI, Siakka P, Pagonidis K, et al. Sustained improvement of vascular endothelial function during anti-TNFalpha treatment in rheumatoid arthritis patients. *Scand J Rheumatol*. 2009 Jan-Feb;38(1):6-10.
2247. Sidiropoulos PI, Siakka P, Raptopoulou A, et al. An open label, single dose study to evaluate the safety, efficacy, and effects on CD25 expression of ciclosporin in patients with active rheumatoid arthritis despite treatment with methotrexate and infliximab. *Ann Rheum Dis*. 2006 Apr;65(4):538-41.
2248. Sieper J, Baraliakos X, Listing J, et al. Persistent reduction of spinal inflammation as assessed by magnetic resonance imaging in patients with ankylosing spondylitis after 2 yrs of treatment with the anti-tumour necrosis factor agent infliximab. *Rheumatology (Oxford)*. 2005 Dec;44(12):1525-30.
2249. Sills ES, Perloe M, Tucker MJ, et al. Successful ovulation induction, conception, and normal delivery after chronic therapy with etanercept: a recombinant fusion anti-cytokine treatment for rheumatoid arthritis. *Am J Reprod Immunol*. 2001 Nov;46(5):366-8.
2250. Simms R, Kipgen D, Dahill S, et al. ANCA-associated renal vasculitis following anti-tumor necrosis factor alpha therapy. *Am J Kidney Dis*. 2008 Mar;51(3):e11-4.
2251. Simsek I, Erdem H, Pay S, et al. Optic neuritis occurring with anti-tumour necrosis factor alpha therapy. *Ann Rheum Dis*. 2007 Sep;66(9):1255-8.
2252. Singh JA, Mahowald ML. Intra-articular botulinum toxin A as an adjunctive therapy for refractory joint pain in patients with rheumatoid arthritis receiving biologics: a report of two cases. *Joint Bone Spine*. 2009 Mar;76(2):190-4.
2253. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. *Cochrane Database Syst Rev* 2010(1):CD008341.
2254. Singh JA, Pando JA, Tomaszewski J, et al. Quantitative analysis of immunohistologic features of very early rheumatoid synovitis in disease modifying antirheumatic drug- and corticosteroid-naive patients. *J Rheumatol*. 2004 Jul;31(7):1281-5.
2255. Singh P, Taylor SF, Murali R, et al. Disseminated mucormycosis and orbital ischaemia in combination immunosuppression with a tumour necrosis factor alpha inhibitor. *Clin Experiment Ophthalmol*. 2007 Apr;35(3):275-80.
2256. Singh R, Cuchacovich R, Huang W, et al. Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. *J Rheumatol*. 2002 Mar;29(3):636-7.
2257. Singh S, Samant R, Joshi VR. Adult onset Still's disease: a study of 14 cases. *Clin Rheumatol*. 2008 Jan;27(1):35-9.
2258. Sinha A, Patient C. Rheumatoid arthritis in pregnancy: successful outcome with anti-TNF agent (Etanercept). *J Obstet Gynaecol*. 2006 Oct;26(7):689-91.
2259. Sinigaglia L, Nervetti A, Mela Q, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. *J Rheumatol*. 2000 Nov;27(11):2582-9.
2260. Sinsawaiwong S, Tiyaun N, Hirunpat C, et al. Simultaneous bilateral painful ophthalmoplegia and exudative retinal detachment in rheumatoid arthritis. *J Med Assoc Thai*. 1999 Nov;82(11):1170-3.
2261. Slifman NR, Gershon SK, Lee JH, et al. *Listeria monocytogenes* infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. *Arthritis Rheum*. 2003 Feb;48(2):319-24.
2262. Sliwinska-Stanczyk P, Pazdur J, Ziolkowska M, et al. The effect of methylprednisolone on proliferation of PBMCs obtained from steroid-sensitive and steroid-resistant rheumatoid arthritis patients. *Scand J Rheumatol*. 2007 May-Jun;36(3):167-71.
2263. Slovis BS, Eyler AE. A 33-year-old man with pharyngitis, transient rash, and multiorgan system failure. *Chest*. 2007 Sep;132(3):1080-3.

2264. Smedby KE, Hjalgrim H, Askling J, et al. Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype. *J Natl Cancer Inst.* 2006 Jan 4;98(1):51-60.
2265. Smeets TJ, Kraan MC, van Loon ME, et al. Tumor necrosis factor alpha blockade reduces the synovial cell infiltrate early after initiation of treatment, but apparently not by induction of apoptosis in synovial tissue. *Arthritis Rheum.* 2003 Aug;48(8):2155-62.
2266. Smith AP, Musacchio MJ, O'Toole JE. Spinal epidural abscess associated with infliximab treatment for psoriatic arthritis. Case report. *J Neurosurg Spine.* 2008 Sep;9(3):261-4.
2267. Smith D, Letendre S. Viral pneumonia as a serious complication of etanercept therapy. *Ann Intern Med.* 2002 Jan 15;136(2):174.
2268. Smith GR, Tymms KE, Falk M. Etanercept treatment of renal amyloidosis complicating rheumatoid arthritis. *Intern Med J.* 2004 Sep-Oct;34(9-10):570-2.
2269. Smith KJ, Skelton HG. Rapid onset of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis after starting tumor necrosis factor alpha receptor IgG1-Fc fusion complex therapy. *J Am Acad Dermatol.* 2001 Dec;45(6):953-6.
2270. Smith MD, Slavotinek J, Au V, et al. Successful treatment of rheumatoid arthritis is associated with a reduction in synovial membrane cytokines and cell adhesion molecule expression. *Rheumatology (Oxford).* 2001 Sep;40(9):965-77.
2271. Smith N, Ding T, Butt S, et al. The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practice. *Rheumatology (Oxford).* 2008 Sep;47(9):1389-91.
2272. Smitten AL, Choi HK, Hochberg MC, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. *Arthritis Rheum* 2007;57(8):1431-8.
2273. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. *J Rheumatol* 2008;35(3):387-93.
2274. Smolen J, Landewe RB, Mease P, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Ann Rheum Dis* 2009;68(6):797-804.
2275. Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet* 2008;371(9617):987-97.
2276. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. *Arthritis Rheum* 2005;52(4):1020-30.
2277. Smolen JS, Han C, van der Heijde D, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. *Arthritis Rheum.* 2006 Mar;54(3):716-22.
2278. Smolen JS, Han C, van der Heijde DM, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. *Ann Rheum Dis* 2009;68(6):823-7.
2279. Smolen JS, Kay J, Doyle MK, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. *Lancet* 2009;374(9685):210-21.
2280. Snowden JA, Biggs JC, Milliken ST, et al. A phase I/II dose escalation study of intensified cyclophosphamide and autologous blood stem cell rescue in severe, active rheumatoid arthritis. *Arthritis Rheum.* 1999 Nov;42(11):2286-92.

2281. Sobhani I, Brousse N, Vissuzaine C, et al. A diffuse T lymphocytic gastrointestinal mucosal infiltration associated with Sjogren's syndrome resulting in a watery diarrhea syndrome and responsive to immunosuppressive therapy. *Am J Gastroenterol.* 1998 Dec;93(12):2584-6.
2282. Soderlin MK, Lindroth Y, Jacobsson LT. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden. *Rheumatology (Oxford)* 2007;46(8):1355-8.
2283. Soh MC, Hart HH, Corkill M. Pericardial effusions with tamponade and visceral constriction in patients with rheumatoid arthritis on tumour necrosis factor (TNF)-inhibitor therapy. *Int J Rheum Dis.* 2009 Apr;12(1):74-7.
2284. Sokka T, Kautiainen H, Toloza S, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. *Ann Rheum Dis.* 2007 Nov;66(11):1491-6.
2285. Sokka T, Mottonen T, Hannonen P. Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 years. *Scand J Rheumatol.* 1999;28(5):282-7.
2286. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. *J Rheumatol.* 2002 Dec;29(12):2521-4.
2287. Sokka T, Pincus T. Eligibility of patients in routine care for major clinical trials of anti-tumor necrosis factor alpha agents in rheumatoid arthritis. *Arthritis Rheum.* 2003 Feb;48(2):313-8.
2288. Sokka T, Pincus T. Ascendancy of weekly low-dose methotrexate in usual care of rheumatoid arthritis from 1980 to 2004 at two sites in Finland and the United States. *Rheumatology (Oxford).* 2008 Oct;47(10):1543-7.
2289. Sokolove J, Strand V, Greenberg JD, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. *Ann Rheum Dis* 2010;69(9):1612-7.
2290. Sokolovic S, Kasumagic S, Mackic-Durovic M, et al. The impact of Rituximab therapy on the chromosomes of patients with Rheumatoid arthritis. *Bosn J Basic Med Sci.* 2010 May;10(2):121-4.
2291. Solau-Gervais E, Legrand JL, Cortet B, et al. Magnetic resonance imaging of the hand for the diagnosis of rheumatoid arthritis in the absence of anti-cyclic citrullinated peptide antibodies: a prospective study. *J Rheumatol.* 2006 Sep;33(9):1760-5.
2292. Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. *Ann Rheum Dis.* 2002 Sep;61(9):850-1.
2293. Solomon DH, Katz JN, Cabral D, et al. Osteoporosis management in patients with rheumatoid arthritis: Evidence for improvement. *Arthritis Rheum.* 2006 Dec 15;55(6):873-7.
2294. Solomon DH, Kuntz KM. Should postmenopausal women with rheumatoid arthritis who are starting corticosteroid treatment be screened for osteoporosis? A cost-effectiveness analysis. *Arthritis Rheum.* 2000 Sep;43(9):1967-75.
2295. Solomon DH, Stedman M, Licari A, et al. Agreement between patient report and medical record review for medications used for rheumatoid arthritis: the accuracy of self-reported medication information in patient registries. *Arthritis Rheum.* 2007 Mar 15;57(2):234-9.
2296. Somer BG, Tsai DE, Downs L, et al. Improvement in Sjogren's syndrome following therapy with rituximab for marginal zone lymphoma. *Arthritis Rheum.* 2003 Jun 15;49(3):394-8.
2297. Sommer WH, Ganiere V, Gachoud D, et al. Neurological and pulmonary adverse effects of subcutaneous methotrexate therapy. *Scand J Rheumatol.* 2008 Jul-Aug;37(4):306-9.

2298. Sorajja P, Poirier MK, Bundrick JB, et al. Autonomic failure and proximal skeletal myopathy in a patient with primary Sjogren syndrome. *Mayo Clin Proc.* 1999 Jul;74(7):695-7.
2299. Sordet C, Gottenberg JE, Hellmich B, et al. Lack of efficacy of rituximab in Felty's syndrome. *Ann Rheum Dis.* 2005 Feb;64(2):332-3.
2300. Sorensen LK, Havemose-Poulsen A, Bendtzen K, et al. Aggressive periodontitis and chronic arthritis: blood mononuclear cell gene expression and plasma protein levels of cytokines and cytokine inhibitors. *J Periodontol.* 2009 Feb;80(2):282-9.
2301. Soubrier M, Haik S, Hauw JJ, et al. Creutzfeldt-Jakob disease in a patient treated by etanercept for rheumatoid arthritis (RA): just a coincidence? *Joint Bone Spine.* 2010 Mar;77(2):174-5.
2302. Soubrier M, Jeannin G, Kemeny JL, et al. Organizing pneumonia after rituximab therapy: Two cases. *Joint Bone Spine.* 2008 May;75(3):362-5.
2303. Soubrier M, Jouanel P, Mathieu S, et al. Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis. *Joint Bone Spine.* 2008 Jan;75(1):22-4.
2304. Soubrier M, Mathieu S, Payet S, et al. Elderly-onset rheumatoid arthritis. *Joint Bone Spine.* 2010 Jul;77(4):290-6.
2305. Soubrier M, Puechal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. *Rheumatology (Oxford).* 2009 Nov;48(11):1429-34.
2306. Sowter MC, Burgess NA, Woodsford PV, et al. Delayed presentation of an extradural abscess complicating thoracic extradural analgesia. *Br J Anaesth.* 1992 Jan;68(1):103-5.
2307. Spadaro A, Scrivo R, Riccieri V, et al. Effect of tumor necrosis factor alpha antagonists in a patient with rheumatoid arthritis and primary biliary cirrhosis. *Joint Bone Spine.* 2008 Jan;75(1):87-9.
2308. Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. *Pharmacoeconomics.* 2006;24(12):1221-32.
2309. Spanakis E, Sidiropoulos P, Papadakis J, et al. Modest but sustained increase of serum high density lipoprotein cholesterol levels in patients with inflammatory arthritides treated with infliximab. *J Rheumatol.* 2006 Dec;33(12):2440-6.
2310. Sperling RI, Coblyn JS, Larkin JK, et al. Inhibition of leukotriene B4 synthesis in neutrophils from patients with rheumatoid arthritis by a single oral dose of methotrexate. *Arthritis Rheum.* 1990 Aug;33(8):1149-55.
2311. Sprekeler R, Lemmel EM, Obert HJ. Correlation of clinical and serological findings in patients with rheumatoid arthritis treated for one year with interferon-gamma. *Z Rheumatol.* 1990 Jan-Feb;49(1):1-7.
2312. Squirrell DM, Winfield J, Amos RS. Peripheral ulcerative keratitis 'corneal melt' and rheumatoid arthritis: a case series. *Rheumatology (Oxford).* 1999 Dec;38(12):1245-8.
2313. Sri JC, Tsai CL, Deng A, et al. Osteomyelitis occurring during infliximab treatment of severe psoriasis. *J Drugs Dermatol.* 2007 Feb;6(2):207-10.
2314. Srivastava KC, Mustafa T. Ginger (*Zingiber officinale*) in rheumatism and musculoskeletal disorders. *Med Hypotheses.* 1992 Dec;39(4):342-8.
2315. St Clair EW, van der Heijde DM, Smolen JS, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum.* 2004 Nov;50(11):3432-43.
2316. Stafford L, Bleasel J, Giles A, et al. Androgen deficiency and bone mineral density in men with rheumatoid arthritis. *J Rheumatol.* 2000 Dec;27(12):2786-90.
2317. Stalenheim G, Gudbjornsson B. Anti-inflammatory drugs do not alleviate bronchial hyperreactivity in Sjogren's syndrome. *Allergy.* 1997 Apr;52(4):423-7.

2318. Stamp LK, O'Donnell JL, Chapman PT, et al. Determinants of red blood cell methotrexate polyglutamate concentrations in rheumatoid arthritis patients receiving long-term methotrexate treatment. *Arthritis Rheum.* 2009 Aug;60(8):2248-56.
2319. Stamp LK, O'Donnell JL, Chapman PT, et al. Methotrexate polyglutamate concentrations are not associated with disease control in rheumatoid arthritis patients receiving long-term methotrexate therapy. *Arthritis Rheum.* 2010 Feb;62(2):359-68.
2320. Stanescu D, Bodaghi B, Huong du LT, et al. Pseudotumor cerebri associated with Sjogren's syndrome. *Graefes Arch Clin Exp Ophthalmol.* 2003 Apr;241(4):339-42.
2321. Starmans-Kool MJ, Peeters HR, Houben HH. Pustular skin lesions in patients treated with infliximab: report of two cases. *Rheumatol Int.* 2005 Sep;25(7):550-2.
2322. Starosta MA, Brandwein SR. Clinical manifestations and treatment of rheumatoid pachymeningitis. *Neurology.* 2007 Mar 27;68(13):1079-80.
2323. Steens SC, Steup-Beekman GM, Bosma GP, et al. The effect of corticosteroid medication on quantitative MR parameters of the brain. *AJNR Am J Neuroradiol.* 2005 Nov-Dec;26(10):2475-80.
2324. Steinfeld SD, Demols P, Salmon I, et al. Infliximab in patients with primary Sjogren's syndrome: a pilot study. *Arthritis Rheum.* 2001 Oct;44(10):2371-5.
2325. Stepien KE, Han DP, Schell J, et al. Spectral-domain optical coherence tomography and adaptive optics may detect hydroxychloroquine retinal toxicity before symptomatic vision loss. *Trans Am Ophthalmol Soc.* 2009 Dec;107:28-33.
2326. Sterling LP. Rheumatoid arthritis: current concepts and management, Part 2. *Am Pharm.* 1990 Sep;NS30(9):49-54.
2327. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. *J Rheumatol.* 2004 Aug;31(8):1538-45.
2328. Sterry W, Ortonne JP, Kirkham B, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. *Bmj.* 2010;340:c147.
2329. Stewart M, Malkovska V, Krishnan J, et al. Lymphoma in a patient with rheumatoid arthritis receiving methotrexate treatment: successful treatment with rituximab. *Ann Rheum Dis.* 2001 Sep;60(9):892-3.
2330. Stewart MW, Palmer DG, Knight RG. A self-report articular index measure of arthritic activity: investigations of reliability, validity and sensitivity. *J Rheumatol.* 1990 Aug;17(8):1011-5.
2331. Stock CJ, Ogilvie EM, Samuel JM, et al. Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis. *Genes Immun.* 2008 Jun;9(4):349-57.
2332. Stokes MB, Foster K, Markowitz GS, et al. Development of glomerulonephritis during anti-TNF-alpha therapy for rheumatoid arthritis. *Nephrol Dial Transplant.* 2005 Jul;20(7):1400-6.
2333. Stoll ML, Solomon DH, Batra KL, et al. TNFalpha inhibitors may improve asthma symptoms: a case series of 12 patients with rheumatoid arthritis and asthma. *J Clin Rheumatol.* 2009 Jun;15(4):198-200.
2334. Stone M, Salonen D, Lax M, et al. Clinical and imaging correlates of response to treatment with infliximab in patients with ankylosing spondylitis. *J Rheumatol.* 2001 Jul;28(7):1605-14.
2335. Stone MA, Inman RD, Wright JG, et al. Validation exercise of the Ankylosing Spondylitis Assessment Study (ASAS) group response criteria in ankylosing spondylitis patients treated with biologics. *Arthritis Rheum.* 2004 Jun 15;51(3):316-20.
2336. Stone MA, Payne U, Pacheco-Tena C, et al. Cytokine correlates of clinical response patterns to infliximab treatment of ankylosing spondylitis. *Ann Rheum Dis.* 2004 Jan;63(1):84-7.

2337. Strangfeld A, Hierse F, Rau R, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. *Arthritis Res Ther* 2010;12(1):R5.
2338. Strangfeld A, Listing J, Herzer P, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. *Jama* 2009;301(7):737-44.
2339. Stranzl T, Wolf J, Leeb BF, et al. Expression of folylpolyglutamyl synthetase predicts poor response to methotrexate therapy in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2003 Jan-Feb;21(1):27-32.
2340. Stratigos AJ, Antoniou C, Stamathioudaki S, et al. Discoid lupus erythematosus-like eruption induced by infliximab. *Clin Exp Dermatol*. 2004 Mar;29(2):150-3.
2341. Straub RH, Gunzler C, Miller LE, et al. Anti-inflammatory cooperativity of corticosteroids and norepinephrine in rheumatoid arthritis synovial tissue in vivo and in vitro. *Faseb J*. 2002 Jul;16(9):993-1000.
2342. Straub RH, Harle P, Atzeni F, et al. Sex hormone concentrations in patients with rheumatoid arthritis are not normalized during 12 weeks of anti-tumor necrosis factor therapy. *J Rheumatol*. 2005 Jul;32(7):1253-8.
2343. Straub RH, Harle P, Yamana S, et al. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis: a randomized, double-blind, placebo-controlled study. *Arthritis Rheum*. 2006 Jun;54(6):1778-85.
2344. Straub RH, Kittner JM, Heijnen C, et al. Infusion of epinephrine decreases serum levels of cortisol and 17-hydroxyprogesterone in patients with rheumatoid arthritis. *J Rheumatol*. 2002 Aug;29(8):1659-64.
2345. Straub RH, Paimela L, Peltomaa R, et al. Inadequately low serum levels of steroid hormones in relation to interleukin-6 and tumor necrosis factor in untreated patients with early rheumatoid arthritis and reactive arthritis. *Arthritis Rheum*. 2002 Mar;46(3):654-62.
2346. Straub RH, Pongratz G, Cutolo M, et al. Increased cortisol relative to adrenocorticotrophic hormone predicts improvement during anti-tumor necrosis factor therapy in rheumatoid arthritis. *Arthritis Rheum*. 2008 Apr;58(4):976-84.
2347. Straub RH, Pongratz G, Hirvonen H, et al. Acute cold stress in rheumatoid arthritis inadequately activates stress responses and induces an increase of interleukin 6. *Ann Rheum Dis*. 2009 Apr;68(4):572-8.
2348. Straub RH, Pongratz G, Scholmerich J, et al. Long-term anti-tumor necrosis factor antibody therapy in rheumatoid arthritis patients sensitizes the pituitary gland and favors adrenal androgen secretion. *Arthritis Rheum*. 2003 Jun;48(6):1504-12.
2349. Straub RH, Sarzi-Puttini P, Atzeni F, et al. Anti-tumour necrosis factor antibody treatment does not change serum levels of cortisol binding globulin in patients with rheumatoid arthritis but it increases androstenedione relative to cortisol. *Ann Rheum Dis*. 2005 Sep;64(9):1353-6.
2350. Straub RH, Weidler C, Demmel B, et al. Renal clearance and daily excretion of cortisol and adrenal androgens in patients with rheumatoid arthritis and systemic lupus erythematosus. *Ann Rheum Dis*. 2004 Aug;63(8):961-8.
2351. Strober B, Teller C, Yamauchi P, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. *Br J Dermatol*. 2008 Aug;159(2):322-30.
2352. Strober BE. Successful treatment of psoriasis and psoriatic arthritis with etanercept and methotrexate in a patient newly unresponsive to infliximab. *Arch Dermatol*. 2004 Mar;140(3):366.
2353. Strober BE, Clarke S. Etanercept for the treatment of psoriasis: combination therapy with other modalities. *J Drugs Dermatol*. 2004 May-Jun;3(3):270-2.
2354. Stucki G, Bruhlmann P, Stoll T, et al. Low serum creatine kinase activity is associated with muscle weakness in patients with rheumatoid arthritis. *J Rheumatol*. 1996 Apr;23(4):603-8.
2355. Studenski SA. Rheumatology, geriatrics, and a way forward. *J Am Geriatr Soc*. 2002 Oct;50(10):1737-8.



2356. Suarez-Almazor ME, Soskolne CL, Saunders LD, et al. Use of second line drugs for the treatment of rheumatoid arthritis in Edmonton, Alberta. Patterns of prescription and longterm effectiveness. *J Rheumatol.* 1995 May;22(5):836-43.
2357. Sugihara M, Tsutsumi A, Suzuki E, et al. Effects of infliximab therapy on gene expression levels of tumor necrosis factor alpha, tristetraprolin, T cell intracellular antigen 1, and Hu antigen R in patients with rheumatoid arthritis. *Arthritis Rheum.* 2007 Jul;56(7):2160-9.
2358. Sugimori S, Watanabe T, Tabuchi M, et al. Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs. *Digestion.* 2008;78(4):208-13.
2359. Sugimoto T, Yasuda M, Sakaguchi M, et al. Acute interstitial nephritis associated with etanercept. *Rheumatol Int.* 2008 Oct;28(12):1283-4.
2360. Sugioka Y, Inui K, Koike T. Use of etanercept in a patient with rheumatoid arthritis on hemodialysis. *Mod Rheumatol.* 2008;18(3):293-5.
2361. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. *Arthritis Rheum* 2006;55(4):531-6.
2362. Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. *Pulm Pharmacol Ther.* 2008;21(1):234-8.
2363. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. *Arthritis Rheum.* 2006 May;54(5):1435-9.
2364. Sulit DJ, Clarke JE. Psoriatic arthritis in a military aviator. *Aviat Space Environ Med.* 2005 Jul;76(7):684-8.
2365. Sulli A, Maestroni GJ, Villaggio B, et al. Melatonin serum levels in rheumatoid arthritis. *Ann N Y Acad Sci.* 2002 Jun;966:276-83.
2366. Sulli A, Montecucco CM, Caporali R, et al. Glucocorticoid effects on adrenal steroids and cytokine responsiveness in polymyalgia rheumatica and elderly onset rheumatoid arthritis. *Ann N Y Acad Sci.* 2006 Jun;1069:307-14.
2367. Sundberg E, Grundtman C, Af Klint E, et al. Systemic TNF blockade does not modulate synovial expression of the pro-inflammatory mediator HMGB1 in rheumatoid arthritis patients--a prospective clinical study. *Arthritis Res Ther.* 2008;10(2):R33.
2368. Suresh R, Gupta S, Sathananthan R. Sulphasalazine induced three-week syndrome. *J Clin Rheumatol.* 2009 Sep;15(6):311-2.
2369. Suwannalai P, Auethavekiat P, Udomsubpayakul U, et al. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study at the university-based hospital. *Int J Rheum Dis* 2009;12(2):118-24.
2370. Suzuki K, Kimura Y, Aoki M, et al. Persistent plaques and linear pigmentation in adult-onset Still's disease. *Dermatology.* 2001;202(4):333-5.
2371. Suzuki K, Saito K, Tsujimura S, et al. Tacrolimus, a calcineurin inhibitor, overcomes treatment unresponsiveness mediated by P-glycoprotein on lymphocytes in refractory rheumatoid arthritis. *J Rheumatol.* 2010 Mar;37(3):512-20.
2372. Suzuki T, Tsutsumi A, Suzuki H, et al. Tristetraprolin (TTP) gene polymorphisms in patients with rheumatoid arthritis and healthy individuals. *Mod Rheumatol.* 2008;18(5):472-9.
2373. Suzuki Y, Inoue K, Chiba J, et al. Histological analysis of synovium by treatment of etanercept for rheumatoid arthritis. *Int J Rheum Dis.* 2009 Apr;12(1):7-13.
2374. Suzuki Y, Mizushima Y. Osteoporosis in rheumatoid arthritis. *Osteoporos Int.* 1997;7 Suppl 3:S217-22.

2375. Suzuki Y, Uehara R, Tajima C, et al. Elevation of serum hepatic aminotransferases during treatment of rheumatoid arthritis with low-dose methotrexate. Risk factors and response to folic acid. *Scand J Rheumatol.* 1999;28(5):273-81.
2376. Svenson M, Geborek P, Saxne T, et al. Monitoring patients treated with anti-TNF-alpha biopharmaceuticals: assessing serum infliximab and anti-infliximab antibodies. *Rheumatology (Oxford).* 2007 Dec;46(12):1828-34.
2377. Svensson B, Ahlmen M, Forslind K. Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options. *Clin Exp Rheumatol.* 2003 May-Jun;21(3):327-32.
2378. Svensson B, Hafstrom I, Forslind K, et al. Increased expression of proto-oncogene survivin predicts Joint destruction and persistent disease activity in early rheumatoid arthritis. *Ann Med.* 2010;42(1):45-54.
2379. Svensson B, Schaufelberger C, Teleman A, et al. Remission and response to early treatment of RA assessed by the Disease Activity Score. BARFOT study group. Better Anti-rheumatic Farmacotherapy. *Rheumatology (Oxford).* 2000 Sep;39(9):1031-6.
2380. Swale VJ, Perrett CM, Denton CP, et al. Etanercept-induced systemic lupus erythematosus. *Clin Exp Dermatol.* 2003 Nov;28(6):604-7.
2381. Swaneveld FH, van Vugt RM, de Boer JP, et al. A 57-year-old man who developed arthritis during R-CHOP chemotherapy for non-Hodgkin lymphoma. *Clin Rheumatol.* 2008 Feb;27(2):249-51.
2382. Swanson DL, Barnes SA, Mengden Koon SJ, et al. Caffeine consumption and methotrexate dosing requirement in psoriasis and psoriatic arthritis. *Int J Dermatol.* 2007 Feb;46(2):157-9.
2383. Sweet DD, Isac G, Morrison B, et al. Purulent pericarditis in a patient with rheumatoid arthritis treated with etanercept and methotrexate. *Cjem.* 2007 Jan;9(1):40-2.
2384. Szeto T, Peterson J, Silva F. A case of tuberculous peritonitis in the United States in a patient with rheumatoid arthritis treated with adalimumab. *J Clin Rheumatol.* 2010 Apr;16(3):135-7.
2385. Szturmowicz M, Wilinska E, Paczek A, et al. Primary Sjogren's Syndrome with two extraglandular sites involvement - case report. *Pneumonol Alergol Pol.* 2010;78(6):445-50.
2386. Taban M, Dupps WJ, Mandell B, et al. Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. *Ocul Immunol Inflamm.* 2006 Jun;14(3):145-50.
2387. Tack CJ, Kleijwegt FS, Van Riel PL, et al. Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis. *Diabetologia.* 2009 Jul;52(7):1442-4.
2388. Tada Y, Fukuoka M, Mitamura M, et al. Nocardiosis in adult-onset Still's disease and vasculitis syndrome. *Am J Med Sci.* 2008 Jul;336(1):77-80.
2389. Tai TL, O'Rourke KP, McWeeney M, et al. Pneumocystis carinii pneumonia following a second infusion of infliximab. *Rheumatology (Oxford).* 2002 Aug;41(8):951-2.
2390. Taira T, Matsuyama W, Mitsuyama H, et al. Increased serum high mobility group box-1 level in Churg-Strauss syndrome. *Clin Exp Immunol.* 2007 May;148(2):241-7.
2391. Taiwo B, Lee C, Venkat D, et al. Can tumor necrosis factor alpha blockade predispose to severe babesiosis? *Arthritis Rheum.* 2007 Feb 15;57(1):179-81.
2392. Takahashi A, Takeda I, Kanno T, et al. CD8-positive T cell-induced liver damage was found in a patient with polymyositis. *Intern Med.* 2006;45(18):1059-63.
2393. Takahashi H, Shigehara K, Yamamoto M, et al. Interferon gamma assay for detecting latent tuberculosis infection in rheumatoid arthritis patients during infliximab administration. *Rheumatol Int.* 2007 Oct;27(12):1143-8.

2394. Takahashi H, Tezuka F, Fujita S, et al. Vascular changes in major and lingual minor salivary glands in primary Sjogren's syndrome. *Anal Cell Pathol.* 1995 Dec;9(4):243-56.
2395. Takahashi M, Mizutani H, Nakamura Y, et al. A case of multicentric reticulohistiocytosis, systemic sclerosis and Sjogren syndrome. *J Dermatol.* 1997 Aug;24(8):530-4.
2396. Takahashi T, Satoh M, Satoh H. Unilateral acute exacerbation of pulmonary fibrosis in association with Sjogren's syndrome. *Intern Med.* 1996 Oct;35(10):811-4.
2397. Takami A, Nakao S, Miyamori H, et al. Adult-onset Still's disease with submassive hepatic necrosis. *Intern Med.* 1995 Feb;34(2):89-91.
2398. Takasugi JE, Godwin JD. Lung abscess caused by *Rhodococcus equi*. *J Thorac Imaging.* 1991 Apr;6(2):72-4.
2399. Takatori R, Takahashi KA, Tokunaga D, et al. ABCB1 C3435T polymorphism influences methotrexate sensitivity in rheumatoid arthritis patients. *Clin Exp Rheumatol.* 2006 Sep-Oct;24(5):546-54.
2400. Takeuchi T, Miyasaka N, Inoue K, et al. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. *Mod Rheumatol* 2009;19(5):478-87.
2401. Takeuchi T, Tatsuki Y, Nogami Y, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. *Ann Rheum Dis.* 2008 Feb;67(2):189-94.
2402. Takeuchi T, Yamanaka H, Inoue E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). *Mod Rheumatol.* 2008;18(5):447-54.
2403. Talip F, Walker N, Khan W, et al. Treatment of Felty's syndrome with leflunomide. *J Rheumatol.* 2001 Apr;28(4):868-70.
2404. Tam LS, Griffith JF, Yu AB, et al. Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation. *Clin Rheumatol.* 2007 Jun;26(6):941-6.
2405. Tam LS, Tomlinson B, Chu TT, et al. Impact of TNF inhibition on insulin resistance and lipids levels in patients with rheumatoid arthritis. *Clin Rheumatol.* 2007 Sep;26(9):1495-8.
2406. Tam MM, Meehan CJ. Subcutaneous granuloma annulare in a patient with rheumatoid arthritis and diabetes mellitus. *Australas J Dermatol.* 1996 Nov;37(4):199-201.
2407. Tambo Y, Fujimura M, Yasui M, et al. Eosinophilic pneumonia (EP) associated with rheumatoid arthritis in which drug-induced eosinophilic pneumonia could be ruled out. *Intern Med.* 2008;47(6):527-31.
2408. Tamura S, Koreeda T, Nakano T, et al. A case of rheumatoid arthritis which developed after recovery from adult respiratory distress syndrome. *Jpn J Med.* 1990 Nov-Dec;29(6):611-5.
2409. Tan AL, Marzo-Ortega H, O'Connor P, et al. Efficacy of anakinra in active ankylosing spondylitis: a clinical and magnetic resonance imaging study. *Ann Rheum Dis.* 2004 Sep;63(9):1041-5.
2410. Tan RJ, Gibbons LJ, Potter C, et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. *Ann Rheum Dis* 2010;69(6):1029-35.
2411. Tanaka A, Shigematsu H, Kojima M, et al. Methotrexate-associated lymphoproliferative disorder arising in a patient with adult Still's disease. *J Oral Maxillofac Surg.* 2008 Jul;66(7):1492-5.
2412. Tanaka E, Inoue E, Kawaguchi Y, et al. Acceptability and usefulness of mizoribine in the management of rheumatoid arthritis in methotrexate-refractory patients and elderly patients, based on analysis of data from a large-scale observational cohort study. *Mod Rheumatol.* 2006;16(4):214-9.

2413. Tanaka N, Sakahashi H, Hirose K, et al. Volume of a wash and the other conditions for maximum therapeutic effect of arthroscopic lavage in rheumatoid knees. *Clin Rheumatol*. 2006 Feb;25(1):65-9.
2414. Tanaka Y, Takeuchi T, Inoue E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). *Mod Rheumatol*. 2008;18(2):146-52.
2415. Tanaka Y, Takeuchi T, Mimori T, et al. Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study. *Ann Rheum Dis*. 2010 Jul;69(7):1286-91.
2416. Tang B, Rahman M, Waters HC, et al. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. *Clin Ther*. 2008 Jul;30(7):1375-84.
2417. Taniguchi A, Urano W, Tanaka E, et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. *Pharmacogenet Genomics*. 2007 Jun;17(6):383-90.
2418. Tanno M, Nakajima A, Ishiwata T, et al. Effect of general anesthesia on the abnormal immune response in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2004 Nov-Dec;22(6):727-32.
2419. Taraborelli M, Andreoli L, Archetti S, et al. Methylenetetrahydrofolate reductase polymorphisms and methotrexate: no association with response to therapy nor with drug-related adverse events in an Italian population of rheumatic patients. *Clin Exp Rheumatol* 2009;27(3):499-502.
2420. Targonska-Stepniak B, Majdan M, Dryglewska M. Leptin serum levels in rheumatoid arthritis patients: relation to disease duration and activity. *Rheumatol Int*. 2008 Apr;28(6):585-91.
2421. Tascioglu F, Oner C, Armagan O. The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis. *Rheumatol Int*. 2003 Sep;23(5):231-5.
2422. Tassiopoulos S, Benopoulou O, Mytilineou E, et al. Late onset of long-lasting fever as a sole complication of treatment with anti-TNFalpha. *Clin Exp Rheumatol*. 2005 Jan-Feb;23(1):122-3.
2423. Tateiwa T, Shinmura K, Ko M, et al. Iliopsoas bursitis associated with rapid destruction of a rheumatoid hip joint. *J Orthop Sci*. 2009 Jul;14(4):455-8.
2424. Tauber T, Turetz J, Barash J, et al. Optic neuritis associated with etanercept therapy for juvenile arthritis. *J Aapos*. 2006 Feb;10(1):26-9.
2425. Taylor JC, Orkin R, Lanham J. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. *Rheumatology (Oxford)*. 2003 Jul;42(7):901-2.
2426. Taylor WJ, Rajapakse CN, Harris KA, et al. Inpatient treatment of rheumatoid arthritis with synacthen depot: a double blind placebo controlled trial with 6 month followup. *J Rheumatol*. 1999 Dec;26(12):2544-50.
2427. Tchetchverikov I, Kraan MC, van El B, et al. Leflunomide and methotrexate reduce levels of activated matrix metalloproteinases in complexes with alpha2 macroglobulin in serum of rheumatoid arthritis patients. *Ann Rheum Dis*. 2008 Jan;67(1):128-30.
2428. Teh J, Stevens K, Williamson L, et al. Power Doppler ultrasound of rheumatoid synovitis: quantification of therapeutic response. *Br J Radiol*. 2003 Dec;76(912):875-9.
2429. Tektonidou MG, Skopouli FN. Visceral leishmaniasis in a patient with psoriatic arthritis treated with infliximab: reactivation of a latent infection? *Clin Rheumatol*. 2008 Apr;27(4):541-2.
2430. Temekonidis TI, Alamanos Y, Nikas SN, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. *Ann Rheum Dis*. 2003 Dec;62(12):1218-20.

2431. Temekonidis TI, Georgiadis AN, Alamanos Y, et al. Infliximab treatment in combination with cyclosporin A in patients with severe refractory rheumatoid arthritis. *Ann Rheum Dis.* 2002 Sep;61(9):822-5.
2432. ten Tusscher MP, Jacobs PJ, Busch MJ, et al. Bilateral anterior toxic optic neuropathy and the use of infliximab. *BMJ.* 2003 Mar 15;326(7389):579.
2433. Teng YK, Levarht EW, Hashemi M, et al. Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment. *Arthritis Rheum.* 2007 Dec;56(12):3909-18.
2434. Teng YK, Levarht EW, Toes RE, et al. Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. *Ann Rheum Dis.* 2009 Jun;68(6):1011-6.
2435. Tengstrand B, Carlstrom K, Fellander-Tsai L, et al. Abnormal levels of serum dehydroepiandrosterone, estrone, and estradiol in men with rheumatoid arthritis: high correlation between serum estradiol and current degree of inflammation. *J Rheumatol.* 2003 Nov;30(11):2338-43.
2436. Tengstrand B, Hafstrom I. Bone mineral density in men with rheumatoid arthritis is associated with erosive disease and sulfasalazine treatment but not with sex hormones. *J Rheumatol.* 2002 Nov;29(11):2299-305.
2437. Tengstrand B, Larsson E, Klareskog L, et al. Randomized withdrawal of long-term prednisolone treatment in rheumatoid arthritis: effects on inflammation and bone mineral density. *Scand J Rheumatol.* 2007 Sep-Oct;36(5):351-8.
2438. Terrier B, Lacroix C, Guillevin L, et al. Diagnostic and prognostic relevance of neuromuscular biopsy in primary Sjogren's syndrome-related neuropathy. *Arthritis Rheum.* 2007 Dec 15;57(8):1520-9.
2439. Terslev L, Torp-Pedersen S, Qvistgaard E, et al. Spectral Doppler and resistive index. A promising tool in ultrasonographic evaluation of inflammation in rheumatoid arthritis. *Acta Radiol.* 2003 Nov;44(6):645-52.
2440. Terslev L, Torp-Pedersen S, Qvistgaard E, et al. Effects of treatment with etanercept (Enbrel, TNRF:Fc) on rheumatoid arthritis evaluated by Doppler ultrasonography. *Ann Rheum Dis.* 2003 Feb;62(2):178-81.
2441. Theodoridou A, Kartsios C, Yiannaki E, et al. Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy. *Rheumatol Int.* 2006 Dec;27(2):201-2.
2442. Thomaidis T, Schorn C, Flaig W, et al. Immunoabsorption with tryptophan columns: a therapeutic option for the treatment of rheumatoid arthritis with septic complications. *J Clin Apher.* 2009;24(1):37-41.
2443. Thomas JE, Taoka CR, Gibbs BT, et al. Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept. *Hawaii Med J.* 2006 Jan;65(1):12-5.
2444. Thomas JW, Pflugfelder SC. Therapy of progressive rheumatoid arthritis-associated corneal ulceration with infliximab. *Cornea.* 2005 Aug;24(6):742-4.
2445. Thomason RW, Craig FE, Banks PM, et al. Epstein-Barr virus and lymphoproliferation in methotrexate-treated rheumatoid arthritis. *Mod Pathol.* 1996 Mar;9(3):261-6.
2446. Thompson AE, Bashook PG. Rheumatologists' recommended patient information when prescribing methotrexate for rheumatoid arthritis. *Clin Exp Rheumatol.* 2010 Jul-Aug;28(4):539-45.
2447. Thonhofer R, Gaugg M, Kriessmayr M, et al. Spontaneous remission of marginal zone B cell lymphoma in a patient with seropositive rheumatoid arthritis after discontinuation of infliximab-methotrexate treatment. *Ann Rheum Dis.* 2005 Jul;64(7):1098-9.
2448. Thonhofer R, Soleiman A, Kriessmayr M, et al. Decrease of proteinuria in a patient with adult-onset Still's disease and glomerulonephritis after anti-TNFalpha therapy. *Scand J Rheumatol.* 2006 Nov-Dec;35(6):485-8.
2449. Thorne JE, Volpe NJ, Liu GT. Magnetic resonance imaging of acquired Brown syndrome in a patient with psoriasis. *Am J Ophthalmol.* 1999 Feb;127(2):233-5.

2450. Thorne JE, Woreta FA, Dunn JP, et al. Risk of cataract development among children with juvenile idiopathic arthritis-related uveitis treated with topical corticosteroids. *Ophthalmology*. 2010 Jul;117(7):1436-41.
2451. Thumboo J, Uramoto K, Shbeeb MI, et al. Risk factors for the development of psoriatic arthritis: a population based nested case control study. *J Rheumatol*. 2002 Apr;29(4):757-62.
2452. Thurlings RM, Vos K, Gerlag DM, et al. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. *Arthritis Rheum*. 2008 Dec;58(12):3657-64.
2453. Thurlings RM, Vos K, Wijbrandts CA, et al. Synovial tissue response to rituximab: mechanism of action and identification of biomarkers of response. *Ann Rheum Dis*. 2008 Jul;67(7):917-25.
2454. Tiderius CJ, Sandin J, Svensson J, et al. Knee cartilage quality assessed with dGEMRIC in rheumatoid arthritis patients before and after treatment with a TNF inhibitor. *Acta Radiol*. 2010 Nov;51(9):1034-7.
2455. Tikiz H, Arslan O, Pirildar T, et al. The effect of anti-tumor necrosis factor (TNF)-alpha therapy with etanercept on endothelial functions in patients with rheumatoid arthritis. *Anadolu Kardiyol Derg*. 2010 Apr;10(2):98-103.
2456. Tikly M, Zannettou N, Hopley M. A longitudinal study of rheumatoid arthritis in South Africans. *MedGenMed*. 2003 Feb 5;5(1):2.
2457. Tiliakos AN, Tiliakos NA. Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary? *J Rheumatol*. 2003 Dec;30(12):2727.
2458. Tilling L, Townsend S, David J. Methotrexate and hepatic toxicity in rheumatoid arthritis and psoriatic arthritis. *Clin Drug Investig*. 2006;26(2):55-62.
2459. Todoerti M, Scire CA, Boffini N, et al. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. *Ann N Y Acad Sci* 2010;1193(1):139-45.
2460. Toh ML, Marotte H, Blond JL, et al. Overexpression of synoviolin in peripheral blood and synoviocytes from rheumatoid arthritis patients and continued elevation in nonresponders to infliximab treatment. *Arthritis Rheum*. 2006 Jul;54(7):2109-18.
2461. Tokayer A, Carsons SE, Chokshi B, et al. High levels of interleukin 13 in rheumatoid arthritis sera are modulated by tumor necrosis factor antagonist therapy: association with dendritic cell growth activity. *J Rheumatol*. 2002 Mar;29(3):454-61.
2462. Tokuda H, Sakai F, Yamada H, et al. Clinical and radiological features of Pneumocystis pneumonia in patients with rheumatoid arthritis, in comparison with methotrexate pneumonitis and Pneumocystis pneumonia in acquired immunodeficiency syndrome: a multicenter study. *Intern Med*. 2008;47(10):915-23.
2463. Tolusso B, Pietrapertosa D, Morelli A, et al. IL-1B and IL-1RN gene polymorphisms in rheumatoid arthritis: relationship with protein plasma levels and response to therapy. *Pharmacogenomics*. 2006 Jul;7(5):683-95.
2464. Toms TE, Panoulas VF, John H, et al. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. *Arthritis Res Ther*. 2009;11(4):R110.
2465. Tong D, Eather S, Manolios N. Psoriatic arthritis and chronic lymphoedema: treatment efficacy by adalimumab. *Clin Rheumatol*. 2009 Nov;28(11):1349-50.
2466. Toonen EJ, Coenen MJ, Kievit W, et al. The tumour necrosis factor receptor superfamily member 1b 676T>G polymorphism in relation to response to infliximab and adalimumab treatment and disease severity in rheumatoid arthritis. *Ann Rheum Dis*. 2008 Aug;67(8):1174-7.

2467. Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. *J Dermatol Sci*. 2010 Jul;59(1):40-9.
2468. Torikai E, Kageyama Y, Suzuki M, et al. The effect of infliximab on chemokines in patients with rheumatoid arthritis. *Clin Rheumatol*. 2007 Jul;26(7):1088-93.
2469. Torikai E, Kageyama Y, Takahashi M, et al. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis. *Mod Rheumatol*. 2006;16(6):350-4.
2470. Toritsuka Y, Nakamura N, Lee SB, et al. Osteoclastogenesis in iliac bone marrow of patients with rheumatoid arthritis. *J Rheumatol*. 1997 Sep;24(9):1690-6.
2471. Torrance GW, Tugwell P, Amorosi S, et al. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. *Rheumatology (Oxford)*. 2004 Jun;43(6):712-8.
2472. Torre-Cisneros J, Del Castillo M, Caston JJ, et al. Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis. *Rheumatology (Oxford)*. 2005 Sep;44(9):1132-5.
2473. Torsteinsdottir I, Arvidson NG, Hallgren R, et al. Monocyte activation in rheumatoid arthritis (RA): increased integrin, Fc gamma and complement receptor expression and the effect of glucocorticoids. *Clin Exp Immunol*. 1999 Mar;115(3):554-60.
2474. Toubi E, Kessel A, Slobodin G, et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2007 Jun;66(6):818-20.
2475. Tourinho TF, Capp E, Brenol JC, et al. Physical activity prevents bone loss in premenopausal women with rheumatoid arthritis: a cohort study. *Rheumatol Int*. 2008 Aug;28(10):1001-7.
2476. Tournadre A, Ledoux-Eberst J, Poujol D, et al. Exacerbation of interstitial lung disease during etanercept therapy: Two cases. *Joint Bone Spine*. 2008 Mar;75(2):215-8.
2477. Toussirot E, Berthelot JM, Pertuiset E, et al. Pulmonary nodulosis and aseptic granulomatous lung disease occurring in patients with rheumatoid arthritis receiving tumor necrosis factor-alpha-blocking agent: a case series. *J Rheumatol*. 2009 Nov;36(11):2421-7.
2478. Toussirot E, Nguyen NU, Dumoulin G, et al. Relationship between growth hormone-IGF-I-IGFBP-3 axis and serum leptin levels with bone mass and body composition in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2005 Jan;44(1):120-5.
2479. Toussirot E, Pertuiset E, Sordet C, et al. Safety of rituximab in rheumatoid arthritis patients with a history of severe or recurrent bacterial infection: observational study of 30 cases in everyday practice. *Joint Bone Spine*. 2010 Mar;77(2):142-5.
2480. Toussirot E, Wendling D. Bacillus calmette-guerin vaccination in a patient treated with infliximab. *J Rheumatol*. 2005 Dec;32(12):2500-1.
2481. Toy WC, Jasin HE. An unusual case of hypokalemic paralysis associated with primary Sjogren's syndrome. *J Ark Med Soc*. 2008 Jun;104(12):286-7.
2482. Toyoda T, Inokuchi S, Saito S, et al. Bone loss of the radius in rheumatoid arthritis. Comparison between 34 patients and 40 controls. *Acta Orthop Scand*. 1996 Jun;67(3):269-73.
2483. Toyokawa Y, Kingetsu I, Yasuda C, et al. Pancytopenia, including macrocytic anemia, associated with leflunomide in a rheumatoid arthritis patient. *Mod Rheumatol*. 2007;17(5):436-40.
2484. Toyozawa S, Yamamoto Y, Nishide T, et al. Case report: a case of pyoderma gangrenosum with intractable leg ulcers treated by allogeneic cultured dermal substitutes. *Dermatol Online J*. 2008;14(11):17.

2485. Traer EA, Williams MR, Keenan JN. Erysipelothrix rhusiopathiae infection of a total knee arthroplasty an occupational hazard. *J Arthroplasty*. 2008 Jun;23(4):609-11.
2486. Tresch S, Trueb RM, Kamarachev J, et al. Disseminated herpes zoster mimicking rheumatoid vasculitis in a rheumatoid arthritis patient on etanercept. *Dermatology*. 2009;219(4):347-9.
2487. Trethewey P. The role of tumor necrosis factor inhibitors in patients with RA. *Jaapa*. 2002 Sep;15(9):23-4, 7, 30 passim.
2488. True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. *J Rheumatol*. 2002 Jul;29(7):1561-3.
2489. Tsai TC, Chen CY, Lin WT, et al. Sjogren's syndrome complicated with IgA nephropathy and leukocytoclastic vasculitis. *Ren Fail*. 2008;30(7):755-8.
2490. Tsakonas E, Fitzgerald AA, Fitzcharles MA, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. *J Rheumatol*. 2000 Mar;27(3):623-9.
2491. Tsubota K, Fujita H, Tadano K, et al. Abnormal expression and function of Fas ligand of lacrimal glands and peripheral blood in Sjogren's syndrome patients with enlarged exocrine glands. *Clin Exp Immunol*. 2002 Jul;129(1):177-82.
2492. Tsujimura S, Saito K, Nawata M, et al. Overcoming drug resistance induced by P-glycoprotein on lymphocytes in patients with refractory rheumatoid arthritis. *Ann Rheum Dis*. 2008 Mar;67(3):380-8.
2493. Tsukahara S, Momohara S, Ikari K, et al. Disturbances of the symphysis pubis in rheumatoid arthritis: report of two cases. *Mod Rheumatol*. 2007;17(4):344-7.
2494. Tsuzaka K, Itami Y, Takeuchi T, et al. ADAMTS5 is a biomarker for prediction of response to infliximab in patients with rheumatoid arthritis. *J Rheumatol*. 2010 Jul;37(7):1454-60.
2495. Tubach F, Salmon D, Ravaud P, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. *Arthritis Rheum*. 2009 Jul;60(7):1884-94.
2496. Tudhope SJ, von Delwig A, Falconer J, et al. Profound invariant natural killer T-cell deficiency in inflammatory arthritis. *Ann Rheum Dis*. 2010 Oct;69(10):1873-9.
2497. Turesson C, Riesbeck K. Septicemia with Staphylococcus aureus, beta-hemolytic streptococci group B and G, and Escherichia coli in a patient with rheumatoid arthritis treated with a recombinant human interleukin 1 receptor antagonist (Anakinra). *J Rheumatol*. 2004 Sep;31(9):1876.
2498. Ueki Y, Sagawa A, Tanimura K, et al. A multicenter study of leukocytapheresis in rheumatoid arthritis. *Clin Exp Rheumatol*. 2007 Nov-Dec;25(6):810-6.
2499. Umeda N, Ito S, Hayashi T, et al. A patient with rheumatoid arthritis who had a normal delivery under etanercept treatment. *Intern Med*. 2010;49(2):187-9.
2500. Uneda S, Sonoki T, Nakamura Y, et al. Rapid vanishing of tumors by withdrawal of methotrexate in Epstein-Barr virus-related B cell lymphoproliferative disorder. *Intern Med*. 2008;47(15):1445-6.
2501. Unger L, Kayser M, Nusslein HG. Successful treatment of severe rheumatoid vasculitis by infliximab. *Ann Rheum Dis*. 2003 Jun;62(6):587-8.
2502. Unlu E, Pamuk ON, Cakir N. Color and duplex Doppler sonography to detect sacroiliitis and spinal inflammation in ankylosing spondylitis. Can this method reveal response to anti-tumor necrosis factor therapy? *J Rheumatol*. 2007 Jan;34(1):110-6.
2503. Usui Y, Kimula Y, Miura H, et al. A case of bronchiolitis obliterans organizing pneumonia associated with primary Sjogren's syndrome who died of superimposed diffuse alveolar damage. *Respiration*. 1992;59(2):122-4.



2504. Uthman I, Bizri AR, Hajj Ali R, et al. Miliary tuberculosis presenting as tenosynovitis in a case of rheumatoid arthritis. *J Infect*. 1998 Sep;37(2):196-8.
2505. Uthman I, Husari A, Touma Z, et al. Fatal streptococcal toxic shock syndrome in a patient with rheumatoid arthritis treated with etanercept. *Rheumatology (Oxford)*. 2005 Sep;44(9):1200-1.
2506. Uthman I, Vazquez-Abad D, Senecal JL. Distinctive features of idiopathic inflammatory myopathies in French Canadians. *Semin Arthritis Rheum*. 1996 Aug;26(1):447-58.
2507. Vaglio A, Palmisano A, Ferretti S, et al. Peripheral inflammatory arthritis in patients with chronic periaortitis: report of five cases and review of the literature. *Rheumatology (Oxford)*. 2008 Mar;47(3):315-8.
2508. Vaidya B, Pearce SH, Charlton S, et al. An association between the CTLA4 exon 1 polymorphism and early rheumatoid arthritis with autoimmune endocrinopathies. *Rheumatology (Oxford)*. 2002 Feb;41(2):180-3.
2509. Valentino R, Savastano S, Tommaselli AP, et al. Hormonal pattern in women affected by rheumatoid arthritis. *J Endocrinol Invest*. 1993 Sep;16(8):619-24.
2510. Valenzuela-Castano A, Garcia-Lopez A, Perez-Vilches D, et al. The predictive value of the HLA shared epitope for severity of radiological joint damage in patients with rheumatoid arthritis. A 10 year observational prospective study. *J Rheumatol*. 2000 Mar;27(3):571-4.
2511. Valleala H, Mandelin J, Laasonen L, et al. Effect of cyclical intermittent etidronate therapy on circulating osteoprotegerin levels in patients with rheumatoid arthritis. *Eur J Endocrinol*. 2003 May;148(5):527-30.
2512. Vallerskog T, Heimburger M, Gunnarsson I, et al. Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis. *Arthritis Res Ther*. 2006;8(6):R167.
2513. Valtysdottir ST, Wide L, Hallgren R. Low serum dehydroepiandrosterone sulfate in women with primary Sjogren's syndrome as an isolated sign of impaired HPA axis function. *J Rheumatol*. 2001 Jun;28(6):1259-65.
2514. Valtysdottir ST, Wide L, Hallgren R. Mental wellbeing and quality of sexual life in women with primary Sjogren's syndrome are related to circulating dehydroepiandrosterone sulphate. *Ann Rheum Dis*. 2003 Sep;62(9):875-9.
2515. van Baarsen LG, Wijbrandts CA, Rustenburg F, et al. Regulation of IFN response gene activity during infliximab treatment in rheumatoid arthritis is associated with clinical response to treatment. *Arthritis Res Ther*. 2010;12(1):R11.
2516. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Ann Rheum Dis*. 2004 May;63(5):508-16.
2517. van de Putte LB, Rau R, Breedveld FC, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. *Ann Rheum Dis*. 2003 Dec;62(12):1168-77.
2518. van den Bemt BJ, den Broeder AA, Snijders GF, et al. Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study. *Ann Rheum Dis*. 2008 Dec;67(12):1697-701.
2519. Van den Bosch F, Kruithof E, Baeten D, et al. Effects of a loading dose regimen of three infusions of chimeric monoclonal antibody to tumour necrosis factor alpha (infliximab) in spondyloarthritis: an open pilot study. *Ann Rheum Dis*. 2000 Jun;59(6):428-33.

2520. Van den Bosch F, Kruithof E, De Vos M, et al. Crohn's disease associated with spondyloarthritis: effect of TNF-alpha blockade with infliximab on articular symptoms. *Lancet*. 2000 Nov 25;356(9244):1821-2.
2521. Van den Bosch F, Manger B, Goupille P, et al. Effectiveness of adalimumab in treating patients with active psoriatic arthritis and predictors of good clinical responses for arthritis, skin and nail lesions. *Ann Rheum Dis*. 2010 Feb;69(2):394-9.
2522. van den Brink HR, van Wijk MJ, Bijlsma JW. Influence of steroid hormones on proliferation of peripheral blood mononuclear cells in patients with rheumatoid arthritis. *Br J Rheumatol*. 1992 Oct;31(10):663-7.
2523. van den Brink HR, van Wijk MJ, Geertzen RG, et al. Influence of corticosteroid pulse therapy on the serum levels of soluble interleukin 2 receptor, interleukin 6 and interleukin 8 in patients with rheumatoid arthritis. *J Rheumatol*. 1994 Mar;21(3):430-4.
2524. van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. *Arthritis Rheum*. 2009 Mar 15;61(3):291-9.
2525. van der Bijl AE, Breedveld FC, Antoni CE, et al. An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status. *Clin Rheumatol*. 2008 Aug;27(8):1021-8.
2526. van der Bijl AE, Emmer BJ, Breedveld FC, et al. Advanced magnetic resonance imaging of the brain in patients treated with TNF-alpha blocking agents. *Clin Exp Rheumatol*. 2007 Mar-Apr;25(2):301-4.
2527. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. *Arthritis Rheum*. 2007 Jul;56(7):2129-34.
2528. van der Heide A, Jacobs JW, Bijlsma JW, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. *Ann Intern Med*. 1996 Apr 15;124(8):699-707.
2529. van der Heijde D, Burmester G, Melo-Gomes J, et al. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. *Ann Rheum Dis*. 2008 Feb;67(2):182-8.
2530. van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). *Arthritis Rheum*. 2005 Feb;52(2):582-91.
2531. van der Heijde D, Klareskog L, Boers M, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. *Ann Rheum Dis*. 2005 Nov;64(11):1582-7.
2532. van der Heijde D, Klareskog L, Rodriguez-Valverde V, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis Rheum*. 2006 Apr;54(4):1063-74.
2533. van der Heijde D, Klareskog L, Singh A, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. *Ann Rheum Dis*. 2006 Mar;65(3):328-34.
2534. van der Heijde D, Landewe R, Klareskog L, et al. Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. *Arthritis Rheum*. 2005 Jan;52(1):49-60.
2535. van der Helm-van Mil AH, le Cessie S, van Dongen H, et al. A prediction rule for disease outcome in patients with recent-onset undifferentiated arthritis: how to guide individual treatment decisions. *Arthritis Rheum*. 2007 Feb;56(2):433-40.
2536. van der Klooster JM, Bosman RJ, Oudemans-van Straaten HM, et al. Disseminated tuberculosis, pulmonary aspergillosis and cutaneous herpes simplex infection in a patient with infliximab and methotrexate. *Intensive Care Med*. 2003 Dec;29(12):2327-9.

2537. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. *Arthritis Rheum*. 2009 Jan 15;61(1):4-12.
2538. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. *Ann Rheum Dis*. 2007 Oct;66(10):1356-62.
2539. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. *Ann Rheum Dis* 2009;68(6):914-21.
2540. van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. *Ann Rheum Dis*. 2009 Jul;68(7):1153-8.
2541. van der Laken CJ, Lems WF, van Soesbergen RM, et al. Paraplegia in a patient receiving anti-tumor necrosis factor therapy for rheumatoid arthritis: comment on the article by Mohan et al. *Arthritis Rheum*. 2003 Jan;48(1):269-70.
2542. van der Laken CJ, Voskuyl AE, Roos JC, et al. Imaging and serum analysis of immune complex formation of radiolabelled infliximab and anti-infliximab in responders and non-responders to therapy for rheumatoid arthritis. *Ann Rheum Dis*. 2007 Feb;66(2):253-6.
2543. van der Pouw Kraan TC, Wijbrandts CA, van Baarsen LG, et al. Responsiveness to anti-tumour necrosis factor alpha therapy is related to pre-treatment tissue inflammation levels in rheumatoid arthritis patients. *Ann Rheum Dis*. 2008 Apr;67(4):563-6.
2544. van der Veen MJ, Bijlsma JW. Effects of different regimes of corticosteroid treatment on calcium and bone metabolism in rheumatoid arthritis. *Clin Rheumatol*. 1992 Sep;11(3):388-92.
2545. van der Veen MJ, Bijlsma JW. The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. *Clin Rheumatol*. 1993 Dec;12(4):500-5.
2546. van der Veen MJ, Dekker JJ, Dinant HJ, et al. Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. *J Rheumatol*. 1995 Sep;22(9):1766-8.
2547. Van Doornum S, McColl G, Wicks IP. Tumour necrosis factor antagonists improve disease activity but not arterial stiffness in rheumatoid arthritis. *Rheumatology (Oxford)*. 2005 Nov;44(11):1428-32.
2548. van Ede A, den Broeder A, Wagenaar M, et al. Etanercept-related extensive pulmonary nodulosis in a patient with rheumatoid arthritis. *J Rheumatol*. 2007 Jul;34(7):1590-2.
2549. van Eijk IC, Peters MJ, Nurmohamed MT, et al. Decrease of fructosamine levels during treatment with adalimumab in patients with both diabetes and rheumatoid arthritis. *Eur J Endocrinol*. 2007 Mar;156(3):291-3.
2550. van Everdingen AA, Huisman AM, Wenting MJ, et al. Down regulation of glucocorticoid receptors in early-diagnosed rheumatoid arthritis. *Clin Exp Rheumatol*. 2002 Jul-Aug;20(4):463-8.
2551. van Halm VP, Nurmohamed MT, Twisk JW, et al. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. *Arthritis Res Ther* 2006;8(5):R151.
2552. van Ingen J, Boeree M, Janssen M, et al. Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy. *Nat Clin Pract Rheumatol*. 2007 Jul;3(7):414-9.
2553. van Leeuwen MA, van der Heijde DM, van Rijswijk MH, et al. Interrelationship of outcome measures and process variables in early rheumatoid arthritis. A comparison of radiologic damage, physical disability, joint counts, and acute phase reactants. *J Rheumatol*. 1994 Mar;21(3):425-9.

2554. van Leeuwen MA, van Rijswijk MH, van der Heijde DM, et al. The acute-phase response in relation to radiographic progression in early rheumatoid arthritis: a prospective study during the first three years of the disease. *Br J Rheumatol*. 1993 Jun;32 Suppl 3:9-13.
2555. van Lieshout AW, Fransen J, Flendrie M, et al. Circulating levels of the chemokine CCL18 but not CXCL16 are elevated and correlate with disease activity in rheumatoid arthritis. *Ann Rheum Dis*. 2007 Oct;66(10):1334-8.
2556. van Middendorp H, Geenen R, Sorbi MJ, et al. Neuroendocrine-immune relationships between emotion regulation and health in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2005 Jul;44(7):907-11.
2557. van Oosterhout M, Levarht EW, Sont JK, et al. Clinical efficacy of infliximab plus methotrexate in DMARD naive and DMARD refractory rheumatoid arthritis is associated with decreased synovial expression of TNF alpha and IL18 but not CXCL12. *Ann Rheum Dis*. 2005 Apr;64(4):537-43.
2558. van Roon EN, Hoekstra M, Tobi H, et al. Leflunomide in the treatment of rheumatoid arthritis. An analysis of predictors for treatment continuation. *Br J Clin Pharmacol*. 2005 Sep;60(3):319-25.
2559. van Roon EN, van den Bemt PM, Jansen TL, et al. An evidence-based assessment of the clinical significance of drug-drug interactions between disease-modifying antirheumatic drugs and non-antirheumatic drugs according to rheumatologists and pharmacists. *Clin Ther*. 2009 Aug;31(8):1737-46.
2560. van Roon JA, Hartgring SA, Wenting-van Wijk M, et al. Persistence of interleukin 7 activity and levels on tumour necrosis factor alpha blockade in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2007 May;66(5):664-9.
2561. van Staa TP, Geusens P, Bijlsma JW, et al. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. *Arthritis Rheum*. 2006 Oct;54(10):3104-12.
2562. van Thiel RJ, van der Burg S, Groote AD, et al. Bronchiolitis obliterans organizing pneumonia and rheumatoid arthritis. *Eur Respir J*. 1991 Jul;4(7):905-11.
2563. Van Tilt I, Lories RJ, Westhovens R, et al. Unusual cervical spine involvement in psoriatic arthritis: a case series. *Clin Rheumatol*. 2009 Nov;28(11):1343-6.
2564. van Tuyl LH, Lems WF, Voskuyl AE, et al. Tight control and intensified COBRA combination treatment in early rheumatoid arthritis: 90% remission in a pilot trial. *Ann Rheum Dis*. 2008 Nov;67(11):1574-7.
2565. van Tuyl LH, Plass AM, Lems WF, et al. Facilitating the use of COBRA combination therapy in early rheumatoid arthritis: a pilot implementation study. *J Rheumatol*. 2009 Jul;36(7):1380-6.
2566. van Vollenhoven R, Harju A, Brannemark S, et al. Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense. *Ann Rheum Dis*. 2003 Dec;62(12):1195-8.
2567. van Vollenhoven RF, Cifaldi MA, Ray S, et al. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. *Arthritis Care Res (Hoboken)* 2010;62(2):226-34.
2568. van Vollenhoven RF, Emery P, Bingham CO, 3rd, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. *J Rheumatol* 2010;37(3):558-67.
2569. van Vollenhoven RF, Ernestam S, Geborek P, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. *Lancet* 2009;374(9688):459-66.

2570. van Vollenhoven RF, Ernestam S, Harju A, et al. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. *Arthritis Res Ther.* 2003;5(6):R347-51.
2571. van Vollenhoven RF, Houbiers JG, Buttgereit F, et al. The selective estrogen receptor alpha agonist Org 37663 induces estrogenic effects but lacks antirheumatic activity: a phase IIa trial investigating efficacy and safety of Org 37663 in postmenopausal female rheumatoid arthritis patients receiving stable background methotrexate or sulfasalazine. *Arthritis Rheum.* 2010 Feb;62(2):351-8.
2572. van Vollenhoven RF, Klareskog L. Infliximab dosage and infusion frequency in clinical practice: experiences in the Stockholm biologics registry STURE. *Scand J Rheumatol.* 2007 Nov-Dec;36(6):418-23.
2573. van Woerkom JM, Kruize AA, Geenen R, et al. Safety and efficacy of leflunomide in primary Sjogren's syndrome: a phase II pilot study. *Ann Rheum Dis.* 2007 Aug;66(8):1026-32.
2574. Vander Cruyssen B, Durez P, Westhovens R, et al. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. *Arthritis Res Ther.* 2010;12(3):R77.
2575. Vandergheynst F, Gosset J, van de Borne P, et al. Myopericarditis revealing adult-onset Still's disease. *Acta Clin Belg.* 2005 Sep-Oct;60(4):205-8.
2576. Vandooren B, Kruithof E, Yu DT, et al. Involvement of matrix metalloproteinases and their inhibitors in peripheral synovitis and down-regulation by tumor necrosis factor alpha blockade in spondylarthropathy. *Arthritis Rheum.* 2004 Sep;50(9):2942-53.
2577. Varani K, Massara A, Vincenzi F, et al. Normalization of A2A and A3 adenosine receptor up-regulation in rheumatoid arthritis patients by treatment with anti-tumor necrosis factor alpha but not methotrexate. *Arthritis Rheum.* 2009 Oct;60(10):2880-91.
2578. Varatharajan N, Lim IG, Anandacoomarasamy A, et al. Methotrexate: long-term safety and efficacy in an Australian consultant rheumatology practice. *Intern Med J.* 2009 Apr;39(4):228-36.
2579. Vasques Godinho FM, Parreira Santos MJ, Canas da Silva J. Refractory adult onset Still's disease successfully treated with anakinra. *Ann Rheum Dis.* 2005 Apr;64(4):647-8.
2580. Vassallo R, Matteson E, Thomas CF, Jr. Clinical response of rheumatoid arthritis-associated pulmonary fibrosis to tumor necrosis factor-alpha inhibition. *Chest.* 2002 Sep;122(3):1093-6.
2581. Vassilopoulos D, Apostolopoulou A, Hadziyannis E, et al. Long-term safety of anti-TNF treatment in patients with rheumatic diseases and chronic or resolved hepatitis B virus infection. *Ann Rheum Dis.* 2010 Jul;69(7):1352-5.
2582. Vassilopoulos D, Sialevris K, Malahtari S, et al. Subacute thyroiditis presenting as fever of unknown origin in a patient with rheumatoid arthritis under etanercept treatment. *J Clin Rheumatol.* 2010 Mar;16(2):88-9.
2583. Vastesaegeer N, Xu S, Aletaha D, et al. A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. *Rheumatology (Oxford).* 2009 Sep;48(9):1114-21.
2584. Vavricka SR, Wettstein T, Speich R, et al. Pulmonary granulomas after tumour necrosis factor alpha antagonist therapy. *Thorax.* 2003 Mar;58(3):278-9.
2585. Vazquez I, Graell E, Gratacos J, et al. Prognostic markers of clinical remission in early rheumatoid arthritis after two years of DMARDs in a clinical setting. *Clin Exp Rheumatol.* 2007 Mar-Apr;25(2):231-8.
2586. Vazquez-Del Mercado M, Delgado-Rizo V, Munoz-Valle JF, et al. Expression of interleukin-1 beta, tumor necrosis factor alpha, interleukins-6, -10 and -4, and metalloproteases by freshly isolated mononuclear cells from early never-treated and non-acute treated rheumatoid arthritis patients. *Clin Exp Rheumatol.* 1999 Sep-Oct;17(5):575-83.

2587. Vena GA, Altomare G, Ayala F, et al. Incidence of psoriasis and association with comorbidities in Italy: a 5-year observational study from a national primary care database. *Eur J Dermatol*. 2010 Sep-Oct;20(5):593-8.
2588. Venarucci D, Catalini P, Scendoni P, et al. Evaluation of certain immunity parameters in rheumatoid arthritis, treated with cortisone. *Panminerva Med*. 1994 Dec;36(4):188-91.
2589. Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to tumor necrosis factor-alpha antagonists. *J Rheumatol*. 2008 Sep;35(9):1745-53.
2590. Vera-Llonch M, Massarotti E, Wolfe F, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. *Rheumatology (Oxford)*. 2008 Apr;47(4):535-41.
2591. Verbruggen LA, Versaen H, Rebmann V, et al. Soluble HLA-DR levels in serum are associated with therapy and genetic factors in rheumatoid arthritis. *Hum Immunol*. 2002 Sep;63(9):758-64.
2592. Vergara G, Silvestre JF, Betlloch I, et al. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. *Arch Dermatol*. 2002 Sep;138(9):1258-9.
2593. Vergunst CE, Gerlag DM, von Moltke L, et al. MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study. *Arthritis Rheum*. 2009 Dec;60(12):3572-81.
2594. Verhave JC, van Altena R, Wijnands MJ, et al. Tuberculous peritonitis during infliximab therapy. *Neth J Med*. 2008 Feb;66(2):77-80.
2595. Verhelst X, Orlent H, Colle I, et al. Subfulminant hepatitis B during treatment with adalimumab in a patient with rheumatoid arthritis and chronic hepatitis B. *Eur J Gastroenterol Hepatol*. 2010 Apr;22(4):494-9.
2596. Verhoef CM, van Roon JA, Vianen ME, et al. The immune suppressive effect of dexamethasone in rheumatoid arthritis is accompanied by upregulation of interleukin 10 and by differential changes in interferon gamma and interleukin 4 production. *Ann Rheum Dis*. 1999 Jan;58(1):49-54.
2597. Verhoeven AC, Boers M, te Koppele JM, et al. Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. *Rheumatology (Oxford)*. 2001 Nov;40(11):1231-7.
2598. Verschueren K, Van Essche E, Verschueren P, et al. Development of sarcoidosis in etanercept-treated rheumatoid arthritis patients. *Clin Rheumatol*. 2007 Nov;26(11):1969-71.
2599. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. *Rheumatology (Oxford)*. 2008 Jan;47(1):59-64.
2600. Verstappen SM, Jacobs JW, van der Veen MJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial). *Ann Rheum Dis*. 2007 Nov;66(11):1443-9.
2601. Verwilghen J, Lovis R, De Boer M, et al. Expression of functional B7 and CTLA4 on rheumatoid synovial T cells. *J Immunol*. 1994 Aug 1;153(3):1378-85.
2602. Vidal F, Fontova R, Richart C. Severe neutropenia and thrombocytopenia associated with infliximab. *Ann Intern Med*. 2003 Aug 5;139(3):W-W63.
2603. Vieira Serrao V, Martins A, Lopes MJ. Infliximab in recalcitrant generalized pustular arthropathic psoriasis. *Eur J Dermatol*. 2008 Jan-Feb;18(1):71-3.
2604. Vigna-Perez M, Abud-Mendoza C, Portillo-Salazar H, et al. Immune effects of therapy with Adalimumab in patients with rheumatoid arthritis. *Clin Exp Immunol*. 2005 Aug;141(2):372-80.
2605. Vignes S, Le Moing V, Meekel P, et al. Acquired hemophilia: a rare complication of Sjogren's syndrome. *Clin Exp Rheumatol*. 1996 Sep-Oct;14(5):559-60.

2606. Viguier M, Richette P, Aubin F, et al. Onset of psoriatic arthritis in patients treated with efalizumab for moderate to severe psoriasis. *Arthritis Rheum.* 2008 Jun;58(6):1796-802.
2607. Vila AT, Puig L, Fernandez-Figueras MT, et al. Adverse cutaneous reactions to anakinra in patients with rheumatoid arthritis: clinicopathological study of five patients. *Br J Dermatol.* 2005 Aug;153(2):417-23.
2608. Vila LM, Molina MJ. Chronic anemia and thrombocytosis as the initial presentation of Still's disease in an elderly patient. *Gerontology.* 2007;53(5):289-92.
2609. Vine JE, Hymes SR, Warner NB, et al. Pustular psoriasis induced by hydroxychloroquine: a case report and review of the literature. *J Dermatol.* 1996 May;23(5):357-61.
2610. Vintimilla M, Joseph A, Ranganathan P. Acquired factor VIII inhibitor in Sjogren's syndrome. *Arthritis Care Res (Hoboken).* 2010 Jul;62(7):1047-50.
2611. Virkki LM, Konttinen YT, Peltomaa R, et al. Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice. *Clin Exp Rheumatol.* 2008 Nov-Dec;26(6):1059-66.
2612. Virkki LM, Porola P, Forsblad-d'Elia H, et al. Dehydroepiandrosterone (DHEA) substitution treatment for severe fatigue in DHEA-deficient patients with primary Sjogren's syndrome. *Arthritis Care Res (Hoboken).* 2010 Jan 15;62(1):118-24.
2613. Vis M, Bos WH, Wolbink G, et al. IgM-rheumatoid factor, anti-cyclic citrullinated peptide, and anti-citrullinated human fibrinogen antibodies decrease during treatment with the tumor necrosis factor blocker infliximab in patients with rheumatoid arthritis. *J Rheumatol.* 2008 Mar;35(3):425-8.
2614. Vis M, Nurmohamed MT, Wolbink G, et al. Short term effects of infliximab on the lipid profile in patients with rheumatoid arthritis. *J Rheumatol.* 2005 Feb;32(2):252-5.
2615. Vis M, Voskuyl AE, Wolbink GJ, et al. Bone mineral density in patients with rheumatoid arthritis treated with infliximab. *Ann Rheum Dis.* 2005 Feb;64(2):336-7.
2616. Vis M, Wolbink GJ, Lodder MC, et al. Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. *Arthritis Rheum.* 2003 Oct;48(10):2996-7.
2617. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. *Ann Rheum Dis.* 2010 Jul;69(7):1333-7.
2618. Visvanathan S, Wagner C, Rojas J, et al. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. *J Rheumatol.* 2009 Jul;36(7):1371-9.
2619. Visvanathan S, Wagner C, Smolen J, et al. IgG and IgM anticardiolipin antibodies following treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. *Arthritis Rheum.* 2006 Sep;54(9):2840-4.
2620. Vital EM, Dass S, Rawstron AC, et al. Management of nonresponse to rituximab in rheumatoid arthritis: predictors and outcome of re-treatment. *Arthritis Rheum.* 2010 May;62(5):1273-9.
2621. Vivarelli M, D'Urbano LE, Insalaco A, et al. Macrophage migration inhibitory factor (MIF) and oligoarticular juvenile idiopathic arthritis (o-JIA): association of MIF promoter polymorphisms with response to intra-articular glucocorticoids. *Clin Exp Rheumatol.* 2007 Sep-Oct;25(5):775-81.
2622. Vlachaki E, Psathakis K, Tsintiris K, et al. Delayed response to anti-tuberculosis treatment in a patient on infliximab. *Respir Med.* 2005 May;99(5):648-52.
2623. Vlachoyiannopoulos PG, Kanellopoulos PG, Ioannidis JP, et al. Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. *Rheumatology (Oxford).* 2003 May;42(5):645-51.

2624. Vogl D, Falk W, Dorner M, et al. Serum levels of pregnenolone and 17-hydroxypregnenolone in patients with rheumatoid arthritis and systemic lupus erythematosus: relation to other adrenal hormones. *J Rheumatol.* 2003 Feb;30(2):269-75.
2625. Volpe A, Caramaschi P, Carletto A, et al. Psoriasis onset during infliximab treatment: description of two cases. *Rheumatol Int.* 2006 Oct;26(12):1158-60.
2626. Vonkeman H, ten Napel C, Rasker H, et al. Disseminated primary varicella infection during infliximab treatment. *J Rheumatol.* 2004 Dec;31(12):2517-8.
2627. Voog U, Alstergren P, Eliasson S, et al. Progression of radiographic changes in the temporomandibular joints of patients with rheumatoid arthritis in relation to inflammatory markers and mediators in the blood. *Acta Odontol Scand.* 2004 Feb;62(1):7-13.
2628. Vordenbaumen S, Neuen-Jacob E, Richter J, et al. Inclusion body myositis in a patient with long standing rheumatoid arthritis treated with anti-TNFalpha and rituximab. *Clin Rheumatol.* 2010 May;29(5):555-8.
2629. Vos K, Thurlings RM, Wijbrandts CA, et al. Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. *Arthritis Rheum.* 2007 Mar;56(3):772-8.
2630. Voskuyl AE, Van de Laar MA, Moens HJ, et al. Extra-articular manifestations of rheumatoid arthritis: risk factors for serious gastrointestinal events. *Ann Rheum Dis.* 1993 Nov;52(11):771-5.
2631. Voskuyl AE, Zwinderman AH, Westedt ML, et al. Factors associated with the development of vasculitis in rheumatoid arthritis: results of a case-control study. *Ann Rheum Dis.* 1996 Mar;55(3):190-2.
2632. Voulgarelis M, Giannouli S, Anagnostou D, et al. Combined therapy with rituximab plus cyclophosphamide/doxorubicin/vincristine/prednisone (CHOP) for Sjogren's syndrome-associated B-cell aggressive non-Hodgkin's lymphomas. *Rheumatology (Oxford).* 2004 Aug;43(8):1050-3.
2633. Voulgari PV, Alamanos Y, Nikas SN, et al. Infliximab therapy in established rheumatoid arthritis: an observational study. *Am J Med.* 2005 May;118(5):515-20.
2634. Voulgari PV, Markatseli TE, Exarchou SA, et al. Granuloma annulare induced by anti-tumour necrosis factor therapy. *Ann Rheum Dis.* 2008 Apr;67(4):567-70.
2635. Voulgari PV, Venetsanopoulou AI, Exarchou SA, et al. Sustained clinical response and high infliximab survival in psoriatic arthritis patients: a 3-year long-term study. *Semin Arthritis Rheum.* 2008 Apr;37(5):293-8.
2636. Voutilainen M, Sokka T, Juhola M, et al. Nonsteroidal anti-inflammatory drug-associated upper gastrointestinal lesions in rheumatoid arthritis patients. Relationships to gastric histology, *Helicobacter pylori* infection, and other risk factors for peptic ulcer. *Scand J Gastroenterol.* 1998 Aug;33(8):811-6.
2637. Vrzogic P, Pasic A, Podobnik-Takac T. Psoriasis vulgaris and arthritis psoriatica gravis mutilans. *Acta Dermatovenerol Croat.* 2003;11(1):22-8.
2638. Vytasek R, Sedova L, Vilim V. Increased concentration of two different advanced glycation end-products detected by enzyme immunoassays with new monoclonal antibodies in sera of patients with rheumatoid arthritis. *BMC Musculoskeletal Disord.* 2010;11:83.
2639. Wachi K, Prasertsuntarasai T, Kishimoto M, et al. T-cell lymphopenia associated with infliximab and cyclophosphamide. *Am J Med Sci.* 2005 Jul;330(1):48-51.
2640. Wagner U, Pierer M, Wahle M, et al. Ex vivo homeostatic proliferation of CD4+ T cells in rheumatoid arthritis is dysregulated and driven by membrane-anchored TNFalpha. *J Immunol.* 2004 Aug 15;173(4):2825-33.
2641. Waguri-Nagaya Y, Kobayashi M, Goto H, et al. Septic arthritis of the right ankle caused by *Staphylococcus aureus* infection in a rheumatoid arthritis patient treated with etanercept. *Mod Rheumatol.* 2007;17(4):338-40.



2642. Wakabayashi H, Sudo A, Hasegawa M, et al. Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis. *Clin Rheumatol*. 2010;29(6):671-5.
2643. Wakefield RJ, Freeston JE, Hensor EM, et al. Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis. *Arthritis Rheum*. 2007 Dec 15;57(8):1564-7.
2644. Wall E, Walker-Bone K. Use of bisphosphonates and dual-energy X-ray absorptiometry scans in the prevention and treatment of glucocorticoid-induced osteoporosis in rheumatology. *Qjm*. 2008 Apr;101(4):317-23.
2645. Wallace DJ, Metzger AL, Stecher VJ, et al. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. *Am J Med*. 1990 Sep;89(3):322-6.
2646. Wallberg-Jonsson S, Johansson H, Ohman ML, et al. Extent of inflammation predicts cardiovascular disease and overall mortality in seropositive rheumatoid arthritis. A retrospective cohort study from disease onset. *J Rheumatol*. 1999 Dec;26(12):2562-71.
2647. Wallberg-Jonsson S, Ohman M, Rantapaa-Dahlqvist S. Which factors are related to the presence of atherosclerosis in rheumatoid arthritis? *Scand J Rheumatol*. 2004;33(6):373-9.
2648. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. *J Rheumatol*. 1997 Mar;24(3):445-51.
2649. Walsh CA, Fearon U, FitzGerald O, et al. Decreased CD20 expression in rheumatoid arthritis synovium following 8 weeks of rituximab therapy. *Clin Exp Rheumatol*. 2008 Jul-Aug;26(4):656-8.
2650. Walsh CA, Minnock P, Slattery C, et al. Quality of life and economic impact of switching from established infliximab therapy to adalimumab in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2007 Jul;46(7):1148-52.
2651. Walsh LJ, Wong CA, Pringle M, et al. Use of oral corticosteroids in the community and the prevention of secondary osteoporosis: a cross sectional study. *BMJ*. 1996 Aug 10;313(7053):344-6.
2652. Wang M, Tsai RT, Ou WC, et al. Treatment with cytotoxic immunosuppression agents increases urinary excretion of JCV in patients with autoimmune disease. *J Med Virol*. 2000 Dec;62(4):505-10.
2653. Wang SJ, Yang YH, Lin YT, et al. Attained adult height in juvenile rheumatoid arthritis with or without corticosteroid treatment. *Clin Rheumatol*. 2002 Sep;21(5):363-8.
2654. Ward MM, Fries JF. Trends in antirheumatic medication use among patients with rheumatoid arthritis, 1981-1996. *J Rheumatol*. 1998 Mar;25(3):408-16.
2655. Wardwell NR, Jr., Miller R, Ware LB. Pulmonary alveolar proteinosis associated with a disease-modifying antirheumatoid arthritis drug. *Respirology*. 2006 Sep;11(5):663-5.
2656. Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. *Jama*. 2007 Jul 11;298(2):187-93.
2657. Wasserman MJ, Weber DA, Guthrie JA, et al. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. *J Rheumatol*. 2004 Oct;31(10):1912-7.
2658. Wasserteil V, Bruce S, Sessoms SL, et al. Pyoderma gangrenosum treated with hyperbaric oxygen therapy. *Int J Dermatol*. 1992 Aug;31(8):594-6.
2659. Watanabe H, Suzuki R, Asano T, et al. A case of emphysematous pyelonephritis in a patient with rheumatoid arthritis taking corticosteroid and low-dose methotrexate. *Int J Rheum Dis*. 2010 May;13(2):180-3.
2660. Watanabe T, Tsuchida T, Furue M, et al. Annular erythema, dermatomyositis, and Sjogren's syndrome. *Int J Dermatol*. 1996 Apr;35(4):285-7.

2661. Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. *Arch Intern Med.* 2002 May 27;162(10):1105-10.
2662. Weaver AL, Lautzenheiser RL, Schiff MH, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. *Curr Med Res Opin.* 2006 Jan;22(1):185-98.
2663. Weidler C, Struharova S, Schmidt M, et al. Tumor necrosis factor inhibits conversion of dehydroepiandrosterone sulfate (DHEAS) to DHEA in rheumatoid arthritis synovial cells: a prerequisite for local androgen deficiency. *Arthritis Rheum.* 2005 Jun;52(6):1721-9.
2664. Weinblatt ME, Abbott GF, Koreishi AF. Case records of the Massachusetts General Hospital. Case 13-2009. A 54-year-old woman with respiratory failure and a cavitary lesion in the lung. *N Engl J Med.* 2009 Apr 23;360(17):1770-9.
2665. Weinblatt ME, Kavanaugh A, Burgos-Vargas R, et al. Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial. *Arthritis Rheum.* 2008 Nov;58(11):3309-18.
2666. Weinblatt ME, Kavanaugh A, Genovese MC, et al. An oral spleen tyrosine kinase (Syk) inhibitor for rheumatoid arthritis. *N Engl J Med.* 2010 Sep 30;363(14):1303-12.
2667. Weinblatt ME, Keystone EC, Furst DE, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum.* 2003 Jan;48(1):35-45.
2668. Weinblatt ME, Kremer JM, Bankhurst AD, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med.* 1999 Jan 28;340(4):253-9.
2669. Weinblatt ME, Schiff MH, Ruderman EM, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. *Arthritis Rheum.* 2008 Jul;58(7):1921-30.
2670. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. *Clin Ther.* 2003 Jun;25(6):1700-21.
2671. Weisman MH, Paulus HE, Burch FX, et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. *Rheumatology (Oxford)* 2007;46(7):1122-5.
2672. Weiss AH, Wallace CA, Sherry DD. Methotrexate for resistant chronic uveitis in children with juvenile rheumatoid arthritis. *J Pediatr.* 1998 Aug;133(2):266-8.
2673. Weitoft T, Forsberg C. Importance of immobilization after intraarticular glucocorticoid treatment for elbow synovitis: a randomized controlled study. *Arthritis Care Res (Hoboken).* 2010 May;62(5):735-7.
2674. Weitoft T, Larsson A, Ronnblom L. Serum levels of sex steroid hormones and matrix metalloproteinases after intra-articular glucocorticoid treatment in female patients with rheumatoid arthritis. *Ann Rheum Dis.* 2008 Mar;67(3):422-4.
2675. Weitoft T, Ronnblom L. Glucocorticoid resorption and influence on the hypothalamic-pituitary-adrenal axis after intra-articular treatment of the knee in resting and mobile patients. *Ann Rheum Dis.* 2006 Jul;65(7):955-7.
2676. Weitoft T, Uddenfeldt P. Importance of synovial fluid aspiration when injecting intra-articular corticosteroids. *Ann Rheum Dis.* 2000 Mar;59(3):233-5.

2677. Wells G, Becker JC, Teng J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. *Ann Rheum Dis*. 2009 Jun;68(6):954-60.
2678. Wells G, Li T, Maxwell L, et al. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. *Ann Rheum Dis* 2008;67(2):260-5.
2679. Wells G, Li T, Tugwell P. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. *Ann Rheum Dis*. 2010 Oct;69(10):1768-73.
2680. Wells GA, Boers M, Li T, et al. Investigating the validity of the minimal disease activity state for patients with rheumatoid arthritis treated with abatacept. *J Rheumatol*. 2009 Feb;36(2):260-5.
2681. Wendling D, Materne GE, Michel F, et al. Infliximab continuation rates in patients with rheumatoid arthritis in everyday practice. *Joint Bone Spine*. 2005 Jul;72(4):309-12.
2682. Wendling D, Streit G, Toussirot E, et al. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. *Joint Bone Spine*. 2008 Oct;75(5):540-3.
2683. Wessels JA, de Vries-Bouwstra JK, Heijmans BT, et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. *Arthritis Rheum*. 2006 Apr;54(4):1087-95.
2684. Wessels JA, Kooloos WM, De Jonge R, et al. Relationship between genetic variants in the adenosine pathway and outcome of methotrexate treatment in patients with recent-onset rheumatoid arthritis. *Arthritis Rheum*. 2006 Sep;54(9):2830-9.
2685. Wessels JA, van der Kooij SM, le Cessie S, et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. *Arthritis Rheum*. 2007 Jun;56(6):1765-75.
2686. West SG, Troutner JL, Baker MR, et al. Sacral insufficiency fractures in rheumatoid arthritis. *Spine*. 1994 Sep 15;19(18):2117-21.
2687. Westhovens R, Houssiau F, Joly J, et al. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. *J Rheumatol*. 2006 May;33(5):847-53.
2688. Westhovens R, Nijs J, Taelman V, et al. Body composition in rheumatoid arthritis. *Br J Rheumatol*. 1997 Apr;36(4):444-8.
2689. Weusten BL, Jacobs JW, Bijlsma JW. Corticosteroid pulse therapy in active rheumatoid arthritis. *Semin Arthritis Rheum*. 1993 Dec;23(3):183-92.
2690. Weycker D, Yu EB, Woolley JM, et al. Retrospective study of the costs of care during the first year of therapy with etanercept or infliximab among patients aged > or =65 years with rheumatoid arthritis. *Clin Ther*. 2005 May;27(5):646-56.
2691. White D, Fayez S, Doube A. Atherogenic lipid profiles in rheumatoid arthritis. *N Z Med J*. 2006;119(1240):U2125.
2692. White KL. Psoriasis and psoriatic arthritis, axial type. *Dermatol Online J*. 2001 Dec;7(2):12.
2693. Wiatrowski M, Furfaro N. Patient profiles in psoriatic disease: a case-based approach. *Dermatol Nurs*. 2007 Oct;Suppl:5-19; quiz 20-1.
2694. Wick MC, Ernestam S, Lindblad S, et al. Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital. *Scand J Rheumatol*. 2005 Sep-Oct;34(5):353-8.

2695. Wiens A, Correr CJ, Pontarolo R, et al. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. *Scand J Immunol* 2009;70(4):337-44.
2696. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. *Pharmacotherapy* 2010;30(4):339-53.
2697. Wijbrandts CA, Dijkgraaf MG, Kraan MC, et al. The clinical response to infliximab in rheumatoid arthritis is in part dependent on pretreatment tumour necrosis factor alpha expression in the synovium. *Ann Rheum Dis*. 2008 Aug;67(8):1139-44.
2698. Wijbrandts CA, Klaasen R, Dijkgraaf MG, et al. Bone mineral density in rheumatoid arthritis patients 1 year after adalimumab therapy: arrest of bone loss. *Ann Rheum Dis*. 2009 Mar;68(3):373-6.
2699. Wijbrandts CA, Remans PH, Klarenbeek PL, et al. Analysis of apoptosis in peripheral blood and synovial tissue very early after initiation of infliximab treatment in rheumatoid arthritis patients. *Arthritis Rheum*. 2008 Nov;58(11):3330-9.
2700. Wijngaarden S, van de Winkel JG, Bijlsma JW, et al. Treatment of rheumatoid arthritis patients with anti-TNF-alpha monoclonal antibody is accompanied by down-regulation of the activating Fc gamma receptor I on monocytes. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1):89-95.
2701. Wikaningrum R, Highton J, Parker A, et al. Pathogenic mechanisms in the rheumatoid nodule: comparison of proinflammatory cytokine production and cell adhesion molecule expression in rheumatoid nodules and synovial membranes from the same patient. *Arthritis Rheum*. 1998 Oct;41(10):1783-97.
2702. Wiland P, Wiela-Hojenska A, Glowska A, et al. Renal function in rheumatoid arthritis patients treated with methotrexate and infliximab. *Clin Exp Rheumatol*. 2004 Jul-Aug;22(4):469-72.
2703. Wilder RL. Adrenal and gonadal steroid hormone deficiency in the pathogenesis of rheumatoid arthritis. *J Rheumatol Suppl*. 1996 Mar;44:10-2.
2704. Williams CS, Butler E, Roman GC. Treatment of myelopathy in Sjogren syndrome with a combination of prednisone and cyclophosphamide. *Arch Neurol*. 2001 May;58(5):815-9.
2705. Wilson ML, Sewell LD, Mowad CM. Primary cutaneous Cryptococcosis during therapy with methotrexate and adalimumab. *J Drugs Dermatol*. 2008 Jan;7(1):53-4.
2706. Winfield H, Lain E, Horn T, et al. Eosinophilic cellulitislike reaction to subcutaneous etanercept injection. *Arch Dermatol*. 2006 Feb;142(2):218-20.
2707. Wirnsberger RM, de Vries J, Wouters EF, et al. Clinical presentation of sarcoidosis in The Netherlands an epidemiological study. *Neth J Med*. 1998 Aug;53(2):53-60.
2708. Wislowska M, Jakubicz D. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. *Rheumatol Int*. 2007 May;27(7):641-7.
2709. Wittkowski H, Foell D, af Klint E, et al. Effects of intra-articular corticosteroids and anti-TNF therapy on neutrophil activation in rheumatoid arthritis. *Ann Rheum Dis*. 2007 Aug;66(8):1020-5.
2710. Wolbink GJ, Voskuyl AE, Lems WF, et al. Relationship between serum trough infliximab levels, pretreatment C reactive protein levels, and clinical response to infliximab treatment in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2005 May;64(5):704-7.
2711. Wolf J, Kapral T, Grisar J, et al. Glucocorticoid treatment in rheumatoid arthritis: low-dose therapy does not reduce responsiveness to higher doses. *Clin Exp Rheumatol*. 2008 Jan-Feb;26(1):113-6.
2712. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. *Arthritis Rheum*. 2006 Feb;54(2):628-34.
2713. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. *Scand J Rheumatol* 2007;36(3):172-8.

2714. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. *J Rheumatol*. 2000 Jul;27(7):1668-73.
2715. Wolfe F, Marmor MF. Rates and predictors of hydroxychloroquine retinal toxicity in patients with rheumatoid arthritis and systemic lupus erythematosus. *Arthritis Care Res (Hoboken)*. 2010 Jun;62(6):775-84.
2716. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. *Arthritis Rheum*. 2004 Jun;50(6):1740-51.
2717. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. *Am J Med*. 2004 Mar 1;116(5):305-11.
2718. Wolfe F, Michaud K. Assessment of pain in rheumatoid arthritis: minimal clinically significant difference, predictors, and the effect of anti-tumor necrosis factor therapy. *J Rheumatol*. 2007 Aug;34(8):1674-83.
2719. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. *Arthritis Rheum* 2007;56(5):1433-9.
2720. Wolfe F, Michaud K, Anderson J, et al. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. *Arthritis Rheum*. 2004 Feb;50(2):372-9.
2721. Wolfe F, Michaud K, Li T. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. *J Rheumatol*. 2006 Oct;33(10):1942-51.
2722. Wollina U, Hansel G, Koch A, et al. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. *Am J Clin Dermatol*. 2008;9(1):1-14.
2723. Wollina U, Konrad H. Treatment of recalcitrant psoriatic arthritis with anti-tumor necrosis factor-alpha antibody. *J Eur Acad Dermatol Venereol*. 2002 Mar;16(2):127-9.
2724. Wondergem MJ, Voskuyl AE, van Agtmael MA. A case of legionellosis during treatment with a TNFalpha antagonist. *Scand J Infect Dis*. 2004;36(4):310-1.
2725. Wong JB, Singh G, Kavanaugh A. Estimating the cost-effectiveness of 54 weeks of infliximab for rheumatoid arthritis. *Am J Med*. 2002 Oct 1;113(5):400-8.
2726. Wong T, Majchrzak B, Bogoch E, et al. Therapeutic implications for interferon-alpha in arthritis: a pilot study. *J Rheumatol*. 2003 May;30(5):934-40.
2727. Wood KL, Hage CA, Knox KS, et al. Histoplasmosis after treatment with anti-tumor necrosis factor-alpha therapy. *Am J Respir Crit Care Med*. 2003 May 1;167(9):1279-82.
2728. Wooten MD, Reddy GV, Johnson RD. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis. *Del Med J*. 2000 Dec;72(12):517-9.
2729. Wright T, Cron RQ. Pediatric rheumatology for the adult rheumatologist II: uveitis in juvenile idiopathic arthritis. *J Clin Rheumatol*. 2007 Aug;13(4):205-10.
2730. Wu E, Chen L, Birnbaum H, et al. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. *Curr Med Res Opin*. 2007 Aug;23(8):1749-59.
2731. Wulfraat NM, Sanders LA, Kuis W. Autologous hemopoietic stem-cell transplantation for children with refractory autoimmune disease. *Curr Rheumatol Rep*. 2000 Aug;2(4):316-23.
2732. Wung PK, Pipeling MR, Wigley FM. "Still" ill? *Am J Med*. 2008 Jun;121(6):491-3.
2733. Xiao H, Xu J, Zhou X, et al. Associations between the genetic polymorphisms of MTHFR and outcomes of methotrexate treatment in rheumatoid arthritis. *Clin Exp Rheumatol*. 2010 Sep-Oct;28(5):728-33.

2734. Xu JX, Hoshida Y, Hongyo T, et al. Analysis of p53 and Bak gene mutations in lymphoproliferative disorders developing in rheumatoid arthritis. *J Cancer Res Clin Oncol*. 2007 Feb;133(2):125-33.
2735. Xu Z, Vu T, Lee H, et al. Population pharmacokinetics of golimumab, an anti-tumor necrosis factor-alpha human monoclonal antibody, in patients with psoriatic arthritis. *J Clin Pharmacol*. 2009 Sep;49(9):1056-70.
2736. Yakushiji F, Kita M, Hiroi N, et al. Exacerbation of rheumatoid arthritis after removal of adrenal adenoma in Cushing's syndrome. *Endocr J*. 1995 Apr;42(2):219-23.
2737. Yam LY, Wong R. Bronchiolitis obliterans and rheumatoid arthritis. Report of a case in a Chinese patient on d-penicillamine and review of the literature. *Ann Acad Med Singapore*. 1993 May;22(3):365-8.
2738. Yamada H, Kato EH, Ebina Y, et al. Fetal treatment of congenital heart block ascribed to anti-SSA antibody: case reports with observation of cardiohemodynamics and review of the literature. *Am J Reprod Immunol*. 1999 Oct;42(4):226-32.
2739. Yamada S, Takagi H, Tsuchiya H, et al. Comparative studies on effect of risedronate and alfacalcidol against glucocorticoid-induced osteoporosis in rheumatoid arthritic patients. *Yakugaku Zasshi*. 2007 Sep;127(9):1491-6.
2740. Yamada T, Okuda Y, Takasugi K, et al. Relative serum amyloid A (SAA) values: the influence of SAA1 genotypes and corticosteroid treatment in Japanese patients with rheumatoid arthritis. *Ann Rheum Dis*. 2001 Feb;60(2):124-7.
2741. Yamamoto M, Takahashi H, Wakasugi H, et al. Leukoencephalopathy during administration of etanercept for refractory rheumatoid arthritis. *Mod Rheumatol*. 2007;17(1):72-4.
2742. Yamanaka H, Inoue E, Singh G, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. *Mod Rheumatol*. 2007;17(4):283-9.
2743. Yamanaka H, Tanaka Y, Sekiguchi N, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan (RECONFIRM). *Mod Rheumatol*. 2007;17(1):28-32.
2744. Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. *Dermatol Clin*. 2004 Oct;22(4):449-59, ix.
2745. Yamauchi PS, Turner L, Lowe NJ, et al. Treatment of recurrent Sweet's syndrome with coexisting rheumatoid arthritis with the tumor necrosis factor antagonist etanercept. *J Am Acad Dermatol*. 2006 Mar;54(3 Suppl 2):S122-6.
2746. Yamazawa K, Matsui H, Sekiya S. Gastric perforation induced by combination chemotherapy in a patient with long-term use of corticosteroids. *Int J Gynaecol Obstet*. 2002 Aug;78(2):165-6.
2747. Yamout B, El-Hajj T, Barada W, et al. Successful treatment of refractory neuroSjogren with Rituximab. *Lupus*. 2007;16(7):521-3.
2748. Yang C, Gu J, Rihl M, et al. Serum levels of matrix metalloproteinase 3 and macrophage colony-stimulating factor 1 correlate with disease activity in ankylosing spondylitis. *Arthritis Rheum*. 2004 Oct 15;51(5):691-9.
2749. Yang DH, Chang DM, Lai JH, et al. Etanercept as a rescue agent in patient with adult onset Still's disease complicated with congestive heart failure. *Rheumatol Int*. 2008 Nov;29(1):95-8.
2750. Yasuda M, Yasuda D, Tomooka K, et al. Plasma concentration of human atrial natriuretic hormone in patients with connective tissue diseases. *Clin Rheumatol*. 1993 Jun;12(2):231-5.
2751. Yasunori K, Masaaki T, Tetsuyuki N, et al. Reduction of urinary levels of pyridinoline and deoxypyridinoline and serum levels of soluble receptor activator of NF-kappaB ligand by etanercept in patients with rheumatoid arthritis. *Clin Rheumatol*. 2008 Sep;27(9):1093-101.

2752. Yazdani C, McLaughlin T, Cummins G, et al. Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. *Am J Manag Care*. 2001 Sep;7(13 Suppl):S419-26.
2753. Yazdani-Biuki B, Stadlmaier E, Mulabecirovic A, et al. Blockade of tumour necrosis factor {alpha} significantly alters the serum level of IgG- and IgA-rheumatoid factor in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2005 Aug;64(8):1224-6.
2754. Yazdani-Biuki B, Wohlfahrt K, Mulabecirovic A, et al. Long term treatment of psoriatic arthritis with infliximab. *Ann Rheum Dis*. 2004 Nov;63(11):1531-2; author reply 2.
2755. Yazici S, Yazici M, Erer B, et al. The platelet indices in patients with rheumatoid arthritis: mean platelet volume reflects disease activity. *Platelets*. 2010;21(2):122-5.
2756. Yazici Y, Erkan D. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? *Ann Rheum Dis*. 2004 May;63(5):607-8; author reply 8.
2757. Yazici Y, Erkan D, Kulman I, et al. Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world". *Ann Rheum Dis*. 2002 Jul;61(7):638-40.
2758. Yazici Y, Erkan D, Lockshin MD. A preliminary study of etanercept in the treatment of severe, resistant psoriatic arthritis. *Clin Exp Rheumatol*. 2000 Nov-Dec;18(6):732-4.
2759. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: continued efficacy and changing patterns of use after two years. *Clin Exp Rheumatol*. 2002 Jan-Feb;20(1):115.
2760. Yazici Y, Krasnokutsky S, Barnes JP, et al. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. *J Rheumatol*. 2009 May;36(5):907-13.
2761. Yazici Y, McMorris BJ, Darkow T, et al. Patient and physician perception of the infusion process of the biologic agents abatacept, infliximab, and rituximab for the treatment of rheumatoid arthritis. *Clin Exp Rheumatol*. 2009 Nov-Dec;27(6):907-13.
2762. Yee CS, Filer A, Pace A, et al. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study. *Rheumatology (Oxford)*. 2003 Jul;42(7):856-9.
2763. Yeh HM, Liu MF, Chang KK, et al. Adult-onset Still's disease complicated with hemophagocytic syndrome. *J Formos Med Assoc*. 2010 Jan;109(1):85-8.
2764. Yelin E, Trupin L, Katz P, et al. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. *Arthritis Rheum*. 2003 Nov;48(11):3046-54.
2765. Yelin EH, Trupin LS, Katz PP. Impact of managed care on the use of biologic agents for rheumatoid arthritis. *Arthritis Rheum*. 2005 Jun 15;53(3):423-30.
2766. Yeo SW, Park SN. Immune-mediated sensorineural hearing loss in a patient with ankylosing spondylitis: a case report. *Otolaryngol Head Neck Surg*. 2001 Jul;125(1):113-4.
2767. Yigla M, Simsolo C, Goralnik L, et al. The problem of empyematous pleural effusion in rheumatoid arthritis: report of two cases and review of the literature. *Clin Rheumatol*. 2002 May;21(2):180-3.
2768. Yilmaz L, Ozoran K, Gunduz OH, et al. Alendronate in rheumatoid arthritis patients treated with methotrexate and glucocorticoids. *Rheumatol Int*. 2001 Feb;20(2):65-9.
2769. Yim K, Nazeer SH, Kiska D, et al. Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept. *Scand J Infect Dis*. 2004;36(2):150-4.
2770. Yocum DE, Furst DE, Bensen WG, et al. Safety of tacrolimus in patients with rheumatoid arthritis: long-term experience. *Rheumatology (Oxford)*. 2004 Aug;43(8):992-9.

2771. Yokoo H, Nakazato Y, Harigaya Y, et al. Massive myelinolytic leukoencephalopathy in a patient medicated with low-dose oral methotrexate for rheumatoid arthritis: an autopsy report. *Acta Neuropathol.* 2007 Oct;114(4):425-30.
2772. Yokota S, Imagawa T, Mori M, et al. Efficacy and safety of tocilizumab in patients with systemic-onset juvenile idiopathic arthritis: a randomised, double-blind, placebo-controlled, withdrawal phase III trial. *Lancet.* 2008 Mar 22;371(9617):998-1006.
2773. Yokoyama E, Muto M. Adult variant of self-healing papular mucinosis in a patient with rheumatoid arthritis: predominant proliferation of dermal dendritic cells expressing CD34 or factor XIIIa in association with dermal deposition of mucin. *J Dermatol.* 2006 Jan;33(1):30-5.
2774. Yonezawa T, Tsuji H, Matsui H, et al. Subaxial lesions in rheumatoid arthritis. Radiographic factors suggestive of lower cervical myelopathy. *Spine.* 1995 Jan 15;20(2):208-15.
2775. Yoshida A, Morozumi K, Suganuma T, et al. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis. *Am J Nephrol.* 1991;11(4):284-8.
2776. Yoshida K, Bandoh S, Fujita J, et al. Pyothorax caused by *Nocardia otitidiscaviarum* in a patient with rheumatoid vasculitis. *Intern Med.* 2004 Jul;43(7):615-9.
2777. Yoshida K, Yokoyama T, Toyokawa Y, et al. Cryofibrinogenemia associated with Sjogren's syndrome: a case of successful treatment with high-dose corticosteroid. *Intern Med.* 2007;46(13):1039-42.
2778. Yoshioka T, Tachihara A, Koyama T, et al. Rapid destruction of the hip joint associated with enlarged iliopsoas bursa in a patient with refractory rheumatoid arthritis. *J Nippon Med Sch.* 2008 Aug;75(4):233-8.
2779. Yosipovitch G, Tang MB. Practical management of psoriasis in the elderly: epidemiology, clinical aspects, quality of life, patient education and treatment options. *Drugs Aging.* 2002;19(11):847-63.
2780. You CG, Yin YS, Xie XD, et al. Sex influences on the penetrance of IL-1beta and IL-1RN genotypes for rheumatoid arthritis in the Chinese population. *J Int Med Res.* 2007 May-Jun;35(3):323-8.
2781. You CR, Kim HR, Yoon CH, et al. Macrophage activation syndrome in juvenile rheumatoid arthritis successfully treated with cyclosporine A: a case report. *J Korean Med Sci.* 2006 Dec;21(6):1124-7.
2782. Youm JY, Woo JH, Kim TH, et al. Interleukin-1beta and interleukin-1 receptor antagonist gene polymorphisms in Korean patients with adult-onset Still's disease. *Scand J Rheumatol.* 2007 Sep-Oct;36(5):390-3.
2783. Young MG, Rijhsinghani S. Leflunomide and acute hypocalcemia. *Endocr Pract.* 2007 Nov-Dec;13(7):805-7.
2784. Young PJ, Weeden S, Kirwan JR. The analysis of a bivariate multi-state Markov transition model for rheumatoid arthritis with an incomplete disease history. *Stat Med.* 1999 Jul 15;18(13):1677-90.
2785. Yount S, Sorensen MV, Cella D, et al. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. *Clin Exp Rheumatol.* 2007 Nov-Dec;25(6):838-46.
2786. Yousem SA, Dacic S. Pulmonary lymphohistiocytic reactions temporally related to etanercept therapy. *Mod Pathol.* 2005 May;18(5):651-5.
2787. Yu EN, Meniconi ME, Tufail F, et al. Outcomes of treatment with immunomodulatory therapy in patients with corticosteroid-resistant juvenile idiopathic arthritis-associated chronic iridocyclitis. *Ocul Immunol Inflamm.* 2005 Sep-Oct;13(5):353-60.
2788. Yu EN, Paredes I, Foster CS. Surgery for hypotony in patients with juvenile idiopathic arthritis-associated uveitis. *Ocul Immunol Inflamm.* 2007 Jan-Feb;15(1):11-7.
2789. Yu X, Ma J, Tian J, et al. A controlled study of double filtration plasmapheresis in the treatment of active rheumatoid arthritis. *J Clin Rheumatol.* 2007 Aug;13(4):193-8.



2790. Yukawa E, Mori S, Ueda K, et al. Population pharmacokinetic investigation of low-dose methotrexate in rheumatoid arthritics Japanese patients. *J Clin Pharm Ther.* 2007 Dec;32(6):573-8.
2791. Yukawa S, Yamaoka K, Sawamukai N, et al. Involvement of mast cells in systemic sclerosis. *Nihon Rinsho Meneki Gakkai Kaishi.* 2010;33(2):81-6.
2792. Yukioka M, Komatsubara Y, Yukioka K, et al. Adrenocorticotrophic hormone and dehydroepiandrosterone sulfate levels of rheumatoid arthritis patients treated with glucocorticoids. *Mod Rheumatol.* 2006;16(1):30-5.
2793. Yum HK, Kim ES, Ok KS, et al. Lymphocytic interstitial pneumonitis associated with Epstein-Barr virus in Systemic Lupus Erythematosus and Sjogren's Syndrome. Complete remission with corticosteroid and cyclophosphamide. *Korean J Intern Med.* 2002 Sep;17(3):198-203.
2794. Yun JE, Lee SW, Kim TH, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. *Clin Exp Rheumatol.* 2002 Mar-Apr;20(2):127-32.
2795. Zabinski SJ, Sculco TP, Dicarlo EF, et al. Osteonecrosis in the rheumatoid femoral head. *J Rheumatol.* 1998 Sep;25(9):1674-80.
2796. Zamarron C, Maceiras F, Gonzalez J, et al. Worsening of obstructive sleep apnoeas in a patient with rheumatoid arthritis treated with anti-tumor necrosis factor. *Respir Med.* 2004 Feb;98(2):123-5.
2797. Zamarron C, Maceiras F, Mera A, et al. Effect of the first infliximab infusion on sleep and alertness in patients with active rheumatoid arthritis. *Ann Rheum Dis.* 2004 Jan;63(1):88-90.
2798. Zandbelt MM, de Wilde P, van Damme P, et al. Etanercept in the treatment of patients with primary Sjogren's syndrome: a pilot study. *J Rheumatol.* 2004 Jan;31(1):96-101.
2799. Zandbelt MM, van den Hoogen FH, de Wilde PC, et al. Reversibility of histological and immunohistological abnormalities in sublabial salivary gland biopsy specimens following treatment with corticosteroids in Sjogren's syndrome. *Ann Rheum Dis.* 2001 May;60(5):511-3.
2800. Zangrilli A, Papoutsaki M, Talamonti M, et al. Long-term efficacy of adalimumab in generalized pustular psoriasis. *J Dermatolog Treat.* 2008;19(3):185-7.
2801. Zautra AJ, Burleson MH, Matt KS, et al. Interpersonal stress, depression, and disease activity in rheumatoid arthritis and osteoarthritis patients. *Health Psychol.* 1994 Mar;13(2):139-48.
2802. Zeidler HK, Kvien TK, Hannonen P, et al. Progression of joint damage in early active severe rheumatoid arthritis during 18 months of treatment: comparison of low-dose cyclosporin and parenteral gold. *Br J Rheumatol.* 1998 Aug;37(8):874-82.
2803. Zhang LL, Wei W, Xiao F, et al. A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid arthritis. *Arthritis Rheum.* 2008 Jul 15;59(7):905-10.
2804. Zhang W, Bansback N, Guh D, et al. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. *J Rheumatol.* 2008 Sep;35(9):1729-36.
2805. Zhao B, Takami M, Miyamoto Y, et al. Characterization of synovial cell clones isolated from rheumatoid arthritis patients: possible involvement of TNF-alpha in reduction of osteoprotegerin in synovium. *Cytokine.* 2008 Jan;41(1):61-70.
2806. Zhou H. Clinical pharmacokinetics of etanercept: a fully humanized soluble recombinant tumor necrosis factor receptor fusion protein. *J Clin Pharmacol.* 2005 May;45(5):490-7.
2807. Zhou H, Buckwalter M, Boni J, et al. Population-based pharmacokinetics of the soluble TNF $\alpha$  etanercept: a clinical study in 43 patients with ankylosing spondylitis compared with post hoc data from patients with rheumatoid arthritis. *Int J Clin Pharmacol Ther.* 2004 May;42(5):267-76.

2808. Zhou H, Mayer PR, Wajdula J, et al. Unaltered etanercept pharmacokinetics with concurrent methotrexate in patients with rheumatoid arthritis. *J Clin Pharmacol*. 2004 Nov;44(11):1235-43.
2809. Zhu G, Liu G, Liu Y, et al. Liver abnormalities in adult onset Still's disease: a retrospective study of 77 Chinese patients. *J Clin Rheumatol*. 2009 Sep;15(6):284-8.
2810. Ziakas PD, Giannouli S, Tzioufas AG, et al. Lymphoma development in a patient receiving anti-TNF therapy. *Haematologica*. 2003 Jul;88(7):ECR25.
2811. Zikou AK, Argyropoulou MI, Voulgari PV, et al. Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with adalimumab. *J Rheumatol*. 2006 Feb;33(2):219-23.
2812. Zink A, Listing J, Kary S, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. *Ann Rheum Dis*. 2005 Sep;64(9):1274-9.
2813. Zink A, Listing J, Ziemer S, et al. Practice variation in the treatment of rheumatoid arthritis among German rheumatologists. *J Rheumatol*. 2001 Oct;28(10):2201-8.
2814. Zintzaras E, Dahabreh IJ, Giannouli S, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis: a systematic review and meta-analysis of dosage regimens. *Clin Ther*. 2008 Nov;30(11):1939-55.
2815. Ziolkowska M, Kurowska M, Radzikowska A, et al. High levels of osteoprotegerin and soluble receptor activator of nuclear factor kappa B ligand in serum of rheumatoid arthritis patients and their normalization after anti-tumor necrosis factor alpha treatment. *Arthritis Rheum*. 2002 Jul;46(7):1744-53.
2816. Ziswiler HR, Aeberli D, Villiger PM, et al. High-resolution ultrasound confirms reduced synovial hyperplasia following rituximab treatment in rheumatoid arthritis. *Rheumatology (Oxford)*. 2009 Aug;48(8):939-43.
2817. Zoli A, Ferlisi EM, Lizzio M, et al. Prolactin/cortisol ratio in rheumatoid arthritis. *Ann N Y Acad Sci*. 2002 Jun;966:508-12.
2818. Zoli A, Lizzio MM, Ferlisi EM, et al. ACTH, cortisol and prolactin in active rheumatoid arthritis. *Clin Rheumatol*. 2002 Aug;21(4):289-93.
2819. Zoukos Y, Leonard JP, Thomaidis T, et al. beta-Adrenergic receptor density and function of peripheral blood mononuclear cells are increased in multiple sclerosis: a regulatory role for cortisol and interleukin-1. *Ann Neurol*. 1992 Jun;31(6):657-62.

### Reference Source: International Pharmaceutical Abstracts

1. First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. *Rheumatology*. 2006 01/01;45(JUN):7-2.
2. Aggarwal R, Manadan AM, Poliyedath A, et al. Safety of Etanercept in Patients at High Risk for Mycobacterial Tuberculosis Infections. *Journal of Rheumatology*. 2009;36:914.
3. Alcorn N, Saunders S, Madhok R, et al. Benefit-Risk Assessment of Leflunomide An Appraisal of Leflunomide in Rheumatoid Arthritis 10 Years After Licensing. *Drug Safety (New Zealand)*. 2009;32:1123.
4. Aletaha D, Funovits J, Breedveld FC, et al. Rheumatoid Arthritis Joint Progression in Sustained Remission Is Determined by Disease Activity Levels Preceding the Period of Radiographic Assessment. *Arthritis and Rheumatism (USA)* 2009;60:1242.
5. Anonymous. Atlizumab - Anti-IL-6 receptor antibody - Chugai, anti-interleukin-6 receptor antibody - Chugai, MRA - Chugai. *BioDrugs*. 2003;17:369-72.
6. Anonymous. Tocilizumab for rheumatoid arthritis. *Drug and Therapeutics Bulletin (England)*. 2010;48:9.

7. Antoniu SA, Apr. Cytokine Antagonists for the Treatment of Asthma Progress to Date. *BioDrugs (New Zealand)* 2009;23241.
8. Asahina A, Ohshima N, Nakayama H, et al. Henoch-Schonlein purpura in a patient with rheumatoid arthritis receiving etanercept. *European Journal of Dermatology (France)*. 2010;20:521-2.
9. Baggott JE, Morgan SL, Aug. Methotrexate Catabolism to 7-Hydroxymethotrexate in Rheumatoid Arthritis Alters Drug Efficacy and Retention and Is Reduced by Folic Acid Supplementation. *Arthritis and Rheumatism (USA)* 2009;602257.
10. Bansard C, Lequerre T, Daveau M, et al. Can rheumatoid arthritis responsiveness to methotrexate and biologics be predicted? *Rheumatology* 2009;481021.
11. Bansback NJ, Ara R, Barkham N, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. *Rheumatology*. 2006 08/01;/45(Aug):1029-38.
12. Bathon JM, Fleischmann RM, van der Heijde DM, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. *Journal of Rheumatology*. 2006 02/01;/33(Feb):234-43.
13. Bell S. Payers have biologic alternative for patients with moderate to severe rheumatoid arthritis who do not respond to other DMARD therapies. *Biotechnology Healthcare*. 2006 06/01;/3(Jun):24-8.
14. Benhamou M, Rincheval N, Roy C, et al. The Gap Between Practice and Guidelines in the Choice of First-line Disease Modifying Antirheumatic Drug in Early Rheumatoid Arthritis: Results from the ESPOIR Cohort. *Journal of Rheumatology* 2009;36934.
15. Bernatsky S, Habel Y, Rahme E. Observational Studies of Infections in Rheumatoid Arthritis: A Metaanalysis of Tumor Necrosis Factor Antagonists. *Journal of Rheumatology* 2010;37928-31.
16. Bingham CO, Ince A, Haraoui B, et al. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. *Current Medical Research and Opinion (England)* 2009;251131.
17. Borah BJ, Huang XY, Zarotsky V, et al. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. *Current Medical Research and Opinion (England)* 2009;251365.
18. Bours MJ, Peeters RH, Landewe RB, et al. Adenosine 5'-triphosphate infusions reduced disease activity and inflammation in a patient with active rheumatoid arthritis. *Rheumatology (Oxford)*. 2010;49:2223-5.
19. Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: Review of the Efficacy and Tolerability of a Recently Approved Tumor Necrosis Factor-alpha Inhibitor. *Clinical Therapeutics (USA)*. 2010;32:1681-703.
20. Bruce SP. Recent Developments in the Treatment of Rheumatoid Arthritis. *Journal of Pharmacy Practice*. 2009;22:65-74.
21. Bullano MF, McNeeley BJ, Yu YF, et al. Comparison of costs associated with the use of etanercept, infliximab, and adalimumab for the treatment of rheumatoid arthritis. *Managed Care Interface (USA)*. 2006 09/01;/19(Sep):47-53.
22. Butterly SJ, Pillans P, Horn B, et al. Off-label use of rituximab in a tertiary Queensland hospital. *Internal Medicine Journal*. 2010;40:443-52.
23. Cambridge G, Stohl W, Leandro MJ, et al. Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment - Relationships with B cell depletion, circulating antibodies, and clinical relapse. *Arthritis and Rheumatism (USA)*. 2006 03/01;/54(Mar):723-32.
24. Campas-Moya C. Golimumab: A novel anti-INF-alpha human monoclonal antibody for rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. *Drugs of Today (Spain)*. 2010;46:13-22.
25. Cannon CP, Curtis SP, Bolognese JA, et al. Clinical trial design and patient demographics of the multinational etoricoxib and diclofenac arthritis long-term (MEDAL) study program: Cardiovascular outcomes with etoricoxib versus diclofenac in patients with osteoarthritis and rheumatoid arthritis. *American Heart Journal*. 2006 02/01;/152(Feb):237-45.

26. Cannon CP, Curtis SP, FitzGerald GA, et al. Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. *Lancet, The (USA)*. 2006 01/01/;368(Jan):1771-81.
27. Cantaert T, van Baarsen LG, Wijbrandts CA, et al. Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis. *Rheumatology (Oxford)*. 2010;49:156.
28. Carazo JL, Santos LM, Martinez VO. Safety of etanercept in psoriasis - A critical review. *Drug Safety (New Zealand)*. 2006 08/01/;29(Aug):675-85.
29. Cavill I, Auerbach M, Bailie GR, et al. Iron and the anaemia of chronic disease: a review and strategic recommendations. *Current Medical Research and Opinion (England)*. 2006 04/01/;22(Apr):731-7.
30. Chung SJ, Kim JK, Park MC, et al. Reactivation of Hepatitis B Viral Infection in Inactive HBsAg Carriers Following Anti-Tumor Necrosis Factor-alpha Therapy. *Journal of Rheumatology* 2009;36:2416.
31. Coates LC, Helliwell PS. Validation of Minimal Disease Activity Criteria for Psoriatic Arthritis Using Interventional Trial Data. *Arthritis Care and Research*. 2010;62:965.
32. Cohen PR, May. Neutrophilic Dermatoses A Review of Current Treatment Options. *American Journal of Clinical Dermatology (New Zealand)* 2009;10:301.
33. Cohen SB. Updates from B cell trials: Efficacy. *Journal of Rheumatology*. 2006 01/01/;33(MAY):12-7.
34. Cui J, Saevarsdottir S, Thomson B, et al. Rheumatoid Arthritis Risk Allele <it>PTPRC</it> Is Also Associated With Response to Anti-Tumor Necrosis Factor alpha Therapy. *Arthritis and Rheumatism (USA)*. 2010;62:1849.
35. Curtis JR, Chen L, Harrold LR, et al. Physician Preference Motivates the Use of Anti-Tumor Necrosis Factor Therapy Independent of Clinical Disease Activity. *Arthritis Care and Research*. 2010;62:101-7.
36. Curtis SP, Ko AT, Bolognese JA, et al. Pooled analysis of thrombotic cardiovascular events in clinical trials of the COX-2 selective inhibitor etoricoxib. *Current Medical Research and Opinion (England)*. 2006 12/01/;22(Dec):2365-74.
37. DaSilva V, Roux CH, Bernard E, et al. Neuromeningeal Tuberculosis in a Patient with Rheumatoid Arthritis Previously Exposed to Ineffective Etanercept Therapy and Revealed by Infliximab. *Journal of Rheumatology*. 2010;37:471-2.
38. De Rycke L, Baeten D, Kruithof E, et al. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity - Biologic and clinical implications in autoimmune arthritis. *Arthritis and Rheumatism (USA)*. 2005 07/01/;52(Jul):2192-201.
39. de Vlam K, Lories RJ. Efficacy, effectiveness and safety of etanercept in monotherapy for refractory psoriatic arthritis: a 26-week observational study. *Rheumatology*. 2006 03/01/;45(Mar):321-4.
40. de Vries-Bouwstra J, Le Cessie S, Allaart C, et al. Using predicted disease outcome to provide differentiated treatment of early rheumatoid arthritis. *Journal of Rheumatology*. 2006 09/01/;33(Sep):1747-53.
41. Deighton C, Hyrich K, Ding T, et al. BSR and BHPR rheumatoid arthritis guidelines on eligibility criteria for the first biological therapy. *Rheumatology (Oxford)*. 2010;49:1197-9.
42. Dewan P, Jawad A, Goldsmith P, et al. Melanoma in patients with rheumatoid arthritis treated with antitumour necrosis factor: cause or coincidence? Report of two cases. *British Journal of Dermatology (England)* 2009;161:1412.
43. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. *Journal of Managed Care Pharmacy (USA)*. 2006 07/01/;12(Jul):555-69.

44. Driessen RJ, de Jong EM, Salemink GW, et al. Analysis of 4-year Dutch reimbursement application data of biological therapies for psoriatic arthritis. *Rheumatology (Oxford)*. 2010;49:588-91.
45. Duggan ST, Keam SJ, Jun. Certolizumab Pegol In Rheumatoid Arthritis. *BioDrugs (New Zealand)*. 2009;23:407.
46. Eder L, Chandran V, Ueng J, et al. Predictors of response to intra-articular steroid injection in psoriatic arthritis. *Rheumatology (Oxford)*. 2010;49:1367-73.
47. El Miedany Y, Youssef SS, El Gaafary M. Short-term outcome after anti-tumor necrosis factor-alpha therapy in rheumatoid arthritis: Do we need to revise our assessment criteria? *Journal of Rheumatology*. 2006;33(3):490-6.
48. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis and Rheumatism (USA)* 2006;54(May):1390-400.
49. Emery P, Genovese MC, van Vollenhoven R, et al. Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. *Journal of Rheumatology* 2009;36:1429.
50. Emery P, Kosinski M, Li T, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. *Journal of Rheumatology* 2006;33(Apr):681-9.
51. Esposito M, Mazzotta A, de Felice C, et al. Treatment of erythrodermic psoriasis with etanercept. *British Journal of Dermatology (England)*. 2006 01/01;155(Jan):156-9.
52. Finckh A, Bansback N, Marra CA, et al. Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents A Cost-Effectiveness Analysis. *Annals of Internal Medicine (USA)*. 2009;151:612.
53. Fleurence R, Spackman E. Cost-effectiveness of biologic agents for treatment of autoimmune disorders: Structured review of the literature. *Journal of Rheumatology*. 2006 11/01;33(Nov):2124-31.
54. Fouache D, Goeb V, Massy-Guillemant N, et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. *Rheumatology* 2009;48:761.
55. Frey N, Grange S, Woodworth T. Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis. *Journal of Clinical Pharmacology (USA)*. 2010;50:754-66.
56. Furlan AD, Sandoval JA, Mailis-Gagnon A, et al. Opioids for chronic noncancer pain: a meta-analysis of effectiveness and side effects. *Canadian Medical Association Journal (Canada)*. 2006 11/01;174(Nov):1589-94.
57. Gaffo A, Saag KG, Curtis JR. Treatment of rheumatoid arthritis. *American Journal of Health-System Pharmacy (USA)*. 2006 01/01;63(Jan):2451-65.
58. Garcia JJ, Lobato JP, Garrido SL, et al. Biological therapies in rheumatoid arthritis. *Atencion Farmaceutica: European Journal of Clinical Pharmacy*. 2008;10(98):100-11.
59. Garnero P, Thompson E, Woodworth T, et al. Rapid and Sustained Improvement in Bone and Cartilage Turnover Markers With the Anti-Interleukin-6 Receptor Inhibitor Tocilizumab Plus Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Substudy of the Multicenter Double-Blind, Placebo-Controlled Trial of Tocilizumab in Inadequate Responders to Methotrexate Alone. *Arthritis and Rheumatism (USA)*. 2010;62:33.
60. Gladman DD, Sampalis JS, Illouz O, et al. Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study. *Journal of Rheumatology*. 2010;37:1898.

61. Gladman DD, Tom BD, Mease PJ, et al. Informing Response Criteria for Psoriatic Arthritis. I: Discrimination Models Based on Data from 3 Anti-Tumor Necrosis Factor Randomized Studies. *Journal of Rheumatology*. 2010;37:1892-7.
62. Gompels LL, Smith A, Charles PJ, et al. Single-blind randomized trial of combination antibiotic therapy in rheumatoid arthritis. *Journal of Rheumatology*. 2006 02/01;33(Feb):224-7.
63. Gonzalez-Juanatey C, Llorca J, Garcia-Porrua C, et al. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. *Arthritis and Rheumatism-Arthritis Care and Research*. 2006 01/01;55(Jan):150-3.
64. Graudal N, Juergens G. Similar Effects of Disease-Modifying Antirheumatic Drugs, Glucocorticoids, and Biologic Agents on Radiographic Progression in Rheumatoid Arthritis Meta-Analysis of 70 Randomized Placebo-Controlled or Drug-Controlled Studies, Including 112 Comparisons. *Arthritis and Rheumatism (USA)*. 2010;62:2852.
65. Grijalva CG, Kaltenbach L, Arbogast PG, et al. Initiation of rheumatoid arthritis treatments and the risk of serious infections. *Rheumatology (Oxford)* 2010;49:82-90.
66. Hallinen TA, Soini EJ, Eklund K, et al. Cost-utility of different treatment strategies after the failure of tumour necrosis factor inhibitor in rheumatoid arthritis in the Finnish setting. *Rheumatology (Oxford)*. 2010;49:767-77.
67. Haringman JJ, Gerlag DM, Smeets TJ, et al. A randomized controlled trial with an anti-CCL2 (anti-monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis. *Arthritis and Rheumatism (USA)*. 2006 08/01;54(Aug):2387-92.
68. Harris CL, Raisch DW, Abhyankar U, et al. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs. *Annals of Pharmacotherapy (USA)*. 2006 11/01;40(Nov):1924-31.
69. Hassan B, Maxwell JR, Hyrich KL, et al. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2010;49:43-7.
70. Hetland ML, Christensen IJ, Tarp U, et al. Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry. *Arthritis and Rheumatism (USA)* 2010;62:22-32.
71. Hetland ML, Stengaard-Pedersen K, Junker P, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis - An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. *Arthritis and Rheumatism (USA)*. 2006 05/01;54(May):1401-9.
72. Hu CP, Xu ZH, Rahman MU, et al. A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. *Journal of Pharmacokinetics and Pharmacodynamics (USA)*. 2010;37:309-21.
73. Hudson M, Suissa S. Avoiding Common Pitfalls in the Analysis of Observational Studies of New Treatments for Rheumatoid Arthritis. *Arthritis Care and Research*. 2010;62:805-10.
74. Hyrich KL, Watson KD, Silman AJ, et al. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Rheumatology* 2006;45(Dec):1558-65.
75. Isenberg DA. B cell targeted therapies in autoimmune diseases. *Journal of Rheumatology*. 2006 01/01;33(MAY):24-8.

76. Jacobs JW, van Everdingen AA, Verstappen SM, et al. Followup radiographic data on patients with rheumatoid arthritis who participated in a two-year trial of prednisone therapy or placebo. *Arthritis and Rheumatism (USA)*. 2006 05/01;54(May):1422-8.
77. Jarand J, Zochodne DW, Martin LO, et al. Neurological complications of infliximab. *Journal of Rheumatology*. 2006 05/01;33(May):1018-20.
78. Jazayeri JA, Carroll GJ, Vernallis AB. Interleukin-6 subfamily cytokines and rheumatoid arthritis: Role of antagonists. *International Immunopharmacology (USA)*. 2010;10:1-8.
79. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. *Advances in Therapy (USA)*. 2006 02/01;23(Feb):208-17.
80. Kavanaugh AF. B cell targeted therapies: Safety considerations. *Journal of Rheumatology*. 2006 01/01;33(MAY):18-23.
81. Kawai S, Hashimoto H, Kondo H, et al. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. *Journal of Rheumatology*. 2006 11/01;33(Nov):2153-61.
82. Kawai S, Yamamoto K. Safety of tacrolimus, an immunosuppressive agent, in the treatment of rheumatoid arthritis in elderly patients. *Rheumatology*. 2006 04/01;45(Apr):441-4.
83. Kawakami K, Ikari K, Kawamura K, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? *Rheumatology (Oxford)* 2010;49:341-7.
84. Kawashiri SY, Kawakami A, Iwamoto N, et al. Proinflammatory Cytokines Synergistically Enhance the Production of Chemokine Ligand 20 (CCL20) from Rheumatoid Fibroblast-like Synovial Cells *in vitro* and Serum CCL20 Is Reduced *in vivo* by Biologic Disease-modifying Antirheumatic Drugs. *Journal of Rheumatology* 2009;36:2397.
85. Kay LJ, Griffiths ID, Management BSRBR. UK consultant rheumatologists' access to biological agents and views on the BSR Biologics Register. *Rheumatology*. 2006 11/01;45(Nov):1376-9.
86. Kivitz A, Cohen S, Dowd JE, et al. Clinical assessment of pain, tolerability, and preference of an autoinjection pen versus a prefilled syringe for patient self-administration of the fully human, monoclonal antibody adalimumab: The TOUCH trial. *Clinical Therapeutics (USA)*. 2006 10/01;28(Oct):1619-29.
87. Kling MC, Larian AA, Scordi-Bello I, et al. Fatal Influenza A(H1N1) Respiratory Tract Infection in a Patient Having Psoriasis Treated With Infliximab. *Archives of Dermatology (USA)*. 2010;146:651-4.
88. Koeller MD, Aletaha D, Funovits J, et al. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. *Rheumatology* 2009;48:1575.
89. Korkina L, Trakhtman P, De Luca C, et al. EFFICACY AND SAFETY OF BIOLOGICALS AGAINST IMMUNE-MEDIATED DISEASES: DO BENEFITS OUTWEIGH RISKS? *Drugs of Today (Spain)*. 2010;46:119-36.
90. Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis. *Journal of Rheumatology*. 2010;37:2205-15.
91. Kremer JM, Genant HK, Moreland LW, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis - A randomized trial. *Annals of Internal Medicine (USA)* 2006;144(Dec):865-76.

92. Kuan WP, Tam LS, Wong CK, et al. CXCL 9 and CXCL 10 as Sensitive Markers of Disease Activity in Patients with Rheumatoid Arthritis. *Journal of Rheumatology*. 2010;37:257-64.
93. Landewe R, van der Heijde D, Klareskog L, et al. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate - Results from the trial of etanercept and methotrexate with radiographic and patient outcomes. *Arthritis and Rheumatism (USA)*. 2006 10/01;54(Oct):3119-25.
94. Lee YH, Ji JD, Bae SC, et al. Associations Between Tumor Necrosis Factor-alpha (TNF-alpha) -308 and -238 G/A Polymorphisms and Shared Epitope Status and Responsiveness to TNF-alpha Blockers in Rheumatoid Arthritis: A Metaanalysis Update. *Journal of Rheumatology*. 2010;37:740-6.
95. Lee YH, Song GG. Associations between the C677T and A1298C Polymorphisms of *MTHFR* and the Efficacy and Toxicity of Methotrexate in Rheumatoid Arthritis A Meta-Analysis. *Clinical Drug Investigation (New Zealand)*. 2010;30:101-8.
96. Lester SE, Proudman SM, Lee AT, et al. Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis. *Internal Medicine Journal*. 2009;39:296.
97. Looney RJ. B cell-targeted therapy for rheumatoid arthritis - An update on the evidence. *Drugs (New Zealand)*. 2006 05/01;66(May):625-39.
98. Luman KL, Amireh H, Gonzalez ER. A medication utilization evaluation of abatacept: a retrospective study. *ASHP Midyear Clinical Meeting*. 2010;2009:119.
99. Luman KL, Amireh H, Gonzalez ER. A medication utilization evaluation of infliximab: a retrospective study. *ASHP Midyear Clinical Meeting*. 2010;2009:120.
100. Luqmani R, Hennell S, Estrach C, et al. British society for rheumatology and british health professionals in rheumatology guideline for the management of rheumatoid arthritis (the first two years). *Rheumatology*. 2006 09/01;45(Sep):1167-9.
101. Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. *Rheumatology (Oxford)*. 2010;49:91-8.
102. Madland TM, Bjoerkkjaer T, Brunborg LA, et al. Subjective improvement in patients with psoriatic arthritis after short-term oral treatment with seal oil. A pilot study with double blind comparison to soy oil. *Journal of Rheumatology*. 2006 02/01;33(Feb):307-10.
103. Magnusson M, Brisslert M, Zendjanchi K, et al. Epstein-Barr virus in bone marrow of rheumatoid arthritis patients predicts response to rituximab treatment. *Rheumatology (Oxford)*. 2010;49:1911-9.
104. Maignen F, Hauben M, Tsintis P. Modelling the Time to Onset of Adverse Reactions with Parametric Survival Distributions A Potential Approach to Signal Detection and Evaluation. *Drug Safety (New Zealand)*. 2010;33:417-34.
105. Marra C. Rheumatoid arthritis: A primer for pharmacists. *American Journal of Health-System Pharmacy (USA)*. 2006 01/01;63(Feb):S4-10.
106. McCluggage LK, Scholtz JM. Golimumab: A Tumor Necrosis Factor Alpha Inhibitor for the Treatment of Rheumatoid Arthritis. *Annals of Pharmacotherapy (USA)*. 2010;44:135-44.
107. McDermott MF, Jun. RILONACEPT IN THE TREATMENT OF CHRONIC INFLAMMATORY DISORDERS. *Drugs of Today (Spain)* 2009;45423.
108. McLean-Tooke A, Aldridge C, Waugh S, et al. Methotrexate, rheumatoid arthritis and infection risk what is the evidence. *Rheumatology*. 2009;48:867.
109. Mease PJ, Gladman DD, Keystone EC, et al. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis - Results of a randomized, double-blind, placebo-controlled study. *Arthritis and Rheumatism (USA)*. 2006 05/01;54(May):1638-45.



110. Michot C, Costes V, Gerard-Dran D, et al. Subcutaneous panniculitis-like T-cell lymphoma in a patient receiving etanercept for rheumatoid arthritis. *British Journal of Dermatology (England)* 2009;160889.
111. Montecucco C. Remission, a therapeutic goal in inflammatory arthropathies? Clinical data from adalimumab studies. *Drugs (New Zealand)*. 2006 01/01/;66(Mar):1783-95.
112. Muhammad K, Roll P, Einsele H, et al. Delayed Acquisition of Somatic Hypermutations in Repopulated IgD+CD27+ Memory B Cell Receptors After Rituximab Treatment. *Arthritis and Rheumatism (USA)* 2009;602284.
113. Mulleman D, Lin DC, Ducourau E, et al. Trough Infliximab Concentrations Predict Efficacy and Sustained Control of Disease Activity in Rheumatoid Arthritis. *Therapeutic Drug Monitoring (USA)*. 2010;32:232.
114. Nagashima T, Minota S. Subcutaneous calcification following injection of triamcinolone hexacetonide for plantar fasciitis. *Rheumatology*, Dec. 2008;47:1838-40.
115. Nakamura T, Higashi S, Tomoda K, et al. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. *Rheumatology*. 2006 01/01/;45(Jan):43-9.
116. Nannini C, Cantini F, Niccoli L, et al. Single-Center Series and Systematic Review of Randomized Controlled Trials of Malignancies in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Receiving Anti-Tumor Necrosis Factor alpha Therapy: Is There a Need for More Comprehensive Screening Procedures? *Arthritis and Rheumatism-Arthritis Care and Research* 2009;61801.
117. Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, et al. Adalimumab for treating rheumatoid arthritis. *Journal of Rheumatology* 2006;33(Jun):1075-81.
118. Odai T, Matsunawa M, Takahashi R, et al. Correlation of CX3CL1 and CX3CR1 Levels with Response to Infliximab Therapy in Patients with Rheumatoid Arthritis. *Journal of Rheumatology* 2009;361158.
119. Oldfield V, Dhillon S, Plosker GL. Tocilizumab A Review of its Use in the Management of Rheumatoid Arthritis. *Drugs*. 2009;69:609-32.
120. Paul-Pletzer K. Tocilizumab: Blockade of interleukin-6 signaling pathway as a therapeutic strategy for inflammatory disorders. *Drugs of Today (Spain)*. 2006 09/01/;42(Sep):559-76.
121. Phung OJ, Coleman CI, Sep. Golimumab: A human anti-TNF-alpha monoclonal antibody for the treatment of autoimmune joint diseases. *Formulary (USA)* 2009;44264.
122. Pincus T, Chung C, Segurado OG, et al. An index of patient reported outcomes (PRO-Index) discriminates effectively between active and control treatment in 4 clinical trials of adalimumab in rheumatoid arthritis. *Journal of Rheumatology*. 2006 11/01/;33(Nov):2146-52.
123. Plushner SL. Tocilizumab: An Interleukin-6 Receptor Inhibitor for the Treatment of Rheumatoid Arthritis. *Annals of Pharmacotherapy*. 2008;42:1660-8.
124. Polinski JM, Mohr PE, Johnson L, et al. Impact of Medicare Part D on Access to and Cost Sharing for Specialty Biologic Medications for Beneficiaries With Rheumatoid Arthritis. *Arthritis and Rheumatism-Arthritis Care and Research*. 2009;61:745.
125. Prodanovich S, Ricotti C, Glick BP, et al. Etanercept: An Evolving Role in Psoriasis and Psoriatic Arthritis. *American Journal of Clinical Dermatology (New Zealand)*. 2010;11:3-9.
126. Pucino F, Harbus PT, Goldbach-Mansky R. Use of biologics in rheumatoid arthritis: Where are we going? *American Journal of Health-System Pharmacy (USA)*. 2006 01/01/;63(Feb):S19-S41.
127. Quartuccio L, Fabris M, Salvin S, et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. *Rheumatology* 2009;481557.

128. Rachapalli SM, Williams R, Walsh DA, et al. First-line DMARD choice in early rheumatoid arthritis-do prognostic factors play a role? *Rheumatology (Oxford)*. 2010;49:1267-71.
129. Raghavendran RR, Peart F, Grindulis KA. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. *Rheumatology*, Dec. 2008;47.
130. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics - The first step toward individualized therapy in rheumatoid arthritis. *Arthritis and Rheumatism (USA)*. 2006 05/01;54(May):1366-77.
131. Raterman HG, Simsek S, Lems WF, et al. Rituximab and Thyroid Function. *Archives of Internal Medicine (USA)* 2009;169:1073.
132. Reiff A, Lovell DJ, van Adelsberg J, et al. Evaluation of the comparative efficacy and tolerability of rofecoxib and naproxen in children and adolescents with juvenile rheumatoid arthritis: A 12-week randomized controlled clinical trial with a 52-week open-label extension. *Journal of Rheumatology*. 2006 05/01;33(May):985-95.
133. Resman-Targoff BH. Medical therapy: Where are we now? *American Journal of Health-System Pharmacy (USA)*. 2006 01/01;63(Feb):S11-S8.
134. Ristic GG, Lepic T, Gilsic B, et al. Rheumatoid arthritis is an independent risk factor for increased carotid intima-media thickness: impact of anti-inflammatory treatment. *Rheumatology (Oxford)*. 2010;49:1076.
135. Ritchlin CT. Therapies for psoriatic enthesopathy. A systematic review. *Journal of Rheumatology*. 2006 07/01;33(Jul):1435-8.
136. Robinson V, Boers M, Brooks P, et al. Patient-reported pain is central to OMERACT rheumatology core measurement sets. *Drug Information Journal (USA)*. 2006 01/01;40(Jan):111-6.
137. Roman-Blas JA, Castaneda S, Cutolo M, et al. Efficacy and Safety of a Selective Estrogen Receptor beta Agonist, ERB-041, in Patients With Rheumatoid Arthritis: A 12-Week, Randomized, Placebo-Controlled, Phase II Study. *Arthritis Care and Research*. 2010;62:1588-93.
138. Rongioletti F, Burlando M, Parodi A. Adverse Effects of Biological Agents in the Treatment of Psoriasis. *American Journal of Clinical Dermatology (New Zealand)*. 2010;11:35-7.
139. Rottem M, Mader R. Successful Use of Etanercept in Acquired Angioedema in a Patient with Psoriatic Arthritis. *Journal of Rheumatology*. 2010;37:209.
140. Roux CH, Brocq O, Breuil V, et al. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. *Rheumatology*. 2006 10/01;45(Oct):1294-7.
141. Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford)* 2010;49:697-705.
142. Saraux A, Gossec L, Goupille P, et al. Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France. *Rheumatology (Oxford)*. 2010;49:733-40.
143. Schiff MH, Yu EB, Weinblatt ME, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients - Patient-reported outcomes from multiple controlled and open-label extension studies. *Drugs and Aging (New Zealand)*. 2006 02/01;23(Feb):167-78.
144. Schlesselman LS, Hussey AP. Tocilizumab - A humanized anti-IL-6 receptor monoclonal antibody for the treatment of rheumatoid arthritis. *Formulary*. 2008;43:272-9.
145. Scott DL. Pursuit of optimal outcomes in rheumatoid arthritis. *PharmacoEconomics (New Zealand)*. 2004 02/01;22(Feb):13-26.
146. Sebba A. Tocilizumab: The first interleukin-6-receptor inhibitor. *American Journal of Health System Pharmacy*. 2008;65:1413-8.

147. Shadick NA, Cook NR, Karlson EW, et al. C-reactive protein in the prediction of rheumatoid arthritis in women. *Archives of Internal Medicine (USA)*. 2006 01/01/;166(Jan):2490-4.
148. Sheth NU, Hilas O, Charneski L. Abatacept: A novel agent for rheumatoid arthritis. *Journal of Pharmacy Technology (USA)*. 2006 06/01/;22(Jun):336-41.
149. Siddigui MA, Scott LJ. Spotlight on infliximab in Crohn disease and rheumatoid arthritis. *BioDrugs (New Zealand)*. 2006 01/01/;20(Jan):67-70.
150. Siegel JN, Zhen BG. Use of the American College of Rheumatology N (ACR-N) Index of improvement in rheumatoid arthritis - Argument in favor. *Arthritis and Rheumatism (USA)*. 2005 06/01/;52(Jun):1637-41.
151. Signorovitch JE, Wu EQ, Yu AP, et al. Comparative Effectiveness Without Head-to-Head Trials A Method for Matching-Adjusted Indirect Comparisons Applied to Psoriasis Treatment with Adalimumab or Etanercept. *PharmacoEconomics (New Zealand)*. 2010;28:935-45.
152. Sihvonen S, Korpela M, Mustonen J, et al. Mortality in patients with rheumatoid arthritis treated with low-dose oral glucocorticoids. A population-based cohort study. *Journal of Rheumatology*. 2006 09/01/;33(Sep):1740-6.
153. Silverman GJ. Therapeutic B cell depletion and regeneration in rheumatoid arthritis - Emerging patterns and paradigms. *Arthritis and Rheumatism (USA)*. 2006 08/01/;54(Aug):2356-67.
154. Singh JA, Christensen R, Wells GA, et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. *Canadian Medical Association Journal (Canada)* 2009;181787.
155. Smolen JS, Han C, Bala M, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement - A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. *Arthritis and Rheumatism (USA)*. 2005 04/01/;52(Apr):1020-30.
156. Smolen JS, van der Heijde DM, St Clair EW, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab - Results from the ASPIRE trial. *Arthritis and Rheumatism (USA)*. 2006 03/01/;54(Mar):702-10.
157. Snyder RA. Psoriatic Arthritis: A Dermatologist's Perspective. *American Journal of Clinical Dermatology (New Zealand)*. 2010;11:19-22.
158. Sobanko JF, Freeman AF, Palmore TN, et al. A Sri Lankan woman with rheumatoid arthritis and anesthetic plaques. *Journal of the American Academy of Dermatology (USA)* 2009;601018.
159. Solomon DH, Avorn J, Katz JN, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. *Arthritis and Rheumatism (USA)* 2006;54(Dec):3790-8.
160. Soubrier M, Puechal X, Sibilia J, et al. Evaluation of two strategies (initial methotrexate monotherapy <it>vs</it> its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. *Rheumatology*. 2009;48:1429.
161. Stockl KM, Shin JS, Lew HC, et al. Outcomes of a Rheumatoid Arthritis Disease Therapy Management Program Focusing on Medication Adherence. *Journal of Managed Care Pharmacy (USA)*. 2010;16:593-604.
162. Strand V, Cohen S, Crawford B, et al. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. *Rheumatology*. 2004 05/01/;43(May):640-7.
163. Strand V, Singh JA. Newer Biological Agents in Rheumatoid Arthritis Impact on Health-Related Quality of Life and Productivity. *Drugs (New Zealand)*. 2010;70:121-45.

164. Straub RH, Haerle P, Yamana S, et al. Anti-interleukin-6 receptor antibody therapy favors adrenal androgen secretion in patients with rheumatoid arthritis - A randomized, double-blind, placebo-controlled study. *Arthritis and Rheumatism (USA)*. 2006 06/01/;54(Jun):1778-85.
165. Stuhlmüller B, Haeupl T, Hernandez MM, et al. CD11c as a Transcriptional Biomarker to Predict Response to Anti-TNF Monotherapy With Adalimumab in Patients With Rheumatoid Arthritis. *Clinical Pharmacology and Therapeutics (USA)*. 2010;87:311-21.
166. Sweet BV. Abatacept. *American Journal of Health-System Pharmacy (USA)*. 2006 01/01/;63(Jan):2065-77.
167. Takatori S, Kamata Y, Murosaki T, et al. Abrupt Development of Sarcoidosis with a Prodromal Increase in Plasma Osteopontin in a Patient with Rheumatoid Arthritis During Treatment with Etanercept. *Journal of Rheumatology*. 2010;37:210-2.
168. Taylor PC, Steuer A, Gruber J, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. *Arthritis and Rheumatism (USA)*. 2006 01/01/;54(Jan):47-53.
169. Thayer S, Watson C, Song R, et al. Etanercept treatment patterns in managed-care patients with psoriasis or psoriatic arthritis. *Journal of Medical Economics (England)*. 2010;13:228-35.
170. Tielemans MM, Eikendal T, Jansen JB, et al. Identification of NSAID Users at Risk for Gastrointestinal Complications A Systematic Review of Current Guidelines and Consensus Agreements. *Drug Safety (New Zealand)*. 2010;33:443-53.
171. Torikai E, Kageyama Y, Takahashi M, et al. The effect of infliximab on bone metabolism markers in patients with rheumatoid arthritis. *Rheumatology*. 2006 06/01/;45(Jun):761-4.
172. Tran S, Hooker RS, Cipher DJ, et al. Patterns of Biologic Agent Use in Older Males with Inflammatory Diseases An Institution-Focused, Observational Post-Marketing Study. *Drugs and Aging (New Zealand)*. 2009;26:607.
173. Tubach F, Ravaud P, Salmon-Ceron D, et al. Emergence of *Legionella pneumophila* pneumonia in patients receiving tumor necrosis factor-alpha antagonist. *Clinical Infectious Diseases*. 2006 10/01/;43(Oct):E95-100.
174. van Assen S, Holvast A, Benne CA, et al. Humoral Responses After Influenza Vaccination Are Severely Reduced in Patients With Rheumatoid Arthritis Treated With Rituximab. *Arthritis and Rheumatism (USA)*. 2010;62:75-81.
175. van der Linden MP, van der Woude D, Ioan-Facsinay A, et al. Value of Anti-Modified Citrullinated Vimentin and Third-Generation Anti-Cyclic Citrullinated Peptide Compared With Second-Generation Anti-Cyclic Citrullinated Peptide and Rheumatoid Factor in Predicting Disease Outcome in Undifferentiated Arthritis and Rheumatoid Arthritis. *Arthritis and Rheumatism (USA)* 2009;60:2232.
176. Van Rijthoven AW, Bijlsma JW, Canninga-Van Dijk M, et al. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. *Rheumatology*. 2006 10/01/;45(Oct):1317-9.
177. Vanags D, Williams B, Johnson B, et al. Therapeutic efficacy and safety of chaperonin 10 in patients with rheumatoid arthritis: a double-blind randomised trial. *Lancet, The (USA)*. 2006 01/01/;368(Apr):855-63.
178. Varani K, Massara A, Vincenzi F, et al. Normalization of A<INF>2A</INF> and A<INF>3</INF> Adenosine Receptor Up-Regulation in Rheumatoid Arthritis Patients by Treatment With Anti-Tumor Necrosis Factor alpha but Not Methotrexate. *Arthritis and Rheumatism (USA)* 2009;60:2880.

179. Vergles JM, Radic M, Kovacic J, et al. Successful Use of Adalimumab for Treating Rheumatoid Arthritis with Autoimmune Sensorineural Hearing Loss: Two Birds with One Stone. *Journal of Rheumatology*. 2010;37:1080.
180. Villa-Blanco JI, Calvo-Alen J, Sep. Elderly Onset Rheumatoid Arthritis Differential Diagnosis and Choice of First-Line and Subsequent Therapy. *Drugs and Aging (New Zealand)* 2009;26739.
181. Virkki LM, Sumathikutty BC, Aarnio M, et al. Biological Therapy for Psoriatic Arthritis in Clinical Practice: Outcomes Up to 2 Years. *Journal of Rheumatology* 2010;372362-8.
182. Watson DJ, Bolognese JA, Yu C, et al. Use of gastroprotective agents and discontinuations due to dyspepsia with the selective cyclooxygenase-2 inhibitor etoricoxib compared with non-selective NSAIDs. *Current Medical Research and Opinion (England)*. 2004 12/01/;20(Dec):1899-908.
183. Weisman MH, Durez P, Hallegua D, et al. Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis. *Journal of Rheumatology*. 2006 11/01/;33(Nov):2162-6.
184. Welsing PM, Severens JL, Hartman M, et al. The initial validation of a Markov model for the economic evaluation of (New) treatments for rheumatoid arthritis. *Pharmacoeconomics (New Zealand)*. 2006 10/01/;24(Oct):1011-20.
185. Weng HH, Ranganath VK, Khanna D, et al. Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid Arthritis. *Journal of Rheumatology*. 2010;37:550-7.
186. Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. *Rheumatology* 2006;45(Oct):1238-46.
187. Westlake SL, Colebatch AN, Baird J, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. *Rheumatology (Oxford)*. 2010;49:295.
188. White DH, Chapman PT, O'Donnell JL, et al. Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. *Internal Medicine Journal*. 2010;40:561-5.
189. Williams GW, Kivitz AJ, Brown MT, et al. A comparison of valdecoxib and naproxen in the treatment of rheumatoid arthritis symptoms. *Clinical Therapeutics (USA)*. 2006 02/01/;28(Feb):204-21.
190. Wolbink GJ, Vis M, Lems W, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. *Arthritis and Rheumatism (USA)*. 2006 03/01/;54(Mar):711-5.
191. Yuan Y, Trivedi D, Maclean R, et al. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. *Journal of Medical Economics (England)* 2010;13(1):33-41.
192. Zaiac M. The Role of Biological Agents in the Treatment of Nail Psoriasis. *American Journal of Clinical Dermatology (New Zealand)*. 2010;11:27.
193. Zandbelt MM, Houbiers JG, van den Hoogen FH, et al. Intranasal administration of recombinant human cartilage glycoprotein-39. A phase I escalating cohort study in patients with rheumatoid arthritis. *Journal of Rheumatology*. 2006 09/01/;33(Sep):1726-33.
194. Zhang XP, Huang Y, Navarro MT, et al. A Proof-of-Concept and Drug-Drug Interaction Study of Pamapimod, a Novel p38 MAP Kinase Inhibitor, With Methotrexate in Patients With Rheumatoid Arthritis. *Journal of Clinical Pharmacology (USA)*. 2010;50:1031-8.

195. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study - Comparison of patients according to their eligibility for

major randomized clinical trials. *Arthritis and Rheumatism (USA)*. 2006 11/01;/54(Nov):3399-407.

**Reference Source: Handsearches (e.g., Scopus)**

1. Cochrane Collaboration guidelines.
2. The BUGS Project. Stevens A, Hosted by the MRC Biostatistics Unit, Cambridge, UK. Accessed on May 2, 2011. [www.mrc-bsu.cam.ac.uk/bugs/welcome.shtml](http://www.mrc-bsu.cam.ac.uk/bugs/welcome.shtml)
3. Sulfasalazine in early rheumatoid arthritis. The Australian Multicentre Clinical Trial Group. *J Rheumatol*. 1992 Nov;19(11):1672-7.
4. Screening for hydroxychloroquine retinopathy. 2006.
5. National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions--United States, 2003. *MMWR Morb Mortal Wkly Rep* 2007;56(1):4-7.
6. Chapter 9: Analysing data and undertaking meta-analyses. *Cochrane Handbook of Systematic Reviews of Intervention Version 500 (Updated February 2008)*. 2008.
7. Rituxan (Rituximab) [Package Insert]. 2008.
8. Åstensen M, Motta M. Therapy Insight: The use of antirheumatic drugs during nursing. *Nature Clinical Practice Rheumatology*. 2007;3(7):400-6.
9. Åstensen M, Khamashta M, Lockshin M, et al. Anti-inflammatory and immunosuppressive drugs and reproduction. *Arthritis Research and Therapy*. 2006;8(3).
10. Abeles AM, Pillinger MH. The role of the synovial fibroblast in rheumatoid arthritis: Cartilage destruction and the regulation of matrix metalloproteinases. *Bulletin of the NYU Hospital for Joint Diseases*. 2006;64(1-2):20-4.
11. Ackermann C, Kavanaugh A. Economic burden of psoriatic arthritis. *PharmacoEconomics* 2008;26(2):121-9.
12. ACR. Guidelines for the management of rheumatoid arthritis: 2002 Update. *Arthritis Rheum*. 2002 Feb;46(2):328-46.
13. ACR. ACR Hotline: Update on safety issues concerning TNF inhibitors; available at <http://www.rheumatology.org/publications/hotline/0506JAMATNF.asp>. 2006.
14. Agency for Healthcare Research and Quality. Methods reference guide for effectiveness and comparative effectiveness reviews, version 1.0. [Draft posted Oct. 2007]. Rockville, MD. Available at: [http://effectivehealthcare.ahrq.gov/repFiles/2007\\_10DraftMethodsGuide.pdf](http://effectivehealthcare.ahrq.gov/repFiles/2007_10DraftMethodsGuide.pdf) 2007.
15. Agrawal S, Misra R, Aggarwal A. Autoantibodies in rheumatoid arthritis: Association with severity of disease in established RA. *Clinical rheumatology*. 2007;26(2):201-4.
16. Alamanos Y, Voulgari PV, Drosos AA. Incidence and prevalence of psoriatic arthritis: A systematic review. *Journal of Rheumatology*. 2008;35(7):1354-8.
17. Aletaha D, Machold KP, Nell VPK, et al. The perception of rheumatoid arthritis core set measures by rheumatologists. Results of a survey. *Rheumatology*. 2006;45(9):1133-9.
18. Aletaha D, Nell VP, Stamm T, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. *Arthritis Res Ther*. 2005;7(4):R796-806.
19. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Ann Rheum Dis* 2010;69(9):1580-8.
20. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. *Rheumatic Disease Clinics of North America*. 2006;32(1):9-44.

21. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, et al. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. *Clin Exp Rheumatol*. 2006 Nov-Dec;24(6 Suppl 43):S-77-82.
22. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. *BMC Musculoskeletal Disorders* 2008;9.
23. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for monitoring drug therapy in rheumatoid arthritis. *Arthritis Rheum*. 1996 May;39(5):723-31.
24. Anandarajah AP, Ritchlin CT. Pathogenesis of psoriatic arthritis. *Curr Opin Rheumatol*. 2004 Jul;16(4):338-43.
25. Ang DC, Paulus HE, Louie JS. Patient's ethnicity does not influence utilization of effective therapies in rheumatoid arthritis. *J Rheumatol*. 2006 May;33(5):870-8.
26. Angst F, Aeschlimann A, Stucki G. Smallest detectable and minimal clinically important differences of rehabilitation intervention with their implications for required sample sizes using WOMAC and SF-36 quality of life measurement instruments in patients with osteoarthritis of the lower extremities. *Arthritis Rheum* 2001;45(4):384-91.
27. Anonymous. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews. CRD Report Number 4 (2nd edition). 2001 2001.
28. Anonymous. Cortisone Acetate package insert. Pharmacia & Upjohn Co. Kalamazoo, MI. 2002.
29. Anonymous. Cortef (hydrocortisone) package insert. Pharmacia & Upjohn Co. Kalamazoo, MI. 2002.
30. Anonymous. Dexamethasone package insert. Roxane Laboratories, Inc. Columbus, OH. 2003.
31. Anonymous. PredniSONE package insert. Roxane Laboratories, Inc. Columbus, OH. 2003.
32. Anonymous. Kineret (anakinra) package insert. Amgen, Inc. Thousand Oaks, CA. 2004.
33. Anonymous. Hydroxychloroquine package insert. Sandoz, Inc. Broomfield, CO. 2004.
34. Anonymous. Orencia (abatacept) package insert. Bristol-Myers Squibb. Princeton, NJ. 2005.
35. Anonymous. Methotrexate package insert. Mayne Pharma (USA) Inc. Paramus, NJ. 2005.
36. Anonymous. Arava (leflunomide) package insert. Aventis Pharmaceuticals Inc. Kansas City, MO. 2005.
37. Anonymous. Remicade (infliximab) package insert. Centocor, Inc. Malvern, PA. 2006.
38. Anonymous. Humira (adalimumab) package insert. Abbott Labs. North Chicago, IL. 2006.
39. Anonymous. Enbrel (etanercept) package insert. Immunex Corporation. Thousand Oaks, CA. 2006.
40. Anonymous. MethylPREDNIsolone package insert. Sandoz, Inc. Princeton, NJ. 2006.
41. Anonymous. Azulfidine (sulfasalazine) package insert. Pharmacia & Upjohn Co. NY, NY. 2006.
42. Anonymous. Rituxan (rituximab) package insert. Genetech, Inc. South San Francisco, CA. 2007.
43. Arkfeld DG. The potential utility of B cell-directed biologic therapy in autoimmune diseases. *Rheumatology international*. 2008;28(3):205-15.
44. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. *Arthritis Rheum*. 1988 Mar;31(3):315-24.
45. Askling J, ForeD CM, Brandt L, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. *Ann Rheum Dis*. 2005 Oct;64(10):1421-6.

46. Ateş A, Kinikli G, Turgay M, et al. Effects of rheumatoid factor isotypes on disease activity and severity in patients with rheumatoid arthritis: A comparative study. *Clinical rheumatology*. 2007;26(4):538-45.
47. Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. *BMC Health Serv Res*. 2004 Dec 22;4(1):38.
48. Baecklund E, Ekblom A, Sørensen P, et al. Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study. *Bmj*. 1998 Jul 18;317(7152):180-1.
49. Balk EM, Lau J, Bonis PA. Reading and critically appraising systematic reviews and meta-analyses: a short primer with a focus on hepatology. *J Hepatol*. 2005;43(4):729-36.
50. Bansback NJ, Ara R, Barkham N, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. *Rheumatology (Oxford)*. 2006 Aug;45(8):1029-38.
51. Bendtzen K, Geborek P, Svenson M, et al. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. *Arthritis Rheum*. 2006 Dec;54(12):3782-9.
52. Berends MAM, Snoek J, De Jong EMGJ, et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. *Alimentary Pharmacology and Therapeutics*. 2006;24(5):805-11.
53. Berglin E, Johansson T, Sundin U, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. *Annals of the rheumatic diseases*. 2006;65(4):453-8.
54. Bergman GJ, Hochberg MC, Boers M, et al. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. *Semin Arthritis Rheum* 2010;39(6):425-41.
55. Berliner AR, Haas M, Choi MJ. Sarcoidosis: the nephrologist's perspective. *Am J Kidney Dis*. 2006 Nov;48(5):856-70.
56. Bermas BL. Use of immunosuppressive drugs in pregnancy and lactation. 2007.
57. Bliddal H, Terslev L, Qvistgaard E, et al. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. *Scand J Rheumatol*. 2006 Sep-Oct;35(5):341-5.
58. BlueCross BlueShield Technology Evaluation Center (TEC). Special report: evidence on sequencing of conventional and biological disease-modifying anti-rheumatic drugs. 2003 2003;18(11).
59. Boers M. Add-on or step-up trials for new drug development in rheumatoid arthritis: a new standard? *Arthritis Rheum*. 2003 Jun;48(6):1481-3.
60. Boers M. Abatacept in rheumatoid arthritis: a new branch on the "biologics" tree. *Ann Intern Med*. 2006 Jun 20;144(12):933-5.
61. Boetticher NC, Peine CJ, Kwo P, et al. A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. *Gastroenterology*. 2008 Dec;135(6):1953-60.
62. Boini S, Fillemin F. Review. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. *Ann Rheum Dis*. 2001;60:817-27.
63. Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. *Ann Rheum Dis*. 2001 Sep;60(9):817-27.
64. Bolen J, Helmick CG, Sacks JJ, et al. Prevalence of self-reported arthritis or chronic joint symptoms among adults--United States, 2001. *MMWR Morb Mortal Wkly Rep*. 2002 Oct 25;51(42):948-50.
65. Bologna C, Viu P, Picot MC, et al. Long-term follow-up of 453 rheumatoid arthritis patients treated with methotrexate: an open, retrospective, observational study. *Br J Rheumatol*. 1997 May;36(5):535-40.



66. Bond SJ, Farewell VT, Schentag CT, et al. Predictors for radiological damage in psoriatic arthritis: Results from a single centre. *Ann Rheum Dis*. 2006 Aug 17.
67. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA*. 2006 May 17;295(19):2275-85.
68. Bongartz T, Warren FC, Mines D, et al. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. *Ann Rheum Dis* 2009;68(7):1177-83.
69. Borman P, Toy GG, Babaoglu S, et al. A comparative evaluation of quality of life and life satisfaction in patients with psoriatic and rheumatoid arthritis. *Clin Rheumatol*. 2006 Apr 19.
70. Bradburn MJ, Deeks JJ, Berlin JA, et al. Much ado about nothing: A comparison of the performance of meta-analytical methods with rare events. *Statistics in Medicine*. 2007;26(1):53-77.
71. Braun J, McHugh N, Singh A, et al. Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. *Rheumatology (Oxford)*. 2007 Jun;46(6):999-1004.
72. Braun J, Sieper J. Biological therapies in the spondyloarthritides--the current state. *Rheumatology (Oxford)*. 2004 Sep;43(9):1072-84.
73. Bren L. The importance of patient-reported outcomes... it's all about the patients. *FDA Consumer*. 2006;40(6).
74. Brennan FM, McInnes IB. Evidence that cytokines play a role in rheumatoid arthritis. *Journal of Clinical Investigation*. 2008;118(11):3537-45.
75. Bruce SP, Boyce EG. Update on abatacept: A selective costimulation modulator for rheumatoid arthritis. *Annals of Pharmacotherapy*. 2007;41(7-8):1153-62.
76. Bruce TO. Comorbid depression in rheumatoid arthritis: pathophysiology and clinical implications. *Curr Psychiatry Rep* 2008;10(3):258-64.
77. Bruynesteyn K, van der Heijde D, Boers M, et al. Determination of the minimal clinically important difference in rheumatoid arthritis joint damage of the Sharp/van der Heijde and Larsen/Scott scoring methods by clinical experts and comparison with the smallest detectable difference. *Arthritis Rheum*. 2002 Apr;46(4):913-20.
78. Buch MH, Bingham SJ, Bejarano V, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. *Arthritis Rheum*. 2007 Apr 15;57(3):448-53.
79. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. *J Clin Epidemiol*. 1997 Jun;50(6):683-91.
80. Bucher HC, Guyatt GH, Griffith LE, et al. The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials. *J Clin Epidemiol*. 1997 Jun;50(6):683-91.
81. Bukhari MA, Wiles NJ, Lunt M, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. *Arthritis Rheum*. 2003 Jan;48(1):46-53.
82. Burmester GR, Mease P, Dijkmans BA, et al. Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases. *Ann Rheum Dis*. 2009 Dec;68(12):1863-9.
83. Canadian Agency for Drugs and Technologies in Health. CADTH Therapeutic Review: Clinical and Economic Overview: Biological Response Modifier Agents for Adults with Rheumatoid Arthritis. 2010.
84. Cannella AC, O'Dell JR. Early rheumatoid arthritis: pitfalls in diagnosis and review of recent clinical trials. *Drugs*. 2006;66(10):1319-37.

85. Capell H, Madhok R, Porter D, et al. Combination therapy with sulphasalazine and methotrexate is more effective than either drug alone in rheumatoid arthritis (ra) patients with a suboptimal response to sulphasalazine: Results from the double blind placebo controlled mascot study. *Ann Rheum Dis*. 2006 August 22, 2006;ard.2006.057133.
86. Carlin CS, Feldman SR, Krueger JG, et al. A 50% reduction in the Psoriasis Area and Severity Index (PASI 50) is a clinically significant endpoint in the assessment of psoriasis. *J Am Acad Dermatol*. 2004 Jun;50(6):859-66.
87. Carmona L, Descalzo MÃ, Perez-Pampin E, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. *Annals of the rheumatic diseases*. 2007;66(7):880-5.
88. Carmona L, Hernandez-Garcia C, Vadillo C, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. *J Rheumatol*. 2003 Jul;30(7):1436-9.
89. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. *J Rheumatol*. 2006 Jul;33(7):1452-6.
90. Cassell S, Tutuncu Z, Kremer J, et al. Psoriatic arthritis patients have different rates of adverse events than rheumatoid arthritis patients when treated with TNF inhibitors: analysis from CORRONA Database [Abstract 491]. *Arthritis Rheum*. 2005;52(Suppl 9):S211-S2.
91. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. *J Rheumatol*. 2005 Nov;32(11):2130-5.
92. Cheifetz A, Smedley M, Martin S, et al. The incidence and management of infusion reactions to infliximab: a large center experience. *Am J Gastroenterol*. 2003 Jun;98(6):1315-24.
93. Chen Y, Jobanputra P, Barton P, et al. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness. *Health Technology Assessment*. 2006;10(42).
94. Chernoff MC, Wang M, Anderson JJ, et al. Problems and suggested solutions in creating an archive of clinical trials data to permit later meta-analysis: an example of methotrexate trials in rheumatoid arthritis. *Control Clin Trials*. 1995 Oct;16(5):342-55.
95. Choy EH, Panayi GS. Cytokine pathways and joint inflammation in rheumatoid arthritis. *N Engl J Med*. 2001 Mar 22;344(12):907-16.
96. Chung CP, Thompson JL, Koch GG, et al. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. *Annals of the rheumatic diseases*. 2006;65(12):1602-7.
97. Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation*. 2003 Jul 1;107(25):3133-40.
98. Coburn LA, Wise PE, Schwartz DA. The successful use of adalimumab to treat active Crohn's disease of an ileoanal pouch during pregnancy. *Digestive Diseases and Sciences*. 2006;51(11):2045-7.
99. Cohen JD, Dougados M, Goupille P, et al. Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis. *Journal of Rheumatology*. 2006;33(10):1936-41.
100. Coletta AP, Clark AL, Banarjee P, et al. Clinical trials update: RENEWAL (RENAISSANCE and RECOVER) and ATTACH. *Eur J Heart Fail*. 2002 Aug;4(4):559-61.
101. Combe B, Codreanu C, Fiocco U, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: A double-blind comparison. *Annals of the rheumatic diseases*. 2006;65(10):1357-62.

102. Combe B, Landewe R, Lukas C, et al. EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCSIT). *Annals of the rheumatic diseases*. 2007;66(1):34-45.
103. Connell L, McInnes IB. New cytokine targets in inflammatory rheumatic diseases. *Best Practice and Research: Clinical Rheumatology*. 2006;20(5):865-78.
104. Cope AP. T cells in rheumatoid arthritis. *Arthritis Research and Therapy*. 2008;10(SUPPL. 1).
105. Corbo M, Tay LK, Leon F, et al. A single dose of abatacept does not prevent the development of a positive immune response to tetanus and pneumococcal vaccines. *Ann Rheum Dis*. 2006;65(SUPPL. II):184.
106. Cvetkovic RS, Scott LJ. Adalimumab: a review of its use in adult patients with rheumatoid arthritis. *BioDrugs*. 2006;20(5):293-311.
107. Davis MJ, Dawes PT, Fowler PD, et al. Should disease-modifying agents be used in mild rheumatoid arthritis? *Br J Rheumatol*. 1991 Dec;30(6):451-4.
108. De Filippis L, Caliri A, Anghelone S, et al. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. *Panminerva Med* 2006;48(2):129-35.
109. Deeks JJ, Dinnes J, D'Amico R, et al. Evaluating non-randomised intervention studies. *Health Technol Assess*. 2003;7(27):iii-x, 1-173.
110. Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. *Pharmacotherapy* 2011;31(1):39-51.
111. Dixon WG, Hyrich KL, Watson KD, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). *Ann Rheum Dis* 2010;69(3):522-8.
112. Dixon WG, Symmons DP, Lunt M, et al. Serious infection following anti-tumor necrosis factor alpha therapy in patients with rheumatoid arthritis: lessons from interpreting data from observational studies. *Arthritis Rheum* 2007;56(9):2896-904.
113. Dixon WG, Watson K, Lunt M, et al. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum*. 2006 Jul 25;54(8):2368-76.
114. Donahue KE, Gartlehner G, Jonas DE, et al. Comparative effectiveness of drug therapy for rheumatoid arthritis and psoriatic arthritis in adults. Comparative Effectiveness Review No. 11. (Prepared by RTI-University of North Carolina Evidence-based Practice Center under Contract No. 290-02-0016.) Rockville, MD: Agency for Healthcare Research and Quality; 2007.
115. Edmonds J, Saudan A, Lassere M, et al. Introduction to reading radiographs by the Scott modification of the Larsen method. *J Rheumatol*. 1999;26:740-2.
116. Efthimiou P, Kontzias A, Ward CM, et al. Adult-onset Still's disease: can recent advances in our understanding of its pathogenesis lead to targeted therapy? *Nat Clin Pract Rheumatol*. 2007 Jun;3(6):328-35.
117. Egger M, Smith GD, Altman DG. *Systematic Reviews in Health Care* (2nd edition). 2001 2001.
118. Emery P, Breedveld FC, Jubb RW, et al. Efficacy and safety of leflunomide vs. methotrexate in rheumatoid arthritis (RA): results of a double-blind, randomized, 2-year trial. *Arthritis and Rheumatism*. 1999;42(9 (Suppl)):S271.
119. Emery P, Fleischmann R, Filipowicz-Sosnowska A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis Rheum* 2006;54(5):1390-400.

120. Feagan BG, Yan S, Bala M, et al. The effects of infliximab maintenance therapy on health-related quality of life. *Am J Gastroenterol.* 2003 Oct;98(10):2232-8.
121. Felson DT, Anderson JJ, Boers M, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials. *Arthritis Rheum.* 1993 Jun;36(6):729-40.
122. Felson DT, Anderson JJ, Boers M, et al. ACR preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum.* 1995;38(6):727-35.
123. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum* 1995;38(6):727-35.
124. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. *Arthritis Rheum.* 1990 Oct;33(10):1449-61.
125. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. *Arthritis Rheum.* 1994 Oct;37(10):1487-91.
126. Fernandez-Espartero MC, Perez-Zafrilla B, Naranjo A, et al. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. *Semin Arthritis Rheum* 2010;40(4):330-7.
127. Finckh A, Liang MH, Van Herckenrode CM, et al. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. *Arthritis and rheumatism.* 2006;55(6):86-172.
128. Finckh A, Simard JF, Gabay C, et al. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. *Ann Rheum Dis.* 2006 Jun;65(6):746-52.
129. Firestein GS. Etiology and pathogenesis of rheumatoid arthritis. *Kelley's Testbook of Rheumatology* 2005;7.
130. Fleischmann R, Iqbal I. Risk: benefit profile of etanercept in elderly patients with rheumatoid arthritis, ankylosing spondylitis or psoriatic arthritis. *Drugs Aging.* 2007;24(3):239-54.
131. Fleischmann R, Iqbal I, Nandeshwar P, et al. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept. *Drug Saf.* 2002;25(3):173-97.
132. Fleischmann RM, Baumgartner SW, Tindall EA, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. *J Rheumatol.* 2003 Apr;30(4):691-6.
133. Flendrie M, Vissers WH, Creemers MC, et al. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. *Arthritis Res Ther.* 2005;7(3):R666-76.
134. Food and Drug Administration. FDA alert on rituximab, available at: <http://www.fda.gov/cder/drug/infopage/rituximab/default.htm>. 2006.
135. Frankel EH, Strober BE, Crowley JJ, et al. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. *Cutis.* 2007 Apr;79(4):322-6.
136. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. *Rheum Dis Clin North Am* 2009;35(4):745-57, vii-viii.
137. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. *Dermatologica.* 1978;157(4):238-44.
138. Friedrich-Rust M, Ong M, Martens S, et al. Performance of Transient Elastography for the Staging of Liver Fibrosis: A Meta-Analysis. *Gastroenterology.* 2008;134(4).
139. Fries JF, Spitz P, Kraines RG, et al. Measurement of patient outcome in arthritis. *Arthritis Rheum.* 1980 Feb;23(2):137-45.
140. Fries JF, Williams CA, Morfeld D, et al. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. *Arthritis Rheum.* 1996 Apr;39(4):616-22.

141. Furst D, Luggen M, Thompson A, et al. Adding leflunomide to patients with active rheumatoid arthritis patients while receiving methotrexate improves physical function and health related quality of life. *Arthritis and Rheumatism*. 2000;43(Suppl):S344.
142. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. *Annals of the rheumatic diseases*. 2007;66(SUPPL. 3).
143. Furst DE, Keystone EC, Kirkham B, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. *Annals of the rheumatic diseases*. 2008;67(SUPPL. 3).
144. Galloway JB, Hyrich KL, Mercer LK, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. *Rheumatology (Oxford, England)* 2011;50(1):124-31.
145. Galvañ VG, Oltra MR, Rueda D, et al. Severe acute hepatitis related to hydroxychloroquine in a woman with mixed connective tissue disease. *Clinical rheumatology*. 2007;26(6):971-2.
146. Gartlehner G, Hansen R, Thieda P, et al. Drug Class Review on Targeted Immune Modulators, Final AHRQ-approved report December 2006, available at <http://www.ohsu.edu/drugeffectiveness/reports/draft.cfm>. 2006.
147. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. *J Rheumatol*. 2006.
148. Gelfand JM, Gladman DD, Mease PJ, et al. Epidemiology of psoriatic arthritis in the population of the United States. *J Am Acad Dermatol* 2005;53(4):573.
149. Genant HK, Peterfy C, Westhovens R. Abatacept sustains inhibition of radiographic progression over 2 years in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from the long-term extension of the AIM trial. *Ann Rheum Dis*. 2006;65(SUPPL. II):57-8.
150. Genovese M, Kaine J, Lowenstein M. Ocrelizumab, a novel humanized anti-CD20 antibody: Week 72 results from a phase I/II clinical trial in patients with rheumatoid arthritis [abstract]. American College of Rheumatology Annual Meeting. 2007.
151. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. *J Rheumatol* 2007;34(5):1040-50.
152. Gilaberte Y, Coscojuela C, Vazquez C, et al. Perforating folliculitis associated with tumour necrosis factor-alpha inhibitors administered for rheumatoid arthritis. *Br J Dermatol*. 2007 Feb;156(2):368-71.
153. Gladman DD. Effectiveness of psoriatic arthritis therapies. *Semin Arthritis Rheum*. 2003 Aug;33(1):29-37.
154. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. *Ann Rheum Dis* 2005;64 Suppl 2ii14-7.
155. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. *Health Technol Assess*. 2005 Jul;9(26):1-134, iii-iv.
156. Glenny AM, Altman DG, Song F, et al. Indirect comparisons of competing interventions. *Health Technol Assess* 2005;9(26):1-134, iii-iv.
157. Golding A, Haque UJ, Giles JT. Rheumatoid arthritis and reproduction. *Rheum Dis Clin North Am*. 2007 May;33(2):319-43, vi-vii.
158. Goldman JA, Xia HA, White B, et al. Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept. *Ann Rheum Dis*. 2006 Dec;65(12):1649-52.
159. Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, et al. Development of sarcoidosis during etanercept therapy. *Arthritis Rheum*. 2006 Oct 15;55(5):817-20.

160. Goodman SN. Toward evidence-based medical statistics. 2: The Bayes factor. *Ann Intern Med.* 1999 Jun 15;130(12):1005-13.
161. Gottlieb AB, Boehncke WH, Darif M. Safety and efficacy of alefacept in elderly patients and other special populations. *J Drugs Dermatol.* 2005 Nov-Dec;4(6):718-24.
162. Greenberg JD, Reed G, Kremer JM, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. *Ann Rheum Dis* 2010;69(2):380-6.
163. Greiner A, Plischke H, Kellner H, et al. Association of Anti-Cyclic Citrullinated Peptide Antibodies, Anti-Citrullin Antibodies, and IgM and IgA Rheumatoid Factors with Serological Parameters of Disease Activity in Rheumatoid Arthritis. *Ann N Y Acad Sci.* 2005 Jun;1050:295-303.
164. Grismer LE, Gill SA, Harris MD. Liver biopsy in psoriatic arthritis to detect methotrexate hepatotoxicity. *J Clin Rheumatol.* 2001 Aug;7(4):224-7.
165. Guyatt G, Gutterman D, Baumann MH, et al. Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force. *Chest.* 2006 Jan;129(1):174-81.
166. Häkkinen A, Kautiainen H, Hannonen P, et al. Muscle strength, pain, and disease activity explain individual subdimensions of the Health Assessment Questionnaire disability index, especially in women with rheumatoid arthritis. *Annals of the rheumatic diseases.* 2006;65(1):30-4.
167. Hallert E, Husberg M, Skogh T. Costs and course of disease and function in early rheumatoid arthritis: a 3-year follow-up (the Swedish TIRA project). *Rheumatology (Oxford).* 2006 Mar;45(3):325-31.
168. Han C, Robinson DW, Jr., Hackett MV, et al. Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. *J Rheumatol.* 2006 Nov;33(11):2167-72.
169. Hara M, Abe T, Sugawara S, et al. Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study. *Mod Rheumatol.* 2007;17(1):1-9.
170. Harris RP, Helfand M, Woolf SH, et al. Current methods of the US Preventive Services Task Force: a review of the process. *Am J Prev Med.* 2001 Apr;20(3 Suppl):21-35.
171. Hasan U. Tumour necrosis factor inhibitors--what we need to know. *N Z Med J.* 2006;119(1246):U2336.
172. Hays RD, Morales LS. The RAND-36 measure of health-related quality of life. *Ann Med* 2001;33(5):350-7.
173. Heiberg MS, Kaufmann C, Rodevand E, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. *Ann Rheum Dis.* 2007 Aug;66(8):1038-42.
174. Heiberg MS, Rodevand E, Mikkelsen K, et al. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: Results from a 6-month longitudinal, observational, multicentre study. *Annals of the rheumatic diseases* 2006;65(10):1379-83.
175. Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. *J Rheumatol.* 2006 Jul;33(7):1439-41.
176. Helliwell PS, Ibrahim G. Ethnic differences in responses to disease modifying drugs. *Rheumatology (Oxford).* 2003 Oct;42(10):1197-201.
177. Helliwell PS, Taylor WJ. Classification and diagnostic criteria for psoriatic arthritis. *Ann Rheum Dis.* 2005 Mar;64 Suppl 2:ii3-8.
178. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. *Arthritis Rheum* 2008;58(1):15-25.
179. Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: A systematic review of scales in use. *Arthritis Care and Research.* 2007;57(3):429-39.

180. Higgins JP, Whitehead A. Borrowing strength from external trials in a meta-analysis. *Stat Med* 1996;15(24):2733-49.
181. Hochberg MC, Tracy JK, Flores RH. "Stepping-up" from methotrexate: a systematic review of randomised placebo controlled trials in patients with rheumatoid arthritis with an incomplete response to methotrexate. *Ann Rheum Dis*. 2001 Nov;60 Suppl 3:iii51-4.
182. Hochberg MC, Tracy JK, Hawkins-Holt M, et al. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. *Ann Rheum Dis*. 2003 2003;62 Suppl 2:ii13-6.
183. Huedo-Medina TB, SÃ¡nchez-Meca J, MarÃ¡n-MartÃ¡nez F, et al. Assessing heterogeneity in meta-analysis: Q statistic or  $I^2$  Index? *Psychological Methods*. 2006;11(2):193-206.
184. Hurst NP, Kind P, Ruta D, et al. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). *Br J Rheumatol*. 1997 May;36(5):551-9.
185. Huscher D, Merkesdal S, Thiele K, et al. Cost of illness in rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis and systemic lupus erythematosus in Germany. *Ann Rheum Dis*. 2006 Sep;65(9):1175-83.
186. Husted JA, Gladman DD, Farewell VT, et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. *Arthritis Rheum*. 2001 Apr;45(2):151-8.
187. Hyrich KL, Symmons DP, Watson KD, et al. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum*. 2006 May 30;54(6):1786-94.
188. ICH. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline Clinical Safety Data Management: Definitions and Standards for Expedited Reporting E2A; available at <http://www.ich.org/LOB/media/MEDIA436.pdf>. 1994.
189. Jansen JP, Crawford B, Bergman G, et al. Bayesian meta-analysis of multiple treatment comparisons: an introduction to mixed treatment comparisons. *Value Health*. 2008 Sep-Oct;11(5):956-64.
190. Javitz HS, Ward MM, Farber E, et al. The direct cost of care for psoriasis and psoriatic arthritis in the United States. *J Am Acad Dermatol*. 2002 Jun;46(6):850-60.
191. Jobanputra P, Barton P, Bryan S, et al. The effectiveness of infliximab and etanercept for the treatment of rheumatoid arthritis: a systematic review and economic evaluation. *Health Technol Assess*. 2002;6(21):1-110.
192. Kaine J, Kivitz A, Birbara C, et al. Effect of adalimumab (Humira®) on response to pneumococcal and influenza virus vaccines in patients with rheumatoid arthritis (RA). *Ann Rheum Dis*. 2006;65(SUPPL. II):304.
193. Kaine JL, Kivitz AJ, Birbara C, et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. *J Rheumatol*. 2007 Feb;34(2):272-9.
194. Kapetanovic M, Saxne T, Nilsson J. Influenza vaccination as model for testing immune modulation of anti-TNF and methotrexate therapy in rheumatoid arthritis patients. *Ann Rheum Dis*. 2006;65(SUPPL. II):184.
195. Katchamart W, Ortiz Z, Shea B, et al. Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis (an update systematic review and metaanalysis). *Arthritis Rheum*. 2008;58(SUPPL.).
196. Kavanaugh A, Antoni C, Mease P, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. *J Rheumatol* 2006;33(11):2254-9.

197. Kavanaugh A, Krueger GG, Beutler A, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. *Ann Rheum Dis*. 2007 Apr;66(4):498-505.
198. Kavanaugh AF, Ritchlin CT. Systematic review of treatments for psoriatic arthritis: an evidence based approach and basis for treatment guidelines. *J Rheumatol*. 2006 Jul;33(7):1417-21.
199. Kievit W, Fransen J, Kupper HH, et al. The drug survival of adalimumab compared to etanercept and infliximab in the treatment of patients with rheumatoid arthritis in daily clinical practice. *Ann Rheum Dis*. 2006 June 1, 2006;65(Suppl 2):325-.
200. Kim HY, Lee SK, Song YW, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. *APLAR Journal of Rheumatology* 2007;10(1):9-16.
201. Kind P. The EuroQol instrument: An index of health-related quality of life. *Quality of life and Pharmacoeconomics in Clinical Trials*. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1996.
202. Kirwan JR, Bijlsma JW, Boers M, et al. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. *Cochrane Database Syst Rev* 2007(1):CD006356.
203. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. *Arthritis Rheum* 2000;43(7):1478-87.
204. Kremer J, Westhovens R, Luggen M. Long-term efficacy and safety of abatacept through 3 years of treatment in rheumatoid arthritis patients in the AIM and ATTAIN trials [abstract]. American College of Rheumatology Meeting.
205. Kremer JL, Blanco R, Brzosko M, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: The LITHE study. *Arthritis Rheum* 2010.
206. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. *Arthritis Rheum*. 1997 May;40(5):984-5.
207. Kremer JM, Caldwell JR, Cannon GW, et al. The combination of leflunomide and methotrexate in patients with active rheumatoid arthritis who are failing on methotrexate treatment alone: a double-blind placebo-controlled study. *Arthritis Rheum*. 2000;43(Suppl 9):S224.
208. Kremer JM, Dougados M, Emery P, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. *Arthritis Rheum*. 2005 Aug;52(8):2263-71.
209. Kristensen LE, Christensen R, Bliddal H, et al. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: A systematic literature review. *Scandinavian Journal of Rheumatology* 2007;36(6):411-7.
210. Laivoranta-Nyman S, Mottonen T, Hannonen P, et al. Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis. *Clin Exp Rheumatol*. 2006 Nov-Dec;24(6):636-42.
211. Landewe R, van der Heijde D, van der Linden S, et al. Twenty-eight-joint counts invalidate the DAS28 remission definition owing to the omission of the lower extremity joints: a comparison with the original DAS remission. *Ann Rheum Dis*. 2006 May;65(5):637-41.
212. Lard LR, Visser H, Speyer I, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. *Am J Med*. 2001 Oct 15;111(6):446-51.



213. Larsen A. Radiological grading of rheumatoid arthritis. An interobserver study. *Scand J Rheumatol.* 1973;2(3):136-8.
214. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. *J Rheumatol.* 1995;22:1974-5.
215. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. *Acta Radiol Diagn (Stockh).* 1977 Jul;18(4):481-91.
216. Lau J, Ioannidis JPA, Terrin N, et al. The case of the misleading funnel plot. *British Medical Journal.* 2006;333(7568):597-600.
217. Lawrence RC, Felson DT, Helmick CG, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. *Arthritis Rheum* 2008;58(1):26-35.
218. Lee YH, Woo JH, Rho YH, et al. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. *Rheumatology international* 2008;28(6):553-9.
219. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. *Ann Rheum Dis* 2009;68(7):1136-45.
220. Lequerre T, Vittecoq O, Klemmer N, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. *J Rheumatol.* 2006 Jul;33(7):1307-14.
221. Li X, Gignac MA, Anis AH. The indirect costs of arthritis resulting from unemployment, reduced performance, and occupational changes while at work. *Med Care* 2006;44(4):304-10.
222. Liao KP, Batra KL, Chibnik L, et al. Anti-cyclic citrullinated peptide revised criteria for the classification of rheumatoid arthritis. *Ann Rheum Dis* 2008;67(11):1557-61.
223. Lim LL, Fraunfelder FW, Rosenbaum JT. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. *Arthritis Rheum.* 2007 Oct;56(10):3248-52.
224. Lindqvist E, Saxne T, Geborek P, et al. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. *Ann Rheum Dis.* 2002 Dec;61(12):1055-9.
225. Lindsay K, Gough A. Psoriatic arthritis, methotrexate and the liver - Are rheumatologists putting their patients at risk? *Rheumatology.* 2008;47(7):939-41.
226. Listing J, Strangfeld A, Rau R, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low-- results from RABBIT, the German biologics register. *Arthritis Res Ther.* 2006;8(3):R66.
227. Lu G, Ades AE. Combination of direct and indirect evidence in mixed treatment comparisons. *Stat Med.* 2004 Oct 30;23(20):3105-24.
228. Lumley T. Network meta-analysis for indirect treatment comparisons. *Stat Med.* 2002 Aug 30;21(16):2313-24.
229. MÃ¼ki-PetÃ¼jÃ¼ KM, Booth AD, Hall FC, et al. Ezetimibe and Simvastatin Reduce Inflammation, Disease Activity, and Aortic Stiffness and Improve Endothelial Function in Rheumatoid Arthritis. *Journal of the American College of Cardiology.* 2007;50(9):852-8.
230. Mader R, Keystone E. Optimizing treatment with biologics. *Journal of Rheumatology.* 2007;34(SUPPL. 80):16-24.
231. Maetzel A, Wong A, Strand V, et al. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. *Rheumatology (Oxford).* 2000 Sep;39(9):975-81.
232. Manadan AM, Mohan AK. Tuberculosis and etanercept treatment. *Arthritis Rheum.* 2002;46:S166.
233. Marcora SM, Chester KR, Mittal G, et al. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. *Am J Clin Nutr.* 2006 Dec;84(6):1463-72.

234. Markham T, Mathews C, Rogers S, et al. Downregulation of the inhibitor of apoptosis protein survivin in keratinocytes and endothelial cells in psoriasis skin following infliximab therapy. *British Journal of Dermatology*. 2006;155(6):1191-6.
235. Martin M, Kosinski M, Bjorner JB, et al. Item response theory methods can improve the measurement of physical function by combining the modified health assessment questionnaire and the SF-36 physical function scale. *Qual Life Res*. 2007 May;16(4):647-60.
236. Mau W, Listing J, Huscher D, et al. Employment across chronic inflammatory rheumatic diseases and comparison with the general population. *J Rheumatol*. 2005 Apr;32(4):721-8.
237. McHorney CA, Ware JE, Jr., Lu JF, et al. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. *Med Care*. 1994 Jan;32(1):40-66.
238. McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med Care*. 1993 Mar;31(3):247-63.
239. McHorney CA, Ware JE, Jr., Rogers W, et al. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. *Med Care*. 1992 May;30(5 Suppl):MS253-65.
240. McInnes IB, Schett G. Cytokines in the pathogenesis of rheumatoid arthritis. *Nature Reviews Immunology*. 2007;7(6):429-42.
241. Mease P. Psoriatic arthritis update. *Bulletin of the NYU Hospital for Joint Diseases*. 2006;64(1-2):25-31.
242. Mease PJ, Antoni CE, Gladman DD, et al. Psoriatic arthritis assessment tools in clinical trials. *Ann Rheum Dis*. 2005 Mar;64 Suppl 2:ii49-54.
243. Mease PJ, Gladman DD, Keystone EC. Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. *Arthritis Rheum*. 2006 May;54(5):1638-45.
244. Michaud K, Messer J, Choi HK, et al. Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients. *Arthritis Rheum*. 2003 Oct;48(10):2750-62.
245. Miller LG, Hays RD. Adherence to combination antiretroviral therapy: synthesis of the literature and clinical implications. *AIDS Read*. 2000 Mar;10(3):177-85.
246. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. *Quality of Reporting of Meta-analyses*. *Lancet*. 1999 Nov 27;354(9193):1896-900.
247. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *Int J Surg* 2010;8(5):336-41.
248. Moreland LW, Baumgartner SW, Schiff MH, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. *N Engl J Med*. 1997 Jul 17;337(3):141-7.
249. Moreland LW, Cohen SB, Baumgartner S, et al. Long-term use of etanercept in patients with DMARD-refractory arthritis. *Arthritis Rheum*. 1992;42(Suppl 9):S401.
250. Moreland LW, Genovese MC, Sato R, et al. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. *Arthritis Rheum*. 2006 Apr 15;55(2):287-93.
251. Moreland LW, Weinblatt ME, Keystone EC, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. *J Rheumatol*. 2006 May;33(5):854-61.
252. Moss ML, Sklair-Tavron L, Nudelman R. Drug Insight: Tumor necrosis factor-converting enzyme as a pharmaceutical target for rheumatoid arthritis. *Nature Clinical Practice Rheumatology*. 2008;4(6):300-9.

253. Mroczkowski PJ, Weinblatt ME, Kremer JM. Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis. *Clin Exp Rheumatol*. 1999 Nov-Dec;17(6 Suppl 18):S66-8.
254. Muller-Ladner U, Pap T, Gay RE, et al. Mechanisms of disease: the molecular and cellular basis of joint destruction in rheumatoid arthritis. *Nat Clin Pract Rheumatol*. 2005 Dec;1(2):102-10.
255. Multi-Parameter Evidence Synthesis (MPES) Research Group. Available at: <https://www.bris.ac.uk/cobm/research/mpes/mtc.html>.
256. Munafo A, Priestley A, Nestorov I, et al. Safety, pharmacokinetics and pharmacodynamics of atacicept in healthy volunteers. *European Journal of Clinical Pharmacology*. 2007;63(7):647-56.
257. Munoz P, Giannella M, Valerio M, et al. Cryptococcal meningitis in a patient treated with infliximab. *Diagn Microbiol Infect Dis*. 2007 Apr;57(4):443-6.
258. Nam JL, Winthrop KL, van Vollenhoven RF, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. *Ann Rheum Dis* 2010;69(6):976-86.
259. Nash P. Therapies for axial disease in psoriatic arthritis. A systematic review. *J Rheumatol*. 2006 Jul;33(7):1431-4.
260. Nathan DM, Angus PW, Gibson PR. Hepatitis B and C virus infections and anti-tumor necrosis factor- $\alpha$  therapy: Guidelines for clinical approach. *Journal of Gastroenterology and Hepatology*. 2006;21(9):1366-71.
261. Nishimoto N, Kishimoto T. Humanized antihuman IL-6 receptor antibody, tocilizumab. *Handbook of experimental pharmacology*. 2008(181):151-60.
262. Nixon RM, Bansback N, Brennan A. Using mixed treatment comparisons and meta-regression to perform indirect comparisons to estimate the efficacy of biologic treatments in rheumatoid arthritis. *Statistics in Medicine*. 2007;26(6):1237-54.
263. Norris SL, Atkins D. Challenges in using nonrandomized studies in systematic reviews of treatment interventions. *Ann Intern Med*. 2005 Jun 21;142(12 Pt 2):1112-9.
264. O'Dell J, Leff R, Paulsen G, et al. Methotrexate (M)-Hydroxychloroquine (H)-Sulfasalazine (S) versus M-H or M-S for rheumatoid arthritis (RA): results of a double-blind study. *Arthritis Rheum*. 1999;42(Suppl 9):S117.
265. O'Dell JR, Haire CE, Erikson N, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. *N Engl J Med*. 1996 May 16;334(20):1287-91.
266. Ogrendik M. Levofloxacin treatment in patients with rheumatoid arthritis receiving methotrexate. *South Med J*. 2007 Feb;100(2):135-9.
267. Ohsugi Y. Recent advances in immunopathophysiology of interleukin-6: An innovative therapeutic drug, tocilizumab (recombinant humanized anti-human interleukin-6 receptor antibody), unveils the mysterious etiology of immune-mediated inflammatory diseases. *Biological and Pharmaceutical Bulletin*. 2007;30(11):2001-6.
268. Ojeda-Urbe M, Gilliot C, Jung G, et al. Administration of rituximab during the first trimester of pregnancy without consequences for the newborn. *Journal of Perinatology*. 2006;26(4):252-5.
269. Okada SK, Siegel JN. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. *Jama*. 2006 Nov 8;296(18):2201-2; author reply 3-4.
270. Olivieri I, Mantovani LG, D'Angelo S, et al. Psoriatic arthritis: pharmacoeconomic considerations. *Curr Rheumatol Rep* 2009;11(4):263-9.
271. Oren C, Mendelbaum M, Paran D. Vaccination against influenza in rheumatoid arthritis patients: The effect of rituximab on the humoral response. *Arthritis Rheum* 2006;54(SUPPL. 9).

272. Ornetti P, Chevillotte H, Zerrak A, et al. Anti-tumour necrosis factor-alpha therapy for rheumatoid and other inflammatory arthropathies: update on safety in older patients. *Drugs Aging*. 2006;23(11):855-60.
273. Orozco G, Rueda B, Martin J. Genetic basis of rheumatoid arthritis. *Biomed Pharmacother*. 2006 Dec;60(10):656-62.
274. Ory PA. Interpreting radiographic data in rheumatoid arthritis. *Ann Rheum Dis*. 2003 Jul;62(7):597-604.
275. Ostergaard M, Baslund B, Rigby W. Ofatumumab, a human CD20 monoclonal antibody, in the treatment of rheumatoid arthritis: Early results from an ongoing, double-blind, randomized, placebo-controlled clinical trial [abstract]. *American College of Rheumatology Annual Meeting*. 2007.
276. Owens DK, Lohr KN, Atkins D, et al. AHRQ series paper 5: grading the strength of a body of evidence when comparing medical interventions--agency for healthcare research and quality and the effective health-care program. *J Clin Epidemiol*. 2010 May;63(5):513-23.
277. Ozminkowski RJ, Burton WN, Goetzel RZ, et al. The impact of rheumatoid arthritis on medical expenditures, absenteeism, and short-term disability benefits. *J Occup Environ Med*. 2006 Feb;48(2):135-48.
278. Pallavicini FB, Caporali R, Sarzi-Puttini P, et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. *Autoimmun Rev* 2010;9(3):175-80.
279. Papp KA, Caro I, Leung HM, et al. Efalizumab for the treatment of psoriatic arthritis. *J Cutan Med Surg*. 2007 Mar-Apr;11(2):57-66.
280. Pieringer H, Stuby U, Biesenbach G. Patients with Rheumatoid Arthritis Undergoing Surgery: How Should We Deal with Antirheumatic Treatment? *Seminars in Arthritis and Rheumatism*. 2007;36(5):278-86.
281. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. *J Rheumatol*. 1992 Dec;19(12):1885-94.
282. Pincus T, O'Dell JR, Kremer JM. Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: a preventive strategy. *Ann Intern Med*. 1999 Nov 16;131(10):768-74.
283. Pincus T, Yazici Y, Bergman M. A practical guide to scoring a Multi-Dimensional Health Assessment Questionnaire (MDHAQ) and Routine Assessment of Patient Index Data (RAPID) scores in 10-20 seconds for use in standard clinical care, without rulers, calculators, websites or computers. *Best Practice and Research: Clinical Rheumatology*. 2007;21(4):755-87.
284. Pinzani M, Vizzutti F, Arena U, et al. Technology Insight: Noninvasive assessment of liver fibrosis by biochemical scores and elastography. *Nature Clinical Practice Gastroenterology and Hepatology*. 2008;5(2):95-106.
285. Popovic M, Stefanovic D, Pejnovic N, et al. Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporine, and levamisole) in patients with rheumatoid arthritis. *Transplant Proc*. 1998 Dec;30(8):4135-6.
286. Pouchot J. How can we improve the management of adult-onset Still's disease? *Joint Bone Spine*. 2007 Mar;74(2):117-9.
287. Prevoo ML, van Gestel AM, van THMA, et al. Remission in a prospective study of patients with rheumatoid arthritis. *American Rheumatism Association preliminary remission criteria in relation to the disease activity score*. *Br J Rheumatol*. 1996 Nov;35(11):1101-5.
288. Pugner KM, Scott DI, Holmes JW, et al. The costs of rheumatoid arthritis: an international long-term view. *Semin Arthritis Rheum*. 2000 Apr;29(5):305-20.

289. Quinn MA, Conaghan PG, O'Connor PJ. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month ran-liver disease? *Hepatology*. 2006;43:352-61.
290. Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995 -- Status and Review. In: Spilker B, ed. *Quality of Life and Pharmacoeconomics in Clinical Trials*. 2nd ed. Philadelphia: Lippincott-Raven Publishers 1996:227-37.
291. Ranganath VK, Furst DE. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. *Rheum Dis Clin North Am*. 2007 Feb;33(1):197-217.
292. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. *Annals of the rheumatic diseases* 2008;67(6):855-9.
293. Reddy SM, Bingham Iii CO. Outcome measures in psoriatic arthritis clinical trials. *Curr Rheumatol Rep* 2005;7(4):299-305.
294. Reich K, Nestle FO, Papp K, et al. Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial. *Br J Dermatol*. 2006 Jun;154(6):1161-8.
295. Rioda WT, Adorni G. Infliximab treatment in psoriatic arthritis: our experience. *Acta Biomed*. 2006 Aug;77(2):95-102.
296. Ritchie DA, Boyle JA, McInnes JM, et al. Evaluation of a simple articular index for joint tenderness in rheumatoid arthritis. *Ann Rheum Dis*. 1969 Mar;28(2):196.
297. Ritchie DM, Boyle JA, McInnes JM, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. *Q J Med*. 1968 Jul;37(147):393-406.
298. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. *Ann Rheum Dis*. 2009 Sep;68(9):1387-94.
299. Roux CH, Brocq O, Breuil V, et al. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)- $\hat{\pm}$  therapy. *Rheumatology*. 2007;46(4):695-8.
300. Ruderman EM, Markenson J. Granulomatous infections and tumor necrosis factor antagonists therapy: update through June 2002. *Arthritis Rheum*. 2003;48(9):S241.
301. Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. *Arthritis Res Ther* 2009;11(2):R52.
302. Saag KG, Gim GT, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Care and Research*. 2008;59(6):762-84.
303. Salliot C, Gossec L, Ruysse-Witrand A, et al. Infections during tumour necrosis factor- $\{\alpha\}$  blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. *Rheumatology*. 2006 July 31, 2006:kel236.
304. Salliot C, Gossec L, Ruysse-Witrand A, et al. Infections during tumour necrosis factor- $\hat{\pm}$  blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 709 patients. *Rheumatology* 2007;46(2):327-34.
305. Samsa G, Edelman D, Rothman ML, et al. Determining clinically important differences in health status measures: a general approach with illustration to the Health Utilities Index Mark II. *Pharmacoeconomics* 1999;15(2):141-55.
306. Sauriol L, Laporta M, Edwardes MD, et al. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach. *Clin Ther*. 2001 Jun;23(6):942-56.
307. Sbeity ZH, Baydoun L, Schmidt S, et al. Visual field changes in methotrexate therapy. Case report and review of the literature. *J Med Liban*. 2006 Jul-Sep;54(3):164-7.

308. Schaible TF. Long term safety of infliximab. *Can J Gastroenterol.* 2000 Sep;14 Suppl C:29C-32C.
309. Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. *BMC Medical Informatics and Decision Making.* 2007;7.
310. Schiff MH, Burmester GR, Kent JD, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. *Ann Rheum Dis.* 2006 Jul;65(7):889-94.
311. Schuna AA. Rituximab for the treatment of rheumatoid arthritis. *Pharmacotherapy.* 2007;27(12 I):1702-10.
312. Scott DL, Coulton BL, Bacon PA, et al. Methods of X-ray assessment in rheumatoid arthritis: a re-evaluation. *Br J Rheumatol.* 1985 Feb;24(1):31-9.
313. Scott DL, Houssien DA, Laasonen L. Proposed modification to Larsen's scoring methods for hand and wrist radiographs. *Br J Rheum.* 1995;34:56.
314. Setoguchi S, Solomon DH, Weinblatt ME, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. *Arthritis Rheum.* 2006 Sep;54(9):2757-64.
315. Sharp JT, Young DY, Bluhm GB, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? *Arthritis Rheum.* 1985 Dec;28(12):1326-35.
316. Shea BJ, Grimshaw JM, Wells GA, et al. Development of AMSTAR: A measurement tool to assess the methodological quality of systematic reviews. *BMC Medical Research Methodology.* 2007;7.
317. Smolen JS, Aletaha D, Keystone E. Superior efficacy of combination therapy for rheumatoid arthritis: fact or fiction? *Arthritis Rheum.* 2005 Oct;52(10):2975-83.
318. Smolen JS, Keystone EC, Emery P, et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. *Annals of the rheumatic diseases.* 2007;66(2):143-50.
319. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis* 2010;69(6):964-75.
320. Sokka T, Pincus T. Most patients receiving routine care for rheumatoid arthritis in 2001 did not meet inclusion criteria for most recent clinical trials or american college of rheumatology criteria for remission. *J Rheumatol.* 2003 Jun;30(6):1138-46.
321. Sokoll KB, Helliwell PS. Comparison of disability and quality of life in rheumatoid and psoriatic arthritis. *J Rheumatol.* 2001 Aug;28(8):1842-6.
322. Solomon DH. The comparative safety and effectiveness of TNF-alpha antagonists [corrected]. *J Manag Care Pharm.* 2007 Jan;13(1 Suppl):S7-18.
323. Song F, Altman DG, Glenny AM, et al. Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. *Bmj.* 2003 Mar 1;326(7387):472.
324. Soriano ER, McHugh NJ. Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. *J Rheumatol.* 2006 Jul;33(7):1422-30.
325. Stewart AL, Hays RD, Ware JE, Jr. The MOS short-form general health survey. Reliability and validity in a patient population. *Med Care.* 1988 Jul;26(7):724-35.
326. Stewart AL, Ware JE. *Measuring Functioning and Well-Being: The Medical Outcomes Study Approach.* Durham, NC: Duke University Press; 1992.
327. Strand. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: Evidence from randomized controlled trials (American Journal of Managed Care). *American Journal of Managed Care.* 2008;14(4):234.
328. Strand V, Balbir-Gurman A, Pavelka K, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. *Rheumatology (Oxford)* 2006;45(12):1505-13.

329. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. *Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum.* 1999 Sep;42(9):1870-8.
330. Szekanecz Z, Koch AE. Macrophages and their products in rheumatoid arthritis. *Current Opinion in Rheumatology.* 2007;19(3):289-95.
331. Tak PP, Thurlings RM, Rossier C, et al. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. *Arthritis and rheumatism.* 2008;58(1):61-72.
332. Tanaka Y. Biologics: current therapeutic strategies for rheumatoid arthritis. *Nippon rinsho Japanese journal of clinical medicine.* 2007;65(7):1179-84.
333. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum.* 2006 Aug;54(8):2665-73.
334. Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. *Liver International.* 2006;26(9):1029-39.
335. Todd DJ, Costenbader KH, Weinblatt ME. Abatacept in the treatment of rheumatoid arthritis. *International Journal of Clinical Practice.* 2007;61(3):494-500.
336. Tracey D, Klareskog L, Sasso EH, et al. Tumor necrosis factor antagonist mechanisms of action: A comprehensive review. *Pharmacology and Therapeutics.* 2008;117(2):244-79.
337. Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. *Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum.* 2000 Mar;43(3):506-14.
338. Turesson C, Schaid DJ, Weyand CM, et al. The impact of HLA-DRB1 genes on extra-articular disease manifestations in rheumatoid arthritis. *Arthritis Res Ther.* 2005;7(6):R1386-93.
339. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. *J Rheumatol.* 1999 Mar;26(3):743-5.
340. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. *J Rheumatol.* 2000 Jan;27(1):261-3.
341. van der Heijde D, Da Silva JC, Dougados M, et al. Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. *Ann Rheum Dis.* 2006 Dec;65(12):1572-7.
342. van der Heijde D, Dankert T, Nieman F, et al. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. *Rheumatology (Oxford).* 1999 Oct;38(10):941-7.
343. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. *Arthritis Rheum* 2007;56(8):2698-707.
344. van der Heijde D, Klareskog L, Landewe R, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum* 2007;56(12):3928-39.
345. van der Heijde DM. Overview of radiologic efficacy of new treatments. *Rheum Dis Clin North Am.* 2004 May;30(2):285-93, vi.
346. van der Heijde DM, van Leeuwen MA, van Riel PL, et al. Biannual radiographic assessments of hands and feet in a three-year prospective followup of patients with early rheumatoid arthritis. *Arthritis Rheum.* 1992 Jan;35(1):26-34.
347. van Dongen H, van Aken J, Lard LR, et al. Efficacy of methotrexate treatment in patients with probable rheumatoid arthritis: a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum.* 2007 May;56(5):1424-32.

348. van Gestel AM, Anderson JJ, van Riel PL, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. *American College of Rheumatology European League of Associations for Rheumatology. J Rheumatol* 1999;26(3):705-11.
349. van Gestel AM, Prevoo ML, van 't Hof MA, et al. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum* 1996;39(1):34-40.
350. van Riel PL, Taggart AJ, Sany J, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. *Ann Rheum Dis.* 2006 Feb 7.
351. van Tuyl LH, Vlad SC, Felson DT, et al. Defining remission in rheumatoid arthritis: results of an initial American College of Rheumatology/European League Against Rheumatism consensus conference. *Arthritis Rheum* 2009;61(5):704-10.
352. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. *Br J Rheumatol.* 1998 Jun;37(6):612-9.
353. Visser K, Katchamart W, Loza E, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Annals of the rheumatic diseases.* 2009;68(7):1086-93.
354. Visvanathan S, Keenan GF, Baker DG, et al. Response to pneumococcal vaccine in patients with early rheumatoid arthritis receiving infliximab plus methotrexate or methotrexate alone. *J Rheumatol.* 2007 May;34(5):952-7.
355. Visvanathan S, Marini JC, Smolen JS, et al. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. *J Rheumatol.* 2007 Jul;34(7):1465-74.
356. Wailoo A, Brennan A, Bansback N, et al. Modeling the cost effectiveness of etanercept, adalimumab and anakinra compared to infliximab in the treatment of patients with rheumatoid arthritis in the Medicare program. *AHRQ Technology Assessment Program.* 2006.
357. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. *Clin Infect Dis.* 2004 May 1;38(9):1261-5.
358. Walters SJ, Brazier JE. What is the relationship between the minimally important difference and health state utility values? The case of the SF-6D. *Health Qual Life Outcomes* 2003;14.
359. Ware JE, Jr., Kosinski M, Bayliss MS, et al. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. *Med Care.* 1995 Apr;33(4 Suppl):AS264-79.
360. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care.* 1992 Jun;30(6):473-83.
361. Ware JE, Snow KK, Kosinski M, et al. SF-36® Health Survey Manual and Interpretation Guide. 1993.
362. Weinblatt ME, Bathon JM, Kremer JM, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and long-standing rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2010.
363. Weinblatt ME, Keystone EC, Furst DE, et al. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. *Ann Rheum Dis.* 2006 Jun;65(6):753-9.



364. Weinblatt ME, Kremer JM, Coblyn JS, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. *Arthritis Rheum*. 1999 Jul;42(7):1322-8.
365. Wells GA, Sultan SA, Chen L. Indirect evidence: Indirect treatment comparisons in meta-analysis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2009.
366. Wells GA, Tugwell P, Kraag GR, et al. Minimum important difference between patients with rheumatoid arthritis: the patient's perspective. *J Rheumatol* 1993;20(3):557-60.
367. Welton NJ, Caldwell DM, Adamopoulos E, et al. Mixed treatment comparison meta-analysis of complex interventions: psychological interventions in coronary heart disease. *Am J Epidemiol* 2009;169(9):1158-65.
368. Westhovens R, Cole JC, Li T, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. *Rheumatology (Oxford)*. 2006 Oct;45(10):1238-46.
369. Whitehead A. Meta-analysis of controlled clinical trials. Chichester, UK: John Wiley & Sons, Ltd.; 2002.
370. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. *Arthritis Rheum* 1984;27(4):376-81.
371. Wood AJ. Thrombotic thrombocytopenic purpura and clopidogrel--a need for new approaches to drug safety. *N Engl J Med*. 2000 Jun 15;342(24):1824-6.
372. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. *Health Technol Assess*. 2006 Sep;10(31):1-258.
373. Yamamoto M, Takahashi H, Ohara M, et al. A new conceptualization for Mikulicz's disease as an IgG4-related plasmacytic disease. *Mod Rheumatol*. 2006;16(6):335-40.
374. Yamanaka H, Inoue E, Tanaka E, et al. Influence of methotrexate dose on its efficacy and safety in rheumatoid arthritis patients: Evidence based on the variety of prescribing approaches among practicing Japanese rheumatologists in a single institute-based large observational cohort (IORRA). *Modern Rheumatology*. 2007;17(2):98-105.
375. Yelin E. Work disability in rheumatic diseases. *Current Opinion in Rheumatology*. 2007;19(2):91-6.
376. Young MS, Furfaro N. The rheumatology/dermatology collaboration. *Dermatol Nurs*. 2006 Oct;Suppl:10-22.
377. Zachariae H, Zachariae R, Blomqvist K, et al. Quality of life and prevalence of arthritis reported by 5,795 members of the Nordic Psoriasis Associations. Data from the Nordic Quality of Life Study. *Acta Derm Venereol*. 2002;82(2):108-13.
378. Zhao LK, Liao ZT, Li CH, et al. Evaluation of quality of life using ASQoL questionnaire in patients with ankylosing spondylitis in a Chinese population. *Rheumatol Int*. 2007 May;27(7):605-11.
379. Zink A, Strangfeld A, Schneider M, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study: comparison of patients according to their eligibility for major randomized clinical trials. *Arthritis Rheum*. 2006 Nov;54(11):3399-407

**Reference Source: Embase**

1. Abrahamian H, Endler G, Exner M, et al. Association of low-grade inflammation with nephropathy in type 2 diabetic patients: role of elevated CRP-levels and 2 different genopolymorphisms of proinflammatory cytokines. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association* 2007(1):38-41.
2. Abrahamyan L, Beyene J, Feng J, et al. Response times follow lognormal or gamma distribution in arthritis patients. *Journal of Clinical Epidemiology*. 2010;63(12):1363-9.
3. Accardo S, Serio B, Samanta E, et al. Controlled-Release Naproxen in Rheumatoid Arthritis. *CURR THER RES CLIN EXP*. 1991;49I(6):936-42.
4. Adams J, Burrige J, Mullee M, et al. The clinical effectiveness of static resting splints in early rheumatoid arthritis: A randomized controlled trial. *Rheumatology*. 2008;47(10):1548-53.
5. Agnew-Blais JC, Coblyn JS, Katz JN, et al. Measuring quality of care for rheumatic diseases using an electronic medical record. *Annals of the Rheumatic Diseases*. 2009;68(5):680-4.
6. Aguilar-Chavez EA, Gamez-Nava JI, Lopez-Olivo MA, et al. Circulating leptin and bone mineral density in rheumatoid arthritis. *Journal of Rheumatology*. 2009;36(3):512-6.
7. Ahern MJ, Wetherall M, Leslie A, et al. A Comparison of Ketoprofen Sr and Sulindac in the Elderly With Rheumatoid Arthritis. *Br J Clin Pract*. 1992;46(4):229-33.
8. Alarcon G, Castaneda O, Nair M, et al. Controlled Trial of Methotrexate Versus 10-Deazaaminopterin in the Treatment of Rheumatoid Arthritis. *Ann Rheum Dis*. 1992;51(5):600-3.
9. Alarcon GS, Castaneda O, Ferrandiz M, et al. Efficacy and Safety of 10-Deazaaminopterin in the Treatment of Rheumatoid Arthritis. A One-Year Continuation, Double-Blind Study. *Arthritis Rheum*. 1992;35(11):1318-21.
10. Alarcon I, Moreland G, Jaffe L, et al. The Use of Methotrexate Perioperatively in Patients With Rheumatoid Arthritis Undergoing Major Joint Replacement Surgery: Will We Ever Have Consensus About Its Use? *J Clin Rheumatol*. 1996;2(1):6-8.
11. Albert DA, Huang G, Dubrow G, et al. Criteria for Improvement in Rheumatoid Arthritis: Alternatives to the American College of Rheumatology 20. *J Rheumatol*. 2004;31(5):856-66.
12. Aletaha D, Smolen J, Ward MM. Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. *Arthritis and Rheumatism*. 2006;54(9):2784-92.
13. Ali ML, Alam MN, Haq SA, et al. Efficacy of Methotrexate in Rheumatoid Arthritis. *Bangladesh Medical Research Council bulletin*. 1997;23(3):72-6.
14. Allen ZA, Shanahan EM, Crotty M. Does suprascapular nerve block reduce shoulder pain following stroke: A double-blind randomised controlled trial with masked outcome assessment. *BMC Neurology*. 2010;10.
15. Almarzouqi M, Scarsbrook D, Klinkhoff A. Gold therapy in women planning pregnancy: Outcomes in one center. *Journal of Rheumatology*. 2007;34(9):1827-31.
16. Alten R, Doring G, Cutolo M, et al. Hypothalamus-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with nighttime-release prednisone. *Journal of Rheumatology*. 2010;37(10):2025-31.
17. Alten R, Gromnica-Ihle E, Pohl C, et al. Inhibition of Leukotriene B4-Induced Cd11b/Cd18 (Mac-1) Expression by Biil 284, a New Long Acting Ltb4 Receptor Antagonist, in Patients With Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 2004;63(2):170-6.
18. Alten RE, Zerbini C, Jeka S, et al. Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy. 2010.

19. Anaya JM, Fabre D, Bressolle F, et al. Effect of Etodolac on Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1994;21(2):293-8.
20. Anders HJ, Rihl M, Loch O, et al. Prediction of Creatinine Clearance From Serum Creatinine in Patients With Rheumatoid Arthritis: Comparison of Six Formulae and One Nomogram. *Clinical rheumatology*. 2000;19(1):26-9.
21. Andersen LS, Hansen EL, Knudsen JB, et al. Prospectively Measured Red Cell Folate Levels in Methotrexate Treated Patients With Rheumatoid Arthritis: Relation to Withdrawal and Side Effects. *The Journal of rheumatology*. 1997;24(5):830-7.
22. Anderson JJ, O'Neill A, Woodworth T, et al. Health Status Response of Rheumatoid Arthritis to Treatment With Dab486il-2. *Arthritis care and research : the official journal of the Arthritis Health Professions Association*. 1996;9(2):112-9.
23. Anderson KO, Bradley LA, Turner RA, et al. Pain Behavior of Rheumatoid Arthritis Patients Enrolled in Experimental Drug Trials. *Arthritis care and research : the official journal of the Arthritis Health Professions Association*. 1994;7(2):64-8.
24. Andrianakos A, Trontzas P, Christoyannis F, et al. Prevalence and management of rheumatoid arthritis in the general population of Greece - The ESORDIG study. *Rheumatology*. 2006;45(12):1549-54.
25. Antoni C, Kalden J. Combination Therapy of the Chimeric Monoclonal Anti-Tumor Necrosis Factor Alpha Antibody (Infliximab) With Methotrexate in Patients With Rheumatoid Arthritis. *Clinical and experimental rheumatology*. 1999;17(6 Suppl 18):S73-7.
26. Appel H, Mertz A, Distler A, et al. The 19 Kda Protein of Yersinia Enterocolitica O:3 Is Recognized on the Cellular and Humoral Level by Patients With Yersinia Induced Reactive Arthritis. *J Rheumatol* 1999 Sep;26(9):1964-71. 1999;26(9):1964-71.
27. April P, Abeles M, Baraf H, et al. Does the Acetyl Group of Aspirin Contribute to the Antiinflammatory Efficacy of Salicylic Acid in the Treatment of Rheumatoid Arthritis? *Seminars in arthritis and rheumatism*. 1990;19(4 Suppl 2):20-8.
28. Arborelius MJ, Konttinen YT, Nordstrom DC, et al. Gly-X-Y Repeat Sequences in the Treatment of Active Rheumatoid Arthritis. *Rheumatology international*. 1999;18(4):129-35.
29. Arendt-Nielsen L, Drewes AM, Svendsen L, et al. Quantitative Assessment of Joint Pain Following Treatment of Rheumatoid Arthritis With Ibuprofen Cream. *Scandinavian journal of rheumatology*. 1994;23(6):334-7.
30. Arnold MH, O'Callaghan J, McCredie M, et al. Comparative Controlled Trial of Low-Dose Weekly Methotrexate Versus Azathioprine in Rheumatoid Arthritis: 3-Year Prospective Study. *British journal of rheumatology*. 1990;29(2):120-5.
31. Arvidson NG, Gudbjornsson B, Larsson A, et al. The Timing of Glucocorticoid Administration in Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 1997;56(1):27-31.
32. Aryaeian N, Shahram F, Djalali M, et al. Effect of conjugated linoleic acids, vitamin E and their combination on the clinical outcome of Iranian adults with active rheumatoid arthritis. *International Journal of Rheumatic Diseases*. 2009;12(1):20-8.
33. Asahina A, Nakagawa H, Etoh T, et al. Adalimumab in Japanese patients with moderate to severe chronic plaque psoriasis: Efficacy and safety results from a Phase II/III randomized controlled study. *Journal of Dermatology*. 2010;37(4):299-310.
34. Assous N, Gossec L, Dougados M, et al. Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: An open label observational study [3]. *Clinical and Experimental Rheumatology*. 2007;25(3).

35. Astrauskiene D. Efficacy of Empirically Prescribed Amoxicillin and Amoxicillin + Clavulanic Acid in Children's Reactive Arthritis: a Randomised Trial. *Clinical and experimental rheumatology*. 2003;21(4):515-21.
36. Atkinson M, Khanna V, Menard H, et al. A Comparison of Tenoxicam and Piroxicam in the Treatment of Rheumatoid Arthritis. *The Journal of rheumatology*. 1992;19(4):538-42.
37. Atkinson MH, Buchanan WW, Fitzgerald AA, et al. A Comparison of Flurbiprofen and Naproxen in the Treatment of Rheumatoid Arthritis: a Canadian Multi-Centre Study. *Current medical research and opinion*. 1990;12(2):76-85.
38. Azuma T, Oishi M, Takei M, et al. Tacrolimus-related nocturnal myoclonus of the lower limbs in elderly patients with rheumatoid arthritis. *Modern Rheumatology*. 2007;17(3):247-50.
39. Bacon P, Luqmani RA, Bossingham DH, et al. A Comparison of Two Formulations of Indomethacin ('flexin Continus' Tablets and 'indocid' Capsules) in the Treatment of Rheumatoid Arthritis. *Current medical research and opinion*. 1990;12(2):128-34.
40. Baerwald C, Goebel KM, Krause A, et al. A randomized controlled trial of ciamexon versus placebo in the immunomodulatory treatment of rheumatoid arthritis. *Arthritis Rheum*. 1990 May;33(5):733-8.
41. Bagge E, Geijer M, Tarkowski A. Intra-Articular Administration of Polyclonal Immunoglobulin G in Rheumatoid Arthritis. A Double-Blind, Placebo-Controlled Pilot Study. *Scandinavian journal of rheumatology*. 1996;25(3):174-6.
42. Bahadori B, Uitz E, Thonhofer R, et al. (omega)-3 fatty acids infusions as adjuvant therapy in rheumatoid arthritis. *Journal of Parenteral and Enteral Nutrition*. 2010;34(2):151-5.
43. Bakker MF, Jacobs JWG, Welsing PMJ, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. *Annals of the rheumatic diseases*. 2010;69(10):1849-52.
44. Barnett ML, Kremer JM, St Clair EW, et al. Treatment of Rheumatoid Arthritis With Oral Type II Collagen. Results of a Multicenter, Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 1998;41(2):290-7.
45. Barrera P, Boerbooms AM, Demacker PN, et al. Circulating Soluble Tumor Necrosis Factor Receptors, Interleukin-2 Receptors, Tumor Necrosis Factor Alpha, and Interleukin-6 Levels in Rheumatoid Arthritis. Longitudinal Evaluation During Methotrexate and Azathioprine Therapy. *Arthritis and rheumatism*. 1994;33(11):1017-24.
46. Barrera P, Haagsma C, Boerbooms A, et al. Effect of Methotrexate Alone or in Combination With Sulphasalazine on the Production and Circulating Concentrations of Cytokines and Their Antagonists. Longitudinal Evaluation in Patients With Rheumatoid Arthritis. *British journal of rheumatology*. 1995;34(8):747-55.
47. Barrera P, Joosten LA, den Broeder AA, et al. Effects of Treatment With a Fully Human Anti-Tumour Necrosis Factor Alpha Monoclonal Antibody on the Local and Systemic Homeostasis of Interleukin 1 and Tnfalpha in Patients With Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 2001;60(7):660-9.
48. Barrera P, van der Maas A, van Ede AE, et al. Drug Survival, Efficacy and Toxicity of Monotherapy With a Fully Human Anti-Tumour Necrosis Factor- $\alpha$  Antibody Compared With Methotrexate in Long-Standing Rheumatoid Arthritis. *Rheumatology* 2002;41(4):430-9.
49. Baslund B, Tvede N, Danneskiold-Samsøe B, et al. Targeting Interleukin-15 in Patients With Rheumatoid Arthritis: a Proof-of-Concept Study. *Arthritis and rheumatism*. 2005;52(9):2686-92.
50. Bateman J, Penfold R, Rigby SP. Comment on: Kidney disease in RA patients: Prevalence and implication on RA-related drugs management: The MATRIX study. *Rheumatology*. 2008;47(8).

51. Battistone MJ, Manaster BJ, Reda DJ, et al. The Prevalence of Sacroiliitis in Psoriatic Arthritis: New Perspectives From a Large, Multicenter Cohort. A Department of Veterans Affairs Cooperative Study. *Skeletal radiology*. 1999;28(4):196-201.
52. Bazzani C, Filippini M, Caporali R, et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes. *Autoimmunity Reviews* 2009;8(3):260-5.
53. Beard AJ, Sleath B, Blalock SJ, et al. Predictors of rheumatoid arthritis patient-physician communication about medication costs during visits to rheumatologists. *Arthritis Care and Research*. 2010;62(5):632-9.
54. Bejarano V, Conaghan PG, Proudman SM, et al. Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis. *Annals of the Rheumatic Diseases*. 2009;68(5):761-3.
55. Bejarano V, Conaghan PG, Quinn MA, et al. Benefits 8 years after a remission induction regime with an infliximab and methotrexate combination in early rheumatoid arthritis. *Rheumatology*. 2010;49(10):1971-4.
56. Benenson E, Timina O. Prospidine Versus Methotrexate Pulse in Highly Active Rheumatoid Arthritis: a Controlled 6-Month Clinical Trial. *Clinical rheumatology*. 1994;13(1):54-9.
57. Bengtsson A, Bengtsson M, Nilsson I, et al. Effects of Intravenous Regional Administration of Methylprednisolone Plus Mepivacaine in Rheumatoid Arthritis. *Scandinavian journal of rheumatology*. 1998;27(4):277-80.
58. Benitha R, Tikly M. Functional disability and health-related quality of life in South Africans with rheumatoid arthritis and systemic lupus erythematosus. *Clinical Rheumatology*. 2007;26(1):24-9.
59. Bensen W, Weaver A, Espinoza L, et al. Efficacy and Safety of Valdecoxib in Treating the Signs and Symptoms of Rheumatoid Arthritis: a Randomized, Controlled Comparison With Placebo and Naproxen. *Rheumatology (Oxford)*. 2002;41(9):1008-16.
60. Berliner MN, Giesecke T, Bornhovd KD. Impact of transdermal fentanyl on quality of life in rheumatoid arthritis. *Clinical Journal of Pain*. 2007;23(6):530-4.
61. Bianchi L, Giunta A, Papoutsaki M, et al. Efficacy and safety of long-term infliximab therapy in moderate to severe psoriasis and psoriatic arthritis. *Giornale Italiano di Dermatologia e Venereologia*. 2006;141(1):73-8.
62. Bianchi Porro G, Montrone F, Lazzaroni M, et al. Clinical and Gastroscopic Evaluation of Amtolmetin Guacyl Versus Diclofenac in Patients With Rheumatoid Arthritis. *Ital J Gastroenterol Hepatol*. 1999;31(5):378-85.
63. Bingham ICO, Looney RJ, Deodhar A, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. 2010.
64. Bird H, Broggin M. Paroxetine Versus Amitriptyline for Treatment of Depression Associated With Rheumatoid Arthritis: a Randomized, Double Blind, Parallel Group Study. *The Journal of rheumatology*. 2000;27(12):2791-7.
65. Blackburn WDJ, Prupas HM, Silverfield JC, et al. Tenidap in Rheumatoid Arthritis. A 24-Week Double-Blind Comparison With Hydroxychloroquine-Plus-Piroxicam, and Piroxicam Alone. *Arthritis and rheumatism*. 1995;38(10):1447-56.
66. Bluhm GB, Sharp JT, Tilley BC, et al. Radiographic Results From the Minocycline in Rheumatoid Arthritis (Mira) Trial. *The Journal of rheumatology*. 1997;24(7):1295-302.
67. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. *N Engl J Med*. 2000;343(21):1520-8.
68. Bombardier C, Peloso P, Goldsmith C. Salsalate, a Nonacetylated Salicylate, Is as Efficacious as Diclofenac in Patients With Rheumatoid Arthritis. Salsalate-Diclofenac Study Group. *The Journal of rheumatology*. 1995;22(4):617-24.

69. Bonilla E, Lee YY, Phillips PE, et al. Hypoglycaemia after initiation of treatment with etanercept in a patient with type 2 diabetes mellitus [5]. *Annals of the Rheumatic Diseases*. 2007;66(12).
70. Borg AA, Davis MJ, Fowler PD, et al. Rifampicin in Early Rheumatoid Arthritis. *Scandinavian journal of rheumatology*. 1993;22(2):39-42.
71. Borg G, Allander E, Berg E, et al. Auranofin Treatment in Early Rheumatoid Arthritis May Postpone Early Retirement. Results From a 2-Year Double Blind Trial. *The Journal of rheumatology*. 1991;18(7):1015-20.
72. Borrs-Blasco J, Gracia-Prez A, Rosique-Robles JD, et al. Acceptability of switching adalimumab from a prefilled syringe to an autoinjection pen. *Expert Opinion on Biological Therapy*. 2010;10(3):301-7.
73. Bos WH, Dijkmans BAC, Boers M, et al. Effect of dexamethasone on autoantibody levels and arthritis development in patients with arthralgia: A randomised trial. *Annals of the rheumatic diseases*. 2010;69(3):571-4.
74. Bourikas LA, Sidiropoulos PI, Goulielmos GN, et al. Concomitant onset of Graves disease and rheumatoid arthritis after a serious life event [5]. *Journal of Clinical Rheumatology*. 2006;12(6):326-7.
75. Bradley JD, Dmitrienko AA, Kivitz AJ, et al. A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial of LY333013, a Selective Inhibitor of Group II Secretory Phospholipase A2, in the Treatment of Rheumatoid Arthritis. *The Journal of rheumatology*. 2005;32(3):417-23.
76. Breedveld FC, Han C, Bala M, et al. Association Between Baseline Radiographic Damage and Improvement in Physical Function After Treatment of Patients With Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 2005;64(1):52-5.
77. Bressolle F, Kinowski J, Morel J, et al. Folic Acid Alters Methotrexate Availability in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 2000;27(9):2110-4.
78. Bridges Jr SL, Causey ZL, Burgos PI, et al. Radiographic severity of rheumatoid arthritis in African Americans: Results from a multicenter observational study. *Arthritis Care and Research*. 2010;62(5):624-31.
79. Brooks PJ, Spruill WJ, Parish RC, et al. Pharmacokinetics of Methotrexate Administered by Intramuscular and Subcutaneous Injections in Patients With Rheumatoid Arthritis. *Arthritis & Rheumatism*. 1990;33(1):91-4.
80. Buchanan WW, Kean WF, St-Jean J, et al. Clinical Evaluation of a Sustained Release Compared to a Standard Formulation of Tiaprofenic Acid (Surgam (R)) in Rheumatoid Arthritis: a Canadian Multicenter Study. *J RHEUMATOL*. 1991;18(7):1046-54.
81. Buckley L, Vacek P, Cooper S. Administration of Folic Acid After Low Dose Methotrexate in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1990;17(9):1158-61.
82. Cacace E, Anedda C, Ruggiero V, et al. Etanercept in rheumatoid arthritis: Long term anti-inflammatory efficacy in clinical practice. *European Journal of Inflammation*. 2006;4(3):171-6.
83. Caldwell J. Comparison of the Efficacy, Safety, and Pharmacokinetic Profiles of Extended-Release Ketoprofen and Piroxicam in Patients With Rheumatoid Arthritis. *Clinical therapeutics*. 1994;16(2):222-35.
84. Calguneri M, Pay S, Caliskaner Z, et al. Combination Therapy Versus Monotherapy for the Treatment of Patients With Rheumatoid Arthritis. *Clinical and experimental rheumatology*. 1999;17(6):699-704.
85. Camp NJ, Cox A, di Giovine FS, et al. Evidence of a Pharmacogenomic Response to Interleukin-L Receptor Antagonist in Rheumatoid Arthritis. *Genes Immun*. 2005;6(6):467-71.
86. Cannon GW, Reading JC, Ward JR, et al. Clinical and Laboratory Outcomes During the Treatment of Rheumatoid Arthritis With Methotrexate. *Scandinavian journal of rheumatology*. 1990;19(4):285-94.

87. Cantatore F, Acquista C, Pipitone V. Evaluation of Bone Turnover and Osteoclastic Cytokines in Early Rheumatoid Arthritis Treated With Alendronate. *The Journal of rheumatology*. 1999;41(3):247-51.
88. Capell H, Maiden N, Madhok R, et al. Intention-to-Treat Analysis of 200 Patients With Rheumatoid Arthritis 12 Years After Random Allocation to Either Sulfasalazine or Penicillamine. *The Journal of rheumatology*. 1998;25(10):1880-6.
89. Capell H, Marabani M, Madhok R, et al. Degree and Extent of Response to Sulphasalazine or Penicillamine Therapy for Rheumatoid Arthritis: Results From a Routine Clinical Environment Over a Two-Year Period. *The Quarterly journal of medicine*. 1990;75(276):335-44.
90. Caperton E, Heim Duthoy K, Matzke G, et al. Ceftriaxone Therapy of Chronic Inflammatory Arthritis. A Double-Blind Placebo Controlled Trial. *Archives of internal medicine*. 1990;150(8):1677-82.
91. Carmichael S, Beal J, Day R, et al. Combination Therapy With Methotrexate and Hydroxychloroquine for Rheumatoid Arthritis Increases Exposure to Methotrexate. *The Journal of rheumatology*. 2002;29(10):2077-83.
92. Carpenter M, West S, Vogelgesang S, et al. Postoperative joint infections in rheumatoid arthritis patients on methotrexate therapy. *Orthopedics*. 1996;19(3):207-10.
93. Carpentier N, Bertin P, Marquet P, et al. Is There an Optimal Time to Administer Methotrexate in the Treatment of Rheumatoid Arthritis? *The Journal of rheumatology*. 1998;25(7):1270-5.
94. Cavazzana I, Franceschini F, Quinzanini M, et al. Anti-Ro/SSA antibodies in rheumatoid arthritis: Clinical and immunologic associations. *Clinical and Experimental Rheumatology*. 2006;24(1):59-64.
95. Cazzola M, Antivalle M, Sarzi Puttini P, et al. Oral Type Ii Collagen in the Treatment of Rheumatoid Arthritis. A Six-Month Double Blind Placebo-Controlled Study. *Clinical and experimental rheumatology*. 2000;18(5):571-7.
96. Chan FKL, Hung LCT, Suen BY, et al. Celecoxib versus diclofenac plus omeprazole in high-risk arthritis patients: results of a randomized double-blind trial. *Gastroenterology*. 2004;127(4):1038-43.
97. Chan G, Goh F, Hodgson T, et al. Outpatient follow-up for patients with rheumatoid arthritis in relation to New Zealand Rheumatology Association guidelines at Dunedin Hospital. *New Zealand Medical Journal*. 2008;121(1274):34-41.
98. Chandrashekara S, Syed M, Swapna R. Is three selected parameters adequate to monitor rheumatoid arthritis? *Clinical Rheumatology*. 2007;26(6):911-4.
99. Chard M, Crisp A. Astemizole, an H1 Antagonist, Has No Additional Therapeutic Effect in Rheumatoid Arthritis. *The Journal of rheumatology*. 1991;18(2):203-4.
100. Charles P, Elliott MJ, Davis D, et al. Regulation of Cytokines, Cytokine Inhibitors, and Acute-Phase Proteins Following Anti-Tnf-Alpha Therapy in Rheumatoid Arthritis. *Journal of immunology (Baltimore, Md : 1950)*. 1999;163(3):1521-8.
101. Chen DY, Chou SJ, Hsieh TY, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. 2009.
102. Chiang E, Selhub J, Bagley P, et al. Pyridoxine Supplementation Corrects Vitamin B6 Deficiency but Does Not Improve Inflammation in Patients With Rheumatoid Arthritis. *Arthritis Res Ther*. 2005;7(6):R1404-11.
103. Chijiwa T, Nishiya K, Hashimoto K. Serum Transferrin Receptor Levels in Patients With Rheumatoid Arthritis Are Correlated With Indicators for Anaemia. *Clinical rheumatology*. 2001;20(5):307-13.
104. Chong BF, Wong HK. Treatment of psoriasis with etanercept in a patient with a history of primary B-cell lymphoma. *Clinical and Experimental Dermatology*. 2009;34(5):e11-e3.

105. Choy EH, Kingsley GH, Khoshaba B, et al. A Two Year Randomised Controlled Trial of Intramuscular Depot Steroids in Patients With Established Rheumatoid Arthritis Who Have Shown an Incomplete Response to Disease Modifying Antirheumatic Drugs. *Ann Rheum Dis*. 2005;64(9):1288-93.
106. Choy EHS, Scott DL, Kingsley GH, et al. Treating Rheumatoid Arthritis Early With Disease Modifying Drugs Reduces Joint Damage: a Randomised Double Blind Trial of Sulphasalazine Vs Diclofenac Sodium. *Clinical and experimental rheumatology*. 2002;20(3):351-8.
107. Christensen AF, Lottenburger T, Lindegaard H, et al. Differential association of the N-propeptide of collagen IIA (PII-ANP) and collagen II C-telopeptide (CTX-II) with synovitis and erosions in early and longstanding rheumatoid arthritis. *Clinical and Experimental Rheumatology*. 2009;27(2):307-14.
108. Ciconelli R, Ferraz M, Visionsi R, et al. A Randomized Double-Blind Controlled Trial of Sulphasalazine Combined With Pulses of Methylprednisolone or Placebo in the Treatment of Rheumatoid Arthritis. *British journal of rheumatology*. 1996;35(2):150-4.
109. Claessen SJJ, Hazes JMW, Huisman MAM, et al. Use of risk stratification to target therapies in patients with recent onset arthritis; Design of a prospective randomized multicenter controlled trial. 2009.
110. Clark P, Casas E, Tugwell P, et al. Hydroxychloroquine Compared With Placebo in Rheumatoid Arthritis. A Randomized Controlled Trial. *Annals of internal medicine*. 1993;119(11):1067-71.
111. Clegg DO, Reda DJ, Weisman MH, et al. Comparison of Sulfasalazine and Placebo in the Treatment of Psoriatic Arthritis. A Department of Veterans Affairs Cooperative Study. *Arthritis and rheumatism*. 1996;39(12):2021-7.
112. Cohen G, Gossec L, Dougados M, et al. Radiological damage in patients with rheumatoid arthritis on sustained remission. *Annals of the Rheumatic Diseases*. 2007;66(3):358-63.
113. Cohen S, Cannon G, Schiff M, et al. Two-Year, Blinded, Randomized, Controlled Trial of Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. *Arthritis and rheumatism*. 2001;44(9):1984-92.
114. Cohen S, Zwillich SH, Chow V, et al. Co-administration of the JAK inhibitor CP-690,550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. *British Journal of Clinical Pharmacology*. 2010;69(2):143-51.
115. Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis and Rheumatism* 2006;54(9):2793-806.
116. Cojocaru L, Rusali A, Craiu E, et al. The efficacy and safety of simvastatin in patients with rheumatoid arthritis. *Archives of the Balkan Medical Union*. 2010;45(1):49-53.
117. Colombel JF, Sandborn WJ, Rutgeerts P, et al. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology* 2007(1):52-65.
118. Combe B, Goupille P, Kuntz J, et al. Sulphasalazine in Psoriatic Arthritis: a Randomized, Multicentre, Placebo-Controlled Study. *British journal of rheumatology*. 1996;35(7):664-8.
119. Combe B, Velicitat P, Garzon N, et al. Comparison of Intramuscular and Oral Meloxicam in Rheumatoid Arthritis Patients. *Inflammation research : official journal of the European Histamine Research Society* [et al]. 2001;50(Suppl 1):S10-6.
120. Cordero OJ, Salgado FJ, Mera-Varela A, et al. Serum Interleukin-12, Interleukin-15, Soluble Cd26, and Adenosine Deaminase in Patients With Rheumatoid Arthritis. *Rheumatology international*. 2001;21(2):69-74.



121. Corkill MM, Kirkham BW, Chikanza IC, et al. Intramuscular Depot Methylprednisolone Induction of Chrysotherapy in Rheumatoid Arthritis: a 24-Week Randomized Controlled Trial. *British journal of rheumatology*. 1990;29(4):274-9.
122. Corvetta A, Della B, Luchetti M, et al. Tenoxicam and Ketoprofen Level Monitoring With High Performance Liquid Chromatography in Patients Affected by Rheumatoid Arthritis. *CLIN EXP RHEUMATOL*. 1991;9(2):143-8.
123. Courvoisier N, Dougados M, Cantagrel A, et al. Prognostic factors of 10-year radiographic outcome in early rheumatoid arthritis: A prospective study. *Arthritis Research and Therapy*. 2008;10(5).
124. Crowley B, Hamill J, Lyndon S, et al. Controlled-Release Indomethacin and Sustained-Release Diclofenac Sodium in the Treatment of Rheumatoid Arthritis: a Comparative Controlled Clinical Trial. *Current medical research and opinion*. 1990;12(3):143-50.
125. Cush J, Jasin H, Johnson R, et al. Relationship Between Clinical Efficacy and Laboratory Correlates of Inflammatory and Immunologic Activity in Rheumatoid Arthritis Patients Treated With Nonsteroidal Antiinflammatory Drugs. *Arthritis and rheumatism*. 1990;33(5):623-33.
126. Cush J, Lipsky P, Postlethwaite A, et al. Correlation of Serologic Indicators of Inflammation With Effectiveness of Nonsteroidal Antiinflammatory Drug Therapy in Rheumatoid Arthritis. *Arthritis & Rheumatism*. 1990;33(1):19-28.
127. Dalbeth N, Yeoman S, Dockerty JL, et al. A Randomised Placebo Controlled Trial of Delipidated, Deglycolipidated Mycobacterium Vaccae as Immunotherapy for Psoriatic Arthritis. *Annals of the rheumatic diseases*. 2004;63(6):790-4.
128. Danis V, Franic G, Rathjen D, et al. Circulating Cytokine Levels in Patients With Rheumatoid Arthritis: Results of a Double Blind Trial With Sulphasalazine. *Annals of the rheumatic diseases*. 1992;51(8):946-50.
129. Dawczynski C, Schubert R, Hein G, et al. Long-term moderate intervention with n-3 long-chain PUFA-supplemented dairy products: Effects on pathophysiological biomarkers in patients with rheumatoid arthritis. *British Journal of Nutrition*. 2009;101(10):1517-26.
130. de Boer IG, Peeters A, Runday HK, et al. The usage of functional wrist orthoses in patients with rheumatoid arthritis. *Disability and Rehabilitation*. 2008;30(4):286-95.
131. De Graaf T, Van Ommen E, Van der Stelt M, et al. Effects of Low Dose Methotrexate Therapy on the Concentration and the Glycosylation of Alpha 1-Acid Glycoprotein in the Serum of Patients With Rheumatoid Arthritis: a Longitudinal Study. *The Journal of rheumatology*. 1994;21(12):2209-16.
132. Deighton CM, George E, Kiely PDW, et al. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). *Rheumatology*. 2006;45(6):649-52.
133. Dennison W, Loeser R, Turner R, et al. A Double Blind Placebo Controlled Trial of Low Dose Clotrimazole in Rheumatoid Arthritis. *The Journal of rheumatology*. 1990;17(8):1003-7.
134. DeWitt EM, Glick HA, Albert DA, et al. Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior. *Archives of Internal Medicine*. 2006;166(1):57-63.
135. Di Munno O, Mazzantini M, Milani S, et al. Clinical Equivalence Between Deflazacort Oral Drops and Tablets in Active Rheumatoid Arthritis. *Clinical rheumatology*. 1999;18(2):140-4.
136. Dick W, Franchimont P, Veys E. Double-Blind Comparison of Etodolac and Piroxicam in the Treatment of Rheumatoid Arthritis. *Clinical therapeutics*. 1993;15(1):148-59.
137. Dimitrijevic M, Bartlett R. Leflunomide, a Novel Immunomodulating Drug, Inhibits Homotypic Adhesion of Peripheral Blood and Synovial Fluid Mononuclear Cells in Rheumatoid Arthritis. *Inflammation research : official journal of the European Histamine Research Society [et al]*. 1996;30(8):4132-3.

138. Dixon WG, Watson KD, Lunt M, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register. *Arthritis and Rheumatism* 2007;56(9):2905-12.
139. Dooley MA, Cush JJ, Lipsky PE, et al. The Effects of Nonsteroidal Antiinflammatory Drug Therapy in Early Rheumatoid Arthritis on Serum Levels of Soluble Interleukin 2 Receptor, Cd4, and Cd8. *The Journal of rheumatology*. 1993;20(11):1857-62.
140. Dore RK, Cohen SB, Lane NE, et al. Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. *Annals of the rheumatic diseases*. 2010;69(5):872-5.
141. Dougados M, Combe B, Cantagrel A, et al. Combination Therapy in Early Rheumatoid Arthritis: a Randomised, Controlled, Double Blind 52 Week Clinical Trial of Sulphasalazine and Methotrexate Compared With the Single Components. *Annals of the rheumatic diseases*. 1999;58(4):220-5.
142. Drevlow BE, Lovis R, Haag MA, et al. Recombinant Human Interleukin-1 Receptor Type I in the Treatment of Patients With Active Rheumatoid Arthritis. *Arthritis and rheumatism*. 1996;39(2):257-65.
143. Drewes AM, Andreassen A, Jennum P, et al. Zopiclone as Night Medication in Rheumatoid Arthritis. *Scandinavian journal of rheumatology*. 1998;27(3):180-7.
144. Drosos AA, Tsifetaki N, Tsiakou EK, et al. Influence of Methotrexate on Radiographic Progression in Rheumatoid Arthritis: a Sixty-Month Prospective Study. *Clinical and experimental rheumatology*. 1997;15(3):263-7.
145. Duffy T, Belton O, Bresnihan B, et al. Inhibition of PGE2 Production by Nimesulide Compared With Diclofenac in the Acutely Inflamed Joint of Patients With Arthritis. *Drugs*. 2003;63(Suppl 1):31-6.
146. Dugina JL, Petrov VI, Babayeva AR, et al. A Randomized, Open-Label, Comparative, 6-Month Trial of Oral Ultra-Low Doses of Antibodies to Tumor Necrosis Factor-Alpha and Diclofenac in Rheumatoid Arthritis. *Int J Tissue React*. 2005;27(1):15-21.
147. Dupuis LL, Koren G, Shore A, et al. Methotrexate-Nonsteroidal Antiinflammatory Drug Interaction in Children With Arthritis. *Journal of Rheumatology*. 1990;17(11):1469-73.
148. Eastell R, Devogelaer JP, Peel NF, et al. Prevention of Bone Loss With Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA*. 2000;11(4):331-7.
149. Eder L, Chandran V, Schentag CT, et al. Time and predictors of response to tumour necrosis factor-(alpha) blockers in psoriatic arthritis: An analysis of a longitudinal observational cohort. *Rheumatology*. 2010;49(7):1361-6.
150. Edwards JCW, Leandro MJ, Cambridge G. B Lymphocyte Depletion in Rheumatoid Arthritis: Targeting of Cd20. *Curr Dir Autoimmun*. 2005;1422(8):175-92.
151. Eggelmeijer F, Papapoulos S, van Paassen H, et al. Clinical and Biochemical Response to Single Infusion of Pamidronate in Patients With Active Rheumatoid Arthritis: a Double Blind Placebo Controlled Study. *The Journal of rheumatology*. 1994;21(11):2016-20.
152. Eggelmeijer F, Papapoulos SE, van Paassen HC, et al. Increased Bone Mass With Pamidronate Treatment in Rheumatoid Arthritis. Results of a Three-Year Randomized, Double-Blind Trial. *Arthritis and rheumatism*. 1996;39(3):396-402.
153. Egsmose C, Lund B, Borg G, et al. Patients With Rheumatoid Arthritis Benefit From Early 2nd Line Therapy: 5 Year Followup of a Prospective Double Blind Placebo Controlled Study. *The Journal of rheumatology*. 1995;22(12):2208-13.

154. Egsmose C, TM H, Andersen LS, et al. Limited Effect of Sulphasalazine Treatment in Reactive Arthritis. A Randomised Double Blind Placebo Controlled Trial. *Annals of the rheumatic diseases*. 1997;56(1):32-6.
155. Eichler HG, Mavros P, Geling O, et al. Association Between Health-Related Quality of Life and Clinical Efficacy Endpoints in Rheumatoid Arthritis Patients After Four Weeks Treatment With Anti-Inflammatory Agents. *International journal of clinical pharmacology and therapeutics*. 2005;43(5):209-16.
156. Elewski B, Leonardi C, Gottlieb AB, et al. Comparison of clinical and pharmacokinetic profiles of etanercept 25 mg twice weekly and 50 mg once weekly in patients with psoriasis. *The British journal of dermatology* 2007(1):138-42.
157. Emery P. Disease Modification in Rheumatoid Arthritis With Leflunomide. *Scandinavian journal of rheumatology Supplement*. 1999;112(9):9-14.
158. Emery P, Breedveld FC, Lemmel EM, et al. A Comparison of the Efficacy and Safety of Leflunomide and Methotrexate for the Treatment of Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2000;39(6):655-65.
159. Emery P, Clarke A, Williams P, et al. Nabumetone Compared With Naproxen in the Treatment of Rheumatoid Arthritis: a Multicenter, Double Blind, Randomized, Parallel Group Trial in Hospital Outpatients. *The Journal of rheumatology Supplement*. 1992;36:41-7.
160. Emery P, Durez P, Dougados M, et al. Impact of T-cell costimulation modulation in patients with undifferentiated inflammatory arthritis or very early rheumatoid arthritis: A clinical and imaging study of abatacept (the ADJUST trial). *Annals of the rheumatic diseases*. 2010;69(3):510-6.
161. Emery P, Genovese MC, Fleischmann RM, et al. Efficacy of Golimumab, a human anti-TNF(alpha) antibody, by baseline CRP level in patients with rheumatoid arthritis: Results from three phase 3, randomized, double-blind, placebo-controlled studies. *Rheumatology* 2010;49i101.
162. Emery P, Zeidler H, Kvien TK, et al. Celecoxib Versus Diclofenac in Long-Term Management of Rheumatoid Arthritis: Randomised Double-Blind Comparison. *Lancet*. 2000;354(9196):2106-11.
163. Ergun T, Inanc N, Tuney D, et al. Skin manifestations of rheumatoid arthritis: A study of 215 Turkish patients. *International Journal of Dermatology*. 2008;47(9):894-902.
164. Eriksson LO, Sturfelt G, Thysell H, et al. Effects of Sulindac and Naproxen on Prostaglandin Excretion in Patients With Impaired Renal Function and Rheumatoid Arthritis. *The American journal of medicine*. 1990;89(3):313-21.
165. Faarvang K, Egsmose C, Kryger P, et al. Hydroxychloroquine and Sulphasalazine Alone and in Combination in Rheumatoid Arthritis: a Randomised Double Blind Trial. *Annals of the rheumatic diseases*. 1993;52(10):711-5.
166. Fallatah HI, Akbar HO, Qari YA. Autoimmune hepatitis: Single-center experience of clinical presentation, response to treatment and prognosis in Saudi Arabia. *Saudi Journal of Gastroenterology*. 2010;16(2):95-9.
167. Farr M, Kitas G, Waterhouse L, et al. Sulphasalazine in Psoriatic Arthritis: a Double-Blind Placebo-Controlled Study. *British journal of rheumatology*. 1990;29(1):46-0.
168. Fernandez A, Quintana G, Rondon F, et al. Lupus arthropathy: A case series of patients with rhupus. *Clinical Rheumatology*. 2006;25(2):164-7.
169. Ferraz MB, Pinheiro GR, Helfenstein M, et al. Combination Therapy With Methotrexate and Chloroquine in Rheumatoid Arthritis. A Multicenter Randomized Placebo-Controlled Trial. *Scandinavian journal of rheumatology*. 1994;23(5):231-6.
170. Fleischmann R. Safety and efficacy of etanercept in the elderly. *Aging Health*. 2006;2(2):189-97.
171. Flicinski J, Brzosko M, Olewniczak S. Multiple haemangiomas in a psoriatic arthritis patient treated with cyclosporine [13]. *Acta Dermato Venereologica*. 2006;86(3):271-2.

172. Foell D, Kane D, Bresnihan B, et al. Expression of the Pro-Inflammatory Protein S100a12 (En-Rage) in Rheumatoid and Psoriatic Arthritis. *Rheumatology (Oxford)*. 2003;42(11):1383-9.
173. Foell D, Wulffraat N, Wedderburn LR, et al. Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission a randomized clinical trial. *JAMA - Journal of the American Medical Association*. 2010;303(13):1266-73.
174. Franck H, Ittel T, Tasch O, et al. Osteocalcin in Patients With Rheumatoid Arthritis. A One-Year Followup Study. *The Journal of rheumatology*. 1994;21(7):1256-9.
175. Fransen J, Visser K, Van Dongen H, et al. Validity of the disease activity score in undifferentiated arthritis. *Arthritis Care and Research*. 2010;62(10):1392-8.
176. Fraser AD, van Kuijk AWR, Westhovens R, et al. A Randomised, Double Blind, Placebo Controlled, Multicentre Trial of Combination Therapy With Methotrexate Plus Ciclosporin in Patients With Active Psoriatic Arthritis. *Ann Rheum Dis*. 2005;64(6):859-64.
177. Fraser S, Hopkins R, Hunter J, et al. Sulphasalazine in the Management of Psoriatic Arthritis. *British journal of rheumatology*. 1993;32(10):923-5.
178. Friedman DM, Llanos C, Izmirly PM, et al. Evaluation of fetuses in a study of intravenous immunoglobulin as preventive therapy for congenital heart block: Results of a multicenter, prospective, open-label clinical trial. *Arthritis and rheumatism*. 2010;62(4):1138-46.
179. Furst D, Erikson N, Clute L, et al. Adverse Experience With Methotrexate During 176 Weeks of a Longterm Prospective Trial in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1990;12:1628-35.
180. Furst D, Felson D, Thoren G, et al. Immunoabsorption for the Treatment of Rheumatoid Arthritis: Final Results of a Randomized Trial. *Prosorba Trial Investigators. Ther Apher*. 2002;6(1):99.
181. Furst DE, Kolba KS, Fleischmann R, et al. Dose Response and Safety Study of Meloxicam up to 22.5 Mg Daily in Rheumatoid Arthritis: a 12 Week Multicenter, Double Blind, Dose Response Study Versus Placebo and Diclofenac. *The Journal of rheumatology*. 2002;29(3):436-46.
182. Furuya T, Kotake S, Inoue E, et al. Risk factors associated with incident fractures in Japanese men with rheumatoid arthritis: A prospective observational cohort study. *Journal of Bone and Mineral Metabolism*. 2008;26(5):499-505.
183. Furuya T, Kotake S, Inoue E, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: A prospective 54-month observational study. *Journal of Rheumatology*. 2007;34(2):303-10.
184. Furuya Y, Ozeki T, Takayanagi R, et al. Theory based analysis of anti-inflammatory effect of infliximab on Crohn's disease. *Drug metabolism and pharmacokinetics* 2007(1):20-5.
185. Furuzawa-Carballeda J, Fenutria-Ausmequet R, Gil-Espinosa V, et al. Polymerized-type I collagen for the treatment of patients with rheumatoid arthritis. Effect of intramuscular administration in a double blind placebo-controlled clinical trial. *Clinical and Experimental Rheumatology*. 2006;24(5):514-20.
186. Garnero P, Thompson E, Woodworth T, et al. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. 2010.
187. Gasparyan AY, Stavropoulos-Kalinoglou A, Toms TE, et al. Association of mean platelet volume with hypertension in rheumatoid arthritis. *Inflammation and Allergy - Drug Targets*. 2010;9(1):45-50.

188. Genant HK. Interleukin-1 Receptor Antagonist Treatment of Rheumatoid Arthritis Patients: Radiologic Progression and Correlation of Genant/Sharp and Larsen Scoring Methods. *Seminars in arthritis and rheumatism*. 2001;30(5 Suppl 2):26-32.
189. Genant HK, Peterfy CG, Westhovens R, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: Results from the long-term extension of the AIM trial. *Annals of the Rheumatic Diseases*. 2007;67(8):1084-9.
190. Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis and Rheumatism* 2008;58(10):2968-80.
191. Genta MS, Kardes H, Gabay C. Clinical evaluation of a cohort of patients with rheumatoid arthritis treated with anti-TNF-alpha in the community. *Joint Bone Spine*. 2006;73(1):51-6.
192. Gerlag DM, Haringman JJ, Smeets TJM, et al. Effects of Oral Prednisolone on Biomarkers in Synovial Tissue and Clinical Improvement in Rheumatoid Arthritis. *Arthritis and rheumatism*. 2004;50(12):3783-91.
193. Gerlag DM, Hollis S, Layton M, et al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. *Arthritis and rheumatism*. 2010;62(11):3154-60.
194. Geusens P, Alten R, Rovinsky J, et al. Efficacy, Safety and Tolerability of Lumiracoxib in Patients With Rheumatoid Arthritis. *Int J Clin Pract*. 2004;58(11):1033-41.
195. Geusens P, Truitt K, Sfikakis P, et al. A Placebo and Active Comparator-Controlled Trial of Rofecoxib for the Treatment of Rheumatoid Arthritis. *Scandinavian journal of rheumatology*. 2002;31(4):230-8.
196. Ghosh B, Halder S, Ghosh A, et al. Early rheumatoid arthritis: Clinical and therapeutic evaluation in a tertiary care centre in India. *Indian Journal of Rheumatology* 2008;3(2):48-51.
197. Giannini EH, Ilowite NT, Lovell DJ, et al. Long-term safety and effectiveness of etanercept in children with selected categories of juvenile idiopathic arthritis. 2009.
198. Gladman D, Blake R, Brubacher B, et al. Chloroquine Therapy in Psoriatic Arthritis. *The Journal of rheumatology*. 1992;19(11):1724-6.
199. Gladman DD, Mease PJ, Cifaldi MA, et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. *Ann Rheum Dis* 2007;66(2):163-8.
200. Gladman DD, Mease PJ, Ritchlin CT, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. *Arthritis Rheum*. 2007 Feb;56(2):476-88.
201. Godfrey C, Sweeney K, Miller K, et al. The Population Pharmacokinetics of Long-Term Methotrexate in Rheumatoid Arthritis. *British journal of clinical pharmacology*. 1998;46(4):369-76.
202. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, et al. Comparison of treatment strategies in early rheumatoid arthritis: A randomized trial. *Annals of Internal Medicine* 2007;146(6):406-15.
203. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Kerstens PJSM, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. 2010.
204. Gonzalez-Alvaro I, Descalzo MA, Carmona L. Trends towards an improved disease state in rheumatoid arthritis over time: Influence of new therapies and changes in management approach: Analysis of the EMECAR cohort. *Arthritis Research and Therapy*. 2008;10(6).

205. Goodnough L, Marcus R. The Erythropoietic Response to Erythropoietin in Patients With Rheumatoid Arthritis. *The Journal of laboratory and clinical medicine*. 1997;130(4):381-6.
206. Gossec L, van der Heijde D, Melian A, et al. Efficacy of Cyclo-Oxygenase-2 Inhibition by Etoricoxib and Naproxen on the Axial Manifestations of Ankylosing Spondylitis in the Presence of Peripheral Arthritis. *Annals of the rheumatic diseases*. 2005;64(1):1563-7.
207. Gøtzsche P, Johansen H. Meta-Analysis of Short-Term Low Dose Prednisolone Versus Placebo and Non-Steroidal Anti-Inflammatory Drugs in Rheumatoid Arthritis. *British medical journal*. 1998;316(7144):1606-7.
208. Gotzsche PC, Hansen M, Stoltenberg M, et al. Randomized, Placebo Controlled Trial of Withdrawal of Slow-Acting Antirheumatic Drugs and of Observer Bias in Rheumatoid Arthritis. *Scandinavian Journal of Rheumatology*. 1996;25(4):194-0.
209. Graell E, Vazquez I, Larrosa M, et al. Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: Prognostic factors after two years of follow-up. *Clinical and Experimental Rheumatology*. 2009;27(2):284-91.
210. Graham DY, White RH, Moreland LW, et al. Duodenal and Gastric Ulcer Prevention With Misoprostol in Arthritis Patients Taking Nsaids. *Misoprostol Study Group*. *Annals of internal medicine*. 1993;119(4):257-62.
211. Greenberg JD, Bingham ICO, Abramson SB, et al. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals. *Arthritis Care and Research*. 2006;55(4):543-50.
212. Greenwood MC, Rathi J, Hakim AJ, et al. Regression to the mean using the disease activity score in eligibility and response criteria for prescribing TNF-alpha inhibitors in adults with rheumatoid arthritis. *Rheumatology*. 2007;46(7):1165-7.
213. Griffith SM, Fisher J, Clarke S, et al. Do Patients With Rheumatoid Arthritis Established on Methotrexate and Folic Acid 5 Mg Daily Need to Continue Folic Acid Supplements Long Term? *Rheumatology (Oxford)*. 2000;39(10):1102-9.
214. Grigor C, Capell H, Stirling A, et al. Effect of a Treatment Strategy of Tight Control for Rheumatoid Arthritis (the Ticora Study): a Single-Blind Randomised Controlled Trial. *Lancet*. 2004;364(9430):263-9.
215. Gulec G, Yenilmez C, Ayranci U. Sulfasalazine plus chloroquine-induced mood disorder in a patient with rheumatoid arthritis. *Iranian Journal of Medical Sciences*. 2009;34(1):72-5.
216. Guler-Yuksel M, Allaart CF, Watt I, et al. Treatment with TNF-(alpha) inhibitor infliximab might reduce hand osteoarthritis in patients with rheumatoid arthritis. *Osteoarthritis and Cartilage*. 2010;18(10):1256-62.
217. Gupta AK, Grober JS, Hamilton TA, et al. Sulfasalazine Therapy for Psoriatic Arthritis: a Double Blind, Placebo Controlled Trial. *The Journal of rheumatology*. 1996;22(5):894-8.
218. Haagsma C, Russel F, Vree T, et al. Combination of Methotrexate and Sulphasalazine in Patients With Rheumatoid Arthritis: Pharmacokinetic Analysis and Relationship to Clinical Response. *British journal of clinical pharmacology*. 1997;36(10):1082-8.
219. Haagsma C, van Riel P, de Jong A, et al. Combination of Sulphasalazine and Methotrexate Versus the Single Components in Early Rheumatoid Arthritis: a Randomized, Controlled, Double-Blind, 52 Week Clinical Trial. *British journal of rheumatology*. 1997;36(10):1082-8.
220. Haagsma C, van Riel P, van de Putte L. Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions. *British journal of rheumatology*. 1995;34(Suppl 2):104-8.
221. Haagsma CJ, Blom HJ, van Riel PL, et al. Influence of Sulphasalazine, Methotrexate, and the Combination of Both on Plasma Homocysteine Concentrations in Patients With Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 1999;58(2):79-84.

222. Haagsma CJ, van Riel PL, de Rooij DJ, et al. Combination of Methotrexate and Sulphasalazine Vs Methotrexate Alone: a Randomized Open Clinical Trial in Rheumatoid Arthritis Patients Resistant to Sulphasalazine Therapy. *British journal of rheumatology*. 1994;33(11):1049-55.
223. Haar D, Solvkjaer M, Unger B, et al. A Double-Blind Comparative Study of Hydroxychloroquine and Dapsone, Alone and in Combination, in Rheumatoid Arthritis. *Scandinavian journal of rheumatology*. 1993;22(3):113-8.
224. Hafstrom I, Albertsson K, Boonen A, et al. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: An open 2-year continuation study. 2009.
225. Hakala M, Risteli J, Aman S, et al. Combination drug strategy in recent-onset rheumatoid arthritis suppresses collagen I degradation and is associated with retardation of radiological progression. *Scandinavian Journal of Rheumatology*. 2008;37(2):90-3.
226. Hamalainen H, Kaarela K, Kroger H, et al. Changes in bone mineral density in premenopausal women with rheumatoid arthritis during a two-year follow-up. *Joint Bone Spine*. 2007;74(5):482-7.
227. Hamilton J, McInnes I, Thomson E, et al. Comparative Study of Intramuscular Gold and Methotrexate in a Rheumatoid Arthritis Population From a Socially Deprived Area. *Annals of the rheumatic diseases*. 2001;60(6):566-72.
228. Hamilton R, Kremer J. Why Intramuscular Methotrexate May Be More Efficacious Than Oral Dosing in Patients With Rheumatoid Arthritis. *British journal of rheumatology*. 1997;36(1):86-90.
229. Hamilton S, Campbell N, Kara M, et al. The Effect of Ingestion of Ferrous Sulfate on the Absorption of Oral Methotrexate in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 2003;30(9):1948-50.
230. Hannequin JR. Efficacy of Arthrotec in the Treatment of Rheumatoid Arthritis. *Scandinavian journal of rheumatology Supplement*. 1992;96:7-14.
231. Hannonen P, Mottonen T, Hakola M, et al. Sulfasalazine in Early Rheumatoid Arthritis. A 48-Week Double-Blind, Prospective, Placebo-Controlled Study. *Arthritis and rheumatism*. 1993;36(11):1501-9.
232. Hansen M, Podenphant J, Florescu A, et al. A Randomised Trial of Differentiated Prednisolone Treatment in Active Rheumatoid Arthritis. Clinical Benefits and Skeletal Side Effects. *Annals of the rheumatic diseases*. 1999;58(11):713-8.
233. Hansen TM, Kryger P, Elling H, et al. Double Blind Placebo Controlled Trial of Pulse Treatment With Methylprednisolone Combined With Disease Modifying Drugs in Rheumatoid Arthritis. *British medical journal*. 1990;301(6749):268-70.
234. Hanyuda M, Kasama T, Isozaki T, et al. Activated Leucocytes Express and Secrete Macrophage Inflammatory Protein-1alpha Upon Interaction With Synovial Fibroblasts of Rheumatoid Arthritis Via a Beta2-Integrin/Icam-1 Mechanism. *Rheumatology (Oxford)*. 2003;42(11):1390-7.
235. Haringman J, Kraan M, Smeets TJ, et al. Chemokine Blockade and Chronic Inflammatory Disease: Proof of Concept in Patients With Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 2003;62(8):715-21.
236. Hartmann SN, Rordorf CM, Milosavljev S, et al. Lumiracoxib Does Not Affect Methotrexate Pharmacokinetics in Rheumatoid Arthritis Patients. *The Annals of pharmacotherapy*. 2004;38(10):1582-7.
237. Hasegawa J, Nagashima M, Yamamoto M, et al. Bone Resorption and Inflammatory Inhibition Efficacy of Intermittent Cyclical Etidronate Therapy in Rheumatoid Arthritis. *The Journal of rheumatology*. 2004;38(10):1582-7.
238. Hatakka K, Martio J, Korpela M, et al. Effects of Probiotic Therapy on the Activity and Activation of Mild Rheumatoid Arthritis--a Pilot Study. *Scandinavian journal of rheumatology*. 2003;32(4):211-5.

239. Haugeberg G, Green MJ, Quinn MA, et al. Hand bone loss in early undifferentiated arthritis: Evaluating bone mineral density loss before the development of rheumatoid arthritis. *Annals of the Rheumatic Diseases*. 2006;65(6):736-40.
240. Haugeberg G, Strand A, Kvien T, et al. Reduced Loss of Hand Bone Density With Prednisolone in Early Rheumatoid Arthritis: Results From a Randomized Placebo-Controlled Trial. *Archives of internal medicine*. 2005;165(11):1293-7.
241. Hazes JM, Taylor P, Strand V, et al. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. *Rheumatology*. 2010;49(10):1900-10.
242. Hemmings F, Farhan M, Rowland J, et al. Tolerability and Pharmacokinetics of the Collagenase-Selective Inhibitor Trocade in Patients With Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2001;40(5):537-43.
243. Henriksson K, Uribe A, Sandstedt B, et al. Helicobacter Pylori Infection, Abo Blood Group, and Effect of Misoprostol on Gastroduodenal Mucosa in Nsaid-Treated Patients With Rheumatoid Arthritis. *Digestive diseases and sciences*. 1993;38(9):1688-96.
244. Hepburn T, Totoritis M, Davis C. Antibody-Mediated Stripping of Cd4 From Lymphocyte Cell Surface in Patients With Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2003;42(1):54-61.
245. Hernandez-Cruz B, Ariza-Ariza R, Cardiel-Rios MH. Cost of the standard rheumatology care in active rheumatoid arthritis patients seen in a tertiary care center in Mexico City. *Reumatologia Clinica*. 2006;2(3):124-30.
246. Herrick A, Grennan D, Griffen K, et al. Lack of Interaction Between Flucloxacillin and Methotrexate in Patients With Rheumatoid Arthritis. *British journal of clinical pharmacology*. 1996;41(3):223-7.
247. Hetland ML, Ejbjerg B, Horslev-Petersen K, et al. MRI bone oedema is the strongest predictor of subsequent radiographic progression in early rheumatoid arthritis. Results from a 2-year randomised controlled trial (CIMESTRA). 2009.
248. Hetland ML, Lindegaard HM, Hansen A, et al. Do changes in prescription practice in patients with rheumatoid arthritis treated with biological agents affect treatment response and adherence to therapy? Results from the nationwide Danish DANBIO Registry. *Annals of the Rheumatic Diseases*. 2008;67(7):1023-6.
249. Heurkens A, Westedt M, Breedveld F. Prednisone Plus Azathioprine Treatment in Patients With Rheumatoid Arthritis Complicated by Vasculitis. *Archives of internal medicine*. 1991;151(11):2249-54.
250. Hewlett S, Mitchell K, Haynes J, et al. Patient-Initiated Hospital Follow-up for Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2000;39(9):990-7.
251. Hickling P, Jacoby R, Kirwan J. Joint Destruction After Glucocorticoids Are Withdrawn in Early Rheumatoid Arthritis. Arthritis and Rheumatism Council Low Dose Glucocorticoid Study Group. *British journal of rheumatology*. 1994;21(3):435-41.
252. Hidaka T, Suzuki K, Kawakami M, et al. Dynamic Changes in Cytokine Levels in Serum and Synovial Fluid Following Filtration Leukocytapheresis Therapy in Patients With Rheumatoid Arthritis. *J Clin Apher*. 2001;16(2):74-81.
253. Hidaka T, Suzuki K, Matsuki Y, et al. Changes in Cd4+ T Lymphocyte Subsets in Circulating Blood and Synovial Fluid Following Filtration Leukocytapheresis Therapy in Patients With Rheumatoid Arthritis. *Ther Apher*. 1999;3(2):178-85.
254. Hilliquin P, Chermat I, Zard V, Menkes CJ. A Double Blind, Placebo Controlled Study of a Platelet Activating Factor Antagonist in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1998;25(8):1502-7.



255. Hoekstra M, Haagsma C, Neef C, et al. Bioavailability of Higher Dose Methotrexate Comparing Oral and Subcutaneous Administration in Patients With Rheumatoid Arthritis. *Journal of Rheumatology*. 2004;31(4):645-8.
256. Hoekstra M, van Ede A, Haagsma C, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. *Annals of the rheumatic diseases*. 2003;62(5):423-6.
257. Hoffman GS, Cid MC, Rendt-Zagar KE, et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. *Annals of internal medicine* 2007(9):621-30.
258. Holm B, Jacobsen S, Skjodt H, et al. Keitel functional test for patients with rheumatoid arthritis: Translation, reliability, validity, and responsiveness. *Physical Therapy*. 2008;88(5):664-78.
259. Hor BTY, Vasoo S, Koh ET. The use of anti-tumour necrosis factor-alpha therapies for rheumatoid arthritis in Singapore. *APLAR Journal of Rheumatology*. 2006;9(2):157-60.
260. Horng MS. Early rheumatoid arthritis: Is there a best treatment? *Journal of Clinical Outcomes Management*. 2007;14(5):233-4.
261. Huang F, Wang L, Zhang J, et al. Risk of tuberculosis in a Chinese registry of rheumatoid arthritis and ankylosing spondylitis for tumour necrosis factor-alpha antagonists. *APLAR Journal of Rheumatology*. 2006;9(2):170-4.
262. Huang SC, Wei JCC, Wu DJ, et al. Vitamin B6 supplementation improves pro-inflammatory responses in patients with rheumatoid arthritis. *European Journal of Clinical Nutrition*. 2010;64(9):1007-13.
263. Huffstutter J, Craig WD, Schimizzi G, et al. A multicenter, randomized, open study to evaluate the impact of an electronic data capture system on the care of patients with rheumatoid arthritis. *Current Medical Research and Opinion*. 2007;23(8):1967-79.
264. Hughes RA, Carr AJ, Carr M, et al. Improving patient safety: Reducing medication errors through use of acceptable, accessible medicines packaging. *Pharmaceutical Journal*. 2008;280(7484):22-5.
265. Huisman AM, Siewertsz van Everdingen AA, Wenting MJG, et al. Glucocorticoid Receptor up-Regulation in Early Rheumatoid Arthritis Treated With Low Dose Prednisone or Placebo. *Clinical and experimental rheumatology*. 2003;21(2):217-20.
266. Hunter J, Parnham M, Balaguer X. Aceclofenac in Rheumatoid Arthritis: a Useful and Novel Anti-Inflammatory. *Clinical rheumatology*. 1996;15(4):329-34.
267. Hurowitz EJ, Gould JS, Fleisig GS, et al. Outcome analysis of agility total ankle replacement with prior adjunctive procedures: Two to six year followup. *Foot and Ankle International*. 2007;28(3):308-12.
268. Huskisson EC. Four Commonly Prescribed Non-Steroidal Anti-Inflammatory Drugs for Rheumatoid Arthritis. *European journal of rheumatology and inflammation*. 1991;11(2):8-12.
269. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. *Gastroenterology* 2007(3):863-73; quiz 1165-6.
270. Iagnocco A, Cerioni A, Coari G, et al. Intra-articular methotrexate in the treatment of rheumatoid arthritis and psoriatic arthritis: A clinical and sonographic study. *Clinical Rheumatology*. 2006;25(2):159-63.
271. Ichikawa Y, Saito T, Yamanaka H, et al. Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. *Journal of Rheumatology*. 2010;37(4):723-9.
272. Iglehart IWR, Sutton JD, Bender JC, et al. Intravenous Pulsed Steroids in Rheumatoid Arthritis: a Comparative Dose Study. *The Journal of rheumatology*. 1990;17(2):159-62.

273. Ince A, Yazici Y, Hamuryudan V, et al. The Frequency and Clinical Characteristics of Methotrexate (Mtx) Oral Toxicity in Rheumatoid Arthritis (Ra): a Masked and Controlled Study. *Clinical rheumatology*. 1996;15(5):491-4.
274. Iqbal M, Baig J, Ali A, et al. The Effects of Non-Steroidal Anti-Inflammatory Drugs on the Disposition of Methotrexate in Patients With Rheumatoid Arthritis. *Biopharmaceutics & drug disposition*. 1998;19(3):163-7.
275. Ishikawa H, Murasawa A, Nakazono K, et al. The patient-based outcome of upper-extremity surgeries using the DASH questionnaire and the effect of disease activity of the patients with rheumatoid arthritis. *Clinical Rheumatology*. 2008;27(8):967-73.
276. Islam M, Alam M, Haq S, et al. Efficacy of Sulphasalazine Plus Methotrexate in Rheumatoid Arthritis. *Bangladesh Medical Research Council bulletin*. 2000;26(1):1-7.
277. Isozaki T, Sato M, Takahashi R, et al. Effects of low-dose tacrolimus therapy in combination with methotrexate in patients with methotrexate-refractory rheumatoid arthritis. 2010;229-34.
278. Izumi Y, Tominaga M, Iwanaga N, et al. Twenty-four-week follow-up examination of a leukocytapheresis therapy in rheumatoid arthritis. *Modern Rheumatology*. 2006;16(1):20-3.
279. Jacobs J, Rasker J, van Riel P, et al. Rheumajecta and Vasolastine in the Treatment of Rheumatoid Arthritis--the Results of a Placebo-Controlled, Double-Blind Trial of a Complementary Treatment. *Scandinavian journal of rheumatology*. 1991;20(6):434-40.
280. Jahangier ZN, Jacobs JWG, Lafeber FPJG, et al. Is Radiation Synovectomy for Arthritis of the Knee More Effective Than Intraarticular Treatment With Glucocorticoids? Results of an Eighteen-Month, Randomized, Double-Blind, Placebo-Controlled, Crossover Trial. *Arthritis and rheumatism*. 2005;52(11):3391-402.
281. Jabez Ocampo J, Richaud Patin Y, Simon J, et al. Weekly Dose of Leflunomide for the Treatment of Refractory Rheumatoid Arthritis: an Open Pilot Comparative Study. *Joint, bone, spine : revue du rhumatisme*. 2004;51(1):147-8.
282. Jakob A, Porstmann R, Rompel R. Skin ulceration after leflunomide treatment in two patients with rheumatoid arthritis. [German, English]. *JDDG Journal of the German Society of Dermatology*. 2006;4(4):324-7.
283. Jamal S, Patra K, Keystone EC. Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. 2009.
284. Jaswal S, Mehta H, Sood A, et al. Antioxidant Status in Rheumatoid Arthritis and Role of Antioxidant Therapy. 338. 2003;1-2:international journal of clinical chemistry.
285. Jelinek G, Will R, Dusci L, et al. Intravenous Regional Administration of Methylprednisolone in Rheumatoid Arthritis. *Rheumatology international*. 1991;11(4-5):147-50.
286. Jenks K, Stebbings S, Burton J, et al. Probiotic therapy for the treatment of spondyloarthritis: A randomized controlled trial. *Journal of Rheumatology*. 2010;37(10):2118-25.
287. Jessop JD, O'Sullivan MM, Lewis PA, et al. A Long-Term Five-Year Randomized Controlled Trial of Hydroxychloroquine, Sodium Aurothiomalate, Auranofin and Penicillamine in the Treatment of Patients With Rheumatoid Arthritis. *British journal of rheumatology*. 1998;37(9):992-1002.
288. Jeurissen ME, Boerbooms AM, van de Putte LB, et al. Influence of Methotrexate and Azathioprine on Radiologic Progression in Rheumatoid Arthritis. A Randomized, Double-Blind Study. *Annals of internal medicine*. 1991;114(12):999-1004.
289. Jones G, Sebba A, Gu J, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. 2010.

290. Joyce D, Will R, Hoffman D, et al. Exacerbation of Rheumatoid Arthritis in Patients Treated With Methotrexate After Administration of Folic Acid. *Annals of the rheumatic diseases*. 1991;50(12):913-4.
291. Kafediska I, Spasovski D, Gruev T, et al. Association between Sharp's radiographic index and acute phase reactants in rheumatoid arthritis. *Journal of Medical Biochemistry*. 2008;27(4):447-53.
292. Kageyama Y, Sano M, Ishihara C, et al. Flexor tendon ruptures in both small fingers of a patient with rheumatoid arthritis [2]. *Journal of Clinical Rheumatology*. 2006;12(2):103-4.
293. Kahn KL, MacLean CH, Wong AL, et al. Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort. *Arthritis Care and Research*. 2007;57(5):707-15.
294. Kalden JR, Schattenkirchner M, Sorensen H, et al. The Efficacy and Safety of Leflunomide in Patients With Active Rheumatoid Arthritis: a Five-Year Followup Study. *Arthritis and rheumatism*. 2003;48(6):1513-20.
295. Kalden JR, Scott DL, Smolen JS, et al. Improved Functional Ability in Patients With Rheumatoid Arthritis - Longterm Treatment With Leflunomide Versus Sulfasalazine. *Journal of Rheumatology*. 2001;28(9):1983-91.
296. Kalden Nemeth D, Grebmeier J, Antoni C, et al. Nmr Monitoring of Rheumatoid Arthritis Patients Receiving Anti-Tnf-Alpha Monoclonal Antibody Therapy. *Rheumatology international*. 1997;16(6):249-55.
297. Kaltwasser J, Nash P, Gladman D, et al. Efficacy and Safety of Leflunomide in the Treatment of Psoriatic Arthritis and Psoriasis: a Multinational, Double-Blind, Randomized, Placebo-Controlled Clinical Trial. *Arthritis and rheumatism*. 2004;50(6):1393-50.
298. Kamel M, Serafi T. Fucose Concentrations in Sera From Patients With Rheumatoid Arthritis. *Clinical and experimental rheumatology*. 1995;13(2):243-6.
299. Kanbe K, Inoue K. Efficacy of arthroscopic synovectomy for the effect attenuation cases of infliximab in rheumatoid arthritis. *Clinical Rheumatology*. 2006;25(6):877-81.
300. Kanik K, Yarboro C, Naparstek Y, et al. Failure of Low-Dose Intravenous Immunoglobulin Therapy to Suppress Disease Activity in Patients With Treatment-Refractory Rheumatoid Arthritis. *Arthritis and rheumatism*. 1997;82(4):1279-83.
301. Karim A, Tolbert D, Hunt T, et al. Celecoxib, a Specific Cox-2 Inhibitor, Has No Significant Effect on Methotrexate Pharmacokinetics in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1999;26(12):2539-43.
302. Kavanaugh A, Genovese M, Baughman J, et al. Allele and Antigen-Specific Treatment of Rheumatoid Arthritis: a Double Blind, Placebo Controlled Phase 1 Trial. *The Journal of rheumatology*. 2003;30(3):449-54.
303. Kavanaugh A, Menter A, Mendelsohn A, et al. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: A randomized, placebo-controlled, phase II trial. *Current Medical Research and Opinion*. 2010;26(10):2385-92.
304. Kawai S, Uchida E, Kondo M, et al. Efficacy and safety of ketoprofen patch in patients with rheumatoid arthritis: A randomized, double-blind, placebo-controlled study. *Journal of Clinical Pharmacology*. 2010;50(10):1171-9.
305. Kekow J, Moots RJ, Emery P, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial. 2010.
306. Kerstens P, Boerbooms A, Jeurissen M, et al. Radiological and Clinical Results of Longterm Treatment of Rheumatoid Arthritis With Methotrexate and Azathioprine. *The Journal of rheumatology*. 2000;27(5):1148-55.

307. Kerstens P, Boerbooms A, Jeurissen M, et al. Accelerated Nodulosis During Low Dose Methotrexate Therapy for Rheumatoid Arthritis. An Analysis of Ten Cases. *The Journal of rheumatology*. 1992;19(6):867-71.
308. Kerstens P, Boerbooms A, Jeurissen M, et al. Antiperinuclear Factor and Disease Activity in Rheumatoid Arthritis. Longitudinal Evaluation During Methotrexate and Azathioprine Therapy. *The Journal of rheumatology*. 1994;21(12):2190-4.
309. Keystone E, Haraoui B, Bykerk V. Role of Adalimumab in the Treatment of Early Rheumatoid Arthritis. *Clinical and experimental rheumatology*. 2003;21(5 Suppl 31):S198-9.
310. Khan S, Otter S, Springett K. The effects of reflexology on foot pain and quality of life in a patient with rheumatoid arthritis: A case report. *Foot*. 2006;16(2):112-6.
311. Kiely P, Williams R, Walsh D, et al. Contemporary patterns of care and disease activity outcome in early rheumatoid arthritis: The ERAN cohort. *Rheumatology*. 2009;48(1):57-60.
312. Kim H, Song Y. A Comparison Between Bucillamine and D-Penicillamine in the Treatment of Rheumatoid Arthritis. *Rheumatology international*. 1997;17(1):5-9.
313. Kimball AB, Bensimon AG, Guerin A, et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. *American Journal of Clinical Dermatology* 2011;12(1):51-62.
314. Kirkham B, Corkill M, Davison S, et al. Response to Glucocorticoid Treatment in Rheumatoid Arthritis: in Vitro Cell Mediated Immune Assay Predicts in Vivo Responses. *The Journal of rheumatology*. 1991;18(6):821-5.
315. Kirkham B, Davison S, Corkill M, et al. Serial Soluble Interleukin 2 Receptor Levels in Rheumatoid Arthritis: Differences in Response to Glucocorticoid Treatment and Chrysotherapy. *The Journal of rheumatology*. 1993;20(6):935-9.
316. Kirkham B, Navarro F, Corkill M, et al. In Vivo Analysis of Disease Modifying Drug Therapy Activity in Rheumatoid Arthritis by Sequential Immunohistological Analysis of Synovial Membrane Interleukin 1 Beta. *The Journal of rheumatology*. 1994;21(9):1615-9.
317. Kirwan J, Byron M, Watt I. The Relationship Between Soft Tissue Swelling, Joint Space Narrowing and Erosive Damage in Hand X-Rays of Patients With Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2001;40(3):688-95.
318. Kirwan JR, Hallgren R, Mielants H, et al. A Randomised Placebo Controlled 12 Week Trial of Budesonide and Prednisolone in Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 2004;63-6-688-95.
319. Kloppenburg M, Breedveld F, Terwiel J, et al. Minocycline in Active Rheumatoid Arthritis. A Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 1994;37(5):629-36.
320. Kloppenburg M, Dijkmans B, Verweij C, et al. Inflammatory and Immunological Parameters of Disease Activity in Rheumatoid Arthritis Patients Treated With Minocycline. *Immunopharmacology*. 1996;31(2-3):163-9.
321. Knijff Dutmer E, Kalsbeek Batenburg E, Koerts J, et al. Platelet Function Is Inhibited by Non-Selective Non-Steroidal Anti-Inflammatory Drugs but Not by Cyclo-Oxygenase-2-Selective Inhibitors in Patients With Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2002;41(4):458-61.
322. Knijff Dutmer E, Martens A, vd Laar M. Effects of Nabumetone Compared With Naproxen on Platelet Aggregation in Patients With Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 1999;58(4):257-9.
323. Knijff-Dutmer E, Drossaers-Bakker W, Verhoeven A, et al. Rheumatoid Factor Measured by Fluoroimmunoassay: a Responsive Measure of Rheumatoid Arthritis Disease Activity That Is Associated With Joint Damage. *Annals of the rheumatic diseases*. 2002;61(7):603-7.

324. Knudsen LS, Klarlund M, Skjodt H, et al. Biomarkers of inflammation in patients with unclassified polyarthritis and early rheumatoid arthritis. Relationship to disease activity and radiographic outcome. *Journal of Rheumatology*. 2008;35(7):1277-87.
325. Kollerup G, Hansen M, Horslev Petersen K. Urinary Hydroxypyridinium Cross-Links of Collagen in Rheumatoid Arthritis. Relation to Disease Activity and Effects of Methylprednisolone. *British journal of rheumatology*. 1994;33(9):816-20.
326. Kondo H, Abe T, Hashimoto H, et al. Efficacy and Safety of Tacrolimus (Fk506) in Treatment of Rheumatoid Arthritis: a Randomized, Double Blind, Placebo Controlled Dose-Finding Study. *The Journal of rheumatology*. 2004;31(2):243-51.
327. Kopp S, Akerman S, Nilner M. Short-Term Effects of Intra-Articular Sodium Hyaluronate, Glucocorticoid, and Saline Injections on Rheumatoid Arthritis of the Temporomandibular Joint. *Journal of craniomandibular disorders : facial & oral pain*. 1991;5(4):231-8.
328. Kornasoff D, Maisenbacher J, Bowdler J, et al. The Efficacy and Tolerability of Aceclofenac Compared to Indomethacin in Patients With Rheumatoid Arthritis. *Rheumatology international*. 1996;15(6):225-30.
329. Korpela M, Laasonen L, Hannonen P, et al. Retardation of Joint Damage in Patients With Early Rheumatoid Arthritis by Initial Aggressive Treatment With Disease-Modifying Antirheumatic Drugs: Five-Year Experience From the Fin-Raco Study. *Arthritis and rheumatism*. 2004;50(7):2072-81.
330. Korthals-de Bos I, Van Tulder M, Boers M, et al. Indirect and Total Costs of Early Rheumatoid Arthritis: a Randomized Comparison of Combined Step-Down Prednisolone, Methotrexate, and Sulfasalazine With Sulfasalazine Alone. *The Journal of rheumatology*. 2004;31(9):1709-16.
331. Kraan MC, de Koster BM, Elferink JG, et al. Inhibition of Neutrophil Migration Soon After Initiation of Treatment With Leflunomide or Methotrexate in Patients With Rheumatoid Arthritis: Findings in a Prospective, Randomized, Double-Blind Clinical Trial in Fifteen Patients. *Arthritis and rheumatism*. 2000;43(7):1488-95.
332. Kraan MC, Reece RJ, Barg EC, et al. Modulation of Inflammation and Metalloproteinase Expression in Synovial Tissue by Leflunomide and Methotrexate in Patients With Active Rheumatoid Arthritis. Findings in a Prospective, Randomized, Double-Blind, Parallel-Design Clinical Trial in Thirty-Nine Patients at Two Centers. *Arthritis and rheumatism*. 2000;43(8):1820-30.
333. Kraan MC, Smeets TJM, van Loon MJ, et al. Differential Effects of Leflunomide and Methotrexate on Cytokine Production in Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 2004;63(9):1056-61.
334. Kremer J, Genovese M, Cannon GW, et al. Combination Leflunomide and Methotrexate (Mtx) Therapy for Patients With Active Rheumatoid Arthritis Failing Mtx Monotherapy: Open-Label Extension of a Randomized, Double-Blind, Placebo Controlled Trial. *The Journal of rheumatology*. 2004;31(8):1521-31.
335. Kremer JM, Davies JM, Rynes RI, et al. Every-Other-Week Methotrexate in Patients With Rheumatoid Arthritis. A Double-Blind, Placebo-Controlled Prospective Study. *Arthritis and rheumatism*. 1995;38(5):601-7.
336. Kremer JM, Genovese MC, Cannon GW, et al. Concomitant Leflunomide Therapy in Patients With Active Rheumatoid Arthritis Despite Stable Doses of Methotrexate. A Randomized, Double-Blind, Placebo-Controlled Trial. *Annals of internal medicine*. 2002;137(9):726-33.
337. Kristensen LE, Geborek P, Saxne T. Dose escalation of infliximab therapy in arthritis patients is related to diagnosis and concomitant methotrexate treatment: Observational results from the South Swedish Arthritis Treatment Group register. *Rheumatology*. 2009;48(3):243-5.

338. Krug H, Broadwell L, Berry M, et al. Tolerability and Efficacy of Nabumetone and Naproxen in the Treatment of Rheumatoid Arthritis. *Clinical therapeutics*. 2000;22(1):40-52.
339. Kumar K, Gordon C, Toescu V, et al. Beliefs about medicines in patients with rheumatoid arthritis and systemic lupus erythematosus: A comparison between patients of South Asian and White British origin. *Rheumatology*. 2008;47(5):690-7.
340. Kurowski M, Menninger H, Pauli E. The Efficacy and Relative Bioavailability of Diclofenac Resinate in Rheumatoid Arthritis Patients. *International journal of clinical pharmacology and therapeutics*. 1994;32(8):433-40.
341. Kuuliala A, Leirisalo-Repo M, Mottonen T, et al. Serum Soluble Interleukin-2 Receptor Predicts Early Remission in Patients With Recent-Onset Rheumatoid Arthritis Treated With a Single Disease-Modifying Antirheumatic Drug. *Clinical and experimental rheumatology*. 2005;23(2):243-6.
342. Kvien TK, Gaston JSH, Bardin T, et al. Three Month Treatment of Reactive Arthritis With Azithromycin: a EULAR Double Blind, Placebo Controlled Study. *Annals of the rheumatic diseases*. 2004;63(9):1113-9.
343. Laan RF, van Riel PL, van de Putte LB, et al. Low-Dose Prednisone Induces Rapid Reversible Axial Bone Loss in Patients With Rheumatoid Arthritis. A Randomized, Controlled Study. *Annals of internal medicine*. 1993;119(10):963-8.
344. Laas K, Peltomaa R, Puolakka K, et al. Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice. *Clinical and Experimental Rheumatology* 2009;27(2):315-20.
345. Laasila K, Laasonen L, Leirisalo RM. Antibiotic Treatment and Long Term Prognosis of Reactive Arthritis. *Annals of the rheumatic diseases*. 2003;62(7):655-8.
346. Lacki J, Leszczynski P, Mackiewicz S. Intravenous Cyclophosphamide Combined With Methylprednisolone in the Treatment of Severe Refractory Rheumatoid Arthritis: the Effect on Lymphocytes. *Journal of investigational allergology & clinical immunology : official organ of the International Association of Asthmology (INTERASMA) and Sociedad Latinoamericana de Alergia e Inmunología*. 1996;6(4):232-6.
347. Lacki J, Mackiewicz S, Wiktorowicz K. Lymphocyte Phenotype Studies of Rheumatoid Arthritis Patients Treated With Methotrexate. *Archivum immunologiae et therapiae experimentalis*. 1994;42(4):287-90.
348. Lacki J, Samborski W, Mackiewicz S. Interleukin-10 and Interleukin-6 in Lupus Erythematosus and Rheumatoid Arthritis, Correlations With Acute Phase Proteins. *Clinical rheumatology*. 1997;16(3):275-8.
349. Lacki JK, Schochat T, Sobieska M, et al. Immunological Studies in Patients With Rheumatoid Arthritis Treated With Methotrexate or Cyclophosphamide. *Zeitschrift für Rheumatologie*. 1994;53(2):76-82.
350. Laharie D, Seneschal J, Schaefferbeke T, et al. Assessment of liver fibrosis with transient elastography and FibroTest in patients treated with methotrexate for chronic inflammatory diseases: A case-control study. *Journal of Hepatology*. 2010;53(6):1035-40.
351. Laine L, Connors L, Griffin MR, et al. Prescription rates of protective co-therapy for NSAID users at high GI risk and results of attempts to improve adherence to guidelines. 2009.
352. Laine L, Curtis SP, Cryer B, et al. Assessment of upper gastrointestinal safety of etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. *Lancet*. 2007;369(9560):465-73.

353. Laine L, Curtis SP, Cryer B, et al. Risk factors for NSAID-associated upper GI clinical events in a long-term prospective study of 34 701 arthritis patients. *Alimentary Pharmacology and Therapeutics*. 2010;32(10):1240-8.
354. Laine L, Goldkind L, Curtis SP, et al. How common is diclofenac-associated liver injury? Analysis of 17,289 arthritis patients in a long-term prospective clinical trial. *American Journal of Gastroenterology*. 2009;104(2):356-62.
355. Lambert CM, Sandhu S, Lochhead A, et al. Dose Escalation of Parenteral Methotrexate in Active Rheumatoid Arthritis That Has Been Unresponsive to Conventional Doses of Methotrexate: a Randomized, Controlled Trial. *Arthritis and rheumatism*. 2004;50(2):364-71.
356. Landewe R, Geusens P, van der Heijde D, et al. Arthritis Instantaneously Causes Collagen Type I and Type II Degradation in Patients With Early Rheumatoid Arthritis: a Longitudinal Analysis. *Ann Rheum Dis*. 2006;65(1):40-4.
357. Lard LR, Boers M, Verhoeven A, et al. Early and Aggressive Treatment of Rheumatoid Arthritis Patients Affects the Association of HLA Class II Antigens With Progression of Joint Damage. *Arthritis and rheumatism*. 2002;46(4):899-905.
358. Larsen A, Kvien TK, Schattenkirchner M, et al. Slowing of Disease Progression in Rheumatoid Arthritis Patients During Long-Term Treatment With Leflunomide or Sulfasalazine. *Scandinavian journal of rheumatology*. 2001;30(3):135-42.
359. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. *The New England journal of medicine* 2007(15):1517-26.
360. Lauhio A, Leirisalo Repo M, Lahdevirta J, et al. Double-Blind, Placebo-Controlled Study of Three-Month Treatment With Lymeicycline in Reactive Arthritis, With Special Reference to Chlamydia Arthritis. *Arthritis and rheumatism*. 1991;34(1):6-14.
361. Le Gallez P, Bird H, Wright V. A Comparison of Choline Magnesium Trisalicylate and Acetylsalicylic Acid in Patients With Rheumatoid Arthritis. *Current medical research and opinion*. 1990;12(2):71-5.
362. Lee EY, Lee EB, Park BJ, et al. Tramadol 37.5-mg/acetaminophen 325-mg combination tablets added to regular therapy for rheumatoid arthritis pain: A 1-Week, randomized, double-blind, placebo-controlled trial. *Clinical Therapeutics*. 2006;28(12):2052-60.
363. Lee KKC, You JHS, Ho JTS, et al. Economic Analysis of Celecoxib Versus Diclofenac Plus Omeprazole for the Treatment of Arthritis in Patients at Risk of Ulcer Disease. *Alimentary pharmacology & therapeutics*. 2003;18(2):217-22.
364. Lee VWY, Chan CW, Chan LH, et al. The direct medical cost of rheumatoid arthritis in Hong Kong. *Journal of Medical Economics*. 2007;10(4):443-53.
365. Lehman A, Esdaile J, Klinkhoff A, et al. A 48-Week, Randomized, Double-Blind, Double-Observer, Placebo-Controlled Multicenter Trial of Combination Methotrexate and Intramuscular Gold Therapy in Rheumatoid Arthritis: Results of the Metgo Study. *Arthritis Rheum*. 2005;52(5):1360-70.
366. Lemmel EM. Comparison of Pyritinol and Auranofin in the Treatment of Rheumatoid Arthritis. *British Journal of Rheumatology*. 1993;32(5):375-82.
367. Lemmel EM, Bolten W, Burgos-Vargas R, et al. Efficacy and Safety of Meloxicam in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1997;24(2):282-90.
368. Lerndal T, Svensson B. A Clinical Study of Cph 82 Vs Methotrexate in Early Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2000;39(3):316-20.
369. Levalampi T, Korpela M, Vuolteenaho K, et al. Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: Adverse events and other reasons leading to discontinuation of the treatment. *Rheumatology International*. 2008;28(3):261-9.

370. Leventhal L, Boyce E, Zurier R. Treatment of Rheumatoid Arthritis With Gammalinolenic Acid. *Annals of internal medicine*. 1993;119(9):867-73.
371. Levi S, Goodlad RA, Lee CY, et al. Effects of Nonsteroidal Anti-Inflammatory Drugs and Misoprostol on Gastroduodenal Epithelial Proliferation in Arthritis. *Gastroenterology*. 1992;102(5):1609-11.
372. Lewandowski B, Bernacka K, Kucharewicz B, et al. Assessment of Beta-2-Microglobulin Concentration in Serum and Urine in Rheumatoid Arthritis. *Roczniki Akademii Medycznej w Bia&#322;ymstoku* (1995). 1996;41(2):482-91.
373. Li LC, Maetzel A, Davis AM, et al. Primary therapist model for patients referred for rheumatoid arthritis rehabilitation: A cost-effectiveness analysis. *Arthritis Care and Research*. 2006;55(3):402-10.
374. Li T, Wells G, Westhovens R, et al. Validation of a simple activity participation measure for rheumatoid arthritis clinical trials. *Rheumatology*. 2009;48(2):170-5.
375. Lightfoot R. Comparison of the Efficacy and Safety of Etodolac and Piroxicam in Patients With Rheumatoid Arthritis. Etodolac Study 326 Rheumatoid Arthritis Investigators Group. *The Journal of rheumatology Supplement*. 1997;47:10-6.
376. Lin Q, Gu JR, Li TW, et al. Value of the peripheral blood B-cells subsets in patients with ankylosing spondylitis. 2009.
377. Lin Q, Lin Z, Gu J, et al. Abnormal high-expression of CD154 on T lymphocytes of ankylosing spondylitis patients is down-regulated by etanercept treatment. 2010.
378. Lipsky P, Isakson P. Outcome of Specific Cox-2 Inhibition in Rheumatoid Arthritis. *The Journal of rheumatology Supplement*. 1997;49:9-14.
379. Lisse JR. Clinical Efficacy and Safety of Naprelan Versus Naprosyn in the Treatment of Rheumatoid Arthritis. *The American journal of orthopedics*. 1996;25(9 Suppl):21-9.
380. Litinsky I, Paran D, Levartovsky D, et al. The effects of leflunomide on clinical parameters and serum levels of IL-6, IL-10, MMP-1 and MMP-3 in patients with resistant rheumatoid arthritis. *Cytokine*. 2006;33(2):106-10.
381. Littman B, Drury C, Zimmerer R, et al. Rheumatoid Arthritis Treated With Tenidap and Piroxicam. Clinical Associations With Cytokine Modulation by Tenidap. *Arthritis and rheumatism*. 1995;38(1):29-37.
382. Liu C, Batliwalla F, Li W, et al. Genome-wide association scan identifies candidate polymorphisms associated with differential response to anti-TNF treatment in rheumatoid arthritis. *Molecular Medicine*. 2008;14(9-10):575-81.
383. Lonauer G, Tisscher J, Lim H, et al. Double-Blind Comparison of Etodolac and Diclofenac in Patients With Rheumatoid Arthritis. *Current medical research and opinion*. 1993;13(2):70-7.
384. Lopez-Gonzalez R, Hernandez-Garcia C, Abasolo L, et al. Differences between rheumatology attending physicians and training residents in the management of rheumatoid arthritis in Spain. *Scandinavian Journal of Rheumatology*. 2008;37(6):419-26.
385. Lopez-Mendez A, Daniel WW, Reading JC, et al. Radiographic Assessment of Disease Progression in Rheumatoid Arthritis Patients Enrolled in the Cooperative Systematic Studies of the Rheumatic Diseases Program Randomized Clinical Trial of Methotrexate, Auranofin, or a Combination of the Two. *Arthritis and rheumatism*. 1993;36(10):1364-9.
386. Louly PG, Medeiros-Souza P, Santos-Neto L. N-of-1 double-blind, randomized controlled trial of tramadol to treat chronic cough. 2009.
387. Lu C, Zha Q, Chang A, et al. Pattern differentiation in traditional chinese medicine can help define specific indications for biomedical therapy in the treatment of rheumatoid arthritis. 2009.



388. Luis M, Pacheco-Tena C, Cazarin-Barrientos J, et al. Comparison of Two Schedules for Administering Oral Low-Dose Methotrexate (Weekly Versus Every-Other-Week) in Patients With Rheumatoid Arthritis in Remission: a Twenty-Four Week, Single Blind, Randomized Study. *Arthritis and rheumatism*. 1999;42(10):2160-5.
389. Maccagno A, Di Giorgio E, Roldan E, et al. Double Blind Radiological Assessment of Continuous Oral Pamidronic Acid in Patients With Rheumatoid Arthritis. *Scandinavian journal of rheumatology*. 1994;23(4):211-4.
390. Machold K, Neumann K, Smolen J. Recombinant Human Interferon Gamma in the Treatment of Rheumatoid Arthritis: Double Blind Placebo Controlled Study. *Annals of the rheumatic diseases*. 1992;51(9):1039-43.
391. Machold KP, Landewe R, Smolen JS, et al. The Stop Arthritis Very Early (SAVE) trial, an international multicentre, randomised, double-blind, placebo-controlled trial on glucocorticoids in very early arthritis. *Annals of the rheumatic diseases*. 2010;69(3):495-502.
392. Maetzel A, Strand V, Tugwell P, et al. Economic Comparison of Leflunomide and Methotrexate in Patients With Rheumatoid Arthritis: an Evaluation Based on a 1-Year Randomised Controlled Trial. *PharmacoEconomics*. 2002;20(1):61-70.
393. Maillefert JF, Combe B, Goupille P, et al. Long Term Structural Effects of Combination Therapy in Patients With Early Rheumatoid Arthritis: Five Year Follow up of a Prospective Double Blind Controlled Study. *Annals of the rheumatic diseases*. 2003;62(8):764-6.
394. Maksymowych WP, Salonen D, Inman RD, et al. Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: A randomized placebo-controlled study. *Journal of Rheumatology*. 2010;37(8):1728-34.
395. Manorot M, Rojanasathien N, Louthrenoo W, et al. Comparative Studies of Quality and Bioavailability of Methotrexate in Thai Patients With Rheumatoid Arthritis. *Journal of the Medical Association of Thailand = Chotmaihet thangphaet*. 1998;81(12):978-85.
396. Mariette X, Tubach F, Bagheri H, et al. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. *Annals of the rheumatic diseases* 2010;69(2):400-8.
397. Marshall D, Hunter J, Capell H. Double Blind, Placebo Controlled Study of Metronidazole as a Disease Modifying Agent in the Treatment of Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 1992;51(6):758-60.
398. Martens H, Sheets P, Tenover J, et al. Decreased Testosterone Levels in Men With Rheumatoid Arthritis: Effect of Low Dose Prednisone Therapy. *The Journal of rheumatology*. 1994;21(8):1427=31.
399. Martin Mola E, Gijon Banos J, Ansoleaga J. Aceclofenac in Comparison to Ketoprofen in the Treatment of Rheumatoid Arthritis. *Rheumatology international*. 1995;15(3):111-6.
400. Matsumoto AK, Melian A, Mandel DR, et al. A Randomized, Controlled, Clinical Trial of Etoricoxib in the Treatment of Rheumatoid Arthritis. *The Journal of rheumatology*. 2002;29(8):1623-30.
401. Matsuno H, Yudoh K, Kondo M, et al. Biochemical Effect of Intra-Articular Injections of High Molecular Weight Hyaluronate in Rheumatoid Arthritis Patients. *Inflammation research : official journal of the European Histamine Research Society [et al]*. 1999;48(3):154-9.
402. Matteson EL, Yocum DE, St Clair EW, et al. Treatment of Active Refractory Rheumatoid Arthritis With Humanized Monoclonal Antibody Campath-1h Administered by Daily Subcutaneous Injection. *Arthritis and rheumatism*. 1995;38(9):1187-93.

403. Mayo P, Skeith K, Russell A, et al. Decreased Dromotropic Response to Verapamil Despite Pronounced Increased Drug Concentration in Rheumatoid Arthritis. *British journal of clinical pharmacology*. 2000;50(6):605-13.
404. Mazzantini M, Di Munno O, Metelli M, et al. Single Infusion of Neridronate (6-Amino-1-Hydroxyhexylidene-1,1-Bisphosphonate) in Patients With Active Rheumatoid Arthritis: Effects on Disease Activity and Bone Resorption Markers. *Aging Clin Exp Res*. 2002;14(3):197-201.
405. McCarey DW, McInnes IB, Madhok R, et al. Trial of Atorvastatin in Rheumatoid Arthritis (Tara): Double-Blind, Randomised Placebo-Controlled Trial. *Lancet*. 2004;262(9426):2015-21.
406. Mcgee B, Small RE, Singh R, et al. B Lymphocytic Clonal Expansion in Rheumatoid Arthritis. *The Journal of rheumatology*. 1996;23(1):36-43.
407. McInnes I, Porter D, Murphy E, et al. Low Dose Desensitisation Does Not Reduce the Toxicity of Sulphasalazine in Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 1996;55(5):328-30.
408. McKendry R, Kraag G, Seigel S, et al. Therapeutic Value of Colchicine in the Treatment of Patients With Psoriatic Arthritis. *Annals of the rheumatic diseases*. 1993;52(11):826-8.
409. McKendry RJ. Azathioprine and Methotrexate as Combination Chemotherapy in Rheumatoid Arthritis. *The Journal of rheumatology Supplement*. 1990;25:28-33.
410. McLachlan A, Tett S, Cutler D, et al. Disposition of the Enantiomers of Hydroxychloroquine in Patients With Rheumatoid Arthritis Following Multiple Doses of the Racemate. *British journal of clinical pharmacology*. 1993;36(1):78-81.
411. McLachlan A, Tett S, Cutler D, et al. Bioavailability of Hydroxychloroquine Tablets in Patients With Rheumatoid Arthritis. *British journal of rheumatology*. 1994;33(3):235-9.
412. Mease PJ. Cytokine Blockers in Psoriatic Arthritis. *Annals of the rheumatic diseases*. 2001;60(Suppl 3):iii37-40.
413. Mease PJ, Hobbs K, Chalmers A, et al. Local delivery of a recombinant adenoassociated vector containing a tumour necrosis factor alpha antagonist gene in inflammatory arthritis: A phase 1 dose-escalation safety and tolerability study. 2009.
414. Mease PJ, Signorovitch J, Yu AP, et al. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: A pooled analysis of randomized clinical trials. *Dermatology*. 2010;220(1):1-7.
415. Mease PJ, Wei N, Fudman EJ, et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: Results of a phase 1/2 study. *Journal of Rheumatology*. 2010;37(4):692-703.
416. Mehta S, Dasarathy S, Tandon R, et al. A Prospective Randomized Study of the Injurious Effects of Aspirin and Naproxen on the Gastroduodenal Mucosa in Patients With Rheumatoid Arthritis. *The American journal of gastroenterology*. 1992;87(8):996-1000.
417. Meineke I, Turck D. Population Pharmacokinetic Analysis of Meloxicam in Rheumatoid Arthritis Patients. *British journal of clinical pharmacology*. 2003;55(1):32-8.
418. Melikterminas E, Ranganath V, Furst DE. Treatment of the elderly rheumatoid arthritis patient. *Future Rheumatology*. 2008;3(3):235-8.
419. Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. *J Am Acad Dermatol*. 2007 Jan;56(1):31 e1-15.
420. Merkel PA, Dooley MA, Dawson DV, et al. Interleukin-2 Receptor Levels in Sera of Patients With Rheumatoid Arthritis Treated With Sulfasalazine, Parenteral Gold, or Placebo. *The Journal of rheumatology*. 1996;23(11):1856-61.

421. Michaels R, Reading J, Beezhold D, et al. Serum Phospholipase A2 Activity in Patients With Rheumatoid Arthritis Before and After Treatment With Methotrexate, Auranofin, or Combination of the Two. *Journal of Rheumatology*. 1996;23(2):226-9.
422. Mierau M, Schoels M, Gonda G, et al. Assessing remission in clinical practice. *Rheumatology*. 2007;46(6):975-9.
423. Miese FR, Ostendorf B, Wittsack HJ, et al. Metacarpophalangeal joints in rheumatoid arthritis: Delayed gadolinium-enhanced MR imaging of cartilage - A feasibility study. *Radiology*. 2010;257(2):441-7.
424. Miyake K, Kusunoki M, Shinji Y, et al. Bisphosphonate increases risk of gastroduodenal ulcer in rheumatoid arthritis patients on long-term nonsteroidal antiinflammatory drug therapy. *Journal of Gastroenterology*. 2009;44(2):113-20.
425. Miyake K, Ueki N, Suzuki K, et al. Preventive Therapy for Non-Steroidal Anti-Inflammatory Drug-Induced Ulcers in Japanese Patients With Rheumatoid Arthritis: the Current Situation and a Prospective Controlled-Study of the Preventive Effects of Lansoprazole or Famotidine. *Alimentary pharmacology & therapeutics*. 2005;21(Suppl 2):67-72.
426. Miyamoto S, Kageyama Y, Ozeki T, et al. Effects of Glucocorticoids on Bone Mineral Density in Rheumatoid Arthritis Patients. A Longitudinal Study. *Archives of orthopaedic and trauma surgery*. 1999;199(1-2):18-21.
427. Mladenovic V, Domljan Z, Rozman B, et al. Safety and Effectiveness of Leflunomide in the Treatment of Patients With Active Rheumatoid Arthritis. Results of a Randomized, Placebo-Controlled, Phase II Study. *Arthritis and rheumatism*. 1995;38(11):1595-603.
428. Montrone F, Petrillo M, Caruso I, et al. A Comparison of Severe Gastric Damage as a Result of Pirprofen and Naproxen Treatment in Rheumatoid Arthritis: a Controlled Endoscopic Study. *Journal of internal medicine*. 1994;236(2):153-9.
429. Moore A, Gordon KB, Kang S, et al. A randomized, open-label trial of continuous versus interrupted etanercept therapy in the treatment of psoriasis. *Journal of the American Academy of Dermatology* 2007(4):598-603.
430. Moreland L, R G, King K, et al. Results of a Phase-I/II Randomized, Masked, Placebo-Controlled Trial of Recombinant Human Interleukin-11 (Rhil-11) in the Treatment of Subjects With Active Rheumatoid Arthritis. *Arthritis Res*. 2001;3(4):247-52.
431. Moreland LW. Disease modifiers: Making the right therapeutic choices for our patients. *Journal of Rheumatology*. 2007;34(SUPPL. 79):21-6.
432. Moreland LW, Pratt PW, Mayes MD, et al. Double-Blind, Placebo-Controlled Multicenter Trial Using Chimeric Monoclonal Anti-Cd4 Antibody, Cm-T412, in Rheumatoid Arthritis Patients Receiving Concomitant Methotrexate. *Arthritis and rheumatism*. 1995;38(11):1581-8.
433. Morgan AW, Hale G, Rebello PRUB, et al. A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. *Qjm*. 2008;101(4):299-306.
434. Morris V, Cruwys S, Kidd B. Characterisation of Capsaicin-Induced Mechanical Hyperalgesia as a Marker for Altered Nociceptive Processing in Patients With Rheumatoid Arthritis. *Pain*. 1997;71(2):179-86.
435. Mottonen T, Hannonen P, Korpela M, et al. Delay to Institution of Therapy and Induction of Remission Using Single-Drug or Combination-Disease-Modifying Antirheumatic Drug Therapy in Early Rheumatoid Arthritis. *Arthritis Rheum*. 2002;46(4):894-8.
436. Mottonen T, Hannonen P, Leirisalo-Repo M, et al. Comparison of Combination Therapy With Single-Drug Therapy in Early Rheumatoid Arthritis: a Randomised Trial. *Lancet*. 1999;353(9164):1568-73.

437. Mould DR, Davis CB, Minthorn EA, et al. A Population Pharmacokinetic-Pharmacodynamic Analysis of Single Doses of Clenoliximab in Patients With Rheumatoid Arthritis. *Clinical pharmacology and therapeutics*. 1999;66(3):246-57.
438. Muller Fassbender HR. A 6-Month Randomized Dose Range Study of Om-8980 in Rheumatoid Arthritis. *Br J Rheumatol*. 1993;32(8):746-50.
439. Muller-Ladner U, Rockwitz K, Brandt-Jurgens J, et al. Tolerability and patient/physician satisfaction with subcutaneously administered methotrexate provided in two formulations of different drug concentrations in patients with rheumatoid arthritis. *Open Rheumatology Journal*. 2010;4:15-22.
440. Mur E, Hartig F, Eibl G, et al. Randomized Double Blind Trial of an Extract From the Pentacyclic Alkaloid-Chemotype of *Uncaria Tomentosa* for the Treatment of Rheumatoid Arthritis. *The Journal of rheumatology*. 2002;29(4):678-81.
441. Nagafuchi H, Suzuki N, Kaneko A, et al. Prolactin Locally Produced by Synovium Infiltrating T Lymphocytes Induces Excessive Synovial Cell Functions in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1999;26(9):1890-900.
442. Nair R, Saag KG. The use of low-dose glucocorticoids for the treatment of early rheumatoid arthritis: What can we learn about bone effects of glucocorticoids from randomized controlled trials? *Current Rheumatology Reports*. 2006;8(1):47-8.
443. Nakamura H, Ueki Y, Sakito S, et al. Clinical Effects of Actarit in Rheumatoid Arthritis: Improvement of Early Disease Activity Mediated by Reduction of Serum Concentrations of Nitric Oxide. *Clinical and experimental rheumatology*. 2000;18(4):455-50.
444. Naredo E, Collado P, Cruz A, et al. Longitudinal power Doppler ultrasonographic assessment of joint inflammatory activity in early rheumatoid arthritis: Predictive value in disease activity and radiologic progression. *Arthritis Care and Research*. 2007;57(1):116-24.
445. Nehring AK, Dua U, Mollee P, et al. Epstein-Barr virus T-cell immunity despite rituximab. *British journal of haematology* 2007(4):628-32.
446. Nieto-Colonia AM, Santos WS, Kuesseyan SP, et al. Antibodies to citrullinated peptides are not associated with the rate of joint destruction in patients with a well-established diagnosis of rheumatoid arthritis. *Brazilian Journal of Medical and Biological Research*. 2008;41(3):188-92.
447. Nikolaisen C, Figenschau Y, Nossent JC. Anemia in early rheumatoid arthritis is associated with interleukin 6-mediated bone marrow suppression, but has no effect on disease course or mortality. *Journal of Rheumatology*. 2008;35(3):380-6.
448. Nisar M, Carlisle L, Amos R. Methotrexate and Sulphasalazine as Combination Therapy in Rheumatoid Arthritis. *British journal of rheumatology*. 1994;33(7):651-4.
449. Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study. 2009.
450. Nishimoto N, Yoshizaki K, Miyasaka N, et al. Treatment of Rheumatoid Arthritis With Humanized Anti-Interleukin-6 Receptor Antibody: a Multicenter, Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 2004;50(6):1761-9.
451. Nived O, Sturfelt G, Eckernas S, et al. A Comparison of 6 Months' Compliance of Patients With Rheumatoid Arthritis Treated With Tenoxicam and Naproxen. Use of Patient Computer Data to Assess Response to Treatment. *The Journal of rheumatology*. 1994;21(8):1537-41.
452. Nobunaga M, Yasuda M. Comparison of Clinical Effects of Bucillamine Between Additive Combination and Single Administration Study in Rheumatoid Arthritis. *Agents and actions Supplements*. 1993;44:105-9.
453. Nomura T, Kodama K, Nishimura M, et al. Animation as a useful tool for assessing functional status in psoriatic arthritis. *Journal of Dermatological Science*. 2006;44(3):172-4.

454. Nourmohammadi I, Athari-Nikazm S, Vafa MR, et al. Effects of antioxidant supplementations on oxidative stress in rheumatoid arthritis patients. *Journal of Biological Sciences*. 2010;10(1):63-6.
455. Numo R. Multicentre Double-Blind Study of the Efficacy, Safety and Tolerance of Pirazolac Compared With Sulindac in Patients With Rheumatoid Arthritis. *Drugs under experimental and clinical research*. 1990;16(1):17-27.
456. Nunez M, Nunez E, Yoldi C, et al. Health-related quality of life in rheumatoid arthritis: Therapeutic education plus pharmacological treatment versus pharmacological treatment only. *Rheumatology International*. 2006;26(8):752-7.
457. Ochi T, Hakomori S, Fujimoto M, et al. Therapeutic Effect of Intradermal Injections With Difucosyl Lactosamine (Dimeric Lex) on Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1993;20(12):2038-45.
458. O'Connor K, Burke R, Riminton S. Hospital supply of off-label immunomodulatory drugs. 2009.
459. O'Dell JR, Blakely KW, Mallek JA, et al. Treatment of Early Seropositive Rheumatoid Arthritis: a Two-Year, Double-Blind Comparison of Minocycline and Hydroxychloroquine. *Arthritis and rheumatism*. 2001;44(10):2235-41.
460. O'Dell JR, Leff R, Paulsen G, et al. Treatment of Rheumatoid Arthritis With Methotrexate and Hydroxychloroquine, Methotrexate and Sulfasalazine, or a Combination of the Three Medications: Results of a Two-Year, Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 2002;46(5):1164-70.
461. O'Dell JR, Paulsen G, Haire CE, et al. Treatment of Early Seropositive Rheumatoid Arthritis With Minocycline: Four-Year Followup of a Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 1999;42(8):1691-5.
462. Odio C, Ramirez T, Arias G, et al. Double Blind, Randomized, Placebo-Controlled Study of Dexamethasone Therapy for Hematogenous Septic Arthritis in Children. *The Pediatric infectious disease journal*. 2003;22(10):883-8.
463. Ogrendik M. Treatment of rheumatoid arthritis with ornidazole: A randomized, double-blind, placebo-controlled study. *Rheumatology International*. 2006;26(12):1132-7.
464. Ollendorf DA, Klingman D, Hazard E, et al. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. *Clinical Therapeutics*. 2009;31(4):825-35.
465. Olsen N, Teal G, Brooks R. IgM-Rheumatoid Factor and Responses to Second-Line Drugs in Rheumatoid Arthritis. *Agents and actions*. 1991;34(1-2):124-9.
466. Olsen NJ, Brooks RH, Cush JJ, et al. A Double-Blind, Placebo-Controlled Study of Anti-Cd5 Immunoconjugate in Patients With Rheumatoid Arthritis. *Arthritis and rheumatism*. 1996;39(7):1102-8.
467. Osiri M, Deesomchok U, Tugwell P. Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice. *Clinical Rheumatology* 2006;25(5):721-7.
468. Osterhaus JT, Purcaru O, Richard L. Discriminant validity, responsiveness and reliability of the rheumatoid arthritis-specific Work Productivity Survey (WPS-RA). 2009.
469. Paleolog E, Young S, Stark A, et al. Modulation of Angiogenic Vascular Endothelial Growth Factor by Tumor Necrosis Factor Alpha and Interleukin-1 in Rheumatoid Arthritis. *Arthritis and rheumatism*. 1998;41(7):1258-65.
470. Paleolog EM, Hunt M, Elliott MJ, et al. Deactivation of Vascular Endothelium by Monoclonal Anti-Tumor Necrosis Factor Alpha Antibody in Rheumatoid Arthritis. *Arthritis and rheumatism*. 1996;39(7):1082-91.

471. Palosaari K, Vuotila J, Takalo R, et al. Bone oedema predicts erosive progression on wrist MRI in early RA - A 2-yr observational MRI and NC scintigraphy study. *Rheumatology*. 2006;45(12):1542-8.
472. Pandya S, Aggarwal A, Misra R. Methotrexate Twice Weekly Vs Once Weekly in Rheumatoid Arthritis: a Pilot Double-Blind, Controlled Study. *Rheumatology international*. 2002;22(1):1-4.
473. Panicheeva S, Ngsriwongse S, Mokkhavea C, et al. Original Versus Generic Piroxicams, Their Cost-Effective Evaluation in Rheumatoid Arthritis (Ra) Patients. *Journal of the Medical Association of Thailand = Chotmaihet thangphaet*. 1992;75(2):104-9.
474. Park JY, Kim KA, Lee YH, et al. Pharmacokinetic comparison and bioequivalence of two leflunomide formulations in humans: A single dose, randomized, open-label, two-way crossover study. *International Journal of Clinical Pharmacology and Therapeutics*. 2010;48(4):291-5.
475. Pascual-Ramos V, Contreras-Yanez I, Villa AR, et al. Medication persistence over 2 years of follow-up in a cohort of early rheumatoid arthritis patients: Associated factors and relationship with disease activity and with disability. *Arthritis Research and Therapy*. 2009;11(1).
476. Pasero G, Marcolongo R, Serni U, et al. A Multi-Centre, Double-Blind Comparative Study of the Efficacy and Safety of Aceclofenac and Diclofenac in the Treatment of Rheumatoid Arthritis. *Current medical research and opinion*. 1995;13(6):305-15.
477. Paul BJ, Thachil EJ, Jayachandran NV, et al. Clinical efficacy and adverse effects of weekly single dose leflunomide in refractory rheumatoid arthritis. *Indian Journal of Rheumatology*. 2007;2(1):3-7.
478. Paulus H, Egger M, Ward J, et al. Analysis of Improvement in Individual Rheumatoid Arthritis Patients Treated With Disease-Modifying Antirheumatic Drugs, Based on the Findings in Patients Treated With Placebo. The Cooperative Systematic Studies of Rheumatic Diseases Group. *Arthritis and rheumatism*. 1990;33(4):477-84.
479. Pavelka K, Jarosova K, Suchy D, et al. Increasing the infliximab dose in rheumatoid arthritis patients: A randomised, double blind study failed to confirm its efficacy. 2009.
480. Pavelka K, Recker D, Verburg K. Valdecoxib Is as Effective as Diclofenac in the Management of Rheumatoid Arthritis With a Lower Incidence of Gastrointestinal Ulcers: Results of a 26-Week Trial. *Rheumatology (Oxford)*. 2003;42(10):1207-15.
481. Pease C, Pope JE, Thorne C, et al. Canadian variation by province in rheumatoid arthritis initiating anti-tumor necrosis factor therapy: Results from the optimization of adalimumab trial. *Journal of Rheumatology*. 2010;37(12):2469-74.
482. Peeters HR, Jongen-Lavrencic M, Bakker CH, et al. Recombinant Human Erythropoietin Improves Health-Related Quality of Life in Patients With Rheumatoid Arthritis and Anaemia of Chronic Disease; Utility Measures Correlate Strongly With Disease Activity Measures. *Rheumatology international*. 1999;18(5-6):201-6.
483. Peeters HR, Jongen-Lavrencic M, Vreugdenhil G, et al. Effect of Recombinant Human Erythropoietin on Anaemia and Disease Activity in Patients With Rheumatoid Arthritis and Anaemia of Chronic Disease: a Randomised Placebo Controlled Double Blind 52 Weeks Clinical Trial. *Annals of the rheumatic diseases*. 1996;55(10):739-44.
484. Peltomaa R, Paimela L, Helve T, et al. Comparison of Intramuscular Gold and Sulphasalazine in the Treatment of Early Rheumatoid Arthritis. A One Year Prospective Study. *Scandinavian journal of rheumatology*. 1995;24(6):330-5.

485. Pentek M, Kobelt G, Czirjak L, et al. Costs of rheumatoid arthritis in Hungary. *Journal of Rheumatology*. 2007;34(6):1437-9.
486. Peretz A, Siderova V, Neve J. Selenium Supplementation in Rheumatoid Arthritis Investigated in a Double Blind, Placebo-Controlled Trial. *Scandinavian journal of rheumatology*. 2001;30(4):208-12.
487. Perez Ruiz F, Alonso Ruiz A, Ansoleaga J. Comparative Study of the Efficacy and Safety of Aceclofenac and Tenoxicam in Rheumatoid Arthritis. *Clinical rheumatology*. 1996;15(5):473-7.
488. Pettersson T, Soderblom T, Nyberg P, et al. Pleural Fluid Soluble Interleukin 2 Receptor in Rheumatoid Arthritis and Systemic Lupus Erythematosus. *The Journal of rheumatology*. 1994;21(10):1820-4.
489. Pincus T, Swearingen CJ, Luta G, et al. Efficacy of prednisone 1-4 mg/day in patients with rheumatoid arthritis: A randomised, double-blind, placebo controlled withdrawal clinical trial. 2009.
490. Pisoni L, Murgio A, Paresce E, et al. Effectiveness and safety of leflunomide in the clinical practice. A different experience [1]. *Clinical and Experimental Rheumatology*. 2007;25(1).
491. Plant M, O'Sullivan MM, Lewis P, et al. What Factors Influence Functional Ability in Patients With Rheumatoid Arthritis. Do They Alter Over Time? *Rheumatology (Oxford)*. 2005;44(9):1181-5.
492. Plant MJ, Williams AL, O'Sullivan MM, et al. Relationship Between Time-Integrated C-Reactive Protein Levels and Radiologic Progression in Patients With Rheumatoid Arthritis. *Arthritis and rheumatism*. 2000;43(7):1473-7.
493. Podas T, Nightingale JMD, Oldham R, et al. Is rheumatoid arthritis a disease that starts in the intestine? A pilot study comparing an elemental diet with oral prednisolone. *Postgraduate Medical Journal*. 2007;83(976):128-31.
494. Polisson RP, Dooley MA, Dawson DV, et al. Interleukin-2 Receptor Levels in the Sera of Rheumatoid Arthritis Patients Treated With Methotrexate. *Arthritis and rheumatism*. 1994;37(1):50-6.
495. Popp W, Rauscher H, Ritschka L, et al. Prediction of Interstitial Lung Involvement in Rheumatoid Arthritis; the Value of Clinical Data, Chest Roentgenogram, Lung Function, and Serologic Parameters. *CHEST*. 1992;102(2):391-4.
496. Porter D, Capell H. The 'natural' History of Active Rheumatoid Arthritis Over 3-6 Months--an Analysis of Patients Enrolled Into Trials of Potential Disease-Modifying Anti-Rheumatic Drugs, and Treated With Placebo. *British journal of rheumatology*. 1993;32(6):423-8.
497. Porter D, Madhok R, Hunter J, et al. Prospective Trial Comparing the Use of Sulphasalazine and Auranofin as Second Line Drugs in Patients With Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 1992;52(6):416-4.
498. Porter D, McInnes I, Hunter J, et al. Outcome of second line therapy in rheumatoid arthritis. *Annals of the rheumatic diseases*. 1994;53(12):812-5.
499. Prins AMA, Vos K, Franssen EJF. Instability of topical ciclosporin emulsion for nail psoriasis [4]. *Dermatology*. 2007;215(4):362-3.
500. Prochorec-Sobieszek M, Chelstowska M, Rymkiewicz G, et al. Biclinal T-cell receptor gammadelta+ large granular lymphocyte leukemia associated with rheumatoid arthritis. *Leukemia and Lymphoma*. 2008;49(4):828-31.
501. Pullerits R, D'Elia HF, Tarkowski A, et al. The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: A randomized controlled trial. 2009.
502. Puolakka K, Kautiainen H, Mottonen T, et al. Early Suppression of Disease Activity Is Essential for Maintenance of Work Capacity in Patients With Recent-Onset Rheumatoid Arthritis: Five-Year Experience From the Fin-Raco Trial. *Arthritis and rheumatism*. 2005;52(1):36-41.

503. Puolakka K, Kautiainen H, Mottonen T, et al. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis. *Scandinavian Journal of Rheumatology*. 2009;38(2):96-103.
504. Puolakka K, Kautiainen H, Mottonen T, et al. Impact of Initial Aggressive Drug Treatment With a Combination of Disease-Modifying Antirheumatic Drugs on the Development of Work Disability in Early Rheumatoid Arthritis: a Five-Year Randomized Followup Trial. *Arthritis and rheumatism*. 2004;50(1):55-62.
505. Puri S, Bery A, Sekhon JS, et al. Prescription practices of general physicians in the treatment of rheumatoid arthritis. *Indian Journal of Rheumatology*. 2008;3(2):86-7.
506. Rao U, Naidu M, Kumar T, et al. Comparison of Phenytoin With Auranofin and Chloroquine in Rheumatoid Arthritis--a Double Blind Study. *The Journal of rheumatology*. 1995;22(7):1235-40.
507. Raspe H, Deck R, Mattussek S. The Outcome of Traditional or Comprehensive Outpatient Care for Rheumatoid Arthritis (Ra). Results of an Open, Non-Randomized, 2-Year Prospective Study. *Zeitschrift für Rheumatologie*. 1992;51(Suppl 1):61-6.
508. Rau R, Herborn G, Karger T, et al. A Double-Blind Comparison of Parenteral Methotrexate and Parenteral Gold in the Treatment of Early Erosive Rheumatoid Arthritis: an Interim Report on 102 Patients After 12 Months. *Seminars in arthritis and rheumatism*. 1991;21(2 Suppl 1):13-30.
509. Rau R, Herborn G, Menninger H, et al. Comparison of Intramuscular Methotrexate and Gold Sodium Thiomalate in the Treatment of Early Erosive Rheumatoid Arthritis: 12 Month Data of a Double-Blind Parallel Study of 174 Patients. *British journal of rheumatology*. 1997;36(3):345-52.
510. Rau R, Herborn G, Menninger H, et al. Progression in Early Erosive Rheumatoid Arthritis: 12 Month Results From a Randomized Controlled Trial Comparing Methotrexate and Gold Sodium Thiomalate. *British journal of rheumatology*. 1998;37(11):1220-6.
511. Rau R, Wassenberg S, Zeidler H. Low Dose Prednisolone Therapy (LDPT) Retards Radiographically Detectable Destruction in Early Rheumatoid Arthritis--Preliminary Results of a Multicenter, Randomized, Parallel, Double Blind Study. *Zeitschrift für Rheumatologie*. 2000;59(Suppl 2):II/90-6.
512. Reece RJ, Kraan MC, Radjenovic A, et al. Comparative Assessment of Leflunomide and Methotrexate for the Treatment of Rheumatoid Arthritis, by Dynamic Enhanced Magnetic Resonance Imaging. *Arthritis and rheumatism*. 2002;46(2):366-72.
513. Reginster J, Distel M, Bluhmki E. A Double-Blind, Three-Week Study to Compare the Efficacy and Safety of Meloxicam 7.5 Mg and Meloxicam 15 Mg in Patients With Rheumatoid Arthritis. *British journal of rheumatology*. 1996;35(Suppl 1):17-21.
514. Rell Bakalarska M, Filipowicz Sosnowska A, Garwolinska H, et al. Assessment of the Results of Combined Treatment With Cyclophosphamide and Prednisone or Methotrexate and Prednisone in Patients With Rheumatoid Arthritis With Concomitant Vasculitis. *Reumatologia*. 1998;36(1):15-22.
515. Rheumatoid Arthritis Clinical Trial Archive Group. The Effect of Age and Renal Function on the Efficacy and Toxicity of Methotrexate in Rheumatoid Arthritis. *J Rheumatol*. 1995;22(2):218-23.
516. Rigopoulos D, Gregoriou S, Lazaridou E, et al. Treatment of nail psoriasis with adalimumab: An open label unblinded study: ORIGINAL ARTICLE. *Journal of the European Academy of Dermatology and Venereology*. 2010;24(5):530-4.
517. Robak T, Gladalska A, Stepień H. The Tumour Necrosis Factor Family of Receptors/Ligands in the Serum of Patients With Rheumatoid Arthritis. *European cytokine network*. 1998;9(2):145-54.



518. Robinson AJ, Taylor DH, Wright GD. Infliximab therapy reduces periodontoid rheumatoid pannus formation [5]. *Rheumatology*. 2008;47(2):225-6.
519. Rodriguez de la Serna A, Geli Ferrer C, Diaz Lopez C, et al. Comparative Double-Blind Study of Droxicam (New Nsaid) Versus Indomethacin in Rheumatoid Arthritis. *European journal of rheumatology and inflammation*. 1991;11(4):35-44.
520. Rozman B. Clinical Experience With Leflunomide in Rheumatoid Arthritis. *The Journal of rheumatology*. 1998;52(Suppl):27-32.
521. Rubbert-Roth A, Tak PP, Zerbini C, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a Phase III randomized study (MIRROR). *Rheumatology*. 2010;49(9):1683-93.
522. Russell AS, Wallenstein GV, Li T, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. *Ann Rheum Dis*. 2007 Feb;66(2):189-94.
523. Sacerdote P, Carrabba M, Galante A, et al. Plasma and Synovial Fluid Interleukin-1, Interleukin-6 and Substance P Concentrations in Rheumatoid Arthritis Patients: Effect of the Nonsteroidal Anti Inflammatory Drugs Indomethacin, Diclofenac and Naproxen. *Inflammation research : official journal of the European Histamine Research Society [et al]*. 1995;44(11):486-90.
524. Salaffi F, Filippucci E, Carotti M, et al. Inter-observer agreement of standard joint counts in early rheumatoid arthritis: A comparison with grey scale ultrasonography - A preliminary study. *Rheumatology*. 2008;47(1):54-8.
525. Salemi S, Picchianti-Diamanti A, Germano V, et al. Influenza vaccine administration in rheumatoid arthritis patients under treatment with TNF(alpha) blockers: Safety and immunogenicity. *Clinical Immunology*. 2010;134(2):113-20.
526. Salvarani C, Macchioni P, Manzini C, et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica: a randomized trial. *Annals of internal medicine* 2007(9):631-9.
527. Sanchez Andrada S, Rodriguez Valverde V. A Double-Blind Randomised Controlled Trial of Droxicam Versus Indomethacin in Rheumatoid Arthritis. *European journal of rheumatology and inflammation*. 1991;11(4):35-44.
528. Sander O, Rau R. Treatment of Refractory Rheumatoid Arthritis With a Tumor Necrosis Factor Alpha Receptor Fusion Protein (Tnfr 55-Igg1) - a Monocentric Observation in 80 Patients. *Zeitschrift fur Rheumatologie*. 1998;57(5):307-11.
529. Sands BE, Kozarek R, Spainhour J, et al. Safety and tolerability of concurrent natalizumab treatment for patients with Crohn's disease not in remission while receiving infliximab. *Inflammatory bowel diseases* 2007(1):2-11.
530. Sany J, Anaya JM, Canovas F, et al. Influence of Methotrexate on the Frequency of Postoperative Infectious Complications in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1993;20(7):1129-32.
531. Sarzi Puttini P, Santandrea S, Boccassini L, et al. The Role of Nsaids in Psoriatic Arthritis: Evidence From a Controlled Study With Nimesulide. *Clinical and experimental rheumatology*. 2001;19(1 Suppl 22):S17-20.
532. Sasso E, Merrill C, Furst T. Immunoglobulin Binding Properties of the ProSORBA Immunoadsorption Column in Treatment of Rheumatoid Arthritis. *Ther Apher*. 2001;5(2):84-91.
533. Saul P, Korlipara K. Acemetacin and Indomethacin in the Treatment of Rheumatoid Arthritis: a Double-Blind Comparative Study in General Practice. *Current medical research and opinion*. 1991;12(5):332-41.
534. Savolainen E, Kautiainen H, Koivula MK, et al. Change of diagnoses and outcome of patients with early inflammatory joint diseases during a mean 13-month follow-up. *Scandinavian Journal of Rheumatology*. 2007;36(3):194-7.

535. Schattenkirchner M. Double-Blind Comparison of Etodolac and Piroxicam in Patients With Rheumatoid Arthritis. *Curr Med Res Opin.* 1991;12(8):497-506.
536. Scheel AK, Hermann KGA, Ohrndorf S, et al. Prospective 7 year follow up imaging study comparing radiography, ultrasonography, and magnetic resonance imaging in rheumatoid arthritis finger joints. *Annals of the Rheumatic Diseases.* 2006;65(5):595-600.
537. Schiff MH. Role of Interleukin 1 and Interleukin 1 Receptor Antagonist in the Mediation of Rheumatoid Arthritis. *Ann Rheum Dis.* 2000;59(Suppl 1):i103-8.
538. Schirmer M, Mur E, Pfeiffer K, et al. The Safety Profile of Low-Dose Cladribine in Refractory Rheumatoid Arthritis. A Pilot Trial. *Scandinavian journal of rheumatology.* 1997;26(5):376-9.
539. Schlumpf U, Hofmann P. Comparison of Medium- and High-Dose Methylprednisolone Pulse Therapy in Rheumatoid Arthritis. *Zeitschrift fur Rheumatologie.* 1990;49(3):160-4.
540. Schmajuk G, Schneeweiss S, Katz JN, et al. Treatment of older adult patients diagnosed with rheumatoid arthritis: Improved but not optimal. *Arthritis Care and Research.* 2007;57(6):928-34.
541. Schnabel A, Herlyn K, Burchardi C, et al. Long-Term Tolerability of Methotrexate at Doses Exceeding 15 Mg Per Week in Rheumatoid Arthritis. *Rheumatology international.* 1996;15(5):195-200.
542. Schnabel A, Reinhold K, Willmann V, et al. Side Effects and Efficacy of 15 Mg and 25 Mg Methotrexate Per Week in Rheumatoid Arthritis. *Z RHEUMATOL.* 1994;53(3):142-9.
543. Schnabel A, Reinhold Keller E, Willmann V, et al. Tolerability of Methotrexate Starting With 15 or 25 Mg/Week for Rheumatoid Arthritis. *Rheumatology international.* 1994;14(1):33-8.
544. Schnitzer TJ, Truitt K, Fleischmann R, et al. The Safety Profile, Tolerability, and Effective Dose Range of Rofecoxib in the Treatment of Rheumatoid Arthritis. *Clinical Therapeutics.* 1999;21(10):1688-702.
545. Schrohenloher R, Koopman W, Woodworth T, et al. Suppression of in Vitro IgM Rheumatoid Factor Production by Diphtheria Toxin Interleukin 2 Recombinant Fusion Protein (Dab 486il-2) in Patients With Refractory Rheumatoid Arthritis. *The Journal of rheumatology.* 1996;23(11):1845-8.
546. Schuerwegh AJ, van Offel JF, Bridts CH, et al. Influence of Longterm Therapy With Methotrexate and Low Dose Corticosteroids on Type 1 and Type 2 Cytokine Production in Cd4+ and Cd8+ T Lymphocytes of Patients With Rheumatoid Arthritis. *The Journal of rheumatology.* 2001;28(8):1793-9.
547. Schuerwegh AJ, Van Offel JF, Stevens WJ, et al. Influence of Therapy With Chimeric Monoclonal Tumour Necrosis Factor-Alpha Antibodies on Intracellular Cytokine Profiles of T Lymphocytes and Monocytes in Rheumatoid Arthritis Patients. *Rheumatology (Oxford).* 2003;42(4):541-8.
548. Schwartz JI, Agrawal NG, Wong PH, et al. Lack of Pharmacokinetic Interaction Between Rofecoxib and Methotrexate in Rheumatoid Arthritis Patients. *Journal of clinical pharmacology.* 2001;41(10):1120-30.
549. Scott BL, Ramakrishnan A, Fosdal M, et al. Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): A phase II study. *British Journal of Haematology.* 2010;149(5):706-10.
550. Scott DL. Leflunomide Improves Quality of Life in Rheumatoid Arthritis. *Scandinavian journal of rheumatology Supplement.* 1999;112:23-9.
551. Scott DL, Smolen JS, Kalden JR, et al. Treatment of Active Rheumatoid Arthritis With Leflunomide: Two Year Follow up of a Double Blind, Placebo Controlled Trial Versus Sulfasalazine. *Annals of the rheumatic diseases.* 2001;60(10):913-23.
552. Seideman P. Additive Effect of Combined Naproxen and Paracetamol in Rheumatoid Arthritis. *British journal of rheumatology.* 1993;32(12):1077-82.

553. Seideman P. Better Effect of Methotrexate on C-Reactive Protein During Daily Compared to Weekly Treatment in Rheumatoid Arthritis. *Clinical rheumatology*. 1993;12(2):347-9.
554. Seideman P, Beck O, Eksborg S, et al. The Pharmacokinetics of Methotrexate and Its 7-Hydroxy Metabolite in Patients With Rheumatoid Arthritis. *British journal of clinical pharmacology*. 1993;35(4):409-12.
555. Seppala E, Nissila M, Isomaki H, et al. Effects of Non-Steroidal Anti-Inflammatory Drugs and Prednisolone on Synovial Fluid White Cells, Prostaglandin E2, Leukotriene B4 and Cyclic Amp in Patients With Rheumatoid Arthritis. *Scandinavian journal of rheumatology*. 1990;19(1):71-5.
556. Sharif M, Salisbury C, Taylor D, et al. Changes in Biochemical Markers of Joint Tissue Metabolism in a Randomized Controlled Trial of Glucocorticoid in Early Rheumatoid Arthritis. *Arthritis and rheumatism*. 1998;41(7):1203-9.
557. Sharp JT, Strand V, Leung H, et al. Treatment With Leflunomide Slows Radiographic Progression of Rheumatoid Arthritis: Results From Three Randomized Controlled Trials of Leflunomide in Patients With Active Rheumatoid Arthritis. *Arthritis and rheumatism*. 2000;43(3):495-505.
558. Shashikumar NS, Shivamurthy MC, Chandrashekar S. Evaluation of efficacy of combination of methotrexate and hydroxychloroquine with leflunomide in active rheumatoid arthritis. *Indian Journal of Pharmacology* 2010;42(6):358-61.
559. Sheeran T, Roobottom C, Wanklyn P, et al. The Effect of Bed Rest and Intra-Articular Steroids on the Acute Phase Response in Rheumatoid Arthritis. *Clinical and experimental rheumatology*. 1993;11(1):49-52.
560. Sheldon P. Ileum-Targeted Steroid Therapy in Rheumatoid Arthritis: Double-Blind, Placebo-Controlled Trial of Controlled-Release Budesonide. *Rheumatology international*. 2003;23(4):154-8.
561. Shi W, Wang Y, Li L, et al. Safety and Efficacy of Oral Nonsteroidal Anti-Inflammatory Drugs in Patients With Rheumatoid Arthritis: a Six-Month Randomised Study. *Clinical Drug Investigation*. 2004;24(2):89-101.
562. Shikiar R, Heffernan M, Langley RG, et al. Adalimumab treatment is associated with improvement in health-related quality of life in psoriasis: patient-reported outcomes from a phase II randomized controlled trial. *The Journal of dermatological treatment* 2007(1):25-31.
563. Shiokawa Y, Shichikawa K, Nobunaga M, et al. Clinical Study of a New Anti-Rheumatic Drug, Ms-932 on Rheumatoid Arthritis: Double-Blind Comparative Study With Placebo. *Rinsho Iyaku (Journal of Clinical Therapeutics and Medicines)*. 1991;7(Suppl 2):113-47.
564. Shiozawa S, Shiozawa K, Kita M, et al. A Preliminary Study on the Effect of Alpha-Interferon Treatment on the Joint Inflammation and Serum Calcium in Rheumatoid Arthritis. *British journal of rheumatology*. 1992;31(6):405-8.
565. Shiroky J, Neville C, Skelton J. High Dose Intravenous Methotrexate for Refractory Rheumatoid Arthritis. *The Journal of rheumatology*. 1992;19(2):247-51.
566. Shiroky JB, Neville C, Esdaile JM, et al. Low-Dose Methotrexate With Leucovorin (Folinic Acid) in the Management of Rheumatoid Arthritis. Results of a Multicenter Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 1993;36(6):795-803.
567. Siddiqui AK, Huberfeld SI, Weidenheim KM, et al. Hydroxychloroquine-induced toxic myopathy causing respiratory failure. *Chest*. 2007;131(2):588-90.
568. Sieper J, Fendler C, Laitko S, et al. No Benefit of Long-Term Ciprofloxacin Treatment in Patients With Reactive Arthritis and Undifferentiated Oligoarthritis: a Three-Month, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study. *Arthritis and rheumatism*. 1999;42(7):1386-96.

569. Sigidin Y, Loukina G, Skurkovich B, et al. Randomized, Double-Blind Trial of Anti-Interferon-Gamma Antibodies in Rheumatoid Arthritis. *Scandinavian journal of rheumatology*. 2001;30(4):203-7.
570. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol Reduces Serious Gastrointestinal Complications in Patients With Rheumatoid Arthritis Receiving Nonsteroidal Anti-Inflammatory Drugs. A Randomized, Double-Blind, Placebo-Controlled Trial. *Annals of internal medicine*. 1995;123(4):241-9.
571. Simon F, Parola P, Grandadam M, et al. Chikungunya infection: An emerging rheumatism among travelers returned from Indian Ocean islands. Report of 47 cases. *Medicine*. 2007;86(3):123-37.
572. Simon L, Robinson D, Basch C. Naproxen Levels in Plasma and Synovial Fluid of Patients With Rheumatoid Arthritis. *CLIN THER*. 1991;13(Suppl A):35-43.
573. Simon LS, Weaver AL, Graham DY, et al. Anti-Inflammatory and Upper Gastrointestinal Effects of Celecoxib in Rheumatoid Arthritis: a Randomized Controlled Trial. *JAMA*. 1999;282(20):1921-8.
574. Slaughter JR, Parker JC, Martens MP, et al. Clinical Outcomes Following a Trial of Sertraline in Rheumatoid Arthritis. *Psychosomatics*. 2002;43(1):36-41.
575. Smieja M, MacPherson DW, Kean W, et al. Randomised, Blinded, Placebo Controlled Trial of Doxycycline for Chronic Seronegative Arthritis. *Annals of the rheumatic diseases*. 2001;60(12):1088-94.
576. Smith AM, Sperling JW, O'Driscoll SW, et al. Arthroscopic shoulder synovectomy in patients with rheumatoid arthritis. *Arthroscopy Journal of Arthroscopic and Related Surgery*. 2006;22(1):50-6.
577. Smith DM, Johnson JA, Loeser R, et al. Evaluation of Tenidap (Cp-66,248) on Human Neutrophil Arachidonic Acid Metabolism, Chemotactic Potential and Clinical Efficacy in the Treatment of Rheumatoid Arthritis. *Agents and actions*. 1990;31(1-2):102-9.
578. Smolen J, Emery P. Efficacy and Safety of Leflunomide in Active Rheumatoid Arthritis. *Rheumatology*. 2000;39(Suppl 1):48-56.
579. Smolen JS. Efficacy and Safety of the New Dmard Leflunomide: Comparison to Placebo and Sulfasalazine in Active Rheumatoid Arthritis. *Scandinavian journal of rheumatology Supplement*. 1999;112:15-21.
580. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and Safety of Leflunomide Compared With Placebo and Sulphasalazine in Active Rheumatoid Arthritis: a Double-Blind, Randomised, Multicentre Trial. *Lancet*. 1999;353(9149):259-66.
581. Snowden JA, Biggs JC, Milliken ST, et al. A Randomised, Blinded, Placebo-Controlled, Dose Escalation Study of the Tolerability and Efficacy of Filgrastim for Haemopoietic Stem Cell Mobilisation in Patients With Severe Active Rheumatoid Arthritis. *Bone marrow transplantation*. 1998;22(11):1035-41.
582. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. *Annals of the Rheumatic Diseases*. 2008;67(1):37-42.
583. Song YW, Lee EY, Koh EM, et al. Assessment of comparative pain relief and tolerability of SKI306X compared with celecoxib in patients with rheumatoid arthritis: A 6-week, multicenter, randomized, double-blind, double-dummy, phase III, noninferiority clinical trial. *Clinical Therapeutics*. 2007;29(5):862-73.
584. Spalding SJ, Kent CK, Boudreau R, et al. Three-dimensional and thermal surface imaging produces reliable measures of joint shape and temperature: A potential tool for quantifying arthritis. *Arthritis Research and Therapy*. 2008;10(1).
585. Sreekanth V, Handa R, Wali J, et al. Doxycycline in the Treatment of Rheumatoid Arthritis--a Pilot Study. *The Journal of the Association of Physicians of India*. 2000;48(8):804-7.
586. St Clair EW, Cohen SB, Lee ML, et al. Treatment of Rheumatoid Arthritis With a Dr4/1 Peptide. *The Journal of rheumatology*. 2000;27(8):1855-63.

587. St Clair EW, Wagner CL, Fasanmade AA, et al. The Relationship of Serum Infliximab Concentrations to Clinical Improvement in Rheumatoid Arthritis: Results From Attract, a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 2002;46(6):1451-9.
588. Steen KSS, Nurmohamed MT, Visman I, et al. Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis. *Annals of the Rheumatic Diseases*. 2008;67(2):256-9.
589. Stenberg VI, Fiechtner JJ, Rice JR, et al. Endocrine Control of Inflammation: Rheumatoid Arthritis Double-Blind, Crossover Clinical Trial. *International journal of clinical pharmacology research*. 1992;12(1):11-8.
590. Stewart C, Fleming R, Arkin C, et al. Coadministration of Naproxen and Low-Dose Methotrexate in Patients With Rheumatoid Arthritis. *Clinical Pharmacology & Therapeutics*. 1990;47(4):540-6.
591. Stichenwirth M, Riedl E, Pehamberger H, et al. Pyoderma Gangrenosum in a patient with seronegative rheumatoid arthritis during therapy with adalimumab: Toxic effects of adalimumab or failure of adalimumab to prevent the onset of this phenomenon? *Archives of Dermatology*. 2008;144(6):817-8.
592. Stoch SA, Saag KG, Greenwald M, et al. Once-weekly oral alendronate 70 mg in patients with glucocorticoid-induced bone loss: A 12-month randomized, placebo-controlled clinical trial. 2009.
593. Strand V, Cohen S, Schiff M, et al. Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate. *Archives of Internal Medicine*. 1999;159(21):2542-50.
594. Stubenrauch K, Wessels U, Birnboeck H, et al. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. *Clinical Therapeutics*. 2010;32(9):1597-609.
595. Suarez Almazor M, Russell A. Parenteral Methotrexate or Gold for Rheumatoid Arthritis: a Follow up. *Clinical & Experimental Rheumatology*. 1990;8(2):163-6.
596. Subbanna PKT, Chandy SJ, Danda D, et al. Correlation between serum methotrexate concentrations and disease remission status in rheumatoid arthritis patients on triple disease-modifying antirheumatic drug therapy [1]. *Indian Journal of Pharmacology*. 2007;39(2):117-8.
597. Sugiura F, Kojima T, Oguchi T, et al. A case of peripheral neuropathy and skin ulcer in a patient with rheumatoid arthritis after a single infusion of tocilizumab. *Modern Rheumatology*. 2009;19(2):199-203.
598. Sundal E, Bertelletti D. Thymopentin Treatment of Rheumatoid Arthritis. *Progress in drug research Fortschritte der Arzneimittelforschung Progrès des recherches pharmaceutiques*. 1994;44(10):1145-9.
599. Suzuki A, Yamada R, Ohtake-Yamanaka M, et al. Anti-Citrullinated Collagen Type I Antibody Is a Target of Autoimmunity in Rheumatoid Arthritis. *Biochemical and biophysical research communications*. 2005;333(2):418-26.
600. Svensson B, Boonen A, Albertsson K, et al. Low-Dose Prednisolone in Addition to the Initial Disease-Modifying Antirheumatic Drug in Patients With Early Active Rheumatoid Arthritis Reduces Joint Destruction and Increases the Remission Rate: a Two-Year Randomized Trial. *Arthritis and rheumatism*. 2005;52(11):3360-70.
601. Symmons D, Tricker K, Harrison M, et al. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs - Results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. *Rheumatology*. 2006;45(5):558-65.

602. Symmons D, Tricker K, Roberts C, et al. The British Rheumatoid Outcome Study Group (BrosG) Randomised Controlled Trial to Compare the Effectiveness and Cost-Effectiveness of Aggressive Versus Symptomatic Therapy in Established Rheumatoid Arthritis. *Health Technol Assess.* 2005;9(34):iii-iv, ix-x, 1-78.
603. Szmyrka-Kaczmarek M, Nowak B, Swierkot J, et al. Antinuclear antibodies and anti-cyclic citrullinated peptide antibodies in patients treated with adalimumab. *Central European Journal of Immunology.* 2008;33(3):120-6.
604. Taha AS, McLaughlin S, Holland PJ, et al. Effect on Gastric and Duodenal Mucosal Prostaglandins of Repeated Intake of Therapeutic Doses of Naproxen and Etodolac in Rheumatoid Arthritis. *Annals of the rheumatic diseases.* 1990;49(6):354-8.
605. Tak PP, Taylor PC, Breedveld FC, et al. Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis. *Arthritis and rheumatism.* 1996;39(7):1077-81.
606. Tak PP, van der Lubbe PA, Cauli A, et al. Reduction of Synovial Inflammation After Anti-Cd4 Monoclonal Antibody Treatment in Early Rheumatoid Arthritis. *Arthritis and rheumatism.* 1995;38(10):1457-65.
607. Takada K, Danning C, Kuroiwa T, et al. Lymphocyte Depletion With Fludarabine in Patients With Psoriatic Arthritis: Clinical and Immunological Effects. *Annals of the rheumatic diseases.* 2003;62(11):1112-5.
608. Takahashi M, Suzuki M, Kushida K, et al. Relationship Between Pentosidine Levels in Serum and Urine and Activity in Rheumatoid Arthritis. *British journal of rheumatology.* 1997;36(6):637-42.
609. Tanno M, Nakamura I, Kobayashi S, et al. New-onset demyelination induced by infliximab therapy in two rheumatoid arthritis patients. *Clinical Rheumatology.* 2006;25(6):929-33.
610. Taukumova L, Mouravjoy Y, Gribakin S. Mucocutaneous Side Effects and Continuation of Aurotherapy in Patients With Rheumatoid Arthritis. *Advances in experimental medicine and biology.* 1999;455:367-73.
611. Taylor P, Steuer A, Gruber J, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. *Arthritis and rheumatism.* 2006;54(1):47-53.
612. Taylor PC, Steuer A, Gruber J, et al. Comparison of Ultrasonographic Assessment of Synovitis and Joint Vascularity With Radiographic Evaluation in a Randomized, Placebo-Controlled Study of Infliximab Therapy in Early Rheumatoid Arthritis. *Arthritis and rheumatism.* 2004;50(4):1107-16.
613. Tebib J, Mariette X, Bourgeois P, et al. Masitinib in the treatment of active rheumatoid arthritis: Results of a multicentre, open-label, dose-ranging, phase 2a study. 2009.
614. Tebib JG, Manil LM, Modder G, et al. Better Results With Rhenium-186 Radiosynoviorthesis Than With Cortivazol in Rheumatoid Arthritis (Ra): a Two-Year Follow-up Randomized Controlled Multicentre Study. *Clinical and experimental rheumatology.* 2004;22(5):609-16.
615. Tegelberg A, Kopp S. A 3-Year Follow-up of Temporomandibular Disorders in Rheumatoid Arthritis and Ankylosing Spondylitis. *Acta odontologica Scandinavica.* 1996;54(1):14-8.
616. Teir J, Koduri G, Meadows A, et al. An audit of recording cardiovascular risk factors in patients with rheumatoid arthritis and systemic lupus erythematosus in centres in East Anglia and the South East. *Rheumatology.* 2008;47(8):1252-4.
617. ten Klooster PM, Drossaers-Bakker KW, Taal E, et al. Can we assess baseline pain and global health retrospectively? *Clinical and Experimental Rheumatology.* 2007;25(2):176-81.

618. Ten Klooster PM, Veehof MM, Taal E, et al. Changes in priorities for improvement in patients with rheumatoid arthritis during 1 year of anti-tumour necrosis factor treatment. *Annals of the Rheumatic Diseases*. 2007;66(11):1485-90.
619. ten Wolde S, Breedveld FC, Hermans J, et al. Randomised Placebo-Controlled Study of Stopping Second-Line Drugs in Rheumatoid Arthritis. *Lancet*. 1996;347(8998):347-52.
620. Tenembaum SN. Therapy of multiple sclerosis in children and adolescents. *Clinical Neurology and Neurosurgery*. 2010;112(7):633-40.
621. Tesser J, Fleischmann R, Dore R, et al. Concomitant Medication Use in a Large, International, Multicenter, Placebo Controlled Trial of Anakinra, a Recombinant Interleukin 1 Receptor Antagonist, in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 2004;31(4):649-54.
622. Tett S, Cutler D, Beck C, et al. Concentration-Effect Relationship of Hydroxychloroquine in Patients With Rheumatoid Arthritis--a Prospective, Dose Ranging Study. *The Journal of rheumatology*. 2000;27(7):1656-60.
623. The Australian Multicentre Clinical Trial Group. Sulfasalazine in Early Rheumatoid Arthritis. *J Rheumatol*. 1992 7;19(11):1672.
624. Thurlings RM, Boumans M, Tekstra J, et al. Relationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patients. *Arthritis Care and Research*. 2010;62(12):3607-14.
625. Tikiz C, Utuk O, Pirildar T, et al. Effects of Angiotensin-Converting Enzyme Inhibition and Statin Treatment on Inflammatory Markers and Endothelial Functions in Patients With Longterm Rheumatoid Arthritis. *The Journal of rheumatology*. 2005;32(11):2095-101.
626. Tilley BC, Alarcon GS, Heyse SP, et al. Minocycline in Rheumatoid Arthritis. A 48-Week, Double-Blind, Placebo-Controlled Trial. *Mira Trial Group. Annals of internal medicine*. 1995;122(2):81-9.
627. Torsteinsdottir I, Groth T, U L. Production and Elimination of Hyaluronan in Rheumatoid Arthritis Patients: Estimation With a Loading Test. *Seminars in arthritis and rheumatism*. 1999;28(4):268-79.
628. Toussiro E, Pertuiset E, Kantelip B, et al. Sarcoidosis occurring during anti-TNF-alpha treatment for inflammatory rheumatic diseases: Report of two cases. *Clinical and Experimental Rheumatology*. 2008;26(3):471-5.
629. Tracy T, Worster T, Bradley J, et al. Methotrexate Disposition Following Concomitant Administration of Ketoprofen, Piroxicam and Flurbiprofen in Patients With Rheumatoid Arthritis. *British journal of clinical pharmacology*. 1994;37(5):453-6.
630. Tugwell P, Bombardier C, Buchanan WW, et al. Methotrexate in Rheumatoid Arthritis. Impact on Quality of Life Assessed by Traditional Standard-Item and Individualized Patient Preference Health Status Questionnaires. *Archives of internal medicine*. 1990;150(1):59-62.
631. Turiel M, Tomasoni L, Sitia S, et al. Effects of long-term disease-modifying antirheumatic drugs on endothelial function in patients with early rheumatoid arthritis. *Cardiovascular Therapeutics*. 2010;28(5):e53-e64.
632. Tutuncu Z, Kavanaugh A. Treatment of elderly rheumatoid arthritis. *Future Rheumatology*. 2007;2(3):313-9.
633. Uddenfeldt P, Leden I, Rubin B. A Double-Blind Comparison of Oral Ketoprofen 'controlled Release' and Indomethacin Suppository in the Treatment of Rheumatoid Arthritis With Special Regard to Morning Stiffness and Pain on Awakening. *Current medical research and opinion*. 1993;13(3):127-32.
634. Uutela T, Hannonen P, Kautianen H, et al. Positive treatment response improves the health-related quality of life of patients with early rheumatoid arthritis. *Clinical and Experimental Rheumatology*. 2009;27(1):108-11.

635. Valleala H, Laasonen L, Koivula M-K, et al. Two Year Randomized Controlled Trial of Etidronate in Rheumatoid Arthritis: Changes in Serum Aminoterminal Telopeptides Correlate With Radiographic Progression of Disease. *The Journal of rheumatology*. 2003;30(3):468-73.
636. Valleala H, Laitinen K, Pylkkanen L, et al. Clinical and Biochemical Response to Single Infusion of Clodronate in Active Rheumatoid Arthritis - Double Blind Placebo Controlled Study. *Inflammation Research*. 2001;50(12):598-601.
637. Van Aken J, Van Dongen H, Le Cessie S, et al. Comparison of long term outcome of patients with rheumatoid arthritis presenting with undifferentiated arthritis or with rheumatoid arthritis: An observational cohort study. *Annals of the Rheumatic Diseases*. 2006;65(1):20-5.
638. van Berlo WTM, van de Wiel HBM, Taal E, et al. Sexual functioning of people with rheumatoid arthritis: A multicenter study. *Clinical Rheumatology*. 2007;26(1):30-8.
639. Van Den Bemt B, Van Den Hoogen F, Benraad B, et al. Adherence rates and associations with nonadherence in patients with rheumatoid arthritis using disease modifying antirheumatic drugs. 2009.
640. Van Der Bijl AE, Teng YKO, Van Oosterhout M, et al. Efficacy of intraarticular infliximab in patients with chronic or recurrent gonarthrosis: A clinical randomized trial. 2009.
641. Van Der Heijde D, Breedveld FC, Kavanaugh A, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-Year results of PREMIER. *Journal of Rheumatology*. 2010;37(11):2237-46.
642. Van Der Kooij SM, Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, et al. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. *Annals of the Rheumatic Diseases* 2008;67(2):266-9.
643. van der Lubbe PA, Dijkmans BA, Markusse HM, et al. A Randomized, Double-Blind, Placebo-Controlled Study of Cd4 Monoclonal Antibody Therapy in Early Rheumatoid Arthritis. *Arthritis and rheumatism*. 1995;38(8):1097-106.
644. van der Lubbe PA, Reiter C, Breedveld FC, et al. Chimeric Cd4 Monoclonal Antibody Cm-T412 as a Therapeutic Approach to Rheumatoid Arthritis. *Arthritis and rheumatism*. 1993;36(10):1375-9.
645. van der Lubbe PA, Reiter C, Miltenburg AM, et al. Treatment of Rheumatoid Arthritis With a Chimeric Cd4 Monoclonal Antibody (Cm-T412): Immunopharmacological Aspects and Mechanisms of Action. *Scandinavian journal of immunology*. 1994;39(3):286-94.
646. van der Veen M, Bijlsma J. The Effect of Methylprednisolone Pulse Therapy on Methotrexate Treatment of Rheumatoid Arthritis. *Clinical rheumatology*. 1993;12(4):74-6.
647. van Ede AE, Laan RFJM, Blom HJ, et al. Homocysteine and Folate Status in Methotrexate-Treated Patients With Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2002;41(6):658-65.
648. Van Eijk Y, Boonen A, Schulpen G, et al. Safety and patient satisfaction of infliximab administration in an extramural setting supervised by a rheumatology specialist nurse. *Annals of the Rheumatic Diseases*. 2006;65(2).
649. van Everdingen AA, Jacobs JWG, Siewertsz Van Reesema DR, et al. Low-Dose Prednisone Therapy for Patients With Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Annals of internal medicine*. 2002;136(1):1-12.
650. van Everdingen AA, Siewertsz van Reesema DR, Jacobs JWG, et al. Low-Dose Glucocorticoids in Early Rheumatoid Arthritis: Discordant Effects on Bone Mineral Density and Fractures? *Clinical and experimental rheumatology*. 2003;21(2):155-60.



651. van Everdingen AA, Siewertsz van Reesema DR, Jacobs JWG, et al. The Clinical Effect of Glucocorticoids in Patients With Rheumatoid Arthritis May Be Masked by Decreased Use of Additional Therapies. *Arthritis and rheumatism*. 2004;51(2):217-20.
652. van Holten J, Pavelka K, Vencovsky J, et al. A Multicentre, Randomised, Double Blind, Placebo Controlled Phase II Study of Subcutaneous Interferon Beta-1a in the Treatment of Patients With Active Rheumatoid Arthritis. *Ann Rheum Dis*. 2005;64(1):64-9.
653. van Jaarsveld CH, Jacobs JW, van der Veen MJ, et al. Aggressive Treatment in Early Rheumatoid Arthritis: a Randomised Controlled Trial. *Annals of the Rheumatic Diseases*. 2000;59(6):468-77.
654. van Jaarsveld CH, Jahangier ZN, Jacobs JW, et al. Toxicity of Anti-Rheumatic Drugs in a Randomized Clinical Trial of Early Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2000;39(12):1374-82.
655. Van Kuijk AWR, Gerlag DM, Vos K, et al. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: Effects of adalimumab treatment on synovial tissue. 2009.
656. Van Offel JF, Schuerwegh AJ, Bridts CH, et al. Influence of Cyclic Intravenous Pamidronate on Proinflammatory Monocytic Cytokine Profiles and Bone Density in Rheumatoid Arthritis Treated With Low Dose Prednisolone and Methotrexate. *Clinical and experimental rheumatology*. 2001;19(1):13-20.
657. Van Riel PLCM, Freundlich B, MacPeck D, et al. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: The ADORE trial. *Annals of the Rheumatic Diseases* 2008;67(8):1104-10.
658. van Roon J, Wijngaarden S, Lafeber FPJG, et al. Interleukin 10 Treatment of Patients With Rheumatoid Arthritis Enhances Fc Gamma Receptor Expression on Monocytes and Responsiveness to Immune Complex Stimulation. *The Journal of rheumatology*. 2003;30(4):648-51.
659. van Roon JA, van Roy JL, Gmelig-Meyling FH, et al. Prevention and Reversal of Cartilage Degradation in Rheumatoid Arthritis by Interleukin-10 and Interleukin-4. *Arthritis and rheumatism*. 1996;39(5):829-35.
660. van Schaardenburg D, Valkema R, Dijkmans BA, et al. Prednisone Treatment of Elderly-Onset Rheumatoid Arthritis. Disease Activity and Bone Mass in Comparison With Chloroquine Treatment. *Arthritis and rheumatism*. 1995;38(3):334-42.
661. Verdickt W, Moran C, Hantzel H, et al. A Double-Blind Comparison of the Gastrointestinal Safety and Efficacy of Diclofenac and a Fixed Dose Combination of Diclofenac and Misoprostol in the Treatment of Rheumatoid Arthritis. *Scandinavian journal of rheumatology*. 1992;21(2):85-91.
662. Verhoef J, Toussaint PJ, Zwetsloot-Schonk JHM, et al. Effectiveness of the introduction of an international classification of functioning, disability and health-based rehabilitation tool in multidisciplinary team care in patients with rheumatoid arthritis. *Arthritis Care and Research*. 2007;57(2):240-8.
663. Verhoeven AC, Bibo JC, Boers M, et al. Cost-Effectiveness and Cost-Utility of Combination Therapy in Early Rheumatoid Arthritis: Randomized Comparison of Combined Step-Down Prednisolone, Methotrexate and Sulphasalazine With Sulphasalazine Alone. *British journal of rheumatology*. 1998;37(10):1102-9.
664. Verstappen S, Jacobs J, Bijlsma JW. The Utrecht Experience With Different Treatment Strategies in Early Rheumatoid Arthritis. *Clinical and experimental rheumatology*. 2003;21(5 Suppl 31):S165-8.
665. Verstappen S, van Albada Kuipers G, Bijlsma J, et al. A Good Response to Early Dmard Treatment of Patients With Rheumatoid Arthritis in the First Year Predicts Remission During Follow up. *Ann Rheum Dis*. 2005;64(1):38-43.

666. Verstappen SMM, Jacobs JWG, Bijlsma JWI, et al. Five-Year Followup of Rheumatoid Arthritis Patients After Early Treatment With Disease-Modifying Antirheumatic Drugs Versus Treatment According to the Pyramid Approach in the First Year. *Arthritis and rheumatism*. 2003;48(7):1797-807.
667. Verstappen SMM, McCoy MJ, Roberts C, et al. Beneficial effects of a 3-week course of intramuscular glucocorticoid injections in patients with very early inflammatory polyarthritis: Results of the STIVEA trial. *Annals of the rheumatic diseases*. 2010;69(3):503-9.
668. Veys E, Menkes C, Emery P. A Randomized, Double-Blind Study Comparing Twenty-Four-Week Treatment With Recombinant Interferon-Gamma Versus Placebo in the Treatment of Rheumatoid Arthritis. *Arthritis and rheumatism*. 1997;40(1):62-8.
669. Vis M, Havaardsholm EA, Haugeberg G, et al. Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. *Annals of the Rheumatic Diseases*. 2006;65(11):1495-9.
670. Vischer TL. Follow-up With Om-8980 After a Double-Blind Study of Om-8980 and Auranofin in Rheumatoid Arthritis. *Clinical rheumatology*. 1990;9(3):356-61.
671. Vlak T, Eldar R. Disability in Rheumatoid Arthritis After Monotherapy With Dmards. *International Journal Rehabilitation Research*. 2003;26(3):207-12.
672. von Scheele B, Pena B, Wong J, et al. Economic Evaluation of Oral Valdecoxib Versus Diclofenac in the Treatment of Patients With Rheumatoid Arthritis in a Randomized Clinical Trial. *Rheumatology (Oxford)*. 2003;42(Suppl 3):iii53-9.
673. Wailoo AJ, Bansback N, Brennan A, et al. Biologic drugs for rheumatoid arthritis in the medicare program: A cost-effectiveness analysis. *Arthritis and Rheumatism*. 2008;58(4):939-46.
674. Wakefield D, McCluskey P, Verma M, et al. Ciprofloxacin Treatment Does Not Influence Course or Relapse Rate of Reactive Arthritis and Anterior Uveitis. *Arthritis and rheumatism*. 1999;42(9):1894-7.
675. Walitt B, Pettinger M, Weinstein A, et al. Effects of postmenopausal hormone therapy on rheumatoid arthritis: The women's health initiative randomized controlled trials. *Arthritis Care and Research*. 2008;59(3):302-10.
676. Walsh JK, Muehlbach MJ, Lauter SA, et al. Effects of Triazolam on Sleep, Daytime Sleepiness, and Morning Stiffness in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1996;23(2):245-52.
677. Wassenberg S, Rau R, Steinfeld P, et al. Very Low-Dose Prednisolone in Early Rheumatoid Arthritis Retards Radiographic Progression Over Two Years: a Multicenter, Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 2005;52(11):3371-80.
678. Weinblatt M, Maier A, Coblyn J. Low Dose Leucovorin Does Not Interfere With the Efficacy of Methotrexate in Rheumatoid Arthritis: an 8 Week Randomized Placebo Controlled Trial. *The Journal of rheumatology*. 1993;20(6):950-2.
679. Weinblatt M, Maier A, Fraser P, et al. Longterm Prospective Study of Methotrexate in Rheumatoid Arthritis: Conclusion After 132 Months of Therapy. *The Journal of rheumatology*. 1988;25(2):238-42.
680. Weinblatt M, Polisson R, Blotner SD, et al. The Effects of Drug Therapy on Radiographic Progression of Rheumatoid Arthritis. Results of a 36-Week Randomized Trial Comparing Methotrexate and Auranofin. *Arthritis and rheumatism*. 1993;36(5):613-9.
681. Weinblatt M, Schiff M, Goldman A, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. *Annals of the rheumatic diseases* 2007(2):228-34.

682. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in Rheumatoid Arthritis. A Five-Year Prospective Multicenter Study. *Arthritis and rheumatism*. 1994;37(10):1492-8.
683. Weinblatt ME, Kaplan H, Germain BF, et al. Low-Dose Methotrexate Compared With Auranofin in Adult Rheumatoid Arthritis. A Thirty-Six-Week, Double-Blind Trial. *Arthritis and rheumatism*. 1990;33(3):330-8.
684. Weinblatt ME, Kaplan H, Germain BF, et al. Methotrexate in Rheumatoid Arthritis: Effects on Disease Activity in a Multicenter Prospective Study. *The Journal of rheumatology*. 1991;18(3):334-8.
685. Weinblatt ME, Kremer JM, Coblyn JS, et al. Zileuton, a 5-Lipoxygenase Inhibitor in Rheumatoid Arthritis. *The Journal of rheumatology*. 1992;19(10):1537-41.
686. Weinblatt ME, Maddison PJ, Bulpitt KJ, et al. Campath-1h, a Humanized Monoclonal Antibody, in Refractory Rheumatoid Arthritis. An Intravenous Dose-Escalation Study. *Arthritis and rheumatism*. 1995;38(11):1589-94.
687. Weinblatt ME, Weissman BN, Holdsworth DE, et al. Long-Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis. 84-Month Update. *Arthritis and rheumatism*. 1992;35(2):129-37.
688. Weitoft T, Larsson A, Saxne T, et al. Changes of Cartilage and Bone Markers After Intra-Articular Glucocorticoid Treatment With and Without Postinjection Rest in Patients With Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 2005;64(12):1750-3.
689. Wendling D, Racadot E, Wijdenes J, et al. A Randomized, Double Blind, Placebo Controlled Multicenter Trial of Murine Anti-Cd4 Monoclonal Antibody Therapy in Rheumatoid Arthritis. *The Journal of rheumatology*. 1998;25(8):1457-61.
690. Wendling D, Wijdenes J, Racadot E, et al. Therapeutic use of monoclonal anti-CD4 antibody in rheumatoid arthritis. *J Rheumatol*. 1991 Mar;18(3):325-7.
691. Westhovens R, Robles M, Ximenes AC, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. 2009.
692. Westhovens R, Verwilghen J, Dequeker J. Total Lymphoid Irradiation in Rheumatoid Arthritis. A Ten-Year Followup. *Arthritis and rheumatism*. 1997;40(3):426-9.
693. Whitehead J, Thomas P. A Sequential Trial of Pain Killers in Arthritis: Issues of Multiple Comparisons With Control and of Interval-Censored Survival Data. *Journal of Biopharmaceutical Statistics*. 1997;7(3):333-53.
694. Wijnands M, van Riel P, van 't Hof M, et al. Longterm Treatment With Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis: a Prospective Drug Survival Study. *The Journal of rheumatology*. 1991;18(2):184-7.
695. Williams HJ, Ward JR, Reading JC, et al. Comparison of Auranofin, Methotrexate, and the Combination of Both in the Treatment of Rheumatoid Arthritis. A Controlled Clinical Trial. *Arthritis and rheumatism*. 1992;35(3):259-69.
696. Willich SN, Rossmagel K, Roll S, et al. Rose hip herbal remedy in patients with rheumatoid arthritis - a randomised controlled trial. 2010.
697. Willkens R, Sharp J, Stablein D, et al. Comparison of Azathioprine, Methotrexate, and the Combination of the Two in the Treatment of Rheumatoid Arthritis. A Forty-Eight-Week Controlled Clinical Trial With Radiologic Outcome Assessment. *Arthritis and rheumatism*. 1995;38(12):1799-806.
698. Willkens R, Stablein D. Combination Treatment of Rheumatoid Arthritis Using Azathioprine and Methotrexate: a 48 Week Controlled Clinical Trial. *The Journal of rheumatology Supplement*. 1996;44:64-8.
699. Willkens RF, Urowitz MB, Stablein DM, et al. Comparison of Azathioprine, Methotrexate, and the Combination of Both in the Treatment of Rheumatoid Arthritis. A Controlled Clinical Trial. *Arthritis and rheumatism*. 1992;35(8):849-56.

700. Wojtulewski JA, Schattenkirchner M, Barcelo P, et al. A Six-Month Double-Blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 Mg Daily and Naproxen 750 Mg Daily in Patients With Rheumatoid Arthritis. *British journal of rheumatology*. 1996;35(Suppl 1):22-8.
701. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. *Arthritis and Rheumatism* 2007;56(9):2886-95.
702. Wong M, Oakley SP, Young L, et al. Infliximab improves vascular stiffness in patients with rheumatoid arthritis. 2009.
703. Wood Nd AMDSHSMGRSS. Cartilage Protective Agent (Cpa) Ro 32-3555, a New Matrix Metalloproteinase Inhibitor for the Treatment of Rheumatoid Arthritis. *Agents and Actions Supplements*. 1998;36(8):1087-8.
704. Woodworth TG. Early Clinical Studies of IL-2 Fusion Toxin in Patients With Severe Rheumatoid Arthritis and Recent Onset Insulin-Dependent Diabetes Mellitus. *Clinical and experimental rheumatology*. 1993;11(Suppl 8):S177-80.
705. Wu E, Chen L, Birnbaum H, et al. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. *Current Medical Research and Opinion*. 2008;24(8):2229-40.
706. Wylie G, Appelboom T, Bolten W, et al. A Comparative Study of Tenidap, a Cytokine-Modulating Anti-Rheumatic Drug, and Diclofenac in Rheumatoid Arthritis: a 24-Week Analysis of a 1-Year Clinical Trial. *British journal of rheumatology*. 1995;34(6):554-63.
707. Yang ZX, Li ZB, Sun ZC, et al. Correlations between serum macrophage migration inhibitory factor and active rheumatoid arthritis. *Journal of Clinical Rehabilitative Tissue Engineering Research*. 2008;12(37):7390-3.
708. Yasuda M, Sakai K, Oribe M, et al. Efficacy of Additive Dmard Therapy in Patients With Rheumatoid Arthritis. Double Blind Controlled Trial Using Bucillamine and Placebo With Maintenance Doses of Gold Sodium Thiomalate. *J Rheumatol*. 1994;21(1):33-50.
709. Yocum D, Furst D, Kaine JL, et al. Efficacy and Safety of Tacrolimus in Patients With Rheumatoid Arthritis: a Double-Blind Trial. *Arthritis Rheum*. 2003;48(12):3328-37.
710. Yxfeldt A, Wallberg-Jonsson S, Hultdin J, et al. Homocysteine in Patients With Rheumatoid Arthritis in Relation to Inflammation and B-Vitamin Treatment. *Scand J Rheumatol*. 2003;32(4):205-10.
711. Zanette SdA, Born IG, Brenol JCT, et al. A pilot study of acupuncture as adjunctive treatment of rheumatoid arthritis. *Clinical Rheumatology*. 2008;27(5):627-35.
712. Zhang FC, Hou Y, Huang F, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A preliminary study from China. *APLAR Journal of Rheumatology* 2006;9(2):127-30.
713. Zhao S, Fiechtner JI, Tindall E, et al. Evaluation of Health-Related Quality of Life of Rheumatoid Arthritis Patients Treated With Celecoxib. *Arthritis care and research : the official journal of the Arthritis Health Professions Association*. 2000;13(2):112-21.
714. Zhou X, Zhou Z, Jin M, et al. Clinical Study of Qingluo Tongbi Granules in Treating 63 Patients With Rheumatoid Arthritis of the Type of Yin-Deficiency and Heat in Collaterals. *J Tradit Chin Med*. 2004;24(2):83-7.
715. Ziebland S, Fitzpatrick R, Jenkinson C, et al. Comparison of Two Approaches to Measuring Change in Health Status in Rheumatoid Arthritis: the Health Assessment Questionnaire (Haq) and Modified Haq. *Annals of the rheumatic diseases*. 1992;51(11):1202-5.
716. Zoppi M, Peretti G, Boccard E. Placebo-Controlled Study of the Analgesic Efficacy of an Effervescent Formulation of 500 Mg Paracetamol in Arthritis of the Knee or the Hip. *European Journal of Pain*. 1995;16(1-2):42-8.

717. Zuo X, Duan L, Cao Z, et al. A Clinical Study on Rheumatoid Arthritis Treated by Cu.zn-Sod. Bulletin of Hunan Medical University. 1995;20(3):275-7.

### Reference Source: Dossiers

1. Askling J, Fored CM, Baecklund E, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. *Ann Rheum Dis*. 2005 Oct;64(10):1414-20.
2. Baecklund E, Iliadou A, Askling J, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. *Arthritis Rheum*. 2006 Mar;54(3):692-701.
3. Bernstein LE, Berry J, Kim S, et al. Effects of etanercept in patients with the metabolic syndrome. *Arch Intern Med*. 2006 Apr 24;166(8):902-8.
4. Breedveld FC, Kalden JR. Appropriate and effective management of rheumatoid arthritis. *Ann Rheum Dis*. 2004 Jun;63(6):627-33.
5. Brodszky V, Pentek M, Gulacsi L. Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. *Scand J Rheumatol*. 2008 Sep-Oct;37(5):399-400.
6. Cardiel MH. First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. *Rheumatology (Oxford)*. 2006 Jun;45 Suppl 2:ii7-ii22.
7. Cella D, Yount S, Sorensen M, et al. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. *J Rheumatol*. 2005 May;32(5):811-9.
8. Combe BG, Codreanu C, Fiocco U, et al. Double-blind comparison of Etanercept and Sulphasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving Sulphasalazine. *Ann Rheum Dis*. 2006 Apr 10.
9. Emery P. Role of adalimumab, a novel TNF antagonist in advancing rheumatoid arthritis control. *Drugs Today (Barc)*. 2003;39 Suppl B:17-23.
10. Fleischmann RM, Tesser J, Schiff MH, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2006 Aug;65(8):1006-12.
11. Hashimoto J, Garnero P, van der Heijde D, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. *Mod Rheumatol*. 2010 Jun 24.
12. Haugeberg G, Conaghan PG, Quinn M, et al. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. *Ann Rheum Dis*. 2009 Dec;68(12):1898-901.
13. Jones G, Crotty M, Brooks P. Psoriatic arthritis: a quantitative overview of therapeutic options. The Psoriatic Arthritis Meta-Analysis Study Group. *Br J Rheumatol*. 1997 Jan;36(1):95-9.
14. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. *Ann Rheum Dis*. 2006 Aug;65(8):1038-43.
15. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. *Ann Rheum Dis*. 1999 November 1, 1999;58(90001):70i-2.

16. Kempeni J. Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody. *Ann Rheum Dis.* 2000 November 1;59(90001):44i-5.
17. Keystone EC. Appropriate and effective rheumatoid arthritis control: role of TNF antagonists. *Drugs Today (Barc).* 2003;39 Suppl B:9-15.
18. Klareskog L, Gaubitz M, Rodriguez-Valverde V, et al. A Long-Term, Open-Label Trial of the Safety and Efficacy of Etanercept (ENBREL(R)) In Patients With Rheumatoid Arthritis Not Treated With Other DMARDs (3-year Interim Report). *Ann Rheum Dis.* 2006 Mar 15.
19. Machold KP, Smolen JS. Adalimumab - a new TNF-alpha antibody for treatment of inflammatory joint disease. *Expert Opin Biol Ther.* 2003 Apr;3(2):351-60.
20. Mease PJ. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. *Expert Opin Biol Ther* 2005;5(11):1491-504.
21. Migliore A, Bizzi E, Lagana B, et al. The safety of anti-TNF agents in the elderly. *Int J Immunopathol Pharmacol* 2009;22(2):415-26.
22. Parekh K, Ching D, Rahman MU, et al. Onset of Wegener's granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event? *Rheumatology (Oxford).* 2010 Sep;49(9):1785-7.
23. Pavelka K. Adalimumab in the treatment of rheumatoid arthritis. *Aging Health.* 2006;2(4):533-45.
24. Rau R. Adalimumab (a fully human anti-tumour necrosis factor {alpha} monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials. *Ann Rheum Dis.* 2002 November 1; 2002;61(90002):70ii-3.
25. Rigopoulos D, Gregoriou S, Stratigos A, et al. Evaluation of the efficacy and safety of infliximab on psoriatic nails: an unblinded, nonrandomized, open-label study. *Br J Dermatol.* 2008 Aug;159(2):453-6.
26. Salfeld JG. Use of new biotechnology to design rational drugs against newly defined targets. *Best Pract Res Clin Rheumatol.* 2004 Feb;18(1):81-95.
27. Saliu OY, Sofer C, Stein DS, et al. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. *J Infect Dis.* 2006 Aug 15;194(4):486-92.
28. Santora LC, Kaymakcalan Z, Sakorafas P, et al. Characterization of noncovalent complexes of recombinant human monoclonal antibody and antigen using cation exchange, size exclusion chromatography, and BIAcore. *Anal Biochem.* 2001 Dec 15;299(2):119-29.
29. Simpson D, Scott LJ. Adalimumab : in psoriatic arthritis. *Drugs.* 2006;66(11):1487-96.
30. Smolen JS. Objectives and strategies for rheumatoid arthritis therapy: yesterday vs. today. *Drugs Today (Barc).* 2003;39 Suppl B:3-8.
31. Suissa S, Ernst P, Hudson M, et al. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. *Am J Med.* 2004 Jul 15;117(2):87-92.
32. van de Putte L, Nichol MB. Adalimumab for Rheumatoid Arthritis: Considerations for Reimbursement by Third-Party Payors *Disease Management & Health Outcomes.* 2004;12(1):1-8.
33. Voulgari PV, Venetsanopoulou AI, Epagelis EK, et al. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience. *Ann Rheum Dis.* 2007 Feb;66(2):270-1.
34. Weinblatt M, Combe B, Covucci A, et al. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. *Arthritis Rheum.* 2006 Aug 31;54(9):2807-16.
35. Westhovens R, Yocum D, Han J, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. *Arthritis Rheum.* 2006 Apr;54(4):1075-86.

36. Yazici Y, Adler NM, Yazici H. Most tumour necrosis factor inhibitor trials in rheumatology are undeservedly called 'efficacy and safety' trials: a survey of power

considerations. *Rheumatology (Oxford)*. 2008 Jul;47(7):1054-7.

### Reference Source: The Cochrane Library

1. Aerts NE, Ebo DG, Bridts CH, et al. T cell signal transducer and activator of transcription (STAT) 4 and 6 are affected by adalimumab therapy in rheumatoid arthritis. *Clinical and experimental rheumatology* 2010(2):208-14.
2. Akobeng AK, Thomas AG. Enteral nutrition for maintenance of remission in Crohn's disease. *Cochrane Database of Systematic Reviews* 2007(3).
3. Alfadhli A, McDonald J, Feagan B. Methotrexate for Induction of Remission in Refractory Crohn's Disease. *The Cochrane Database of Systematic Reviews*. 2004;2004(4).
4. Blumenauer B, Judd M, Cranney A, et al. Etanercept for the Treatment of Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2003;2003(3).
5. Blumenauer B, Judd M, Wells G, et al. Infliximab for the Treatment of Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2002;2002(3).
6. Bongartz T. Tocilizumab for rheumatoid and juvenile idiopathic arthritis. *Lancet*. 2008(9617):961-3.
7. Bravo Vergel Y, Palmer S, Erhorn S, et al. Adalimumab for the treatment of moderate to severe psoriatic arthritis. *Health Technology Assessment*. 2010.
8. Burls A, Clark WK, Jobanputra P. Anakinra for Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2005;2005(1).
9. Chen J, Liu C. Methotrexate for Ankylosing Spondylitis. *The Cochrane Database of Systematic Reviews*. 2003;2003(3).
10. Chen J, Liu C. Sulfasalazine for Ankylosing Spondylitis. *The Cochrane Database of Systematic Reviews*. 2005;2005(2).
11. Chen J, Liu C, Lin J. Methotrexate for ankylosing spondylitis. *Cochrane Database of Systematic Reviews* 2006(4).
12. Christensen AF, Hørslev-Petersen K, Christgau S, et al. Uncoupling of collagen II metabolism in newly diagnosed, untreated rheumatoid arthritis is linked to inflammation and antibodies against cyclic citrullinated peptides. *The Journal of rheumatology* 2010(6):1113-20.
13. Clark W, Jobanputra P, Barton P, et al. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis (Brief record). *Health Technology Assessment*. 2004(18):1-118.
14. Clarke R, Derry S, Moore RA, et al. Single dose oral etoricoxib for acute postoperative pain in adults. *Cochrane Database of Systematic Reviews* 2009(2).
15. Coombs JH, Bloom BJ, Breedveld FC, et al. Improved pain, physical functioning and health status in patients with rheumatoid arthritis treated with CP-690,550, an orally active Janus kinase (JAK) inhibitor: results from a randomised, double-blind, placebo-controlled trial. *Annals of the rheumatic diseases* 2010(2):413-6.
16. Criswell L, Saag K, Sems KM, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. 1998.
17. Criswell L, Saag KG, Sems KM, et al. Moderate-Term, Low-Dose Corticosteroids for Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 1998;1998(3).
18. de Courten B, Barber Melissa N, Johnston Renea V, et al. Hypolipidemic and antihypertensive drugs for prevention of cardiovascular complications in patients with rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2008(3).

19. Deodhar A, Dore RK, Mandel D, et al. Denosumab-mediated increase in hand bone mineral density associated with decreased progression of bone erosion in rheumatoid arthritis patients. *Arthritis care & research* 2010(4):569-74.
20. Derry S, Barden J, McQuay Henry J, et al. Single dose oral celecoxib for acute postoperative pain in adults. *Cochrane Database of Systematic Reviews* 2008(4).
21. Egan M, Brosseau L, Farmer M, et al. Splints and Orthosis for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2001;2001(4).
22. Englbrecht M, Wang Y, Ronneberger M, et al. Measuring joint involvement in polyarticular psoriatic arthritis: an introduction of alternatives. *Arthritis care & research* 2010(7):977-83.
23. Flint Wagner HG, Lisse J, Lohman TG, et al. Assessment of a sixteen-week training program on strength, pain, and function in rheumatoid arthritis patients. *Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases*. 2009;15(4):165-71.
24. Garner S, Fidan D, Frankish R, et al. Celecoxib for Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2002;2002(4).
25. Garner S, Fidan DD, Frankish RR, et al. Rofecoxib for Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2005;2005(1).
26. Garner Sarah E, Fidan D, Frankish Ruth R, et al. Rofecoxib for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2005(1).
27. Gøtzsche P, Johansen H. Short-Term Low-Dose Corticosteroids Vs Placebo and Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2005;2005(1).
28. Hashimoto J, Garner P, van der Heijde D, et al. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. *Modern rheumatology / the Japan Rheumatism Association*. 2009;19(3):273-82.
29. Health Technology A. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation (Project record). *Health Technology Assessment*. 2010.
30. Health Technology A. The clinical and cost effectiveness of etanercept, infliximab and adalimumab - psoriatic arthritis (guidance review 104 and 125) (Project record). *Health Technology Assessment*. 2010.
31. Homer D, Nightingale P, Jobanputra P. Providing patients with information about disease-modifying anti-rheumatic drugs: Individually or in groups? A pilot randomized controlled trial comparing adherence and satisfaction. *Musculoskeletal care*. 2009;7(2):78-92.
32. Jones G, Crotty M, Brooks P. Interventions for Treating Psoriatic Arthritis. *The Cochrane Database of Systematic Reviews*. 2000;2000(3).
33. Keystone E, Genovese MC, Klareskog L, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. *Annals of the rheumatic diseases* 2010(6):1129-35.
34. Kirwan J, Shea B, Boers M. Glucocorticoids for Slowing Radiological Progression in Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2005;2005(1).
35. Klarenbeek NB, van der Kooij SM, Huizinga TJ, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. *Annals of the rheumatic diseases*. 2010(7):1342-5.



36. Lawson MM, Thomas AG, Akobeng AK. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. *Cochrane Database of Systematic Reviews* 2006(3).
37. Lekander I, Borgstrom F, Svarvar P, et al. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. *International Journal of Technology Assessment in Health Care*. 2010;26(1):54-61.
38. Li L, Judd M, Pencharz JN. Comprehensive Physiotherapy for Rheumatoid Arthritis. Li L, Judd M, Pencharz JN Comprehensive physiotherapy for rheumatoid arthritis *The Cochrane Database of Systematic Reviews: Protocols* 2004 Issue 2 John Wiley & Sons, Ltd Chichester, UK DOI: 101002/14651858CD004802: John Wiley & Sons, Ltd. 2004;2004(2).
39. Lin JF, Chen JM, Liu C. A systematic review of methotrexate for ankylosing spondylitis (Brief record). *Chinese Journal of Evidence-Based Medicine* 2007(4):260-6.
40. Little C, Parsons T. Herbal Therapy for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2000;2000(4).
41. Little Christine V, Parsons T, Logan S. Herbal therapy for treating osteoarthritis. 2000. Available at: <http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD002947/frame.html>
42. Lopez-Olivo Maria A, Amezaga M, McGahan L, et al. Rituximab for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2008(4).
43. Lu D, Song H, Shi G. Anti-TNF- $\alpha$  treatment for pelvic pain associated with endometriosis. *Cochrane Database of Systematic Reviews* 2010(3).
44. Lukas C, van der Heijde D, Fatenajad S, et al. Repair of erosions occurs almost exclusively in damaged joints without swelling. *Annals of the rheumatic diseases* 2010(5):851-5.
45. Lv D, Song H, Shi G. Anti-TNF- $\alpha$  treatment for pelvic pain associated with endometriosis. 2009. Available at: <http://www.mrw.interscience.wiley.com/cochrane/clsysrev/articles/CD008088/frame.html>
46. Lv D, Song H, Shi G. Anti-TNF- $\alpha$  treatment for pelvic pain associated with endometriosis. *Cochrane Database of Systematic Reviews* 2010(3).
47. Maxwell L, Singh Jasvinder A. Abatacept for rheumatoid arthritis. *Cochrane Database of Systematic Reviews*. 2008(3).
48. Maxwell L, Singh Jasvinder A. Abatacept for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2009(4).
49. Navarro Sarabia F, Ariza Ariza R, Hernandez Cruz B, et al. Adalimumab for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2005;2005(3).
50. Osiri M, Shea B, Robinson V, et al. Leflunomide for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews* 2002;2002(3).
51. Osiri M, Shea B, Welch V, et al. Leflunomide for the treatment of rheumatoid arthritis. 2002.
52. Ramiro S, Radner H, van der Heijde D, et al. Combination therapy for pain management in inflammatory arthritis. *Cochrane Database of Systematic Reviews* 2010(12).
53. Rooney T, Roux-Lombard P, Veale DJ, et al. Synovial tissue and serum biomarkers of disease activity, therapeutic response and radiographic progression: analysis of a proof-of-concept randomised clinical trial of cytokine blockade. *Annals of the rheumatic diseases* 2010(4):706-14.
54. Ruiz Garcia V, Burls A, Cabello López Juan CL, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. *Cochrane Database of Systematic Reviews*. 2009(1).
55. Schiff M, Pritchard C, Huffstutter JE, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. *Annals of the rheumatic diseases*. 2009;68(11):1708-14.

56. Sharp JT, Tsuji W, Ory P, et al. Denosumab prevents metacarpal shaft cortical bone loss in patients with erosive rheumatoid arthritis. *Arthritis care & research* 2010(4):537-44.
57. Singh Jasvinder A, Beg S, Lopez Olivo Maria A. Tocilizumab for rheumatoid arthritis. 2010.
58. Singh Jasvinder A, Beg S, Lopez-Olivo Maria A. Tocilizumab for rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2010(7).
59. Singh Jasvinder A, Christensen R, Wells George A, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database of Systematic Reviews*. 2009(2).
60. Singh Jasvinder A, Christensen R, Wells George A, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database of Systematic Reviews* 2009(4).
61. Smolen JS, Aletaha D, Grisar JC, et al. Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. *Annals of the rheumatic diseases* 2010(6):1058-64.
62. Smolen JS, van der Heijde DM, Aletaha D, et al. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. *Annals of the rheumatic diseases*. 2009;68(10):1535-40.
63. Suarez Almazor M, Belseck E, Shea BJ, et al. Antimalarials for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2000;2000(4).
64. Suarez Almazor M, Belseck E, Shea BJ, et al. Methotrexate for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 1998;1998(2).
65. Suarez Almazor M, Belseck E, Shea BJ, et al. Sulfasalazine for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 1998;1998(2).
66. Suarez Almazor M, Belseck E, Spooner C. Penicillamine for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2000;2000(4).
67. Suarez Almazor M, Spooner C, Belseck E. Azathioprine for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2000;2000(4).
68. Suarez Almazor M, Spooner CH, Belseck E, et al. Auranofin Versus Placebo in Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2000;2000(2).
69. Suarez-Almazor Maria E, Belseck E, Shea B, et al. Sulfasalazine for treating rheumatoid arthritis. *Cochrane Database of Systematic Reviews*. 1998(2).
70. Suarez-Almazor Maria E, Belseck E, Shea B, et al. Cyclophosphamide for treating rheumatoid arthritis. *Cochrane Database of Systematic Reviews* 2000(4).
71. Tirunagari Shravan K, Derry S, Moore RA, et al. Single dose oral etodolac for acute postoperative pain in adults. *Cochrane Database of Systematic Reviews* 2009(3).
72. Towheed T, Hochberg Marc C, Shea B, et al. Analgesia and non-aspirin, non-steroidal anti-inflammatory drugs for osteoarthritis of the hip. *Cochrane Database of Systematic Reviews* 2006(1).
73. van der Heijde D, Burmester G, Melo Gomes J, et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. *Annals of the rheumatic diseases* 2009;68(7):1113-8.
74. van Tuyl LH, Boers M, Lems WF, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. *Annals of the rheumatic diseases*. 2010(5):807-12.
75. Verstappen SM, Bakker MF, Heurkens AH, et al. Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. *Annals of the rheumatic diseases* 2010(6):1044-8.
76. Vidal L, Gafter-Gvili A, Leibovici L, et al. Rituximab as maintenance therapy for patients with follicular lymphoma. *Cochrane Database of Systematic Reviews* 2007(2).

77. Wallen Margaret M, Gillies D. Intra-articular steroids and splints/rest for children with juvenile idiopathic arthritis and adults with rheumatoid arthritis. *Cochrane Database of Systematic Reviews*. 2006(1).
78. Westhovens R, Kremer JM, Moreland LW, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. *The Journal of rheumatology*. 2009;36(4):736-42.
79. Wienecke T, Gøtzsche P. Paracetamol Versus Nonsteroidal Anti-Inflammatory Drugs for Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2004;2004(1).

## Appendix D. Excluded Studies

### Wrong Language

1. Garcia JJ, Lobato JP, Garrido SL, Fernandez ME, Eyaralar JR. Biological therapies in rheumatoid arthritis. *Atencion Farmaceutica: European Journal of Clinical Pharmacy*. 2008;10(98):100-11.
2. Rau R, Wassenberg S, Zeidler H. Low Dose Prednisolone Therapy (LDPT) Retards Radiographically Detectable Destruction in Early Rheumatoid Arthritis--Preliminary Results of a Multicenter, Randomized, Parallel, Double Blind Study. *Zeitschrift für Rheumatologie*. 2000;59(Supple 2):II/90-6.
3. Sander O, Rau R. Treatment of Refractory Rheumatoid Arthritis With a Tumor Necrosis Factor Alpha Receptor Fusion Protein (Tnfr 55-Igg1) - a Monocentric Observation in 80 Patients. *Zeitschrift für Rheumatologie*. 1998;57(5):307-11.
4. Schnabel A, Reinhold K, Willmann V, Dihlmann W, Gross W. Side Effects and Efficacy of 15 Mg and 25 Mg Methotrexate Per Week in Rheumatoid Arthritis. *Z RHEUMATOL*. 1994;53(3):142-9.

### Wrong Outcome

1. Aletaha D, Funovits J, Breedveld FC, Sharp J, Smolen JS, et al., et al. Rheumatoid Arthritis Joint Progression in Sustained Remission Is Determined by Disease Activity Levels Preceding the Period of Radiographic Assessment. *Arthritis and Rheumatism (USA)* 2009:1242.
2. Aletaha D, Funovits J, Keystone EC, Smolen JS. Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. *Arthritis Rheum*. 2007 Oct;56(10):3226-35.
3. Ang DC, Paulus HE, Louie JS. Patient's ethnicity does not influence utilization of effective therapies in rheumatoid arthritis. *J Rheumatol*. 2006 May;33(5):870-8.
4. Aslanidis S, Pyrpasopoulou A, Douma S, Petidis K. Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? *Arthritis Rheum*. 2008 Jan;58(1):327-8.
5. Bacquet-Deschryver H, Jouen F, Quillard M, Menard JF, Goeb V, Lequerre T, et al. Impact of three anti-TNFalpha biologics on existing and emergent autoimmunity in rheumatoid arthritis and spondylarthropathy patients. *J Clin Immunol*. 2008 Sep;28(5):445-55.
6. Baskan BM, Sivas F, Alemdaroglu E, Duran S, Ozoran K. Association of bone mineral density and vertebral deformity in patients with rheumatoid arthritis. *Rheumatol Int*. 2007 Apr;27(6):579-84.
7. Baslund B, Tvede N, Danneskiold-Samsøe B, Larsson P, Panayi G, Petersen J, et al. Targeting Interleukin-15 in Patients With Rheumatoid Arthritis: a Proof-of-Concept Study. *Arthritis and rheumatism*. 2005;52(9):2686-92.
8. Bendtzen K, Geborek P, Svenson M, Larsson L, Kapetanovic MC, Saxne T. Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab. *Arthritis Rheum*. 2006 Dec;54(12):3782-9.

9. Bingham ICO, Looney RJ, Deodhar A, Halsey N, Greenwald M, Coddling C, et al. Immunization responses in rheumatoid arthritis patients treated with rituximab: Results from a controlled clinical trial. 2010.
10. Bobbio-Pallavicini F, Caporali R, Alpini C, Avasse S, Epis OM, Klersy C, et al. High IgA rheumatoid factor levels are associated with poor clinical response to tumour necrosis factor alpha inhibitors in rheumatoid arthritis. *Ann Rheum Dis.* 2007 Mar;66(3):302-7.
11. Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. *J Clin Pharmacol.* 2007 Sep;47(9):1119-28.
12. Breedveld FC, Han C, Bala M, van der Heijde D, Baker D, Kavanaugh AF, et al. Association Between Baseline Radiographic Damage and Improvement in Physical Function After Treatment of Patients With Rheumatoid Arthritis. *Annals of the rheumatic diseases.* 2005;64(1):52-5.
13. Buch MH, Seto Y, Bingham SJ, Bejarano V, Bryer D, White J, et al. C-reactive protein as a predictor of infliximab treatment outcome in patients with rheumatoid arthritis: defining subtypes of nonresponse and subsequent response to etanercept. *Arthritis Rheum.* 2005 Jan;52(1):42-8.
14. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose methotrexate on the bone mineral density of patients with rheumatoid arthritis. *J Rheumatol.* 1997 Aug;24(8):1489-94.
15. Carmona L, Hernandez-Garcia C, Vadillo C, Pato E, Balsa A, Gonzalez-Alvaro I, et al. Increased risk of tuberculosis in patients with rheumatoid arthritis. *J Rheumatol.* 2003 Jul;30(7):1436-9.
16. Cassell S, Kavanaugh AF. Therapies for psoriatic nail disease. A systematic review. *J Rheumatol.* 2006 Jul;33(7):1452-6.
17. Cella D, Yount S, Sorensen M, Chartash E, Sengupta N, Grober J. Validation of the Functional Assessment of Chronic Illness Therapy Fatigue Scale relative to other instrumentation in patients with rheumatoid arthritis. *J Rheumatol.* 2005 May;32(5):811-9.
18. Chung CP, Russell AS, Segami MI, Ugarte CA. The effect of low-dose prednisone on bone mineral density in Peruvian rheumatoid arthritis patients. *Rheumatol Int.* 2005 Mar;25(2):114-7.
19. Chung CP, Thompson JL, Koch GG, Amara I, Strand V, Pincus T. Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities. *Annals of the rheumatic diseases.* 2006;65(12):1602-7.
20. Coates LC, Helliwell PS. Validation of Minimal Disease Activity Criteria for Psoriatic Arthritis Using Interventional Trial Data. *Arthritis Care and Research.* 2010;62:965.
21. Colwell CW, Jr., Robinson CA, Stevenson DD, Vint VC, Morris BA. Osteonecrosis of the femoral head in patients with inflammatory arthritis or asthma receiving corticosteroid therapy. *Orthopedics.* 1996 Nov;19(11):941-6.
22. Cooper C, Coupland C, Mitchell M. Rheumatoid arthritis, corticosteroid therapy and hip fracture. *Ann Rheum Dis.* 1995 Jan;54(1):49-52.

23. Criswell LA, Lum RF, Turner KN, Woehl B, Zhu Y, Wang J, et al. The influence of genetic variation in the HLA-DRB1 and LTA-TNF regions on the response to treatment of early rheumatoid arthritis with methotrexate or etanercept. *Arthritis Rheum.* 2004 Sep;50(9):2750-6.
24. Cui J, Saevarsdottir S, Thomson B, Padyukov L, van der Helm-van Mil AH, Nititham J, et al. Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. *Arthritis Rheum.* 2010/03/24 ed 2010:1849-61.
25. Cunnane G, Madigan A, Murphy E, FitzGerald O, Bresnihan B. The effects of treatment with interleukin-1 receptor antagonist on the inflamed synovial membrane in rheumatoid arthritis. *Rheumatology (Oxford).* 2001 Jan;40(1):62-9.
26. Curkendall S, Patel V, Gleeson M, Campbell RS, Zagari M, Dubois R. Compliance with biologic therapies for rheumatoid arthritis: do patient out-of-pocket payments matter? *Arthritis Rheum.* 2008 Oct 15;59(10):1519-26.
27. Cypiene A, Laucevicius A, Venalis A, Ryliskyte L, Dadoniene J, Petrulioniene Z, et al. Non-invasive assessment of arterial stiffness indices by applanation tonometry and pulse wave analysis in patients with rheumatoid arthritis treated with TNF-alpha blocker remicade (infliximab). *Proc West Pharmacol Soc.* 2007;50:119-22.
28. Dahlqvist SR, Engstrand S, Berglin E, Johnson O. Conversion towards an atherogenic lipid profile in rheumatoid arthritis patients during long-term infliximab therapy. *Scand J Rheumatol.* 2006 Mar-Apr;35(2):107-11.
29. de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Verpoort KN, Schreuder GM, Ewals JA, Terwiel JP, et al. Progression of joint damage in early rheumatoid arthritis: association with HLA-DRB1, rheumatoid factor, and anti-citrullinated protein antibodies in relation to different treatment strategies. *Arthritis Rheum.* 2008 May;58(5):1293-8.
30. Dervieux T, Greenstein N, Kremer J. Pharmacogenomic and metabolic biomarkers in the folate pathway and their association with methotrexate effects during dosage escalation in rheumatoid arthritis. *Arthritis Rheum.* 2006 Oct;54(10):3095-103.
31. di Comite G, Marinosci A, Di Matteo P, Manfredi A, Rovere-Querini P, Baldissera E, et al. Neuroendocrine modulation induced by selective blockade of TNF-alpha in rheumatoid arthritis. *Ann N Y Acad Sci.* 2006 Jun;1069:428-37.
32. Doan QV, Chiou CF, Dubois RW. Review of eight pharmacoeconomic studies of the value of biologic DMARDs (adalimumab, etanercept, and infliximab) in the management of rheumatoid arthritis. *Journal of Managed Care Pharmacy (USA).* 2006 07/01;12(Jul):555-69.
33. Eklund KK, Leirisalo-Repo M, Ranta P, Maki T, Kautiainen H, Hannonen P, et al. Serum IL-1beta levels are associated with the presence of erosions in recent onset rheumatoid arthritis. *Clin Exp Rheumatol.* 2007 Sep-Oct;25(5):684-9.
34. Ernestam S, Hafstrom I, Werner S, Carlstrom K, Tengstrand B. Increased DHEAS levels in patients with rheumatoid arthritis after treatment with tumor necrosis factor antagonists: evidence for improved adrenal function. *J Rheumatol.* 2007 Jul;34(7):1451-8.
35. Felder M, Ruegsegger P. Bone loss in patients with rheumatoid arthritis--effect of steroids measured by low dose quantitative computed tomography. *Rheumatol Int.* 1991;11(1):41-4.

36. Finckh A, Bansback N, Marra CA, Anis AH, Liang MH, et al., et al. Treatment of Very Early Rheumatoid Arthritis With Symptomatic Therapy, Disease-Modifying Antirheumatic Drugs, or Biologic Agents A Cost-Effectiveness Analysis. *Annals of Internal Medicine (USA)*. 2009;151:612.
37. Finckh A, Simard JF, Gabay C, Guerne PA. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. *Ann Rheum Dis*. 2006 Jun;65(6):746-52.
38. Frey N, Grange S, Woodworth T. Population Pharmacokinetic Analysis of Tocilizumab in Patients With Rheumatoid Arthritis. *Journal of Clinical Pharmacology (USA)*. 2010;50:754-66.
39. Garnero P, Tabassi NC, Voorzanger-Rousselot N. Circulating dickkopf-1 and radiological progression in patients with early rheumatoid arthritis treated with etanercept. *J Rheumatol*. 2008 Dec;35(12):2313-5.
40. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: Results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone. 2010.
41. Garnero P, Thompson E, Woodworth T, Smolen JS. Rapid and Sustained Improvement in Bone and Cartilage Turnover Markers With the Anti-Interleukin-6 Receptor Inhibitor Tocilizumab Plus Methotrexate in Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate Results From a Substudy of the Multicenter Double-Blind, Placebo-Controlled Trial of Tocilizumab in Inadequate Responders to Methotrexate Alone. *Arthritis and Rheumatism (USA)*. 2010;62:33.
42. Garton MJ, Reid DM. Bone mineral density of the hip and of the anteroposterior and lateral dimensions of the spine in men with rheumatoid arthritis. Effects of low-dose corticosteroids. *Arthritis Rheum*. 1993 Feb;36(2):222-8.
43. Genant HK. Interleukin-1 Receptor Antagonist Treatment of Rheumatoid Arthritis Patients: Radiologic Progression and Correlation of Genant/Sharp and Larsen Scoring Methods. *Seminars in arthritis and rheumatism*. 2001;30(5 Suppl 2):26-32.
44. Georgiadis AN, Papavasiliou EC, Lourida ES, Alamanos Y, Kostara C, Tselepis AD, et al. Atherogenic lipid profile is a feature characteristic of patients with early rheumatoid arthritis: effect of early treatment--a prospective, controlled study. *Arthritis Res Ther*. 2006;8(3):R82.
45. Gibofsky A, Palmer WR, Goldman JA, Lautzenheiser RL, Markenson JA, Weaver A, et al. Real-world utilization of DMARDs and biologics in rheumatoid arthritis: the RADIUS (Rheumatoid Arthritis Disease-Modifying Anti-Rheumatic Drug Intervention and Utilization Study) study. *Curr Med Res Opin*. 2006 Jan;22(1):169-83.
46. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Kerstens PJ, Grillet BA, de Jager MH, et al. Patient preferences for treatment: report from a randomised comparison of treatment strategies in early rheumatoid arthritis (BeSt trial). *Ann Rheum Dis*. 2007 Sep;66(9):1227-32.
47. Gonnet-Gracia C, Barnetche T, Richez C, Blanco P, Dehais J, Schaeffer T. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. *Clin Exp Rheumatol*. 2008 May-Jun;26(3):401-7.

48. Gonzalez-Alvaro I, Descalzo MA, Carmona L. Trends towards an improved disease state in rheumatoid arthritis over time: Influence of new therapies and changes in management approach: Analysis of the EMECAR cohort. *Arthritis Research and Therapy*. 2008;10(6).
49. Gonzalez-Juanatey C, Llorca J, Garcia-Porrúa C, Martín J, Gonzalez-Gay MA. Effect of anti-tumor necrosis factor alpha therapy on the progression of subclinical atherosclerosis in severe rheumatoid arthritis. *Arthritis and Rheumatism-Arthritis Care and Research*. 2006 01/01/;55(Jan):150-3.
50. Gotzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL, et al. Randomized, Placebo Controlled Trial of Withdrawal of Slow-Acting Antirheumatic Drugs and of Observer Bias in Rheumatoid Arthritis. *Scandinavian Journal of Rheumatology*. 1996;25(4):194-0.
51. Grassi W, De Angelis R, Cervini C. Corticosteroid prescribing in rheumatoid arthritis and psoriatic arthritis. *Clin Rheumatol*. 1998;17(3):223-6.
52. Grijalva CG, Chung CP, Stein CM, Mitchel EF, Jr., Griffin MR. Changing patterns of medication use in patients with rheumatoid arthritis in a Medicaid population. *Rheumatology (Oxford)*. 2008 Jul;47(7):1061-4.
53. Guler-Yuksel M, Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Groenendaal JH, Mallee C, et al. Changes in hand and generalised bone mineral density in patients with recent-onset rheumatoid arthritis. *Ann Rheum Dis*. 2009 Mar;68(3):330-6.
54. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Hulsmans HM, de Beus WM, et al. Changes in bone mineral density in patients with recent onset, active rheumatoid arthritis. *Ann Rheum Dis*. 2008 Jun;67(6):823-8.
55. Guler-Yuksel M, Bijsterbosch J, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Roday HK, Peeters AJ, et al. Bone mineral density in patients with recently diagnosed, active rheumatoid arthritis. *Ann Rheum Dis*. 2007 Nov;66(11):1508-12.
56. Haagsma CJ, Blom HJ, van Riel PL, van't Hof MA, Giesendorf BA, van Oppenraaij-Emmerzaal D, et al. Influence of Sulphasalazine, Methotrexate, and the Combination of Both on Plasma Homocysteine Concentrations in Patients With Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 1999;58(2):79-84.
57. Hafstrom I, Rohani M, Deneberg S, Wornert M, Jogestrang T, Frostegard J. Effects of low-dose prednisolone on endothelial function, atherosclerosis, and traditional risk factors for atherosclerosis in patients with rheumatoid arthritis--a randomized study. *J Rheumatol*. 2007 Sep;34(9):1810-6.
58. Hall GM, Daniels M, Doyle DV, Spector TD. Effect of hormone replacement therapy on bone mass in rheumatoid arthritis patients treated with and without steroids. *Arthritis Rheum*. 1994 Oct;37(10):1499-505.
59. Hall GM, Spector TD, Delmas PD. Markers of bone metabolism in postmenopausal women with rheumatoid arthritis. Effects of corticosteroids and hormone replacement therapy. *Arthritis Rheum*. 1995 Jul;38(7):902-6.
60. Hall GM, Spector TD, Griffin AJ, Jawad AS, Hall ML, Doyle DV. The effect of rheumatoid arthritis and steroid therapy on bone density in postmenopausal women. *Arthritis Rheum*. 1993 Nov;36(11):1510-6.
61. Halpern MT, Cifaldi MA, Kvien TK. Impact of adalimumab on work participation in rheumatoid arthritis: comparison of an open-label extension study and a registry-based control group. *Ann Rheum Dis*. 2009 Jun;68(6):930-7.



62. Halvorsen EH, Haavardsholm EA, Pollmann S, Boonen A, van der Heijde D, Kvien TK, et al. Serum IgG antibodies to peptidylarginine deiminase 4 predict radiographic progression in patients with rheumatoid arthritis treated with tumour necrosis factor-alpha blocking agents. *Ann Rheum Dis.* 2009 Feb;68(2):249-52.
63. Hansen M, Florescu A, Stoltenberg M, Podenphant J, Pedersen-Zbinden B, Horslev-Petersen K, et al. Bone loss in rheumatoid arthritis. Influence of disease activity, duration of the disease, functional capacity, and corticosteroid treatment. *Scand J Rheumatol.* 1996;25(6):367-76.
64. Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, et al. A combination of biochemical markers of cartilage and bone turnover, radiographic damage and body mass index to predict the progression of joint destruction in patients with rheumatoid arthritis treated with disease-modifying anti-rheumatic drugs. *Modern rheumatology / the Japan Rheumatism Association.* 2009;19(3):273-82.
65. Hashimoto J, Garnero P, van der Heijde D, Miyasaka N, Yamamoto K, Kawai S, et al. Humanized anti-interleukin-6-receptor antibody (tocilizumab) monotherapy is more effective in slowing radiographic progression in patients with rheumatoid arthritis at high baseline risk for structural damage evaluated with levels of biomarkers, radiography, and BMI: data from the SAMURAI study. *Mod Rheumatol.* 2010 Jun 24.
66. Hatemi G, Melikoglu M, Fresko I, Masatlioglu S, Tascilar K, Yazici H. Infliximab does not suppress the tuberculin skin test (purified protein derivative). *J Rheumatol.* 2007 Mar;34(3):474-80.
67. Haugeberg G, Orstavik RE, Uhlig T, Falch JA, Halse JI, Kvien TK. Bone loss in patients with rheumatoid arthritis: results from a population-based cohort of 366 patients followed up for two years. *Arthritis Rheum.* 2002 Jul;46(7):1720-8.
68. Haugeberg G, Strand A, Kvien T, Kirwan J. Reduced Loss of Hand Bone Density With Prednisolone in Early Rheumatoid Arthritis: Results From a Randomized Placebo-Controlled Trial. *Archives of internal medicine.* 2005;165(11):1293-7.
69. Helliwell PS. Therapies for dactylitis in psoriatic arthritis. A systematic review. *J Rheumatol.* 2006 Jul;33(7):1439-41.
70. Hirano Y, Kojima T, Kanayama Y, Shioura T, Hayashi M, Kida D, et al. Influences of anti-tumour necrosis factor agents on postoperative recovery in patients with rheumatoid arthritis. *Clin Rheumatol.* 2010/01/14 ed 2010:495-500.
71. Hornung N, Ellingsen T, Attermann J, Stengaard-Pedersen K, Poulsen JH. Patients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacy. *J Rheumatol.* 2008 Sep;35(9):1709-15.
72. Hu CP, Xu ZH, Rahman MU, Davis HM, Zhou HH. A latent variable approach for modeling categorical endpoints among patients with rheumatoid arthritis treated with golimumab plus methotrexate. *Journal of Pharmacokinetics and Pharmacodynamics (USA).* 2010;37:309-21.
73. Imrich R, Vidas M, Rovinsky J, Aldag JC, Masi AT. Adrenal plasma steroid relations in glucocorticoid-naive premenopausal rheumatoid arthritis patients during insulin-induced hypoglycemia test compared to matched normal control females. *Endocr Regul.* 2009 Apr;43(2):65-73.

74. James HM, Gillis D, Hissaria P, Lester S, Somogyi AA, Cleland LG, et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. *J Rheumatol*. 2008 Apr;35(4):562-71.
75. Jiang Y, Genant HK, Watt I, Cobby M, Bresnihan B, Aitchison R, et al. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. *Arthritis Rheum*. 2000 May;43(5):1001-9.
76. Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, et al. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. *Ann Rheum Dis*. 2004 Sep;63(9):1075-8.
77. Josipovic B. Levels of dehydroepiandrosterone sulfate in female patients with early stage of rheumatoid arthritis. *Ann N Y Acad Sci*. 1999 Jun 22;876:145-7.
78. Kahn KL, MacLean CH, Liu H, Rubenstein LZ, Wong AL, Harker JO, et al. Application of explicit process of care measurement to rheumatoid arthritis: Moving from evidence to practice. *Arthritis Rheum*. 2006 Dec 15;55(6):884-91.
79. Kahn KL, MacLean CH, Wong AL, Rubenstein LZ, Liu H, Fitzpatrick DM, et al. Assessment of American College of Rheumatology quality criteria for rheumatoid arthritis in a pre-quality criteria patient cohort. *Arthritis Care and Research*. 2007;57(5):707-15.
80. Kaine JL, Kivitz AJ, Birbara C, Luo AY. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. *J Rheumatol*. 2007 Feb;34(2):272-9.
81. Kalla AA, Meyers OL, Kotze TJ, Laubscher R. Corticosteroid therapy and bone mass--comparison of rheumatoid arthritis and systemic lupus erythematosus. *S Afr Med J*. 1994 Jul;84(7):404-9.
82. Kievit W, Fransen J, Oerlemans AJ, Kuper HH, van der Laar MA, de Rooij DJ, et al. The efficacy of anti-TNF in rheumatoid arthritis, a comparison between randomised controlled trials and clinical practice. *Ann Rheum Dis*. 2007 Nov;66(11):1473-8.
83. Klarenbeek NB, van der Kooij SM, Huizinga TJ, Goekoop-Ruiterman YP, Hulsmans HM, van Krugten MV, et al. Blood pressure changes in patients with recent-onset rheumatoid arthritis treated with four different treatment strategies: a post hoc analysis from the BeSt trial. *Annals of the rheumatic diseases*. 2010(7):1342-5.
84. Klimiuk PA, Sierakowski S, Domyslawska I, Chwiecko J. Regulation of serum chemokines following infliximab therapy in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2006 Sep-Oct;24(5):529-33.
85. Kobelt G, Eberhardt K, Geborek P. TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. *Ann Rheum Dis*. 2004 Jan;63(1):4-10.
86. Kopp S, Alstergren P, Ernestam S, Nordahl S, Bratt J. Interleukin-1beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis. *Scand J Rheumatol*. 2006 May-Jun;35(3):182-8.

87. Korcowska I, Olewicz-Gawlik A, Trefler J, Hrycaj P, Krzysztof Lacki J. Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients? *Clin Rheumatol*. 2008 May;27(5):565-72.
88. Korthals-de Bos I, Van Tulder M, Boers M, Verhoeven AC, Ader HJ, Bibo J, et al. Indirect and Total Costs of Early Rheumatoid Arthritis: a Randomized Comparison of Combined Step-Down Prednisolone, Methotrexate, and Sulfasalazine With Sulfasalazine Alone. *The Journal of rheumatology*. 2004;31(9):1709-16.
89. Kraan MC, Reece RJ, Barg EC, Smeets TJ, Farnell J, Rosenburg R, et al. Modulation of Inflammation and Metalloproteinase Expression in Synovial Tissue by Leflunomide and Methotrexate in Patients With Active Rheumatoid Arthritis. Findings in a Prospective, Randomized, Double-Blind, Parallel-Design Clinical Trial in Thirty-Nine Patients at Two Centers. *Arthritis and rheumatism*. 2000;43(8):1820-30.
90. Kristensen LE, Christensen R, Bliddal H, Geborek P, Danneskiold-Samsøe B, Saxne T. The number needed to treat for adalimumab, etanercept, and infliximab based on ACR50 response in three randomized controlled trials on established rheumatoid arthritis: A systematic literature review. *Scandinavian Journal of Rheumatology* 2007;411-7.
91. Kroot EJ, van Gestel AM, Swinkels HL, Albers MM, van de Putte LB, van Riel PL. Chronic comorbidity in patients with early rheumatoid arthritis: a descriptive study. *J Rheumatol*. 2001 Jul;28(7):1511-7.
92. Kuuliala A, Leirisalo-Repo M, Mottonen T, Hannonen P, Nissila M, Kautiainen H, et al. Serum Soluble Interleukin-2 Receptor Predicts Early Remission in Patients With Recent-Onset Rheumatoid Arthritis Treated With a Single Disease-Modifying Antirheumatic Drug. *Clinical and experimental rheumatology*. 2005;23(2):243-6.
93. Lacroix BD, Lovern MR, Stockis A, Sargentini-Maier ML, Karlsson MO, Friberg LE. A pharmacodynamic Markov mixed-effects model for determining the effect of exposure to certolizumab pegol on the ACR20 score in patients with rheumatoid arthritis. *Clin Pharmacol Ther*. 2009 Oct;86(4):387-95.
94. Lau J, Ioannidis JPA, Terrin N, Schmid CH, Olkin I. The case of the misleading funnel plot. *British Medical Journal*. 2006;333(7568):597-600.
95. Lodder MC, de Jong Z, Kostense PJ, Molenaar ET, Staal K, Voskuyl AE, et al. Bone mineral density in patients with rheumatoid arthritis: relation between disease severity and low bone mineral density. *Ann Rheum Dis*. 2004 Dec;63(12):1576-80.
96. Macias I, Garcia-Perez S, Ruiz-Tudela M, Medina F, Chozas N, Giron-Gonzalez JA. Modification of pro- and antiinflammatory cytokines and vascular-related molecules by tumor necrosis factor- $\alpha$  blockade in patients with rheumatoid arthritis. *J Rheumatol*. 2005 Nov;32(11):2102-8.
97. Maetzel A, Strand V, Tugwell P, Wells G, Bombardier C. Economic Comparison of Leflunomide and Methotrexate in Patients With Rheumatoid Arthritis: an Evaluation Based on a 1-Year Randomised Controlled Trial. *Pharmacoeconomics*. 2002;20(1):61-70.
98. Marcora SM, Chester KR, Mittal G, Lemmey AB, Maddison PJ. Randomized phase 2 trial of anti-tumor necrosis factor therapy for cachexia in patients with early rheumatoid arthritis. *Am J Clin Nutr*. 2006 Dec;84(6):1463-72.

99. Marotte H, Pallot-Prades B, Grange L, Tebib J, Gaudin P, Alexandre C, et al. The shared epitope is a marker of severity associated with selection for, but not with response to, infliximab in a large rheumatoid arthritis population. *Ann Rheum Dis*. 2006 Mar;65(3):342-7.
100. Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, Isaacs JD, et al. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. *Hum Mol Genet*. 2008 Nov 15;17(22):3532-8.
101. Mease PJ, Wei N, Fudman EJ, Kivitz AJ, Schechtman J, Trapp RG, et al. Safety, tolerability, and clinical outcomes after intraarticular injection of a recombinant adeno-associated vector containing a tumor necrosis factor antagonist gene: Results of a phase 1/2 study. *Journal of Rheumatology*. 2010;37(4):692-703.
102. Ollendorf DA, Klingman D, Hazard E, Ray S. Differences in annual medication costs and rates of dosage increase between tumor necrosis factor-antagonist therapies for rheumatoid arthritis in a managed care population. *Clinical Therapeutics*. 2009;31(4):825-35.
103. Ollendorf DA, Peterson AN, Doyle J, Huse DM. Impact of leflunomide versus biologic agents on the costs of care for rheumatoid arthritis in a managed care population. *Am J Manag Care*. 2002 May;8(7 Suppl):S203-13.
104. Oren C, Mendelbaum M, Paran D. Vaccination against influenza in rheumatoid arthritis patients: The effect of rituximab on the humoral response. *Arthritis Rheum* 2006.
105. Pincus T, Marcum SB, Callahan LF. Longterm drug therapy for rheumatoid arthritis in seven rheumatology private practices: II. Second line drugs and prednisone. *J Rheumatol*. 1992 Dec;19(12):1885-94.
106. Potter C, Hyrich KL, Tracey A, Lunt M, Plant D, Symmons DP, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. *Ann Rheum Dis* 2009;69-74.
107. Quinn MA, Conaghan PG, O'Connor PJ, Karim Z, Greenstein A, Brown A, et al. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2005 Jan;52(1):27-35.
108. Rajakulendran S, Gadsby K, Deighton C. Rheumatoid arthritis, alcohol, leflunomide and methotrexate. Can changes to the BSR guidelines for leflunomide and methotrexate on alcohol consumption be justified? *Musculoskeletal Care*. 2008 Dec;6(4):233-45.
109. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Safety of anti-TNF-alpha therapy in rheumatoid arthritis and spondylarthropathies with concurrent B or C chronic hepatitis. *Rheumatology*. 2006 10/01;45(Oct):1294-7.
110. Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. *J Infect Dis*. 2006 Aug 15;194(4):486-92.
111. Sanmarti R, Gomez-Centeno A, Ercilla G, Larrosa M, Vinas O, Vazquez I, et al. Prognostic factors of radiographic progression in early rheumatoid arthritis: a two year prospective study after a structured therapeutic strategy using DMARDs and very low doses of glucocorticoids. *Clin Rheumatol*. 2007 Jul;26(7):1111-8.

112. Scheinberg M, Guedes-Barbosa LS, Manguiera C, Rosseto EA, Mota L, Oliveira AC, et al. Yellow fever revaccination during infliximab therapy. *Arthritis Care Res (Hoboken)*. 2010/06/11 ed 2010:896-8.
113. Sennels H, Sorensen S, Ostergaard M, Knudsen L, Hansen M, Skjodt H, et al. Circulating levels of osteopontin, osteoprotegerin, total soluble receptor activator of nuclear factor-kappa B ligand, and high-sensitivity C-reactive protein in patients with active rheumatoid arthritis randomized to etanercept alone or in combination with methotrexate. *Scand J Rheumatol*. 2008 Jul-Aug;37(4):241-7.
114. Seriola B, Paolino S, Sulli A, Fasciolo D, Cutolo M. Effects of anti-TNF-alpha treatment on lipid profile in patients with active rheumatoid arthritis. *Ann N Y Acad Sci*. 2006 Jun;1069:414-9.
115. Seriola B, Paolino S, Sulli A, Ferretti V, Cutolo M. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. *Ann N Y Acad Sci*. 2006 Jun;1069:420-7.
116. Smolen JS, van der Heijde DM, Aletaha D, Xu S, Han J, Baker D, et al. Progression of radiographic joint damage in rheumatoid arthritis: independence of erosions and joint space narrowing. *Annals of the rheumatic diseases*. 2009;68(10):1535-40.
117. Soderlin MK, Geborek P. Changing pattern in the prescription of biological treatment in rheumatoid arthritis. A 7-year follow-up of 1839 patients in southern Sweden. *Annals of the Rheumatic Diseases*. 2008;67(1):37-42.
118. Sokka T, Kautiainen H, Toloza S, Makinen H, Verstappen SM, Lund Hetland M, et al. QUEST-RA: quantitative clinical assessment of patients with rheumatoid arthritis seen in standard rheumatology care in 15 countries. *Ann Rheum Dis*. 2007 Nov;66(11):1491-6.
119. Sokka T, Mottonen T, Hannonen P. Mortality in early "sawtooth" treated rheumatoid arthritis patients during the first 8-14 years. *Scand J Rheumatol*. 1999;28(5):282-7.
120. Sokka T, Pincus T. Contemporary disease modifying antirheumatic drugs (DMARD) in patients with recent onset rheumatoid arthritis in a US private practice: methotrexate as the anchor drug in 90% and new DMARD in 30% of patients. *J Rheumatol*. 2002 Dec;29(12):2521-4.
121. Strand V, Cohen S, Crawford B, Smolen JS, Scott DL, et al. Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritis. *Rheumatology*. 2004 05/01;43(May):640-7.
122. Strober B, Teller C, Yamauchi P, Miller JL, Hooper M, Yang YC, et al. Effects of etanercept on C-reactive protein levels in psoriasis and psoriatic arthritis. *Br J Dermatol*. 2008 Aug;159(2):322-30.
123. Stubenrauch K, Wessels U, Birnboeck H, Ramirez F, Jahreis A, Schleypen J. Subset analysis of patients experiencing clinical events of a potentially immunogenic nature in the pivotal clinical trials of tocilizumab for rheumatoid arthritis: Evaluation of an antidrug antibody ELISA using clinical adverse event-driven immunogenicity testing. *Clinical Therapeutics*. 2010;32(9):1597-609.
124. Suissa S, Ernst P, Hudson M. TNF-alpha antagonists and the prevention of hospitalisation for chronic obstructive pulmonary disease. *Pulm Pharmacol Ther*. 2008;21(1):234-8.
125. Symmons D, Tricker K, Harrison M, Roberts C, Davis M, Dawes P, et al. Patients with stable long-standing rheumatoid arthritis continue to deteriorate despite intensified treatment with traditional disease modifying anti-rheumatic drugs - Results of the British Rheumatoid Outcome Study Group randomized controlled clinical trial. *Rheumatology*. 2006;45(5):558-65.

126. Tan RJ, Gibbons LJ, Potter C, Hyrich KL, Morgan AW, Wilson AG, et al. Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. *Ann Rheum Dis*. 2010/05/07 ed 2010:1029-35.
127. Tang B, Rahman M, Waters HC, Callegari P. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis. *Clin Ther*. 2008 Jul;30(7):1375-84.
128. Tascioglu F, Oner C, Armagan O. The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis. *Rheumatol Int*. 2003 Sep;23(5):231-5.
129. Tikly M, Zannettou N, Hopley M. A longitudinal study of rheumatoid arthritis in South Africans. *MedGenMed*. 2003 Feb 5;5(1):2.
130. Toms TE, Panoulas VF, John H, Douglas KM, Kitas GD. Methotrexate therapy associates with reduced prevalence of the metabolic syndrome in rheumatoid arthritis patients over the age of 60- more than just an anti-inflammatory effect? A cross sectional study. *Arthritis Res Ther*. 2009;11(4):R110.
131. Torikai E, Kageyama Y, Takahashi M, Nagano A. The effect of methotrexate on bone metabolism markers in patients with rheumatoid arthritis. *Mod Rheumatol*. 2006;16(6):350-4.
132. Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, et al. Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2007 Jun;66(6):818-20.
133. van der Bijl AE, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Ten Wolde S, Han KH, van Krugten MV, et al. Infliximab and methotrexate as induction therapy in patients with early rheumatoid arthritis. *Arthritis Rheum*. 2007 Jul;56(7):2129-34.
134. van der Heijde D, Landewe R, Klareskog L, Rodriguez-Valverde V, Settas L, Pedersen R, et al. Presentation and analysis of data on radiographic outcome in clinical trials: experience from the TEMPO study. *Arthritis Rheum*. 2005 Jan;52(1):49-60.
135. Verhoeven AC, Bibo JC, Boers M, Engel GL, van der Linden S. Cost-Effectiveness and Cost-Utility of Combination Therapy in Early Rheumatoid Arthritis: Randomized Comparison of Combined Step-Down Prednisolone, Methotrexate and Sulphasalazine With Sulphasalazine Alone. *British journal of rheumatology*. 1998;37(10):1102-9.
136. Verhoeven AC, Boers M, te Koppele JM, van der Laan WH, Markusse HM, Geusens P, et al. Bone turnover, joint damage and bone mineral density in early rheumatoid arthritis treated with combination therapy including high-dose prednisolone. *Rheumatology (Oxford)*. 2001 Nov;40(11):1231-7.
137. Visvanathan S, Marini JC, Smolen JS, Clair EW, Pritchard C, Shergy W, et al. Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis. *J Rheumatol*. 2007 Jul;34(7):1465-74.
138. Visvanathan S, Wagner C, Rojas J, Kay J, Dasgupta B, Matteson EL, et al. E-selectin, interleukin 18, serum amyloid a, and matrix metalloproteinase 9 are associated with clinical response to golimumab plus methotrexate in patients with active rheumatoid arthritis despite methotrexate therapy. *J Rheumatol*. 2009 Jul;36(7):1371-9.

139. Wallace DJ, Metzger AL, Stecher VJ, Turnbull BA, Kern PA. Cholesterol-lowering effect of hydroxychloroquine in patients with rheumatic disease: reversal of deleterious effects of steroids on lipids. *Am J Med.* 1990 Sep;89(3):322-6.
140. Wells G, Li T, Tugwell P. Investigation into the impact of abatacept on sleep quality in patients with rheumatoid arthritis, and the validity of the MOS-Sleep questionnaire Sleep Disturbance Scale. *Ann Rheum Dis.* 2010 Oct;69(10):1768-73.
141. Wells GA, Boers M, Li T, Tugwell PS. Investigating the validity of the minimal disease activity state for patients with rheumatoid arthritis treated with abatacept. *J Rheumatol.* 2009 Feb;36(2):260-5.
142. Wells GA, Sultan SA, Chen L. Indirect evidence: Indirect treatment comparisons in meta-analysis. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health. 2009.
143. Weng HH, Ranganath VK, Khanna D, Oh M, Western Consortium P, et al. Equivalent Responses to Disease-modifying Antirheumatic Drugs Initiated at Any Time During the First 15 Months After Symptom Onset in Patients with Seropositive Rheumatoid Arthritis. *Journal of Rheumatology.* 2010;37:550-7.
144. Wolbink GJ, Vis M, Lems W, Voskuyl AE, Dijkmans B, et al. Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis. *Arthritis and Rheumatism (USA).* 2006 03/01;54(Mar):711-5.
145. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Cost of care for patients with rheumatoid arthritis receiving TNF-antagonist therapy using claims data. *Curr Med Res Opin.* 2007 Aug;23(8):1749-59.
146. Wu E, Chen L, Birnbaum H, Yang E, Cifaldi M. Retrospective claims data analysis of dosage adjustment patterns of TNF antagonists among patients with rheumatoid arthritis. *Current Medical Research and Opinion.* 2008;24(8):2229-40.
147. Yamanaka H, Inoue E, Singh G, Tanaka E, Nakajima A, Taniguchi A, et al. Improvement of disease activity of rheumatoid arthritis patients from 2000 to 2006 in a large observational cohort study IORRA in Japan. *Mod Rheumatol.* 2007;17(4):283-9.
148. Yazici Y, Krasnokutsky S, Barnes JP, Hines PL, Wang J, Rosenblatt L. Changing patterns of tumor necrosis factor inhibitor use in 9074 patients with rheumatoid arthritis. *J Rheumatol.* 2009 May;36(5):907-13.
149. Yee CS, Filer A, Pace A, Douglas K, Situnayake D, Rowe IF. The prevalence of patients with rheumatoid arthritis in the West Midlands fulfilling the BSR criteria for anti-tumour necrosis factor therapy: an out-patient study. *Rheumatology (Oxford).* 2003 Jul;42(7):856-9.
150. Zink A, Strangfeld A, Schneider M, Herzer P, Listing J, et al. Effectiveness of tumor necrosis factor inhibitors in rheumatoid arthritis in an observational cohort study - Comparison of patients according to their eligibility for major randomized clinical trials. *Arthritis and Rheumatism (USA).* 2006 11/01;54(Nov):3399-407.

### **Drug Not Included in the Report**

1. Adams J, Burridge J, Mullee M, Hammond A, Cooper C. The clinical effectiveness of static resting splints in early rheumatoid arthritis: A randomized controlled trial. *Rheumatology.* 2008;47(10):1548-53.

2. Anderson JJ, O'Neill A, Woodworth T, Haddad J, Sewell KL, Moreland LW. Health Status Response of Rheumatoid Arthritis to Treatment With Dab486il-2. *Arthritis care and research : the official journal of the Arthritis Health Professions Association*. 1996;9(2):112-9.
3. Bae SC, Corzillius M, Kuntz KM, Liang MH. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis. *Rheumatology (Oxford)*. 2003 Jan;42(1):46-53.
4. Bakker MF, Jacobs JWG, Welsing PMJ, Van Der Werf JH, Linn-Rasker SP, Van Der Veen MJ, et al. Are switches from oral to subcutaneous methotrexate or addition of ciclosporin to methotrexate useful steps in a tight control treatment strategy for rheumatoid arthritis? A post hoc analysis of the CAMERA study. *Annals of the rheumatic diseases*. 2010;69(10):1849-52.
5. Bejarano V, Conaghan PG, Proudman SM, Buch MH, Brown AK, Emery P. Long-term efficacy and toxicity of ciclosporin A in combination with methotrexate in poor prognosis rheumatoid arthritis. *Annals of the Rheumatic Diseases*. 2009;68(5):761-3.
6. Blyth T, Hunter JA, Stirling A. Pain relief in the rheumatoid knee after steroid injection. A single-blind comparison of hydrocortisone succinate, and triamcinolone acetonide or hexacetonide. *Br J Rheumatol*. 1994 May;33(5):461-3.
7. Capell H, Marabani M, Madhok R, Torley H, Hunter J. Degree and Extent of Response to Sulphasalazine or Penicillamine Therapy for Rheumatoid Arthritis: Results From a Routine Clinical Environment Over a Two-Year Period. *The Quarterly journal of medicine*. 1990;75(276):335-44.
8. Capell HA, Madhok R, Hunter JA, Porter D, Morrison E, Larkin J, et al. Lack of radiological and clinical benefit over two years of low dose prednisolone for rheumatoid arthritis: results of a randomised controlled trial. *Ann Rheum Dis*. 2004 Jul;63(7):797-803.
9. Capell HA, Murphy EA, Hunter JA. Rheumatoid arthritis: workload and outcome over 10 years. *Q J Med*. 1991 Jun;79(290):461-76.
10. Choy EH, Kingsley GH, Khoshaba B, Pipitone N, Scott DL. A Two Year Randomised Controlled Trial of Intramuscular Depot Steroids in Patients With Established Rheumatoid Arthritis Who Have Shown an Incomplete Response to Disease Modifying Antirheumatic Drugs. *Ann Rheum Dis*. 2005;64(9):1288-93.
11. Choy EHS, Scott DL, Kingsley GH, Williams P, Wojtulewski J, Papasavvas G, et al. Treating Rheumatoid Arthritis Early With Disease Modifying Drugs Reduces Joint Damage: a Randomised Double Blind Trial of Sulphasalazine Vs Diclofenac Sodium. *Clinical and experimental rheumatology*. 2002;20(3):351-8.
12. Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, et al. Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis. *Arthritis Rheum*. 2009 Feb;60(2):335-44.
13. Cohen SB, Dore RK, Lane NE, Ory PA, Peterfy CG, Sharp JT, et al. Denosumab treatment effects on structural damage, bone mineral density, and bone turnover in rheumatoid arthritis: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, phase II clinical trial. *Arthritis Rheum*. 2008 May;58(5):1299-309.
14. Conaghan PG, O'Connor P, McGonagle D, Astin P, Wakefield RJ, Gibbon WW, et al. Elucidation of the relationship between synovitis and bone damage: a randomized magnetic resonance imaging study of individual joints in patients with early rheumatoid arthritis. *Arthritis Rheum*. 2003 Jan;48(1):64-71.



15. Damjanov N, Kauffman RS, Spencer-Green GT. Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies. *Arthritis Rheum.* 2009 May;60(5):1232-41.
16. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Frequency of infection in patients with rheumatoid arthritis compared with controls: a population-based study. *Arthritis Rheum.* 2002 Sep;46(9):2287-93.
17. Eberhardt R, Kruger K, Reiter W, Gross W, Zwingers T. Long-term therapy with the new glucocorticosteroid deflazacort in rheumatoid arthritis. Double-blind controlled randomized 12-months study against prednisone. *Arzneimittelforschung.* 1994 May;44(5):642-7.
18. Egsmose C, TM H, Andersen LS, Beier JM, Christensen L, Ejstrup L, et al. Limited Effect of Sulphasalazine Treatment in Reactive Arthritis. A Randomised Double Blind Placebo Controlled Trial. *Annals of the rheumatic diseases.* 1997;56(1):32-6.
19. Felson DT, Anderson JJ, Meenan RF. The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis. *Arthritis Rheum.* 1994 Oct;37(10):1487-91.
20. Ferraz MB, Pinheiro GR, Helfenstein M, Albuquerque E, Rezende C, Roimicher L, et al. Combination Therapy With Methotrexate and Chloroquine in Rheumatoid Arthritis. A Multicenter Randomized Placebo-Controlled Trial. *Scandinavian journal of rheumatology.* 1994;23(5):231-6.
21. Finckh A, Liang MH, Van Herckenrode CM, De Pablo P. Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: A meta-analysis. *Arthritis and rheumatism.* 2006;55(6):86-172.
22. Fraser AD, van Kuijk AWR, Westhovens R, Karim Z, Wakefield R, Gerards AH, et al. A Randomised, Double Blind, Placebo Controlled, Multicentre Trial of Combination Therapy With Methotrexate Plus Ciclosporin in Patients With Active Psoriatic Arthritis. *Ann Rheum Dis.* 2005;64(6):859-64.
23. Furtado RN, Oliveira LM, Natour J. Polyarticular corticosteroid injection versus systemic administration in treatment of rheumatoid arthritis patients: a randomized controlled study. *J Rheumatol.* 2005 Sep;32(9):1691-8.
24. Gerlag DM, Hollis S, Layton M, Vencovsky J, Szekanecz Z, Braddock M, et al. Preclinical and clinical investigation of a CCR5 antagonist, AZD5672, in patients with rheumatoid arthritis receiving methotrexate. *Arthritis and rheumatism.* 2010;62(11):3154-60.
25. Gøtzsche P, Johansen H. Short-Term Low-Dose Corticosteroids Vs Placebo and Nonsteroidal Antiinflammatory Drugs in Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews.* 2005;2005(1).
26. Gough A, Sheeran T, Arthur V, Panayi G, Emery P. Adverse interaction between intramuscular methylprednisolone and sulphasalazine in patients with early rheumatoid arthritis. A pilot study. *Scand J Rheumatol.* 1994;23(1):46-8.
27. Graell E, Vazquez I, Larrosa M, Rodriguez-Cros JR, Hernandez MV, Gratacos J, et al. Disability measured by the modified health assessment questionnaire in early rheumatoid arthritis: Prognostic factors after two years of follow-up. *Clinical and Experimental Rheumatology.* 2009;27(2):284-91.

28. Graudal N, Juergens G. Similar Effects of Disease-Modifying Antirheumatic Drugs, Glucocorticoids, and Biologic Agents on Radiographic Progression in Rheumatoid Arthritis Meta-Analysis of 70 Randomized Placebo-Controlled or Drug-Controlled Studies, Including 112 Comparisons. *Arthritis and Rheumatism (USA)*. 2010;62:2852.
29. Gray RE, Doherty SM, Galloway J, Coulton L, de Broe M, Kanis JA. A double-blind study of deflazacort and prednisone in patients with chronic inflammatory disorders. *Arthritis Rheum*. 1991 Mar;34(3):287-95.
30. Griffith SM, Fisher J, Clarke S, Montgomery B, Jones PW, Saklatvala J, et al. Do Patients With Rheumatoid Arthritis Established on Methotrexate and Folic Acid 5 Mg Daily Need to Continue Folic Acid Supplements Long Term? *Rheumatology (Oxford)*. 2000;39(10):1102-9.
31. Hannonen P, Mottonen T, Hakola M, Oka M. Sulfasalazine in Early Rheumatoid Arthritis. A 48-Week Double-Blind, Prospective, Placebo-Controlled Study. *Arthritis and rheumatism*. 1993;36(11):1501-9.
32. Hetland ML, Stengaard-Pedersen K, Junker P, Horslev-Petersen K, Grp CS, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis - An investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. *Arthritis and Rheumatism (USA)*. 2006 05/01;54(May):1401-9.
33. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Ellingsen T, Andersen LS, et al. Combination treatment with methotrexate, cyclosporine, and intraarticular betamethasone compared with methotrexate and intraarticular betamethasone in early active rheumatoid arthritis: an investigator-initiated, multicenter, randomized, double-blind, parallel-group, placebo-controlled study. *Arthritis Rheum*. 2006 May;54(5):1401-9.
34. Hetland ML, Stengaard-Pedersen K, Junker P, Lottenburger T, Hansen I, Andersen LS, et al. Aggressive combination therapy with intra-articular glucocorticoid injections and conventional disease-modifying anti-rheumatic drugs in early rheumatoid arthritis: second-year clinical and radiographic results from the CIMESTR study. *Ann Rheum Dis*. 2008 Jun;67(6):815-22.
35. Hetland ML, Stengaard-Pedersen K, Junker P, Ostergaard M, Ejbjerg BJ, Jacobsen S, et al. Radiographic progression and remission rates in early rheumatoid arthritis - MRI bone oedema and anti-CCP predicted radiographic progression in the 5-year extension of the double-blind randomised CIMESTR trial. *Ann Rheum Dis*. 2010 Oct;69(10):1789-95.
36. Hu D, Bao C, Chen S, Gu J, Li Z, Sun L, et al. A comparison study of a recombinant tumor necrosis factor receptor:Fc fusion protein (rhTNFR:Fc) and methotrexate in treatment of patients with active rheumatoid arthritis in China. *Rheumatol Int*. 2009 Jan;29(3):297-303.
37. Ichikawa Y, Saito T, Yamanaka H, Akizuki M, Kondo H, Kobayashi S, et al. Clinical activity after 12 weeks of treatment with nonbiologics in early rheumatoid arthritis may predict articular destruction 2 years later. *Journal of Rheumatology*. 2010;37(4):723-9.
38. Jessop JD, O'Sullivan MM, Lewis PA, Williams LA, Camilleri JP, Plant MJ, et al. A Long-Term Five-Year Randomized Controlled Trial of Hydroxychloroquine, Sodium Aurothiomalate, Auranofin and Penicillamine in the Treatment of Patients With Rheumatoid Arthritis. *British journal of rheumatology*. 1998;37(9):992-1002.

39. Jeurissen ME, Boerbooms AM, van de Putte LB, Doesburg WH, Mulder J, Rasker JJ, et al. Methotrexate versus azathioprine in the treatment of rheumatoid arthritis. A forty-eight-week randomized, double-blind trial. *Arthritis Rheum.* 1991 Aug;34(8):961-72.
40. Johnsen AK, Schiff MH, Mease PJ, Moreland LW, Maier AL, Coblyn JS, et al. Comparison of 2 doses of etanercept (50 vs 100 mg) in active rheumatoid arthritis: a randomized double blind study. *J Rheumatol.* 2006 Apr;33(4):659-64.
41. Katchamart W, Trudeau J, Phumethum V, Bombardier C. Methotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritis. *Cochrane Database Syst Rev.* 2010;4:CD008495.
42. Kavanaugh A, Menter A, Mendelsohn A, Shen YK, Lee S, Gottlieb AB. Effect of ustekinumab on physical function and health-related quality of life in patients with psoriatic arthritis: A randomized, placebo-controlled, phase II trial. *Current Medical Research and Opinion.* 2010;26(10):2385-92.
43. Kawai S, Hashimoto H, Kondo H, Murayama T, Abe T, et al. Comparison of tacrolimus and mizoribine in a randomized, double-blind controlled study in patients with rheumatoid arthritis. *Journal of Rheumatology.* 2006 11/01;33(Nov):2153-61.
44. Kirwan J, Byron M, Watt I. The Relationship Between Soft Tissue Swelling, Joint Space Narrowing and Erosive Damage in Hand X-Rays of Patients With Rheumatoid Arthritis. *Rheumatology (Oxford).* 2001;40(3):688-95.
45. Kirwan JR. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. *N Engl J Med.* 1995 Jul 20;333(3):142-6.
46. Kremer J, Ritchlin C, Mendelsohn A, Baker D, Kim L, Xu Z, et al. Golimumab, a new human anti-tumor necrosis factor alpha antibody, administered intravenously in patients with active rheumatoid arthritis: Forty-eight-week efficacy and safety results of a phase III randomized, double-blind, placebo-controlled study. *Arthritis Rheum.* 2010/02/05 ed 2010:917-28.
47. Lambert CM, Sandhu S, Lochhead A, Hurst NP, McRorie E, Dhillon V. Dose Escalation of Parenteral Methotrexate in Active Rheumatoid Arthritis That Has Been Unresponsive to Conventional Doses of Methotrexate: a Randomized, Controlled Trial. *Arthritis and rheumatism.* 2004;50(2):364-71.
48. Lard LR, Visser H, Speyer I, vander Horst-Bruinsma IE, Zwinderman AH, Breedveld FC, et al. Early versus delayed treatment in patients with recent-onset rheumatoid arthritis: comparison of two cohorts who received different treatment strategies. *Am J Med.* 2001 Oct 15;111(6):446-51.
49. Lerndal T, Svensson B. A Clinical Study of Cph 82 Vs Methotrexate in Early Rheumatoid Arthritis. *Rheumatology (Oxford).* 2000;39(3):316-20.
50. Lu LJ, Bao CD, Dai M, Teng JL, Fan W, Du F, et al. Multicenter, randomized, double-blind, controlled trial of treatment of active rheumatoid arthritis with T-614 compared with methotrexate. *Arthritis Rheum.* 2009 Jul 15;61(7):979-87.
51. Ma MH, Kingsley GH, Scott DL. A systematic comparison of combination DMARD therapy and tumour necrosis inhibitor therapy with methotrexate in patients with early rheumatoid arthritis. *Rheumatology (Oxford).* 2010;49:91-8.

52. Messina OD, Barreira JC, Zanchetta JR, Maldonado-Cocco JA, Bogado CE, Sebastian ON, et al. Effect of low doses of deflazacort vs prednisone on bone mineral content in premenopausal rheumatoid arthritis. *J Rheumatol.* 1992 Oct;19(10):1520-6.
53. Migliore A, Bizzi E, Massafra U, Vacca F, Martin Martin LS, Ferlito C, et al. Can Cyclosporine-A associated to methotrexate maintain remission induced by anti-TNF agents in rheumatoid arthritis patients? (Cynar pilot study). *Int J Immunopathol Pharmacol.* 2010 Jul-Sep;23(3):783-90.
54. Mladenovic V, Domljan Z, Rozman B, Jajic I, Mihajlovic D, Dordevic J, et al. Safety and Effectiveness of Leflunomide in the Treatment of Patients With Active Rheumatoid Arthritis. Results of a Randomized, Placebo-Controlled, Phase II Study. *Arthritis and rheumatism.* 1995;38(11):1595-603.
55. Moreland L, R G, King K, Chase W, Weisman M, Greco T, et al. Results of a Phase-I/II Randomized, Masked, Placebo-Controlled Trial of Recombinant Human Interleukin-11 (Rhil-11) in the Treatment of Subjects With Active Rheumatoid Arthritis. *Arthritis Res.* 2001;3(4):247-52.
56. Nishimoto N, Yoshizaki K, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Treatment of Rheumatoid Arthritis With Humanized Anti-Interleukin-6 Receptor Antibody: a Multicenter, Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism.* 2004;50(6):1761-9.
57. Paulus HE, Di Primeo D, Sanda M, Lynch JM, Schwartz BA, Sharp JT, et al. Progression of radiographic joint erosion during low dose corticosteroid treatment of rheumatoid arthritis. *J Rheumatol.* 2000 Jul;27(7):1632-7.
58. Peltomaa R, Paimela L, Helve T, Leirisalo-Repo M. Comparison of Intramuscular Gold and Sulphasalazine in the Treatment of Early Rheumatoid Arthritis. A One Year Prospective Study. *Scandinavian journal of rheumatology.* 1995;24(6):330-5.
59. Perdriger A, Mariette X, Kuntz JL, Brocq O, Kara-Terki R, Loet XL, et al. Safety of infliximab used in combination with leflunomide or azathioprine in daily clinical practice. *J Rheumatol.* 2006 May;33(5):865-9.
60. Plant M, O'Sullivan MM, Lewis P, Camilleri J, Coles E, Jessop J. What Factors Influence Functional Ability in Patients With Rheumatoid Arthritis. Do They Alter Over Time? *Rheumatology (Oxford).* 2005;44(9):1181-5.
61. Porter D, McInnes I, Hunter J, Capell H. Outcome of second line therapy in rheumatoid arthritis. *Annals of the rheumatic diseases.* 1994;53(12):812-5.
62. Sany J, Kaiser MJ, Jorgensen C, Trape G. Study of the tolerance of infliximab infusions with or without betamethasone premedication in patients with active rheumatoid arthritis. *Ann Rheum Dis.* 2005 Nov;64(11):1647-9.
63. Suarez Almazor M, Belseck E, Shea BJ, Homik J, Wells G, Tugwell P. Antimalarials for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews.* 2000;2000(4).
64. Suarez Almazor M, Belseck E, Shea BJ, Tugwell P, Wells G. Methotrexate for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews.* 1998;1998(2).
65. Suarez Almazor M, Belseck E, Shea BJ, Tugwell P, Wells G. Sulfasalazine for Treating Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews.* 1998;1998(2).

66. Suarez Almazor M, Spooner C, Belseck E. Azathioprine for Treating Rheumatoid Arthritis. The Cochrane Database of Systematic Reviews. 2000;2000(4).
67. Sugimori S, Watanabe T, Tabuchi M, Kameda N, Machida H, Okazaki H, et al. Evaluation of small bowel injury in patients with rheumatoid arthritis by capsule endoscopy: effects of anti-rheumatoid arthritis drugs. *Digestion*. 2008;78(4):208-13.
68. Tak PP, Thurlings RM, Rossier C, Nestorov I, Dimic A, Mircetic V, et al. Atacicept in patients with rheumatoid arthritis: Results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. *Arthritis and rheumatism*. 2008;58(1):61-72.
69. Tebib JG, Manil LM, Modder G, Verrier P, De Rycke Y, Bonmartin A, et al. Better Results With Rhenium-186 Radiosynoviorthesis Than With Cortivazol in Rheumatoid Arthritis (Ra): a Two-Year Follow-up Randomized Controlled Multicentre Study. *Clinical and experimental rheumatology*. 2004;22(5):609-16.
70. The Australian Multicentre Clinical Trial Group. Sulfasalazine in Early Rheumatoid Arthritis. *J Rheumatol*. 1992 7;19(11):1672.
71. Tsakonas E, Fitzgerald AA, Fitzcharles MA, Cividino A, Thorne JC, M'Seffar A, et al. Consequences of delayed therapy with second-line agents in rheumatoid arthritis: a 3 year followup on the hydroxychloroquine in early rheumatoid arthritis (HERA) study. *J Rheumatol*. 2000 Mar;27(3):623-9.
72. van der Heide A, Jacobs JW, Bijlsma JW, Heurkens AH, van Booma-Frankfort C, van der Veen MJ, et al. The effectiveness of early treatment with "second-line" antirheumatic drugs. A randomized, controlled trial. *Ann Intern Med*. 1996 Apr 15;124(8):699-707.
73. van Everdingen AA, Jacobs JW, Siewertsz Van Reesema DR, Bijlsma JW. Low-Dose Prednisone Therapy for Patients With Early Active Rheumatoid Arthritis: Clinical Efficacy, Disease-Modifying Properties, and Side Effects: a Randomized, Double-Blind, Placebo-Controlled Clinical Trial. *Annals of internal medicine*. 2002;136(1):1-12.
74. van Everdingen AA, Siewertsz van Reesema DR, Jacobs JW, Bijlsma JW. Low-Dose Glucocorticoids in Early Rheumatoid Arthritis: Discordant Effects on Bone Mineral Density and Fractures? *Clinical and experimental rheumatology*. 2003;21(2):155-60.
75. van Jaarsveld CH, Jacobs JW, van der Veen MJ, Blaauw AA, Kruize AA, Hofman DM, et al. Aggressive Treatment in Early Rheumatoid Arthritis: a Randomised Controlled Trial. *Annals of the Rheumatic Diseases*. 2000;59(6):468-77.
76. van Jaarsveld CH, Jahangier ZN, Jacobs JW, Blaauw AA, van Albada-Kuipers GA, ter Borg EJ, et al. Toxicity of Anti-Rheumatic Drugs in a Randomized Clinical Trial of Early Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2000;39(12):1374-82.
77. van Schaardenburg D, Valkema R, Dijkmans BA, Papapoulos S, Zwinderman AH, Han KH, et al. Prednisone Treatment of Elderly-Onset Rheumatoid Arthritis. Disease Activity and Bone Mass in Comparison With Chloroquine Treatment. *Arthritis and rheumatism*. 1995;38(3):334-42.
78. Verhoeven AC, Boers M, Tugwell P. Combination therapy in rheumatoid arthritis: updated systematic review. *Br J Rheumatol*. 1998 Jun;37(6):612-9.

79. Verstappen S, van Albada Kuipers G, Bijlsma J, Blaauw A, Schenk Y, Haanen H, et al. A Good Response to Early Dmard Treatment of Patients With Rheumatoid Arthritis in the First Year Predicts Remission During Follow up. *Ann Rheum Dis*. 2005;64(1):38-43.
80. Verstappen SMM, Jacobs JWG, Bijlsma JWJ, Heurkens AHM, van Booma-Frankfort C, Borg EJt, et al. Five-Year Followup of Rheumatoid Arthritis Patients After Early Treatment With Disease-Modifying Antirheumatic Drugs Versus Treatment According to the Pyramid Approach in the First Year. *Arthritis and rheumatism*. 2003;48(7):1797-807.
81. Wallberg-Jonsson S, Ohman ML, Dahlqvist SR. Cardiovascular morbidity and mortality in patients with seropositive rheumatoid arthritis in Northern Sweden. *J Rheumatol*. 1997 Mar;24(3):445-51.
82. Wallen Margaret M, Gillies D. Intra-articular steroids and splints/rest for children with juvenile idiopathic arthritis and adults with rheumatoid arthritis. *Cochrane Database of Systematic Reviews*. 2006(1).
83. Wassenberg S, Rau R, Steinfeld P, Zeidler H. Very Low-Dose Prednisolone in Early Rheumatoid Arthritis Retards Radiographic Progression Over Two Years: a Multicenter, Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 2005;52(11):3371-80.
84. Weinblatt ME, Kaplan H, Germain BF, Merriman RC, Solomon SD, Wall B, et al. Methotrexate in Rheumatoid Arthritis: Effects on Disease Activity in a Multicenter Prospective Study. *The Journal of rheumatology*. 1991;18(3):334-8.
85. Wolfe F, Hawley DJ. The comparative risk and predictors of adverse gastrointestinal events in rheumatoid arthritis and osteoarthritis: a prospective 13 year study of 2131 patients. *J Rheumatol*. 2000 Jul;27(7):1668-73.
86. Wolfe F, Michaud K, Li T. Sleep disturbance in patients with rheumatoid arthritis: evaluation by medical outcomes study and visual analog sleep scales. *J Rheumatol*. 2006 Oct;33(10):1942-51.
87. Zhang LL, Wei W, Xiao F, Xu JH, Bao CD, Ni LQ, et al. A randomized, double-blind, multicenter, controlled clinical trial of chicken type II collagen in patients with rheumatoid arthritis. *Arthritis Rheum*. 2008 Jul 15;59(7):905-10.

### **Wrong Population**

1. Abe T, Takeuchi T, Miyasaka N, Hashimoto H, Kondo H, Ichikawa Y, et al. A multicenter, double-blind, randomized, placebo controlled trial of infliximab combined with low dose methotrexate in Japanese patients with rheumatoid arthritis. *J Rheumatol*. 2006 Jan;33(1):37-44.
2. Allaart CF, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Breedveld FC, Dijkmans BA. Aiming at low disease activity in rheumatoid arthritis with initial combination therapy or initial monotherapy strategies: the BeSt study. *Clin Exp Rheumatol*. 2006 Nov-Dec;24(6 Suppl 43):S-77-82.
3. Alonso-Ruiz A, Pijoan JI, Ansuategui E, Urkaregi A, Calabozo M, Quintana A. Tumor necrosis factor alpha drugs in rheumatoid arthritis: Systematic review and metaanalysis of efficacy and safety. *BMC Musculoskeletal Disorders* 2008.

4. Anis A, Zhang W, Emery P, Sun H, Singh A, Freundlich B, et al. The effect of etanercept on work productivity in patients with early active rheumatoid arthritis: results from the COMET study. *Rheumatology (Oxford)* 2009;1283-9.
5. Askling J, Foreb CM, Baecklund E, Brandt L, Backlin C, Ekbom A, et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. *Ann Rheum Dis.* 2005 Oct;64(10):1414-20.
6. Askling J, Foreb CM, Brandt L, Baecklund E, Bertilsson L, Coster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. *Arthritis Rheum.* 2005 Jul;52(7):1986-92.
7. Askling J, Foreb CM, Brandt L, Baecklund E, Bertilsson L, Feltelius N, et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. *Ann Rheum Dis.* 2005 Oct;64(10):1421-6.
8. Askling J, van Vollenhoven RF, Granath F, Raaschou P, Foreb CM, Baecklund E, et al. Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment? *Arthritis Rheum* 2009;3180-9.
9. Baecklund E, Iliadou A, Askling J, Ekbom A, Backlin C, Granath F, et al. Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis. *Arthritis Rheum.* 2006 Mar;54(3):692-701.
10. Bathon JM, Fleischmann RM, Van der Heijde D, Tesser JR, Peloso PM, Chon Y, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. *J Rheumatol.* 2006 Feb;33(2):234-43.
11. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC, et al. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. *N Engl J Med.* 2000 Nov 30;343(22):1586-93.
12. Bazzani C, Filippini M, Caporali R, Bobbio-Pallavicini F, Favalli EG, Marchesoni A, et al. Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: Clinical outcomes. *Autoimmunity Reviews* 2009;260-5.
13. Bejarano V, Quinn M, Conaghan PG, Reece R, Keenan AM, Walker D, et al. Effect of the early use of the anti-tumor necrosis factor adalimumab on the prevention of job loss in patients with early rheumatoid arthritis. *Arthritis Rheum* 2008;1467-74.
14. Bergman GJ, Hochberg MC, Boers M, Wintfeld N, Kielhorn A, Jansen JP. Indirect comparison of tocilizumab and other biologic agents in patients with rheumatoid arthritis and inadequate response to disease-modifying antirheumatic drugs. *Semin Arthritis Rheum* 2010;425-41.
15. Bergstrom L, Yocum DE, Ampel NM, Villanueva I, Lisse J, Gluck O, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. *Arthritis Rheum.* 2004 Jun;50(6):1959-66.
16. Bernatsky S, Habel Y, Rahme E. Observational Studies of Infections in Rheumatoid Arthritis: A Metaanalysis of Tumor Necrosis Factor Antagonists. *Journal of Rheumatology* 2010;928-31.
17. Bernatsky S, Hudson M, Suissa S. Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis. *Rheumatology (Oxford)* 2007;1157-60.

18. Blumenauer B, Judd M, Cranney A, Burls A, Coyle D, Hochberg M, et al. Etanercept for the Treatment of Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2003;2003(3).
19. Blumenauer B, Judd M, Wells G, Burls A, Cranney A, Hochberg M, et al. Infliximab for the Treatment of Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2002;2002(3).
20. Boers M, Verhoeven AC, Markusse HM, van de Laar MA, Westhovens R, van Denderen JC, et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. *Lancet*. 1997 Aug 2;350(9074):309-18.
21. Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. *JAMA*. 2006 May 17;295(19):2275-85.
22. Bongartz T, Warren FC, Mines D, Matteson EL, Abrams KR, Sutton AJ. Etanercept therapy in rheumatoid arthritis and the risk of malignancies: a systematic review and individual patient data meta-analysis of randomised controlled trials. *Ann Rheum Dis* 2009;1177-83.
23. Boss B, Neeck G, Engelhardt B, Riedel W. Influence of corticosteroids on neutrophils, lymphocytes, their subsets, and T-cell activity markers in patients with active rheumatoid arthritis, compared to healthy controls. *Ann N Y Acad Sci*. 1999 Jun 22;876:198-200.
24. Brassard P, Kezouh A, Suissa S. Antirheumatic drugs and the risk of tuberculosis. *Clin Infect Dis* 2006;717-22.
25. Brassard P, Lowe AM, Bernatsky S, Kezouh A, Suissa S. Rheumatoid arthritis, its treatments, and the risk of tuberculosis in Quebec, Canada. *Arthritis Rheum* 2009:300-4.
26. Breedveld FC, Emery P, Keystone E, Patel K, Furst DE, Kalden JR, et al. Infliximab in active early rheumatoid arthritis. *Ann Rheum Dis* 2004:149-55.
27. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, van Vollenhoven R, et al. The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum*. 2006 Jan;54(1):26-37.
28. Bresnihan B, Alvaro-Gracia JM, Cobby M, Doherty M, Domljan Z, Emery P, et al. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. *Arthritis Rheum* 1998:2196-204.
29. Brown SL, Greene MH, Gershon SK, Edwards ET, Braun MM. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. *Arthritis Rheum*. 2002 Dec;46(12):3151-8.
30. Burmester GR, Mariette X, Montecucco C, Monteagudo-Saez I, Malaise M, Tzioufas AG, et al. Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial. *Ann Rheum Dis* 2007:732-9.



31. Cannon GW, Holden WL, Juhaeri J, Dai W, Scarazzini L, Stang P. Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. *J Rheumatol*. 2004 Oct;31(10):1906-11.
32. Capell H, Madhok R, Porter D, Munro R, McInnes I, Hunter J, et al. Combination therapy with sulphasalazine and methotrexate is more effective than either drug alone in rheumatoid arthritis (ra) patients with a suboptimal response to sulphasalazine: Results from the double blind placebo controlled mascot study. *Ann Rheum Dis*. 2006 August 22, 2006:ard.2006.057133.
33. Chakravarty EF, Michaud K, Wolfe F. Skin cancer, rheumatoid arthritis, and tumor necrosis factor inhibitors. *J Rheumatol*. 2005 Nov;32(11):2130-5.
34. Chakravarty EF, Sanchez-Yamamoto D, Bush TM. The use of disease modifying antirheumatic drugs in women with rheumatoid arthritis of childbearing age: a survey of practice patterns and pregnancy outcomes. *J Rheumatol*. 2003 Feb;30(2):241-6.
35. Cheifetz A, Smedley M, Martin S, Reiter M, Leone G, Mayer L, et al. The incidence and management of infusion reactions to infliximab: a large center experience. *Am J Gastroenterol*. 2003 Jun;98(6):1315-24.
36. Chopra A, Saluja M, Lagu-Joshi V, Sarmukadam S. Leflunomide (Arava) is a useful DMARD in Indian (Asian) patients: a clinic-based observational study of 1-year treatment. *Clin Rheumatol* 2008:1039-44.
37. Choy EH, Smith CM, Farewell V, Walker D, Hassell A, Chau L, et al. Factorial randomised controlled trial of glucocorticoids and combination disease modifying drugs in early rheumatoid arthritis. *Ann Rheum Dis* 2008:656-63.
38. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation*. 2003 Jul 1;107(25):3133-40.
39. Clark W, Jobanputra P, Barton P, Burls A. The clinical and cost-effectiveness of anakinra for the treatment of rheumatoid arthritis in adults: a systematic review and economic analysis. *Health Technol Assess*. 2004 May;8(18):iii-iv, ix-x, 1-105.
40. Cohen S, Cannon G, Schiff M, Weaver A, Fox R, Olsen N, et al. Two-Year, Blinded, Randomized, Controlled Trial of Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. *Arthritis and rheumatism*. 2001;44(9):1984-92.
41. Cohen S, Hurd E, Cush J, Schiff M, Weinblatt ME, Moreland LW, et al. Treatment of rheumatoid arthritis with anakinra, a recombinant human interleukin-1 receptor antagonist, in combination with methotrexate: results of a twenty-four-week, multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2002 Mar;46(3):614-24.
42. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, Genovese MC, et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. *Arthritis and Rheumatism* 2006:2793-806.

43. Cohen SB, Keystone E, Genovese MC, Emery P, Peterfy C, Tak PP, et al. Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate. *Ann Rheum Dis*. 2010/05/05 ed 2010:1158-61.
44. Cohen SB, Moreland LW, Cush JJ, Greenwald MW, Block S, Shergy WJ, et al. A multicentre, double blind, randomised, placebo controlled trial of anakinra (Kineret), a recombinant interleukin 1 receptor antagonist, in patients with rheumatoid arthritis treated with background methotrexate. *Ann Rheum Dis*. 2004 Sep;63(9):1062-8.
45. Cohen SB, Woolley JM, Chan W. Interleukin 1 receptor antagonist anakinra improves functional status in patients with rheumatoid arthritis. *J Rheumatol*. 2003 Feb;30(2):225-31.
46. Cole J, Busti A, Kazi S. The incidence of new onset congestive heart failure and heart failure exacerbation in Veteran's Affairs patients receiving tumor necrosis factor alpha antagonists. *Rheumatol Int* 2007:369-73.
47. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study. *Ann Rheum Dis* 2009:1146-52.
48. Combe B, Codreanu C, Fiocco U, Gaubitz M, Geusens PP, Kvien TK, et al. Etanercept and sulfasalazine, alone and combined, in patients with active rheumatoid arthritis despite receiving sulfasalazine: A double-blind comparison. *Annals of the rheumatic diseases*. 2006;65(10):1357-62.
49. Curtis JR, Kramer JM, Martin C, Saag KG, Patkar N, Shatin D, et al. Heart failure among younger rheumatoid arthritis and Crohn's patients exposed to TNF-alpha antagonists. *Rheumatology (Oxford)* 2007:1688-93.
50. Curtis JR, Patkar N, Xie A, Martin C, Allison JJ, Saag M, et al. Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists. *Arthritis Rheum* 2007:1125-33.
51. Curtis JR, Xi J, Patkar N, Xie A, Saag KG, Martin C. Drug-specific and time-dependent risks of bacterial infection among patients with rheumatoid arthritis who were exposed to tumor necrosis factor alpha antagonists. *Arthritis Rheum* 2007:4226-7.
52. Dass S, Bowman SJ, Vital EM, Ikeda K, Pease CT, Hamburger J, et al. Reduction of fatigue in Sjogren syndrome with rituximab: results of a randomised, double-blind, placebo-controlled pilot study. *Ann Rheum Dis*. 2008 Nov;67(11):1541-4.
53. Davaine AC, Saraux A, Prigent S, Kupfer-Bessagnet I, Roswag D, Plantin P, et al. Cutaneous events during treatment of chronic inflammatory joint disorders with anti-tumour necrosis factor alpha: a cross-sectional study. *J Eur Acad Dermatol Venereol*. 2008 Dec;22(12):1471-7.
54. De Bandt M, Sibilia J, Le Loet X, Prouzeau S, Fautrel B, Marcelli C, et al. Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey. *Arthritis Res Ther*. 2005;7(3):R545-51.
55. de Nijs RN, Jacobs JW, Bijlsma JW, Lems WF, Laan RF, Houben HH, et al. Prevalence of vertebral deformities and symptomatic vertebral fractures in corticosteroid treated patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2001 Dec;40(12):1375-83.

56. De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Hammoud M, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. *Clin Rheumatol*. 2010/01/19 ed 2010:517-24.
57. den Broeder AA, Creemers MC, Franssen J, de Jong E, de Rooij DJ, Wymenga A, et al. Risk factors for surgical site infections and other complications in elective surgery in patients with rheumatoid arthritis with special attention for anti-tumor necrosis factor: a large retrospective study. *J Rheumatol* 2007:689-95.
58. Devine EB, Alfonso-Cristancho R, Sullivan SD. Effectiveness of biologic therapies for rheumatoid arthritis: an indirect comparisons approach. *Pharmacotherapy* 2011:39-51.
59. Dixon WG, Hyrich KL, Watson KD, Lunt M, Galloway J, Ustianowski A, et al. Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). *Ann Rheum Dis* 2010:522-8.
60. Dixon WG, Watson K, Lunt M, Hyrich KL, Silman AJ, Symmons DP. Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum*. 2006 Jul 25;54(8):2368-76.
61. Dixon WG, Watson KD, Lunt M, Hyrich KL, Silman AJ, Symmons DPM, et al. Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: Results from the British Society for Rheumatology Biologics Register. *Arthritis and Rheumatism* 2007:2905-12.
62. Doran MF, Crowson CS, Pond GR, O'Fallon WM, Gabriel SE. Predictors of infection in rheumatoid arthritis. *Arthritis Rheum*. 2002 Sep;46(9):2294-300.
63. Dougados M, Combe B, Cantagrel A, Goupille P, Olive P, Schattenkirchner M, et al. Combination Therapy in Early Rheumatoid Arthritis: a Randomised, Controlled, Double Blind 52 Week Clinical Trial of Sulphasalazine and Methotrexate Compared With the Single Components. *Annals of the rheumatic diseases*. 1999;58(4):220-5.
64. Duclos M, Gossec L, Ruysse-Witrand A, Salliot C, Luc M, Guignard S, et al. Retention rates of tumor necrosis factor blockers in daily practice in 770 rheumatic patients. *J Rheumatol* 2006:2433-8.
65. Duftner C, Dejaco C, Larcher H, Schirmer M, Herold M. Biologicals in rheumatology: Austrian experiences from a rheumatic outpatient clinic. *Rheumatol Int*. 2008 Nov;29(1):69-73.
66. Edwards CJ, Cooper C, Fisher D, Field M, van Staa TP, Arden NK. The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis. *Arthritis Rheum* 2007:1151-7.
67. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. *N Engl J Med*. 2004 Jun 17;350(25):2572-81.
68. Emery P, Breedveld F, van der Heijde D, Ferraccioli G, Dougados M, Robertson D, et al. Two-year clinical and radiographic results with combination etanercept-methotrexate therapy versus monotherapy in early rheumatoid arthritis: a two-year, double-blind, randomized study. *Arthritis Rheum*. 2010/02/27 ed 2010:674-82.

69. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D, et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. *Lancet* 2008;375-82.
70. Emery P, Breedveld FC, Lemmel EM, Kaltwasser JP, Dawes PT, Gomor B, et al. A Comparison of the Efficacy and Safety of Leflunomide and Methotrexate for the Treatment of Rheumatoid Arthritis. *Rheumatology (Oxford)*. 2000;39(6):655-65.
71. Emery P, Deodhar A, Rigby WF, Isaacs JD, Combe B, Racewicz AJ, et al. Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX iNadequate rEsponders (SERENE)). *Ann Rheum Dis*. 2010/05/22 ed 2010:1629-35.
72. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Grp DS, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment - Results of a phase IIb randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis and Rheumatism (USA)* 2006:1390-400.
73. Emery P, Fleischmann R, Filipowicz-Sosnowska A, Schechtman J, Szczepanski L, Kavanaugh A, et al. The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial. *Arthritis Rheum* 2006:1390-400.
74. Emery P, Fleischmann RM, Moreland LW, Hsia EC, Strusberg I, Durez P, et al. Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: twenty-four-week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first-line therapy for early-onset rheumatoid arthritis. *Arthritis Rheum* 2009:2272-83.
75. Emery P, Keystone E, Tony HP, Cantagrel A, van Vollenhoven R, Sanchez A, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis* 2008:1516-23.
76. Emery P, Kosinski M, Li T, Martin M, Russell AS, et al. Treatment of rheumatoid arthritis patients with abatacept and methotrexate significantly improved health-related quality of life. *Journal of Rheumatology* 2006:681-9.
77. Faarvang K, Egsmose C, Kryger P, Podenphant J, Ingeman Nielsen M, Hansen TM. Hydroxychloroquine and Sulphasalazine Alone and in Combination in Rheumatoid Arthritis: a Randomised Double Blind Trial. *Annals of the rheumatic diseases*. 1993;52(10):711-5.
78. Feagan BG, Yan S, Bala M, Bao W, Lichtenstein GR. The effects of infliximab maintenance therapy on health-related quality of life. *Am J Gastroenterol*. 2003 Oct;98(10):2232-8.
79. Feltelius N, Fored CM, Blomqvist P, Bertilsson L, Geborek P, Jacobsson LT, et al. Results from a nationwide postmarketing cohort study of patients in Sweden treated with etanercept. *Ann Rheum Dis*. 2005 Feb;64(2):246-52.

80. Fernandez-Nebro A, Irigoyen MV, Urena I, Belmonte-Lopez MA, Coret V, Jimenez-Nunez FG, et al. Effectiveness, predictive response factors, and safety of anti-tumor necrosis factor (TNF) therapies in anti-TNF-naive rheumatoid arthritis. *J Rheumatol* 2007;2334-42.
81. Fernandez-Nebro A, Tomero E, Ortiz-Santamaria V, Castro MC, Olive A, de Haro M, et al. Treatment of rheumatic inflammatory disease in 25 patients with secondary amyloidosis using tumor necrosis factor alpha antagonists. *Am J Med.* 2005 May;118(5):552-6.
82. Finckh A, Ciurea A, Brulhart L, Kyburz D, Moller B, Dehler S, et al. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. *Arthritis Rheum* 2007:1417-23.
83. Finckh A, Ciurea A, Brulhart L, Moller B, Walker UA, Courvoisier D, et al. Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? *Ann Rheum Dis* 2010:387-93.
84. Finckh A, Dehler S, Gabay C. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors in rheumatoid arthritis: a population-based study. *Ann Rheum Dis* 2009:33-9.
85. Fleischmann R, Baumgartner SW, Weisman MH, Liu T, White B, Peloso P. Long term safety of etanercept in elderly subjects with rheumatic diseases. *Ann Rheum Dis* 2006:379-84.
86. Fleischmann R, Vencovsky J, van Vollenhoven RF, Borenstein D, Box J, Coteur G, et al. Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study. *Ann Rheum Dis.* 2009 Jun;68(6):805-11.
87. Fleischmann RM, Baumgartner SW, Tindall EA, Weaver AL, Moreland LW, Schiff MH, et al. Response to etanercept (Enbrel) in elderly patients with rheumatoid arthritis: a retrospective analysis of clinical trial results. *J Rheumatol.* 2003 Apr;30(4):691-6.
88. Fleischmann RM, Schechtman J, Bennett R, Handel ML, Burmester GR, Tesser J, et al. Anakinra, a recombinant human interleukin-1 receptor antagonist (r-metHuIL-1ra), in patients with rheumatoid arthritis: A large, international, multicenter, placebo-controlled trial. *Arthritis Rheum.* 2003 Apr;48(4):927-34.
89. Fleischmann RM, Tesser J, Schiff MH, Schechtman J, Burmester GR, Bennett R, et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. *Ann Rheum Dis.* 2006 Aug;65(8):1006-12.
90. Flendrie M, Creemers MC, Welsing PM, den Broeder AA, van Riel PL. Survival during treatment with tumour necrosis factor blocking agents in rheumatoid arthritis. *Ann Rheum Dis.* 2003 Nov;62 Suppl 2:ii30-3.
91. Flendrie M, Creemers MC, Welsing PM, van Riel PL. The influence of previous and concomitant leflunomide on the efficacy and safety of infliximab therapy in patients with rheumatoid arthritis: a longitudinal observational study. *Rheumatology (Oxford).* 2005 Apr;44(4):472-8.
92. Flendrie M, Vissers WH, Creemers MC, de Jong EM, van de Kerkhof PC, van Riel PL. Dermatological conditions during TNF-alpha-blocking therapy in patients with rheumatoid arthritis: a prospective study. *Arthritis Res Ther.* 2005;7(3):R666-76.

93. Fouache D, Goeb V, Massy-Guillemant N, Avenel G, Vittecoq O, et al., et al. Paradoxical adverse events of anti-tumour necrosis factor therapy for spondyloarthropathies: a retrospective study. *Rheumatology* 2009;761.
94. Franklin J, Lunt M, Bunn D, Symmons D, Silman A. Risk and predictors of infection leading to hospitalisation in a large primary-care-derived cohort of patients with inflammatory polyarthritis. *Ann Rheum Dis*. 2007 Mar;66(3):308-12.
95. Fuerst M, Mohl H, Baumgartel K, Ruther W. Leflunomide increases the risk of early healing complications in patients with rheumatoid arthritis undergoing elective orthopedic surgery. *Rheumatol Int* 2006;1138-42.
96. Furst DE, Schiff MH, Fleischmann RM, Strand V, Birbara CA, Compagnone D, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). *J Rheumatol*. 2003 Dec;30(12):2563-71.
97. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP, et al. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. *Rheumatology (Oxford, England)* 2011;124-31.
98. Gartlehner G, Hansen RA, Jonas BL, Thieda P, Lohr KN. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. *J Rheumatol*. 2006.
99. Gaujoux-Viala C, Smolen JS, Landewe R, Dougados M, Kvien TK, Mola EM, et al. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. *Ann Rheum Dis*. 2010 Jun;69(6):1004-9.
100. Geborek P, Bladstrom A, Turesson C, Gulfe A, Petersson IF, Saxne T, et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. *Ann Rheum Dis*. 2005 May;64(5):699-703.
101. Geborek P, Crnkic M, Petersson IF, Saxne T. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden. *Ann Rheum Dis*. 2002 Sep;61(9):793-8.
102. Genovese MC, Bathon JM, Fleischmann RM, Moreland LW, Martin RW, Whitmore JB, et al. Longterm safety, efficacy, and radiographic outcome with etanercept treatment in patients with early rheumatoid arthritis. *J Rheumatol*. 2005 Jul;32(7):1232-42.
103. Genovese MC, Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. *Arthritis Rheum*. 2002 Jun;46(6):1443-50.
104. Genovese MC, Cohen S, Moreland L, Liem D, Robbins S, Newmark R, et al. Combination therapy with etanercept and anakinra in the treatment of patients with rheumatoid arthritis who have been treated unsuccessfully with methotrexate. *Arthritis Rheum*. 2004 May;50(5):1412-9.
105. Genovese MC, McKay JD, Nasonov EL, Mysler EF, Da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to

- disease-modifying antirheumatic drugs: The tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis and Rheumatism* 2008:2968-80.
106. Ghosh B, Halder S, Ghosh A, Dhar S. Early rheumatoid arthritis: Clinical and therapeutic evaluation in a tertiary care centre in India. *Indian Journal of Rheumatology* 2008:48-51.
  107. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. *Arthritis Rheum.* 2005 Nov;52(11):3381-90.
  108. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Allaart CF, Van Zeben D, Kerstens PJSM, Hazes JMW, et al. Comparison of treatment strategies in early rheumatoid arthritis: A randomized trial. *Annals of Internal Medicine* 2007:406-15.
  109. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. *Arthritis Rheum.* 2003 Aug;48(8):2122-7.
  110. Greenberg JD, Reed G, Kremer JM, Tindall E, Kavanaugh A, Zheng C, et al. Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry. *Ann Rheum Dis* 2010:380-6.
  111. Grijalva CG, Chung CP, Arbogast PG, Stein CM, Mitchel EF, Jr., Griffin MR. Assessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritis. *Med Care* 2007:S66-76.
  112. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF, Griffin MR. Initiation of rheumatoid arthritis treatments and the risk of serious infections. *Rheumatology (Oxford)* 2010:82-90.
  113. Guignard S, Gossec L, Bandinelli F, Dougados M. Comparison of the clinical characteristics of vasculitis occurring during anti-tumor necrosis factor treatment or not in rheumatoid arthritis patients. A systematic review of 2707 patients, 18 vasculitis. *Clin Exp Rheumatol* 2008:S23-9.
  114. Haagsma C, van Riel P, de Jong A, van de Putte L. Combination of Sulphasalazine and Methotrexate Versus the Single Components in Early Rheumatoid Arthritis: a Randomized, Controlled, Double-Blind, 52 Week Clinical Trial. *British journal of rheumatology.* 1997;36(10):1082-8.
  115. Hafstrom I, Albertsson K, Boonen A, Van Der Heijde D, Landewe R, Svensson B. Remission achieved after 2 years treatment with low-dose prednisolone in addition to diseasemodifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: An open 2-year continuation study. 2009.
  116. Hansen M, Podenphant J, Florescu A, Stoltenberg M, Borch A, Kluger E, et al. A Randomised Trial of Differentiated Prednisolone Treatment in Active Rheumatoid Arthritis. Clinical Benefits and Skeletal Side Effects. *Annals of the rheumatic diseases.* 1999;58(11):713-8.
  117. Harley CR, Frytak JR, Tandon N. Treatment compliance and dosage administration among rheumatoid arthritis patients receiving infliximab, etanercept, or methotrexate. *Am J Manag Care.* 2003 Oct;9(6 Suppl):S136-43.

118. Harrison MJ, Dixon WG, Watson KD, King Y, Groves R, Hyrich KL, et al. Rates of new-onset psoriasis in patients with rheumatoid arthritis receiving anti-tumour necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. *Ann Rheum Dis* 2009;209-15.
119. Hassett AL, Li T, Buyske S, Savage SV, Gignac MA. The multi-faceted assessment of independence in patients with rheumatoid arthritis: preliminary validation from the ATTAIN study. *Curr Med Res Opin* 2008;1443-53.
120. Heiberg MS, RÅ,devand E, Mikkelsen K, Kaufmann C, Didriksen A, Mowinckel P, et al. Adalimumab and methotrexate is more effective than adalimumab alone in patients with established rheumatoid arthritis: Results from a 6-month longitudinal, observational, multicentre study. *Annals of the rheumatic diseases* 2006;1379-83.
121. Helliwell PS, Ibrahim G. Ethnic differences in responses to disease modifying drugs. *Rheumatology (Oxford)*. 2003 Oct;42(10):1197-201.
122. Hetland ML, Christensen IJ, Tarp U, Dreyer L, All Dept Rheumatology D, et al. Direct Comparison of Treatment Responses, Remission Rates, and Drug Adherence in Patients With Rheumatoid Arthritis Treated With Adalimumab, Etanercept, or Infliximab Results From Eight Years of Surveillance of Clinical Practice in the Nationwide Danish DANBIO Registry. *Arthritis and Rheumatism (USA)* 2010;22-32.
123. Hjardem E, Ostergaard M, Podenphant J, Tarp U, Andersen LS, Bing J, et al. Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? *Ann Rheum Dis* 2007;1184-9.
124. Hochberg MC, Tracy JK, Hawkins-Holt M, Flores RH. Comparison of the efficacy of the tumour necrosis factor alpha blocking agents adalimumab, etanercept, and infliximab when added to methotrexate in patients with active rheumatoid arthritis. *Ann Rheum Dis*. 2003 2003;62 Suppl 2:ii13-6.
125. Hoff M, Kvien TK, Kalvesten J, Elden A, Haugeberg G. Adalimumab therapy reduces hand bone loss in early rheumatoid arthritis: explorative analyses from the PREMIER study. *Ann Rheum Dis* 2009;1171-6.
126. Hyrich KL, Lunt M, Watson KD, Symmons DP, Silman AJ. Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study. *Arthritis Rheum* 2007;13-20.
127. Hyrich KL, Symmons DP, Watson KD, Silman AJ. Comparison of the response to infliximab or etanercept monotherapy with the response to cotherapy with methotrexate or another disease-modifying antirheumatic drug in patients with rheumatoid arthritis: Results from the British Society for Rheumatology Biologics Register. *Arthritis Rheum*. 2006 May 30;54(6):1786-94.
128. Hyrich KL, Watson KD, Silman AJ, Symmons DP, Register BSRB. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. *Rheumatology* 2006;1558-65.
129. Iwatani M, Inoue E, Nakamura T, Nakajima A, Hara M, Tomatsu T, et al. Efficacy profile of bucillamine in rheumatoid arthritis patients in a large observational cohort study, IORRA. *Mod Rheumatol* 2006;376-80.
130. Jacobsson LT, Turesson C, Gulfe A, Kapetanovic MC, Petersson IF, Saxne T, et al. Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. *J Rheumatol*. 2005 Jul;32(7):1213-8.



131. Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. *Expert Rev Clin Immunol.* 2010/04/21 ed 2010:189-95.
132. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: The AMBITION study. 2010.
133. Karanikolas G, Charalambopoulos D, Vaiopoulos G, Andrianakos A, Rapti A, Karras D, et al. Adjunctive anakinra in patients with active rheumatoid arthritis despite methotrexate, or leflunomide, or cyclosporin-A monotherapy: a 48-week, comparative, prospective study. *Rheumatology (Oxford)* 2008:1384-8.
134. Karlsson JA, Kristensen LE, Kapetanovic MC, Gulfe A, Saxne T, Geborek P. Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register. *Rheumatology (Oxford)* 2008:507-13.
135. Karstila KL, Rantalaiho VM, Mustonen JT, Mottonen TT, Hannonen PJ, Leirisalo-Repo M, et al. Renal safety of initial combination versus single DMARD therapy in patients with early rheumatoid arthritis: an 11-year experience from the FIN-RACo Trial. *Clin Exp Rheumatol.* 2010/03/30 ed 2010:73-8.
136. Katz JA, Antoni C, Keenan GF, Smith DE, Jacobs SJ, Lichtenstein GR. Outcome of pregnancy in women receiving infliximab for the treatment of Crohn's disease and rheumatoid arthritis. *Am J Gastroenterol.* 2004 Dec;99(12):2385-92.
137. Kavanaugh A, Klareskog L, van der Heijde D, Li J, Freundlich B, Hooper M. Improvements in clinical response between 12 and 24 weeks in patients with rheumatoid arthritis on etanercept therapy with or without methotrexate. *Ann Rheum Dis* 2008:1444-7.
138. Kavanaugh A, Smolen JS, Emery P, Purcaru O, Keystone E, Richard L, et al. Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis. *Arthritis Rheum* 2009:1592-600.
139. Kavanaugh A, St Clair EW, McCune WJ, Braakman T, Lipsky P. Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy. *J Rheumatol.* 2000 Apr;27(4):841-50.
140. Kawakami K, Ikari K, Kawamura K, Tsukahara S, Momohara S, et al. Complications and features after joint surgery in rheumatoid arthritis patients treated with tumour necrosis factor-alpha blockers: perioperative interruption of tumour necrosis factor-alpha blockers decreases complications? *Rheumatology (Oxford)* 2010:341-7.
141. Kay J, Matteson EL, Dasgupta B, Nash P, Durez P, Hall S, et al. Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: a randomized, double-blind, placebo-controlled, dose-ranging study. *Arthritis Rheum* 2008:964-75.
142. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. *N Engl J Med.* 2001 Oct 11;345(15):1098-104.
143. Kekow J, Moots RJ, Emery P, Durez P, Koenig A, Singh A, et al. Patient-reported outcomes improve with etanercept plus methotrexate in active early rheumatoid arthritis and the improvement is strongly associated with remission: The COMET trial. 2010.

144. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. *Arthritis Rheum* 2008;785-93.
145. Keystone E, Emery P, Peterfy CG, Tak PP, Cohen S, Genovese MC, et al. Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies. *Ann Rheum Dis* 2009;216-21.
146. Keystone E, Freundlich B, Schiff M, Li J, Hooper M. Patients with moderate rheumatoid arthritis (RA) achieve better disease activity states with etanercept treatment than patients with severe RA. *J Rheumatol* 2009;522-31.
147. Keystone E, Genovese MC, Klareskog L, Hsia EC, Hall S, Miranda PC, et al. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: 52-week results of the GO-FORWARD study. *Annals of the rheumatic diseases* 2010;1129-35.
148. Keystone E, Heijde D, Mason D, Jr., Landewe R, Vollenhoven RV, Combe B, et al. Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum* 2008;3319-29.
149. Keystone EC, Genovese MC, Klareskog L, Hsia EC, Hall ST, Miranda PC, et al. Golimumab, a human antibody to tumour necrosis factor {alpha} given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study. *Ann Rheum Dis* 2009;789-96.
150. Keystone EC, Kavanaugh AF, Sharp JT, Tannenbaum H, Hua Y, Teoh LS, et al. Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: a randomized, placebo-controlled, 52-week trial. *Arthritis Rheum*. 2004 May;50(5):1400-11.
151. Kievit W, Adang EM, Fransen J, Kuper HH, van de Laar MA, Jansen TL, et al. The effectiveness and medication costs of three anti-tumour necrosis factor alpha agents in the treatment of rheumatoid arthritis from prospective clinical practice data. *Ann Rheum Dis* 2008;1229-34.
152. Kim HY, Lee SK, Song YW, Yoo DH, Koh EM, Yoo B, et al. A randomized, double-blind, placebo-controlled, phase III study of the human anti-tumor necrosis factor antibody adalimumab administered as subcutaneous injections in Korean rheumatoid arthritis patients treated with methotrexate. *APLAR Journal of Rheumatology* 2007;9-16.
153. Kimel M, Cifaldi M, Chen N, Revicki D. Adalimumab plus methotrexate improved SF-36 scores and reduced the effect of rheumatoid arthritis (RA) on work activity for patients with early RA. *J Rheumatol* 2008;206-15.
154. Kirwan JR, Bijlsma JW, Boers M, Shea BJ. Effects of glucocorticoids on radiological progression in rheumatoid arthritis. *Cochrane Database Syst Rev* 2007;CD006356.
155. Kirwan JR, Hallgren R, Mielants H, Wollheim F, Bjorck E, Persson T, et al. A Randomised Placebo Controlled 12 Week Trial of Budesonide and Prednisolone in Rheumatoid Arthritis. *Annals of the rheumatic diseases*. 2004;63-6-688-95.

156. Klareskog L, van der Heijde D, de Jager JP, Gough A, Kalden J, Malaise M, et al. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet*. 2004 Feb 28;363(9410):675-81.
157. Korpela M, Laasonen L, Hannonen P, Kautiainen H, Leirisalo-Repo M, Hakala M, et al. Retardation of Joint Damage in Patients With Early Rheumatoid Arthritis by Initial Aggressive Treatment With Disease-Modifying Antirheumatic Drugs: Five-Year Experience From the Fin-Raco Study. *Arthritis and rheumatism*. 2004;50(7):2072-81.
158. Kosinski M, Kujawski SC, Martin R, Wanke LA, Buatti MC, Ware JE, Jr., et al. Health-related quality of life in early rheumatoid arthritis: impact of disease and treatment response. *Am J Manag Care*. 2002 Mar;8(3):231-40.
159. Kremer JL, Blanco R, Brzosko M, Burgos-Vargas R, Halland AM, Vernon E, et al. Tocilizumab inhibits structural joint damage in rheumatoid arthritis patients with inadequate responses to methotrexate at 1 year: The LITHE study. *Arthritis Rheum* 2010.
160. Kremer JM, Dougados M, Emery P, Durez P, Sibilia J, Shergy W, et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve-month results of a phase iib, double-blind, randomized, placebo-controlled trial. *Arthritis Rheum*. 2005 Aug;52(8):2263-71.
161. Kremer JM, Genant HK, Moreland LW, Russell AS, Westhovens R, et al. Effects of abatacept in patients with methotrexate-resistant active rheumatoid arthritis - A randomized trial. *Annals of Internal Medicine (USA)* 2006:865-76.
162. Kremer JM, Genovese MC, Cannon GW, Caldwell JR, Cush JJ, Furst DE, et al. Concomitant Leflunomide Therapy in Patients With Active Rheumatoid Arthritis Despite Stable Doses of Methotrexate. A Randomized, Double-Blind, Placebo-Controlled Trial. *Annals of internal medicine*. 2002;137(9):726-33.
163. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S, et al. Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. *N Engl J Med* 2003:1907-15.
164. Kristensen LE, Saxne T, Geborek P. The LUNDEX, a new index of drug efficacy in clinical practice: results of a five-year observational study of treatment with infliximab and etanercept among rheumatoid arthritis patients in southern Sweden. *Arthritis Rheum*. 2006 Feb;54(2):600-6.
165. Kristensen LE, Saxne T, Nilsson JA, Geborek P. Impact of concomitant DMARD therapy on adherence to treatment with etanercept and infliximab in rheumatoid arthritis. Results from a six-year observational study in southern Sweden. *Arthritis Res Ther* 2006:R174.
166. Kuriya B, Arkema EV, Bykerk VP, Keystone EC. Efficacy of initial methotrexate monotherapy versus combination therapy with a biological agent in early rheumatoid arthritis: a meta-analysis of clinical and radiographic remission. *Ann Rheum Dis*. 2010/04/28 ed 2010:1298-304.
167. Kwon HJ, Cote TR, Cuffe MS, Kramer JM, Braun MM. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. *Ann Intern Med*. 2003 May 20;138(10):807-11.
168. Lacaille D, Guh DP, Abrahamowicz M, Anis AH, Esdaile JM. Use of nonbiologic disease-modifying antirheumatic drugs and risk of infection in patients with rheumatoid arthritis. *Arthritis Rheum* 2008:1074-81.

169. Lan JL, Chou SJ, Chen DY, Chen YH, Hsieh TY, Young M, Jr. A comparative study of etanercept plus methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis: a 12-week, double-blind, randomized, placebo-controlled study. *J Formos Med Assoc.* 2004 Aug;103(8):618-23.
170. Landewe RB, Boers M, Verhoeven AC, Westhovens R, van de Laar MA, Markusse HM, et al. COBRA combination therapy in patients with early rheumatoid arthritis: long-term structural benefits of a brief intervention. *Arthritis Rheum.* 2002 Feb;46(2):347-56.
171. Langer HE, Missler-Karger B. Kineret: efficacy and safety in daily clinical practice: an interim analysis of the Kineret response assessment initiative (kreative) protocol. *Int J Clin Pharmacol Res.* 2003;23(4):119-28.
172. Larsen A, Kvien TK, Schattenkirchner M, Rau R, Scott DL, Smolen JS, et al. Slowing of Disease Progression in Rheumatoid Arthritis Patients During Long-Term Treatment With Leflunomide or Sulfasalazine. *Scandinavian journal of rheumatology.* 2001;30(3):135-42.
173. Lebowitz M, Blum R, Berkowitz E, Kim D, Zitnik R, Osteen C, et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. *Arch Dermatol.* 2005 Jul;141(7):861-4.
174. Lee JH, Slifman NR, Gershon SK, Edwards ET, Schwieterman WD, Siegel JN, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. *Arthritis Rheum.* 2002 Oct;46(10):2565-70.
175. Lee YH, Woo JH, Rho YH, Choi SJ, Ji JD, Song GG. Meta-analysis of the combination of TNF inhibitors plus MTX compared to MTX monotherapy, and the adjusted indirect comparison of TNF inhibitors in patients suffering from active rheumatoid arthritis. *Rheumatology international* 2008;553-9.
176. Leombruno JP, Einarson TR, Keystone EC. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. *Ann Rheum Dis* 2009;1136-45.
177. Li P, Blum MA, Von Feldt J, Hennessy S, Doshi JA. Adherence, discontinuation, and switching of biologic therapies in medicaid enrollees with rheumatoid arthritis. *Value Health.* 2010/11/09 ed 2010:805-12.
178. Li T, Gignac M, Wells G, Shen S, Westhovens R. Decreased external home help use with improved clinical status in rheumatoid arthritis: an exploratory analysis of the Abatacept in Inadequate responders to Methotrexate (AIM) trial. *Clin Ther* 2008;734-48.
179. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M, et al. Infections in patients with rheumatoid arthritis treated with biologic agents. *Arthritis Rheum.* 2005 Nov;52(11):3403-12.
180. Listing J, Strangfeld A, Kekow J, Schneider M, Kapelle A, Wassenberg S, et al. Does tumor necrosis factor alpha inhibition promote or prevent heart failure in patients with rheumatoid arthritis? *Arthritis Rheum* 2008;667-77.
181. Listing J, Strangfeld A, Rau R, Kekow J, Gromnica-Ihle E, Klopsch T, et al. Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low--results from RABBIT, the German biologics register. *Arthritis Res Ther.* 2006;8(3):R66.

182. Maetzel A, Wong A, Strand V, Tugwell P, Wells G, Bombardier C. Meta-analysis of treatment termination rates among rheumatoid arthritis patients receiving disease-modifying anti-rheumatic drugs. *Rheumatology (Oxford)*. 2000 Sep;39(9):975-81.
183. Maillefert JF, Combe B, Goupille P, Cantagrel A, Dougados M. Long Term Structural Effects of Combination Therapy in Patients With Early Rheumatoid Arthritis: Five Year Follow up of a Prospective Double Blind Controlled Study. *Annals of the rheumatic diseases*. 2003;62(8):764-6.
184. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. *Arthritis Rheum*. 1998 Sep;41(9):1552-63.
185. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Furst D, Weisman MH, et al. Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. *Arthritis Rheum*. 2004 Apr;50(4):1051-65.
186. Maini RN, Taylor PC, Szechinski J, Pavelka K, Broll J, Balint G, et al. Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis Rheum* 2006;2817-29.
187. Malysheva OA, Wahle M, Wagner U, Pierer M, Arnold S, Hantzschel H, et al. Low-dose prednisolone in rheumatoid arthritis: adverse effects of various disease modifying antirheumatic drugs. *J Rheumatol* 2008;979-85.
188. Marchesoni A, Zaccara E, Gorla R, Bazzani C, Sarzi-Puttini P, Atzeni F, et al. TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. *Ann N Y Acad Sci* 2009;837-46.
189. Mariette X, Tubach F, Bagheri H, Bardet M, Berthelot JM, Gaudin P, et al. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. *Annals of the rheumatic diseases* 2010;400-8.
190. Martinez Lopez JA, Loza E, Carmona L. Systematic review on the safety of methotrexate in rheumatoid arthritis regarding the reproductive system (fertility, pregnancy, and breastfeeding). *Clin Exp Rheumatol* 2009;678-84.
191. Mathias SD, Colwell HH, Miller DP, Moreland LW, Buatti M, Wanke L. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. *Clin Ther*. 2000 Jan;22(1):128-39.
192. Matthey DL, Brownfield A, Dawes PT. Relationship between pack-year history of smoking and response to tumor necrosis factor antagonists in patients with rheumatoid arthritis. *J Rheumatol* 2009;1180-7.
193. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE, et al. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. *Clin Infect Dis* 2009;1364-71.
194. Mease PJ, Revicki DA, Szechinski J, Greenwald M, Kivitz A, Barile-Fabris L, et al. Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial. *J Rheumatol* 2008;20-30.
195. Mertens M, Singh JA. Anakinra for rheumatoid arthritis. *Cochrane Database Syst Rev* 2009;CD005121.

196. Mertz LE, Blair JE. Coccidioidomycosis in rheumatology patients: incidence and potential risk factors. *Ann N Y Acad Sci* 2007:343-57.
197. Michaud K, Wolfe F. The association of rheumatoid arthritis and its treatment with sinus disease. *J Rheumatol* 2006:2412-5.
198. Migliore A, Bizzi E, Lagana B, Altomonte L, Zaccari G, Granata M, et al. The safety of anti-TNF agents in the elderly. *Int J Immunopathol Pharmacol.* 2009/06/10 ed 2009:415-26.
199. Miyasaka N. Clinical investigation in highly disease-affected rheumatoid arthritis patients in Japan with adalimumab applying standard and general evaluation: the CHANGE study. *Mod Rheumatol* 2008:252-62.
200. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. *Clin Infect Dis.* 2004 Aug 1;39(3):295-9.
201. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandberg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. *Arthritis Rheum.* 2001 Dec;44(12):2862-9.
202. Moreland LW, Baumgartner SW, Schiff MH, Tindall EA, Fleischmann RM, Weaver AL, et al. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. *N Engl J Med.* 1997 Jul 17;337(3):141-7.
203. Moreland LW, Schiff MH, Baumgartner SW, Tindall EA, Fleischmann RM, Bulpitt KJ, et al. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial. *Ann Intern Med.* 1999 Mar 16;130(6):478-86.
204. Moreland LW, Weinblatt ME, Keystone EC, Kremer JM, Martin RW, Schiff MH, et al. Etanercept treatment in adults with established rheumatoid arthritis: 7 years of clinical experience. *J Rheumatol.* 2006 May;33(5):854-61.
205. Mottonen T, Hannonen P, Leirisalo-Repo M, Nissila M, Kautiainen H, Korpela M, et al. Comparison of Combination Therapy With Single-Drug Therapy in Early Rheumatoid Arthritis: a Randomised Trial. *Lancet.* 1999;353(9164):1568-73.
206. Nadareishvili Z, Michaud K, Hallenbeck JM, Wolfe F. Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study. *Arthritis Rheum* 2008:1090-6.
207. Nagashima M, Matsuoka T, Saitoh K, Koyama T, Kikuchi O, Yoshino S. Treatment continuation rate in relation to efficacy and toxicity in long-term therapy with low-dose methotrexate, sulfasalazine, and bucillamine in 1,358 Japanese patients with rheumatoid arthritis. *Clin Exp Rheumatol* 2006:260-7.
208. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EM, et al. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. *Ann Rheum Dis* 2010:976-86.
209. Nannini C, Cantini F, Niccoli L, Cassara E, Lally EV, et al., et al. Single-Center Series and Systematic Review of Randomized Controlled Trials of Malignancies in Patients With Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis Receiving Anti-Tumor Necrosis Factor alpha Therapy: Is There a

- Need for More Comprehensive Screening Procedures? *Arthritis and Rheumatism-Arthritis Care and Research* 2009:801.
210. Naranjo A, Sokka T, Descalzo MA, Calvo-Alen J, Horslev-Petersen K, Luukkainen RK, et al. Cardiovascular disease in patients with rheumatoid arthritis: results from the QUEST-RA study. *Arthritis Res Ther* 2008:R30.
211. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. *Ann Rheum Dis* 2007:1162-7.
212. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. *Mod Rheumatol* 2009:12-9.
213. Nuki G, Bresnihan B, Bear MB, McCabe D. Long-term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin-1 receptor antagonist) in patients with rheumatoid arthritis: extension phase of a randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*. 2002 Nov;46(11):2838-46.
214. O'Dell JR, Haire CE, Erikson N, Drymalski W, Palmer W, Eckhoff PJ, et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. *N Engl J Med*. 1996 May 16;334(20):1287-91.
215. O'Dell JR, Leff R, Paulsen G, Haire C, Mallek J, Eckhoff PJ, et al. Treatment of Rheumatoid Arthritis With Methotrexate and Hydroxychloroquine, Methotrexate and Sulfasalazine, or a Combination of the Three Medications: Results of a Two-Year, Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 2002;46(5):1164-70.
216. O'Dell JR, Petersen K, Leff R, Palmer W, Schned E, Blakely K, et al. Etanercept in combination with sulfasalazine, hydroxychloroquine, or gold in the treatment of rheumatoid arthritis. *J Rheumatol*. 2006 Feb;33(2):213-8.
217. Osiri M, Deesomchok U, Tugwell P. Disease activity and functional changes of RA patients receiving different DMARDs in clinical practice. *Clinical Rheumatology* 2006:721-7.
218. Osiri M, Shea B, Welch V, Suarez Almazor Maria E, Strand V, Tugwell P, et al. Leflunomide for the treatment of rheumatoid arthritis. 2002.
219. Pallavicini FB, Caporali R, Sarzi-Puttini P, Atzeni F, Bazzani C, Gorla R, et al. Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. *Autoimmun Rev* 2010:175-80.
220. Pan SM, Dehler S, Ciurea A, Ziswiler HR, Gabay C, Finckh A. Comparison of drug retention rates and causes of drug discontinuation between anti-tumor necrosis factor agents in rheumatoid arthritis. *Arthritis Rheum* 2009:560-8.
221. Puechal X, Miceli-Richard C, Mejjad O, Lafforgue P, Marcelli C, Solau-Gervais E, et al. Anti-tumour necrosis factor treatment in patients with refractory systemic vasculitis associated with rheumatoid arthritis. *Ann Rheum Dis*. 2008 Jun;67(6):880-4.

222. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Julkunen H, et al. Impact of Initial Aggressive Drug Treatment With a Combination of Disease-Modifying Antirheumatic Drugs on the Development of Work Disability in Early Rheumatoid Arthritis: a Five-Year Randomized Followup Trial. *Arthritis and rheumatism*. 2004;50(1):55-62.
223. Rheumatoid Arthritis Clinical Trial Archive Group. The Effect of Age and Renal Function on the Efficacy and Toxicity of Methotrexate in Rheumatoid Arthritis. *J Rheumatol*. 1995;22(2):218-23.
224. Russell AS, Wallenstein GV, Li T, Martin MC, Maclean R, Blaisdell B, et al. Abatacept improves both the physical and mental health of patients with rheumatoid arthritis who have inadequate response to methotrexate treatment. *Ann Rheum Dis*. 2007 Feb;66(2):189-94.
225. Saag KG, Koehnke R, Caldwell JR, Brasington R, Burmeister LF, Zimmerman B, et al. Low dose long-term corticosteroid therapy in rheumatoid arthritis: an analysis of serious adverse events. *Am J Med*. 1994 Feb;96(2):115-23.
226. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. *Ann Rheum Dis* 2009:25-32.
227. Salliot C, Gossec L, Ruysen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor- $\alpha$  blocker therapy for rheumatic diseases in daily practice: a systematic retrospective study of 709 patients. *Rheumatology*. 2006 July 31, 2006:kel236.
228. Salliot C, Gossec L, Ruysen-Witrand A, Luc M, Duclos M, Guignard S, et al. Infections during tumour necrosis factor- $\alpha$  blocker therapy for rheumatic diseases in daily practice: A systematic retrospective study of 709 patients. *Rheumatology* 2007:327-34.
229. Schafer JA, Kjesbo NK, Gleason PP. Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis. *J Manag Care Pharm*. 2010 Jul-Aug;16(6):402-16.
230. Schaible TF. Long term safety of infliximab. *Can J Gastroenterol*. 2000 Sep;14 Suppl C:29C-32C.
231. Schiff M, Keiserman M, Codding C, Songcharoen S, Berman A, Nayiager S, et al. Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate. *Ann Rheum Dis* 2008:1096-103.
232. Schiff MH, Burmester GR, Kent JD, Pangan AL, Kupper H, Fitzpatrick SB, et al. Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis. *Ann Rheum Dis*. 2006 Jul;65(7):889-94.
233. Schiff MH, DiVittorio G, Tesser J, Fleischmann R, Schechtman J, Hartman S, et al. The safety of anakinra in high-risk patients with active rheumatoid arthritis: six-month observations of patients with comorbid conditions. *Arthritis Rheum*. 2004 Jun;50(6):1752-60.
234. Schipper LG, Fransen J, Barrera P, den Broeder AA, Van Riel PL. Methotrexate therapy in rheumatoid arthritis after failure to sulphasalazine: to switch or to add? *Rheumatology (Oxford)* 2009:1247-53.



235. Schipper LG, Fransen J, Barrera P, Van Riel PL. Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naive to both drugs. *Rheumatology (Oxford)* 2009;828-33.
236. Schneeweiss S, Setoguchi S, Weinblatt ME, Katz JN, Avorn J, Sax PE, et al. Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis. *Arthritis Rheum* 2007;1754-64.
237. Schoels M, Kapral T, Stamm T, Smolen JS, Aletaha D. Step-up combination versus switching of non-biological disease-modifying antirheumatic drugs in rheumatoid arthritis: results from a retrospective observational study. *Ann Rheum Dis* 2007;1059-65.
238. Scott DL, Smolen JS, Kalden JR, van de Putte LB, Larsen A, Kvien TK, et al. Treatment of Active Rheumatoid Arthritis With Leflunomide: Two Year Follow up of a Double Blind, Placebo Controlled Trial Versus Sulfasalazine. *Annals of the rheumatic diseases*. 2001;60(10):913-23.
239. Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. *J Rheumatol*. 2007 Apr;34(4):706-11.
240. Setoguchi S, Schneeweiss S, Avorn J, Katz JN, Weinblatt ME, Levin R, et al. Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis. *Am Heart J* 2008;336-41.
241. Setoguchi S, Solomon DH, Weinblatt ME, Katz JN, Avorn J, Glynn RJ, et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. *Arthritis Rheum*. 2006 Sep;54(9):2757-64.
242. Sharp JT, Strand V, Leung H, Hurley F, Loew-Friedrich I. Treatment With Leflunomide Slows Radiographic Progression of Rheumatoid Arthritis: Results From Three Randomized Controlled Trials of Leflunomide in Patients With Active Rheumatoid Arthritis. *Arthritis and rheumatism*. 2000;43(3):495-505.
243. Shin IS, Baer AN, Kwon HJ, Papadopoulos EJ, Siegel JN. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. *Arthritis Rheum*. 2006 May;54(5):1429-34.
244. Sichletidis L, Settas L, Spyrtos D, Chloros D, Patakas D. Tuberculosis in patients receiving anti-TNF agents despite chemoprophylaxis. *Int J Tuberc Lung Dis*. 2006 Oct;10(10):1127-32.
245. Signorovitch JE, Wu EQ, Yu AP, Gerrits CM, Mulani PM, et al. Comparative Effectiveness Without Head-to-Head Trials A Method for Matching-Adjusted Indirect Comparisons Applied to Psoriasis Treatment with Adalimumab or Etanercept. *Pharmacoeconomics (New Zealand)*. 2010;28:935-45.
246. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Tugwell P, et al., et al. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. *Canadian Medical Association Journal (Canada)* 2009;787.
247. Singh JA, Noorbaloochi S, Singh G. Golimumab for rheumatoid arthritis. *Cochrane Database Syst Rev*. 2010/01/22 ed 2010:CD008341.
248. Singh Jasvinder A, Beg S, Lopez-Olivo Maria A. Tocilizumab for rheumatoid arthritis. *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd 2010.

249. Singh Jasvinder A, Christensen R, Wells George A, Suarez-Almazor Maria E, Buchbinder R, Lopez-Olivo Maria A, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd 2009.
250. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. *Arthritis Rheum*. 2003 Feb;48(2):319-24.
251. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. *Arthritis Rheum* 2007:1431-8.
252. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. *J Rheumatol* 2008:387-93.
253. Smolen J, Landewe RB, Mease P, Brzezicki J, Mason D, Luijgens K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Ann Rheum Dis* 2009:797-804.
254. Smolen JS. Efficacy and Safety of the New Dmard Leflunomide: Comparison to Placebo and Sulfasalazine in Active Rheumatoid Arthritis. *Scandinavian journal of rheumatology Supplement*. 1999;112:15-21.
255. Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet* 2008:987-97.
256. Smolen JS, Han C, Bala M, Maini RN, Kalden JR, van der Heijde D, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement: a detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. *Arthritis Rheum* 2005:1020-30.
257. Smolen JS, Han C, van der Heijde D, Emery P, Bathon JM, Keystone E, et al. Infliximab treatment maintains employability in patients with early rheumatoid arthritis. *Arthritis Rheum*. 2006 Mar;54(3):716-22.
258. Smolen JS, Han C, van der Heijde DM, Emery P, Bathon JM, Keystone E, et al. Radiographic changes in rheumatoid arthritis patients attaining different disease activity states with methotrexate monotherapy and infliximab plus methotrexate: the impacts of remission and tumour necrosis factor blockade. *Ann Rheum Dis* 2009:823-7.
259. Smolen JS, Kalden JR, Scott DL, Rozman B, Kvien TK, Larsen A, et al. Efficacy and Safety of Leflunomide Compared With Placebo and Sulphasalazine in Active Rheumatoid Arthritis: a Double-Blind, Randomised, Multicentre Trial. *Lancet*. 1999;353(9149):259-66.
260. Smolen JS, Kay J, Doyle MK, Landewe R, Matteson EL, Wollenhaupt J, et al. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial. *Lancet* 2009:210-21.
261. Soderlin MK, Lindroth Y, Jacobsson LT. Trends in medication and health-related quality of life in a population-based rheumatoid arthritis register in Malmo, Sweden. *Rheumatology (Oxford)* 2007:1355-8.

262. Sokolove J, Strand V, Greenberg JD, Curtis JR, Kavanaugh A, Kremer JM, et al. Risk of elevated liver enzymes associated with TNF inhibitor utilisation in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2010/05/08 ed 2010:1612-7.
263. Solomon DH, Avorn J, Katz JN, Weinblatt ME, Schneeweiss S, et al. Immunosuppressive medications and hospitalization for cardiovascular events in patients with rheumatoid arthritis. *Arthritis and Rheumatism (USA)* 2006:3790-8.
264. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P, et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum*. 2004 Nov;50(11):3432-43.
265. Strand V, Balbir-Gurman A, Pavelka K, Emery P, Li N, Yin M, et al. Sustained benefit in rheumatoid arthritis following one course of rituximab: improvements in physical function over 2 years. *Rheumatology (Oxford)* 2006:1505-13.
266. Strand V, Cohen S, Schiff M, Weaver A, Fleischmann R, Cannon G, et al. Treatment of Active Rheumatoid Arthritis With Leflunomide Compared With Placebo and Methotrexate. *Archives of Internal Medicine*. 1999;159(21):2542-50.
267. Strand V, Tugwell P, Bombardier C, Maetzel A, Crawford B, Dorrier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. *Arthritis Rheum*. 1999 Sep;42(9):1870-8.
268. Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W, et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. *Arthritis Res Ther*. 2010/01/13 ed 2010:R5.
269. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C, et al. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. *Jama* 2009:737-44.
270. Suissa S, Bernatsky S, Hudson M. Antirheumatic drug use and the risk of acute myocardial infarction. *Arthritis Rheum* 2006:531-6.
271. Suissa S, Ernst P, Hudson M, Bitton A, Kezouh A. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. *Am J Med*. 2004 Jul 15;117(2):87-92.
272. Suissa S, Hudson M, Ernst P. Leflunomide use and the risk of interstitial lung disease in rheumatoid arthritis. *Arthritis Rheum*. 2006 May;54(5):1435-9.
273. Svensson B, Ahlmen M, Forslind K. Treatment of early RA in clinical practice: a comparative study of two different DMARD/corticosteroid options. *Clin Exp Rheumatol*. 2003 May-Jun;21(3):327-32.
274. Svensson B, Boonen A, Albertsson K, van der Heijde D, Keller C, Hafstrom I. Low-Dose Prednisolone in Addition to the Initial Disease-Modifying Antirheumatic Drug in Patients With Early Active Rheumatoid Arthritis Reduces Joint Destruction and Increases the Remission Rate: a Two-Year Randomized Trial. *Arthritis and rheumatism*. 2005;52(11):3360-70.
275. Tesser J, Fleischmann R, Dore R, Bennett R, Solinger A, Joh T, et al. Concomitant Medication Use in a Large, International, Multicenter, Placebo Controlled Trial of Anakinra, a Recombinant Interleukin 1

- Receptor Antagonist, in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 2004;31(4):649-54.
276. Todoerti M, Scire CA, Boffini N, Bugatti S, Montecucco C, Caporali R. Early disease control by low-dose prednisone comedication may affect the quality of remission in patients with early rheumatoid arthritis. *Ann N Y Acad Sci*. 2010/04/20 ed 2010:139-45.
277. Tran S, Hooker RS, Cipher DJ, Reimold A, Jul. Patterns of Biologic Agent Use in Older Males with Inflammatory Diseases An Institution-Focused, Observational Post-Marketing Study. *Drugs and Aging (New Zealand)*. 2009;26:607.
278. van de Putte LB, Atkins C, Malaise M, Sany J, Russell AS, van Riel PL, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. *Ann Rheum Dis*. 2004 May;63(5):508-16.
279. van de Putte LB, Rau R, Breedveld FC, Kalden JR, Malaise MG, van Riel PL, et al. Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study. *Ann Rheum Dis*. 2003 Dec;62(12):1168-77.
280. van der Heijde D, Klareskog L, Boers M, Landewe R, Codreanu C, Bolosiu HD, et al. Comparison of different definitions to classify remission and sustained remission: 1 year TEMPO results. *Ann Rheum Dis*. 2005 Nov;64(11):1582-7.
281. van der Heijde D, Klareskog L, Landewe R, Bruyn GA, Cantagrel A, Durez P, et al. Disease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritis. *Arthritis Rheum* 2007:3928-39.
282. van der Heijde D, Klareskog L, Rodriguez-Valverde V, Codreanu C, Bolosiu H, Melo-Gomes J, et al. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis Rheum*. 2006 Apr;54(4):1063-74.
283. van der Heijde D, Klareskog L, Singh A, Tornero J, Melo-Gomes J, Codreanu C, et al. Patient reported outcomes in a trial of combination therapy with etanercept and methotrexate for rheumatoid arthritis: the TEMPO trial. *Ann Rheum Dis*. 2006 Mar;65(3):328-34.
284. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, Ewals JA, Han KH, Hazes JM, et al. Patient-reported outcomes in a randomized trial comparing four different treatment strategies in recent-onset rheumatoid arthritis. *Arthritis Rheum*. 2009 Jan 15;61(1):4-12.
285. van der Kooij SM, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Guler-Yuksel M, Zwinderman AH, Kerstens PJ, et al. Drug-free remission, functioning and radiographic damage after 4 years of response-driven treatment in patients with recent-onset rheumatoid arthritis. *Ann Rheum Dis* 2009:914-21.
286. Van Der Kooij SM, Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Peeters AJ, Van Krugten MV, Breedveld FC, et al. Probability of continued low disease activity in patients with recent onset rheumatoid arthritis treated according to the disease activity score. *Annals of the Rheumatic Diseases* 2008:266-9.
287. van Halm VP, Nurmohamed MT, Twisk JW, Dijkmans BA, Voskuyl AE. Disease-modifying antirheumatic drugs are associated with a reduced risk for cardiovascular disease in patients with rheumatoid arthritis: a case control study. *Arthritis Res Ther* 2006:R151.

288. van Riel PL, Taggart AJ, Sany J, Gaubitz M, Nab HW, Pedersen R, et al. Efficacy and safety of combination etanercept and methotrexate versus etanercept alone in patients with rheumatoid arthritis with an inadequate response to methotrexate: The ADORE study. *Ann Rheum Dis*. 2006 Feb 7.
289. Van Riel PL, Freundlich B, MacPeck D, Pedersen R, Foehl JR, Singh A. Patient-reported health outcomes in a trial of etanercept monotherapy versus combination therapy with etanercept and methotrexate for rheumatoid arthritis: The ADORE trial. *Annals of the Rheumatic Diseases* 2008;1104-10.
290. van Vollenhoven RF, Cifaldi MA, Ray S, Chen N, Weisman MH. Improvement in work place and household productivity for patients with early rheumatoid arthritis treated with adalimumab plus methotrexate: work outcomes and their correlations with clinical and radiographic measures from a randomized controlled trial companion study. *Arthritis Care Res (Hoboken)*. 2010/03/02 ed 2010:226-34.
291. van Vollenhoven RF, Ernestam S, Geborek P, Petersson IF, Coster L, Waltbrand E, et al. Addition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trial. *Lancet* 2009;459-66.
292. Wailoo A, Brennan A, Bansback N, Nixon R, Wolfe F, Michaud K. Modeling the cost effectiveness of etanercept, adalimumab and anakinra compared to infliximab in the treatment of patients with rheumatoid arthritis in the Medicare program. AHRQ Technology Assessment Program. 2006.
293. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. *Clin Infect Dis*. 2004 May 1;38(9):1261-5.
294. Wasserman MJ, Weber DA, Guthrie JA, Bykerk VP, Lee P, Keystone EC. Infusion-related reactions to infliximab in patients with rheumatoid arthritis in a clinical practice setting: relationship to dose, antihistamine pretreatment, and infusion number. *J Rheumatol*. 2004 Oct;31(10):1912-7.
295. Weaver AL, Lautzenheiser RL, Schiff MH, Gibofsky A, Perruquet JL, Luetkemeyer J, et al. Real-world effectiveness of select biologic and DMARD monotherapy and combination therapy in the treatment of rheumatoid arthritis: results from the RADIUS observational registry. *Curr Med Res Opin*. 2006 Jan;22(1):185-98.
296. Weinblatt M, Combe B, Covucci A, Aranda R, Becker JC, Keystone E. Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease-modifying antirheumatic drugs: A one-year randomized, placebo-controlled study. *Arthritis Rheum*. 2006 Aug 31;54(9):2807-16.
297. Weinblatt M, Schiff M, Goldman A, Kremer J, Luggen M, Li T, et al. Selective costimulation modulation using abatacept in patients with active rheumatoid arthritis while receiving etanercept: a randomised clinical trial. *Annals of the rheumatic diseases* 2007:228-34.
298. Weinblatt ME, Keystone EC, Furst DE, Kavanaugh AF, Chartash EK, Segurado OG. Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study. *Ann Rheum Dis*. 2006 Jun;65(6):753-9.
299. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA, et al. Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum*. 2003 Jan;48(1):35-45.

300. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med*. 1999 Jan 28;340(4):253-9.
301. Weisman MH, Paulus HE, Burch FX, Kivitz AJ, Fierer J, Dunn M, et al. A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases. *Rheumatology (Oxford)* 2007:1122-5.
302. Wells G, Li T, Maxwell L, Maclean R, Tugwell P. Responsiveness of patient reported outcomes including fatigue, sleep quality, activity limitation, and quality of life following treatment with abatacept for rheumatoid arthritis. *Ann Rheum Dis* 2008:260-5.
303. Wendling D, Streit G, Toussirot E, Prati C. Herpes zoster in patients taking TNFalpha antagonists for chronic inflammatory joint disease. *Joint Bone Spine*. 2008 Oct;75(5):540-3.
304. Westhovens R, Cole JC, Li T, Martin M, Sherrer Y, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. *Rheumatology* 2006:1238-46.
305. Westhovens R, Robles M, Ximenes AC, Nayiager S, Wollenhaupt J, Durez P, et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis and poor prognostic factors. 2009.
306. Westhovens R, Yocum D, Han J, Berman A, Strusberg I, Geusens P, et al. The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities: a large, randomized, placebo-controlled trial. *Arthritis Rheum*. 2006 Apr;54(4):1075-86.
307. Wiens A, Correr CJ, Pontarolo R, Venson R, Quinalha JV, Otuki MF. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. *Scand J Immunol* 2009:337-44.
308. Wiens A, Venson R, Correr CJ, Otuki MF, Pontarolo R. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. *Pharmacotherapy*. 2010/03/26 ed 2010:339-53.
309. Wolfe F, Caplan L, Michaud K. Treatment for rheumatoid arthritis and the risk of hospitalization for pneumonia: associations with prednisone, disease-modifying antirheumatic drugs, and anti-tumor necrosis factor therapy. *Arthritis Rheum*. 2006 Feb;54(2):628-34.
310. Wolfe F, Caplan L, Michaud K. Rheumatoid arthritis treatment and the risk of severe interstitial lung disease. *Scand J Rheumatol* 2007:172-8.
311. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. *Arthritis Rheum*. 2004 Jun;50(6):1740-51.
312. Wolfe F, Michaud K. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy. *Am J Med*. 2004 Mar 1;116(5):305-11.
313. Wolfe F, Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. *Arthritis Rheum* 2007:1433-9.

314. Wolfe F, Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: Analyses from a large US observational study. *Arthritis and Rheumatism* 2007;2886-95.
315. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. *Arthritis Rheum.* 2004 Feb;50(2):372-9.
316. Zhang FC, Hou Y, Huang F, Wu DH, Bao CD, Ni LQ, et al. Infliximab versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: A preliminary study from China. *APLAR Journal of Rheumatology* 2006:127-30.
317. Zink A, Listing J, Kary S, Ramlau P, Stoyanova-Scholz M, Babinsky K, et al. Treatment continuation in patients receiving biological agents or conventional DMARD therapy. *Ann Rheum Dis.* 2005 Sep;64(9):1274-9.

### Wrong Publication Type

1. Cochrane Collaboration guidelines.
2. Anakinra (Kineret) for rheumatoid arthritis. *Med Lett Drugs Ther.* 2002 Feb 18;44(1124):18-9.
3. Is it true that vaccines may not be safe for people with rheumatoid arthritis (which I have)? Does that mean I shouldn't get a flu shot? *Johns Hopkins Med Lett Health After 50.* 2004 Oct;17(8):8.
4. First Latin American position paper on the pharmacological treatment of rheumatoid arthritis. *Rheumatology.* 2006 01/01;45(JUN):7-2.
5. Screening for hydroxychloroquine retinopathy. 2006.
6. Rituxan (Rituximab) [Package Insert]. 2008.
7. Aletaha D, Smolen JS. The definition and measurement of disease modification in inflammatory rheumatic diseases. *Rheumatic Disease Clinics of North America.* 2006;32(1):9-44.
8. Anandacoomarasamy A, Kannangara S, Barnsley L. Cutaneous vasculitis associated with infliximab in the treatment of rheumatoid arthritis. *Intern Med J.* 2005 Oct;35(10):638-40.
9. Andres E, Limbach FX, Goichot B, Sibia J. Silent thyroiditis associated with etanercept in rheumatoid arthritis. *Ann Rheum Dis.* 2002 Jun;61(6):565.
10. Arend SM, Kuijper EJ, Allaart CF, Muller WH, Van Dissel JT. Cavitating pneumonia after treatment with infliximab and prednisone. *Eur J Clin Microbiol Infect Dis.* 2004 Aug;23(8):638-41.
11. Armstrong DJ, McCarron MT, Wright GD. Successful treatment of rheumatoid vasculitis-associated foot-drop with infliximab. *J Rheumatol.* 2005 Apr;32(4):759; author reply -60.
12. Arnold EL, Khanna D, Paulus H, Goodman MP. Acute injection site reaction to intraarticular etanercept administration. *Arthritis Rheum.* 2003 Jul;48(7):2078-9.
13. Ashok D, Ayliffe WH, Kiely PD. Necrotizing scleritis associated with rheumatoid arthritis: long-term remission with high-dose infliximab therapy. *Rheumatology (Oxford).* 2005 Jul;44(7):950-1.

14. Asli B, Wechsler B, Lemaitre C. Inhibition of tumor necrosis factor alpha and ankylosing spondylitis. *N Engl J Med*. 2003 Jan 23;348(4):359-61; author reply -61.
15. Assous N, Gossec L, Dougados M, Kahan A, Allanore Y. Efficacy of rituximab in patients with rheumatoid arthritis refractory or with contra-indication to anti-tumor necrosis factor-alpha drugs in daily practice: An open label observational study [3]. *Clinical and Experimental Rheumatology*. 2007;25(3).
16. Bankhurst AD. Etanercept and methotrexate combination therapy. *Clin Exp Rheumatol*. 1999 Nov-Dec;17(6 Suppl 18):S69-72.
17. Bartke U, Venten I, Kreuter A, Gubbay S, Altmeyer P, Brockmeyer NH. Human immunodeficiency virus-associated psoriasis and psoriatic arthritis treated with infliximab. *Br J Dermatol*. 2004 Apr;150(4):784-6.
18. Bennett AN, Wong M, Zain A, Panayi G, Kirkham B. Adalimumab-induced asthma. *Rheumatology (Oxford)*. 2005 Sep;44(9):1199-200.
19. Bermas BL. Use of immunosuppressive drugs in pregnancy and lactation. 2007.
20. Bleumink GS, ter Borg EJ, Ramselaar CG, Ch Stricker BH. Etanercept-induced subacute cutaneous lupus erythematosus. *Rheumatology (Oxford)*. 2001 Nov;40(11):1317-9.
21. Boatright MD, Wang BW. Clinical infection with *Strongyloides stercoralis* following etanercept use for rheumatoid arthritis. *Arthritis Rheum*. 2005 Apr;52(4):1336-7.
22. Bravo Vergel Y, Palmer S, Erhorn S, Young V, Brent S, Dyker A, et al. Adalimumab for the treatment of moderate to severe psoriatic arthritis. *Health Technology Assessment*. 2010.
23. Brocq O, Albert C, Roux C, Gerard D, Breuil V, Ziegler LE. Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients. *Joint Bone Spine*. 2004 Nov;71(6):601-3.
24. Brodszky V, Pentek M, Gulacsi L. Efficacy of adalimumab, etanercept, and infliximab in psoriatic arthritis based on ACR50 response after 24 weeks of treatment. *Scand J Rheumatol*. 2008 Sep-Oct;37(5):399-400.
25. Bruce SP, Boyce EG. Update on abatacept: A selective costimulation modulator for rheumatoid arthritis. *Annals of Pharmacotherapy*. 2007;41(7-8):1153-62.
26. Burls A, Clark WK, Jobanputra P. Anakinra for Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2005;2005(1).
27. Chevillotte-Maillard H, Ornetti P, Mistrih R, Sidot C, Dupuis J, Dellas JA, et al. Survival and safety of treatment with infliximab in the elderly population. *Rheumatology (Oxford)*. 2005 May;44(5):695-6.
28. Clelland S, Hunek JR. Etanercept injection site reaction. *Dermatol Nurs*. 2005 Oct;17(5):375-.
29. Clunie G, Voules S, Watts R. Dose reduction of etanercept--can we treat more patients using a fixed budget? *Rheumatology (Oxford)*. 2003 Apr;42(4):600-1.
30. Cobo Ibanez T, Yehia Tayel M, Balsa Criado A, Hernandez Sanz A, Martin Mola E. Safety and efficacy of leflunomide and infliximab versus methotrexate and infliximab combination therapy in rheumatoid arthritis. *Rheumatology (Oxford)*. 2005 Nov;44(11):1467-8.



31. Cocito D, Bergamasco B, Tavella A, Poglio F, Paolasso I, Costa P, et al. Multifocal motor neuropathy during treatment with infliximab. *J Peripher Nerv Syst*. 2005 Dec;10(4):386-7.
32. Cohen CD, Horster S, Sander CA, Bogner JR. Kaposi's sarcoma associated with tumour necrosis factor alpha neutralising therapy. *Ann Rheum Dis*. 2003 Jul;62(7):684.
33. Cohen JD, Zaltni S, Kaiser MJ, Bozonnat MC, Jorgensen C, Daures JP, et al. Secondary addition of methotrexate to partial responders to etanercept alone is effective in severe rheumatoid arthritis. *Ann Rheum Dis*. 2004 Feb;63(2):209-10.
34. Cohen MD, Conn DL. Benefits of low-dose corticosteroids in rheumatoid arthritis. *Bull Rheum Dis*. 1997 Jun;46(4):4-7.
35. Combe B, Landewe R, Lukas C, Bolosiu HD, Breedveld F, Dougados M, et al. EULAR recommendations for the management of early arthritis: Report of a task force of the European Standing Committee for International Clinical Studies Including Therapeutics (ESCISIT). *Annals of the rheumatic diseases*. 2007;66(1):34-45.
36. Cunnane G, Warnock M, Fye KH, Daikh DI. Accelerated nodulosis and vasculitis following etanercept therapy for rheumatoid arthritis. *Arthritis Rheum*. 2002 Aug;47(4):445-9.
37. Das P, Raghu P, Amit Kumar D, Garg P. Strongyloides hyperinfection in rheumatoid arthritis. *Int J Surg Pathol*. 2007 Oct;15(4):391-2.
38. Day R. Adverse reactions to TNF-alpha inhibitors in rheumatoid arthritis. *Lancet*. 2002 Feb 16;359(9306):540-1.
39. De Bandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. *Clin Rheumatol*. 2003 Feb;22(1):56-61.
40. Deighton CM, George E, Kiely PDW, Ledingham J, Luqmani RA, Scott DGI. Updating the British Society for Rheumatology guidelines for anti-tumour necrosis factor therapy in adult rheumatoid arthritis (again). *Rheumatology*. 2006;45(6):649-52.
41. Duggan ST, Keam SJ, Jun. Certolizumab Pegol In Rheumatoid Arthritis. *BioDrugs (New Zealand)*. 2009;23:407.
42. Dumont-Berset M, Laffitte E, Gerber C, Dudler J, Panizzon RG. Eczematous drug eruption after infliximab. *Br J Dermatol*. 2004 Dec;151(6):1272-3.
43. Emery P. Disease Modification in Rheumatoid Arthritis With Leflunomide. *Scandinavian journal of rheumatology Supplement*. 1999;112(9):9-14.
44. Emery P, Genovese MC, Fleischmann RM, Matteson EL, Hsia EC, Xu S, et al. Efficacy of Golimumab, a human anti-TNF(alpha) antibody, by baseline CRP level in patients with rheumatoid arthritis: Results from three phase 3, randomized, double-blind, placebo-controlled studies. *Rheumatology* 2010;i101.
45. Favalli EG, Arreghini M, Arnoldi C, Panni B, Marchesoni A, Tosi S, et al. Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. *Arthritis Rheum*. 2004 Apr 15;51(2):301-2.
46. Fleischmann R. The clinical efficacy and safety of certolizumab pegol in rheumatoid arthritis. *Expert Opin Biol Ther*. 2010 May;10(5):773-86.

47. Franklin CM. Clinical experience with soluble TNF p75 receptor in rheumatoid arthritis. *Semin Arthritis Rheum.* 1999 Dec;29(3):172-81.
48. Furst DE. Anakinra: review of recombinant human interleukin-I receptor antagonist in the treatment of rheumatoid arthritis. *Clin Ther.* 2004 Dec;26(12):1960-75.
49. Furst DE, Keystone EC, Kirkham B, Fleischmann R, Mease P, Breedveld FC, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. *Annals of the rheumatic diseases.* 2008;67(SUPPL. 3).
50. Gadadhar H, Hawkins S, Huffstutter JE, Panda M. Cutaneous mucormycosis complicating methotrexate, prednisone, and infliximab therapy. *J Clin Rheumatol.* 2007 Dec;13(6):361-2.
51. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, van Zeben D, Kerstens PJ, Hazes JM, et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial. *Arthritis Rheum.* 2008 Feb;58(2 Suppl):S126-35.
52. Goldenberg MM. Etanercept, a novel drug for the treatment of patients with severe, active rheumatoid arthritis. *Clin Ther.* 1999 Jan;21(1):75-87; discussion 1-2.
53. Golding A, Haque UJ, Giles JT. Rheumatoid arthritis and reproduction. *Rheum Dis Clin North Am.* 2007 May;33(2):319-43, vi-vii.
54. Gupta N, Fox CM, Grisolano SW. Disseminated histoplasmosis with colonic ulcers in a patient receiving infliximab. *Gastrointest Endosc.* 2009 Sep;70(3):597-8.
55. Health Technology A. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor: a systematic review and economic evaluation (Project record). *Health Technology Assessment.* 2010.
56. Health Technology A. The clinical and cost effectiveness of etanercept, infliximab and adalimumab - psoriatic arthritis (guidance review 104 and 125) (Project record). *Health Technology Assessment.* 2010.
57. Hewlett S, Hehir M, Kirwan JR. Measuring fatigue in rheumatoid arthritis: A systematic review of scales in use. *Arthritis Care and Research.* 2007;57(3):429-39.
58. Hirche D, Rubbert A, Lunau L, Krieg T, Eming SA. Successful treatment of refractory rheumatoid arthritis-associated leg ulcerations with adalimumab. *Br J Dermatol.* 2005 May;152(5):1062-4.
59. Hong BK, Kumar C, Marottoli RA. "MAC" attack. *Am J Med.* 2009 Dec;122(12):1096-8.
60. Horng MS. Early rheumatoid arthritis: Is there a best treatment? *Journal of Clinical Outcomes Management.* 2007;14(5):233-4.
61. Hoshida Y, Yamamoto S, Wada N, Xu JX, Sasaki T, Aozasa K. Infliximab-associated lymphoproliferative disorders. *Int J Hematol.* 2005 May;81(4):356-7.
62. Hrycaj P, Korczowska I, Lacki JK. Severe Parkinson's disease in rheumatoid arthritis patient treated with infliximab. *Rheumatology (Oxford).* 2003 May;42(5):702-3.
63. Inoue K, Takano H, Yanagisawa R, Yoshikawa T. Effects of tumor necrosis factor-alpha inhibitors on lung lesions with rheumatoid arthritis. *Chest.* 2003 Jul;124(1):413-4; author reply 4.

64. Josefina M, Ana CJ, Ariel V, Silvio AA. Development of pseudogout during etanercept treatment. *J Clin Rheumatol*. 2007 Jun;13(3):177.
65. Ju JH, Kim SI, Lee JH, Lee SI, Yoo WH, Choe JY, et al. Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. *Arthritis Rheum* 2007;2094-6.
66. Kaiser MJ, Bozonnet MC, Jorgensen C, Daures JP, Sany J. Effect of etanercept on tenosynovitis and nodules in rheumatoid arthritis. *Arthritis Rheum*. 2002 Feb;46(2):559-60.
67. Kelaidi C, Tulliez M, Lecoq-Lafon C, Pham XV, Kahan A, Dreyfus F, et al. Long-term remission of an EBV-positive B cell lymphoproliferative disorder associated with rheumatoid arthritis under methotrexate with anti-CD20 monoclonal antibody (Rituximab) monotherapy. *Leukemia*. 2002 Oct;16(10):2173-4.
68. Kemp E, Nielsen H, Petersen LJ, Gam AN, Dahlager J, Horn T, et al. Newer immunomodulating drugs in rheumatoid arthritis may precipitate glomerulonephritis. *Clin Nephrol*. 2001 Jan;55(1):87-8.
69. Kempeni J. Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7. *Ann Rheum Dis*. 1999 November 1, 1999;58(90001):70i-2.
70. Kempeni J. Update on D2E7: a fully human anti-tumour necrosis factor alpha monoclonal antibody. *Ann Rheum Dis*. 2000 November 1, 2000;59(90001):44i-5.
71. Kirwan J. Early rheumatoid arthritis: combination therapy with disease-modifying antirheumatic drugs and low-dose glucocorticoids? *Nat Clin Pract Rheumatol*. 2006 Apr;2(4):182-3.
72. Kirwan J, Shea B, Boers M. Glucocorticoids for Slowing Radiological Progression in Rheumatoid Arthritis. *The Cochrane Database of Systematic Reviews*. 2005;2005(1).
73. Korkmaz C, Kasifoglu T, Yasar B. Acceleration of left-ventricular diastolic dysfunction and pulmonary hypertension after TNF-alpha blocker. *Ann Pharmacother*. 2005 Jun;39(6):1138-9.
74. Kramer N, Chuzhin Y, Kaufman LD, Ritter JM, Rosenstein ED. Methotrexate pneumonitis after initiation of infliximab therapy for rheumatoid arthritis. *Arthritis Rheum*. 2002 Dec 15;47(6):670-1.
75. Krathen MS, Gottlieb AB, Mease PJ. Pharmacologic Immunomodulation and Cutaneous Malignancy in Rheumatoid Arthritis, Psoriasis, and Psoriatic Arthritis. *Journal of Rheumatology*. 2010;37:2205-15.
76. Kremer J, Westhovens R, Luggen M. Long-term efficacy and safety of abatacept through 3 years of treatment in rheumatoid arthritis patients in the AIM and ATTAIn trials [abstract]. *American College of Rheumatology Meeting*.
77. Kremer JM. Safety, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: followup after a mean of 13.3 years. *Arthritis Rheum*. 1997 May;40(5):984-5.
78. Kreuter A, Rose C, Zillikens D, Altmeyer P. Bullous rheumatoid neutrophilic dermatosis. *J Am Acad Dermatol*. 2005 May;52(5):916-8.
79. Kucharz EJ, Gozdzik J, Kopec M, Kotulska A, Lewicki M, Pieczyrak R, et al. A single infusion of infliximab increases the serum endostatin level in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2003 Mar-Apr;21(2):273-4.
80. Kurschat P, Rubbert A, Poswig A, Scharffetter-Kochanek K, Krieg T, Hunzelmann N. Treatment of psoriatic arthritis with etanercept. *J Am Acad Dermatol*. 2001 Jun;44(6):1052.

81. Liberopoulos EN, Drosos AA, Elisaf MS. Exacerbation of tuberculosis enteritis after treatment with infliximab. *Am J Med.* 2002 Nov;113(7):615.
82. Lindsay K, Gough A. Psoriatic arthritis, methotrexate and the liver - Are rheumatologists putting their patients at risk? *Rheumatology.* 2008;47(7):939-41.
83. Looney RJ. B cell-targeted therapy for rheumatoid arthritis - An update on the evidence. *Drugs (New Zealand).* 2006 05/01;66(May):625-39.
84. Luqmani R, Hennell S, Estrach C, Birrell F, Audit Working G, et al. British society for rheumatology and british health professionals in rheumatology guideline for the management of rheumatoid arthritis (the first two years). *Rheumatology.* 2006 09/01;45(Sep):1167-9.
85. Manadan AM, Block JA, Sequeira W. Mycobacteria tuberculosis peritonitis associated with etanercept therapy. *Clin Exp Rheumatol.* 2003 Jul-Aug;21(4):526.
86. Mang R, Stege H, Ruzicka T, Krutmann J. Response of severe psoriasis to infliximab. *Dermatology.* 2002;204(2):156-7.
87. Marchesoni A, Puttini PS, Gorla R, Caporali R, Arnoldi C, Atzeni F, et al. Cyclosporine in addition to infliximab and methotrexate in refractory rheumatoid arthritis. *Clin Exp Rheumatol.* 2005 Nov-Dec;23(6):916-7.
88. Matsui T, Komiya A, Shimada K, Nakayama H, Tohma S. Neutrophil CD64 as a marker of infection in patients treated with tocilizumab. *Mod Rheumatol.* 2009;19(6):696-7.
89. Maxwell L, Singh Jasvinder A. Abatacept for rheumatoid arthritis. *Cochrane Database of Systematic Reviews.* 2008(3).
90. McCain ME, Quinet RJ, Davis WE. Etanercept and infliximab associated with cutaneous vasculitis. *Rheumatology (Oxford).* 2002 Jan;41(1):116-7.
91. Mease P. Psoriatic arthritis update. *Bulletin of the NYU Hospital for Joint Diseases.* 2006;64(1-2):25-31.
92. Mease PJ. Cytokine Blockers in Psoriatic Arthritis. *Annals of the rheumatic diseases.* 2001;60(Suppl 3):iii37-40.
93. Michaelsson G, Kajermo U, Michaelsson A, Hagforsen E. Infliximab can precipitate as well as worsen palmoplantar pustulosis: possible linkage to the expression of tumour necrosis factor-alpha in the normal palmar eccrine sweat duct? *Br J Dermatol.* 2005 Dec;153(6):1243-4.
94. Misery L, Perrot JL, Gentil-Perret A, Pallot-Prades B, Cambazard F, Alexandre C. Dermatological complications of etanercept therapy for rheumatoid arthritis. *Br J Dermatol.* 2002 Feb;146(2):334-5.
95. Molloy E, Ramakrishnan S, Murphy E, Barry M. Morbidity and mortality in rheumatoid patients during treatment with adalimumab and infliximab. *Rheumatology (Oxford).* 2004 Apr;43(4):522-3.
96. Montagna GL, Malesci D, Buono R, Valentini G. Asthenoazoospermia in patients receiving anti-tumour necrosis factor {alpha} agents. *Ann Rheum Dis.* 2005 Nov;64(11):1667.
97. Murphy FT, Enzenauer RJ, Battafarano DF, David-Bajar K. Etanercept-associated injection-site reactions. *Arch Dermatol.* 2000 Apr;136(4):556-7.

98. Musial J, Undas A, Celinska-Lowenhoff M. Polymyositis associated with infliximab treatment for rheumatoid arthritis. *Rheumatology (Oxford)*. 2003 Dec;42(12):1566-8.
99. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. *Am J Med*. 2002 Jan;112(1):78.
100. Nikas SN, Temekonidis TI, Zikou AK, Argyropoulou MI, Efremidis S, Drosos AA. Treatment of resistant rheumatoid arthritis by intra-articular infliximab injections: a pilot study. *Ann Rheum Dis*. 2004 Jan;63(1):102-3.
101. Nikas SN, Voulgari PV, Takalou IP, Katsimbri P, Drosos AA. Healing of psoriatic skin lesions, and improvement of psoriatic arthritis resistant to immunosuppressive drugs, after infliximab treatment. *Ann Rheum Dis*. 2005 Nov;64(11):1665-7.
102. Novak S, Cikes N. Infliximab-induced lupus or rheumatoid arthritis (RA) overlapping with systemic lupus erythematosus (SLE) unmasked by infliximab. *Clin Exp Rheumatol*. 2004 Mar-Apr;22(2):268.
103. Ornetti P, Solau E, Gaudin P, Sibilia J, Berthelot JM, Puechal X, et al. Increase in methotrexate dose in patients with rheumatoid arthritis who have an inadequate response to infliximab. *Ann Rheum Dis*. 2005 Sep;64(9):1379-80.
104. Ostor AJ, Crisp AJ, Somerville MF, Scott DG. Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. *BMJ*. 2004 Nov 27;329(7477):1266.
105. Ostrov BE. Beneficial effect of etanercept on rheumatoid lymphedema. *Arthritis Rheum*. 2001 Jan;44(1):240-1.
106. Pagliano P, Attanasio V, Fusco U, Mohamed DA, Rossi M, Faella FS. Does etanercept monotherapy enhance the risk of *Listeria monocytogenes* meningitis? *Ann Rheum Dis*. 2004 Apr;63(4):462-3.
107. Parekh K, Ching D, Rahman MU, Stamp LK. Onset of Wegener's granulomatosis during therapy with golimumab for rheumatoid arthritis: a rare adverse event? *Rheumatology (Oxford)*. 2010 Sep;49(9):1785-7.
108. Pisoni L, Murgo A, Paresce E, Zeni S, Fantini F. Effectiveness and safety of leflunomide in the clinical practice. A different experience [1]. *Clinical and Experimental Rheumatology*. 2007;25(1).
109. Popovic M, Stefanovic D, Pejnovic N, Popovic R, Glisic B, Obradovic S, et al. Comparative study of the clinical efficacy of four DMARDs (leflunomide, methotrexate, cyclosporine, and levamisole) in patients with rheumatoid arthritis. *Transplant Proc*. 1998 Dec;30(8):4135-6.
110. Provenzano G, Termini A, Le Moli C, Rinaldi F. Efficacy of infliximab in psoriatic arthritis resistant to treatment with disease modifying antirheumatic drugs: an open pilot study. *Ann Rheum Dis*. 2003 Jul;62(7):680-1.
111. Racunica T, Cassidy D, Cicuttini F, Hall A. Trouble with tumor necrosis factor alpha inhibitors, not just tuberculosis. *Arthritis Care Res (Hoboken)*. 2010/06/11 ed 2010:770-4.
112. Radovits BJ, Kievit W, Laan RF. Tumour necrosis factor-alpha antagonists in the management of rheumatoid arthritis in the elderly: a review of their efficacy and safety. *Drugs Aging*. 2009;26(8):647-64.

113. Rahman N, Healy C, Flint SR, Stassen LF. Cautionary note: a possible association between oral squamous cell carcinoma and tumor necrosis factor antagonists; need for oral screening. *J Clin Rheumatol*. 2010 Jun;16(4):197-9.
114. Reddy AR, Backhouse OC. Does etanercept induce uveitis? *Br J Ophthalmol*. 2003 Jul;87(7):925.
115. Richter C, Wanke L, Steinmetz J, Reinhold-Keller E, Gross WL. Mononeuritis secondary to rheumatoid arthritis responds to etanercept. *Rheumatology (Oxford)*. 2000 Dec;39(12):1436-7.
116. Rimar D, Rozenbaum M, Slobodin G, Boulman N, Rosner I. Etanercept related pseudo-empyema in rheumatoid arthritis. *Clin Rheumatol*. 2010/02/04 ed 2010:547-9.
117. Rinaldi F, Provenzano G, Termini A, Spinello M, La Seta F. Long term infliximab treatment for severe psoriatic arthritis: evidence of sustained clinical and radiographic response. *Ann Rheum Dis*. 2005 Sep;64(9):1375-6.
118. Robinson V, Boers M, Brooks P, Francis D, Wells GA, et al. Patient-reported pain is central to OMERACT rheumatology core measurement sets. *Drug Information Journal (USA)*. 2006 01/01/;40(Jan):111-6.
119. Roux CH, Brocq O, Breuil V, Albert C, Euller-Ziegler L. Pregnancy in rheumatology patients exposed to anti-tumour necrosis factor (TNF)- $\alpha$  therapy. *Rheumatology*. 2007;46(4):695-8.
120. Rozman B. Clinical Experience With Leflunomide in Rheumatoid Arthritis. *The Journal of rheumatology*. 1998;52(Suppl):27-32.
121. Ruiz Garcia V, Burls A, Cabello López Juan CL, Fry- Smith Anne FS, Gálvez Muñoz José G, Jobanputra P, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. *Cochrane Database of Systematic Reviews*. 2009(1).
122. Russell E, Zeihen M, Wergin S, Litton T. Patients receiving etanercept may develop antibodies that interfere with monoclonal antibody laboratory assays. *Arthritis Rheum*. 2000 Apr;43(4):944.
123. Salli A, Sahin N, Paksoy Y, Kucuksarac S, Ugurlu H. Treatment of periodontoid pannus with infliximab in a patient with rheumatoid arthritis. *J Clin Rheumatol*. 2009 Aug;15(5):250-1.
124. Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for rheumatoid arthritis. *N Engl J Med*. 2006 Aug 17;355(7):704-12.
125. Sholsberg J, Jackson R. Best evidence topic report. Intra-articular corticosteroid injections in acute rheumatoid monoarthritis. *Emerg Med J*. 2004 Mar;21(2):204.
126. Simpson D, Scott LJ. Adalimumab : in psoriatic arthritis. *Drugs*. 2006;66(11):1487-96.
127. Singh Jasvinder A, Beg S, Lopez Olivo Maria A. Tocilizumab for rheumatoid arthritis. 2010.
128. Smith D, Letendre S. Viral pneumonia as a serious complication of etanercept therapy. *Ann Intern Med*. 2002 Jan 15;136(2):174.
129. Smolen JS, Landewe R, Breedveld FC, Dougados M, Emery P, Gaujoux-Viala C, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. *Ann Rheum Dis* 2010:964-75.

130. Soliotis F, Glover M, Jawad AS. Severe skin reaction after leflunomide and etanercept in a patient with rheumatoid arthritis. *Ann Rheum Dis*. 2002 Sep;61(9):850-1.
131. Strand. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: Evidence from randomized controlled trials (American Journal of Managed Care). *American Journal of Managed Care*. 2008;14(4):234.
132. Suresh R, Gupta S, Sathananthan R. Sulphasalazine induced three-week syndrome. *J Clin Rheumatol*. 2009 Sep;15(6):311-2.
133. Sweet BV. Abatacept. *American Journal of Health-System Pharmacy (USA)*. 2006 01/01;63(Jan):2065-77.
134. Tack CJ, Kleijwegt FS, Van Riel PL, Roep BO. Development of type 1 diabetes in a patient treated with anti-TNF-alpha therapy for active rheumatoid arthritis. *Diabetologia*. 2009 Jul;52(7):1442-4.
135. Tateiwa T, Shinmura K, Ko M, Mibe J, Yamamoto K. Iliopsoas bursitis associated with rapid destruction of a rheumatoid hip joint. *J Orthop Sci*. 2009 Jul;14(4):455-8.
136. Van Rijthoven AW, Bijlsma JW, Canninga-Van Dijk M, Derksen RH, Van Roon JA. Onset of systemic lupus erythematosus after conversion of infliximab to adalimumab treatment in rheumatoid arthritis with a pre-existing anti-dsDNA antibody level. *Rheumatology*. 2006 10/01;45(Oct):1317-9.
137. Vis M, Voskuyl AE, Wolbink GJ, Dijkmans BA, Lems WF. Bone mineral density in patients with rheumatoid arthritis treated with infliximab. *Ann Rheum Dis*. 2005 Feb;64(2):336-7.
138. Vis M, Wolbink GJ, Lodder MC, Kostense PJ, van de Stadt RJ, de Koning MH, et al. Early changes in bone metabolism in rheumatoid arthritis patients treated with infliximab. *Arthritis Rheum*. 2003 Oct;48(10):2996-7.
139. Voulgari PV, Venetsanopoulou AI, Epagelis EK, Alamanos Y, Takalou I, Drosos AA. Infliximab in refractory psoriatic arthritis with severe psoriasis: a 2-year experience. *Ann Rheum Dis*. 2007 Feb;66(2):270-1.
140. Yazici Y, Erkan D, Lockshin MD. Etanercept in the treatment of severe, resistant psoriatic arthritis: continued efficacy and changing patterns of use after two years. *Clin Exp Rheumatol*. 2002 Jan-Feb;20(1):115.

### **Wrong Study Design**

1. Summaries for patients. Tumor necrosis factor antagonists and heart failure. *Ann Intern Med*. 2003 May 20;138(10):148.
2. Abramovits W, Arrazola P, Gupta AK. Enbrel (etanercept). *Skinmed*. 2004 Nov-Dec;3(6):333-5.
3. Agarwal S, Zaman T, Handa R. Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis. *Singapore Med J* 2009:686-92.
4. Aggarwal A, Panda S, Misra R. Effect of etanercept on matrix metalloproteinases and angiogenic vascular endothelial growth factor: a time kinetic study. *Ann Rheum Dis*. 2004 Jul;63(7):891-2.

5. Aggarwal R, Manadan AM, Poliyedath A, Sequeira W, Block JA, May. Safety of Etanercept in Patients at High Risk for Mycobacterial Tuberculosis Infections. *Journal of Rheumatology*. 2009;36:914.
6. Alcorn N, Saunders S, Madhok R, Dec. Benefit-Risk Assessment of Leflunomide An Appraisal of Leflunomide in Rheumatoid Arthritis 10 Years After Licensing. *Drug Safety (New Zealand)*. 2009;32:1123.
7. Amichai B, Gat A, Grunwald MH. Cutaneous hyperpigmentation during therapy with hydroxychloroquine. *J Clin Rheumatol*. 2007 Apr;13(2):113.
8. Ang HT, Helfgott S. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis? *J Rheumatol*. 2003 Nov;30(11):2315-8.
9. Antoni C, Dechant C, Hanns-Martin Lorenz PD, Wendler J, Ogilvie A, Lueftl M, et al. Open-label study of infliximab treatment for psoriatic arthritis: clinical and magnetic resonance imaging measurements of reduction of inflammation. *Arthritis Rheum*. 2002 Oct 15;47(5):506-12.
10. Antoni C, Kalden J. Combination Therapy of the Chimeric Monoclonal Anti-Tumor Necrosis Factor Alpha Antibody (Infliximab) With Methotrexate in Patients With Rheumatoid Arthritis. *Clinical and experimental rheumatology*. 1999;17(6 Suppl 18):S73-7.
11. Antoni CE, Kavanaugh A, van der Heijde D, Beutler A, Keenan G, Zhou B, et al. Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT). *J Rheumatol*. 2008 May;35(5):869-76.
12. Argyropoulou MI, Glatzouni A, Voulgari PV, Xydis VG, Nikas SN, Efremidis SC, et al. Magnetic resonance imaging quantification of hand synovitis in patients with rheumatoid arthritis treated with infliximab. *Joint Bone Spine*. 2005 Dec;72(6):557-61.
13. Arif S, Cox P, Afzali B, Lombardi G, Lechler RI, Peakman M, et al. Anti-TNFalpha therapy--killing two birds with one stone? *Lancet*. 2010/07/09 ed 2010:2278.
14. Augustsson J, Eksborg S, Ernestam S, Gullstrom E, van Vollenhoven R. Low-dose glucocorticoid therapy decreases risk for treatment-limiting infusion reaction to infliximab in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2007 Nov;66(11):1462-6.
15. Augustsson J, Neovius M, Cullinane-Carli C, Eksborg S, van Vollenhoven RF. Patients with rheumatoid arthritis treated with tumour necrosis factor antagonists increase their participation in the workforce: potential for significant long-term indirect cost gains (data from a population-based registry). *Ann Rheum Dis* 2010:126-31.
16. Bansback NJ, Ara R, Barkham N, Brennan A, Emery P, et al. Estimating the cost and health status consequences of treatment with TNF antagonists in patients with psoriatic arthritis. *Rheumatology*. 2006 08/01;45(Aug):1029-38.
17. Barra L, Pope JE, Payne M. Real-world anti-tumor necrosis factor treatment in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: cost-effectiveness based on number needed to treat to improve health assessment questionnaire. *J Rheumatol*. 2009 Jul;36(7):1421-8.
18. Barrera P, van der Maas A, van Ede AE, Kiemeny BALM, Laan RFJM, van de Putte LBA, et al. Drug Survival, Efficacy and Toxicity of Monotherapy With a Fully Human Anti-Tumour Necrosis Factor-a



- Antibody Compared With Methotrexate in Long-Standing Rheumatoid Arthritis. *Rheumatology* 2002;430-9.
19. Bathon JM, Fleischmann RM, van der Heijde DM, Tesser JR, White B, et al. Safety and efficacy of etanercept treatment in elderly subjects with rheumatoid arthritis. *Journal of Rheumatology*. 2006 02/01;33(Feb):234-43.
  20. Baumgartner SW, Fleischmann RM, Moreland LW, Schiff MH, Markenson J, Whitmore JB. Etanercept (Enbrel) in patients with rheumatoid arthritis with recent onset versus established disease: improvement in disability. *J Rheumatol*. 2004 Aug;31(8):1532-7.
  21. Berends MAM, Snoek J, De Jong EMGJ, Van De Kerkhof PCM, Van Oijen MGH, Van Krieken JH, et al. Liver injury in long-term methotrexate treatment in psoriasis is relatively infrequent. *Alimentary Pharmacology and Therapeutics*. 2006;24(5):805-11.
  22. Bibbo C, Goldberg JW. Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy. *Foot Ankle Int*. 2004 May;25(5):331-5.
  23. Bingham CO, Ince A, Haraoui B, Keystone EC, Baumgartner S, et al., et al. Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study. *Current Medical Research and Opinion (England)* 2009:1131.
  24. Bliddal H, Terslev L, Qvistgaard E, Konig M, Holm CC, Rogind H, et al. A randomized, controlled study of a single intra-articular injection of etanercept or glucocorticosteroids in patients with rheumatoid arthritis. *Scand J Rheumatol*. 2006 Sep-Oct;35(5):341-5.
  25. Blom M, Kievit W, Fransen J, Kuper IH, den Broeder AA, De Gendt CM, et al. The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis. *J Rheumatol*. 2009 Oct;36(10):2171-7.
  26. Blom M, Kievit W, Kuper HH, Jansen TL, Visser H, den Broeder AA, et al. Frequency and effectiveness of dose increase of adalimumab, etanercept, and infliximab in daily clinical practice. *Arthritis Care Res (Hoboken)*. 2010 Sep;62(9):1335-41.
  27. Bodur H, Ataman S, Akbulut L, Evcik D, Kavuncu V, Kaya T, et al. Characteristics and medical management of patients with rheumatoid arthritis and ankylosing spondylitis. *Clin Rheumatol*. 2008 Sep;27(9):1119-25.
  28. Boesen M, Boesen L, Jensen KE, Cimmino MA, Torp-Pedersen S, Terslev L, et al. Clinical outcome and imaging changes after intraarticular (IA) application of etanercept or methylprednisolone in rheumatoid arthritis: magnetic resonance imaging and ultrasound-Doppler show no effect of IA injections in the wrist after 4 weeks. *J Rheumatol*. 2008 Apr;35(4):584-91.
  29. Bohanec Grabar P, Rozman B, Tomsic M, Suput D, Logar D, Dolzan V. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. *Eur J Clin Pharmacol*. 2008 Sep;64(9):871-6.
  30. Bologna C, Jorgensen C, Sany J. Association of methotrexate and corticosteroids in the treatment of patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 1996 Jul-Aug;14(4):401-6.

31. Bombardieri S, Ruiz AA, Fardellone P, Geusens P, McKenna F, Unnebrink K, et al. Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice. *Rheumatology (Oxford)*. 2007 Jul;46(7):1191-9.
32. Bongartz T. Tocilizumab for rheumatoid and juvenile idiopathic arthritis. *Lancet*. 2008(9617):961-3.
33. Borah BJ, Huang XY, Zarotsky V, Globe D, Jun. Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. *Current Medical Research and Opinion (England)* 2009:1365.
34. Boyce EG, Halilovic J, Stan-Ugbene O. Golimumab: Review of the Efficacy and Tolerability of a Recently Approved Tumor Necrosis Factor-alpha Inhibitor. *Clinical Therapeutics (USA)*. 2010;32:1681-703.
35. Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results. *Isr Med Assoc J*. 2008 Apr;10(4):277-81.
36. Bresnihan B, Newmark R, Robbins S, Genant HK. Effects of anakinra monotherapy on joint damage in patients with rheumatoid arthritis. Extension of a 24-week randomized, placebo-controlled trial. *J Rheumatol*. 2004 Jun;31(6):1103-11.
37. Brocq O, Roux CH, Albert C, Breuil V, Aknouche N, Ruitord S, et al. TNFalpha antagonist continuation rates in 442 patients with inflammatory joint disease. *Joint Bone Spine* 2007:148-54.
38. Buch MH, Bingham SJ, Bejarano V, Bryer D, White J, Reece R, et al. Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept. *Arthritis Rheum*. 2007 Apr 15;57(3):448-53.
39. Buchbinder R, Barber M, Heuzenroeder L, Wluka AE, Giles G, Hall S, et al. Incidence of melanoma and other malignancies among rheumatoid arthritis patients treated with methotrexate. *Arthritis Rheum*. 2008 Jun 15;59(6):794-9.
40. Buckley LM, Leib ES, Cartularo KS, Vacek PM, Cooper SM. Effects of low dose corticosteroids on the bone mineral density of patients with rheumatoid arthritis. *J Rheumatol*. 1995 Jun;22(6):1055-9.
41. Bukhari MA, Wiles NJ, Lunt M, Harrison BJ, Scott DG, Symmons DP, et al. Influence of disease-modifying therapy on radiographic outcome in inflammatory polyarthritis at five years: results from a large observational inception study. *Arthritis Rheum*. 2003 Jan;48(1):46-53.
42. Burmester GR, Ferraccioli G, Flipo RM, Monteagudo-Saez I, Unnebrink K, Kary S, et al. Clinical remission and/or minimal disease activity in patients receiving adalimumab treatment in a multinational, open-label, twelve-week study. *Arthritis Rheum*. 2008 Jan 15;59(1):32-41.
43. Cacace E, Anedda C, Ruggiero V, Fornasier D, Denotti A, Perpignano G. Etanercept in rheumatoid arthritis: Long term anti-inflammatory efficacy in clinical practice. *European Journal of Inflammation*. 2006;4(3):171-6.
44. Calguneri M, Pay S, Caliskaner Z, Apras S, Kiraz S, Ertenli I, et al. Combination Therapy Versus Monotherapy for the Treatment of Patients With Rheumatoid Arthritis. *Clinical and experimental rheumatology*. 1999;17(6):699-704.

45. Champion GV, Lebsack ME, Lookabaugh J, Gordon G, Catalano M. Dose-range and dose-frequency study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis. The IL-1Ra Arthritis Study Group. *Arthritis Rheum.* 1996 Jul;39(7):1092-101.
46. Cantini F, Niccoli L, Nannini C, Cassara E, Pasquetti P, Olivieri I, et al. Frequency and duration of clinical remission in patients with peripheral psoriatic arthritis requiring second-line drugs. *Rheumatology (Oxford)* 2008;872-6.
47. Carmona L, Descalzo MÃ, Perez-Pampin E, Ruiz-Montesinos D, Erra A, Cobo T, et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. *Annals of the rheumatic diseases.* 2007;66(7):880-5.
48. Cassano N, Galluccio A, De Simone C, Loconsole F, Massimino SD, Plumari A, et al. Influence of body mass index, comorbidities and prior systemic therapies on the response of psoriasis to adalimumab: an exploratory analysis from the APHRODITE data. *J Biol Regul Homeost Agents.* 2008 Oct-Dec;22(4):233-7.
49. Cauza E, Spak M, Cauza K, Hanusch-Enserer U, Dunky A, Wagner E. Treatment of psoriatic arthritis and psoriasis vulgaris with the tumor necrosis factor inhibitor infliximab. *Rheumatol Int.* 2002 Nov;22(6):227-32.
50. Chambers CD, Johnson DL, Robinson LK, Braddock SR, Xu R, Lopez-Jimenez J, et al. Birth outcomes in women who have taken leflunomide during pregnancy. *Arthritis Rheum.* 2010/02/05 ed 2010:1494-503.
51. Chen DY, Chou SJ, Hsieh TY, Chen YH, Chen HH, Hsieh CW, et al. Randomized, double-blind, placebo-controlled, comparative study of human anti-TNF antibody adalimumab in combination with methotrexate and methotrexate alone in Taiwanese patients with active rheumatoid arthritis. 2009.
52. Ciconelli R, Ferraz M, Visoni R, Oliveira L, Atra E. A Randomized Double-Blind Controlled Trial of Sulphasalazine Combined With Pulses of Methylprednisolone or Placebo in the Treatment of Rheumatoid Arthritis. *British journal of rheumatology.* 1996;35(2):150-4.
53. Cohen G, Courvoisier N, Cohen JD, Zaltini S, Sany J, Combe B. The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis. *Clin Exp Rheumatol.* 2005 Nov-Dec;23(6):795-800.
54. Cohen JD, Dougados M, Goupille P, Cantagrel A, Meyer O, Sibilia J, et al. Health assessment questionnaire score is the best predictor of 5-year quality of life in early rheumatoid arthritis. *Journal of Rheumatology.* 2006;33(10):1936-41.
55. Cole JC, Li T, Lin P, MacLean R, Wallenstein GV. Treatment impact on estimated medical expenditure and job loss likelihood in rheumatoid arthritis: re-examining quality of life outcomes from a randomized placebo-controlled clinical trial with abatacept. *Rheumatology (Oxford).* 2008 Jul;47(7):1044-50.
56. Contreras-Yanez I, Ponce De Leon S, Cabiedes J, Rull-Gabayet M, Pascual-Ramos V. Inadequate therapy behavior is associated to disease flares in patients with rheumatoid arthritis who have achieved remission with disease-modifying antirheumatic drugs. *Am J Med Sci.* 2010 Oct;340(4):282-90.
57. Covelli M, Scioscia C, Iannone F, Lapadula G. Repeated infusions of low-dose infliximab plus methotrexate in psoriatic arthritis: immediate benefits are not maintained after discontinuation of infliximab. *Clin Exp Rheumatol.* 2005 Mar-Apr;23(2):145-51.

58. Criswell L, Saag K, Sems KM, Welch V, Shea B, Wells George A, et al. Moderate-term, low-dose corticosteroids for rheumatoid arthritis. 1998.
59. Cuchacovich M, Ferreira L, Aliste M, Soto L, Cuenca J, Cruzat A, et al. Tumour necrosis factor-alpha (TNF-alpha) levels and influence of -308 TNF-alpha promoter polymorphism on the responsiveness to infliximab in patients with rheumatoid arthritis. *Scand J Rheumatol*. 2004;33(4):228-32.
60. Curtis JR, Martin C, Saag KG, Patkar NM, Kramer J, Shatin D, et al. Confirmation of administrative claims-identified opportunistic infections and other serious potential adverse events associated with tumor necrosis factor alpha antagonists and disease-modifying antirheumatic drugs. *Arthritis Rheum*. 2007 Mar 15;57(2):343-6.
61. Davis JM, 3rd, Maradit Kremers H, Crowson CS, Nicola PJ, Ballman KV, Thorneau TM, et al. Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. *Arthritis Rheum*. 2007 Mar;56(3):820-30.
62. De Felice C, Mazzotta A, Esposito M, Bianchi L, Chimenti S. High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: efficacy, safety and impact on patients' quality of life. *J Dermatolog Treat*. 2006;17(6):355-8.
63. De Filippis L, Caliri A, Anghelone S, Scibilia G, Lo Gullo R, Bagnato G. Improving outcomes in tumour necrosis factor a treatment: comparison of the efficacy of the tumour necrosis factor a blocking agents etanercept and infliximab in patients with active rheumatoid arthritis. *Panminerva Med* 2006:129-35.
64. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, De Keyser F, et al. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity - Biologic and clinical implications in autoimmune arthritis. *Arthritis and Rheumatism (USA)*. 2005 07/01;52(Jul):2192-201.
65. De Rycke L, Baeten D, Kruithof E, Van den Bosch F, Veys EM, De Keyser F. Infliximab, but not etanercept, induces IgM anti-double-stranded DNA autoantibodies as main antinuclear reactivity: biologic and clinical implications in autoimmune arthritis. *Arthritis Rheum*. 2005 Jul;52(7):2192-201.
66. del Porto F, Aloe L, Lagana B, Triaca V, Nofroni I, D'Amelio R. Nerve growth factor and brain-derived neurotrophic factor levels in patients with rheumatoid arthritis treated with TNF-alpha blockers. *Ann N Y Acad Sci*. 2006 Jun;1069:438-43.
67. Delabaye I, De Keyser F. 74-week follow-up of safety of infliximab in patients with refractory rheumatoid arthritis. *Arthritis Res Ther*. 2010;12(3):R121.
68. den Broeder A, van de Putte L, Rau R, Schattenkirchner M, Van Riel P, Sander O, et al. A single dose, placebo controlled study of the fully human anti-tumor necrosis factor-alpha antibody adalimumab (D2E7) in patients with rheumatoid arthritis. *J Rheumatol*. 2002 Nov;29(11):2288-98.
69. Dohn UM, Skjodt H, Hetland ML, Vestergaard A, Moller JM, Knudsen LS, et al. No erosive progression revealed by MRI in rheumatoid arthritis patients treated with etanercept, even in patients with persistent MRI and clinical signs of joint inflammation. *Clin Rheumatol*. 2007 Nov;26(11):1857-61.
70. Dore RK, Mathews S, Schechtman J, Surbeck W, Mandel D, Patel A, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. *Clin Exp Rheumatol*. 2007 Jan-Feb;25(1):40-6.

71. Ducoulombier V, Solau E, Coquerelle P, Houvenagel E, Siame JL, Desprez X, et al. Long-term results of infliximab therapy in rheumatoid arthritis: experience acquired by the North-Pas-de-Calais hospital network. *Joint Bone Spine*. 2007 Jan;74(1):56-9.
72. Dunne CA, Moran CJ, Thompson PW. The effect of regular intramuscular corticosteroid therapy on bone mineral density in rheumatoid patients. *Scand J Rheumatol*. 1995;24(1):48-9.
73. Durez P, Malghem J, Nzeusseu Toukap A, Depresseux G, Lauwerys BR, Westhovens R, et al. Treatment of early rheumatoid arthritis: a randomized magnetic resonance imaging study comparing the effects of methotrexate alone, methotrexate in combination with infliximab, and methotrexate in combination with intravenous pulse methylprednisolone. *Arthritis Rheum* 2007:3919-27.
74. Durez P, Nzeusseu Toukap A, Lauwerys BR, Manicourt DH, Verschueren P, Westhovens R, et al. A randomised comparative study of the short term clinical and biological effects of intravenous pulse methylprednisolone and infliximab in patients with active rheumatoid arthritis despite methotrexate treatment. *Ann Rheum Dis*. 2004 Sep;63(9):1069-74.
75. Durez P, Van den Bosch F, Corluy L, Veys EM, De Clerck L, Peretz A, et al. A dose adjustment in patients with rheumatoid arthritis not optimally responding to a standard dose of infliximab of 3 mg/kg every 8 weeks can be effective: a Belgian prospective study. *Rheumatology (Oxford)*. 2005 Apr;44(4):465-8.
76. Eder L, Chandran V, Schentag CT, Shen H, Cook RJ, Gladman DD. Time and predictors of response to tumour necrosis factor-(alpha) blockers in psoriatic arthritis: An analysis of a longitudinal observational cohort. *Rheumatology*. 2010;49(7):1361-6.
77. Egnatios G, Warthan MM, Pariser R, Hood AF. Pustular psoriasis following treatment of rheumatoid arthritis with TNF-alpha inhibitors. *J Drugs Dermatol*. 2008 Oct;7(10):975-7.
78. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Sasso EH, et al., et al. Less Radiographic Progression with Adalimumab Plus Methotrexate Versus Methotrexate Monotherapy Across the Spectrum of Clinical Response in Early Rheumatoid Arthritis. *Journal of Rheumatology* 2009:1429.
79. Farahani P, Levine M, Gaebel K, Wang EC, Khalidi N. Community-based evaluation of etanercept in patients with rheumatoid arthritis. *J Rheumatol*. 2006 Apr;33(4):665-70.
80. Felson DT, Anderson JJ, Meenan RF. The comparative efficacy and toxicity of second-line drugs in rheumatoid arthritis. Results of two metaanalyses. *Arthritis Rheum*. 1990 Oct;33(10):1449-61.
81. Fernandez-Espartero MC, Perez-Zafrilla B, Naranjo A, Esteban C, Ortiz AM, Gomez-Reino JJ, et al. Demyelinating Disease in Patients Treated with TNF Antagonists in Rheumatology: Data from BIOBADASER, a Pharmacovigilance Database, and a Systematic Review. *Semin Arthritis Rheum* 2010:330-7.
82. Ferri C, Ferraccioli G, Ferrari D, Galeazzi M, Lapadula G, Montecucco C, et al. Safety of anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis and chronic hepatitis C virus infection. *J Rheumatol*. 2008 Oct;35(10):1944-9.
83. Fiehn C, Jacki S, Heilig B, Lampe M, Wiesmuller G, Richter C, et al. Eight versus 16-week re-evaluation period in rheumatoid arthritis patients treated with leflunomide or methotrexate accompanied by moderate dose prednisone. *Rheumatol Int*. 2007 Aug;27(10):975-9.

84. Finckh A, Simard JF, Duryea J, Liang MH, Huang J, Daneel S, et al. The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study. *Arthritis Rheum*. 2006 Jan;54(1):54-9.
85. Fischer P. Resolution of treatment-related arthralgias and serologic findings with a switch of TNF antagonist therapies in a patient with psoriatic arthritis. *J Clin Rheumatol*. 2007 Oct;13(5):294-5.
86. Fleischmann R. Safety and efficacy of etanercept in the elderly. *Aging Health*. 2006;2(2):189-97.
87. Fleischmann RM, Cohen SB, Moreland LW, Schiff M, Mease PJ, Smith DB, et al. Methotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trial. *Curr Med Res Opin*. 2005 Aug;21(8):1181-90.
88. Frankel EH, Strober BE, Crowley JJ, Fivenson DP, Woolley JM, Yu EB, et al. Etanercept improves psoriatic arthritis patient-reported outcomes: results from EDUCATE. *Cutis*. 2007 Apr;79(4):322-6.
89. Fries JF, Williams CA, Morfeld D, Singh G, Sibley J. Reduction in long-term disability in patients with rheumatoid arthritis by disease-modifying antirheumatic drug-based treatment strategies. *Arthritis Rheum*. 1996 Apr;39(4):616-22.
90. Furst D, Erikson N, Clute L, Koehnke R, Burmeister L, Kohler J. Adverse Experience With Methotrexate During 176 Weeks of a Longterm Prospective Trial in Patients With Rheumatoid Arthritis. *The Journal of rheumatology*. 1990;12:1628-35.
91. Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. *Ann Rheum Dis* 2007:893-9.
92. Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Hara M, et al. Risk factors associated with incident fractures in Japanese men with rheumatoid arthritis: A prospective observational cohort study. *Journal of Bone and Mineral Metabolism*. 2008;26(5):499-505.
93. Furuya T, Kotake S, Inoue E, Nanke Y, Yago T, Kobashigawa T, et al. Risk factors associated with incident clinical vertebral and nonvertebral fractures in Japanese women with rheumatoid arthritis: A prospective 54-month observational study. *Journal of Rheumatology*. 2007;34(2):303-10.
94. Genant HK, Peterfy CG, Westhovens R, Becker JC, Aranda R, Vratsanos G, et al. Abatacept inhibits progression of structural damage in rheumatoid arthritis: Results from the long-term extension of the AIM trial. *Annals of the Rheumatic Diseases*. 2007;67(8):1084-9.
95. Genovese MC, Becker JC, Schiff M, Luggen M, Sherrer Y, Kremer J, et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. *N Engl J Med*. 2005 Sep 15;353(11):1114-23.
96. Genovese MC, Schiff M, Luggen M, Becker JC, Aranda R, Teng J, et al. Efficacy and safety of the selective co-stimulation modulator abatacept following 2 years of treatment in patients with rheumatoid arthritis and an inadequate response to anti-tumour necrosis factor therapy. *Ann Rheum Dis*. 2008 Apr;67(4):547-54.
97. George D, Kadlubek P, Batra D, Goldberg G. Infliximab dose and charge escalation patterns in managed care. *Manag Care Interface*. 2004;Suppl A:5-8.

98. Gibson JN, Poyser NL, Morrison WL, Scrimgeour CM, Rennie MJ. Muscle protein synthesis in patients with rheumatoid arthritis: effect of chronic corticosteroid therapy on prostaglandin F2 alpha availability. *Eur J Clin Invest*. 1991 Aug;21(4):406-12.
99. Giles JT, Bartlett SJ, Gelber AC, Nanda S, Fontaine K, Ruffing V, et al. Tumor necrosis factor inhibitor therapy and risk of serious postoperative orthopedic infection in rheumatoid arthritis. *Arthritis Rheum*. 2006 Apr 15;55(2):333-7.
100. Gladman DD, Mease PJ, Choy EH, Ritchlin CT, Perdok RJ, Sasso EH. Risk factors for radiographic progression in psoriatic arthritis: subanalysis of the randomized controlled trial ADEPT. *Arthritis Res Ther*. 2010;12(3):R113.
101. Gladman DD, Mease PJ, Ritchlin CT, Choy EH, Sharp JT, Ory PA, et al. Adalimumab for long-term treatment of psoriatic arthritis: forty-eight week data from the adalimumab effectiveness in psoriatic arthritis trial. *Arthritis Rheum*. 2007 Feb;56(2):476-88.
102. Gladman DD, Sampalis JS, Illouz O, Guerette B, Investigators AS. Responses to Adalimumab in Patients with Active Psoriatic Arthritis Who Have Not Adequately Responded to Prior Therapy: Effectiveness and Safety Results From an Open-label Study. *Journal of Rheumatology*. 2010;37:1898.
103. Goekoop-Ruiterman YPM, De Vries-Bouwstra JK, Kerstens PJSM, Nielen MMJ, Vos K, Van Schaardenburg D, et al. DAS-driven therapy versus routine care in patients with recent-onset active rheumatoid arthritis. 2010.
104. Goldman JA, Xia HA, White B, Paulus H. Evaluation of a modified ACR20 scoring system in patients with rheumatoid arthritis receiving treatment with etanercept. *Ann Rheum Dis*. 2006 Dec;65(12):1649-52.
105. Gonzalez-Lopez MA, Blanco R, Gonzalez-Vela MC, Fernandez-Llaca H, Rodriguez-Valverde V. Development of sarcoidosis during etanercept therapy. *Arthritis Rheum*. 2006 Oct 15;55(5):817-20.
106. Gottenberg JE, Ravaud P, Bardin T, Cacoub P, Cantagrel A, Combe B, et al. Risk factors for severe infections in patients with rheumatoid arthritis treated with rituximab in the autoimmunity and rituximab registry. *Arthritis Rheum*. 2010 Sep;62(9):2625-32.
107. Gottlieb AB, Kircik L, Eisen D, Jackson JM, Boh EE, Strober BE, et al. Use of etanercept for psoriatic arthritis in the dermatology clinic: the Experience Diagnosing, Understanding Care, and Treatment with Etanercept (EDUCATE) study. *J Dermatolog Treat*. 2006;17(6):343-52.
108. Gran JT, Myklebust G. Toxicity of sulphasalazine in rheumatoid arthritis. Possible protective effect of rheumatoid factors and corticosteroids. *Scand J Rheumatol*. 1993;22(5):229-32.
109. Gratacos J, Casado E, Real J, Torre-Alonso JC. Prediction of major clinical response (ACR50) to infliximab in psoriatic arthritis refractory to methotrexate. *Ann Rheum Dis*. 2007 Apr;66(4):493-7.
110. Greenberg JD, Kishimoto M, Strand V, Cohen SB, Oleginski TP, Harrington T, et al. Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort. *Am J Med*. 2008 Jun;121(6):532-8.
111. Grigor C, Capell H, Stirling A, McMahon AD, Lock P, Vallance R, et al. Effect of a Treatment Strategy of Tight Control for Rheumatoid Arthritis (the Ticora Study): a Single-Blind Randomised Controlled Trial. *Lancet*. 2004;364(9430):263-9.

112. Grijalva CG, Kaltenbach L, Arbogast PG, Mitchel EF, Jr., Griffin MR. Adherence to disease-modifying antirheumatic drugs and the effects of exposure misclassification on the risk of hospital admission. *Arthritis Care Res (Hoboken)*. 2010/03/02 ed 2010:730-4.
113. Haagsma C, van Riel P, van de Putte L. Combining Sulphasalazine and Methotrexate in Rheumatoid Arthritis: Early Clinical Impressions. *British journal of rheumatology*. 1995;34(Suppl 2):104-8.
114. Haagsma CJ, van Riel PL, de Rooij DJ, Vree TB, Russel FJ, van't Hof MA, et al. Combination of Methotrexate and Sulphasalazine Vs Methotrexate Alone: a Randomized Open Clinical Trial in Rheumatoid Arthritis Patients Resistant to Sulphasalazine Therapy. *British journal of rheumatology*. 1994;33(11):1049-55.
115. Hafstrom I, Albertsson K, Boonen A, van der Heijde D, Landewe R, Svensson B. Remission achieved after 2 years treatment with low-dose prednisolone in addition to disease-modifying anti-rheumatic drugs in early rheumatoid arthritis is associated with reduced joint destruction still present after 4 years: an open 2-year continuation study. *Ann Rheum Dis*. 2009 Apr;68(4):508-13.
116. Hall SJ, Hickling P. Failure of etanercept to control extra-articular manifestations of rheumatoid arthritis. *J Clin Rheumatol*. 2007 Feb;13(1):54.
117. Hamilton TK. Treatment of psoriatic arthritis and recalcitrant skin disease with combination therapy. *J Drugs Dermatol*. 2008 Nov;7(11):1089-93.
118. Han C, Rahman MU, Doyle MK, Bathon JM, Smolen J, Kavanaugh A, et al. Association of anemia and physical disability among patients with rheumatoid arthritis. *J Rheumatol*. 2007 Nov;34(11):2177-82.
119. Han C, Smolen J, Kavanaugh A, St Clair EW, Baker D, Bala M. Comparison of employability outcomes among patients with early or long-standing rheumatoid arthritis. *Arthritis Rheum*. 2008 Apr 15;59(4):510-4.
120. Harrison MJ, Kim CA, Silverberg M, Paget SA. Does age bias the aggressive treatment of elderly patients with rheumatoid arthritis? *J Rheumatol*. 2005 Jul;32(7):1243-8.
121. Haugeberg G, Conaghan PG, Quinn M, Emery P. Bone loss in patients with active early rheumatoid arthritis: infliximab and methotrexate compared with methotrexate treatment alone. Explorative analysis from a 12-month randomised, double-blind, placebo-controlled study. *Ann Rheum Dis*. 2009 Dec;68(12):1898-901.
122. Hazes JM, Taylor P, Strand V, Purcaru O, Coteur G, Mease P. Physical function improvements and relief from fatigue and pain are associated with increased productivity at work and at home in rheumatoid arthritis patients treated with certolizumab pegol. *Rheumatology*. 2010;49(10):1900-10.
123. Heiberg MS, Kaufmann C, Rodevand E, Mikkelsen K, Koldingsnes W, Mowinckel P, et al. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study. *Ann Rheum Dis*. 2007 Aug;66(8):1038-42.
124. Heiberg MS, Koldingsnes W, Mikkelsen K, Rodevand E, Kaufmann C, Mowinckel P, et al. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. *Arthritis Rheum*. 2008 Feb 15;59(2):234-40.



125. Helliwell PS, Taylor WJ. Treatment of psoriatic arthritis and rheumatoid arthritis with disease modifying drugs -- comparison of drugs and adverse reactions. *J Rheumatol.* 2008 Mar;35(3):472-6.
126. Herenius MM, Hoving JL, Sluiter JK, Raterman HG, Lems WF, Dijkmans BA, et al. Improvement of work ability, quality of life, and fatigue in patients with rheumatoid arthritis treated with adalimumab. *J Occup Environ Med.* 2010 Jun;52(6):618-21.
127. Heytman M, Ahern MJ, Smith MD, Roberts-Thomson PJ. The longterm effect of pulsed corticosteroids on the efficacy and toxicity of chrysotherapy in rheumatoid arthritis. *J Rheumatol.* 1994 Mar;21(3):435-41.
128. Higashida J, Wun T, Schmidt S, Naguwa SM, Tuscano JM. Safety and efficacy of rituximab in patients with rheumatoid arthritis refractory to disease modifying antirheumatic drugs and anti-tumor necrosis factor-alpha treatment. *J Rheumatol.* 2005 Nov;32(11):2109-15.
129. Hirose W, Nishikawa K, Hirose M, Nanki T, Sugimoto H. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging. *Mod Rheumatol.* 2009;19(1):20-6.
130. Hoekstra M, van Ede A, Haagsma C, van de Laar M, Huizinga T, Kruijsen M, et al. Factors associated with toxicity, final dose, and efficacy of methotrexate in patients with rheumatoid arthritis. *Annals of the rheumatic diseases.* 2003;62(5):423-6.
131. Holman AJ, Ng E. Heart rate variability predicts anti-tumor necrosis factor therapy response for inflammatory arthritis. *Auton Neurosci.* 2008 Dec 5;143(1-2):58-67.
132. Hoshida Y, Xu JX, Fujita S, Nakamichi I, Ikeda J, Tomita Y, et al. Lymphoproliferative disorders in rheumatoid arthritis: clinicopathological analysis of 76 cases in relation to methotrexate medication. *J Rheumatol.* 2007 Feb;34(2):322-31.
133. Huang F, Wang L, Zhang J, Deng X, Guo J, Zhang Y. Risk of tuberculosis in a Chinese registry of rheumatoid arthritis and ankylosing spondylitis for tumour necrosis factor-alpha antagonists. *APLAR Journal of Rheumatology.* 2006;9(2):170-4.
134. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor-alpha treatment improves endothelial function in patients with rheumatoid arthritis. *Circulation.* 2002 Oct 22;106(17):2184-7.
135. Huscher D, Thiele K, Gromnica-Ihle E, Hein G, Demary W, Dreher R, et al. Dose-related patterns of glucocorticoid-induced side effects. *Ann Rheum Dis.* 2009 Jul;68(7):1119-24.
136. Hyrich KL, Deighton C, Watson KD, Symmons DP, Lunt M. Benefit of anti-TNF therapy in rheumatoid arthritis patients with moderate disease activity. *Rheumatology (Oxford)* 2009;1323-7.
137. Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons DP. Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. *Rheumatology (Oxford).* 2008 Jul;47(7):1000-5.
138. Inanc N, Direskeneli H. Serious infections under treatment with TNF-alpha antagonists compared to traditional DMARDs in patients with rheumatoid arthritis. *Rheumatol Int.* 2006 Nov;27(1):67-71.
139. Islam M, Alam M, Haq S, Moyenuzzaman M, Patwary M, Rahman M. Efficacy of Sulphasalazine Plus Methotrexate in Rheumatoid Arthritis. *Bangladesh Medical Research Council bulletin.* 2000;26(1):1-7.

140. Iwamoto N, Kawakami A, Fujikawa K, Aramaki T, Kawashiri SY, Tamai M, et al. Prediction of DAS28-ESR remission at 6 months by baseline variables in patients with rheumatoid arthritis treated with etanercept in Japanese population. *Mod Rheumatol* 2009;488-92.
141. Jamal S, Patra K, Keystone EC. Adalimumab response in patients with early versus established rheumatoid arthritis: DE019 randomized controlled trial subanalysis. 2009.
142. Jenks KA, Stamp LK, O'Donnell JL, Savage RL, Chapman PT. Leflunomide-associated infections in rheumatoid arthritis. *J Rheumatol*. 2007 Nov;34(11):2201-3.
143. Jung N, Hellmann M, Hoheisel R, Lehmann C, Haase I, Perniok A, et al. An open-label pilot study of the efficacy and safety of anakinra in patients with psoriatic arthritis refractory to or intolerant of methotrexate (MTX). *Clin Rheumatol*. 2010 Oct;29(10):1169-73.
144. Kalden JR, Schattenkirchner M, Sorensen H, Emery P, Deighton C, Rozman B, et al. The Efficacy and Safety of Leflunomide in Patients With Active Rheumatoid Arthritis: a Five-Year Followup Study. *Arthritis and rheumatism*. 2003;48(6):1513-20.
145. Kalden JR, Scott DL, Smolen JS, Schattenkirchner M, Rozman B, Williams BD, et al. Improved Functional Ability in Patients With Rheumatoid Arthritis - Longterm Treatment With Leflunomide Versus Sulfasalazine. *Journal of Rheumatology*. 2001;28(9):1983-91.
146. Kalden Nemeth D, Grebmeier J, Antoni C, Manger B, Wolf F, Kalden J. Nmr Monitoring of Rheumatoid Arthritis Patients Receiving Anti-Tnf-Alpha Monoclonal Antibody Therapy. *Rheumatology international*. 1997;16(6):249-55.
147. Kaplan MJ. Do tumor-necrosis-factor inhibitors prevent first cardiovascular events in patients with rheumatoid arthritis? *Nat Clin Pract Rheumatol*. 2005 Dec;1(2):74-5.
148. Kastbom A, Bratt J, Ernestam S, Lampa J, Padyukov L, Soderkvist P, et al. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis. *Arthritis Rheum*. 2007 Feb;56(2):448-52.
149. Katz P, Yelin E, Patel V, Huang XY, Chiou CF. Patient-reported outcomes following biologic therapy in a sample of adults with rheumatoid arthritis recruited from community-based rheumatologists. *Arthritis Rheum*. 2009 May 15;61(5):593-9.
150. Kavanaugh A. Anakinra (interleukin-1 receptor antagonist) has positive effects on function and quality of life in patients with rheumatoid arthritis. *Advances in Therapy (USA)*. 2006 02/01;23(Feb):208-17.
151. Kavanaugh A, Krueger GG, Beutler A, Guzzo C, Zhou B, Dooley LT, et al. Infliximab maintains a high degree of clinical response in patients with active psoriatic arthritis through 1 year of treatment: results from the IMPACT 2 trial. *Ann Rheum Dis*. 2007 Apr;66(4):498-505.
152. Kavanaugh A, Lee SJ, Weng HH, Chon Y, Huang XY, Lin SL. Patient-derived joint counts are a potential alternative for determining Disease Activity Score. *J Rheumatol*. 2010/02/17 ed 2010:1035-41.
153. Keystone E, Fleischmann R, Emery P, Furst DE, van Vollenhoven R, Bathon J, et al. Safety and efficacy of additional courses of rituximab in patients with active rheumatoid arthritis: an open-label extension analysis. *Arthritis Rheum*. 2007 Dec;56(12):3896-908.

154. Keystone EC, Schiff MH, Kremer JM, Kafka S, Lovy M, DeVries T, et al. Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum.* 2004 Feb;50(2):353-63.
155. Kielhorn A, Porter D, Diamantopoulos A, Lewis G. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. *Curr Med Res Opin.* 2008 Sep;24(9):2639-50.
156. Kimball AB, Bensimon AG, Guerin A, Yu AP, Wu EQ, Okun MM, et al. Efficacy and safety of adalimumab among patients with moderate to severe psoriasis with co-morbidities: Subanalysis of results from a randomized, double-blind, placebo-controlled, phase III trial. *American Journal of Clinical Dermatology* 2011:51-62.
157. Kimball AB, Jackson JM, Sobell JM, Boh EE, Grekin S, Pharmed EB, et al. Reductions in healthcare resource utilization in psoriatic arthritis patients receiving etanercept therapy: results from the educate trial. *J Drugs Dermatol.* 2007 Mar;6(3):299-306.
158. Kiortsis DN, Mavridis AK, Vasakos S, Nikas SN, Drosos AA. Effects of infliximab treatment on lipoprotein profile in patients with rheumatoid arthritis and ankylosing spondylitis. *J Rheumatol.* 2006 May;33(5):921-3.
159. Klareskog L, Gaubitz M, Rodriguez-Valverde V, Malaise M, Dougados M, Wajdula J. A Long-Term, Open-Label Trial of the Safety and Efficacy of Etanercept (ENBREL(R)) In Patients With Rheumatoid Arthritis Not Treated With Other DMARDs (3-year Interim Report). *Ann Rheum Dis.* 2006 Mar 15.
160. Koeller MD, Aletaha D, Funovits J, Pangan A, Smolen JS, et al., et al. Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. *Rheumatology* 2009:1575.
161. Koike T, Harigai M, Inokuma S, Inoue K, Ishiguro N, Ryu J, et al. Postmarketing surveillance of the safety and effectiveness of etanercept in Japan. *J Rheumatol.* 2009 May;36(5):898-906.
162. Komano Y, Harigai M, Koike R, Sugiyama H, Ogawa J, Saito K, et al. Pneumocystis jiroveci pneumonia in patients with rheumatoid arthritis treated with infliximab: a retrospective review and case-control study of 21 patients. *Arthritis Rheum.* 2009 Mar 15;61(3):305-12.
163. Kononoff A, Heiskanen J, Lumiaho J, Kautiainen H, Kaipainen-Seppanen O. Intensifying treatment of rheumatoid arthritis with combinations of traditional disease-modifying anti-rheumatic drugs among patients with persistent disease did not reduce the need for large joint surgery. *Scand J Rheumatol.* 2007 Nov-Dec;36(6):424-7.
164. Kremer J, Genovese M, Cannon GW, Caldwell J, Cush J, Furst DE, et al. Combination Leflunomide and Methotrexate (Mtx) Therapy for Patients With Active Rheumatoid Arthritis Failing Mtx Monotherapy: Open-Label Extension of a Randomized, Double-Blind, Placebo Controlled Trial. *The Journal of rheumatology.* 2004;31(8):1521-31.
165. Kremer JM, Genant HK, Moreland LW, Russell AS, Emery P, Abud-Mendoza C, et al. Results of a two-year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate. *Arthritis Rheum.* 2008 Apr;58(4):953-63.

166. Kristensen LE, Kapetanovic MC, Gulfe A, Soderlin M, Saxne T, Geborek P. Predictors of response to anti-TNF therapy according to ACR and EULAR criteria in patients with established RA: results from the South Swedish Arthritis Treatment Group Register. *Rheumatology (Oxford)*. 2008 Apr;47(4):495-9.
167. Kroesen S, Widmer AF, Tyndall A, Hasler P. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. *Rheumatology (Oxford)*. 2003 May;42(5):617-21.
168. Kvalvik AG, Lefsaaker L, Dyvik S, Brun JG. Anti-tumor necrosis factor-alpha therapy in the ordinary clinical setting: Three-year effectiveness in patients with rheumatoid arthritis. *Joint Bone Spine*. 2007 Dec;74(6):606-11.
169. Laas K, Peltomaa R, Puolakka K, Kautiainen H, Leirisalo-Repo M. Early improvement of health-related quality of life during treatment with etanercept and adalimumab in patients with rheumatoid arthritis in routine practice. *Clinical and Experimental Rheumatology* 2009:315-20.
170. Laivoranta-Nyman S, Mottonen T, Hannonen P, Korpela M, Kautiainen H, Leirisalo-Repo M, et al. Association of tumour necrosis factor a, b and c microsatellite polymorphisms with clinical disease activity and induction of remission in early rheumatoid arthritis. *Clin Exp Rheumatol*. 2006 Nov-Dec;24(6):636-42.
171. Landewe R, van der Heijde D, Klareskog L, van Vollenhoven R, Fatenejad S. Disconnect between inflammation and joint destruction after treatment with etanercept plus methotrexate - Results from the trial of etanercept and methotrexate with radiographic and patient outcomes. *Arthritis and Rheumatism (USA)*. 2006 10/01;54(Oct):3119-25.
172. Lard LR, Boers M, Verhoeven A, Vos K, Visser H, Hazes JMW, et al. Early and Aggressive Treatment of Rheumatoid Arthritis Patients Affects the Association of Hla Class Ii Antigens With Progression of Joint Damage. *Arthritis and rheumatism*. 2002;46(4):899-905.
173. Lazzarini PE, Acampa M, Hammoud M, Maffei S, Capecchi PL, Selvi E, et al. Arrhythmic risk during acute infusion of infliximab: a prospective, single-blind, placebo-controlled, crossover study in patients with chronic arthritis. *J Rheumatol*. 2008 Oct;35(10):1958-65.
174. Le Loet X, Nordstrom D, Rodriguez M, Rubbert A, Sarzi-Puttini P, Wouters JM, et al. Effect of anakinra on functional status in patients with active rheumatoid arthritis receiving concomitant therapy with traditional disease modifying antirheumatic drugs: evidence from the OMEGA Trial. *J Rheumatol*. 2008 Aug;35(8):1538-44.
175. Lekander I, Borgstrom F, Svarvar P, Ljung T, Carli C, van Vollenhoven RF. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden. *International Journal of Technology Assessment in Health Care*. 2010;26(1):54-61.
176. Lems WF, Jahangier ZN, Jacobs JW, Bijlsma JW. Vertebral fractures in patients with rheumatoid arthritis treated with corticosteroids. *Clin Exp Rheumatol*. 1995 May-Jun;13(3):293-7.
177. Lequerre T, Vittecoq O, Klemmer N, Goeb V, Pouplin S, Menard JF, et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. *J Rheumatol*. 2006 Jul;33(7):1307-14.
178. Lester SE, Proudman SM, Lee AT, Hall CA, Cleland LG, et al., et al. Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis. *Internal Medicine Journal*. 2009;39:296.

179. Levalampi T, Korpela M, Vuolteenaho K, Moilanen E. Etanercept and adalimumab treatment in patients with rheumatoid arthritis and spondyloarthropathies in clinical practice: Adverse events and other reasons leading to discontinuation of the treatment. *Rheumatology International*. 2008;28(3):261-9.
180. Lindgren P, Geborek P, Kobelt G. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden. *Int J Technol Assess Health Care*. 2009 Apr;25(2):181-9.
181. Lindqvist E, Saxne T, Geborek P, Eberhardt K. Ten year outcome in a cohort of patients with early rheumatoid arthritis: health status, disease process, and damage. *Ann Rheum Dis*. 2002 Dec;61(12):1055-9.
182. Lisbona MP, Maymo J, Perich J, Almirall M, Carbonell J. Rapid reduction in tenosynovitis of the wrist and fingers evaluated by MRI in patients with rheumatoid arthritis after treatment with etanercept. *Ann Rheum Dis*. 2010/05/08 ed 2010:1117-22.
183. Lisbona MP, Maymo J, Perich J, Almirall M, Perez-Garcia C, Carbonell J. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks. *J Rheumatol* 2008:394-7.
184. Luzi G, Lagana B, Salemi S, Di Rosa R. Are glucocorticoids a consistent risk factor for infections in rheumatoid arthritis patients under treatment with methotrexate and etanercept? *Clin Ter*. 2009 Mar-Apr;160(2):121-3.
185. Lyons JS, Severns ML. Detection of early hydroxychloroquine retinal toxicity enhanced by ring ratio analysis of multifocal electroretinography. *Am J Ophthalmol*. 2007 May;143(5):801-9.
186. Machado P, Santos A, Pereira C, Loureiro C, Silva J, Chieira C, et al. Increased prevalence of allergic sensitisation in rheumatoid arthritis patients treated with anti-TNFalpha. *Joint Bone Spine* 2009:508-13.
187. Maignen F, Hauben M, Tsintis P. Modelling the Time to Onset of Adverse Reactions with Parametric Survival Distributions A Potential Approach to Signal Detection and Evaluation. *Drug Safety (New Zealand)*. 2010;33:417-34.
188. Malipeddi AS, Rajendran R, Kallarackal G. Disseminated tuberculosis after anti-TNFalpha treatment. *Lancet*. 2007 Jan 13;369(9556):162.
189. Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, et al. Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the GISEA study. *J Rheumatol*. 2007 Aug;34(8):1670-3.
190. Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P. Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor. *Arthritis Rheum*. 2008 May;58(5):1258-63.
191. Martin N, Innes JA, Lambert CM, Turnbull CM, Wallace WA. Hypersensitivity pneumonitis associated with leflunomide therapy. *J Rheumatol*. 2007 Sep;34(9):1934-7.
192. Mastroianni A, Minutilli E, Mussi A, Bordignon V, Trento E, D'Agosto G, et al. Cytokine profiles during infliximab monotherapy in psoriatic arthritis. *Br J Dermatol*. 2005 Sep;153(3):531-6.

193. Maxwell L, Singh Jasvinder A. Abatacept for rheumatoid arthritis. *Cochrane Database of Systematic Reviews*. Chichester, UK: John Wiley & Sons, Ltd 2009.
194. Mazzotta A, Esposito M, Costanzo A, Chimenti S. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study. *Am J Clin Dermatol*. 2009;10(5):319-24.
195. McCluggage LK, Scholtz JM. Golimumab: A Tumor Necrosis Factor Alpha Inhibitor for the Treatment of Rheumatoid Arthritis. *Annals of Pharmacotherapy (USA)*. 2010;44:135-44.
196. McGonagle D, Tan AL, Madden J, Taylor L, Emery P. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistant rheumatoid arthritis. *Rheumatology (Oxford)*. 2008 Jun;47(6):865-7.
197. McLean-Tooke A, Aldridge C, Waugh S, Spickett GP, Kay L, Aug. Methotrexate, rheumatoid arthritis and infection risk what is the evidence. *Rheumatology*. 2009;48:867.
198. Mease PJ, Cohen S, Gaylis NB, Chubick A, Kaell AT, Greenwald M, et al. Efficacy and safety of retreatment in patients with rheumatoid arthritis with previous inadequate response to tumor necrosis factor inhibitors: results from the SUNRISE trial. *J Rheumatol*. 2010/03/03 ed 2010:917-27.
199. Mease PJ, Ory P, Sharp JT, Ritchlin CT, Van den Bosch F, Wellborne F, et al. Adalimumab for long-term treatment of psoriatic arthritis: 2-year data from the Adalimumab Effectiveness in Psoriatic Arthritis Trial (ADEPT). *Ann Rheum Dis*. 2009 May;68(5):702-9.
200. Mease PJ, Signorovitch J, Yu AP, Wu EQ, Gupta SR, Bao Y, et al. Impact of adalimumab on symptoms of psoriatic arthritis in patients with moderate to severe psoriasis: A pooled analysis of randomized clinical trials. *Dermatology*. 2010;220(1):1-7.
201. Mittendorf T, Dietz B, Sterz R, Kupper H, Cifaldi MA, von der Schulenburg JM. Improvement and longterm maintenance of quality of life during treatment with adalimumab in severe rheumatoid arthritis. *J Rheumatol*. 2007 Dec;34(12):2343-50.
202. Montecucco C, Caporali R, Caprotti P, Caprotti M, Notario A. Sex hormones and bone metabolism in postmenopausal rheumatoid arthritis treated with two different glucocorticoids. *J Rheumatol*. 1992 Dec;19(12):1895-900.
203. Moreland LW, Alten R, Van den Bosch F, Appelboom T, Leon M, Emery P, et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose-finding, double-blind, placebo-controlled clinical trial evaluating CTLA-4Ig and LEA29Y eighty-five days after the first infusion. *Arthritis Rheum*. 2002 Jun;46(6):1470-9.
204. Moreland LW, Cohen SB, Baumgartner SW, Tindall EA, Bulpitt K, Martin R, et al. Long-term safety and efficacy of etanercept in patients with rheumatoid arthritis. *J Rheumatol*. 2001 Jun;28(6):1238-44.
205. Moreland LW, Genovese MC, Sato R, Singh A. Effect of etanercept on fatigue in patients with recent or established rheumatoid arthritis. *Arthritis Rheum*. 2006 Apr 15;55(2):287-93.
206. Mori S. A relationship between pharmacokinetics (PK) and the efficacy of infliximab for patients with rheumatoid arthritis: characterization of infliximab-resistant cases and PK-based modified therapy. *Mod Rheumatol*. 2007;17(2):83-91.

207. Mroczkowski PJ, Weinblatt ME, Kremer JM. Methotrexate and leflunomide combination therapy for patients with active rheumatoid arthritis. *Clin Exp Rheumatol*. 1999 Nov-Dec;17(6 Suppl 18):S66-8.
208. Nagasawa H, Kameda H, Sekiguchi N, Amano K, Takeuchi T. Normalisation of physical function by infliximab in patients with RA: factors associated with normal physical function. *Clin Exp Rheumatol*. 2010 May-Jun;28(3):365-72.
209. Nawata M, Saito K, Nakayamada S, Tanaka Y. Discontinuation of infliximab in rheumatoid arthritis patients in clinical remission. *Mod Rheumatol*. 2008;18(5):460-4.
210. Niewold TB, Gibofsky A. Concomitant interferon-alpha therapy and tumor necrosis factor alpha inhibition for rheumatoid arthritis and hepatitis C. *Arthritis Rheum*. 2006 Jul;54(7):2335-7.
211. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): Evidence of safety and efficacy in a 5-year extension study. 2009.
212. Oei HB, Hooker RS, Cipher DJ, Reimold A. High rates of stopping or switching biological medications in veterans with rheumatoid arthritis. *Clin Exp Rheumatol*. 2010/02/13 ed 2009:926-34.
213. Oldfield V, Dhillon S, Plosker GL. Tocilizumab A Review of its Use in the Management of Rheumatoid Arthritis. *Drugs*. 2009;69:609-32.
214. Olivieri I, de Portu S, Salvarani C, Cauli A, Lubrano E, Spadaro A, et al. The psoriatic arthritis cost evaluation study: a cost-of-illness study on tumour necrosis factor inhibitors in psoriatic arthritis patients with inadequate response to conventional therapy. *Rheumatology (Oxford)*. 2008 Nov;47(11):1664-70.
215. Ongaro A, De Mattei M, Pellati A, Caruso A, Ferretti S, Masieri FF, et al. Can tumor necrosis factor receptor II gene 676T>G polymorphism predict the response grading to anti-TNFalpha therapy in rheumatoid arthritis? *Rheumatol Int*. 2008 Jul;28(9):901-8.
216. Ostensen M, Forger F. Management of RA medications in pregnant patients. *Nat Rev Rheumatol*. 2009 Jul;5(7):382-90.
217. Panoulas VF, Douglas KM, Stavropoulos-Kalinoglou A, Metsios GS, Nightingale P, Kita MD, et al. Long-term exposure to medium-dose glucocorticoid therapy associates with hypertension in patients with rheumatoid arthritis. *Rheumatology (Oxford)*. 2008 Jan;47(1):72-5.
218. Pavelka K, Jarosova K, Suchy D, Senolt L, Chroust K, Dusek L, et al. Increasing the infliximab dose in rheumatoid arthritis patients: A randomised, double blind study failed to confirm its efficacy. 2009.
219. Perera LC, Tymms KE, Wilson BJ, Shadbolt B, Brook AS, Dorai Raj AK, et al. Etanercept in severe active rheumatoid arthritis: first Australian experience. *Intern Med J*. 2006 Oct;36(10):625-31.
220. Pfeil A, Lippold J, Eidner T, Lehmann G, Oelzner P, Renz DM, et al. Effects of leflunomide and methotrexate in rheumatoid arthritis detected by digital X-ray radiogrammetry and computer-aided joint space analysis. *Rheumatol Int*. 2009 Jan;29(3):287-95.
221. Pisitkun P, Pattarowas C, Siriwongpairat P, Totemchokchyakarn K, Nantiruj K, Janwityanujit S. Reappraisal of cervical spine subluxation in Thai patients with rheumatoid arthritis. *Clin Rheumatol*. 2004 Feb;23(1):14-8.

222. Plushner SL. Tocilizumab: An Interleukin-6 Receptor Inhibitor for the Treatment of Rheumatoid Arthritis. *Annals of Pharmacotherapy*. 2008;42:1660-8.
223. Polinski JM, Mohr PE, Johnson L, Jun. Impact of Medicare Part D on Access to and Cost Sharing for Specialty Biologic Medications for Beneficiaries With Rheumatoid Arthritis. *Arthritis and Rheumatism-Arthritis Care and Research*. 2009;61:745.
224. Prochorec-Sobieszek M, Chelstowska M, Rymkiewicz G, Majewski M, Warzocha K, Maryniak R. Biclonal T-cell receptor gammadelta+ large granular lymphocyte leukemia associated with rheumatoid arthritis. *Leukemia and Lymphoma*. 2008;49(4):828-31.
225. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al. Early Suppression of Disease Activity Is Essential for Maintenance of Work Capacity in Patients With Recent-Onset Rheumatoid Arthritis: Five-Year Experience From the Fin-Raco Trial. *Arthritis and rheumatism*. 2005;52(1):36-41.
226. Puolakka K, Kautiainen H, Mottonen T, Hannonen P, Korpela M, Hakala M, et al. Use of the Stanford Health Assessment Questionnaire in estimation of long-term productivity costs in patients with recent-onset rheumatoid arthritis. *Scandinavian Journal of Rheumatology*. 2009;38(2):96-103.
227. Quartuccio L, Fabris M, Salvin S, Atzeni F, De Vita S, et al., et al. Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. *Rheumatology* 2009:1557.
228. Quinn MA, Conaghan PG, O'Connor PJ. Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: Results from a twelve-month ran-liver disease? *Hepatology*. 2006;43:352-61.
229. Rahman MU, Strusberg I, Geusens P, Berman A, Yocum D, Baker D, et al. Double-blinded infliximab dose escalation in patients with rheumatoid arthritis. *Ann Rheum Dis*. 2007 Sep;66(9):1233-8.
230. Ranganathan P, McLeod HL. Methotrexate pharmacogenetics - The first step toward individualized therapy in rheumatoid arthritis. *Arthritis and Rheumatism (USA)*. 2006 05/01;54(May):1366-77.
231. Rantalaiho V, Korpela M, Hannonen P, Kautiainen H, Jarvenpaa S, Leirisalo-Repo M, et al. The good initial response to therapy with a combination of traditional disease-modifying antirheumatic drugs is sustained over time: the eleven-year results of the Finnish rheumatoid arthritis combination therapy trial. *Arthritis Rheum*. 2009 May;60(5):1222-31.
232. Rau R, Simianer S, van Riel PL, van de Putte LB, Kruger K, Schattenkirchner M, et al. Rapid alleviation of signs and symptoms of rheumatoid arthritis with intravenous or subcutaneous administration of adalimumab in combination with methotrexate. *Scand J Rheumatol*. 2004;33(3):145-53.
233. Reece RJ, Kraan MC, Radjenovic A, Veale DJ, O'Connor PJ, Ridgway JP, et al. Comparative Assessment of Leflunomide and Methotrexate for the Treatment of Rheumatoid Arthritis, by Dynamic Enhanced Magnetic Resonance Imaging. *Arthritis and rheumatism*. 2002;46(2):366-72.
234. Richards BL, Spies J, McGill N, Richards GW, Vaile J, Bleasel JF, et al. Effect of leflunomide on the peripheral nerves in rheumatoid arthritis. *Intern Med J*. 2007 Feb;37(2):101-7.



235. Rozenbaum M, Boulman N, Slobodin G, Ayubkhanov E, Rosner I. Polyarthritis flare complicating rheumatoid arthritis infliximab therapy: a paradoxical adverse reaction. *J Clin Rheumatol*. 2006 Dec;12(6):269-71.
236. Rubbert-Roth A, Tak PP, Zerbini C, Tremblay JL, Carreno L, Armstrong G, et al. Efficacy and safety of various repeat treatment dosing regimens of rituximab in patients with active rheumatoid arthritis: Results of a Phase III randomized study (MIRROR). *Rheumatology*. 2010;49(9):1683-93.
237. Rudwaleit M, Van den Bosch F, Kron M, Kary S, Kupper H. Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. *Arthritis Res Ther*. 2010;12(3):R117.
238. Saag KG, Gim GT, Patkar NM, Anuntiyo J, Finney C, Curtis JR, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. *Arthritis Care and Research*. 2008;59(6):762-84.
239. Saleem B, Brown AK, Keen H, Nizam S, Freeston J, Karim Z, et al. Disease remission state in patients treated with the combination of tumor necrosis factor blockade and methotrexate or with disease-modifying antirheumatic drugs: A clinical and imaging comparative study. *Arthritis Rheum* 2009:1915-22.
240. Salvarani C, Cantini F, Olivieri I, Macchioni P, Padula A, Niccoli L, et al. Efficacy of infliximab in resistant psoriatic arthritis. *Arthritis Rheum*. 2003 Aug 15;49(4):541-5.
241. Sanchez G, Castro JS, Snih SA, Blanco LP, Esteva MH, Macgregor EG, et al. Durability of treatment with methotrexate in Venezuelan patients with rheumatoid arthritis. *Rheumatol Int*. 2007 Apr;27(6):531-6.
242. Saunders SA, Capell HA, Stirling A, Vallance R, Kincaid W, McMahon AD, et al. Triple therapy in early active rheumatoid arthritis: a randomized, single-blind, controlled trial comparing step-up and parallel treatment strategies. *Arthritis Rheum* 2008:1310-7.
243. Scali JJ, Visentini S, Salomon J, Sevilla D, Ju YC, Morales E, et al. Rapid and deep control of inflammation in rheumatoid arthritis with infliximab and its correlation with acute-phase reactants. *Ann N Y Acad Sci*. 2007 Sep;1110:389-401.
244. Schiff M, Pritchard C, Huffstutter JE, Rodriguez Valverde V, Durez P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumour necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. *Annals of the rheumatic diseases*. 2009;68(11):1708-14.
245. Schiff MH, Yu EB, Weinblatt ME, Moreland LW, Woolley JM, et al. Long-term experience with etanercept in the treatment of rheumatoid arthritis in elderly and younger patients - Patient-reported outcomes from multiple controlled and open-label extension studies. *Drugs and Aging (New Zealand)*. 2006 02/01;23(Feb):167-78.
246. Schnabel A, Herlyn K, Burchardi C, Reinhold Keller E, Gross WL. Long-Term Tolerability of Methotrexate at Doses Exceeding 15 Mg Per Week in Rheumatoid Arthritis. *Rheumatology international*. 1996;15(5):195-200.
247. Schnabel A, Reinhold Keller E, Willmann V, Gross W. Tolerability of Methotrexate Starting With 15 or 25 Mg/Week for Rheumatoid Arthritis. *Rheumatology international*. 1994;14(1):33-8.

248. Scrivo R, Conti F, Spinelli FR, Truglia S, Magrini L, Di Franco M, et al. Switching between TNFalpha antagonists in rheumatoid arthritis: personal experience and review of the literature. *Reumatismo*. 2009 Apr-Jun;61(2):107-17.
249. Shashikumar NS, Shivamurthy MC, Chandrashekara S. Evaluation of efficacy of combination of methotrexate and hydroxychloroquine with leflunomide in active rheumatoid arthritis. *Indian Journal of Pharmacology* 2010:358-61.
250. Shedd AD, Reddy SG, Meffert JJ, Kraus EW, Usatine RP. Acute onset of rash and oligoarthritis. *J Fam Pract*. 2007 Oct;56(10):811-4.
251. Shergy WJ, Isern RA, Cooley DA, Harshbarger JL, Huffstutter JE, Hughes GM, et al. Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis. *J Rheumatol*. 2002 Apr;29(4):667-77.
252. Sheth NU, Hilas O, Charneski L. Abatacept: A novel agent for rheumatoid arthritis. *Journal of Pharmacy Technology (USA)*. 2006 06/01;22(Jun):336-41.
253. Singh Jasvinder A, Christensen R, Wells George A, Suarez-Almazor Maria E, Buchbinder R, Lopez-Olivo Maria A, et al. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. *Cochrane Database of Systematic Reviews*. 2009(2).
254. Sinha A, Patient C. Rheumatoid arthritis in pregnancy: successful outcome with anti-TNF agent (Etanercept). *J Obstet Gynaecol*. 2006 Oct;26(7):689-91.
255. Sinigaglia L, Nervetti A, Mela Q, Bianchi G, Del Puente A, Di Munno O, et al. A multicenter cross sectional study on bone mineral density in rheumatoid arthritis. Italian Study Group on Bone Mass in Rheumatoid Arthritis. *J Rheumatol*. 2000 Nov;27(11):2582-9.
256. Smith N, Ding T, Butt S, Gadsby K, Deighton C. The importance of the baseline Disease Activity Score 28 in determining responders and non-responders to anti-TNF in UK clinical practice. *Rheumatology (Oxford)*. 2008 Sep;47(9):1389-91.
257. Smolen JS, Han C, Bala M, Maini RN, Grp AS, et al. Evidence of radiographic benefit of treatment with infliximab plus methotrexate in rheumatoid arthritis patients who had no clinical improvement - A detailed subanalysis of data from the anti-tumor necrosis factor trial in rheumatoid arthritis with concomitant therapy study. *Arthritis and Rheumatism (USA)*. 2005 04/01;52(Apr):1020-30.
258. Smolen JS, van der Heijde DM, St Clair EW, Emery P, Grp AS, et al. Predictors of joint damage in patients with early rheumatoid arthritis treated with high-dose methotrexate with or without concomitant infliximab - Results from the ASPIRE trial. *Arthritis and Rheumatism (USA)*. 2006 03/01;54(Mar):702-10.
259. Soubrier M, Puechal X, Sibia J, Mariette X, Dougados M, et al., et al. Evaluation of two strategies (initial methotrexate monotherapy <it>vs</it> its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. *Rheumatology*. 2009;48:1429.
260. Soubrier M, Puechal X, Sibia J, Mariette X, Meyer O, Combe B, et al. Evaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trial. *Rheumatology (Oxford)*. 2009 Nov;48(11):1429-34.
261. Spalding JR, Hay J. Cost effectiveness of tumour necrosis factor-alpha inhibitors as first-line agents in rheumatoid arthritis. *Pharmacoeconomics*. 2006;24(12):1221-32.

262. St Clair EW, Wagner CL, Fasanmade AA, Wang B, Schaible T, Kavanaugh A, et al. The Relationship of Serum Infliximab Concentrations to Clinical Improvement in Rheumatoid Arthritis: Results From Attract, a Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. *Arthritis and rheumatism*. 2002;46(6):1451-9.
263. Stern R, Wolfe F. Infliximab dose and clinical status: results of 2 studies in 1642 patients with rheumatoid arthritis. *J Rheumatol*. 2004 Aug;31(8):1538-45.
264. Sterry W, Ortonne JP, Kirkham B, Brocq O, Robertson D, Pedersen RD, et al. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial. *Bmj*. 2010;340:c147.
265. Suarez-Almazor Maria E, Belseck E, Shea B, Tugwell P, Wells George A. Sulfasalazine for treating rheumatoid arthritis. *Cochrane Database of Systematic Reviews*. 1998(2).
266. Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study at the university-based hospital. *Int J Rheum Dis*. 2010/04/09 ed 2009:118-24.
267. Taiwo B, Lee C, Venkat D, Tambar S, Sutton SH. Can tumor necrosis factor alpha blockade predispose to severe babesiosis? *Arthritis Rheum*. 2007 Feb 15;57(1):179-81.
268. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. *Mod Rheumatol* 2009:478-87.
269. Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. *Ann Rheum Dis*. 2008 Feb;67(2):189-94.
270. Takeuchi T, Yamanaka H, Inoue E, Nagasawa H, Nawata M, Ikari K, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year outcome of joint destruction (RECONFIRM-2J). *Mod Rheumatol*. 2008;18(5):447-54.
271. Tam LS, Griffith JF, Yu AB, Li TK, Li EK. Rapid improvement in rheumatoid arthritis patients on combination of methotrexate and infliximab: clinical and magnetic resonance imaging evaluation. *Clin Rheumatol*. 2007 Jun;26(6):941-6.
272. Tanaka Y, Takeuchi T, Inoue E, Saito K, Sekiguchi N, Sato E, et al. Retrospective clinical study on the notable efficacy and related factors of infliximab therapy in a rheumatoid arthritis management group in Japan: one-year clinical outcomes (RECONFIRM-2). *Mod Rheumatol*. 2008;18(2):146-52.
273. Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, et al. Validation of the associations between single nucleotide polymorphisms or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. *Pharmacogenet Genomics*. 2007 Jun;17(6):383-90.
274. Taylor P, Steuer A, Gruber J, McClinton C, Cosgrove D, Blomley M, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. *Arthritis and rheumatism*. 2006 2006;54(1):47-53.

275. Taylor PC, Steuer A, Gruber J, McClinton C, Maini RN, et al. Ultrasonographic and radiographic results from a two-year controlled trial of immediate or one-year-delayed addition of infliximab to ongoing methotrexate therapy in patients with erosive early rheumatoid arthritis. *Arthritis and Rheumatism (USA)*. 2006 01/01;54(Jan):47-53.
276. Theodoridou A, Kartsios C, Yiannaki E, Markala D, Settas L. Reversible T-large granular lymphocyte expansion and neutropenia associated with adalimumab therapy. *Rheumatol Int*. 2006 Dec;27(2):201-2.
277. Thurlings RM, Vos K, Gerlag DM, Tak PP. Disease activity-guided rituximab therapy in rheumatoid arthritis: the effects of re-treatment in initial nonresponders versus initial responders. *Arthritis Rheum*. 2008 Dec;58(12):3657-64.
278. Torii H, Nakagawa H. Infliximab monotherapy in Japanese patients with moderate-to-severe plaque psoriasis and psoriatic arthritis. A randomized, double-blind, placebo-controlled multicenter trial. *J Dermatol Sci*. 2010 Jul;59(1):40-9.
279. Torikai E, Kageyama Y, Suzuki M, Ichikawa T, Nagano A. The effect of infliximab on chemokines in patients with rheumatoid arthritis. *Clin Rheumatol*. 2007 Jul;26(7):1088-93.
280. Torrance GW, Tugwell P, Amorosi S, Chartash E, Sengupta N. Improvement in health utility among patients with rheumatoid arthritis treated with adalimumab (a human anti-TNF monoclonal antibody) plus methotrexate. *Rheumatology (Oxford)*. 2004 Jun;43(6):712-8.
281. Tubach F, Ravaud P, Salmon-Ceron D, Petitpain N, Grp R, et al. Emergence of *Legionella pneumophila* pneumonia in patients receiving tumor necrosis factor-alpha antagonist. *Clinical Infectious Diseases*. 2006 10/01;43(Oct):E95-100.
282. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry. *Arthritis Rheum*. 2009 Jul;60(7):1884-94.
283. Tutuncu Z, Kavanaugh A. Treatment of elderly rheumatoid arthritis. *Future Rheumatology*. 2007;2(3):313-9.
284. van den Hout WB, Goekoop-Ruiterman YP, Allaart CF, de Vries-Bouwstra JK, Hazes JM, Kerstens PJ, et al. Cost-utility analysis of treatment strategies in patients with recent-onset rheumatoid arthritis. *Arthritis Rheum*. 2009 Mar 15;61(3):291-9.
285. Van Der Heijde D, Breedveld FC, Kavanaugh A, Keystone EC, Landewe R, Patra K, et al. Disease activity, physical function, and radiographic progression after longterm therapy with adalimumab plus methotrexate: 5-Year results of PREMIER. *Journal of Rheumatology*. 2010;37(11):2237-46.
286. van der Heijde D, Burmester G, Melo Gomes J, Codreanu C, Martin Mola E, Pedersen R, et al. Inhibition of radiographic progression with combination etanercept and methotrexate in patients with moderately active rheumatoid arthritis previously treated with monotherapy. *Annals of the rheumatic diseases* 2009;1113-8.
287. van der Heijde D, Burmester G, Melo-Gomes J, Codreanu C, Mola EM, Pedersen R, et al. The safety and efficacy of adding etanercept to methotrexate or methotrexate to etanercept in moderately active rheumatoid arthritis patients previously treated with monotherapy. *Ann Rheum Dis*. 2008 Feb;67(2):182-8.

288. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP, van Zeben D, Kerstens PJ, Gerards AH, et al. Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. *Ann Rheum Dis.* 2007 Oct;66(10):1356-62.
289. van der Kooij SM, le Cessie S, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, van Zeben D, Kerstens PJ, et al. Clinical and radiological efficacy of initial vs delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. *Ann Rheum Dis.* 2009 Jul;68(7):1153-8.
290. van der Veen MJ, Bijlsma JW. The effect of methylprednisolone pulse therapy on methotrexate treatment of rheumatoid arthritis. *Clin Rheumatol.* 1993 Dec;12(4):500-5.
291. Van Kuijk AWR, Gerlag DM, Vos K, Wolbink G, De Groot M, De Rie MA, et al. A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: Effects of adalimumab treatment on synovial tissue. 2009.
292. van Staa TP, Geusens P, Bijlsma JW, Leufkens HG, Cooper C. Clinical assessment of the long-term risk of fracture in patients with rheumatoid arthritis. *Arthritis Rheum.* 2006 Oct;54(10):3104-12.
293. van Tuyl LH, Boers M, Lems WF, Landewé RB, Han H, van der Linden S, et al. Survival, comorbidities and joint damage 11 years after the COBRA combination therapy trial in early rheumatoid arthritis. *Annals of the rheumatic diseases.* 2010(5):807-12.
294. van Vollenhoven RF, Emery P, Bingham CO, 3rd, Keystone EC, Fleischmann R, Furst DE, et al. Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials. *J Rheumatol.* 2010/01/30 ed 2010:558-67.
295. van Vollenhoven RF, Ernestam S, Harju A, Bratt J, Klareskog L. Etanercept versus etanercept plus methotrexate: a registry-based study suggesting that the combination is clinically more efficacious. *Arthritis Res Ther.* 2003;5(6):R347-51.
296. Vander Cruyssen B, Durez P, Westhovens R, De Keyser F. Seven-year follow-up of infliximab therapy in rheumatoid arthritis patients with severe long-standing refractory disease: attrition rate and evolution of disease activity. *Arthritis Res Ther.* 2010;12(3):R77.
297. Vera-Llonch M, Massarotti E, Wolfe F, Shadick N, Westhovens R, Sofrygin O, et al. Cost-effectiveness of abatacept in patients with moderately to severely active rheumatoid arthritis and inadequate response to methotrexate. *Rheumatology (Oxford).* 2008 Apr;47(4):535-41.
298. Verschueren P, Esselens G, Westhovens R. Daily practice effectiveness of a step-down treatment in comparison with a tight step-up for early rheumatoid arthritis. *Rheumatology (Oxford).* 2008 Jan;47(1):59-64.
299. Verstappen S, Jacobs J, Bijlsma JW. The Utrecht Experience With Different Treatment Strategies in Early Rheumatoid Arthritis. *Clinical and experimental rheumatology.* 2003;21(5 Suppl 31):S165-8.
300. Verstappen SM, Jacobs JW, van der Veen MJ, Heurkens AH, Schenk Y, ter Borg EJ, et al. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. *Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).* *Ann Rheum Dis.* 2007 Nov;66(11):1443-9.

301. Visser K, Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Roday HK, Seys PE, Kerstens PJ, et al. A matrix risk model for the prediction of rapid radiographic progression in patients with rheumatoid arthritis receiving different dynamic treatment strategies: post hoc analyses from the BeSt study. *Ann Rheum Dis*. 2010 Jul;69(7):1333-7.
302. Visser K, Katchamart W, Loza E, Martinez-Lopez JA, Salliot C, Trudeau J, et al. Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: Integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. *Annals of the rheumatic diseases*. 2009;68(7):1086-93.
303. Vlak T, Eldar R. Disability in Rheumatoid Arthritis After Monotherapy With Dmards. *International Journal Rehabilitation Research*. 2003;26(3):207-12.
304. Voulgari PV, Markatseli TE, Exarchou SA, Zioga A, Drosos AA. Granuloma annulare induced by anti-tumour necrosis factor therapy. *Ann Rheum Dis*. 2008 Apr;67(4):567-70.
305. Wakabayashi H, Sudo A, Hasegawa M, Oka H, Uchida A, Nishioka K. Retrospective clinical study of the efficacy of lower-dose methotrexate and infliximab therapy in patients with rheumatoid arthritis. *Clin Rheumatol*. 2010/03/06 ed 2010:671-5.
306. Wakefield RJ, Freeston JE, Hensor EM, Bryer D, Quinn MA, Emery P. Delay in imaging versus clinical response: a rationale for prolonged treatment with anti-tumor necrosis factor medication in early rheumatoid arthritis. *Arthritis Rheum*. 2007 Dec 15;57(8):1564-7.
307. Wasko MC, Hubert HB, Lingala VB, Elliott JR, Luggen ME, Fries JF, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. *Jama*. 2007 Jul 11;298(2):187-93.
308. Weinblatt ME, Bathon JM, Kremer JM, Fleischmann RM, Schiff MH, Martin RW, et al. Safety and efficacy of etanercept beyond 10 years of therapy in North American patients with early and long-standing rheumatoid arthritis. *Arthritis Care Res (Hoboken)* 2010.
309. Weinblatt ME, Kremer JM, Coblyn JS, Maier AL, Helfgott SM, Morrell M, et al. Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. *Arthritis Rheum*. 1999 Jul;42(7):1322-8.
310. Weinblatt ME, Schiff MH, Ruderman EM, Bingham CO, 3rd, Li J, Louie J, et al. Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study. *Arthritis Rheum*. 2008 Jul;58(7):1921-30.
311. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, et al. Long-Term Prospective Study of Methotrexate in the Treatment of Rheumatoid Arthritis. 84-Month Update. *Arthritis and rheumatism*. 1992;35(2):129-37.
312. Weisman MH, Moreland LW, Furst DE, Weinblatt ME, Keystone EC, Paulus HE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. *Clin Ther*. 2003 Jun;25(6):1700-21.
313. Wells G, Becker JC, Teng J, Dougados M, Schiff M, Smolen J, et al. Validation of the 28-joint Disease Activity Score (DAS28) and European League Against Rheumatism response criteria based on C-reactive

- protein against disease progression in patients with rheumatoid arthritis, and comparison with the DAS28 based on erythrocyte sedimentation rate. *Ann Rheum Dis*. 2009 Jun;68(6):954-60.
314. Westhovens R, Cole JC, Li T, Martin M, Maclean R, Lin P, et al. Improved health-related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti-TNF therapy in a double-blind, placebo-controlled, multicentre randomized clinical trial. *Rheumatology (Oxford)*. 2006 Oct;45(10):1238-46.
315. Westhovens R, Houssiau F, Joly J, Everitt DE, Zhu Y, Sisco D, et al. A phase I study assessing the safety, clinical response, and pharmacokinetics of an experimental infliximab formulation for subcutaneous or intramuscular administration in patients with rheumatoid arthritis. *J Rheumatol*. 2006 May;33(5):847-53.
316. Westhovens R, Kremer JM, Moreland LW, Emery P, Russell AS, Li T, et al. Safety and efficacy of the selective costimulation modulator abatacept in patients with rheumatoid arthritis receiving background methotrexate: a 5-year extended phase IIB study. *The Journal of rheumatology*. 2009;36(4):736-42.
317. Westlake SL, Colebatch AN, Baird J, Kiely P, Edwards CJ, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. *Rheumatology (Oxford)*. 2010;49:295.
318. White DH, Chapman PT, O'Donnell JL, James J, Stamp LK, et al. Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis. *Internal Medicine Journal*. 2010;40:561-5.
319. Wislowska M, Jakubicz D. Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone. *Rheumatol Int*. 2007 May;27(7):641-7.
320. Wollina U, Hansel G, Koch A, Schonlebe J, Kostler E, Haroske G. Tumor necrosis factor-alpha inhibitor-induced psoriasis or psoriasiform exanthemata: first 120 cases from the literature including a series of six new patients. *Am J Clin Dermatol*. 2008;9(1):1-14.
321. Yazici Y, Erkan D, Kulman I, Belostocki K, Harrison MJ. Decreased flares of rheumatoid arthritis during the first year of etanercept treatment: further evidence of clinical effectiveness in the "real world". *Ann Rheum Dis*. 2002 Jul;61(7):638-40.
322. Yelin E, Trupin L, Katz P, Lubeck D, Rush S, Wanke L. Association between etanercept use and employment outcomes among patients with rheumatoid arthritis. *Arthritis Rheum*. 2003 Nov;48(11):3046-54.
323. Yount S, Sorensen MV, Cella D, Sengupta N, Grober J, Chartash EK. Adalimumab plus methotrexate or standard therapy is more effective than methotrexate or standard therapies alone in the treatment of fatigue in patients with active, inadequately treated rheumatoid arthritis. *Clin Exp Rheumatol*. 2007 Nov-Dec;25(6):838-46.
324. Yuan Y, Trivedi D, Maclean R, Rosenblatt L. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States. *Journal of Medical Economics (England)* 2010:33-41.
325. Yun JE, Lee SW, Kim TH, Jun JB, Jung S, Bae SC, et al. The incidence and clinical characteristics of Mycobacterium tuberculosis infection among systemic lupus erythematosus and rheumatoid arthritis patients in Korea. *Clin Exp Rheumatol*. 2002 Mar-Apr;20(2):127-32.

326. Zhang W, Bansback N, Guh D, Li X, Nosyk B, Marra CA, et al. Short-term influence of adalimumab on work productivity outcomes in patients with rheumatoid arthritis. *J Rheumatol*. 2008 Sep;35(9):1729-36.

### **Unable To Obtain Full Text**

1. van der Veen M, Bijlsma J. The Effect of Methylprednisolone Pulse Therapy on Methotrexate Treatment of Rheumatoid Arthritis. *Clinical rheumatology*. 1993;12(4):74-6.



# Appendix E. Evidence Tables

## Index of Studies Included by Key Question

### Key Question 1

#### RCTs and other studies (Evidence Table 1)

Antoni, 2005 (IMPACT 2)<sup>1</sup>  
Antoni, 2005 (IMPACT)<sup>2</sup>  
Genovese, 2007<sup>3</sup>  
Kaltwasser, 2004<sup>4</sup>  
Kavanaugh, 2006 (IMPACT)<sup>5</sup> – found under Antoni, 2005  
Kavanaugh, 2006 (IMPACT2)<sup>6</sup>  
Kavanaugh, 2009<sup>7</sup>  
Kristensen, 2008<sup>8</sup>  
Mease, 2000<sup>9</sup>  
Mease, 2004<sup>10</sup>  
Mease, 2005 (ADEPT)<sup>11</sup>  
Mease, 2006<sup>12</sup>–found under Mease 2004  
Nash, 2006<sup>13</sup>–found under Kaltwasser 2004  
Saad, 2010<sup>14</sup>  
Van der Heijde, 2007<sup>15</sup>–found under Kavanaugh, 2006  
Willkens, 1984<sup>16</sup>

#### Systematic Reviews and Meta-analyses (Evidence Table 2)

Jones, 2000<sup>17</sup>  
Ravindran, 2008<sup>18</sup>  
Woolacott, 2006<sup>19</sup>

## Key Question 2

### RCTs and other studies (Evidence Table 1)

Antoni, 2005 (IMPACT) <sup>2</sup>

Antoni, 2005 (IMPACT 2)<sup>1</sup>

Genovese, 2007<sup>3</sup>

Gladman, 2007(ADEPT) <sup>20</sup>

Kaltwasser, 2004<sup>4</sup>

Kavanaugh, 2006 <sup>5</sup> – found under Antoni, 2005

Kavanaugh, 2006<sup>6</sup>

Kavanaugh, 2006 <sup>21</sup>

Kavanaugh, 2009<sup>7</sup>

Kristensen, 2008<sup>8</sup>

Mease, 2000<sup>9</sup>

Mease, 2004<sup>10</sup>

Mease, 2005<sup>22</sup>

Mease, 2005 (ADEPT) <sup>11</sup>

Mease, 2006<sup>12</sup> – found under Mease 2004

Mease, 2010<sup>23</sup>

Nash, 2006<sup>13</sup> – found under Kaltwasser 2004

Saad, 2009<sup>24</sup>

Saad, 2010<sup>14</sup>

Van der Heijde, 2007<sup>15</sup> – found under Kavanaugh, 2006

Willkens, 1984<sup>16</sup>

### Systematic Reviews and Meta-analyses (Evidence Table 2)

Ravindran, 2008

### **Key Question 3**

#### RCTs and other studies (Evidence Table 1)

Antoni, 2005 (IMPACT 2)

Antoni, 2005 (IMPACT) <sup>2</sup>

Genovese, 2007<sup>3</sup>

Kaltwasser, 2004<sup>4</sup>

Kavanaugh, 2009<sup>7</sup>

Kristensen, 2008<sup>8</sup>

Mease, 2000<sup>9</sup>

Mease, 2005<sup>22</sup>

Mease, 2006 – found under Mease 2004

Saad, 2009<sup>24</sup>

#### Systematic Reviews and Meta-analyses (Evidence Table 2)

Ravindran, 2008<sup>18</sup>

## Abbreviations

ACR	American College of Rheumatology
ADA	adalimumab
AEs	adverse events
AIDS	acquired immunodeficiency syndrome
AIMS	Arthritis Impact Measurement Scales
ANA	anakinra
ARA	American Rheumatism Association criteria (pre-1987)
AS	ankylosing spondylitis
ASHI	Arthritis-Specific Health Index (Medical Outcomes Study Short Form SF-36 Arthritis-specific Health Index)
AUC	area under the curve
BUD	budesonide
Ccs	corticosteroids
CFS	chronic fatigue syndrome
CHF	coronary heart failure
Cm	centimeters
Combo	combination therapy
CI	confidence interval
CHD	coronary heart disease
COPD	Chronic Obstructive Pulmonary Disease
CRP	C-reactive protein
CVD	cardiovascular disease
CXT	cyclophosphamide
CYP	cyclosporine
Ds	days
DM	diabetes mellitus
DAS	Disease Activity Score
DMARD	disease modifying antirheumatic drug
D-HAQ	Dutch version of the Health Assessment Questionnaire (HAQ)
EQ-5D–	Quality of Life Questionnaire
ESR	erythrocyte sedimentation rate
ETA	etanercept
EULAR	European League against Rheumatism
EuroQol EQ-5D	European Quality of Life Questionnaire
EuroQOL VAS	European Quality of Life Visual Analogue Scale
GI	gastrointestinal
HAQ	Health Assessment Questionnaire
HAQ-DI	Disability Index of the Health Assessment Questionnaire (HAQ)
HIV	Human immunodeficiency virus
HLA-DR4	Human immune-response, D-related antigen encoded by the D locus on chromosome 6
HR	hazard ratio
HRQOL	health related quality of life
ICD	International Classification of Diseases
INF	infliximab
ISRs	injection site reactions
ITT	intention to treat
JRA	juvenile rheumatoid arthritis
HCQ	hydroxychloroquine
JSN	joint space narrowing
LEF	leflunomide
MTX	methotrexate
Mg	milligrams
mSharp Scale	Modified Sharp Method for Scoring Radiographs
mos	months
MHAQ	Modified Health Assessment Questionnaire
NSAIDs	non-steroidal anti-inflammatory drugs
NSFHS	National Survey of Functional Health Status
NA	not applicable
NMSC	non-melanoma skin cancer
NR	not reported
NS	not significant

NYHA	New York Heart Association
OA	osteoarthritis
OR	odds ratio
OMERACT	Outcome Measures in Rheumatology Clinical Trials
PASI	Psoriasis Area and Severity Index
PNL	prednisolone
PRED	prednisone
PsA	psoriatic arthritis
PsARC	Psoriatic Arthritis Response Scale
Pt	patient
PY	person-year
QOL	quality of life
RCT	randomized controlled trial
RAI	Ritchie Articular Index
RA	rheumatoid arthritis
RDS	radiological damage score
RF	rheumatoid factor
RIT	rituximab
RR	risk ratio
SAEs	serious adverse events
SAARDs	slow-acting anti-rheumatic drugs
SCC	squamous cell carcinoma
SD	standard deviation
SF-36	Medical Outcomes Study Short Form 36 Health Survey
SJC	swollen joint count
SHS	Sharp/van der Heijde Method (SHS) for Scoring Radiographs
SIR	standardized incidence ratio
SLE	Systemic Lupus Erythematosus
SMR	standardized morbidity ratio
SSZ	sulfasalazine
SSTG	South Swedish Arthritis Treatment Group
TB	Tuberculosis
TIM	targeted immune modulator
TJC	tender joint count
TNF	tumor necrosis factor
Txt	treatment
URTI	upper respiratory tract infection
UTI	urinary tract infection
vs.	versus
yrs	years
w/	with
w/in	with in
w/o	with out

Evidence Table 1. Randomized controlled trials and observational studies

Study	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events (%)	Analysis and Quality Rating
<p>Author, yr: Antoni et al., 2005;<sup>2</sup> Kavanaugh et al., 2006<sup>5</sup> IMPACT Study Country, Setting: Multinational, 9 clinical sites Funding: NIH; Centocor, Inc.; Schering-Plough Research Institute; Competence Network Research Objective: Efficacy and tolerability of INF for the articular and dermatologic manifestations of active PsA Study Design: RCT Overall N:</p>	<p>Inclusion Criteria: • Age ≥ 18 • Failure of 1 or more DMARD • Active peripheral polyarticular arthritis • MTX ≥ 15 mg/wk w/ folic acid supplementation • LEF, SSZ, HCQ, intramuscular gold, penicillamine, or azathioprine stable for 4 wks • Oral corticosteroids (dosage of 10 mg PRE equivalent/d or less) • NSAIDs stable for at least 2 wks</p> <p>Exclusion Criteria: • Monoclonal antibody or fusion protein • History of TB: positive tests for RF or latent TB investigational drug within 3 mos</p>	<p>Interventions: D1: Placebo D2: INF (5mg/kg at wks 0,2,6,14, then every 8 wks) N: D1: 52 D2: 52 Mean age, yrs: D1: 45.2 D2: 45.7 Sex, % female: D1: 42.3 D2: 42.3 Race, % white: NR</p>	<p>Mean disease duration, yrs: D1: 11 D2: 11.7 TJC, mean: D1: 20.4 D2: 23.7 SJC, mean: D1: 14.7 D2: 14.6 DMARD use, %: NR Corticosteroid use, %: NR MTX naive, %: NR Txt resistant, %: NR Pts with Early RA (≤3 yrs): NR Baseline DAS, mean:</p>	<ul style="list-style-type: none"> <li>• ACR50 Placebo 0/52 (0.0%) vs. INF 24/52 (46.2%)</li> <li>• ACR70 Placebo 0/52 (0.0%) vs. INF 15/52 (28.8%)</li> <li>• # of tender joints Placebo -23.6 vs. INF 55.2</li> <li>• # of swollen joints Placebo -1.8 vs. INF 59.9</li> <li>• DAS Placebo 2.8 vs. INF 45.5 <i>P</i> &lt; 0.001</li> <li>• HAQ Placebo -1.6 vs. INF 49.8 <i>P</i> &lt; 0.001</li> <li>• PsARC Placebo -12% vs. INF +86% <i>P</i> &lt; 0.001</li> <li>• ACR20 wk 16 Placebo 5/52 (9.6%) vs. INF 34/52 (65.4%) <i>P</i> &lt; 0.001</li> <li>• At 50 wks</li> <li>• Total modified vdH-S score, 85% and 84% in Placebo/INF and INF/INF groups had no worsening.</li> <li>• Change in erosion scores INF/INF 0.921, placebo/INF 0.536 (<i>P</i> = 0.780)</li> <li>• Change in JSN INF/INF -0.51, placebo/INF -0.47 (<i>P</i> = 0.211)</li> <li>• 16 wks-PsARC INF 75% vs. Placebo 21% (<i>P</i> &lt; 0.001)</li> <li>• PASI75 INF 68% vs, placebo 0% (<i>P</i> &lt; 0.001)</li> </ul>	<p>Overall: D1: 65 D2: 73 D3: 84 Headache: D1: 3 D2: 4 URTI: D1: 5 D2: 1</p>	<p>Overall Attrition Rate (%): 5 ITT Analysis: Yes Quality Rating: Fair</p>

Evidence Table 1. Randomized controlled trials and observational studies (continued)

---

104	D1: 5.4
Study Duration: 50 wks (1-16 wks RCT 16-50 open, all treated with INF)	D2: 5.5  Concomitant MTX, %: 56

---

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events (%)
Author, yr: Antoni, 2005{Antoni, 2005 #41}; Kavanaugh et al., 2006{Kavanaugh, 2006 #651}; van der Heijde et al., 2007{van der Heijde, 2007 #2401}	Inclusion Criteria: • Diagnosed with PsA • Diagnosed at least 6 mos before first infusion of study drug • Inadequate response to current or previous DMARDs or NSAIDs	Interventions: D1: Placebo D2: INF (5 mg/kg at wks 0, 2, 6, 14, 22) N: D1: 100 D2: 100 Mean age, yrs: D1: 46.5 D2: 47.1	Mean disease duration, yrs: D1: 7.5 (7.8) D2: 8.4 (7.2) TJC, mean: D1: 25.1 D2: 24.6 SJC, mean: D1: 14.4 D2: 13.9 DMARD use, %: NR Corticosteroid use, %: D1: 10 D2: 15 MTX naive, %: NR Txt resistant, %: Overall: 100 Pts with Early RA (≤3 yrs): NR Baseline DAS, mean:	ACR mean difference/ absolute difference: ACR 20 At Week 14 D1: 11 D2: 58 p<0.001 At week 24 D1: 16 D2: 54 p<0.001 ACR 50 At week 14 D1: 3 D2: 36 p<0.001 At week 24 D1: 4 D2: 41 p<0.001 ACR 70 At week 14 D1: 1 D2: 15 p<0.001 At week 24 D1: 2 D2: 27 p<0.001 <b>PsARC</b> At week 14 D1: 27 D2: 77 p<0.001 At week 24	Overall: D1: 67 D2: 67 SAEs: D1: 6 D2: 9 Infusion or injection reaction: D1: 6 D2: 7 Dizziness: D1: 5 D2: 4 Headache: D1: 5 D2: 6 URTI: D1: 14 D2: 10 Attrition Rate: Overall
IMPACT 2 Country, Setting: Multinational 36 sites in clinics Funding: Centocor Inc and Schering-Plough Research Objective: Efficacy, health related quality of life and physical function in pts with PsA Study Design: RCT	• Pts had to have active plaque psoriasis with at least 1 qualifying target lesion at least 2 cm in diameter • Negative test for RF in their serum • Stable doses of MTX, oral corticosteroids, NSAIDs Exclusion Criteria: • TNF α inhibitors; active or latent TB • Chronic or clinically significant infection, malignancy, or CHF	Sex, % female: D1: 49 D2: 29 Race, % white: NR			



Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events (%)
Overall N: 200			NR	D1: 32 D2: 70 p<0.001	Wk 14: NR Wk 24: 7.5
Study Duration: 14 to 24 wks (pts with inadequate response entered early escape at wk 16)			Concomitant MTX, %:  D1: 45  D2: 47  PASI: D1: 10.2  D2: 11.4	<b>PASI 50</b> At week 14 D1: 9 D2: 82 p<0.01 At week 24 D1: 8 D2: 75 p<0.01)  <b>PASI 75</b> At week 14 D1: 2 D2: 64 p<0.01 At week 24 D1: 1 D2: 50 p<0.01  HAQ: At week 14 D1: 18.4 D2: 48.6 p<0.001 At week 24 D1: 19.4 D2: 46 p<0.001  DAS: NR  SF-36: Physical	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events (%)
				At week 14 D1: 1.1 D2: 9.1 p<0.001 At week 24 D1: 1.3 D2: 7.7 p<0.001	
				Mental At week 14 D1: 1.2 D2: 3.8 P = 0.001 At week 24 D1: 0.4 D2: 3.9 p=0.047	
				Radiographic measures: Sharp/van der Heijde Total Score, change from baseline D1: 0.82 D2: -0.70 p<0.001	
				<b>Experienced additional                      Radiographic progression                      from baseline as measured by                      Total Score, % of patients</b> At week 24: D1: 12 D2: 3 p=0.017	
				Quality of life scales: Productivity VAS change from baseline, increase At week 14	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events (%)
				D1: 0.3 D2: 2.6 p<0.001	
				Median % change D1: 9.2 D2: 7.5 p<0.0001	
				Emotional impact on work or daily activities, %: To Week 14: D1: 88.0 to 84.4 D2: 85.0 to 52.5 p<0.001	
				Emotional effect on work or daily activities, %: To Week 14: D1: 47.0 to 55.2 D2: 57.0 to 41.4 p<0.01	
				Employment increase among those not employed, n (%): D1: 3/26 (11.5) D2: 0/32 (0) P = 0.084	
				Became employable D1: 6/20 (30) D2: 3/25 (12) p=0.157	
				<b>Median productivity, %</b> D1: 9.2 D2: 67.5 p<0.0001	
				<b>Improvement</b>	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events (%)
				At week 14 D1: 0 D2: 41 p<0.01	
				At week 24 D1: 0 D2: 39 p<0.01	
				<b>Missed workdays</b> At 14 weeks D1: 13 D2: 3.7 p=0.138	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
Author, year, study name, if applicable Genovese et al., 2007 <sup>3</sup>	Inclusion Criteria <ul style="list-style-type: none"> <li>Treatment resistant, previous inadequate response to DMARD therapy</li> </ul>	Interventions, Dose D1: Placebo D2: ADA: 40 mg every other week	Mean disease duration, years (SD) D1: 7.2 yrs (7.0) D2: 7.5 yrs (7.0)	ACR mean difference/ absolute difference (95% CI): ACR 20: D1: 16 D2: 39 (5%-4%) P = 0.012	Attrition/withdrawal, n: Overall D1: 5 D2: 1
Country and setting 16 sites in Canada and United States	<ul style="list-style-type: none"> <li>≥ 18 yrs old</li> </ul>	Number in group D1: 49 D2: 51	Patients with early RA, three years or less, %: NR	ACR 50: D1: 2 D2: 25 P = 0.001	Withdrawals due to adverse events, n: D1: 1 D2: 1
Source of funding Abbott Laboratories	<ul style="list-style-type: none"> <li>General good health determined by medical history, physical exam, laboratory profile, chest radiograph, and 12-lead electrocardiogram</li> </ul>	Mean age, yrs (SD) D1: 47.7 (11.3) D2: 50.4 (11.0)	Treatment resistant, %: 100% inadequate response to previous DMARD treatment	ACR 70: D1: 0 D2: 14 P = 0.013	Withdrawals due to lack of efficacy, n: D1: 1 D2: 0
Research objective Determine safety and efficacy of ADA in pts with inadequate response to DMARDs	<ul style="list-style-type: none"> <li>pts required to have ≥ 3 swollen joints and ≥ 3 tender or painful joints</li> </ul>	Sex, % female D1: 49.0 D2: 43.1	Tender Joint Count, mean (SD) D1: 29.3 (18.1) D2: 25.3 (18.3)	HAQ, mean difference/ absolute difference (CI/SD/P Value): D1: -0.1 ± 0.3 D2: -0.3 ± 0.5 P = 0.010	Adherent/compliant, n: D1: 46 D2: 50
Study design Controlled Trials	<ul style="list-style-type: none"> <li>Active cutaneous lesion of chronic plaque psoriasis or a documented history of chronic plaque psoriasis</li> </ul>	Race, % white D1: 93.9 D2: 98.0	Swollen Joint Count, mean (SD) D1: 18.4 (12.1) D2: 18.2 (10.9)	DAS, mean difference/ absolute difference: NR	<b>Overall adverse events reported, n:</b> D1: 39 D2: 27 P ≤ 0.01
Overall N 102	<ul style="list-style-type: none"> <li>Either currently receiving concomitant DMARD therapy or had a history of DMARD</li> </ul>	Race, % black NR	Corticosteroid use, % At baseline D1: 18.4 D2: 7.8	SF-36, mean difference/ absolute difference (CI/SD/P Value): PCS D1: 2.8 ± 7.1 (n = 45); D2: 5.7 ± 8.5 (n = 49); P = 0.082;	Serious adverse events: Death, n: D1: 0 D2: 0
Duration of study 12 weeks double-blind		Ethnicity, Latino NR	Previous Use D1: 30.6 D2: 9.6	MCS D1: -0.6 ± 7.8 (n = 45) D2: 1.1 ± 7.4 (n = 49) P = 0.242	Congestive heart failure, n: D1: 0 D2: 0
Quality rating Fair			DMARD use, %: At baseline D1: 67.3 D2: 64.7 Previous Use: 100%		Malignancies: Lymphoma or leukemia, n: D1: 0 D2: 0
			MTX naïve, %: D1: 20.4 D2: 19.6		Skin cancer (basal cell or squamous cell), n: D1: 0 D2: 0
			Baseline DAS score		

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
	<p>therapy with inadequate response</p> <ul style="list-style-type: none"> <li>Evidence of previous TB infection were required to have documented history of treatment for latent TB or TB treatment initiated before first dose of study drug.</li> </ul> <p>Exclusion Criteria</p> <ul style="list-style-type: none"> <li>History of previous anti-TNF therapy</li> <li>Intravenous infusions or intraarticular injections of corticosteroids within 4 weeks of baseline</li> <li>Topical psoriasis therapies within 2 weeks of baseline</li> <li>Ultraviolet A (UVA) phototherapy within 2 weeks of baseline visit</li> <li>Oral retinoids within 4 weeks</li> </ul>		<p>NR</p> <p>Required treatment for latent TB</p> <p>D1: 100%</p> <p>D2: 100%</p>	<p>Radiographic measures, mean difference/absolute difference: NR</p> <p>Quality of life scales, mean difference/absolute difference (CI/SD/P Value):</p> <p>Facit-F score (0-52)</p> <p>D1: 2.3 ± 6.7 (n = 46)</p> <p>D2: 2.6 ± 7.1</p> <p>P = 0.783</p> <p>Others, (please name); mean difference/absolute difference (SD):</p> <p>Swollen Joint Count</p> <p>D1: -1.9 ± 11.5</p> <p>D2: -5.7 ± 13.7</p> <p>P = 0.140</p> <p>Tender Joint Count</p> <p>D1: -6.2 ± 10.3</p> <p>D2: -9.7 ± 17.3</p> <p>P = 0.231</p>	<p>Other cancer, n:</p> <p>D1: 0</p> <p>D2: 0</p> <p>Respiratory events: Tuberculosis, n:</p> <p>D1: 0</p> <p>D2: 0</p> <p>Upper respiratory infection, n:</p> <p>D1: 4</p> <p>D2: 7</p> <p>Other infections (any), n:</p> <p>D1: 16</p> <p>D2: 9</p> <p>GI:</p> <p>Diarrhea:</p> <p>D1: 3</p> <p>D2: 1</p> <p>Other:</p> <p>Infusion/injection site reactions, n:</p> <p>D1: 6</p> <p>D2: 6</p> <p>Demyelination or multiple sclerosis, n:</p> <p>D1: 0</p> <p>D2: 0</p> <p>HeD2che, n:</p> <p>D1: 3</p> <p>D2: 0</p> <p>Back pain, n:</p> <p>D1: 3</p> <p>D2: 1</p> <p>Psoriasis aggravated</p> <p>D1: 8</p>

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
	<ul style="list-style-type: none"> <li>• Alefacept or sipilizumab within 12 weeks</li> <li>• Any biologic or investigational therapy within 6 weeks</li> <li>• Current use of or likely to need antiretroviral therapy</li> <li>• Persistent or severe infections or history of active TB, or active nonpsoriatic skin disease which may interfere with assessment of target lesions</li> <li>• Significant history of cardiac, renal, neurologic, psychiatric, endocrinologic, metabolic or hepatic disease</li> <li>• Neurologic symptoms suggestive of CNS demyelinating disease</li> <li>• History of malignancy other than carcinoma in</li> </ul>				<p>D2: 2</p> <p>Aggravated Psoriatic Arthropathy At week 12 D1: 7 D2: 1 <math>P \leq 0.05</math></p> <p>Diverticulitis, n: D1: 0 D2: 1</p>



Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
	<p>situ of cervix or adequately treated nonmetastatic squamous or basal cell skin carcinoma</p> <ul style="list-style-type: none"> <li>• Oral corticosteroids &gt; equivalent of PRED 10mg/d, use of cyclosporine, tacrolimus</li> <li>• Long term (&gt; 3 mths) treatment with MTX or other DMARDs</li> <li>• Unstable dose of MTX or other DMARDs during 4 wks preceding baseline visit</li> <li>• MTX dose &gt; 30 mg/wk</li> </ul>				

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
<p>Author, year, study name, if applicable Gladman et al., 2007,<sup>20</sup> ADEPT This is a companion to ref ID 840 included in first report.</p> <p>Country and setting 50 multinational sites</p> <p>Source of funding Abbott Laboratories</p> <p>Research objective Evaluate effects of D2 on joint-related and skin-related functional impairment, HRQOL, fatigue and pain</p> <p>Study design Controlled Trials</p> <p>Overall N 315</p> <p>Duration of study 24 Weeks</p> <p>Quality rating Fair Why?</p>	<p>Inclusion Criteria</p> <ul style="list-style-type: none"> <li>• Treatment resistant</li> <li>• Inadequate response or intolerance to NSAIDs</li> <li>• Age ≥ 18</li> <li>• Moderate to severe PsA</li> <li>• Active psoriatic skin lesions or a documented history of psoriasis</li> <li>• MTX was allowed if it had been taken for at least 3 months previously, with dosage stable for at least 4 weeks prior to baseline.</li> </ul> <p>Exclusion Criteria</p> <ul style="list-style-type: none"> <li>• Cyclosporine, tacrolimus, DMARDs, or oral retinoid use within 4 weeks of baseline</li> <li>• Topical treatments for PsA within 2 wks other than medicated</li> </ul>	<p>Interventions, Dose D1: Placebo D2: 40 mg every other week</p> <p>Number in group D1: 162 D2: 151 Overall: 313</p> <p>Mean age (years) D1: 49.2 yrs (11.1) D2: 48.6 yrs (12.5)</p> <p>Sex, % female D1: 45.1 D2: 43.7</p> <p>Race, % white D1: 93.8 D2: 97.4</p> <p>Race, % black NR</p> <p>Ethnicity, Latino NR</p>	<p>Mean disease duration, years (SD) D1: 9.2 yrs (8.7) D2: 9.8 yrs (8.3)</p> <p>Patients with early RA, three years or less, %: NR</p> <p>Treatment resistant, %: Inadequate response to previous NSAIDs D1: 100 D2: 100</p> <p>Tender Joint Count, mean (SD) D1: 25.8 (18.0) D2: 23.9 (17.3)</p> <p>Swollen Joint Count, mean (SD) D1: 14.3 (11.1) D2: 14.3 (12.2)</p> <p>Corticosteroid use, % NR</p> <p>DMARD use, %: NR</p> <p>MTX naïve, %: NR</p> <p>Baseline DAS score NR</p> <p>Required treatment for latent TB NR</p> <p>HAQ DI (range 0-3) D1: 1.0 (0.7) D2: 1.0 (0.6)</p>	<p>ACR mean difference/ absolute difference (CI/SD/P Value): NR</p> <p>HAQ, mean difference/ absolute difference (CI/SD/P Value): At Week 12 D1: -0.1 (0.5) D2: -0.4 (0.5) P &lt; 0.001</p> <p>At Week 24 D1: -0.1 (0.4) D2: -0.4 (0.5) P &lt; 0.001</p> <p>DAS, mean difference/ absolute difference (CI/SD/P Value): NR</p> <p>SF-36, mean difference/ absolute difference (CI/SD/P Value): PCS at Week 12 D1: 1.4 (8.7) n = 151 D2: 9.3 (10.0) n = 136 P &lt; 0.001</p> <p>PCS at Week 24 D1: 1.4 (9.6) n = 152 D2: 9.3 (10.1) n = 140 P &lt; 0.001</p> <p>MCS at Week 12 D1: 1.2 (10.2) n = 151 D2: 1.6 (10.1) n = 136) P = 0.708</p> <p>MCS at Week 24 D1: 0.6 (10.4) n = 152</p>	<p>Overall attrition/withdrawal, n: D1: 13 D2: 13</p> <p>Withdrawals due to adverse events, n: D1: 1 D2: 3</p> <p>Withdrawals due to lack of efficacy, n: D1: 4 D2: 1</p> <p>Adherent/compliant, n: D1: 149 D2: 140</p> <p>Withdrew consent, n: D1: 5 D2: 3</p> <p>Protocol Violation D1: 1 D2: 0</p> <p>Other attrition D1: 1 D2: 1</p> <p>Abnormal lab value D1: 0 D2: 2</p> <p>Administrative problems D1: 0 D2: 1</p> <p>This data was extracted from companion study refid 840 included in original report.</p>

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
	shampoos or low-potency topical steroids		SF-36 PCS score D1: 33.3 (9.8) D2: 33.2 (9.9) n = 148	D2: 1.8 (9.3) n = 140 <i>P</i> = 0.288	
	<ul style="list-style-type: none"> <li>• Anti-TNF therapy</li> <li>• Concurrent treatment with MTX at dosages &gt; 30mg/week and/or corticosteroids in a PRED-equivalent dosage of &gt; 10 mg/day</li> </ul>		SF-36 MCS score D1: 46.6 (12.2) D2: 48.1 (10.2) n = 148	Radiographic measures, mean difference/absolute difference: NR	
	<ul style="list-style-type: none"> <li>• History of TB</li> <li>• Central nervous system demyelinating disease</li> <li>• Listeriosis</li> <li>• Severe infection within 30 days or oral antibiotics within 14 days.</li> </ul>		FACIT-fatigue (range 0-52) D1: 30.8 (12.2), n = 161 D2: 30.8 (12.1), n = 150	Quality of life scales, mean difference/absolute difference: NR	
			Patient's assessment of pain (0-100 mm VAS) D1: 48.8 (21.7) n = 161 D2: 51.1 (21.4)	Physical Functioning, n (SD): At Week 12: D1: 3.9 (23.3) D2: 14.4 (22.1) <i>P</i> < 0.001	
			Patient's global assessment of disease activity (0-100 mm VAS): D1: 48.1 (21.2) D2: 47.1 (23.2)	At Week 24: D1: 2.9(23.8 SD) D2: 15.8 (22.9 SD) <i>P</i> < 0.001	
			PASI (range 0-72) D1: 8.3 (7.3) n = 69 D2: 7.4 (6.1) n = 69	Role-physical, n (SD) At Week 12: D1: 7.2 (34.8) D2: 30.1 (41.9) <i>P</i> < 0.001	
			DLQI (range 0-30) D1: 10.3 (7.5) n = 68 D2: 8.6 (6.6) n = 66	At Week 24: D1: 8.9 (43.4) D2: 30.0 (38.5) <i>P</i> < 0.001	
				Bodily pain, n (SD) At Week 12: D1: 3.0 (20.5) D2: 19.6 (23.4) <i>P</i> < 0.001	
				At Week 24: D1: 3.4 (18.9) D2: 21.8 (22.8) <i>P</i> < 0.001	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
				General Health, n (SD) At Week 12: D1: 0.2 (16.7) D2: 12.4 (18.2) P < 0.001 At Week 24: D1: -0.1 (16.8) D2: 11.6 (19.4) P < 0.001	
				Vitality, n (SD) At Week 12: D1: 3.0 (17.2) D2: 13.7 (20.4) P < 0.001 At Week 24: D1: 1.7 (19.1) D2: 12.8 (21.0) P < 0.001	
				Social Functioning,, n (SD) At Week 12: D1: 4.4 (23.4) D2: 11.8 (25.7) P = 0.014 At Week 24: D1: 2.6 (25.4 ) D2: 11.8 (25.8) P = 0.003	
				Role-emotional, n (SD) At Week 12: D1: 4.4 (46.8 SD) D2: 5.7 (45.3 SD) P = 0.762 At Week 24: D1: 4.6 (48.5 SD) D2: 10.3 (40.3 SD) P = 0.255	
				Mental Health, n (SD) At Week 12: D1: 1.8 (15.0) D2: 5.1 (14.9)	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
				<i>P</i> = 0.060	
				At Week 24:	
				D1: 1.1 (14.9)	
				D2: 4.5 (15.3)	
				<i>P</i> = 0.045	
				FACIT-Fatigue, n (SD)	
				At Week 12:	
				D1: 0.6(8.4)	
				D2: 6.5 (11.1)	
				<i>P</i> < 0.001	
				At Week 24:	
				D1: 0.1 (9.6 SD)	
				D2: 7.1 (10.2 SD) <i>P</i> < 0.001	
				Pt's Assessment of Pain, n (SD)	
				At Week 12:	
				D1: 1.6 (24.0 SD)	
				D2: -23.0(27.0 SD) <i>P</i> < 0.001	
				At Week 24:	
				D1: 0.6 (24.1)	
				D2: -24.0 (28.3)	
				<i>P</i> < 0.001	
				Pt's global assessment of disease activity, n (SD):	
				At Week 12:	
				D1: 0.4 (23.1)	
				D2: -19.6 (29.4)	
				<i>P</i> < 0.001	
				Pt's global assessment of disease activity, n (SD)	
				At Week 24:	
				D1: 0.6 (24.5)	
				D2: -21.1 (29.4)	
				<i>P</i> < 0.001	
				DLQI, n (SD)	
				At Week 12:	
				D1: -0.4 (5.8)	
				D2: -5.6 (5.6)	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
				<p><math>P &lt; 0.001</math>                      At Week 24:                      D1: -0.7 (6.7)                      D2: -6.1 (6.3)  <math>P &lt; 0.001</math></p>	
				<p>HAQ DI Patients achieving minimum clinically-important difference (MCID) <math>\geq -0.3</math>, % (SD)                      At Week 12:                      D1: 26                      D2: 51.4  <math>P &lt; 0.001</math>                      At Week 24:                      D1: 26.9                      D2: 52.5,  <math>P &lt; 0.001</math></p>	
				<p>HAQ DI Patients with complete resolution, %;                      At Week 12:                      D1: 14.3                      D2: 33.8  <math>P &lt; 0.001</math></p>	
				<p>HAQ DI Patients with complete resolution, %                      At Week 24                      D1: 13.1                      D2: 34.0  <math>P &lt; 0.001</math></p>	
				<p>SF-36 PCS Patients achieving upper limit of MCID <math>\geq 5</math> points, %                      At Week 12 (%):                      D1: 26.5                      D2: 66.9  <math>P &lt; 0.001</math>                      At Week 24:                      D1: 30.1</p>	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
				D2: 61.7 <i>P</i> < 0.001	
				FACIT-Fatigue Patients achieving upper limit ofMCID ≥ 4 points, % At Week 12: D1: 30.4 D2: 60.7 <i>P</i> < 0.001 At Week 24 (%): D1: 31.5 D2: 61.9, <i>P</i> < 0.001	
				Dermatology Life Quality Index (DLQI)Patients achieving upper limit ofMCID ≥ -5 points, % At Week 12: D1: 21.7 D2: 54.8 <i>P</i> < 0.001 At Week 24: D1: 23.7 D2: 55.0 <i>P</i> = 0.001	
				DLQI Patients with complete resolution, % At Week 12 D1: 4.9 D2: 36.9 <i>P</i> < 0.001 At Week 24 D1: 5.0 D2: 43.6 <i>P</i> < 0.001	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events (%)	Analysis and Quality Rating
Author, yr: Kaltwasser et al., 2004 <sup>4</sup> and Nash et al., 2006 <sup>13</sup>	Inclusion Criteria: • Age 18 to 70 • Diagnosed with PsA • NSAIDs or Css (prednisone dose of 10 mg/day or steroid equivalent administered orally)	Interventions: D1: Placebo D2: LEF	Mean disease duration, yrs: D1: 10 D2: 11	• 56 of 95 leflunomide-treated pts (58.9%; 95% CI, 48.4-68.9) and 27 of 91 placebo-treated pts (29.7% (95% CI, 20.6-40.2)) were classified as responders by PsARC ( $P < 0.0001$ )	Overall: D1: 76.1 D2: 85.4	Overall Attrition Rate (%): 47.9%
Country, Setting: Multinational, multicenter (31)	• Discontinue DMARDs, biologics and systemic antipsoriatic txt 28 days	N: D1: 91 D2: 95	TJC, mean: NR SJC, mean: NR	Change in HAQ total score • Placebo (N:90) $-0.05 \pm 0.46$ ( $P = 0.0267$ ) • Leflunomide (N:94) $-0.19 \pm 0.51$	SAEs: D1: 5.4 D2: 13.5	ITT Analysis: Yes
Funding: Aventis	Exclusion Criteria: • Pregnant or lactating; leflunomide • Impaired renal or hepatic system • Nonpsoriatic inflammatory joint disease or arthritis onset < 16 yrs	Mean age, yrs: Drug 1: 46.9 Drug 2: 48.6	DMARD use, %: D1: 49.5 D2: 61.1	Change in PASI score • Placebo (N:90) $-0.6 \pm 6.1$ $P = 0.0030$ • Leflunomide (N:92) $-2.1 \pm 5.9$	Serious Infections: D1: 0 D2: 0	Quality Rating: Fair
Research Objective: Efficacy and safety of LEF versus placebo in pts with PsA and psoriasis	• RH factor +, rheumatoid nodules, serious infections, malignancy, or CVD, HIV, hepatitis B or C antigen positivity, guttate, pustular, or erythrodermic forms of psoriasis, body weight <45 kg • Impaired bone marrow function; history of drug or alcohol abuse	Sex, % female: D1: 37.4 D2: 42.1	Corticosteroid use, %: D1: 9.9 D2: 15.8	Change in DLQI total score • Placebo (N:89) $-0.2 \pm 5.1$ $P = 0.0173$ • Leflunomide (N:90) $-1.9 \pm 5.1$	Diarrhea: D1: 13.0 D2: 24.0	
Study Design: RCT		Race, % white: D1: 95.6 D2: 97.9	DMARD naive, %: D1: e 50.5 D2: 38.9		Headache: D1: 7.6 D2: 11.5	
Overall: N: 190 (ITT = 186)					Nausea: D1: 8.7 D2: 9.4	
Study Duration: 24 wks			Txt resistant, %: NR			
			Pts with Early RA ( $\leq 3$ yrs): NR			
			Baseline DAS,			



Evidence Table 1. Randomized controlled trials and observational studies (continued)

---

mean:  
NR

Concomitant MTX,  
%: 0

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
<p>Author, year, study name, if applicable Kavanaugh et al., 2009,<sup>7</sup> GO-REVEAL</p> <p>Country and setting 58 investigational sites, multinational</p> <p>Source of funding Centocor Research and Development, Inc. and Schering-Plough Corporation</p> <p>Research objective Assess efficacy and safety of GOL in patients with active PsA</p> <p>Study design Controlled Trials</p> <p>Overall N 405</p> <p>Duration of study 24 wks</p> <p>Quality rating Good</p>	<p><b>Inclusion Criteria</b></p> <ul style="list-style-type: none"> <li>Treatment resistant active PsA despite therapy with DMARDs or NSAIDs</li> <li>active PsA: <math>\geq 3</math> swollen and 3 tender joints, negative rheumatoid factor, at least 1 subset of PsA, presence of plaque psoriasis with lesion <math>\geq 2</math> cm in diameter;</li> <li>MTX, NSAIDs, corticosteroids allowed in stable doses</li> <li>Latent TB allowed if treated prior or concurrent to study</li> </ul> <p><b>Exclusion Criteria</b></p> <ul style="list-style-type: none"> <li>Previous use of anti-TNF agents, RIT, natalizumab, or cytotoxic agents</li> </ul>	<p><b>Interventions, Dose</b></p> <p>D1: Placebo</p> <ul style="list-style-type: none"> <li>At week 16, pts with &lt; 10% improvement from baseline in both swollen and tender joint counts entered early escape = dose escalation from placebo to 50 mg GOL every four weeks</li> </ul> <p>D2:</p> <ul style="list-style-type: none"> <li>GOL: 50 mg every 4 wks</li> <li>At week 16, pts with &lt;10% improvement from baseline in both swollen and tender joint counts entered early escape = dose escalation from 50 mg GOL to 100 mg GOL every four wks.</li> </ul> <p>D3: GOL: 100 mg every 4 wks</p> <p>D4: Randomized to placebo, crossed over to GOL 50 mg</p> <p>D5: Randomized to GOL 50, crossed over to 100 mg</p> <p><b>Number in group</b></p> <p>D1: 113 D2: 146 D3: 146</p> <p><b>Mean age, years (SD)</b></p> <p>D1: 47.0 (10.6) D2: 45.7 (10.7)</p>	<p><b>Mean disease duration, years (SD)</b></p> <p>D1: 7.6 (7.9) D2: 7.2 (6.8) D3: 7.7 (7.8)</p> <p><b>Patients with early RA, three years or less, %:</b></p> <p>D1: 33 D2: 34 D3: 27</p> <p><b>Treatment resistant, %:</b></p> <p>D1: 100 D2: 100 D3: 100</p> <p><b>Tender Joint Count, mean (SD)</b></p> <p>D1: 21.9 (14.7) D2: 24.0 (17.1) D3: 22.5 (15.7)</p> <p><b>Swollen Joint Count, mean (SD)</b></p> <p>D1: 13.4 (9.8) D2: 14.1 (11.4) D3: 12.0 (8.4)</p> <p><b>Corticosteroid use, %</b></p> <p>D1: 17 D2: 13 D3: 18</p> <p><b>DMARD use, %:</b></p> <p><b>MTX</b></p> <p>D1: 48 D2: 49 D3: 47</p> <p><b>MTX naïve, %:</b></p> <p>D1: 33 D2: 34</p>	<p><b>ACR mean difference/ absolute difference (CI/SD/P Value):</b></p> <p><b>At week 14:</b></p> <p>ACR 20: D1: 9 D2: 51 D3: 45 <math>P &lt; 0.001</math> (D1 vs. D2 and D3)</p> <p><b>At week 24:</b></p> <p>ACR 20: D1: 12 D2: 52 D3: 61 <math>P &lt; 0.001</math> (D1 vs. D2 and D3)</p> <p><b>ACR 50 and ACR70 at weeks 14 and 24:</b> Shown in figure only</p> <p><b>HAQ, mean difference/ absolute difference (CI/SD/P Value):</b></p> <p>D1: -0.01 (0.49) D2: 0.33 (0.55) D3: 0.39 (0.50) <math>P &lt; 0.001</math> (D1 vs. D2 and D3)</p> <p><b>DAS, mean difference/absolute difference (SD):</b></p> <p><b>At week 14:</b></p> <p>D1: -0.18 (0.78) D2: -1.38 (1.16) D3: -1.29 (1.16) <math>P &lt; 0.001</math> (D1 vs. D2 and D3)</p>	<p><b>Overall attrition/withdrawal, n:</b></p> <p>D1: 12 D2: 9 D3: 4</p> <p><b>Withdrawals due to adverse event, n:</b></p> <p>D1: 5 D2: 2 D3: 4</p> <p><b>Withdrawals due to lack of efficacy, n:</b></p> <p>D1: 2 D2: 1 D3: 0</p> <p><b>Adherent/compliant, n:</b></p> <p>NR</p> <p><b>Overall adverse events reported, n:</b></p> <p>Through Week 24 D1: 67 D2: 99 D3: 95</p> <p><b>Serious adverse events: SAEs:</b></p> <p>D1: 7 D2: 3 D3: 4</p> <p><b>Prostate cancer, n:</b></p> <p>D1: NR D2: NR D3: 1</p> <p><b>Respiratory events: Tuberculosis, n:</b></p> <p>Overall: 0</p>

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
		D3: 48.2 (10.9)	D3: 27	At week 24: D1: -0.12 (0.97) D2: -1.43 (1.34) D3: -1.56 (1.10) <i>P</i> < 0.001 (D1 vs. D2 and D3)	Pneumonia, n: D1: 2 D2: NR D3: NR
		Sex, % female D1: 39 D2: 39 D3: 41	Baseline DAS28-CRP score, mean (SD) D1: 4.3 (1.0) D2: 4.4 (1.1) D3: 4.3 (1.0)		Upper respiratory infection (n): D1: 7 D2: 17 D3: 13
		Race, % white D1: 97 D2: 97 D3: 97	Required treatment for latent TB D1: 11 D2 & D3: 33	DAS28-CRP No. EULAR response: At week 14: D1: 27 D2: 96 ( <i>P</i> < 0.001) D3: 98 ( <i>P</i> < 0.001)	Other infections, n: D1: Cellulitis: 1, Urosepsis: 1 D2: Abscess: 1 D3: Sepsis/Cholecystitis: 1
		Race, % black NR		At week 24: D1: 27 D2: 94 ( <i>P</i> < 0.001) D3: 114 ( <i>P</i> < 0.001)	Infusion/injection site reactions, n: D1: 3 D2: 4 D3: 6
		Ethnicity, Latino NR		SF-36, mean difference/absolute difference (CI/SD/P Value): D1: 0.63 (7.68) D2: 6.53 (8.88) D3: 7.85 (9.55) <i>P</i> < 0.001 (D1 vs. D2 and D3)	GI: Nausea or vomiting, n: D1: 5 D2: 4 D3: 6
				Radiographic measures, mean difference/absolute difference: NR	Headache, n: D1: 8 D2: 7 D3: 8
				Quality of life scales, mean difference/absolute difference: NR	Dizziness: NR
				<b>Morning stiffness, mean change (SD):</b> At week 14: D1: 23.4 (299.9) D2: -72.4 (201.3) ( <i>P</i> < 0.001)	Nasopharyngitis, n: D1: 5 D2: 10 D3: 19
					Back pain, n:

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
				D3: -86.3 (238.3), ( $P < 0.001$ )	D1: 5
				At week 24:	D2: 6
				D1: -20.4 (257.7)	D3: 7
				D2: -67.2(231.1) ( $P < 0.001$ )	Diarrhea, n:
				D3: -90.1 (234.5), ( $P < 0.001$ )	D1: 4
				PASI90, n:	D2: 5
				At week 14:	D3: 7
				D1: 0	Cough, n:
				D2: 22 ( $P < 0.001$ )	D1: 5
				D3: 26, ( $P < 0.001$ )	D2: 7
				At week 24:	D3: 4
				D1: 0	Elevated ALT levels, n:
				D2: 33 ( $P < 0.001$ )	D1: 4
				D3: 34, ( $P < 0.001$ )	D2: 4
					D3: 5
					Injection-site erythema
					D1: 2
					D2: 4
					D3: 6
					Markedly abnormal ALT levels:
					D1: 4
					D2: 43
					D3: 0
					Markedly abnormal AST levels:
					D1: 3
					D2: 2
					D3: 0
					Markedly abnormal total bilirubin levels:
					D1: 2
					D2: 4
					D3: 2
					Antibodies to GOL:
					D1: NR

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
					D2: 5/114
					D3: 7/143

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
<p>Author, year, study name, if applicable Kristensen et al., 2008<sup>8</sup></p> <p>Country and setting Sweden</p> <p>Source of funding NR</p> <p>Research objective Present efficacy and tolerability data and study impact of concomitant MTX, patterns of joint distribution, and other predictors for drug survival with TNF blocking agents</p> <p>Study design Observational</p> <p>Overall N 261</p> <p>Duration of study 12 months</p> <p>Quality rating Fair</p>	<p><b>Inclusion Criteria</b></p> <ul style="list-style-type: none"> <li>• Diagnosis of PsA</li> <li>• Pts selected for anti-TNF therapy based on high disease activity and/or unacceptable steroid use</li> <li>• Only pts receiving first treatment course of biological therapy</li> </ul> <p><b>Exclusion Criteria</b> NR</p>	<p><b>Interventions, Dose</b> D1: concomitant MTX and anti-TNF</p> <ul style="list-style-type: none"> <li>• MTX: median dose = 15.0 mg/week, interquartile range (IQR) = 10.0-20.0</li> <li>• ETN: 25 mg twice a wk</li> <li>• IFX: 3mg/kg wks 0,2, 6, and every eighth week, could be increased in steps of 100 mg to a maximum dose of 500 mg at 4-8 wk intervals, avg dose after 6 mos = 5 mg/kg every eighth wk</li> </ul> <p>ADA: 40 mg every other wk D2:</p> <ul style="list-style-type: none"> <li>• ETN: 25 mg twice a wk</li> <li>• IFX: 3 mg/kg wks 0, 2, 6, and every eighth week, could be increased in steps of 100 mg to a maximum dose of 500 mg at 4-8 wk intervals, avg dose after 6 mos = 5 mg/kg every eighth wk</li> <li>• ADA: 40 mg every other wk</li> </ul> <p>Number in group D1: 161 D2: 100</p>	<p>Median disease duration, years (IQR) D1: 7.9 (3.7-15.0) D2: 9.4 (4.2-17.8) <i>P</i> = 0.29</p> <p>Patients with early RA, three years or less, %: NR</p> <p>Treatment resistant, %: NR</p> <p>Tender Joint Count, mean (SD) NR</p> <p>Swollen Joint Count, mean (SD) NR</p> <p>Corticosteroid use, % NR</p> <p>DMARD use, %: # of Previous DMARDs (IQR) D1: 2 (1.0-2.0) D2: 2 (1.0-2.0) <i>P</i> = 0.20</p> <p>MTX naïve, %: NR</p> <p>Baseline DAS 28 score, median (IQR) D1: 4.93 calculated for subgroup, n = 125 (3.87-5.71) D2: 4.82 calculated for subgroup, n = 76 (3.83-5.46) <i>P</i> = 0.57</p> <p>Required treatment for</p>	<p>ACR mean difference/ absolute difference: NR</p> <p>HAQ, mean difference/ absolute difference: NR</p> <p>DAS, mean difference/absolute difference: NR</p> <p>SF-36, mean difference/absolute difference: NR</p> <p>Radiographic measures, mean difference/absolute difference: NR</p> <p>Quality of life scales, mean difference/absolute difference: NR</p> <p><b>EULAR overall response rates, (%):</b> At month 3 D1: 104 (78) D2: 67 (75) At month 6 D1: 82 (76) D2: 54 (81) At month 12 D1: 74 (69) D2: 27 (67) EULAR good response rates, %:</p>	<p>Attrition/withdrawal Withdrawals due to adverse events, HR (95% CI): D1: 0.24 (0.11-0.52)</p> <p>Sub-analyses ETN vs. IFX</p> <ul style="list-style-type: none"> <li>• Termination due to adverse events (HR 0.30 95% CI 0.11-0.80, <i>P</i> = 0.02)</li> <li>• Withdrawal due to failure (HR 0.55, 95% CI 0.25-1.20)</li> </ul> <p>Withdrawals due to lack of efficacy, HR (95% CI): D1: 1.39 (0.61-3.18)</p> <ul style="list-style-type: none"> <li>• In corresponding abstraction - no high attrition or differential attrition, although rates are unknown</li> </ul> <p><b>Overall adverse events reported, n:</b> D1: 17 D2: 12</p> <p>Serious adverse events: Death (n): D1: 1 D2: NR</p> <p>Cardiovascular events, n: D1: 3 D2: 2</p> <p>Overall: Includes transient ischemic attack, two acute coronary syndromes, and two tachyarrhythmias.</p> <p>Septicaemia with E-coli bacteria: D1: 0 D2: 1</p>

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, %
		Overall: 261	latent TB	At month 3	Anaphylactic infusion reactions (occurred with IFX): D1: 0 D2: 2  Malignancies: Lymphoma or leukemia (n): D1: 1 D2: 1 Overall: Fatal non-Hodgkin's lymphoma (diffuse large B-cell lymphoma); Chronic lymphatic leukemia (CLL), with probable subclinical debut prior to anti TNF treatment  Other infections: D1: 5 D2: 2 Overall: Designated as 'Infections' - mainly respiratory tract infections  Other: Fractures, n: D1: 2 D2: 1 Overall: Three peripheral fractures and one cervical spinal stenosis requiring surgery  Other Adverse Events, n: D1: 3 D2: 3  Overall: Includes: severe vertigo, irritable bowel disease, benign stenosis of the esophagus, concretum in the
		Mean age, years (SD)	NR	D1: 104 (51)	
		D1: 48.2		D2: 67 (55)	
		D2: 46.0	Regular NSAID use % (n):	At month 6	
		Overall, IQR range:	D1: 60.9 (98)	D1: 82 (60)	
		D1: 38.6 - 53.9 IQR	D2: 48.0 (48)	D2: 54 (59)	
		D2: 36.4 - 58.5 IQR;	<i>P</i> = 0.04	At month 12	
		<i>P</i> = 0.99	HAQ, median (IQR)	D1: 74 (54)	
		Sex, % female	D1: 1.0 (0.63-1.38)	D2: 27 (52)	
		D1: 47.8	D2: 1.0 (0.50-1.50)	Lundex EULAR Overall, %:	
		D2: 55	<i>P</i> = 0.67	At month 3	
		<i>P</i> = 0.07		D1: 74	
		Race, % white		D2: 68	
		NR		At month 6	
		Race, % black		D1: 68	
		NR		D2: 67	
		Ethnicity, Latino		At month 12	
		NR		D1: 55	
				D2: 45	
				Lundex EULAR Good, %:	
				At month 3	
				D1: 48	
				D2: 50	
				At month 6	
				D1: 53	
				D2: 48	
				At month 12	
				D1: 43	
				D2: 35	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events, % urinary tract, non-infectious pleuritis, severe dysplasia of cervix uteri.
-----------------------	----------------------------------	-----------------------------------	--	-----------------	---



Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events (%)	Analysis and Quality Rating
<p>Author, yr: Mease et al., 2000<sup>9</sup></p> <p>Country, Setting: US, single center in Seattle</p> <p>Funding: Immunex Corp.</p> <p>Research Objective: To study the efficacy and safety of etanercept in pts with psoriatic arthritis and psoriasis</p> <p>Study Design: RCT</p> <p>Overall N: 60</p> <p>Study Duration: 12 wks</p>	<p>Inclusion Criteria:</p> <ul style="list-style-type: none"> <li>Age 18 to 70</li> <li>Diagnosed with PsA according to: &gt; 3 swollen, tender, or painful joints</li> <li>Inadequate response to NSAIDs</li> <li>Hepatic transaminase concentrations no greater than 2x upper limit of normal</li> <li>Hemoglobin 85 g/L or higher</li> <li>Platelet count 125,000 per mL or more and serum creatinine 152-4 mmol/L or below</li> <li>MTX &lt; 25 mg/wk and stable for 4 wks</li> <li>Corticosteroids if the dose &lt; 10 mg/d of PRE, stable for at least 2 wks and maintained at a constant dose throughout study</li> </ul> <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> <li>Evidence of skin conditions other than psoriasis</li> </ul>	<p>Interventions:</p> <p>D1: Placebo</p> <p>D2: ETA (25mg 2x wkly)</p> <p>N:</p> <p>D1: 30</p> <p>D2: 30</p> <p>Mean age, yrs:</p> <p>D1: 43.5</p> <p>D2: 46</p> <p>Sex, % female:</p> <p>D1: 40</p> <p>D2: 47</p> <p>Race, % white:</p> <p>D1: 83</p> <p>D2: 90</p>	<p>Mean disease duration, yrs:</p> <p>D1: 9.5</p> <p>D2: 9</p> <p>TJC, mean: NR</p> <p>SJC, mean: NR</p> <p>DMARD use, %: NR</p> <p>Corticosteroid use, %: D1: 40</p> <p>D2: 20</p> <p>MTX naive, %: NR</p> <p>Txt resistant, %: Overall 100</p> <p>Pts with Early RA (<math>\leq 3</math> yrs): NR</p> <p>Baseline DAS, mean: NR</p> <p>Concomitant MTX: D1: 47</p>	<ul style="list-style-type: none"> <li>PsARC ETA 26 (87%) vs. Placebo 7 (23%) <math>P &lt; 0.0001</math> 95% CI, 44-83;</li> <li>ACR50 ETA 15 (50%) vs. Placebo 1 (3%) <math>P = 0.0001</math> 95% CI, 28-66;</li> <li>ACR70 ETA 4 (13%) vs. Placebo 0 (0%) <math>P = 0.0403</math> 95% CI, 1-26;</li> <li>HAQ ETA 0.1 (0,1) vs. Placebo 1.3 (0.9,1.6) <math>P &lt; 0.001</math></li> <li>• ACR20 was achieved by 73% ETA treated pts compared with 13% placebo treated pts (<math>P &lt; 0.0001</math>)</li> <li>• Median % improvements in tender and swollen joint counts at 12 wks ETA 75% and 72% respectively vs. placebo 5% worsening and 19% improvement; disability according to HAQ significantly more improved in ETA than placebo (83% vs. 3%, <math>P &lt; 0.0001</math>)</li> <li>• 26% of ETA vs. 0 of placebo pts achieved 75% improvement in PASI at 12 wks (<math>P = 0.0154</math>); similar differences between ETA and placebo also seen at 25% and 50% improvements in PASI scores</li> </ul>	<p>SAEs:</p> <p>D1: 0</p> <p>D2: 3.3</p> <p>Infusion or injection reaction:</p> <p>D1: 20</p> <p>D2: 3</p> <p>Headache:</p> <p>D1: 13</p> <p>D2: 10</p> <p>URTI:</p> <p>D1: 57</p> <p>D2: 57</p>	<p>Overall Attrition Rate (%): 6.6%</p> <p>ITT Analysis: Yes</p> <p>Quality Rating: Fair</p>

D2: 47

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events (%)	Analysis and Quality Rating
<b>Author, yr:</b>						
Mease et al., 2004; <sup>10</sup> Mease et al., 2006 <sup>12</sup> (2nd yr outcomes)	<p>Inclusion Criteria:</p> <ul style="list-style-type: none"> <li>• Age 18-70</li> <li>• Diagnosed with PsA ≥ 3 swollen and 3 tender joints</li> <li>• Inadequate response to NSAID</li> <li>• At least one of PsA subtypes: distal interphalangeal joint involvement, polyarticular arthritis, arthritis mutilans, asymmetric peripheral arthritis, or ankylosing spondylitis-like arthritis</li> <li>• Stable plaque psoriasis with a qualifying lesion</li> <li>• MTX therapy (stable 2 mo ≤ 25 mg/wk)</li> <li>• Css (stable 4 wks ≤ 10 mg/d of prednisone)</li> </ul> <p>Exclusion Criteria:</p> <ul style="list-style-type: none"> <li>• Oral retinoids, topical vitamin A or D analog preparations, and anthralin</li> </ul>	<p>Interventions:</p> <p>D1: placebo</p> <p>D2: ETA (25 mg 2x wkly)</p> <p>N:</p> <p>D1: 104</p> <p>D2: 101</p> <p>Mean age, yrs:</p> <p>D1: 47.3</p> <p>D2: 47.6</p> <p>Sex, % female:</p> <p>D1: 55</p> <p>D2: 43</p> <p>Race, % white:</p> <p>D1: 91</p> <p>D2: 90</p>	<p>Mean disease duration, yrs:</p> <p>D1: 9.2</p> <p>D2: 9</p> <p>TJC, mean: NR</p> <p>SJC, mean: NR</p> <p>DMARD use, %: NR</p> <p>Corticosteroid use, %: NR</p> <p>D1: 15</p> <p>D2: 19</p> <p>MTX naive, %: NR</p> <p>Txt resistant, %: NR</p> <p>Pts with Early RA (≤3 yrs): NR</p> <p>Baseline DAS, mean: NR</p> <p>Concomitant MTX</p>	<ul style="list-style-type: none"> <li>• At 12 wks, 59% of ETA pts met ACR20 criteria compared with 15% placebo pts (<math>P &lt; 0.0001</math>)</li> <li>• 23% of ETA pts eligible for psoriasis evaluation achieved at least 75% improvement in psoriasis area and severity index, compared with 3% of placebo pts (<math>P = 0.001</math>)</li> <li>• 12 mos; the mean annualized rate of change over one yr of txt in modified Sharp score was -0.03 unit, compared with 1.00 unit in the placebo (<math>P = 0.0001</math>)</li> <li>• HAQ- improvement from baseline in ETA group 54% vs. 6% of placebo group (<math>P &lt; 0.0001</math>)</li> <li>• 72% &amp; 70% of ETA achieved PsARC at 12 and 24 wks, respectively, compared with 31% and 23% of placebo pts</li> </ul>	<p>SAEs:</p> <p>D1: 3.9</p> <p>D2: 4</p> <p>Infusion or injection reaction:</p> <p>D1: 9</p> <p>D2: 36</p> <p>Headache:</p> <p>D1: 5</p> <p>D2: 8</p> <p>URTI:</p> <p>D1: 23</p> <p>D2: 21</p> <p>UTI:</p> <p>D1: 6</p> <p>D2: 6</p>	<p>Overall Attrition Rate (%): 19.5</p> <p>ITT Analysis: Yes</p> <p>Quality Rating: Fair</p>

Evidence Table 1. Randomized controlled trials and observational studies (continued)

---

use, %:

D1: 41

D2: 42

Sharp:

D1: 18.3

D2: 25.89

---

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events (%)	Analysis and Quality Rating
<b>Author, yr:</b> Mease et al., 2005 <sup>11</sup> ADEPT Study	Inclusion Criteria: • Age ≥ 18 • Moderate to severe PsA • Active psoriatic skin lesions or a documented history of psoriasis	Interventions: D1: placebo D2: ADA (40mg every other wk) N: D1: 162 D2: 151	Mean disease duration, yrs: D1: 9.2 D2: 9.8 TJC, mean: D1: 25.8 D2: 23.9 SJC, mean: D1: 14.3 D2: 14.3	• PsARC ADA 60% wk. vs. placebo 23% • ACR50 ADA, 39% vs. placebo, 6% ( <i>P</i> < 0.001) • ACR70 ADA, 23% vs. placebo, 1% ( <i>P</i> < 0.001) • The PASI75 ADA 59% vs. placebo 1% ( <i>P</i> < 0.001) (N:69 per group). • HAQ DI change placebo - 0.1 ± 0.4 vs. ADA -0.4 ± 0.5 ( <i>P</i> < 0.001) • ACR20 ADA 57% vs. placebo 15% (between-group difference 42%, 95% CI, 31-52%; <i>P</i> < 0.001). • Mmean change in modified total Sharp was -0.2 for ADA versus placebo ( <i>P</i> < 0.001) • Erosion scores (mean change ADA 0.0 vs. placebo 0.6 ) and JSN scores (mean change ADA -0.2 vs. placebo 0.4) ( <i>P</i> < 0.001 for both) • SF-36: SF-36 PCS; change in baseline to wk 12 for placebo vs ADA; 1.4 vs 9.3 ( <i>P</i> < 0.001) • Change in baseline to wk 24; 1.4 vs 9.3 ( <i>P</i> < 0.001) • SF-36 MCS • Change in baseline to wk 12; 1.2 vs 1.6 ( <i>P</i> NS) • Change in baseline to wk 12; 0.6 vs 1.8 ( <i>P</i> NS)	Infusion or injection reaction: D1: 3.1 D2: 6.6 Headache: D1: 8.6 D2: 6.0 URTI: D1: 14.8 D2: 12.6 UTI: NR	Overall Attrition Rate (%): 7.6 ITT Analysis: Yes Quality Rating: Fair.
<b>Country, Setting:</b> Multinational, multi-clinic (50)	• Inadequate response or intolerance to NSAIDs	Mean age, yrs: D1: 49.2 D2: 48.6 Sex, % female: D1: 45.1 D2: 43.7 Race, % white: D1: 93.8 D2: 97.4	Mean number previous DMARDS: D1: 1.5 D2: 1.5 Corticosteroid use, %: NR			
<b>Funding:</b> Abbott Laboratories	• MTX ≥ 3 mos with stable dose 4 wks					
<b>Research Objective:</b> Safety and efficacy of ADA compared with placebo in txt of active psoriatic arthritis	Exclusion Criteria: • CYP, tacrolimus, DMARDs, or oral retinoids (4 wks) • Topical txts for psoriasis within 2 wks, other than medicated shampoos or low-potency topical steroids					
<b>Study Design:</b> RCT	• Anti-TNF • History of TB • Central nervous system demyelinating disease		<b>MTX naive, %:</b> NR <b>Txt resistant, %:</b> NR			
<b>Overall N:</b> 313						
<b>Study Duration:</b> 24 wks	• Listeriosis, or severe infection within 30 ds or oral antibiotics within 14 ds		Pts with Early RA (≤3 yrs):			

Evidence Table 1. Randomized controlled trials and observational studies (continued)

---

NR

Baseline PASI (mean):

D1: 8.3

D2: 7.4

Concomitant MTX use,

%:

D1: 50

D2: 51

Baseline HAQ:

D1: 1.0

D2: 1.0

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events
Author, year, study name, if applicable Mease et al., 2010 <sup>23</sup> (*companion with Mease 2004, should be in same evidence Table)	<b>Inclusion Criteria</b> <ul style="list-style-type: none"> <li>• 18 to 70 years of age</li> <li>• diagnosed with PsA with active arthritis</li> <li>• inadequate response to nonsteroidal antiinflammatory drug (NSAID) therapy at time of entry to study</li> </ul>	<b>Interventions, Dose</b> D1: ETA: 25 mg twice weekly D2: Placebo  <b>Number in group</b> 24 week double-blind D1: 101 D2: 104  48 week open-label D1: 88 D2: 81  <b>Mean age (years)</b> D1: NR D2: NR Overall: 47  <b>Sex, % female</b> D1: 43 D2: 55  <b>Race, % white</b> D1: NR D2: NR Overall: 90  <b>Race, % black</b> NR  <b>Ethnicity, Latino</b> NR	<b>Mean disease duration, years</b> Overall: 6 to 7 years  <b>Patients with early RA, three years or less, %:</b> NR  <b>Treatment resistant, %</b> NR  <b>Tender Joint Count, mean</b> NR  <b>Swollen Joint Count, mean</b> NR  <b>Corticosteroid use, %</b> NR  <b>DMARD use, %:</b> NR  <b>MTX naïve, %:</b> NR  <b>Baseline DAS score</b> NR  <b>Required treatment for latent TB</b> NR  <b>Other population characteristics</b> NR	<b>ACR:</b> ACR 20 ACR Pain, mean (SE) At week 24 D1: 1.6 (0.1) D2: 2.8 (0.1)  <b>Start of open label</b> D1: 1.4 (0.1) D2: 3.0 (0.1)  <b>Open-label at week 12</b> D1: 1.4 (0.1) D2: 1.9 (0.1)  <b>Open-label at week 24</b> D1: 1.5 (0.1) D2: 1.9 (0.1)  <b>Open-label at week 36</b> D1: 1.4 (0.1) D2: 1.7 (0.1)  <b>Open-label at week 48</b> D1: 1.3 (0.1) D2: 1.5 (0.1)  <b>Overall:</b> ACR 20%: D1 vs D2: <i>P</i> < 0.0001 ACR Pain: D1 vs D2: <i>P</i> < 0.001  <b>ACR 50:</b> NR <b>ACR 70:</b> NR  <b>HAQ</b> HAQ-DI, mean (SE) At week 24 D1: 0.5 (0.1) D2: 1.0 (0.1)  <b>Start of open label</b> D1: 0.4 (0.1) D2: 1.0 (0.1)	<b>Attrition/withdrawal:</b> NR  <b>Overall adverse events</b> NR  <b>Serious adverse events</b> NR  <b>Malignancies</b> NR  <b>Respiratory events</b> NR  <b>Other infections</b> NR  <b>GI</b> NR  <b>Other</b> NR
Country and setting Multicenter	<b>Exclusion Criteria</b> <ul style="list-style-type: none"> <li>• Pregnant or breastfeeding</li> <li>• Diabetes mellitus requiring insulin</li> <li>• Uncompensated congestive heart failure</li> <li>• Angina pectoris</li> <li>• Uncontrolled hypertension</li> <li>• Severe pulmonary disease requiring therapy</li> <li>• History of cancer other than resected cutaneous basal and squamous cell carcinoma or in situ cervical cancer.</li> </ul>				
Source of funding Pharmaceutical company or other commercial source: Amgen Inc and Wyeth Pharmaceuticals					
Research objective To evaluate the effects of ETA treatment on patient-reported outcomes (PRO) in patients with psoriatic arthritis (PsA).					
Study design Controlled Trials					
Overall N 205					
Duration of study 2 years (three phases: first 24 week double blind; 24 week blinded maintenance; 48 wk open label)					

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events
extension)				Open-label at week 12	
Quality rating				D1: 0.5 (0.1)	
NA				D2: 0.7 (0.1)	
Fair				Open-label at week 24	
				D1: 0.4 (0.1)	
				D2: 0.6 (0.1)	
				Open-label at week 36	
				D1: 0.4 (0.1)	
				D2: 0.6 (0.1)	
				Open-label at week 48	
				D1: 0.4 (0.1)	
				D2: 0.6 (0.1)	
				Overall: $P < 0.001$ at week 4 and at week 12; $P = \text{NR}$ beyond week 12, but Figure shows that both groups maintained improvement achieved up to that point and mean HAQ unchanged or almost unchanged beyond week 12	
				DAS	
				NR	
				SF-36	
				PCS, mean (SE)	
				At week 24	
				D1: 45.1 (1.1)	
				D2: 36.4 (1.0)	
				Start of open label	
				D1: 46.4 (1.2)	
				D2: 36.8 (1.1)	
				Open-label at week 12	
				D1: 46.7 (1.2)	
				D2: 43.9 (1.2)	



Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events
				Open-label at week 24 D1: 47.0 (1.3) D2: 44.4 (1.1)	
				Open-label wk 36 D1: 46.0 (1.3) D2: 44.2 (1.2)/	
				Open-label at week 48 D1: 47.3 (1.2) D2: 44.1 (1.3)	
				MCS, mean (SE) At week 24 D1: 53.6 (0.9)	
				Start of open label D1: 53.7 (1.0)	
				Open-label at week 12 D1: 52.8 (1.0)	
				Open-label at week 24 D1: 51.6 (1.1)	
				Open-label at week 36 D1: 53.6 (1.0)	
				Open-label at week 48 D1: 53.5(1.0)	
				MCS, mean (SE) At week 24: 48.4 (1.2) Start of open label: 49.1 (1.3) At week 12: 51.8 (1.2) At week 24: 49.8 (1.3) At week 36: 49.8 (1.3) At week 48: 50.8(1.3)	
				DB Phase mean improvement in score, units At week 4 Overall: 5.8 vs. 0.5 $P <$	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events
				0.001 At week 24: 9.3 vs. 0.7 ( $P < 0.001$ ) MCS change, units At week 24: 2.7 vs. - 0.1 ( $P = 0.062$ )	
				Radiographic measures At 12 months Overall: radiographic disease progression inhibited in D1 vs.D2: ( $P = 0.0001$ )	
				Quality of life scales NR	
				EQ5D VAS Mean change from baseline At 24 weeks D1: 14.3 D2: 2.1 ( $P < 0.001$ )	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events
Author, year, study name, if applicable Saad et al., 2010 <sup>14</sup> BSRBR	Inclusion Criteria • PsA diagnosis between 2002-2006, started ETN, INF, ADA as first biologic agent within 6 months of registration  Exclusion Criteria NR	Interventions, dose D1: ETA: 25 mg twice weekly or 50 mg once weekly D2: INF: 5 mg/kg at weeks 0, 2, 6, and 8 then every 8 weeks D3: ADA: 40 mg every 2 weeks D4: RF-negative RA pts on oral DMARDs (control arm)  Number in group D1: 333 D2: 171 D3: 92 D4: 1,115  Mean age, years D1: 45.8 D2: 44.8 D3: 47.0 D4: 59.4  Sex, % female D1: 51.1 D2: 55.0 D3: 53.3 D4: 73.5  Race, % white NR  Race, % black NR  Ethnicity, Latino NR	Mean disease duration, years D1: 12.8 (9.0) D2: 12.2 (8.0) D3: 11.4 (8.4) D4: 8.5 (9.7)  Patients with early RA, three years or less, % NR  Treatment resistant, % NR  Tender Joint Count, mean (SD) D1: 13.5 (7.6) D2: 14.1 (8.1) D3: 12.1 (7.1) D4: 8.7 (7.1)  Swollen Joint Count, mean (SD) D1: 8.8 (6.1) D2: 8.8 (6.4) D3: 9.7 (5.7) D4: 6.0 (5.4)  Corticosteroid use, % NR  DMARD use, %: D1: NR D2: NR D3: NR D4: 100  MTX naïve, %: NR  Baseline DAS score (SD) D1: 6.1 (1.2) D2: 6.3 (1.1) D3: 6.0 (1.0)	ACR: NR  HAQ: NR  DAS (SD): At 6 months D1: 3.3 (1.4) D2: 3.9 (1.6) D3: 3.32 (1.37) Overall: 3.5 (1.5)  At 12 months: D1: 3.2 (1.4) D2: 3.7 (1.7) D3: 3.2 (1.5) Overall: 3.4 (1.5)  18 month D1: 3.3 (1.4) D2: 3.5 (1.6) D3: 3.2 (1.5) Overall: 3.3 (1.5)  SF-36: NR  Radiographic measures: NR  Quality of life scales: NR  Others: NR	Attrition/withdrawal: NR  Overall adverse events: NR  Serious adverse events: NR  Malignancies: NR  Respiratory events: NR  Other infections: NR  GI: NR  Other: NR
Country and setting United Kingdom, multicenter					
Source of funding Pharmaceutical company or other commercial source: Abbott Laboratories, Amgen, Schering Plough, Wyeth Pharmaceuticals, Biovitrum					
Research objective To evaluate the risk-benefit profile of anti-TNF therapies in PsA and to study the predictors of treatment responses and disease remission					
Study design Observational					
Overall N 596 (PsA cohort only)					
Duration of study 1776.2 person					

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events
years			D4: 5.0 (1.4) Overall: PsA cohort: 6.2 (1.1)		
Quality rating Fair			Required treatment for latent TB NR  Other population characteristics NR		

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events
Author, year, study name, if applicable Willkens et al., 1984 <sup>16</sup>	Inclusion Criteria <ul style="list-style-type: none"> <li>All participants were between the ages of 20 and 70</li> <li>Had an established diagnosis of PsA</li> </ul>	Interventions, Dose D1: MTX: 7.5 - 15 mg/wk (in doses of 2.5 mg every 12 hours for 3 consecutive doses each week, could be increased to 15 mg/week after 6 weeks. with 3 doses of 5.0 mg taken at 12-hour consecutive intervals) D2: Placebo	Mean disease duration, years D1: 159 months D2: 103 months Overall: NR	ACR NR HAQ NR	Attrition/withdrawal NR
Country and setting United States; multicenter	<ul style="list-style-type: none"> <li>MTX naïve</li> <li>Unsuccessfully treated with antiinflammatory doses of aspirin or NSAIDs</li> </ul>	Number in group D1: 16 D2: 21 Overall: 37	Patients with early RA, three years or less, %: NR Treatment resistant, % D1: Resistant to antiinflammatory does of NSAIDs or aspirin:100 D2: 100 Overall: 100	DAS NR SF-36 NR	Serious adverse events NR
Source of funding Government or non-profit organization: Supported by NIAMDD contract no. 6-2218, by Public Health Service Research Grant # RR-00064 from the Division of Research Resources, and an Arthritis Foundation Clinical Research Center grant to the University of Tennessee Center for Health Sciences.	<ul style="list-style-type: none"> <li>If female, were not of childbearing potential</li> </ul>	Mean age (years) D1: 44 D2: 47 Overall: NR	Tender Joint Count, mean NR Swollen Joint Count, mean NR	Radiographic measures NR	Respiratory events NR
Research objective To evaluate the effectiveness, tolerability and safety of MTX	<ul style="list-style-type: none"> <li>Ultraviolet treatment within a month of starting treatment or during the trial</li> <li>Pregnancy or nursing mothers</li> <li>Conditions, medical or surgical, which would compromise the absorption, metabolism</li> <li>Elevation of hepatic enzymes or serum bilirubin to a level of twice the upper limit of normal</li> </ul>	Sex, % female D1: 62 D2: 56 Overall: 59%	Corticosteroid use, % NR	Quality of life scales NR	Other infections NR
Study design Controlled Trials	<ul style="list-style-type: none"> <li>Exclusion Criteria</li> </ul>	Race, % white D1: 81 D2: 88 Overall: 84	DMARD use, % D1: 0 D2: 0 Overall: 0	Others Mean grip strength on right, mm/Hg D1: 4 D2: -1 Overall: $P = 0.167$	GI: Gastrointestinal distress of stomatitis: D1: 3 D2: 0 Overall: 3
Overall N	<ul style="list-style-type: none"> <li>Positive serologic test for hepatitis B associated</li> </ul>	Race, % black D1: 5 D2: 0 Overall: 3	MTX naïve, %: D1: 100 D2: 100 Overall: 100	Mean grip strength on left, mm/Hg D1: 9 D2: 0 Overall: 0.149	Other NR
		Ethnicity, Latino D1: 10 D2: 6 Overall: 8	Baseline DAS score NR	Morning stiffness, minutes D1: 45 D2: 30 Overall: $P = 0.099$	
			Required treatment for latent TB NR	Physician assessment score, range 1 to 5 D1: 1 D2: 0 Overall: 0.001	
			Other population characteristics Severity of arthritis, Mild	Patient assessment score,	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events
37	antigen		D1: 5	range 1 to 5	
Duration of study	• Significant renal disease		D2: 2	D1: 1	
12 weeks	• Regular or sporadic alcoholic beverage intake of more than 14 oz per week		Severity of arthritis, Moderate	D2: 0	
Quality rating	• Any other experimental drug, previous therapy with MTX or other cytotoxic drug		D1: 10	Overall: 0.087	
Fair	• Preexisting bone marrow hypoplasia		D2: 16	Joint pain/tenderness count	
	• Active infection except for minor self-limited infections		Severity of arthritis, Severe	D1: 4	
	• Recent major surgery		D1: 1	D2: 6	
	• Insulin-dependent diabetes mellitus		D2: 3	Overall: 0.559	
	• Overt obesity as determined by the investigator		Severity of arthritis, Functional class 1:	Joint swelling count	
	• Primary diagnosis of ankylosing spondylitis		D1: 3	D1: 3	
	• Thrombocytopenia and/or leukopenia		D2: 3	D2: 1	
	• History or presence of a malignancy		Severity of arthritis, Functional class 2:	Overall: $P = 0.635$	
			D1: 11	Joint pain/tenderness score	
			D2: 15	D1: 9	
			Severity of arthritis, Functional class 3:	D2: 10	
			D1: 2	Overall: $P = 0.870$	
			D2: 3	Joint swelling score	
			Severity of arthritis, Functional class 4:	D1: 5	
			D1: 0	D2: 2	
			D2: 0	Overall: 0.390	
				Surface area, cm sq.	
				D1: 114	
				D2: 0	
				Overall: 0.039	
				Scaling, scale of 0 to 3	
				D1: 1	
				D2: 0	
				Overall: 0.068	
				Induration, scale of 0 to 3	
				D1: 0	
				D2: 0	
				Overall: 0.950	
				Erythema, scale of 0 to 3	

Evidence Table 1. Randomized controlled trials and observational studies (continued)

Study Characteristics	Inclusion and Exclusion Criteria	Characteristics and Interventions	Baseline Disease and Treatment Characteristics	Health Outcomes	Adverse Events
				D1: 1 D2: 0 Overall: 0.271	

Evidence Table 2. Systematic reviews and meta-analyses

Study Characteristics	Characteristics of Included Studies	Results	Adverse Events	Assessments, Study Appraisals, and Quality Rating
<p><b>Author, year, country, funding:</b></p> <p>Jones, Crotty and Brooks, 2000<sup>17</sup></p> <p>Multinational</p> <p>Cochrane</p> <p><b>Study Design:</b></p> <p>Systematic review.</p> <p><b>Aims of the Review:</b></p> <p>How do various treatments compare in terms of both efficacy and toxicity in the treatment of PsA?;</p> <p>To assess the effects of SSZ, auranofin, etretinate, fumaric acid, IMI gold, azathioprine, efamol marine and MTX, in PsA.</p> <p><b>Number of Patients:</b></p> <p>Twenty randomized trials were identified of which thirteen were included in the quantitative analysis with data from 1022 subjects.</p>	<p><b>Studies included:</b></p> <p>Published data only</p> <p>Carette et al. 1989; Clegg et al. 1996; Gupta et al. 1995; Hopkins et al. 1985; Levy et al. 1972; Peeters et al. 1992</p> <p>Published/unpublished data Combe et al. 1996; Dougados et al. 1995; Farr et al. 1990; Fraser et al. 1993; McKendry et al. 1993; Palit et al. 1990; Willkens et al. 1984</p> <p><b>Characteristics of included studies:</b></p> <p>At least two treatment groups, and the allocation to these must have been by formal randomization; in for quality assessment.;</p> <p><b>Characteristics of included populations:</b></p> <p>patients aged 20 years and over, with a clinical diagnosis of PsA.</p> <p><b>Characteristics of</b></p>	<p>Parenteral high dose MTX (data not available), SSZ, azathioprine and etretinate were the agents that achieved statistical significance in a global index of disease activity; SSZ (improvement in disease index 0.38 units (95% CI 0.21-0.54) and azathioprine (improvement in disease index 2.20 units (95% CI 1.06-3.33) and etretinate (improvement in disease index 0.84 units (95% CI 0.08-1.59) were statistically better than placebo.;</p> <p>In all trials the placebo group improved over baseline (pooled improvement 0.39 DI units, 95% CI 0.26-0.54).; One outstanding difference is the placebo group with PsA improves three times as much as the placebo RA group (p&lt;0.05) Therefore, the results of uncontrolled trials are likely to be misleading in PsA</p>	<p>There was insufficient data to examine toxicity.</p>	<p><b>Publication Bias Assessed:</b></p> <p>Yes</p> <p><b>Heterogeneity Assessed:</b></p> <p>Yes</p> <p><b>Standard Method of Study Appraisals:</b></p> <p>Yes</p> <p><b>Comprehensive Search Strategy:</b></p> <p>Yes</p> <p><b>Quality Rating:</b></p> <p>Good</p>



Evidence Table 2. Systematic reviews and meta-analyses (continued)

---

**interventions:**

All conservative therapeutic agents were eligible for inclusion in this review. Comparative trials without a placebo arm were not included.

---

Evidence Table 2. Systematic reviews and meta-analyses (continued)

Study Characteristics, Quality Rating	Study Information	Study Characteristics	Results	Adverse Events
<p><b>Author, Year:</b> Ravindran et al., 2008<sup>18</sup></p> <p><b>Country and setting:</b> Study conducted in UK - components are multinational</p> <p><b>Funding:</b> NR</p> <p>Aims of Review: Treatments for psoriatic arthritis (PsA) range from tumour necrosis factor (TNF) inhibitors evaluated in large randomised control trials (RCTs) and low-cost disease-modifying anti-rheumatic drugs (DMARDs) studied in less detail. We compared their efficacy and toxicity in a systematic review.</p> <p><b>Quality Rating:</b> Fair</p>	<p><b>Study design:</b> Systematic review and meta-analysis</p> <p><b>Number of Patients:</b> 2039</p> <p><b>Studies Included:</b> 18</p>	<p><b>Characteristics of Included Studies:</b> Placebo controlled RCTs</p> <p><b>Characteristics of Included Populations</b> PsA patients</p> <p><b>Characteristics of Interventions:</b> Current interventions</p>	<p><b>Study Results:</b></p> <ul style="list-style-type: none"> <li>• Efficacy - # of patients withdrawn for lack of efficacy</li> <li>• TNF inhibitors 5 studies n = 882 RR, 0.25 (95% CI, 0.13-0.48) <i>P</i> = 0.0001</li> <li>• Sulfasalazine 5 studies, n = 434, RR (95% CI): 0.45 (0.23-0.89) <i>P</i> = 0.02</li> <li>• Leflunomide 1 study, n = 190, RR (95% CI): 0.44 (0.23-0.83) <i>P</i> = 0.01</li> <li>• All DMARDs 12 studies, n = 1081, RR (95% CI): 0.39 (0.27-0.57) <i>P</i> = 0.00001</li> <li>• All treatment 18 studies, n = 2148, RR (95% CI): 0.35 (0.25-0.49) <i>P</i> = 0.00001</li> </ul>	<p><b>Adverse Events:</b></p> <ul style="list-style-type: none"> <li>• Toxicity - Withdrawals for adverse events</li> <li>• TNF inhibitors 5 studies, n = 882 RR (95% CI): 2.20 (0.82-5.91) <i>P</i> = 0.12 NNT/NNH = 0.25</li> <li>• Sulfasalazine 5 studies, n = 434 RR (95% CI): 1.76 (0.98-3.14) <i>P</i> = 0.06 NNT/NNH = 0.93</li> <li>• Leflunomide 1 study, n = 190 RR (95% CI): 3.86 (1.20-12.39) <i>P</i> = 0.02 NNT/NNH = 0.45</li> <li>• All DMARDs 12 studies n = 1081, RR (95% CI): 2.32 (1.55-3.47) <i>P</i> = 0.0001 NNT/NNH = 0.86</li> <li>• All treatment 18 studies, n = 2148, RR (95% CI): 2.33 (1.61-3.37) <i>P</i> = 0.00001 NNT/NNH = 0.62</li> </ul>

Evidence Table 2. Systematic reviews and meta-analyses (continued)

Study Characteristics	Characteristics of Included Studies	Results	Adverse Events	Assessments, Study Appraisals, and Quality Rating
<b>Author, year, country, funding:</b>	<b>Studies included:</b>	ETA 12 weeks, 65% of ACR	Injection site reactions appear	<b>Publication Bias Assessed:</b>
Woolcott et al., 2006 <sup>19</sup>	three trials of the efficacy of the interventions of interest (two for etanercept and one for infliximab), 23 studies of the adverse effects of the interventions and 14 trials of the efficacy of the DMARDs	20 { RR 4.19 [95% CI 2.74 to 6.42]}, . ACR50 45% RR 10.84 (95% CI 4.47 to 26.28)] ACR 70 12%[ RR 16.28 (95% CI 2.20 to 120.54)], (PsARC) 85%[ RR 2.60 (95% CI 1.96 to 3.45)], INF- 16 weeks, ACR 20 65% [RR 6.80 (95% CI 2.89 to 16.01)], . Almost half achieved an ACR 50 [RR 49.00 (95% CI 3.06 to 785.06)] and over one-quarter achieved an ACR 70 [RR 31.00 (95% CI 1.90 to 504.86)] compared with none of the placebo group, . PsARC 75% [RR 3.55 (95% CI 2.05 to 6.13)]. The beneficial treatment effect on psoriasis was also statistically significant with a mean difference in percentage change from baseline in PASI of -5 (95% CI -6.8 to -3.3), as was the percentage improvement from baseline in HAQ score with infliximab compared with placebo [mean difference 51.4 (95% CI 48.08 to 54.72)], indicating a beneficial effect of infliximab on functional status.	to be the most common adverse effects of etanercept. Overall, ETA appeared to be well tolerated in short-and long-term use, although much of the long-term data are not from patients with psoriatic arthritis. As identified in earlier reviews, the main areas of concern relate to uncommon but serious adverse events the significance of which is not readily discernible from the published reports of clinical trials.	Yes
Multi-national	<b>Characteristics of included studies:</b>			<b>Heterogeneity Assessed:</b>
Health Technology Assessment	RCTs			Yes
<b>Study Design:</b>	<b>Characteristics of included populations:</b>			<b>Standard Method of Study Appraisals:</b>
Systematic review	Adults with PsA			Yes
<b>Aims of the Review:</b>	<b>Characteristics of interventions:</b>			<b>Comprehensive Search Strategy:</b>
to evaluate the clinical effectiveness, safety, tolerability and cost-effectiveness of etanercept and infliximab for the treatment of active and progressive psoriatic arthritis (PsA) in patients who have inadequate response to standard treatment, including disease-modifying antirheumatic drug (DMARD) therapy.	INF and ETA		Overall, infusion reactions, the development of antibodies and infections appear to be the most common adverse effects of infliximab,	Yes
<b>Number of Patients:</b>				<b>Quality Rating:</b>
265 patients were included in the etanercept trials and 104				Good

Evidence Table 2. Systematic reviews and meta-analyses (continued)

---

in the infliximab trial.

---

## References

1. Antoni C, Krueger GG, de Vlam K, et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. *Ann Rheum Dis*. 2005 Aug;64(8):1150-7. PMID: 15677701.
2. Antoni CE, Kavanaugh A, Kirkham B, et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum*. 2005 Apr;52(4):1227-36. PMID: 15818699.
3. Genovese MC, Mease PJ, Thomson GT, et al. Safety and efficacy of adalimumab in treatment of patients with psoriatic arthritis who had failed disease modifying antirheumatic drug therapy. *J Rheumatol*; 2007. p. 1040-50.
4. Kaltwasser J, Nash P, Gladman D, et al. Efficacy and Safety of Leflunomide in the Treatment of Psoriatic Arthritis and Psoriasis: a Multinational, Double-Blind, Randomized, Placebo-Controlled Clinical Trial. *Arthritis and rheumatism*. 2004;50(6):1393-50.
5. Kavanaugh A, Antoni CE, Gladman D, et al. The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. *Ann Rheum Dis*. 2006 Aug;65(8):1038-43. PMID: 16439444.
6. Kavanaugh A, Antoni C, Krueger GG, et al. Infliximab improves health related quality of life and physical function in patients with psoriatic arthritis. *Ann Rheum Dis*. 2006 Apr;65(4):471-7. PMID: 16096330.
7. Kavanaugh A, McInnes I, Mease P, et al. Golimumab, a new human tumor necrosis factor alpha antibody, administered every four weeks as a subcutaneous injection in psoriatic arthritis: Twenty-four-week efficacy and safety results of a randomized, placebo-controlled study. *Arthritis Rheum*; 2009. p. 976-86.
8. Kristensen LE, Gulfe A, Saxne T, et al. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register. *Ann Rheum Dis*; 2008. p. 364-9.
9. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet*. 2000 Jul 29;356(9227):385-90. PMID: 10972371.
10. Mease PJ, Kivitz AJ, Burch FX, et al. Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. *Arthritis Rheum*; 2004. p. 2264-72.
11. Mease PJ, Gladman DD, Ritchlin CT, et al. Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. *Arthritis Rheum*; 2005. p. 3279-89.
12. Mease PJ, Kivitz AJ, Burch FX, et al. Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. *J Rheumatol*; 2006. p. 712-21.
13. Nash P, Thaci D, Behrens F, et al. Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study. *Dermatology*. 2006;212(3):238-49. PMID: 16549920.
14. Saad AA, Ashcroft DM, Watson KD, et al. Efficacy and safety of anti-TNF therapies in psoriatic arthritis: an observational study from the British Society for Rheumatology Biologics Register. *Rheumatology (Oxford)*; 2010. p. 697-705.
15. van der Heijde D, Kavanaugh A, Gladman DD, et al. Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. *Arthritis Rheum*; 2007. p. 2698-707.
16. Willkens RF, Williams HJ, Ward JR, et al. Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis. *Arthritis Rheum*. 1984/04/01 ed; 1984. p. 376-81.
17. Jones G, Crotty M, Brooks P. Interventions for treating psoriatic arthritis. *Cochrane Database Syst Rev*. 2000(3):CD000212.

18. Ravindran V, Scott DL, Choy EH. A systematic review and meta-analysis of efficacy and toxicity of disease modifying anti-rheumatic drugs and biological agents for psoriatic arthritis. *Ann Rheum Dis*; 2008. p. 855-9.
19. Woolacott N, Bravo Vergel Y, Hawkins N, et al. Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation. *Health Technol Assess*. 2006 Sep;10(31):1-258. PMID: 16948890.
20. Gladman DD, Mease PJ, Cifaldi MA, et al. Adalimumab improves joint-related and skin-related functional impairment in patients with psoriatic arthritis: patient-reported outcomes of the Adalimumab Effectiveness in Psoriatic Arthritis Trial. *Ann Rheum Dis*; 2007. p. 163-8.
21. Kavanaugh A, Antoni C, Mease P, et al. Effect of infliximab therapy on employment, time lost from work, and productivity in patients with psoriatic arthritis. *J Rheumatol*; 2006. p. 2254-9.
22. Mease PJ. Adalimumab: an anti-TNF agent for the treatment of psoriatic arthritis. *Expert Opin Biol Ther*; 2005. p. 1491-504.
23. Mease PJ, Woolley JM, Singh A, et al. Patient-reported outcomes in a randomized trial of etanercept in psoriatic arthritis. *J Rheumatol*. 2010/04/17 ed; 2010. p. 1221-7.
24. Saad AA, Ashcroft DM, Watson KD, et al. Persistence with anti-tumour necrosis factor therapies in patients with psoriatic arthritis: observational study from the British Society of Rheumatology Biologics Register. *Arthritis Res Ther*. 2009/04/10 ed; 2009. p. R52.

# Appendix F. Criteria for Assessing the Quality of Individual Studies

## Assessment of Internal Validity

To assess the internal validity of individual studies, the EPC adopted criteria for assessing the internal validity of individual studies from the U.S. Preventive Services Task Force and the NHS Centre for Reviews and Dissemination. To assess the quality of observational studies, we used criteria outlined by Deeks et al., 2003.<sup>1</sup>

### *For Controlled Trials:*

#### Assessment of Internal Validity

#### 1. Was the assignment to the treatment groups really random?

Adequate approaches to sequence generation:

Computer-generated random numbers

Random numbers tables

Inferior approaches to sequence generation:

Use of alteration, case record numbers, birth dates or week days

Not reported

#### 2. Was the treatment allocation concealed?

Adequate approaches to concealment of randomization:

Centralized or pharmacy-controlled randomization

Serially-numbered identical containers

On-site computer-based system with a randomization sequence that is not readable until allocation

Other approaches sequence to clinicians and patients

Inferior approaches to concealment of randomization:

Use of alteration, case record numbers, birth dates or week days

Open random numbers lists

Serially numbered envelopes (even sealed opaque envelopes can be subject to manipulation)

Not reported

3. Were the groups similar at baseline in terms of prognostic factors?
4. Were the eligibility criteria specified?
5. Were outcome assessors blinded to the treatment allocation?
6. Was the care provider blinded?
7. Was the patient kept unaware of the treatment received?
8. Did the article include an intention-to-treat analysis or provide the data needed to calculate it (i.e., number assigned to each group, number of subjects who finished in each group, and their results)?
9. Did the study maintain comparable groups?
10. Did the article report attrition, crossovers, adherence, and contamination?
11. Is there important differential loss to followup or overall high loss to followup? (Give numbers in each group.)



### Assessment of External Validity (Generalizability)

1. How similar is the population to the population to whom the intervention would be applied?
2. How many patients were recruited?
3. What were the exclusion criteria for recruitment? (Give numbers excluded at each step.)
4. What was the funding source and role of funder in the study?
5. Did the control group receive the standard of care?
6. What was the length of followup? (Give numbers at each stage of attrition.)

### *For Observational Studies:*

### Assessment of Internal Validity

1. Were both groups selected from the same source population?
2. Did both groups have the same risk of having the outcome of interest at baseline?
3. Were subjects in both groups recruited over the same time period?

4. Was there any obvious selection bias?
5. Were ascertainment methods adequate and equally applied to both groups?
6. Was an attempt made to blind the outcome assessors?
7. Was the time of followup equal in both groups?
8. Was overall attrition high ( $\geq 20\%$ )?
9. Was differential attrition high ( $\geq 15\%$ )?
10. Did the statistical analysis consider potential confounders or adjust for different lengths of followup?
11. Was the length of followup adequate to assess the outcome of interest?

1. Deeks JJ, Dinnes J, D'Amico R, Sowden AJ, Sakarovich C, Song F, et al. Evaluating non-randomised intervention studies. *Health Technol Assess.* 2003;7(27):iii-x, 1-173.

***For Systematic Reviews and Meta-analyses:***

1. Is the review based on a focused question of interest?
2. Did the search strategy employ a comprehensive, systematic, literature search?

3. Are eligibility criteria for studies clearly described?
4. Did at least 2 persons independently review studies?
5. Did authors use a standard method of critical appraisal before including studies?
6. Was publication bias assessed?
7. Was heterogeneity assessed and addressed?
8. Did statistical analysis maintain trials as the unit of analysis?

# **Appendix G. Clinical and Self-Reported Scales and Instruments Commonly Used in Studies of Drug Therapy for Rheumatoid Arthritis and Psoriatic Arthritis**

## **Introduction**

This appendix provides a brief overview of the various scales and self-reported measures that investigators used to assess outcomes in all the studies reviewed in this systematic review. The main outcome categories involve radiologic assessments of joint damage (erosion or narrowing) and various instruments that patients or subjects used to report on functional capacity or quality of life; the latter fall into two groups, one related to general health measures and one related to condition- or disease-specific instruments. General measures used in rheumatoid and psoriatic arthritis studies are described first; then the disease-specific measures used in rheumatoid and psoriatic arthritis studies are described separately. The new 2010 American College of Rheumatology ACR criteria are presented at the end of the document.

## **Radiographic Measures**

Radiographic assessment of joint damage in hands (including wrists) or both hands and feet are critical to clinical trials in rheumatoid arthritis. The damage can be both joint space narrowing and erosions, and the underlying construct is sometimes referred to as radiographic progression (i.e., changes, whether positive or negative) as detected by radiography and interpretation. Several approaches exist, but the two commonly used are the Sharp Score (and variants) and the Larsen Score. These and other scoring methods have recently been reviewed by Boini and Guillemin;<sup>1</sup> additional citations or sources are given in the brief descriptions below.

## **Sharp Score and Sharp/van der Heijde Score**

The Sharp Score is a means of evaluating joint damage in joints of the hands, including both erosion and joint space narrowing.<sup>2</sup> Although it has undergone modifications since its introduction, the version proposed in 1985 has become the standard approach. In this method, 17 joint areas in each hand are scored for erosions; 18 joint areas in each hand are scored for joint space narrowing. The score per single joint for erosions ranges from 0 to 5 and for joint space narrowing from 0 to 4. In both cases, a higher score is worse. Erosion scores range from 0 to 170 and joint space narrowing scores range from 0 to 144. Thus, the “total Sharp Score” is the sum of the erosion and joint space narrowing scores, or 0 to 314.

The Sharp/van der Heijde (SHS) method, introduced in 1989, overcame one drawback to the Sharp Score, namely its focus on only hands, given that feet can also be involved early in rheumatoid arthritis. Therefore, the SHS method was developed to take account of erosions and joint space narrowing in both hands and feet.<sup>3-4</sup> As with the Sharp Score, higher scores reflect worse damage. Erosion is assessed in 16 joints in each hand and 6 joints in each foot. Each joint is scored from 0 to 5 with a maximal erosion score of 160 in the hands and 120 in the feet. Joint space narrowing and subluxation are assessed in 15 joints in the hands and 6 joints in the feet. Each joint is scored from 0 to 4 with a maximal score of 120 in the hands and 48 in the feet. The

erosion and joint space narrowing scores are combined to give a total SHS score with a maximum of 448 (weighted toward hands because more joints are scored).

Numerous variants on the Sharp or SHS scores have been developed, differing subtly in terms of the numbers of joints measured and other details.<sup>5</sup> Generally, all the Sharp methods are very detailed assessments and the approach, although reliable and sensitive to change, is considered time-consuming and tedious. For a speedier approach, Larsen and colleagues developed a simpler approach.

## **Larsen Scale for Grading Radiographs**

The Larsen Scale is an overall measure of joint damage, originally devised in the 1970s and updated most recently in the late 1990s.<sup>6-10</sup> It produces both a score for each joint (hands and feet) and an overall score that reflects measurement and extent of joint damage. Scores range from 0 (“normal conditions,” i.e., intact bony outlines and normal joint space) to 5 (“mutilating abnormality,” i.e., original bony outlines have been destroyed), so higher scores reflect greater damage. Scores can range from 0 to 250.

## **General Health Measures**

### **Health Assessment Questionnaire**

The Health Assessment Questionnaire (HAQ) is a widely used self-report measure of functional capacity; it is a dominant instrument in studies of patients with arthritis (particularly trials of drugs in patients with rheumatoid arthritis), but it is considered a generic (not disease-specific) instrument. Detailed information on its variations, scoring, etc., can be found at [www.chcr.brown.edu/pcoc/EHAQDESCRSCORINGHAQ372.PDF](http://www.chcr.brown.edu/pcoc/EHAQDESCRSCORINGHAQ372.PDF) (accessed for this purpose 1/18/2007) or [www.hqlo.com/content/1/1/20](http://www.hqlo.com/content/1/1/20) (accessed for this purpose 1/18/2007) and in the seminal reports by Fries et al.<sup>11</sup> and Ramey et al.<sup>12</sup>

The full, five-dimension HAQ consists of four domains: disability, discomfort and pain, toxicity, and dollar costs, plus death (obtained through other sources). More commonly, “the HAQ” as used in the literature refers to the shorter version encompassing the HAQ Disability Index (HAQ-DI), the HAQ pain measure, and a global patient outcome measure. The HAQ-DI is sometimes used alone.

The HAQ-DI, with the past week as the time frame, focuses on whether the respondent “is able to...” do the activity and covers eight categories in 20 items: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and common daily activities. The four responses for the HAQ-DI questions are graded as follows: without any difficulty = 0; with some difficulty = 1; with much difficulty = 2; and unable to do = 3. The highest score for any component question in a category determines the category score. The HAQ-DI also asks about the use of aids and devices to help with various usual activities. Two composite scores can be calculated, one with and one without the aids/devices element; both range from 0 to 3.

The HAQ pain domain is measured on a doubly-anchored horizontal visual analog scale (VAS) of 15 cm in length; one end is labeled “no pain” (score of 0) and the other is labeled “very severe pain” (score of 100). Patients mark a spot on the VAS, and scores are calculated as the length from “no pain” in centimeters (cm) multiplied by 0.2 to yield a value that can range between 0 and 3.

With respect to interpretation, HAQ-DI scores of 0 to 1 are generally considered to represent mild to moderate disability, 1 to 2 moderate to severe disability, and 2 to 3 severe to very severe disability.

The HAQ global health status scale measures quality of life (essentially, as how the patient is feeling) with a 15 cm doubly-anchored horizontal VAS scored from 0 (very well) to 100 (very poor).

## **Medical Outcomes Study Short Form 36 Health Survey**

The Medical Outcomes Study Short Form 36 Health Survey (SF-36) is an internationally known generic health survey instrument. Information can be found at [www.sf-36.org/tools/sf36.shtml](http://www.sf-36.org/tools/sf36.shtml) (accessed for this purpose 2/18/2007) and in a large number of articles documenting its psychometric properties.<sup>13-19</sup> It comprises 36 items in eight independent domains tapping functioning and well-being: physical functioning, role-physical, bodily pain, and general health in one grouping (physical health) and vitality, role-emotional, social functioning, and mental health in another grouping (mental health). The SF-36 provides a separate scale score for each domain (yielding a profile of health) and two summary scores, one for physical health and one for mental health. Each scale is scored from 0 to 100 where higher scores indicate better health and well-being.

A “version 2” of the SF-36 was introduced in the late 1990s to correct some drawbacks in formatting, wording, and other issues and to update the norm-based scoring with 1998 data. It can be fielded in two versions varying by recall period: 4-week recall (the usual approach) and 1-week recall (acute). More recently, it has been tested and used for computer adaptive testing according to item response theory principles.

## **EuroQol EQ-5D Quality of Life Questionnaire**

A third generic quality-of-life instrument is the EuroQol EQ-5D Quality of Life Questionnaire, typically known just as the EQ-5D. More information can be found at <http://www.euroqol.org/> (accessed for this purpose 1/18/2007) and in key descriptive articles,<sup>20</sup> one of which is about patients with rheumatoid arthritis.<sup>21</sup>

The EQ-5D covers health status in five domains (three questions each): mobility, self-care, usual activities, pain or discomfort, and anxiety or depression. It is intended for self-response but can be used in other administration modes. Each item can take one of three response levels – no problems, some moderate problems, extreme problems – identified as level 1, 2, or 3, respectively. This yields a profile of one level for each of the five domains; this is essentially a five-digit number, and no arithmetic properties attach to these values. Users can convert health states in the five-dimensional descriptive system into a weighted health state index by applying scores from EQ-5D “value sets” elicited from general population samples to the profile pattern (e.g., 1, 2, 3, 3, 1).

The EQ-5D also has a global health VAS scale (20 cm) scored from 0 to 100.

## **Rheumatoid Arthritis Measures**

### **American College of Rheumatology 20/50/70**

The American College of Rheumatology (ACR) criteria are concerned with *improvement* in counts of tender and swollen joints and several domains of health.<sup>22</sup> A principal aim of these

criteria is use in studies (particularly trials) of drugs for rheumatoid arthritis. More information can be found at [www.rheumatology.org/publications/response/205070.asp](http://www.rheumatology.org/publications/response/205070.asp) and [www.hopkins-arthritis.som.jhmi.edu/edu/acr/acr.html#remis\\_rheum](http://www.hopkins-arthritis.som.jhmi.edu/edu/acr/acr.html#remis_rheum) (both accessed for this purpose 1/18/2007). Originally these latter involved patient assessment, physician assessment, erythrocyte sedimentation rate, pain scale, and functional questionnaire.

Today, based on work done in the mid 1990s,<sup>23</sup> values for clinical trial patients are defined as improvement in both tender and swollen joint counts and in three of the following: patient’s assessment of pain; patient’s global assessment of disease activity, patient’s assessment of physical function (sometimes referred to as physical disability), the physician’s global assessment of disease activity, and acute phase reactant (C-reactive protein, or CRP). The 20, 50, or 70 designations (sometimes called the ACR Success Criteria) refer to improvements in percentage terms to 20 percent, 50 percent, or 70 percent in the relevant dimensions. A physician’s global assessment of 70 percent improvement is considered remission.

Thus, patients are said to meet ACR 20 criteria when they have at least 20 percent reductions in tender and swollen joint counts and in at least three of the domains. ACR 50 and ACR 70 criteria are defined in a manner similar to that for ACR 20, but with improvement of at least 50 percent and 70 percent in the individual measures, respectively. Table G-1 illustrates, in a study context, how a patient might be said to have an ACR 50 response.

**Table G-1. Example of a patient with an ACR 50 response to treatment**

Outcomes Measured	Baseline	Endpoint
Tender joints count *	12	6
Swollen joints count *	8	3
Patient’s pain score*	60	20
Patient’s physical function (disability) score	80	60
Physician’s global activity score*	50	20
C-reactive protein*	3.6	1.4

\* At least 50 percent improvement between baseline and endpoint measurements.

## Ritchie Articular Index

This is a long-standing approach to doing a graded assessment of the tenderness of 26 joint regions, based on summation of joint responses after applying firm digital pressure.<sup>24</sup> Four grades can be used: 0, patient reported no tenderness; +1, patient complained of pain; +2, patient complained of pain and winced; and +3, patient complained of pain, winced, and withdrew. Thus, the index ranges from 0 to 3 for individual measures and 0 to 78 overall, with higher scores being worse tenderness.

Certain joints are treated as a single unit, such as the metacarpal-phalangeal and proximal interphalangeal joints of each hand and the metatarsal-phalangeal joints of each foot. For example, the maximum score for the five metacarpal-phalangeal joints of the right hand would be 3, not 15. No weights are used for different types of joints (e.g., by size), because the issue is one of measuring changes (improvements) in tenderness; this is especially relevant for rheumatoid arthritis.

## Disease Activity Score

The Disease Activity Score (DAS) is an index of disease activity first developed in the mid 1980s. The history of its development and current definitions, scoring systems, and other details can be found at <http://www.das-score.nl/www.das-score.nl/> (accessed for this purpose

1/19/2007) and in recent articles.<sup>4,25</sup> The DAS originally included the Ritchie Articular Index (see above), the 44 swollen joint count, the erythrocyte sedimentation rate, and a general health assessment on a VAS. A cut-off level of the DAS of 1.6 is considered to be equivalent with being in remission.

More recently, an index of RA disease activity using only 28 joints – the DAS 28 – has been developed, focusing on joint counts for both tenderness (TJC) and swelling (SJC). It also uses either the patient's or a physician's global assessment (PGA) of disease activity (on a 100 mm VAS) and the erythrocyte sedimentation rate (ESR) or C-reactive protein. The formula for calculating a DAS 28 score is as follows:  $= (0.56 \times \text{TJC}^{1/2}) + (0.28 \times \text{SJC}^{1/2}) + (0.7 \times \ln [\text{ESR}]) + (0.014 \times \text{PGA} [\text{in mm}])$ . Numerous formulas to calculate a variety of DAS and DAS 28 scores exist (see the website above), such as when a global patient assessment of health is unavailable.

The DAS 28 yields a score on a scale ranging from 0 to 10. A DAS 28 of 2.6 is considered to correspond to remission; a DAS 28 of 3.2 is a threshold for low disease activity; and a DAS 28 of more than 5.1 is considered high disease activity.

## **EULAR Response Criteria**

The European League Against Rheumatism (EULAR) response criteria classify patients as good, moderate, or nonresponders based on both change in disease activity and current disease activity, using either the DAS or the DAS28 (see description above).<sup>26</sup> For example, to be classified as a good responder a patient must have relevant change in DAS ( $\geq 1.2$ ) and low current disease activity ( $\leq 2.4$ ), while a nonresponder must have  $\leq 0.6$  change in DAS and high disease activity ( $> 3.7$ ).<sup>27</sup>

The EULAR criteria have been validated in multiple clinical trials, and confirmed in an analysis of nine clinical trials that concluded a high level of agreement and equal validity between ACR and EULAR improvement classifications.<sup>28</sup> Good and moderate responders showed significantly more improvement in functional capacity and significantly less progression of joint damage than patients classified as nonresponders.<sup>28</sup>

## **Psoriatic Arthritis Measures**

### **Psoriatic Arthritis Response Criteria**

The psoriatic arthritis response criteria (PsARC) was initially designed for use in a clinical trial that compared sulphasalazine to placebo in the setting of the Veterans Administration.<sup>29</sup> It has since been used as the primary or secondary outcome in all the studies that examined biologics versus placebo in the treatment of PsA. The PsARC includes improvement in at least two of the following, one of which had to be a joint count, and no worsening of any measure: tender or swollen joint count improvement of at least 30%, patient global improvement by one point on a five-point Likert scale, or physician global improvement on the same scale.<sup>29</sup>

### **American College of Rheumatology 20**

The ACR 20 (American College of Rheumatology 20 percent response) is the other outcome that is used as the primary outcome in clinical trials of biologics. The measurement is similar to that of the ACR 20 used for rheumatoid arthritis with modifications made that increased the number of joints tested from 68 tender and 66 swollen to 76 and 78, respectively, with the addition of distal interphalangeal joints of the feet and carpometacarpal joints of the hands.<sup>29</sup> The



outcomes from the ACR 20 are generally poorer when compared to the PsARC due to the variation in items measured; this is due in part to the need to see an improvement in tender *and* swollen joints in the ACR 20 versus an improvement in tender *or* swollen joint counts. An adaptation of the ACR 20 criteria as of 2010 are presented in Table G-2.

Table G-2. 2010 rheumatoid arthritis criteria

<p><b>Target population (Who should be tested?)</b></p> <p>Patients who</p> <ul style="list-style-type: none"> <li>• have at least 1 joint with definite clinical synovitis (swelling) <ul style="list-style-type: none"> <li>○ Criteria aimed at classification of newly presenting patients; patients with erosive disease typical of RA with a history compatible with prior fulfillment of the 2010 criteria should be classified as having RA; patients with longstanding disease, including those whose disease is inactive (with or without treatment) who, based on retrospectively available data, have previously fulfilled the 2010 criteria should be classified as having RA</li> </ul> </li> <li>• with the synovitis not better explained by another disease <ul style="list-style-type: none"> <li>○ Differential diagnoses vary among patients with different presentations, but may include conditions such as systemic lupus erythematosus, psoriatic arthritis, and gout. If it is unclear about the relevant differential diagnoses to consider, an expert rheumatologist should be consulted</li> </ul> </li> </ul>	
<p><b>Classification criteria for RA</b></p> <p>Score-based algorithm:</p> <ul style="list-style-type: none"> <li>• Add score of categories: Joint involvement, serology, reactants, duration <ul style="list-style-type: none"> <li>○ Differential diagnoses vary among patients with different presentations, but may include conditions such as systemic lupus erythematosus, psoriatic arthritis, and gout. If it is unclear about the relevant differential diagnoses to consider, an expert rheumatologist should be consulted</li> </ul> </li> <li>• Score of <math>\geq 6/10</math> needed for classification of a patient as having definite RA <ul style="list-style-type: none"> <li>○ Although patients with a score of <math>&lt;6/10</math> are not classifiable as having RA, their status can be reassessed and the criteria might be fulfilled cumulatively over time</li> </ul> </li> </ul>	<p><b>Score</b></p>
<p><b>Joint involvement</b></p> <p>Joint involvement refers to any <i>swollen</i> or <i>tender</i> joint on examination, which may be confirmed by imaging evidence of synovitis; d Distal interphalangeal joints, first carpometacarpal joints, and first metatarsophalangeal joints are <i>excluded from assessment</i>; categories of joint distribution are classified according to the location and number of involved joints, with placement into the highest category possible based on the pattern of joint involvement</p>	
<p><b>1 large joint</b></p> <ul style="list-style-type: none"> <li>• "Large joints" refers to shoulders, elbows, hips, knees, and ankles</li> </ul>	<p><b>0</b></p>
<p><b>2-10 large joints</b></p>	<p><b>1</b></p>
<p>1-3 small joints (with or without involvement of large joints)</p> <ul style="list-style-type: none"> <li>• "Small joints" refers to the metacarpophalangeal joints, proximal interphalangeal joints,</li> </ul>	<p><b>2</b></p>

second through fifth metatarsophalangeal joints, thumb interphalangeal joints, and wrists.	
<b>4-10 small joints</b> (with or without involvement of large joints)	<b>3</b>
<b>&gt;10 joints</b> (at least 1 small joint) <ul style="list-style-type: none"> <li>In this category, at least 1 of the involved joints must be a small joint; the other joints can include any combination of large and additional small joints, as well as other joints not specifically listed elsewhere (e.g., temporomandibular, acromioclavicular, sternoclavicular, etc.)</li> </ul>	<b>5</b>

Table G-2. 2010 rheumatoid arthritis criteria (continued)

<p><b>Serology</b> (<i>at least 1 test result is needed for classification</i>) (Cf. <a href="http://www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp#fn_08">http://www.rheumatology.org/practice/clinical/classification/ra/ra_2010.asp#fn_08</a>)</p> <ul style="list-style-type: none"> <li>Negative refers to IU values that are less than or equal to the upper limit of normal (ULN) for the laboratory and assay; low-positive refers to IU values that are higher than the ULN but <math>\leq 3</math> times the ULN for the laboratory and assay; high-positive refers to IU values that are <math>&gt;3</math> times the ULN for the laboratory and assay; where rheumatoid factor (RF) information is only available as positive or negative, a positive result should be scored as low-positive for RF. ACPA = anti-citrullinated protein antibody</li> </ul>	
Negative RF <i>and</i> negative ACPA	<b>0</b>
Low-positive RF <i>or</i> low-positive ACPA	<b>2</b>
High-positive RF <i>or</i> high-positive ACPA	<b>3</b>
<p><b>Acute-phase reactants</b> (<i>at least 1 test result is needed for classification</i>)</p> <ul style="list-style-type: none"> <li>Normal/abnormal is determined by local laboratory standards. CRP = C-reactive protein; ESR = erythrocyte sedimentation rate</li> </ul>	
Normal CRP <i>and</i> normal ESR	<b>0</b>
Abnormal CRP <i>or</i> abnormal ESR	<b>1</b>
<p><b>Duration of symptoms</b></p> <ul style="list-style-type: none"> <li>Duration of symptoms refers to patient self-report of the duration of signs or symptoms of synovitis (e.g., pain, swelling, tenderness) of joints that are clinically involved at the time of assessment, regardless of treatment status</li> </ul>	
<6 weeks	<b>0</b>
$\geq 6$ weeks	<b>1</b>

Adapted from: 2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. *Arthritis & Rheumatism*. 2010 Sep; 62(9): 2569–2581.

## The Psoriasis Area and Severity Index

The Psoriasis Area and Severity Index (PASI) was developed to measure the effect of treatments in clinical trials of psoriasis and is utilized to capture the psoriasis component found in psoriatic arthritis. The scale was originally published in 1978 in a trial of 27 patients suffering from severe chronic generalized psoriasis that were treated with Ro 10-9359, a retinoic acid derivative.<sup>30</sup> The PASI is a composite index of disease severity incorporating measures of scaling, erythema, and induration, and it is weighted by severity and affected body surface area. A PASI  $>12$  defines severe, PASI 7-12 moderate, and PASI  $<7$  mild psoriasis.

## References

1. Boini S, Guillemin F. Radiographic scoring methods as outcome measures in rheumatoid arthritis: properties and advantages. *Ann Rheum Dis*. 2001 Sep;60(9):817-27.
2. Sharp JT, Young DY, Bluhm GB, Brook A, Brower AC, Corbett M, et al. How many joints in the hands and wrists should be included in a score of radiologic abnormalities used to assess rheumatoid arthritis? *Arthritis Rheum*. 1985 Dec;28(12):1326-35.
3. van der Heijde D, Dankert T, Nieman F, Rau R, Boers M. Reliability and sensitivity to change of a simplification of the Sharp/van der Heijde radiological assessment in rheumatoid arthritis. *Rheumatology (Oxford)*. 1999 Oct;38(10):941-7.
4. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. *J Rheumatol*. 1999 Mar;26(3):743-5.
5. Ory PA. Interpreting radiographic data in rheumatoid arthritis. *Ann Rheum Dis*. 2003 Jul;62(7):597-604.
6. Larsen A. Radiological grading of rheumatoid arthritis. An interobserver study. *Scand J Rheumatol*. 1973;2(3):136-8.
7. Larsen A, Dale K, Eek M. Radiographic evaluation of rheumatoid arthritis and related conditions by standard reference films. *Acta Radiol Diagn (Stockh)*. 1977 Jul;18(4):481-91.
8. Scott DL, Coulton BL, Bacon PA, Popert AJ. Methods of X-ray assessment in rheumatoid arthritis: a re-evaluation. *Br J Rheumatol*. 1985 Feb;24(1):31-9.
9. Larsen A. How to apply Larsen score in evaluating radiographs of rheumatoid arthritis in long-term studies. *J Rheumatol*. 1995;22:1974-5.
10. Edmonds J, Saudan A, Lassere M, Scott DL. Introduction to reading radiographs by the Scott modification of the Larsen method. *J Rheumatol*. 1999;26:740-2.
11. Fries JF, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum*. 1980 Feb;23(2):137-45.
12. Ramey DR, Fries JF, Singh G. The Health Assessment Questionnaire 1995 -- Status and Review. In: Spilker B, ed. *Quality of Life and Pharmacoeconomics in Clinical Trials*. 2nd ed. Philadelphia: Lippincott-Raven Publishers 1996:227-37.
13. Stewart AL, Hays RD, Ware JE, Jr. The MOS short-form general health survey. Reliability and validity in a patient population. *Med Care*. 1988 Jul;26(7):724-35.
14. Stewart AL, Ware JE. *Measuring Functioning and Well-Being: The Medical Outcomes Study Approach*. Durham, NC: Duke University Press 1992.
15. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care*. 1992 Jun;30(6):473-83.
16. McHorney CA, Ware JE, Jr., Rogers W, Raczek AE, Lu JF. The validity and relative precision of MOS short- and long-form health status scales and Dartmouth COOP charts. Results from the Medical Outcomes Study. *Med Care*. 1992 May;30(5 Suppl):MS253-65.
17. McHorney CA, Ware JE, Jr., Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. *Med Care*. 1993 Mar;31(3):247-63.
18. McHorney CA, Ware JE, Jr., Lu JF, Sherbourne CD. The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. *Med Care*. 1994 Jan;32(1):40-66.

19. Ware JE, Jr., Kosinski M, Bayliss MS, McHorney CA, Rogers WH, Raczek A. Comparison of methods for the scoring and statistical analysis of SF-36 health profile and summary measures: summary of results from the Medical Outcomes Study. *Med Care*. 1995 Apr;33(4 Suppl):AS264-79.
20. Kind P. The EuroQol instrument: An index of health-related quality of life. *Quality of life and Pharmacoeconomics in Clinical Trials*. 2nd ed. Philadelphia: Lippincott-Raven Publishers 1996.
21. Hurst NP, Kind P, Ruta D, Hunter M, Stubbings A. Measuring health-related quality of life in rheumatoid arthritis: validity, responsiveness and reliability of EuroQol (EQ-5D). *Br J Rheumatol*. 1997 May;36(5):551-9.
22. Felson DT, Anderson JJ, Boers M, Bombardier C, Chernoff M, Fried B, et al. The American College of Rheumatology preliminary core set of disease activity measures for rheumatoid arthritis clinical trials. *The Committee on Outcome Measures in Rheumatoid Arthritis Clinical Trials*. *Arthritis Rheum*. 1993 Jun;36(6):729-40.
23. Felson DT, Anderson JJ, Boers M, Bombardier C, Furst D, Goldsmith C, et al. ACR preliminary definition of improvement in rheumatoid arthritis. *Arthritis Rheum*. 1995;38(6):727-35.
24. Ritchie DM, Boyle JA, McInnes JM, Jasani MK, Dalakos TG, Grievson P, et al. Clinical studies with an articular index for the assessment of joint tenderness in patients with rheumatoid arthritis. *Q J Med*. 1968 Jul;37(147):393-406.
25. Aletaha D, Nell VP, Stamm T, Uffmann M, Pflugbeil S, Machold K, et al. Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. *Arthritis Res Ther*. 2005;7(4):R796-806.
26. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. *Arthritis Rheum*. 1996/01/01 ed 1996:34-40.
27. Fransen J, van Riel PL. The Disease Activity Score and the EULAR response criteria. *Rheum Dis Clin North Am*. 2009/12/08 ed 2009:745-57, vii-viii.
28. van Gestel AM, Anderson JJ, van Riel PL, Boers M, Haagsma CJ, Rich B, et al. ACR and EULAR improvement criteria have comparable validity in rheumatoid arthritis trials. *American College of Rheumatology European League of Associations for Rheumatology*. *J Rheumatol*. 1999/03/25 ed 1999:705-11.
29. Mease PJ, Goffe BS, Metz J, VanderStoep A, Finck B, Burge DJ. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. *Lancet*. 2000 Jul 29;356(9227):385-90.
30. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid. *Dermatologica*. 1978;157(4):238-44.

## Appendix H. Characteristics of Studies with Poor Internal Validity

Study	Design	Sample Size	Intervention	Reason for Exclusion
Atteno et al., 2010 <sup>1</sup>	Open-label RCT	100	Adalimumab Etanercept Infliximab	No blinding; no ITT analysis; high risk of selection bias and measurement bias
Saad et al., 2010 <sup>2</sup>	Observational	596	Adalimumab Etanercept Infliximab	High LTF
Virkki et al., 2010 <sup>3</sup>	Observational	127	Etanercept Infliximab	High LTF; completers analysis

ITT = intention to treat; LTF = loss to followup; RCT = randomized controlled trial

### References

1. Atteno M, Peluso R, Costa L, et al. Comparison of effectiveness and safety of infliximab, etanercept, and adalimumab in psoriatic arthritis patients who experienced an inadequate response to previous disease-modifying antirheumatic drugs. *Clin Rheumatol.* 2010/01/13 ed 2010:399-403.
2. Saad AA, Ashcroft DM, Watson KD, et al. Improvements in quality of life and functional status in patients with psoriatic arthritis receiving anti-tumor necrosis factor therapies. *Arthritis Care Res (Hoboken).* 2010/04/15 ed 2010:345-53.
3. Virkki LM, Sumathikutty BC, Aarnio M, et al. Biological Therapy for Psoriatic Arthritis in Clinical Practice: Outcomes Up to 2 Years. *Journal of Rheumatology.* 2010:2362-8.

# Appendix I. Strength of Evidence Tables

Table I-1. Strength of evidence for disease activity and radiographic progression

Number of Studies; # of Subjects	Risk of Bias				Results	Strength of Evidence
	Design/ Quality	Consistency	Directness	Precision		
<b>Oral DMARD vs. placebo</b>						
<b>Methotrexate vs. placebo</b> 1 RCT; N=37	Medium 1 RCT/Fair	Unknown, single study	Direct	Precise	Greater improvement with physician assessment of disease activity with methotrexate than placebo	Low
<b>Sulfasalazine vs. placebo</b> 1 systematic review (including 6 RCTs); N=564	Low 1 Systematic review/Good	Consistent	Direct	Precise	Greater improvement in disease activity with sulfasalazine than placebo	Moderate
<b>Leflunomide vs. placebo</b> 1 RCT; N=190	Medium 1 RCT/Fair	Unknown, single study	Direct	Precise	Greater improvement in disease activity with leflunomide than placebo	Low
<b>Biologic DMARD vs. placebo</b>						
<b>Adalimumab vs. placebo</b> 2 RCTs; N=415	Medium 2 RCT/Fair	Consistent	Direct	Precise	Greater improvement in disease activity with adalimumab than placebo	Moderate
	Medium 1 RCT/Fair	Unknown, single study	Indirect	Precise	Less radiographic change for adalimumab than placebo	Low
<b>Etanercept vs. placebo</b> 1 systematic review, 2 RCTs; N=634	Low 1 Systematic review/Good; 2 RCTs /Fair	Consistent	Direct	Precise	Greater improvement in disease activity with etanercept than placebo	Moderate
	Medium				Less radiographic change for etanercept	

	1 RCT/Fair	Unknown, single study	Indirect	Precise	than placebo	Low
<b>Golimumab vs. placebo</b> 1 RCT; N=405	Low 1 RCT/Good	Unknown, single study	Direct	Precise	Greater improvement in disease activity with golimumab than placebo	Low
<b>Infliximab vs. placebo</b> 1 systematic review, 2 RCTs; N=675	Low Systematic review/Good; 2 RCTs/Fair	Consistent	Direct	Precise	Greater improvement in disease activity with infliximab than placebo	Moderate
	Medium 1 RCT/Fair	Unknown, single study	Indirect	Precise	Less radiographic change for infliximab than placebo	Low
<b>Oral DMARD vs. Oral DMARD</b>						
No studies	n/a	n/a	n/a	n/a	n/a	Insufficient
<b>Biologic DMARD vs. Biologic DMARD</b>						
No studies	n/a	n/a	n/a	n/a	n/a	Insufficient
<b>Biologic DMARD vs. Oral DMARD</b>						
TNF inhibitors vs. sulfasalazine 1 systematic review; N=882	Low Systematic review/Fair	Unknown, single study	Direct	Precise	Greater improvement in disease activity with TNF inhibitors than sulfasalazine	Low
Table I-1. Strength of evidence for disease activity and radiographic progression (continued)						
	<b>Risk of Bias</b>					
<b>Number of Studies;</b>	<b>Design/</b>					<b>Strength of</b>
<b># of Subjects</b>	<b>Quality</b>	<b>Consistency</b>	<b>Directness</b>	<b>Precision</b>	<b>Results</b>	<b>Evidence</b>
<b>Biologic DMARD + Oral DMARD vs. Biologic DMARD</b>						
<b>Anti-TNF(ADA, ETN or INF) + MTX vs. Anti-TNF</b> 2 cohort studies; N=857	Medium 2 Cohort/Fair	Consistent	Direct	Precise	No difference in disease activity	Low
<b>Biologic DMARD + Oral DMARD vs. Oral DMARD</b>						



---

<b>No studies</b>	n/a	n/a	n/a	n/a	n/a	Insufficient
-------------------	-----	-----	-----	-----	-----	--------------

---

ADA = adalimumab; DMARD = disease-modifying antirheumatic drug; INF = infliximab; MTX = methotrexate; N = total sample size; n/a = not applicable; RCT = randomized controlled trial; TNF = tumor necrosis factor; vs. = versus

Table I-2. Strength of evidence for functional capacity and quality of life outcomes

Number of Studies; # of Subjects	Risk of Bias			Precision	Results	Strength of Evidence
	Design/Quality	Consistency	Directness			
<b>Oral DMARD vs. placebo</b>						
<b>Leflunomide vs. placebo</b> 1 RCT; N=190	Medium RCT/Fair	Unknown, single study	Direct	Precise	Greater improvement in functional capacity <sup>a</sup> and quality of life with LEF than placebo	Low
<b>Biologic DMARD vs. placebo</b>						
<b>Adalimumab vs. placebo</b> 2 RCTs; N=415	Medium RCTs/ 2 Fair	Consistent	Direct	Precise	Greater improvement in functional capacity <sup>b</sup> with adalimumab	Moderate
		Inconsistent	Direct	Imprecise	For health-related quality of life, some results favored adalimumab <sup>c</sup>	Low
<b>Etanercept vs. placebo</b> 2 RCTs; N=265	Medium RCTs/2 Fair	Consistent	Direct	Precise	Greater improvement in functional capacity with etanercept	Moderate
		Unknown, single study <sup>d</sup>	Direct	Precise	Greater improvement in quality of life with etanercept	Low
<b>Golimumab vs. placebo</b> 1 RCT; N=405	Low RCT/Good	Unknown, single study	Direct	Precise	Greater improvement in functional capacity and quality of life with golimumab	Low
<b>Infliximab vs. placebo</b> 2 RCTs; N=304	Medium RCTs/2 Fair	Consistent	Direct	Precise	Greater improvement in functional capacity with infliximab	Moderate
		Unknown,	Direct	Imprecise	Greater improvement in quality of life with infliximab	Low

---

single study<sup>d</sup>

---

---

**Oral DMARD vs. Oral DMARD**

---

No studies      n/a              n/a              n/a              n/a              n/a              Insufficient

---

**Biologic DMARDs vs. Biologic DMARDs**

---

No studies      n/a              n/a              n/a              n/a              n/a              Insufficient

---

**Biologic DMARDs vs. Oral DMARDs**

---

No studies      n/a              n/a              n/a              n/a              n/a              Insufficient

---

**Biologic DMARDs + Oral DMARDs vs. Biologic DMARDs**

---

No studies      n/a              n/a              n/a              n/a              n/a              Insufficient

---

**Biologic DMARDs + Oral DMARDs vs. Oral DMARDs**

---

No studies      n/a              n/a              n/a              n/a              n/a              Insufficient

---

<sup>a</sup>Difference was statistically significantly different, but did not reach the threshold for a clinically important difference.

<sup>b</sup>Difference in one of two studies was statistically significantly different (difference in improvement in HAQ of 0.2,  $P = 0.01$ ), but did not reach the threshold for a clinically important difference of  $\geq 0.22$ . In the other study, the difference was both clinically and statistically significant.

<sup>c</sup>Differences were statistically and clinically significant for the SF-36 PCS, but not for the MCS in both studies. Both studies reported results on the dermatology life quality index; one found a difference favoring adalimumab and the other found no statistically significant difference.

<sup>d</sup>Only one of the two trials reported a quality of life outcome.

N = number; n/a = not applicable; RCT = randomized controlled trial

Table I-3. Strength of evidence for adverse events

Number of Studies; # of Subjects	Risk of Bias				Results	Strength of Evidence
	Design/Quality	Consistency	Directness	Precision		
<b>Biologic DMARD vs. Biologic DMARD</b>						
<b>ADA vs. ETN vs. INF</b> 2 observational N=827	Medium 2 cohort/ 1 fair, 1 good	Consistent	Direct	Imprecise	ETN had lower risk of withdrawals due to AEs than INF. Concomitant MTX lowered withdrawals.	Low
<b>Oral DMARD vs. placebo</b>						
<b>LEF vs. placebo</b> 1 RCT N=143 1 meta-analysis (N=190)	Medium RCT and meta-analysis/ fair	Unknown, single study	Direct	Imprecise	Higher rates of diarrhea and increased ALT levels for LEF vs. placebo  LEF had higher withdrawals due to AEs	Insufficient
<b>SFZ vs. placebo</b> 1 meta-analysis (N=434)	Medium meta-analysis/ fair	Consistent	Direct	Imprecise	SFZ had more withdrawals due to AEs than placebo, but not statistically significant	Insufficient
<b>Biologic DMARD vs. placebo</b>						
<b>ADA vs. placebo</b> 2 RCT N=415	Medium RCT/2 fair	Consistent	Direct	Imprecise	Infusion reactions with ADA; worsened psoriasis with placebo	Low
<b>ETN vs. placebo</b> 2 RCT N=265	Medium RCT/2 fair	Consistent	Direct	Imprecise	No difference in adverse events except for more ISRs with ETN	Low
<b>GOL vs. placebo</b> 1 RCT N=405	Medium RCT/1 fair	Unknown, single study	Direct	Imprecise	More infections and malignancies for GOL than placebo	Insufficient
<b>INF vs. placebo</b>	Medium	Consistent	Direct	Imprecise	No differences in adverse events for INF and	Insufficient

2 RCT N=304	RCT/2 fair				placebo	
<b>TNF Inhibitors vs. placebo</b>	Medium meta-analysis/ 1 meta-analysis (N=882) fair	Consistent	Direct	Imprecise	TNF inhibitors as class had more withdrawals due to AEs than placebo, but not statistically significant	Insufficient

ADA = adalimumab; AE = adverse event; ALT = alanine aminotransferase; DMARD = disease-modifying antirheumatic drug; ETN = etanercept; GOL = golimumab; INF = infliximab; ISR = injection site reaction; LEF = leflunomide; MTX = methotrexate; N = total sample size; RCT = randomized controlled trial; vs. = versus